PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH				Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH			Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells	ONCOGENE			English	Article						cell growth inhibition; I3C; Bax; mitochondria; apoptosis	CYTOCHROME-C; BCL-2; INDUCTION; INHIBITION; CYCLE; OVEREXPRESSION; CARCINOGENESIS; ACTIVATION; RELEASE; CYTOSOL	Epidemiological studies have suggested that the consumption of fruits and vegetables that provide several classes of compounds, including Indole3-carbinol (I3C), may have chemopreventive activity against breast cancer. Several in vitro and in vivo animal studies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mechanism(s) by which I3C exerts its biological effects on breast cancer cells has not been fully elucidated. In this study, we investigated the effects of I3C in Her-2/neu over-expressing MDA-MB-435 breast cancer cells and compared these results with parental cells transfected with control vector, We focused our investigation in elucidating the molecular mechanism(s) by which I3C induces apoptosis in breast cancer cells. Our data show that I3C inhibits breast cancer cell growth in a dose dependent manner in Her-2/neu overexpressing and in normal Her-2/neu expressing cells. Induction of apoptosis was also observed in these cell lines when treated with I3C, as measured by poly (ADP-ribose) polymerase (PARP) and caspase-3 activation. In addition, we found that I3C up-regulates Bas, downregulates Bcl-2 and, thereby, increased the ratio of Bax to Bcl-2 favoring apoptosis, These results suggest that the alteration in the expression of these genes may play an important role in mediating the biological effects of I3C. Moreover, we also show the cellular localization of Bax by confocal microscopy, which showed diffuse distribution of Bax throughout the cytoplasmic compartment in breast cancer cells in control culture. However, in 13C treated cells, Bax showed a punctate pattern of distribution that was localized in the mitochondria, From these results, we conclude that the over-expression and translocation of Bax to mitochondria causes mitochondrial depolarization and activation of caspases, which may be one of the mechanism(s) by which I3C induces apoptotic processes in I3C treated breast cancer cells. Overall, our present data provide a novel molecular mechanism(s) by which 13C elicits its biological effects on both Her-2/neu over-expressing and with normal Her-2/neu expressing breast cancer cells, suggesting that 13C could be an effective agent in inducing apoptosis in breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [P30CA22453] Funding Source: Medline; NIEHS NIH HHS [P30ES06639, ES 06639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AIFCR, 1997, FOOD NUTR PREV CANC, P436; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; Bradbury MH, 1997, J CONTAM HYDROL, V28, P11, DOI 10.1016/S0169-7722(97)00002-8; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P337; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Cover CM, 1999, CANCER RES, V59, P1244; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Flagg EW, 2000, EPIDEMIOLOGY, V11, P462, DOI 10.1097/00001648-200007000-00017; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOJIMA T, 1994, CANCER RES, V54, P1446; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li YW, 1998, ONCOGENE, V17, P2915, DOI 10.1038/sj.onc.1202218; LOUB WD, 1975, J NATL CANCER I, V54, P985; MIYASHITA T, 1994, CANCER RES, V54, P3131; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; Nomura M, 1999, CANCER RES, V59, P5542; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SALET C, 1995, INT J RADIAT BIOL, V67, P477, DOI 10.1080/09553009514550551; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7943; SHERTZER HG, 1984, CHEM-BIOL INTERACT, V48, P81, DOI 10.1016/0009-2797(84)90008-5; Tan M, 1997, CANCER RES, V57, P1199; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu DH, 1996, ONCOGENE, V13, P1359	43	76	76	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5764	5771		10.1038/sj.onc.1203959	http://dx.doi.org/10.1038/sj.onc.1203959			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126363				2022-12-28	WOS:000165477700008
J	Karkkainen, MJ; Petrova, TV				Karkkainen, MJ; Petrova, TV			Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis	ONCOGENE			English	Review						angiogenesis; endothelial cells; receptor tyrosine kinases; signal transduction; VEGF receptors; VEGF	SIGNAL-TRANSDUCTION PATHWAYS; TYROSINE KINASE RECEPTOR; FACTOR-RELATED PROTEIN; VEGF-C; PERMEABILITY FACTOR; CELL GROWTH; FLT4 RECEPTOR; NITRIC-OXIDE; MAP KINASE; PHOSPHORYLATION SITES	VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Flt4) are endothelial specific receptor tyrosine kinases, regulated by members of the vascular endothelial growth factor family, VEGFRs are indispensable for embryonic vascular development, and are involved in the regulation of many aspects of physiological and pathological angiogenesis. VEGF-C and VEGF-D, as ligands for VEGFR-3 are also capable of stimulating lymphangiogenesis and at least VEGF-C can enhance lymphatic metastasis, Recent studies have shown that missense mutations within the VEGFR3 tyrosine kinase domain are associated with human hereditary lymphedema, suggesting an important role for this receptor in the development of the lymphatic vasculature.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki	Petrova, TV (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BORG JP, 1995, ONCOGENE, V10, P973; BROCK TA, 1991, AM J PATHOL, V138, P213; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Evans AL, 1999, AM J HUM GENET, V64, P547, DOI 10.1086/302248; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fournier E, 1999, ONCOGENE, V18, P507, DOI 10.1038/sj.onc.1202315; FOURNIER E, 1995, ONCOGENE, V11, P921; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GALLAND F, 1993, ONCOGENE, V8, P1233; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kukk E, 1996, DEVELOPMENT, V122, P3829; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Mangion J, 1999, AM J HUM GENET, V65, P427, DOI 10.1086/302500; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARTANEN T, 2000, IN PRESS FASEB J; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witte MH, 1998, LYMPHOLOGY, V31, P145; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	92	344	385	2	22	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5598	5605		10.1038/sj.onc.1203855	http://dx.doi.org/10.1038/sj.onc.1203855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114740				2022-12-28	WOS:000165659300007
J	Parsons, JT; Martin, KH; Slack, JK; Taylor, JM; Weed, SA				Parsons, JT; Martin, KH; Slack, JK; Taylor, JM; Weed, SA			Focal Adhesion Kinase: a regulator of focal adhesion dynamics and cell movement	ONCOGENE			English	Review						integrins; protein tyrosine kinase; adhesion; migration; phosphorylation	PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; INTEGRIN-MEDIATED ACTIVATION; C-TERMINAL DOMAIN; SIGNAL-TRANSDUCTION; ARP2/3 COMPLEX; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; P21-ACTIVATED KINASE; CONSERVED PROTEIN	Engagement of integrin receptors with extracellular ligands gives rise to the formation of complex multiprotein structures that link the ECM to the cytoplasmic actin cytoskeleton. These adhesive complexes are dynamic, often heterogeneous structures, varying in size and organization, In motile cells, sites of adhesion within filopodia and lamellipodia are relatively small and transient and are referred to as 'focal complexes,' whereas adhesions underlying the body of the cell and localized to the ends of actin stress fibers are referred to as 'focal adhesions', Signal transduction through focal complexes and focal adhesions has been implicated in the regulation of a number of key cellular processes, including growth factor induced mitogenic signals, cell survival and cell locomotion, The formation and remodeling of focal contacts is a dynamic process under the regulation of protein tyrosine kinases and small GTPases of the Rho family. In this review, we consider the role of the focal complex associated protein tyrosine kinase, Focal Adhesion Kinase (FAK), in the regulation of cell movement with the emphasis on how FAK regulates the flow of signals from the ECM to the actin cytoskeleton.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.			Taylor, Joan/0000-0002-8794-5167; Martin, Karen/0000-0001-8916-4092; Weed, Scott/0000-0001-7033-9999	NCI NIH HHS [CA40042] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Brownell J, 1998, REV CONTEMP PHARMACO, V9, P1; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; ILLC D, 1995, NATURE, V377, P539; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Ku H, 2000, J BIOL CHEM, V275, P11333, DOI 10.1074/jbc.275.15.11333; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolan K, 1999, MOL CELL BIOL, V19, P6120; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PATCH LA, 1995, J CELL SCI, V108, P1371; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Taylor JM, 1999, J CELL SCI, V112, P231; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Xiong WC, 1998, J CELL SCI, V111, P1981; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	94	544	568	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5606	5613		10.1038/sj.onc.1203877	http://dx.doi.org/10.1038/sj.onc.1203877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114741				2022-12-28	WOS:000165659300008
J	Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA				Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA			A cancer modifier role for parathyroid hormone-related protein	ONCOGENE			English	Article						linkage disequilibrium; skin cancer	CHEMICAL CARCINOGENESIS; SKIN CARCINOGENESIS; MICE; GROWTH; PEPTIDE; HYPERCALCEMIA; RESISTANCE; CARCINOMA; GENETICS; LINES	The parathyroid hormone-related protein (PTHrP) gene (Pthlh) maps in the distal region of mouse chromosome 6 that contains a quantitative trait locus associated with genetic predisposition to skin tumorigenesis. Here, we report a genetic polymorphism located in the osteostatin encoding region of the Pthlh gene and that produces Thr/ Pro PTHrP variants. Pthlh(Thr) and Pthlh(Pro) alleles were significantly linked with resistance and susceptibility to skin carcinogenesis in phenotypically selected Car-R and Car-S outbred mice. Transfection of human NCI-H520 squamous cell carcinoma cells with the Pthlh(Pro) allele resulted in cells growing in clusters, tending to pile up, and growing at a significantly faster rate in nude mice than non-transfected and Pthlh(Thr)-transfected cells. These results point to the role of the Pthlh gene as a cancer modifier gene in skin tumorigenesis.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, ICU, I-20133 Milan, Italy; ENEA CR Casaccia, Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		Dragani, Tommaso A./K-4493-2016; Peissel, Bernard/E-8187-2017; Zaffaroni, Daniela/I-8731-2017; Manenti, Giacomo/J-3339-2017; Gariboldi, Manuela/K-4744-2016	Dragani, Tommaso A./0000-0001-5915-4598; Peissel, Bernard/0000-0001-9233-3571; Zaffaroni, Daniela/0000-0002-6995-2216; Manenti, Giacomo/0000-0002-4887-4482; Saran, Anna/0000-0002-5587-064X; Gariboldi, Manuela/0000-0001-8406-165X				BANGRAZI C, 1990, CARCINOGENESIS, V11, P1711, DOI 10.1093/carcin/11.10.1711; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Hastings RH, 1999, CHEST, V116, p68S, DOI 10.1378/chest.116.suppl_1.68S; Hastings RH, 1997, AM J PHYSIOL-LUNG C, V272, pL394, DOI 10.1152/ajplung.1997.272.3.L394; Hastings RH, 1996, AM J PHYSIOL-LUNG C, V270, pL353, DOI 10.1152/ajplung.1996.270.3.L353; HEATH DA, 1990, LANCET, V335, P66, DOI 10.1016/0140-6736(90)90537-F; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HOLICK MF, 1994, P NATL ACAD SCI USA, V91, P8014, DOI 10.1073/pnas.91.17.8014; Iwamura M, 1999, CANCER, V86, P1028, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1028::AID-CNCR19>3.0.CO;2-G; Kremer R, 1996, AM J PHYSIOL-CELL PH, V271, pC164, DOI 10.1152/ajpcell.1996.271.1.C164; LI X, 1993, CANCER RES, V53, P2980; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MANGIN M, 1990, GENE, V95, P195, DOI 10.1016/0378-1119(90)90362-U; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; PEISSEL B, 2000, IN PRESS MAMM GENOME; Saran A, 1996, CARCINOGENESIS, V17, P2463, DOI 10.1093/carcin/17.11.2463; *SAS I, 1988, SAS; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Takai E, 1996, CANCER-AM CANCER SOC, V78, P1384, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1384::AID-CNCR3>3.0.CO;2-L; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	24	28	30	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5324	5328		10.1038/sj.onc.1203916	http://dx.doi.org/10.1038/sj.onc.1203916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103933	Bronze			2022-12-28	WOS:000165302300003
J	Van Rompaey, L; Potter, M; Adams, C; Grosveld, G				Van Rompaey, L; Potter, M; Adams, C; Grosveld, G			Tel induces a G1 arrest and suppresses Ras-induced transformation	ONCOGENE			English	Article						Tel; transformation; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; MEDIATED CELLULAR-TRANSFORMATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HEMATOLOGIC MALIGNANCIES; MYELOPROLIFERATIVE DISORDERS; TRANSCRIPTIONAL REPRESSOR; CONGENITAL FIBROSARCOMA; TUMOR-SUPPRESSOR	The Tel gene is a major target of translocations in leukemia and loss of heterozygosity is regularly observed for the non-translocated allele, thus supporting the notion that Tel is a tumor suppressor. Most tumor suppressors influence cellular proliferation, differentiation and cell death and thereby prevent oncogenic transformation and genetic instability. We found that overexpression of Tel retards proliferation of many cell types, primary cells and immortalized cells, by inducing a G1 arrest. Tel's block of cellular proliferation is rescued by high seeding densities. Furthermore, Tel suppressed Ras-mediated colony growth in soft agar and tumor formation in nude mice. The Pointed and DNA binding (DB) domains of Tel were required for all Tel-induced phenotype.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Grosveld, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.				NCI NIH HHS [CA21765, CA72999-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Du W, 1999, CANCER RES, V59, P2059; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hoglund M, 1996, BLOOD, V87, P324, DOI 10.1182/blood.V87.1.324.bloodjournal871324; Iijima Y, 2000, BLOOD, V95, P2126; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; KWIATKOWSKI B, 1999, AM SOC HEMATOLOGY, V94, pA1155; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; La Starza R, 1999, BRIT J HAEMATOL, V107, P340, DOI 10.1046/j.1365-2141.1999.01724.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Sato Y, 1997, BLOOD, V90, P4886; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	62	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5244	5250		10.1038/sj.onc.1203899	http://dx.doi.org/10.1038/sj.onc.1203899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077441				2022-12-28	WOS:000165059700005
J	Bondzi, C; Grant, S; Krystal, GW				Bondzi, C; Grant, S; Krystal, GW			A novel assay for the measurement of Raf-1 kinase activity	ONCOGENE			English	Article						Raf-1; activation-specific antibody; kinase assay	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BIOLOGICAL-ACTIVITY; V-RAF; TAXOL; RESIDUES; GROWTH	Raf-1 is a serine-threonine protein kinase that functions as a central component of the mitogen-activated protein kinase signal transduction pathway, Raf-1 activity is currently assayed in vitro by either measuring P-32 incorporation into MEK, Raf-1's only characterized substrate, or by using the phosphorylated MEK to initiate a coupled assay culminating in the phosphorylation of myelin basic protein by MAP kinase, These assays are plagued by a potential lack of specificity in the case of the former, and the time consuming and error-prone nature of the later indirect assay, In this report, we demonstrate a novel single step assay for Raf-1 kinase activity based on phosphorylation of recombinant MEK-1, detected using an activation-specific MEK antibody that recognizes MEK only when specifically phosphorylated by Raf-1 on Ser 217 and Ser 221, The assay readily detected stem cell factor-mediated Raf-1 activation, MEK phosphorylation by immunoprecipitated Raf-1 plateaued at 10 min following initiation of the kinase reaction and was completely dependent on the inclusion of Raf-1 There was a linear correlation between the degree of MEK phosphorylation and the amount of Raf-1 protein immunoprecipitated, In addition to detecting growth factor-mediated activation, the assay was also able to detect paclitaxel-mediated Raf-1 activation, This assay is rapid, sensitive, and specific and therefore is a marked improvement over currently utilized techniques.	McGuire VA Med Ctr, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol Immunol, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Virginia Commonwealth University	Krystal, GW (corresponding author), McGuire VA Med Ctr, 111K,1201 Broad Rock Blvd, Richmond, VA 23249 USA.				NATIONAL CANCER INSTITUTE [R01CA083705, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA83705, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Krystal GW, 1998, CANCER RES, V58, P4660; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOU Z, 1997, MOL CELL BIOL, V17, P46; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MARIAS R, 1995, EMBO J, V14, P3136; OKUDA K, 1992, BLOOD, V79, P2880; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROWINSKY EK, 1988, CANCER RES, V48, P4093; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Torres K, 1998, CANCER RES, V58, P3620; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	29	22	22	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5030	5033		10.1038/sj.onc.1203862	http://dx.doi.org/10.1038/sj.onc.1203862			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042690				2022-12-28	WOS:000089834300010
J	Cheng, QW; Lee, HH; Li, Y; Parks, TP; Cheng, GH				Cheng, QW; Lee, HH; Li, Y; Parks, TP; Cheng, GH			Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappa B inhibition	ONCOGENE			English	Article						NF-kappa B; Bcl-x; Bfl-1; chemoresistance; chemosensitization	ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; UP-REGULATION; ACTIVATION; EXPRESSION; RECEPTORS; INDUCTION; SURVIVAL; PROTEIN; C-IAP2	In A549 human lung adenocarcinoma cells, we found that TNF-alpha and several commonly used chemotherapeutic agents upregulated the expression of Bcl-x and/or Bfl-1/A1 through an NF-kappa B-dependent pathway. While parental A549 cells were resistant to the cytotoxic effects of both TNF-alpha and chemotherapy agents, NF-kappa B-blocked A549 cells were sensitized to both. Expression of either Bcl-x or Bfl-1/A1 in the NF-kappa B-deficient cells at physiological levels provided differential protection against TNF-alpha and chemotherapeutic treatment. These studies provide a potential mechanism for the phenomenon of chemotherapy-induced chemoresistance, and also reveal a potential strategy by which chemoresistance can be overcome.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; CuraGen Corp, New Haven, CT 06511 USA; Cellegy Pharmaceut Inc, S San Francisco, CA 94080 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU Z, 1997, CELL, V87, P565; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	21	91	98	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4936	4940		10.1038/sj.onc.1203861	http://dx.doi.org/10.1038/sj.onc.1203861			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039911				2022-12-28	WOS:000089757800016
J	Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX				Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX			Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells	ONCOGENE			English	Article						disabled-2; cell positioning; extracellular matrix; basement membrane; Ras pathway	CYTOPLASMIC DOMAIN; APOPTOSIS; INTEGRIN; RECEPTOR; BRAIN; GENE; ORGANIZATION; SUPPRESSION; DOWNSTREAM; DISRUPTION	The physical interaction of epithelial cells with the basement membrane ensures correct positioning and acts as a survival factor for epithelial cells. Cells that detach from the basement membrane often undergo apoptosis; however, in carcinomas, this positional control is absent, permitting disorganized cell proliferation. In the majority of breast and ovarian carcinomas (85-90%), the expression of a candidate tumor suppressor, Disabled-2 (Dab2), is frequently lost. The Dab2-negative tumor cells are no longer in contact with an intact basement membrane, as indicated by the absence of collagen IV (in about 90% of cases), However, in the subset (10-15%) of ovarian tumors in which Dab2, expression is positive, the presence of a basement membrane-like structure around tumor cells was observed. Recombinant adenovirus-mediated expression of Dab2 was used in Dab2-negative ovarian and breast cancer cells, and re-expression of Dab2 was found to lead to cell death or growth arrest. Dab2 expression suppressed MAPK activation and c-fos expression, Plating the infected cells on a basement membrane matrigel rescued the cells from death and growth arrest. Thus, Dab2 exhibits a negative activity for cell growth and survival, which can be countered by attachment of the cells to basement membrane matrix. We conclude that Dab2 functions in cell positioning control and mediates the exigency for basement membrane attachment of epithelial cells, Loss of Dab2 may contribute to the basement membrane-independent, disorganized proliferation of tumor cells in ovarian and breast carcinomas.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Fox Chase Cancer Center; Emory University; Emory University; Emory University; Amgen	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		sheng, zejuan/H-3034-2013		NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79716, CA 75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goffinet AM, 1997, NATURE, V389, P668, DOI 10.1038/39453; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Rice DS, 1998, DEVELOPMENT, V125, P3719; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; THOMSON M, 1991, CAN J PUBLIC HEALTH, V82, P203; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vignoud L, 1997, J CELL SCI, V110, P1421; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WONG KK, 1993, INT J ONCOL, V3, P13; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; XU XX, 1995, J BIOL CHEM, V270, P14181	36	67	67	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4847	4854		10.1038/sj.onc.1203853	http://dx.doi.org/10.1038/sj.onc.1203853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039902				2022-12-28	WOS:000089757800007
J	Bagnoli, M; Tomassetti, A; Figini, M; Flati, S; Dolo, V; Canevari, S; Miotti, S				Bagnoli, M; Tomassetti, A; Figini, M; Flati, S; Dolo, V; Canevari, S; Miotti, S			Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression	ONCOGENE			English	Article						ovarian cancer; caveolin; alpha-folate receptor; transcriptional regulation	HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; BINDING PROTEIN EXPRESSION; D7S522 LOCUS 7Q31.1; IN-VIVO; PROMOTER ACTIVITY; TYROSINE KINASE; GENE-EXPRESSION; MEMBRANE; LINES	Caveolin (cav-1) and the GPI-anchored alpha-folate receptor (alpha FR) are membrane proteins both found associated to caveolar structures, Several studies in tumor cells independently reported cav-l downregulation and alpha FR overexpression, Here we analysed the expression of the two molecules in normal and tumor ovarian samples derived from fresh specimens and from cultured cell lines. Whereas normal ovary surface epithelial cells displayed only cav-l expression, ovarian tumor surgical samples and cell lines (COR, IGROV1, OVCAR3 and OVCA432) displayed high alpha FR and low-level or no cav-l expression, except those cell lines (SKOV3 and SW626) with the lower alpha FR expression, SKOV3, but not two alpha FR-negative non-ovarian cell lines, exhibited down-regulation of cav-l expression following stable alpha FR cDNA transfection, Conversely, cav-l transfection in IGROV1 cells led to downregulated alpha FR expression, together with formation of caveolar structures and reduction of growth capability, Moreover, cav-l expression was induced in IGROV1 cells by transfection with intracellular anti-alpha FR antibodies to downmodulate alpha FR expression, In cav-l transfected cells, transcriptional activity of the alpha FR-specific promoter P1 was reduced by 70% and an additional specific DNA-protein complex was identified by gel-shift assay, indicating that cav-l expression influences alpha FR gene transcription. Together these results support the notion that alpha FR and cav-l protein expression is reciprocally regulated in ovary cancer cells.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of L'Aquila	Miotti, S (corresponding author), Ist Nazl Tumori, Unit Mol Therapies, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		Dolo, Vincenza/AAB-2885-2021; Figini, Mariangela/K-8753-2016; Bagnoli, Marina/K-4773-2018; Tomassetti, Antonella/G-7906-2015	Dolo, Vincenza/0000-0003-0424-6676; Figini, Mariangela/0000-0001-9001-8754; Bagnoli, Marina/0000-0001-7655-4630; Tomassetti, Antonella/0000-0001-6772-9937				ALBERTI S, 1990, BIOCHEM BIOPH RES CO, V171, P1051, DOI 10.1016/0006-291X(90)90790-T; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BOTTERO F, 1993, CANCER RES, V53, P5791; CONEY LR, 1991, CANCER RES, V51, P6125; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Elwood PC, 1997, BIOCHEMISTRY-US, V36, P1467, DOI 10.1021/bi962070h; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Figini M, 1998, CANCER RES, V58, P991; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KRUK PA, 1990, LAB INVEST, V63, P132; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MIOTTI S, 1995, INT J CANCER, V63, P395, DOI 10.1002/ijc.2910630316; Miotti S, 1997, J CELL BIOCHEM, V65, P479; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; Miotti S, 2000, J CELL SCI, V113, P349; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ottone F, 1997, BRIT J CANCER, V76, P77, DOI 10.1038/bjc.1997.339; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAIKAWA Y, 1995, BIOCHEMISTRY-US, V34, P9951, DOI 10.1021/bi00031a018; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toffoli G, 1997, INT J CANCER, V74, P193, DOI 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F	38	75	76	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4754	4763		10.1038/sj.onc.1203839	http://dx.doi.org/10.1038/sj.onc.1203839			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032026				2022-12-28	WOS:000089528800010
J	Poirel, H; Lopez, RG; Lacronique, V; Della Valle, V; Mauchauffe, M; Berger, R; Ghysdael, J; Bernard, OA				Poirel, H; Lopez, RG; Lacronique, V; Della Valle, V; Mauchauffe, M; Berger, R; Ghysdael, J; Bernard, OA			Characterization of a novel ETS gene, TELB, encoding a protein structurally and functionally related to TEL	ONCOGENE			English	Article						transcriptional repression; ETS; TEL	FUSION PROTEIN; HUMAN LEUKEMIA; OLIGOMERIZATION; REPRESSOR; KINASE; BETA	The TEL/ETV6 gene is located at 12p13 and is frequently involved in chromosomal translocations in human malignancies usually resulting in the expression of fusion proteins between the amino terminal part of TEL, and either unrelated transcription factors or protein tyrosine kinases. We report here a novel gene named TELB which is located on human chromosomal band 6p21 and encodes a protein highly related to TEL, TELB is widely expressed in different tissues and, similarly to TEL encodes a sequence-specific transcriptional repressor.	Ctr Etud Polymorphisme Humain, U434, INSERM, F-75010 Paris, France; CNRS, UMR 146, Inst Curie, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bernard, OA (corresponding author), Ctr Etud Polymorphisme Humain, U434, INSERM, 27 Rue Juliette Dodu, F-75010 Paris, France.		Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/R-1938-2019; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392	13	28	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4802	4806		10.1038/sj.onc.1203830	http://dx.doi.org/10.1038/sj.onc.1203830			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032031				2022-12-28	WOS:000089528800015
J	Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL				Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL			Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation	ONCOGENE			English	Article						Ewing's sarcoma; ERK; MAPK; ras; EWS/FLI-1	EWINGS-SARCOMA TRANSLOCATION; EWS/FLI-1 FUSION GENE; PROTEIN-KINASE; DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; HUMAN TUMORS; FAMILY; GROWTH	The chimeric gene EWS/FLI-1, the hallmark of the Ewing's sarcoma and primitive neuroectodermal tumor family, encodes a fusion protein with enhanced transcriptional activation properties and preserved recognition of canonical ETS binding sites. Although EWS/FLI-1 alters the expression of various genes, the precise mechanism by which EWS/FLI-1 acts as an oncogene remains to be defined, In this study we report that members of the mitogen-activated protein kinase (MAPK) signaling pathway, ERK1 and ERK2, are constitutively activated in NTH 3T3 cells expressing EWS/FLI-1, Interference with ERK activation by either highly specific inhibitors of MEK1 or a dominant negative ras mutant profoundly impaired the ability of EWS/FLI-1 to transform NIH3T3 cells to growth in semi-solid medium. An EWS/FLI-1 mutant defective in DNA-binding and transcriptional activation failed to activate ERK ana was also defective in 3T3 cell transformation, Constitutive ERK activation was also evident in several human Ewing's sarcoma tumor-derived cell lines, Interestingly, cells expressing the type II EWS/FLI-1 fusion, recently demonstrated more potent in transcriptional activation, showed even greater MAPK activation than cells expressing the more common type I fusion, These results implicate ERK activation in EWS/ FLI-1 transformation and suggest that this signaling pathway may be important in the pathogenesis of Ewing's sarcoma.	UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ilaria, RL (corresponding author), UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, 5323 Harry Hines Blvd,MC 8593, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; CHEN SY, 1994, ONCOGENE, V9, P2691; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINER MH, 1994, BLOOD, V83, P43; Gioeli D, 1999, CANCER RES, V59, P279; Hahn RG, 1999, SCAND J UROL NEPHROL, V33, P222; HAWLEY RG, 1994, GENE THER, V1, P136; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin PP, 1999, CANCER RES, V59, P1428; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Patton SE, 1998, CANCER RES, V58, P2253; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ries L. A. G., 1999, SEER CANC STAT REV 1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	46	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4523	4530		10.1038/sj.onc.1203811	http://dx.doi.org/10.1038/sj.onc.1203811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002425				2022-12-28	WOS:000089236800009
J	Johnston, AM; Naselli, G; Gonez, LJ; Martin, RM; Harrison, LC; DeAizpurua, HJ				Johnston, AM; Naselli, G; Gonez, LJ; Martin, RM; Harrison, LC; DeAizpurua, HJ			SPAK, a STE20/SPS1-related kinase that activates the p38 pathway	ONCOGENE			English	Article						SPAK; STE20; SPS1; kinase; p38	STE20-LIKE PROTEIN-KINASE; GERMINAL CENTER KINASE; N-TERMINAL KINASE; SACCHAROMYCES-CEREVISIAE; APOPTOSIS; CLONING; LYMPHOCYTES; DOWNSTREAM; COMPONENTS; PROTEASES	We have cloned a member of the STE20/SPS1 protein kinase family from a transformed rat pancreatic beta cell line. SPAK (STE20/SPS1-related, proline alanine-rich kinase) belongs to the SPS1 subfamily of STE20 kinases and is highly conserved between species. SPAK is expressed ubiquitously, although preferentially in brain and pancreas. Biochemical characterization of SPAK catalytic activity demonstrates that is a serine/threonine kinase that can phosphorylate itself and an exogenous substrate in vitro. SPAK is immunoprecipitated from transfected mammalian cells as a complex with another, as yet uncharacterized, serine/threonine kinase which is capable of phosphorylating catalytically-inactive SPAK and myelin basic protein in an in vitro kinase assay. SPAK specifically activates the p38 pathway in cotransfection assays. Like MST1 and MST2, SPAK contains a putative caspase cleavage site at the junction of the catalytic domain and the C-terminal region. Full-length SPAK is expressed in the cytoplasm in transfected cells, while a mutant corresponding to caspase-cleaved SPAK is expressed predominantly in the nucleus. The similarity of SPAK to other SPS1 family members, its ability to activate the p38 pathway, in addition to its putative caspase cleavage site, provide evidence that SPAK may act as a novel mediator of stress-activated signals.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, PO, Melbourne, Vic 3050, Australia; Commonwealth Serum Labs, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Johnston, AM (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, PO, Melbourne, Vic 3050, Australia.							Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cahill MA, 1996, ONCOGENE, V13, P2087; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DeAizpurua HJ, 1997, J BIOL CHEM, V272, P16364, DOI 10.1074/jbc.272.26.16364; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; FRANK G, 1974, EUR J BIOCHEM, V44, P317; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HATZ P, 1994, J BIOL CHEM, V269, P16802; HEJTMANCIK JF, 1986, J BIOL CHEM, V261, P982; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	113	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4290	4297		10.1038/sj.onc.1203784	http://dx.doi.org/10.1038/sj.onc.1203784			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980603				2022-12-28	WOS:000089032900012
J	Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR				Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR			Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22	ONCOGENE			English	Article						boast cancer; BRCA1; BRCA2; familial; chromosome 8p	LINKAGE ANALYSIS; SHORT ARM; OVARIAN-CANCER; BRCA1; MUTATIONS; HETEROZYGOSITY; REGION	Several recent studies indicate that the majority of families with five or fen er cases of breast cancer and no cases of ovarian cancer are not due to BRCA1 or BRCA2. It has been proposed that a further breast cancer susceptibility gene that may account for some of these families is located on chromosome 8p12-p22, We have identified 31 site-specific breast cancer families that have a greater than 80% posterior probability of being due to genes other than BRCA1 or BRCA2. These families have been examined for linkage to 8p12-p22 using markers flanking the putative location of the gene. The overall multi-point LOD score is strongly negative across the whole 44 cM. The individual multi-point LOD score is negative in 23 families and only exceeds 0.5 in a single family (with a multi-point LOD score of 1.22). The maximum heterogeneity LOD score was 0.03 at marker D8S136 with estimated proportion linked (alpha) of 3% (95% CI 0-30%), These data do not lend support to the hypothesis that chromosome 8p12-p22 harbours a familial breast cancer susceptibility gene.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Strangeways Res Lab, CRC, Genet Epidemiol Unit, Cambridge, England; IARC, Lyon, France; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Utah, Sch Med, Div Genet Epidemiol, Salt Lake City, UT USA; Deutsch Krebsforschungszentrum, Div Genet Epidemiol, D-6900 Heidelberg, Germany	University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah; Helmholtz Association; German Cancer Research Center (DKFZ)	Rahman, N (corresponding author), Univ Wales Hosp, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.		Eccles, Diana/K-6327-2019; Rahman, Nazneen/B-8890-2012; DEVILEE, PETER/ABR-2140-2022; Rahman, Nazneen/D-2802-2013	Eccles, Diana/0000-0002-9935-3169; Teare, Marion Dawn/0000-0003-3994-0051; Rahman, Nazneen/0000-0003-4376-0440; Nathanson, Katherine/0000-0002-6740-0901				CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Serova OM, 1997, AM J HUM GENET, V60, P486; SPURR NK, 1995, CYTOGENET CELL GENET, V68, P148; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4170	4173		10.1038/sj.onc.1203735	http://dx.doi.org/10.1038/sj.onc.1203735			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962578				2022-12-28	WOS:000088955100011
J	Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A				Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A			Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients	ONCOGENE			English	Article						HCC; HBV; non-B; non-C; losses; amplifications	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN HEPATOCELLULAR CARCINOMAS; SQUAMOUS-CELL CARCINOMA; GENETIC CHANGES; TUMOR-SUPPRESSOR; ALLELIC LOSSES; SOLID TUMORS; SHORT ARM; HETEROZYGOSITY; DELETIONS	To discriminate among the chromosomal abnormalities associated with the etiology of hepatocellular carcinoma (HCC), we performed a comparative genomic hybridization (CGH) analysis on 34 HCCs resected on noncirrhotic livers from patients serologically negative for both hepatitis B (HBV) and C (HCV) viruses. The results mere compared to those of a previous analysis of 50 HCCs selected on the basis of their positivity for HBV infection, The majority of the abnormalities found in the HBV positive cases (losses of chromosome arms 1p, 8p, 6q, 13q and 14q and gains of 1q, 8q, 6p and 17q) were similarly detected in the virus negative specimens. In contrast, a significant decrease (40% on average) was observed for losses at 4q, 16q and 17p in non-viral HCC samples, suggesting that these abnormalities are tightly associated with HBV infection. Thus, in addition to a common pathway towards malignancy, a subset of alterations may preferentially contribute to virus-induced carcinogenesis. In a parallel CGH study of 10 fibrolamellar carcinomas, a rare subtype of HCC, me found in sis out of the seven informative cases, gains of chromosome arm Iq, This region, which is also preferentially amplified in non fibrolamellar tumors (58%), may contain an essential proto-oncogene commonly implicated in liver carcinogenesis.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France; Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, CNRS, URA 1967, Villejuif, France; Hop Beaujon, Anat Pathol Lab, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Dejean, A (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France.		Terris, Benoit/P-1497-2017; Pineau, Pascal/AAP-5614-2020; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				Arribas R, 1999, LAB INVEST, V79, P111; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; Boige V, 1997, CANCER RES, V57, P1986; CRAIG JR, 1980, CANCER, V46, P372, DOI 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; El-Rifai W, 1997, LAB INVEST, V77, P699; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kato A, 1998, DIGEST DIS SCI, V43, P1, DOI 10.1023/A:1018838731634; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lee DJ, 1997, CLIN CANCER RES, V3, P501; LEREBOURS F, 1999, GENE CHROMOSOME CANC, V2, P145; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; Mertens F, 1997, CANCER RES, V57, P2765; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Orsatti G, 1997, LIVER, V17, P152; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Puisieux A, 1997, PATHOL BIOL, V45, P864; RADFORD DM, 1995, CANCER RES, V55, P5180; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; Sambrook J., 2002, MOL CLONING LAB MANU; Schullerus D, 1999, INT J CANCER, V80, P22, DOI 10.1002/(SICI)1097-0215(19990105)80:1<22::AID-IJC5>3.0.CO;2-S; Schwerdtle RF, 1997, CANCER RES, V57, P5009; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; ZHANG X, 1994, CANCER RES, V54, P4177	39	89	94	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3733	3738		10.1038/sj.onc.1203713	http://dx.doi.org/10.1038/sj.onc.1203713			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949927				2022-12-28	WOS:000088568400005
J	Ghosh, AK; Yuan, W; Mori, Y; Varga, J				Ghosh, AK; Yuan, W; Mori, Y; Varga, J			Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators	ONCOGENE			English	Article						type I collagen; transforming growth factor-beta; coactivators; p300/CBP; signal transduction; Smads	GROWTH-FACTOR-BETA; ADENOVIRAL ONCOPROTEIN E1A; HISTONE ACETYLTRANSFERASES; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; BINDING-PROTEIN; RETINOIC ACID; DNA-BINDING; F9 CELLS; CBP	Transforming growth factor-beta (TGF-beta) stimulation of Type I collagen gene (COL1A2) transcription involves the Smad signal transduction pathway, but the mechanisms of Smad-mediated transcriptional activation are not fully understood. We now demonstrate that the ubiquitous transcriptional coactivators p300 and CREB-binding protein (CBP) enhanced basal as well as TGF-beta- or Smad3-induced COL1A2 promoter activity, and stimulated the expression of endogenous Type I collagen. The adenoviral E1A oncoprotein abrogated stimulation of COL1A2 activity in transfected fibroblasts, and reduced the basal level of collagen gene expression. This effect was due to specific interaction of E1A with cellular p300/CBP because (a) a mutant form of EIA defective in p300 binding failed to abrogate stimulation, and (b) forced expression of D300/CBP restored the ability of TGF-beta to stimulate COL1A2 promoter activity in the presence of EIA, The effect of p300 on COL1A2, transcription appeared to be due, in part, to its intrinsic acetyltransferase activity, as stimulation induced by a histone acetyltransferase-deficient mutant p300 was substantially reduced. Transactivation of COL1A2 by p300 involved the Smad signaling pathway, as Smad4-deficient cells failed to respond to p300, and stimulation nas rescued by overexpression of Smad4, Furthermore, minimal constructs containing only the Smad-binding CAGACA element of COL1A2 were transactivated by p300 in the presence of TGF-beta, These results indicate, for the first time, that the multifunctional p300/CBP coactivators play a major role in Smad-dependent TGF-beta stimulation of collagen gene expression in fibroblasts.	Univ Illinois, Coll Med, Sect Rheumatol MC733, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Varga, J (corresponding author), Univ Illinois, Coll Med, Sect Rheumatol MC733, 1158 Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.				NIAMS NIH HHS [AR-42309, AR-46390] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046390, R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIRIVIA JC, 1993, NATURE, V365, P855; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Muraoka M, 1996, ONCOGENE, V12, P1565; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SOBULO OM, 1997, P NATL ACAD SCI USA, V94, P10215; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	63	182	192	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3546	3555		10.1038/sj.onc.1203693	http://dx.doi.org/10.1038/sj.onc.1203693			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918613				2022-12-28	WOS:000088346500011
J	Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C				Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C			Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism	ONCOGENE			English	Article						GRO-alpha; KC; CXCR2; chemokines; squamous cell carcinoma	PROINFLAMMATORY CYTOKINE EXPRESSION; COLONY-STIMULATING FACTOR; FACTOR-KAPPA-B; CONSTITUTIVE ACTIVATION; ENVIRONMENT PROMOTES; CANCER-CELLS; NECK-CANCER; HUMAN HEAD; IN-VIVO; LINES	Growth Regulated Oncogene-alpha (GRO-alpha) is an autocrine growth factor in melanoma and is a member of the C-X-C family of chemokines which promote chemotaxis of granulocytes and endothelia through binding to CXC Receptor 2, We found previously that variants of murine squamous cell carcinoma PAM 212 which grow and metastasize more rapidly in vivo constitutively express increased levels of murine GRO-alpha, designated mGRO-alpha, or KC, We have examined the possible role of mGRO-alpha. expression in malignant progression of squamous cell carcinoma PAM 212 in homologous BALB/c and BALB CXC Receptor-2 deficient mice, Transfection of the PAM 212 cell line which exhibits low expression of GRO-alpha and malignant potential with a pActin-KC vector encoding mGRO-alpha enabled isolation of PAM-KC expressing cell lines, These PAM-KC transfectants displayed an increased rate of growth and metastasis in BALB/c mice, similar to the highly malignant phenotype observed in spontaneously occurring metastatic variants. Furthermore, the PAM-KC tumors showed an increase in infiltration of host leukocytes and CD31+ blood vessels, consistent with increased CXC chemokine activity. The increased growth of PAM-KC cells was attenuated in CXCR-2 deficient mice, indicating that the increased growth was dependent in part upon host cells responsive to the CXC chemokine, Together, these results show that a CXC chemokine such as GRO-alpha can promote malignant growth of murine squamous cell carcinoma by a host CXCR-2 dependent pathway.	Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Comm Immunol, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Chicago	Van Waes, C (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bldg 10,Rm 5D55,MSC-1419, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R37CA022677, R01CA022677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000016, ZIADC000016] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22677] Funding Source: Medline; NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BALENTIEN E, 1991, ONCOGENE, V6, P1115; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; COHEN RF, 1995, ARCH OTOLARYNGOL, V121, P202; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 1997, J CELL BIOCHEM, P90; Duffey DC, 1999, CANCER RES, V59, P3468; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GUTMAN M, 1994, CANCER BIOTHERAPY, V9, P163, DOI 10.1089/cbr.1994.9.163; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PAK AS, 1995, CLIN CANCER RES, V1, P95; PEKAREK LA, 1995, J EXP MED, V181, P435, DOI 10.1084/jem.181.1.435; Schrieber H, 1999, INFLAMMATION BASIC P, P1117; SEUNG LP, 1995, CANCER RES, V55, P5094; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Strieter RM, 1996, CHEMOKINES DIS, P195; VANWAES C, 2000, IN PRESS NEW FRONTIE; Weidner Noel, 1996, P167; Young MRI, 1997, INT J CANCER, V74, P69, DOI 10.1002/(SICI)1097-0215(19970220)74:1<69::AID-IJC12>3.0.CO;2-D; YUSPA SH, 1980, CANCER RES, V40, P4694	25	149	157	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3477	3486		10.1038/sj.onc.1203687	http://dx.doi.org/10.1038/sj.onc.1203687			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918606				2022-12-28	WOS:000088346500004
J	Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM				Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM			Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice	ONCOGENE			English	Article						medullary thyroid carcinoma; multiple endocrine neoplasia type 2B; human RET transgenic mice	TYROSINE KINASE; SOMATIC MUTATIONS; PROTOONCOGENE; 2A; ACTIVATION; GERMLINE; RECEPTOR; GENE	Multiple endocrine neoplasia type 2B (MEN 2B) is a familial cancer syndrome, in which the cardinal feature is medullary thyroid carcinoma (MTC), a malignant tumor arising from the calcitonin producing thyroid C-cells, MEN 2B is associated with a germline point mutation in the RET proto-oncogene, leading to a Met-->Thr substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein. we used the human calcitonin gene (CALC-1) promoter to generate transgenic mice expressing either the human RET oncogene with the MEN2B-specific 918 Met-->Thr mutation (CALC-MEN2B-RET) or the human nonmutated RET proto-oncogene (CALC-WT-AET) in the C-cells, At 20-22 months of age three out of eight CALC-MEN2B-RET transgenic founders presented with macroscopic bilateral MTC, In two founders nodular C-cell hyperplasia (CCH) was observed. Thyroid abnormalities were never observed in CALC-WT-RET transgenic mice or control non-transgenic mice analysed at this age. In some mice from established CALC-MEN2B-RET transgenic lines nodular CCH was observed from 8 months on whereas MTC was detected in 13% of mice from one CALC-MEN2B-RET line, from the age of 11 months on. These results show for the first time that the MEN2B mutation in the RET oncogene predisposes mice for MTC.	Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University	Acton, DS (corresponding author), Univ Utrecht, Med Ctr, Dept Internal Med, POB 85500, NL-3508 GA Utrecht, Netherlands.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P793; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; DONISKELLER H, 1993, HUM MOL GENET, V2, P1579; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HORN RC, 1951, CANCER, V4, P697, DOI 10.1002/1097-0142(195107)4:4<697::AID-CNCR2820040407>3.0.CO;2-8; Landsvater RM, 1996, CANCER RES, V56, P4853; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CANCER RES, V56, P1241; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; STEINER AL, 1968, MEDICINE, V47, P371, DOI 10.1097/00005792-196809000-00001; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0	23	64	65	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3121	3125		10.1038/sj.onc.1203648	http://dx.doi.org/10.1038/sj.onc.1203648			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871866				2022-12-28	WOS:000087903900011
J	Adryan, B; Decker, HJH; Papas, TS; Hsu, T				Adryan, B; Decker, HJH; Papas, TS; Hsu, T			Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila	ONCOGENE			English	Article						Drosophila; tracheal development; VHL; vascularization	BIOLOGICALLY-ACTIVE PRODUCT; ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN LIGASE COMPLEX; GENETIC INTERFERENCE; RENAL-CARCINOMA; CELL-MIGRATION; PROTEIN; ANGIOGENESIS; TRANSCRIPTION; HYPOXIA	von Hippel-Lindau disease is a hereditary cancer syndrome, Mutations in the VHL tumor suppressor gene predispose individuals to highly vascularized tumors. However, VHL-deficient mice die in utero due to a lack of vascularization in the placenta. To resolve the contradiction, we cloned the Drosophila VHL homologue (d-VHL) and studied its function. It showed an overall 50% similarity to the human counterpart and 76% similarity in the crucial functional domain: the elongin C binding site. The putative d-VHL protein can bind Drosophila elongin C in vitro. During embryogenesis, d-VHL is expressed in the developing tracheal regions where tube outgrowth no longer occurs, Reduced d-VHL activity (using RNA interference methodology) caused breakage of the main vasculature accompanied by excessive looping of smaller branches, whereas overexpression caused a general lack of vasculature. Importantly, human VHL can induce the same gain-of-function phenotypes, VHL is likely involved in halting cell migration at the end of vascular tube outgrowth. Loss of VHL activity can therefore lead to disruption of major vasculature las in the mouse embryo), which requires precise cell movement and tube fusion, or ectopic outgrowth from existing secondary vascular branches las in the adult tumors).	Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55131 Mainz, Germany	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Johannes Gutenberg University of Mainz	Hsu, T (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, HCC 334,86 Jonathan Lucas St, Charleston, SC 29425 USA.			Adryan, Boris/0000-0003-4588-7867; Hsu, Tien/0000-0003-2308-4297	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline; NIGMS NIH HHS [GM57843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Liu YR, 1999, DEVELOPMENT, V126, P1869; Mantrova EY, 1998, GENE DEV, V12, P1166; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	44	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2803	2811		10.1038/sj.onc.1203611	http://dx.doi.org/10.1038/sj.onc.1203611			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851083				2022-12-28	WOS:000087403600001
J	Levy, DE; Gilliland, DG				Levy, DE; Gilliland, DG			Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice	ONCOGENE			English	Article						growth control; myelodisplasin; tumor immunity; cytokine signaling	HEMATOPOIETIC-CELL LINES; SIGNAL-TRANSDUCTION PATHWAYS; INTERFERON-GAMMA RECEPTOR; DNA-BINDING ACTIVITY; TARGETED DISRUPTION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; LEISHMANIA-MAJOR; FUSION PROTEIN; NULL MUTATION	Stat proteins are latent transcription factors activated by tyrosine phosphorylation downstream of cytokine and growth factor receptors and have been implicated in a variety of cell growth regulatory pathways. Constitutive phosphorylation has also been observed in various transformed cell line and in primary malignant tissue, suggesting that Stat protein activation may contribute to the transformed phenotype. One method to distinguish between a causative role in malignancy as opposed to bystander phosphorylation from the increased tyrosine phosphorylation that accompanies transformation is to investigate cell growth and malignancy in the absence of particular Stat proteins using targeted gene disruptions in transgenic mice, Such studies show that Stat1 primarily mediates growth inhibitory signals and contributes to the host rejection of tumors, and that its activation in transformed cells is not necessary for malignancy. Activation of Stat5 can be both necessary and sufficient for malignant transformation, and single Stat5-target genes have been identified that are critical for heightened proliferation. Nonetheless, some malignancies that are characterized by constitutively phosphorylated Stat5 are not altered by the loss of StatS protein. Its role in these cases may be redundant with other transforming events that are in themselves sufficient to cause disease, rendering tyrosine phosphorylation of Stat5 unnecessary in these transformed cells.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Kaplan Canc Ctr, Sch Med, New York, NY 10016 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Howard Hughes Med Inst,Div Hematol & Oncol, Boston, MA 02115 USA	New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788				Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chai SK, 1997, J IMMUNOL, V159, P4720; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVY D, 1990, New Biologist, V2, P923; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Okuda K, 1996, ONCOGENE, V13, P1147; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shuai K, 1996, ONCOGENE, V13, P247; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sternberg DW, 1999, BLOOD, V94, p389A; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; SWIHART K, 1995, J EXP MED, V181, P961, DOI 10.1084/jem.181.3.961; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WAXMAN DJ, 1995, MOL PHARMACOL, V48, P790	57	89	91	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2505	2510		10.1038/sj.onc.1203480	http://dx.doi.org/10.1038/sj.onc.1203480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851049				2022-12-28	WOS:000087459400006
J	Ramana, CV; Chatterjee-Kishore, M; Nguyen, H; Stark, GR				Ramana, CV; Chatterjee-Kishore, M; Nguyen, H; Stark, GR			Complex roles of Stat1 in regulating gene expression	ONCOGENE			English	Review						constitutive transcription; negative regulation; interferons; growth factors; crosstalk	INTERFERON-GAMMA RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; KINASE INHIBITOR P21(WAF1/CIP1); NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; IFN-GAMMA; GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER	Stat1 is a fascinating and complex protein with multiple, yet contrasting transcriptional functions. Upon activation, it drives the expression of many genes but also suppresses the transcription of others, These opposing characteristics also apply to its role in facilitating crosstalk between signal transduction pathways, as it participates in both synergistic activation and inhibition of gene expression, Stat1 is a functional transcription factor even in the absence of inducer-mediated activation, participating in the constitutive expression of some genes. This review summarizes the well studied involvement of Stat1 in IFN-dependent and growth factor-dependent signaling and then describes the roles of Stat1 in positive, negative and constitutive regulation of gene expression as well as its participation in crosstalk between signal transduction pathways.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			chilakamarti, ramana/0000-0002-5153-8252				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ASHIZAWA K, 1989, J CLIN ENDOCR METAB, V69, P475, DOI 10.1210/jcem-69-2-475; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Boehm U, 1998, J IMMUNOL, V161, P6715; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Gollob JA, 1999, J IMMUNOL, V162, P4472; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Han MC, 1997, KSME INT J, V11, P1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Illa I, 1997, AM J PATHOL, V151, P81; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; Johnson LR, 1999, AM J PHYSIOL-CELL PH, V276, pC419, DOI 10.1152/ajpcell.1999.276.2.C419; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Krishnan K, 1996, ONCOGENE, V13, P125; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kung AWC, 1998, J MOL ENDOCRINOL, V20, P293, DOI 10.1677/jme.0.0200293; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li XX, 1998, BIOCHIMIE, V80, P703, DOI 10.1016/S0300-9084(99)80023-6; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, J IMMUNOL, V156, P3174; Min W, 1998, CIRC RES, V83, P815, DOI 10.1161/01.RES.83.8.815; Miyazaki A, 1999, ENDOCRINOLOGY, V140, P4214, DOI 10.1210/en.140.9.4214; Ogbourne S, 1998, BIOCHEM J, V331, P1; Ohe K, 1996, MOL ENDOCRINOL, V10, P826, DOI 10.1210/me.10.7.826; OHMORI Y, 1994, J IMMUNOL, V153, P2204; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OUCHI T, 2000, IN PRESS P NATL ACAD; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Qin HW, 1998, J IMMUNOL, V161, P6664; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TAMAI K, 1995, J BIOL CHEM, V270, P392, DOI 10.1074/jbc.270.1.392; TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VAIRO G, 1995, ONCOGENE, V10, P1969; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	124	235	243	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2619	2627		10.1038/sj.onc.1203525	http://dx.doi.org/10.1038/sj.onc.1203525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851061				2022-12-28	WOS:000087459400018
J	Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H				Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H			Bcl-X-L protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis	ONCOGENE			English	Article						TRAIL; Bcl-X-L; Bax; apoptosis; pancreatic carcinoma; human	MYELOMA CELLS; CYTOCHROME-C; DEATH DOMAIN; LIGAND TRAIL; B-CELLS; FAS; EXPRESSION; BCL-X(L); FAMILY; GENE	In this study we sought to clarify the role of the proapoptotic potential of mitochondria in the death pathway emanating from the TRAIL (APO-2L) and CD95 receptors in pancreatic carcinoma cells. We focused on the role of the Bcl-2 family member Bcl-X-L, using three pancreatic carcinoma cell lines as a model system, two of which have high (Panc-1, PancTuI) and one has low (Colo357) Bcl-X-L expression. In these cell lines, the expression of Bcl-X-L correlated with sensitivity to apoptosis induced by TRAIL or anti-CD95. Flow cytometric analysis revealed cell surface expression of TRAIL-Ri and TRAIL-R2 on PancTuI and Colo357, and TRAIL-R2 on Panc-1 cells. In Colo357 cells retrovirally transduced with Bcl-X-L, caspase-8 activation in response to treatment with TRAIL or anti-CD95 antibody was not different from parental cells and EGFP-transfected controls, however, apoptosis was completely suppressed as measured by the mitochondrial transmembrane potential Delta Psim, caspase-3 activity (PARP cleavage) and DNA-fragmentation, Inhibition of Bcl-X-L function by overexpression of Bax or administration of antisense oligonucleotides against Bcl-X-L mRNA resulted in sensitization of Panc-1 cells to TRAIL and PancTuI cells to anti-CD95 antibody-induced cell death. The results show that Bcl-X-L can protect pancreatic cancer cells from CD95- and TRAIL-mediated apoptosis, Thus, in these epithelial tumour cells the mitochondrially mediated 'type II' pathway of apoptosis induction is not only operative regarding the CD95 system but also regarding the TRAIL system.	Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Deutsch Krebsforschungszentrum, Tumor Immunol Program, Apoptosis Res Grp G0310, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen	Ungefroren, H (corresponding author), Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Trauzold, Anna/P-4398-2014; Kalthoff, Holger/B-1618-2010; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Alam MK, 1997, EUR J IMMUNOL, V27, P3485, DOI 10.1002/eji.1830271249; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BRAMHALL SR, 1997, INT J PANCREATOL, V21, P58; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Gauthier ER, 1996, CANCER RES, V56, P1451; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1999, CANCER RES, V59, P5683; Leverkus M, 2000, CANCER RES, V60, P553; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MEMON SA, 1995, J IMMUNOL, V155, P4644; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Perkins CL, 2000, CANCER RES, V60, P1645; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shinoura N, 1999, CANCER RES, V59, P4119; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, CANCER RES, V58, P1741; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WALCZAK H, 2000, CANCER RES, V60, P351; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhang XD, 1999, CANCER RES, V59, P2747	57	226	243	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5477	5486		10.1038/sj.onc.1203936	http://dx.doi.org/10.1038/sj.onc.1203936			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114725				2022-12-28	WOS:000165396100008
J	Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K				Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K			Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma	ONCOGENE			English	Article						cell cycle; G2 arrest; 14-3-3 sigma; hypermethylation; hepatocarcinogenesis	STRAND CONFORMATION POLYMORPHISM; DNA METHYLATION; CELL-CYCLE; CANCER; P16(INK4A); PROGRESSION; PROMOTER; PROTEIN; CLONING; LINES	The 14-3-3 sigma gene has been implicated in G2/M cell cycle arrest by p53, Frequent inactivation of the 14-3-3 sigma gene by hypermethylation of CpG islands has recently been reported in human breast carcinoma. The aim of this study was to examine the methylation status of CpG islands of the 14-3-3 sigma gene in hepatocellular carcinoma (HCC), The methylation status of the 14-3-3 sigma gene was evaluated in four normal liver tissues and 19 paired specimens of carcinoma and adjacent non-tumorous liver tissues using bisulfite-single strand conformation polymorphism (bisulfite-SSCP), a combination of sodium bisulfite modification and fluorescence-based polymerase chain reaction (PCR)-SSCP, The 14-3-3 sigma protein expression was examined by immunohistochemical staining. Hypermethylation of CpG islands of the 14-3-3 sigma gene was detected in 89% (17/19) of the HCC tissues but not in any of the four normal liver tissues. All of the 14 methylation-positive HCC samples analysed by immunohistochemistry showed loss of 14-3-3 sigma expression, while both of the methylation-negative HCC samples retained the expression, and a significant correlation was found between methylation and loss of expression. Lower levels of methylation were detected in adjacent non-tumorous liver tissues (6/16 in cirrhotic tissues and 1/3 in chronic hepatitis tissues), but the 14-3-3 sigma expression was retained in all of these tissues. In a methylation-positive HCC cell line, HLE, 5-aza-2'-deoxycytidine (5-aza-dC)-induced demethylation of CpG islands led to reactivation of gene expression, indicating that hypermethylation plays a causal role in inactivation of the 14-3-3 sigma gene in HCC, Hypermethylation and the resulting loss of expression of the 14-3-3 sigma gene corresponds to one of the most common abnormalities reported to date in HCC, suggesting their crucial role in the development and/or progression of HCC.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Kosei Gen Hosp, Dept Gastroenterol 3, Sapporo, Hokkaido 0600033, Japan; Sapporo Kosei Gen Hosp, Dept Clin Pathol, Sapporo, Hokkaido 0600033, Japan; Sapporo Med Univ, Dept Clin Pathol, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University; Sapporo Kosei General Hospital; Sapporo Kosei General Hospital; Sapporo Medical University	Sasaki, S (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Burri N, 1999, BIOTECHNIQUES, V26, P232, DOI 10.2144/99262bm10; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1999, GASTROENTEROLOGY, V116, P483, DOI 10.1016/S0016-5085(99)70146-0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JONES PA, 1999, NAT GENET, V11, P136; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Melis R, 1999, ELECTROPHORESIS, V20, P1055, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1055::AID-ELPS1055>3.0.CO;2-O; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; Ostergaard M, 1997, CANCER RES, V57, P4111; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tajima M, 1998, JPN J CANCER RES, V89, P262, DOI 10.1111/j.1349-7006.1998.tb00557.x; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Wilentz RE, 1998, CANCER RES, V58, P4740; Wong IHN, 1999, CANCER RES, V59, P71; Yamamoto H, 1999, CANCER RES, V59, P3313	37	213	227	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5298	5302		10.1038/sj.onc.1203898	http://dx.doi.org/10.1038/sj.onc.1203898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077447				2022-12-28	WOS:000165059700011
J	Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H				Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H			Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells	ONCOGENE			English	Article						HBx; p53; liver cancer; chemotherapeutic drug; subcellular localization; cytoplasmic sequestration	WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVITY; ADENOVIRUS TYPE-5; GENOTOXIC STRESS; GROWTH ARREST; CANCER; DNA; TRANSACTIVATION	Hepatitis B virus X (HBx) protein implicated in the development of liver cancer may inhibit the function of p53 tumor suppressor protein through cytoplasmic retention of p53 protein. Here, we attempt to investigate whether the functional inhibition of p53 protein by HBx protein is reversible. First, we provide the evidence for the association of endogenous p53 protein with HBx by co-immunoprecipitation in stable Chang cells that express HBx protein in an inducible manner (ChangX-34), By immunofluorescence microscopy, the major location of p53 protein of ChangX-34 cells was confirmed at the nuclear periphery as well as in the cytoplasm where HBx protein is mainly expressed. Surprisingly, anticancer drug, adriamycin induces the nuclear translocation of p53 protein sequestered in the cytoplasm, This change is accompanied by the restoration of p53 activity, which results in increased transcriptional activity at the p53-responsive DNA elements as well as increase of p21(WAF1) mRNA expression. Further, we observed the induction of cell death and G1 arrest in these cells upon adriamycin treatment regardless of HBx expression. Together, we demonstrate that functional inhibition of p53 protein through its cytoplasmic retention by HBx protein is reversible. These results may be extended into other tumors of which p53 activity is modulated by viral oncoproteins.	Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Ajou Univ Hosp, Dept Pathol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Microbiol, Suwon 442749, South Korea; Samsung Biomed Res Inst, Ctr Mol Med, Seoul, South Korea	Ajou University; Ajou University; Ajou University Hospital; Ajou University; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center	Cho, H (corresponding author), Ajou Univ, Sch Med, Dept Biochem, Wonchon Dong 5, Suwon 442749, South Korea.			Cho, Hyeseong/0000-0002-4672-8887; Yun, Chawon/0000-0002-0046-4732				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chresta CM, 1996, CANCER RES, V56, P1834; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; GIACCIA AJ, 1998, GENE DEV, V12, P3158; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Greenblatt MS, 1997, CANCER RES, V57, P426; Harris MP, 1996, CANCER GENE THER, V3, P121; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HENKLER F, 1995, CANCER RES, V55, P6084; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; JIANG D, 1993, ONCOGENE, V8, P2805; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim JR, 1998, EXP MOL MED, V30, P145, DOI 10.1038/emm.1998.21; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1997, CANCER RES, V57, P5137; MACGUIRE HF, 1991, SCIENCE, V252, P842; McCormick F, 1999, CANCER J SCI AM, V5, P139; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NATOLI G, 1995, J HEPATOL, V22, P14; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PRICE BD, 1994, CANCER RES, V54, P896; QIN S, 1998, HEPATOLOGY, V27, P1109; QUADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thomas M, 1996, ONCOGENE, V13, P265; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Urban S, 1997, HEPATOLOGY, V26, P1045, DOI 10.1002/hep.510260437; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	53	39	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5163	5172		10.1038/sj.onc.1203896	http://dx.doi.org/10.1038/sj.onc.1203896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064453				2022-12-28	WOS:000090124100005
J	Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P				Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P			NPDC-1, a regulator of neural cell proliferation and differentiation, interacts with E2F-1, reduces its binding to DNA and modulates its transcriptional activity	ONCOGENE			English	Article						cell proliferation; regulatory genes; regulatory proteins; neural differentiation	TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; SKELETAL-MUSCLE; DUAL MECHANISMS; CYCLE ARREST; EXPRESSION; KINASE; PHOSPHORYLATION; INHIBITION; REPRESSION	We have previously identified NPDC-1, a neural factor involved in the control of proliferation and differentiation, and we have shown that the stable introduction of NPDC-1 into transformed cells down-regulates cell proliferation both by increasing the generation time and by suppressing transformed properties. The data presented here indicate that, in vitro, NPDC-1 is able to interact with the transcription factor E2F-1 and some cell cycle proteins, such as D-cyclins and cdk2, In addition, two-hybrid experiments in mammalian cells show that the interaction between NPDC-1 and E2F-1 can also occur in vivo. This interaction reduces the binding of E2F-1 to DNA and its transcriptional activity. Taken together, the data suggest that NPDC-1 could influence cell cycle progression and neural differentiation through its association with E2F-1.	Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rouget, P (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.							BIOU V, 1988, PROTEIN ENG, V2, P185, DOI 10.1093/protein/2.3.185; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dupont E, 1998, J NEUROSCI RES, V51, P257, DOI 10.1002/(SICI)1097-4547(19980115)51:2<257::AID-JNR14>3.0.CO;2-5; GALIANA E, 1995, P NATL ACAD SCI USA, V92, P1560, DOI 10.1073/pnas.92.5.1560; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E., 1988, ANTIBODIES LAB MANUA; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEMESLEVARLOOT L, 1993, COMPUT APPL BIOSCI, V9, P37; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Muller H, 1997, MOL CELL BIOL, V17, P5508; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; UNGER R, 1989, PROTEINS, V5, P355, DOI 10.1002/prot.340050410; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x	35	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					5000	5009		10.1038/sj.onc.1203843	http://dx.doi.org/10.1038/sj.onc.1203843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042687				2022-12-28	WOS:000089834300007
J	Yuasa, M; Masutani, C; Eki, T; Hanaoka, F				Yuasa, M; Masutani, C; Eki, T; Hanaoka, F			Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene	ONCOGENE			English	Article						xeroderma pigmentosum variant (XPV); DNA polymerase eta; genomic structure; chromosome 6; mutation analysis; TATA-less promoter; translesion synthesis	DNA-POLYMERASE-ZETA; THYMINE DIMER; ULTRAVIOLET-LIGHT; MAMMALIAN-CELLS; MOUSE HOMOLOGS; REPLICATION; TRANSCRIPTION; EXTRACTS; BYPASS; HYPERMUTABILITY	The xeroderma pigmentosum variant (XP-V) is one of the most common forms of this cancer-prone syndrome. XP groups A through G are characterized by defective nucleotide excision repair, whereas the XP-V phenotype is proficient in this pathway. The XPV gene encodes DNA polymerase eta, which catalyzes an accurate translesion synthesis, indicating that the XPV gene contributes tumor suppression in normal individuals. Here me describe the genomic structure and chromosomal localization of the XPV gene, which includes 11 exons covering the entire coding sequence, lacks a TATA sequence in the upstream region of the transcription-initiation, and is located at the chromosome band 6p21.1-6p12, Analyses of patient-derived XP-V cell lines strongly suggested that three of four cell lines carried homozygous mutations in the XPV gene, The fourth cell line, XP1RO, carried heterozygous point mutations in the XPV gene, one of which was located at the splice acceptor site of exon 2, resulting in the omission of exon 2 from the mature mRNA, These findings provide a basis for diagnosis and therapy of XP-V patients.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MISRA RR, 1993, MOL CELL BIOL, V13, P1002, DOI 10.1128/MCB.13.2.1002; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; OKUMURA K, 1995, GENOMICS, V25, P274, DOI 10.1016/0888-7543(95)80135-9; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Svoboda DL, 1998, CANCER RES, V58, P2445; TAKAHASHI E, 1990, HUM GENET, V86, P14; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	40	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4721	4728		10.1038/sj.onc.1203842	http://dx.doi.org/10.1038/sj.onc.1203842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032022				2022-12-28	WOS:000089528800006
J	Sitterlin, D; Bergametti, F; Transy, C				Sitterlin, D; Bergametti, F; Transy, C			UVDDB p127-binding modulates activities and intracellular distribution of hepatitis B virus X protein	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA-binding protein; transactivation; apoptosis; nuclear import	NF-KAPPA-B; CELLULAR DNA-REPAIR; HBX PROTEIN; NUCLEAR IMPORT; GENE PRODUCT; DAMAGED DNA; TRANSACTIVATION FUNCTION; TRANSCRIPTION MACHINERY; BINDING; ACTIVATION	Mammalian hepatitis B, viruses encode a unique regulatory protein termed X, which is essential for infection and likely plays a role in the carcinogenic process associated with hepadnaviral infection. Among the numerous properties ascribed to X protein, two have been widely documented: promiscuous transcriptional transactivation and proapoptosis. However, full understanding of the mechanisms underlying these activities requires the identification of the genuine X partners among the multiple X-binding: host proteins. Here we show that (i) mutations in X protein, which markedly alter affinity for the host protein UVDDBp127, inactivate both transactivation and proapoptosis; (ii) ectopic fusion of a functional UVDDB-binding domain to a deficient binding;X mutant restored its activity; (iii) in contrast to the loss-of-binding mutants, a mutant with a strong gain-of-binding exerted trans-dominant negative effects on wt X activity and localized in the nucleus and (iv) increase in intracellular UVDDB concentration enhanced both wt X-mediated transactivation and apoptosis, Taken together, our data provide strong evidence for a common upstream step in X mode of action, consisting of its productive interaction with UVDDB, via a structurally and functionally autonomous module. In addition, they underscore a nuclear location step of the viral protein that depends on its ability to bind UVDDB.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Benning H, 1995, Ger J Ophthalmol, V4, P11; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1998, J VIROL, V72, P9359, DOI 10.1128/JVI.72.11.9359-9364.1998; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4417	4426		10.1038/sj.onc.1203771	http://dx.doi.org/10.1038/sj.onc.1203771			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980617				2022-12-28	WOS:000089271900012
J	Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H				Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H			Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappa B is enhanced by I kappa B alpha super-repressor and parthenolide	ONCOGENE			English	Article						breast cancer; parthenolide; paclitaxel; NF-kB	TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; SESQUITERPENE LACTONE; NEGATIVE REGULATION; DRUG-RESISTANCE; KINASE COMPLEX; CYCLIN D1; ACTIVATION; EXPRESSION; INHIBITION	The transcription factor nuclear factor-kappa B (NF-KB) regulates genes important for tumor invasion, metastasis and chemoresistance. Normally, NF-kappa B remains sequestered in an inactive state by cytoplasmic inhibitor-of-kappa B (I kappa B) proteins, NF-kappa B translocates to nucleus and activates gene expression upon exposure of cells to growth factors and cytokines, We and others have shown previously that NF-kappa B is constitutively active in a subset of breast cancers. In this study, we show that constitutive activation of NF-kappa B leads to overexpression of the antiapoptotic genes c-inhibitor of apoptosis 2 (c-IAP2) and manganese superoxide dismutase (Mn-SOD) in breast cancer cells, Furthermore, expression of the antiapoptotic tumor necrosis factor receptor associated factor 1 (TRAF1) and defender-against cell death (DAD-1) is regulated by NF-kappa B in certain breast cancer cells. We also demonstrate that NF-kappa B-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress I kappa B alpha required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells. The effect of NF-kappa B on paclitaxel-sensitivity appears to be specific to cancer cells because normal fibroblasts derived from embryos lacking p65 subunit of NF-kappa B and wild type littermate embryos were insensitive to paclitaxel-induced G2/M cell cycle arrest. Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of I kappa B alpha by inhibiting NF-kappa B DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. These results suggest that active ingredients of herbs with anti-inflammatory properties may be useful in increasing the sensitivity of cancers with constitutively active NF-kappa B to chemotherapeutic drugs.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Canc Res Inst, 1044 W Walnut St,R4-202, Indianapolis, IN 46202 USA.			Gelfanov, Vasily/0000-0001-5216-5227; Nakshatri, Harikrishna/0000-0001-8876-0052				Amato SF, 1998, CANCER RES, V58, P241; Ambrosone CB, 1999, CANCER RES, V59, P602; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; Ferlini C, 1997, BRIT J CANCER, V75, P884, DOI 10.1038/bjc.1997.156; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fukuda K, 1999, PLANTA MED, V65, P381, DOI 10.1055/s-2006-960795; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habtemariam S, 1998, PLANTA MED, V64, P683, DOI 10.1055/s-2006-957558; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang F, 1998, J PATHOL, V185, P382; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Legrand O, 1998, BLOOD, V91, P4480, DOI 10.1182/blood.V91.12.4480.412k28_4480_4488; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin ZP, 1998, CANCER RES, V58, P3059; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; Miyake H, 2000, CANCER RES, V60, P170; MURPHY JJ, 1988, LANCET, V2, P189; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Panvichian R, 1998, CANCER RES, V58, P4667; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PRICE JE, 1990, CANCER RES, V50, P717; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	76	256	275	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4159	4169		10.1038/sj.onc.1203768	http://dx.doi.org/10.1038/sj.onc.1203768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962577				2022-12-28	WOS:000088955100010
J	Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z				Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z			Mutations in the beta-propeller domain of the Drosophila brain tumor (brat) protein induce neoplasm in the larval brain	ONCOGENE			English	Article						invertebrate; tumorigenesis; tumor suppressor; neuroblastoma; plasmid rescue; NHL repeats	RNA-POLYMERASE-III; DECARBOXYLASE GENE-CLUSTER; RETINOBLASTOMA PROTEIN; SUPPRESSOR GENE; DOPA-DECARBOXYLASE; HUMAN HOMOLOG; RING FINGER; ZINC-FINGER; CAENORHABDITIS-ELEGANS; MALIGNANT NEOPLASMS	Inactivation of both alleles of the fruit fly D. melanogaster brain tumor (brat) gene results in the production of a tumor-like neoplasm in the larval brain, and lethality in the Larval third instar and pupal stages. We cloned the brat gene from a transposon-tagged allele and identified its gene product. hr nt encodes for an 1037 amino acid protein with an N-terminal B-box1 zinc finger followed ba a B-box2 zinc finger, a coiled-coil domain, and a C-terminal beta-propeller domain with six blades. All these motifs are known to mediate protein-protein interactions. Sequence analysis of four br at alleles revealed that all of them are mutated at the beta-propeller domain. The clustering of mutations in this domain strongly suggests that it has a crucial role in the normal function of Brat, and defines a novel protein motif involved in tumor suppression activity. The brat gene is expressed in the embryonic central and peripheral nervous systems including the embryonic brain. In third instar larva br nt expression was detected in the Larval central nervous sa stem including the brain and the ventral ganglion, in two glands - the ring gland and the salivary gland, and in parts of the foregut - the gastric caecae and the proventriculus. A second brat-like gene was found in D, melanogaster, and homologs were identified in the nematode, mouse, rat, and human. Accumulated data suggests that Brat may regulate proliferation and differentiation by secretion/transport mediated processes.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Technion Israel Institute of Technology; Johns Hopkins University	Lev, Z (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Arama, Eli/GYJ-0491-2022					Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CLINE TW, 1976, GENETICS, V83, pS16; DERENZINI M, 1991, VIRCHOWS ARCH B, V61, P1; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Frank DJ, 1998, J CELL BIOL, V140, P1321, DOI 10.1083/jcb.140.6.1321; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Gateff E, 1996, IN VIVO, V10, P211; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gateff E., 1978, GENETICS BIOL DROS B, V2b, P181; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; Hartenstein V., 1993, ATLAS DROSOPHILA DEV; HEDGECOCK EM, 1995, GENETICS, V141, P989; INOUYE S, 1986, EUR J BIOCHEM, V154, P417, DOI 10.1111/j.1432-1033.1986.tb09414.x; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McNellis TW, 1996, PLANT CELL, V8, P1491, DOI 10.1105/tpc.8.9.1491; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBERTSON HM, 1988, GENETICS, V118, P461; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; SMETANA K, 1970, CANCER RES, V30, P1149; Spradling AC, 1999, GENETICS, V153, P135; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; STATHAKIS DG, 1995, GENETICS, V141, P629; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK T, 1993, GENETICS, V135, P71; WATSON KL, 1994, J CELL SCI, P19; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015; WRIGHT TRF, 1976, GENETICS, V84, P287; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983	62	92	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3706	3716		10.1038/sj.onc.1203706	http://dx.doi.org/10.1038/sj.onc.1203706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949924				2022-12-28	WOS:000088568400002
J	Janji, B; Melchior, C; Vallar, L; Kieffer, N				Janji, B; Melchior, C; Vallar, L; Kieffer, N			Cloning of an isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-beta 1 stimulation	ONCOGENE			English	Article						integrin-linked kinase; integrin; TGF-beta; cDNA sequence; melanoma phosphorylation	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE; REGULATED EXPRESSION; NEGATIVE REGULATION; ADHESION; GENE; IDENTIFICATION; SURVIVAL; MICE	We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-beta 1 stimulation, Using mRNA from TGF-beta 1 stimulated HT-144 cells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1, Expression of ILK2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma tell lines, but not in normal human tissues, Moreover, stimulation of HT-144 cells with TGF-beta 1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA, Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a retombinant GST/beta 3 integrin cytoplasmic tail peptide, Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar, Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-beta 1.	Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, L-1150 Luxembourg, Luxembourg	Luxembourg Institute of Health; University of Luxembourg	Kieffer, N (corresponding author), Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, 162A Ave de la Faiencerie, L-1150 Luxembourg, Luxembourg.			Vallar, Laurent/0000-0002-4404-1010; JANJI, Bassam/0000-0002-9763-0943				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Gouon V, 1996, INT J CANCER, V68, P650; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 1999, INT J MOL MED, V3, P563; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Li DM, 1997, CANCER RES, V57, P2124; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MATSUMOTO K, 1995, CANCER METAST REV, V14, P205, DOI 10.1007/BF00690292; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Robertson GP, 1999, CANCER RES, V59, P3596; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0	33	27	30	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3069	3077		10.1038/sj.onc.1203640	http://dx.doi.org/10.1038/sj.onc.1203640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871859				2022-12-28	WOS:000087903900004
J	Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S				Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S			Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCFp45Skp2 pathway	ONCOGENE			English	Article						B-Myb; ubiquitination; p45(Skp2); cyclin A	KINASE INHIBITOR P27; PROTEASOME-DEPENDENT DEGRADATION; F-BOX PROTEIN; CELL-CYCLE; C-MYB; MESSENGER-RNA; BETA-CATENIN; IN-VIVO; A-MYB; ACTIVATION	B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-specific DNA binding protein expressed in virtually all proliferating cells, B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic effects of cyclin Dt and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level, We provide evidence that in addition to triggering B-Myb activity an important effect of cyclin A is to facilitate multiple ubiquitination of B-Myb, The C-terminal domain of B-Myb is of key importance in mediating this effect of cyclin A, Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its half-life is not affected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45(Skp2), respectively the E2 and E3 components of a ubiquitination pathway that regulates the G1/S transition, accelerates degradation of B-Myb, We show that B-Myb physically and functionally interacts with components of the Cdc34-SCFp45Skp2 ubiquitin pathway and propose that B-Myb degradation may be required for controlling the correct alternation of events during progression through the cell division cycle.	Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland; Univ Munster, Inst Biochem, D-48149 Munster, Germany	Novartis; University of Munster	Ferrari, S (corresponding author), Novartis Pharma AG, Dept Oncol, Klybeckstr 141, CH-4057 Basel, Switzerland.		Brondani, Vincent/AAB-8394-2021; Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bartsch O, 1998, BIOLOGY OF TUMORS, P31; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; CURRAN T, 1984, CELL, V36, P259; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Esposito V, 1997, CANCER RES, V57, P3381; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	58	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2986	2995		10.1038/sj.onc.1203618	http://dx.doi.org/10.1038/sj.onc.1203618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871850				2022-12-28	WOS:000087581400005
J	Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD				Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD			Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells	ONCOGENE			English	Article						telomerase; neural precursor cells; fibroblast growth factor 2	MOUSE TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; STEM-CELLS; NEURONAL DIFFERENTIATION; LYMPHOCYTE DEVELOPMENT; PROGENITOR CELLS; IMMORTAL CELLS; GLIOMA-CELLS; TUMOR-CELLS	During brain development, neuronal and glial cells are generated from neural precursors on a precise schedule involving steps of proliferation, fate commitment and differentiation. We report that telomerase activity is highly expressed during embryonic murine cortical neurogenesis and early steps of gliogenesis and progressively decreases thereafter during cortex maturation to be undetectable in the normal adult brain. We evidenced neural precursor cells (NPC) as the principal telomerase-expressing cells in primary cultures from E15 mouse embryo cortices, Their differentiation either in neurons or in glial cells lead to a down regulation of telomerase activity that was directly correlated to the decrease of telomerase core protein (mTERT) mRNA synthesis. Furthermore, we show that FGF2 (fibroblast growth factor 2), one of the main regulators of CNS development, induces a dose-dependant increase of both the proliferation of NPC and telomerase activity in primary cortical cultures without affecting the mTERT mRNA synthesis compared to that of glyceraldehyde-3-phosphate dehydrogenase (mGAPDH). Finally, we evidenced that AZT (3'-azido-2',3'-dideoxythymidine), known to inhibit telomerase activity, blocks in a dose dependant manner the FGF2-induced proliferation of NPC. Altogether, our results are in favor of an important role of telomerase activity during brain organogenesis.	CEA, Lab Radiopathol, DSV, DRR,IPSCI, F-92265 Fontenay Aux Roses, France; CEA, Serv Neurovirol, DSV, DRM,CRSSA,IPSC, F-92265 Fontenay Aux Roses, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boussin, FD (corresponding author), CEA, Lab Radiopathol, DSV, DRR,IPSCI, BP 6, F-92265 Fontenay Aux Roses, France.		Gauthier, Laurent/ABC-7614-2021; Haik, Stephane/M-7247-2018	Gauthier, Laurent/0000-0003-4644-7660; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Boussin, francois/0000-0003-3778-4403; Peyrin, Jean-Michel/0000-0002-8705-8672; Peyrin, Jean-Michel/0000-0002-0108-1266				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Engelhardt M, 1997, BLOOD, V90, P182; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; Gomez DE, 1998, BIOCHEM BIOPH RES CO, V246, P107, DOI 10.1006/bbrc.1998.8555; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Hiratochi M, 1998, DEV GROWTH DIFFER, V40, P59; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Ito H, 1998, CLIN CANCER RES, V4, P1603; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kruk PA, 1996, BIOCHEM BIOPH RES CO, V224, P487, DOI 10.1006/bbrc.1996.1054; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Melana SM, 1998, CLIN CANCER RES, V4, P693; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; Miyagi N, 1998, INT J ONCOL, V12, P1085; Multani AS, 1998, INT J ONCOL, V13, P923; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OLIVERO OA, 1993, MOL CARCINOGEN, V8, P81, DOI 10.1002/mc.2940080204; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Reichman TW, 1997, J CELL BIOCHEM, V67, P13, DOI 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strahl C, 1996, MOL CELL BIOL, V16, P53; Takakura M, 1998, CANCER RES, V58, P1558; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	70	54	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2957	2966		10.1038/sj.onc.1203596	http://dx.doi.org/10.1038/sj.onc.1203596			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871847				2022-12-28	WOS:000087581400002
J	Baksh, S; DeCaprio, JA; Burakoff, SJ				Baksh, S; DeCaprio, JA; Burakoff, SJ			Calcineurin regulation of the mammalian G(0)/G(1) checkpoint element, cyclin dependent kinase 4	ONCOGENE			English	Article						cell cycle; calcineurin; cdk4; cyclin activating kinase; Jurkat cells	RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; PHOSPHORYLATION; PHOSPHATASE; FAMILY; CELLS; NFAT; CDK4	Cyclin dependent kinase 4 (cdk8) activity is controlled by the binding of regulatory subunits and inhibitory factors, as well as tyrosine and serine/threonine phosphorylation, More recently the influence of calcium levels have been demonstrated. Using transient transfections in Jurkat cells, we observed specific binding between cdk4 and the calcium and calmodulin activated serine/threonine phosphatase, calcineurin. Furthermore, we demonstrated that the inhibition of the phosphatase activity of calcineurin with FK506 and cyclosporin A resulted in an overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin was inhibitory to the kinase activity of cdkA In contrast, we were not able to observe a similar effect on the kinase activity of either cdk6 or cdk2, indicating that the phosphatase activity of calcineurin was specific for cdk4, In addition, using an in vitro phosphatase assay for calcineurin, we observed that the exogenous addition of calcineurin resulted in the dephosphorylation of cdk4, an event that downregulated the kinase activity of cdk4 Calcineurin could, therefore, play an opposing role to the action of the cyclin activating kinase complex, an enzyme that upregulates the kinase activity of cdk4, an important G(0)/G(1) checkpoint element in mammalian cells.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Burakoff, SJ (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.		Baksh, Shairaz/GRX-2106-2022					Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KREK W, 1995, METHOD ENZYMOL, V254, P114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	23	47	49	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2820	2827		10.1038/sj.onc.1203585	http://dx.doi.org/10.1038/sj.onc.1203585			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851085				2022-12-28	WOS:000087403600003
J	Coffer, PJ; Koenderman, L; de Groot, RP				Coffer, PJ; Koenderman, L; de Groot, RP			The role of STATs in myeloid differentiation and leukemia	ONCOGENE			English	Review						STAT; cytokine; myeloid; Bcr-Abl; differentiation; leukemia	COLONY-STIMULATING FACTOR; CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; INDUCED ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIA CELL-LINE; MAMMARY-GLAND DEVELOPMENT; HEMATOPOIETIC STEM-CELLS; PERIPHERAL-BLOOD CELLS; ACUTE-PHASE RESPONSE; C-MYC TRANSCRIPTION	Myeloid differentiation is a highly regulated process governed by various cytokines, such as EPO, TPO, G-CSF, IL-3, IL-5 and GM-CSF, These cytokines act in part through activation of the STAT transcription factor family. Tn particular, various isoforms of STAT3 and STAT5 are activated during myeloid differentiation in a cell-type and maturation-state dependent fashion. In vitro studies hale shown that STAT proteins are essential for cytokine-regulated processes such as cellular proliferation, differentiation as well as survival. Similarly, various STAT knock-outs have highlighted the role of STATs in myeloid differentiation in vivo. STATs also appear to play an important role in various myeloid malignancies, which are characterized by arrested maturation and cytokine-independent proliferation of myeloid progenitors. Constitutive activation of STAT3 and/or STAT5 resulting in enhanced transcription of anti-apoptotic-cell-cycle progression genes is likely to contribute to the pathogenesis of various myeloid leukemia's.	Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University	de Groot, RP (corresponding author), SRON, Sorbennelaan 2, NL-3584 CA Utrecht, Netherlands.		Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; 				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Aronica MG, 1996, ONCOGENE, V13, P1017; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Belhoussine R, 1999, ADV EXP MED BIOL, V457, P365; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bovolenta C, 1996, FEBS LETT, V386, P239, DOI 10.1016/0014-5793(96)00453-X; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1999, Mol Cell Biol Res Commun, V1, P95, DOI 10.1006/mcbr.1999.0114; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARROLL M, 1995, P NATL ACAD SCI USA, V92, P2869, DOI 10.1073/pnas.92.7.2869; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; Chakraborty A, 1998, J LEUKOCYTE BIOL, V64, P675, DOI 10.1002/jlb.64.5.675; Chakraborty A, 1999, BLOOD, V94, p471A; Chakraborty A, 1996, BLOOD, V88, P2442, DOI 10.1182/blood.V88.7.2442.bloodjournal8872442; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Frank DA, 1996, LEUKEMIA, V10, P1724; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JIANG HP, 1994, ONCOGENE, V9, P3397; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Krosl J, 1996, J BIOL CHEM, V271, P27432, DOI 10.1074/jbc.271.44.27432; KRUGER A, 1991, ONCOGENE, V6, P245; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Lee C, 1999, J BIOL CHEM, V274, P26767, DOI 10.1074/jbc.274.38.26767; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lokuta MA, 1998, J IMMUNOL, V161, P1594; LOWENBERG B, 1993, BLOOD, V81, P281; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naik SM, 1997, J BIOL CHEM, V272, P1283, DOI 10.1074/jbc.272.2.1283; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OGAWA M, 1993, BLOOD, V81, P2844; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Orlofsky A, 1999, J IMMUNOL, V163, P412; Pinto A, 1998, CRIT REV ONCOL HEMAT, V27, P161, DOI 10.1016/S1040-8428(97)10029-4; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schuringa JJ, 1999, BLOOD, V94, p475A; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Shuai K, 1996, ONCOGENE, V13, P247; Smithgall TE, 1998, PHARMACOL REV, V50, P1; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Weber-Nordt RM, 1999, BLOOD, V94, p75A; WeberNordt RM, 1996, BLOOD, V88, P809; Welte T, 1997, EUR J IMMUNOL, V27, P2737, DOI 10.1002/eji.1830271038; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Williamson EA, 1997, LEUKEMIA, V11, P73, DOI 10.1038/sj.leu.2400551; Woldman I, 1997, J IMMUNOL, V159, P877; Xia Z, 1998, CANCER RES, V58, P3173; Yamada H, 1996, INT J HEMATOL, V65, P31; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	138	177	193	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2511	2522		10.1038/sj.onc.1203479	http://dx.doi.org/10.1038/sj.onc.1203479			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851050				2022-12-28	WOS:000087459400007
J	Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G				Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G			H19 gene expression is up-regulated exclusively by stabilization of the RNA during muscle cell differentiation	ONCOGENE			English	Article						H19; parental imprinting; post-transcriptional regulation; muscle cell differentiation	TUMOR-SUPPRESSOR GENE; MYC MESSENGER-RNA; FACTOR-II GENE; IMPRINTED GENES; ALPHA-FETOPROTEIN; IGF2 EXPRESSION; WILMS-TUMOR; METHYLATION; DELETION; TRANSCRIPTION	H19 is a paternally imprinted gene whose expression produces a 2.4 kb RNA in most tissues during development and in mammalian myoblastic cell lines upon differentiation. Deletion of the active maternal allele of H19 and its flanking regions in the mouse leads to biallelic methylation and loss of imprinting of the neighbouring Igf2 gene, The function of H19 RNA remains unknown and, although polysome-associated, the absence of a conserved open reading frame suggests that it does not encode a protein product. We describe a novel post-transcriptional regulation of H19 gene expression which,in spite of this lack of coding capacity, is dependent on translational activity. We show that stabilization of the RNA is solely responsible for its accumulation during in vitro muscle cell differentiation, This conclusion is based on the finding that inhibition of protein synthesis results in a dramatic destabilization of H19 RNA in proliferating mouse C2C12 myoblastic cells but not in differentiated cells, and on run-on experiments which showed that the rate of transcription of H19 RNA remains constant during muscle cell differentiation. This mechanism could also be involved in H19 gene expression during mouse development in addition to its transcriptional activation which we have shown to occur.	Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Cathala, G (corresponding author), Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, IFR 24,1919 Route de Mende, F-34293 Montpellier 5, France.		Bisbal, Catherine/I-6984-2016; Weber, Michael/P-1914-2016; Forne, Thierry/D-3718-2013	Bisbal, Catherine/0000-0003-1086-020X; Weber, Michael/0000-0003-3484-5821; Forne, Thierry/0000-0002-9179-1551; Milligan, Laura/0000-0001-6985-3034				Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashida T, 1997, J BIOCHEM-TOKYO, V122, P901; Hibi K, 1996, CANCER RES, V56, P480; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Jouvenot Y, 1999, CURR BIOL, V9, P1199, DOI 10.1016/S0960-9822(00)80026-3; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SINGER C, 1995, CANCER RES, V55, P2448; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; VACHER J, 1992, MOL CELL BIOL, V12, P856, DOI 10.1128/MCB.12.2.856; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; WISDOM R, 1990, J BIOL CHEM, V265, P19015; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; Yun K, 1996, AM J PATHOL, V148, P1081	52	38	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5810	5816		10.1038/sj.onc.1203965	http://dx.doi.org/10.1038/sj.onc.1203965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126368				2022-12-28	WOS:000165477700013
J	Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA				Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA			A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer	ONCOGENE			English	Article						glioma; lung cancer; MTAP; tumor suppressor gene	SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CUTANEOUS MALIGNANT-MELANOMA; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; CDKN2 GENE; SHORT ARM; P15 MTS2	Homozygous deletions of human chromosome 9p21 occur frequently in malignant cell lines, and are also common in primary gliomas, lung cancers, and leukemias. Moving from the centromere to the telomere, this complex region encodes the tumor suppressor genes p15(INK4B) (CDKN2B), p14(ARF), P16(INK4A) (CDKN2A), and the housekeeping gene methylthioadenosine phosphorylase (MTAP). However, not all chromosome 9p21 deletions in tumors include these tumor suppressor genes. Here we describe the partial sequence and the exact localization of a nerv gene on chromosome 9p21 centromeric of p15(INK4B) that formed an in frame fusion transcript with MTAP in a glioma xenograft, and that is homozygously deleted in various malignant cell lines, Northern blot revealed corresponding 1.5 kb transcript in non-deleted cell lines as well as in normal lymphocytes, Using a RNA master blot membrane including 50 different tissues, we could show that this new transcript is expressed in all tissues of the adult but not or only at very low levels in most of the fetal tissues tested. The expression pattern is similar to that of p16(INK4A). The localization as well as the deletion pattern makes this transcript a candidate for a new tumor suppressor gene.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Duke Univ, Dept Pediat, Durham, NC 27710 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University	Friedman, H (corresponding author), Univ Ulm, Room 4608,Robert Koch Str 8, D-89070 Ulm, Germany.				NCI NIH HHS [CA6976] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chen ZH, 1997, MOL PHARMACOL, V52, P903, DOI 10.1124/mol.52.5.903; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; HABUCHI T, 1995, ONCOGENE, V11, P1671; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hori Y, 1998, INT J CANCER, V75, P51, DOI 10.1002/(SICI)1097-0215(19980105)75:1<51::AID-IJC9>3.0.CO;2-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kim SK, 1997, CANCER RES, V57, P400; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; LI YJ, 1995, ONCOGENE, V11, P597; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Matsuura K, 1998, ANTICANCER RES, V18, P453; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PUIG S, 1995, AM J HUM GENET, V57, P395; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Stadler WM, 1996, UROL RES, V24, P239, DOI 10.1007/BF00295899; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Wiest JS, 1997, CANCER RES, V57, P1; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	33	44	47	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5747	5754		10.1038/sj.onc.1203942	http://dx.doi.org/10.1038/sj.onc.1203942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126361				2022-12-28	WOS:000165477700006
J	Qiu, Y; Kung, HJ				Qiu, Y; Kung, HJ			Signaling network of the Btk family kinases	ONCOGENE			English	Review						PH domain; Btk; tyrosine kinase; apoptosis; motility	BRUTONS-TYROSINE-KINASE; PLECKSTRIN HOMOLOGY DOMAINS; X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; BETA-GAMMA-SUBUNITS; PROSTATE-CANCER CELLS; SERUM RESPONSE FACTOR; RI CROSS-LINKING; FACTOR-KAPPA-B; SRC-FAMILY	The Btk family kinases represent new members of nonreceptor tyrosine kinases,which include Btk/Atk, Itk/Emt/Tsk, Bmx/Etk, and Tee. They are characterized by having four structural modules: PH (pleckstrin homology) domain, SH3 (Src homology 3) domain, SH2 (Src homology 2) domain and kinase (Src homology 1) domain. Increasing evidence suggests that, like Src-family kinases, Btk family kinases play central but diverse modulatory roles in various cellular processes, They participate in signal transduction in response to virtually all types of extracellular stimuli which are transmitted by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen-receptors and integrins, They are regulated by many non-receptor tyrosine kinases such as Src, Jak, Syk and FAK family kinases, In turn, they regulate many of major signaling pathways including those of PI3K, PLC gamma and PKC, Both genetic and biochemical approaches have been used to dissect the signaling pathways and elucidate their roles in growth, differentiation and apoptosis, An emerging new role of this family of kinases is cytoskeletal reorganization and cell motility, The physiological importance of these kinases was amply demonstrated hy their link to the development of immunodeficiency diseases, due to germ-line mutations. The present article attempts to review the structure and functions of Btk family kinases by summarizing our current knowledge on the interacting partners associated with the different modules of the kinases and the diverse signaling pathways in which they are involved.	Univ Calif Davis, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Ctr Canc, Sacramento, CA 95817 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kung, HJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 4645 2nd Ave, Sacramento, CA 95817 USA.		Kung, Hsing-Jien/C-7651-2013; Roszak, Joanna/F-4003-2010					Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Cory GOC, 1996, J IMMUNOL, V157, P3791; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Gibson S, 1996, J IMMUNOL, V156, P2716; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Islam TC, 2000, J GENE MED, V2, P204; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JUI HY, 2001, IN PRESS J BIOL CHEM; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MANO H, 1995, BLOOD, V85, P343; Mano H, 1999, INT J HEMATOL, V69, P6; MANO H, 1993, ONCOGENE, V8, P417; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Saharinen P, 1997, BLOOD, V90, P4341; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SATO K, 1994, LEUKEMIA, V8, P1663; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yang WC, 1999, EUR J IMMUNOL, V29, P1842, DOI 10.1002/(SICI)1521-4141(199906)29:06<1842::AID-IMMU1842>3.0.CO;2-D; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	112	175	210	4	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5651	5661		10.1038/sj.onc.1203958	http://dx.doi.org/10.1038/sj.onc.1203958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114746				2022-12-28	WOS:000165659300013
J	Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE				Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE			Adenovirus-mediated p16(INK4a) gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner	ONCOGENE			English	Article						apoptosis; adenovirus, p16(INK4a); p53; radiation; lung cancer	RETINOBLASTOMA-PROTEIN; P53; INHIBITION; RB; APOPTOSIS	We examined the influence of adenovirus-mediated wildtype p16(INK4n) (Ad/p16) expression on the radiation sensitivity of NSCLC cell lines, all of which lacked constitutive p16(INK4n) but each of which varied in p53 status: A549 (- p16(INK4n)/+pRb/wt-p53), H322 (- p16(INK4n)/ + pRb/mt-p53), and H1299 (- p16(INK4a)/ +pRb/deleted-p53). The in vitro clonogenic survival results indicate that Ad/p16 enhanced the radiosensitivity of A549 but not H322 or H1299. Further analysis indicated that the apoptosis induced by combination therapy using Ad/p16 plus irradiation was dependent on the endogenous p53 status of the cancer cells. We performed Western blotting to analyst the p53 protein expression of A549 cells treated with either Ad/p16 or Ad/Luc. Endogenous p53 protein levels were higher in A549 cells transfected with Ad/p16 than in those transfected with Ad/Luc. Furthermore, when wt-p53 protein expression was restored in H1299 using Ad/ p53, Ad/p16 stabilized p53 protein expression and radiosensitized the cells. These results suggest that Ad/ p16-induccd stabilization of p53 protein may play an important role in Ad/p16 mediated radiosensitization by enhancing or restoring apoptosis properties. Thus, Ad/p16 plus radiation in combination may be a useful gene therapy strategy for tumors that have wt-p53 but nonfunctional p16(INK4n).	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 066,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, P01CA006294, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA06294, CA16672, P01 CA78778] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG X, 1998, INT J ONCOL, V12, P665; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gallardo D, 1996, CANCER RES, V56, P4891; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; JIN X, 1996, ONCOGENE, V12, P103; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kratzke RA, 1996, CANCER RES, V56, P3415; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McPake CR, 1999, CANCER RES, V59, P4247; Miyakoshi J, 1997, JPN J CANCER RES, V88, P34, DOI 10.1111/j.1349-7006.1997.tb00298.x; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; NEVINS JR, 1992, SCIENCE, V258, P424; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	27	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5359	5366		10.1038/sj.onc.1203935	http://dx.doi.org/10.1038/sj.onc.1203935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103937				2022-12-28	WOS:000165302300007
J	Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA				Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA			Human cortactin as putative cancer antigen	ONCOGENE			English	Article						breast cancer; cortactin; cancer antigen; tumor marker	CHROMOSOME 11Q13 AMPLIFICATION; CYCLIN D1; EMS1 GENE; TUMOR-ANTIGENS; POOR-PROGNOSIS; BREAST-CANCER; CONTACT SITES; PHOSPHORYLATION; EMS1/CORTACTIN; OVEREXPRESSION	Humoral immune response against overexpressed oncogenic or tumor supressor proteins has been demonstrated for many types of cancer, In this study we report on the detection of the autologous antibody response to putative oncogene, human cortactin using serological analysis of breast carcinoma expression library. Cortactin maps to chromosome 11q13, the region amplified in about 15% of primary breast carcinomas and 30% of head and neck squamous cell carcinomas, Cortactin overexpression due to such amplification might affect adhesive properties of human cancer cells and is associated with poor disease prognosis, Accordingly, we detected overexpression of cortactin transcript in autologous tumor and amplification/overexpression of cortactin in tumors of breast cancer patients serologically positive for this marker, We demonstrate that 15% of breast cancer patients elicit humoral immune response against human cortactin.	Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia; Russian Acad Med Sci, Oncol Sci Ctr, Moscow, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Mol Immunol, Moscow 117984, Russia	Lomonosov Moscow State University; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Lagarkova, MA (corresponding author), Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia.		Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/L-1990-2015; Nedospasov, Sergei/C-3043-2018; Lagarkova, Maria/A-3296-2014	Meshcheryakov, Andrey/0000-0002-6009-653X; Lagarkova, Maria/0000-0001-9594-1134				BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brass N, 1999, BLOOD, V93, P2158, DOI 10.1182/blood.V93.7.2158.407a34_2158_2166; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1999, CANCER RES, V59, P5376; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schuuring E, 1998, CELL ADHES COMMUN, V6, P185, DOI 10.3109/15419069809004475; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	22	9	9	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5204	5207		10.1038/sj.onc.1203826	http://dx.doi.org/10.1038/sj.onc.1203826			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064458				2022-12-28	WOS:000090124100010
J	Holtrich, U; Wolf, G; Yuan, JP; Bereiter-Hahn, J; Karn, T; Weiler, M; Kauselmann, G; Rehli, M; Andreesen, R; Kaufmann, M; Kuhl, D; Strebhardt, K				Holtrich, U; Wolf, G; Yuan, JP; Bereiter-Hahn, J; Karn, T; Weiler, M; Kauselmann, G; Rehli, M; Andreesen, R; Kaufmann, M; Kuhl, D; Strebhardt, K			Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages	ONCOGENE			English	Article						polo-like kinase; adhesion; macrophages; serine/threonine kinase	POLO-LIKE KINASES; PROTEIN-KINASE; DROSOPHILA-POLO; SIGNAL-TRANSDUCTION; BINDING PROTEIN; GENE; IDENTIFICATION; CLONING; SPINDLE; CELLS	Members of the polo subfamily of protein kinases play crucial roles in cell proliferation. To study the function of this family in more detail,,ve isolated the cDNA of human Fnk (FGF-inducible kinase) which codes for a serine/threonine kinase of 646 aa, Despite the homology to the proliferation-associated polo-like kinase (Plk), tissue distribution of Fnk transcripts and expression kinetics differed clearly, In contrast to Pile no correlation between cell proliferation and Fnk gene expression was found. Instead high levels of Fnk mRNA were detectable in blood cells undergoing adhesion. The transition of monocytes from peripheral blood to matrix bound macrophages was accompanied by increasing levels of Fnk with time in culture. Neither treatment of monocytes with inducers of differentiation nor withdrawal of serum did influence Fnk mRNA levels significantly, suggesting that cell attachment triggers the onset of Fnk gene transcription, The idea that Fnk is part of the signalling network controlling cellular adhesion was supported by the analysis of the cytoplasmic distribution of the Fnk protein and the influence of its overexpression on the cellular architecture. Fnk as fusion protein with GFP localized at the cellular membrane in COS cells. Dysregulated Fnk gene expression disrupted the cellular f-actin network and induced a spherical morphology. Furthermore, Fnk binds to the Ca2+/integrin-binding protein Cib in two-hybrid-analyses and co-immunoprecipitation in assays. Moreover, both proteins were shown to co-localize in mammalian cells, The homology of Cib with calmodulin and with calcineurin B suggests that Cib might be a regulatory subunit of polo-like kinases.	Goethe Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Biol, D-60439 Frankfurt, Germany; Univ Hamburg, Zentrum Mol Neurobiol, ZMNH, D-20246 Hamburg, Germany; Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Rehli, Michael/E-9093-2011; Kuhl, Dietmar/A-4689-2009; Strebhardt, Klaus/E-8765-2011; Karn, Thomas/AAE-7723-2019; karn, t/C-7452-2013	Rehli, Michael/0000-0003-3992-932X; Kuhl, Dietmar/0000-0002-4772-6701; Karn, Thomas/0000-0002-3264-6573; karn, t/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				BEREITERHAHN J, 1990, J CELL SCI, V96, P171; BRIESEN HV, 1990, VIROLOGY, V178, P597; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LI B, 1996, J BIOL CHEM, V271, P19042; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; VUORI K, 1993, J BIOL CHEM, V268, P21459	38	44	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4832	4839		10.1038/sj.onc.1203845	http://dx.doi.org/10.1038/sj.onc.1203845			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039900				2022-12-28	WOS:000089757800005
J	Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH				Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH			Leukemic cell line, KG-1 has a functional loss of hOGG1 enzyme due to a point mutation and 8-hydroxydeoxyguanosine can kill KG-1	ONCOGENE			English	Article						KG-1; 8-hydroxyguanine; hOGG1; mutation; cytotoxicity	REMOVES 8-HYDROXYGUANINE RESIDUES; OXIDATIVE DNA-DAMAGE; ESCHERICHIA-COLI; ENDONUCLEASE ACTIVITY; OGG1 GENE; GLYCOSYLASE; CLONING; REPAIR; EXCISION; PROTEIN	We tested the cytotoxic action of 8-hydroxyguanine (8ohG) by observing the viability of several leukemic cell lines (KG-1, U937, Jurkat and K 562) in the presence of 8-hydroxydeoxyguanosine (8ohdG), a nucleoside of 8ohG, It was found that 8ohdG showed cytotoxic action only to KG-1 and that only KG-1 showed a homozygous arginine 209 to glutamine mutation in the hOGG1 gene with an almost negligible hOGG1 enzyme activity, Possibly, the selective cytotoxicity in 8ohdG to KG-1 may be due to its low capacity to cope with an increase in the 8ohG level in DNA resulting from the incorporation of 8ohdG present in the culture media. The mutational impairment of hOGG1 in KG-1 is the first report in leukemic cell lines. Using KG-1 with impaired hOGG1, we demonstrated cytotoxicity of 8ohdG probably due to its incorporation into cellular DNA. This new property of KG-1 may allow it to serve as an useful tool for studies of OGG1, oxidative DNA damage and the cytotoxic action of 8ohG.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, Seoul 110744, South Korea; Beijing Med Univ, Sch Pharmaceut Sci, Beijing 100083, Peoples R China; Korea Canc Ctr Hosp, Lab Radiat Effect, Nowon Gu, Seoul 139706, South Korea	Seoul National University (SNU); Peking University; National Cancer Center - Korea (NCC)	Chung, MH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, 28 Yongon Dong, Seoul 110744, South Korea.							Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CALABRESI P, 1991, GOODMAN GILMANS PHAR, P1227; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Choi JY, 1999, FREE RADICAL BIO MED, V27, P848, DOI 10.1016/S0891-5849(99)00141-0; CHUNG MH, 1991, BIOCHEM BIOPH RES CO, V178, P1472, DOI 10.1016/0006-291X(91)91059-L; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; LEE YS, 1993, BIOCHEM BIOPH RES CO, V196, P1545, DOI 10.1006/bbrc.1993.2427; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TU CPD, 1980, GENE, V10, P177, DOI 10.1016/0378-1119(80)90135-3; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	25	50	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4476	4479		10.1038/sj.onc.1203787	http://dx.doi.org/10.1038/sj.onc.1203787			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002420	Green Published			2022-12-28	WOS:000089236800004
J	Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E				Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E			CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70	ONCOGENE			English	Article						calcium; EGF; phospholipase C; Hsp70/Hsc70; signal transduction	SIGNAL-TRANSDUCTION; BCL-2-BINDING PROTEIN; MOLECULAR CHAPERONES; CALCIUM INFLUX; SH3 DOMAINS; CELL-DEATH; RECEPTOR; ACTIVATION; INHIBITION; C-GAMMA-1	CAIR-1/BAG-3 forms an EGF-regulated ternary complex with Hsp70/Hsc70 and latent phospholipase C-gamma (PLC-gamma). The expression of CAIR-1, CAI stressed-1, was induced in A2058 human melanoma cells by continuous exposure to CAI, an inhibitor of non voltage-gated calcium influx. CAIR-1 sequence is identical, save 2 amino acids, to BAG-3 also cloned recently as Bis, a member of the bcl-2-associated athanogene family. We show that CAIR-I/BAG-3 binds to Hsp70/Hsc70 in intact cells and this binding is increased by short term exposure to CAI (P<0.007). CAIR-1/BAG-3 is phosphorylated in vivo in the absence of stimulation. Basal phosphorylation is inhibited by treatment with d-erythrosphingosine (d-ES), a broad inhibitor of the protein kinase C family. CAIR-1/BAG-3 contains several PXXP SH3 binding domains leading to the hypothesis that it is a partner protein of phospholipase C-gamma. PLC-gamma is bound to CAIR-1/BAG-3 in unstimulated cells, It is increased by CAI or d-ES (P=0.05) treatment, and abrogated by EGF (r(2)=0.99); d-ES treatment blocks the EGF-mediated dissociation, We show that CAIR-1/BAG-3 binds to PLC-gamma and Hsp701/Hsc70 through separate and distinct domains. Hsp70/Hsc70 binds to the BAG domain of BAGs-1 and -3, CAIR-1/BAG-3 from control and EGF-treated cell lysates bound selectively to the SH3 domain of PLC-gamma, but not its N-SH2 or C-SH2 domains, Confirming the SH3 interaction, PLC-gamma was pulled down by CAIR-1/BAG-3 PXXP-GST fusions, but GST-PXXP constructs confronted with lysates from EGF-treated cells did not bind PLC-gamma as was seen in intact cells. Hsp70/Hsc70 was brought down by the PLC-gamma SH3 construct equally from native and EGF-treated cells, but did not bind the PXXP construct under either condition. We propose that CAIR-1/BAG-3 may act as a multifunctional signaling protein linking the Hsp70/Hsc70 pathway with those necessary for activation of the EGF receptor tyrosine kinase signaling pathways.	NCI, Mol Signaling Sect, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kohn, E (corresponding author), 10 Ctr Dr,10-2A33, Bethesda, MD 20892 USA.			Price, John/0000-0002-8244-1023				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chang JS, 1997, CANCER RES, V57, P5465; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; HATA A, 1993, J BIOL CHEM, V268, P9122; Hu YL, 1996, ONCOGENE, V12, P1865; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; KOHN EC, 1994, J BIOL CHEM, V269, P21505; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; SCHLIEF R, 1994, ADV ECHO AGENTS, V4, P5; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Yang H, 1998, ANTICANCER RES, V18, P1399; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	122	128	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4385	4395		10.1038/sj.onc.1203797	http://dx.doi.org/10.1038/sj.onc.1203797			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980614				2022-12-28	WOS:000089271900009
J	Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A				Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A			Activation of RSK by UV-light: phosphorylation dynamics and involvement of the MAPK pathway	ONCOGENE			English	Article						RSK; phosphorylation; UV radiation	RIBOSOMAL S6 KINASE; COFFIN-LOWRY-SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; KAPPA-B-ALPHA; PROTEIN-KINASE; MENTAL-RETARDATION; DOCKING SITE; CREB KINASE; HEAT-SHOCK; HISTONE H3	Ribosomal S6 kinases (RSKs) are serine/threonine kinases activated by mitogenic signals through the Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinases (MAPK/ERK), RSKs contain two heterologous complete protein kinase domains. Phosphorylation by ERK of the C-terminal kinase domain allows activation of the N-terminal kinase domain, which mediates substrate phosphorylation, In human, there are three isoforms of RSK (RSK1, RSK2, RSK3), whose functional specificity remains undefined. Importantly, we have shown that mutations in the RSK2 gene lead to the Coffin-Lowry syndrome (CLS), In this study, we characterize two monoclonal antibodies raised against phosphorylated forms of the N- and C-terminal domain of RSK2 (P-S227 and P-T577, respectively). Using these two antibodies, we show that stress signals, such as UV light, induce phosphorylation and activation of the three RSKs to an extent which is comparable to Epidermal Growth Factor (EGF)-mediated activation. The use of specific kinase inhibitors indicates that UV-induced phosphorylation and activation of RSK2 is mediated by the MAPK/ERK pathway, but that the Stress-Activated Protein Kinase 2 (SAPK2)/p38 pathway is also involved. These results modify the view of RSKs as kinases restricted to the mitogenic response and reveal a previously unappreciated role of MAPKs in stress induced signaling.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hanauer, A (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Strasbourg, France.			Merienne, Karine/0000-0003-2549-2315				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; Merienne K, 1998, J MED GENET, V35, P890, DOI 10.1136/jmg.35.11.890; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA Z, 1995, SCIENCE, V269, P403; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; ZHAO Y, 1996, J BIOL CHEM, V271, P29778	57	41	42	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4221	4229		10.1038/sj.onc.1203712	http://dx.doi.org/10.1038/sj.onc.1203712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980595				2022-12-28	WOS:000089032900004
J	Mastrangelo, T; Modena, P; Tornielli, S; Bullrich, F; Testi, MA; Mezzelani, A; Radice, P; Azzarelli, A; Pilotti, S; Croce, CM; Pierotti, MA; Sozzi, G				Mastrangelo, T; Modena, P; Tornielli, S; Bullrich, F; Testi, MA; Mezzelani, A; Radice, P; Azzarelli, A; Pilotti, S; Croce, CM; Pierotti, MA; Sozzi, G			A novel zinc finger gene is fused to EWS in small round cell tumor	ONCOGENE			English	Article						sarcoma; EWS; fusion; POZ/BTB domain; zinc finger	EWINGS-SARCOMA TRANSLOCATION; PLZF-RAR-ALPHA; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; DOMAIN; PROTEINS; LEUKEMIA; SEQUENCE; ALLELE	Ewing sarcoma family of tumors share recurrent translocations that fuse EWS from 22q12 to five different members of transcription factors namely FLI-1 ERG, ETV1, E1AF and FEV. Different classes of DNA binding proteins, ATF1, WT1 and CHOP are fused to EWS generating distinct tumor phenotypes: clear cell sarcoma, desmoplastic small round cell tumor, and myxoid liposarcoma, respectively. We have cloned a novel gene located at 22q12 fused to EWS by a submicroscopic inversion of 22q in a small round cell sarcoma showing a translocation (t(1;22)(p36.1;q12), The gene, designated ZSG (Zinc finger Sarcoma Gene), is a putative Cys(2)-His(2) zinc finger protein which contains a POZ transcriptional repressor-like domain at the N-terminus. The rearrangement involves intron 8 of EWS and exon 1 of ZSG creating a chimeric sequence containing the transactivation domain of EWS fused to zinc finger domain of ZSG, This product lacks the transcriptional repressor domain at the N-terminus of ZSG, A rearrangement of the second ZSG allele was also found in tumor cells. This is the first example of an intra-chromosomal rearrangement of chromosome 22, undetectable by cytogenetics, activating EWS in soft tissue sarcoma.	Ist Nazl Tumori, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Sozzi, G (corresponding author), Ist Nazl Tumori, Via Venezian 1, I-20133 Milan, Italy.		Radice, Paolo/O-3119-2013; Young, Richard A/F-6495-2012; Mezzelani, Alessandra/B-3355-2014; sozzi, gabriella/G-8259-2011; Testi, Maria Adele/D-6994-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Radice, Paolo/0000-0001-6298-4111; Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Testi, Maria Adele/0000-0002-9462-0336; Pierotti, Marco Alessandro/0000-0002-7431-8332; MEZZELANI, ALESSANDRA/0000-0001-7563-5869				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESMAZE C, 1994, CANCER GENET CYTOGEN, V74, P13, DOI 10.1016/0165-4608(94)90022-1; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Gerald WL, 1998, J CLIN ONCOL, V16, P3028, DOI 10.1200/JCO.1998.16.9.3028; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Katz RL, 1997, HUM PATHOL, V28, P502, DOI 10.1016/S0046-8177(97)90042-3; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; LADANYI M, 1994, CANCER RES, V54, P2837; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Ordi J, 1998, AM J SURG PATHOL, V22, P1026, DOI 10.1097/00000478-199808000-00014; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; SHISEKI M, 1994, CANCER RES, V54, P5643; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sozzi G, 1997, HUM PATHOL, V28, P134, DOI 10.1016/S0046-8177(97)90096-4; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695	28	121	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3799	3804		10.1038/sj.onc.1203762	http://dx.doi.org/10.1038/sj.onc.1203762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949935				2022-12-28	WOS:000088568400013
J	Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y				Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y			Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells	ONCOGENE			English	Article						anti-cancer agents; apoptosis; Bcl-2 family; ceramide; glioma cells; sphingomyelinase	DAUNORUBICIN-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C; DNA-DAMAGE; CHEMOTHERAPEUTIC-AGENTS; PERMEABILITY TRANSITION; ISOLATED-MITOCHONDRIA; FAMILY PROTEINS; T-CELLS; DEATH	Ceramide has recently been regarded as a potential mediator of apoptosis, In the present study, the effects of Bcl-2 and Bax on the ceramide-mediated apoptotic pathways mere examined in glioma cells overexpressing Bcl-2 or Bax. Etoposide, cisplatin and tumor necrosis factor-alpha induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3, The growth of C6 cells stably overexpressing either Bcl-2 or Bax was almost equal to that of the vector-transfected cells. Bas overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation. However, Bax had no effect on ceramide formation, Similar findings mere obtained in C6 cells and U87-MG human glioblastoma cells which mere transiently overexpressed with Bax. In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. Tn addition, transient overexpression of Bcl-xL also exerted inhibitory effects on ceramide formation and apoptotic cell death induced by etoposide, These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Decaudin D, 1997, CANCER RES, V57, P62; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KIM MY, 1991, J BIOL CHEM, V266, P484; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakakura C, 1997, SURG TODAY, V27, P676, DOI 10.1007/BF02388231; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWADA M, 2000, IN PRESS CELL DEATH; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Watts JD, 1999, TRENDS BIOCHEM SCI, V24, P228, DOI 10.1016/S0968-0004(99)01411-5; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN DX, 1995, CANCER RES, V55, P4922; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	64	81	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3508	3520		10.1038/sj.onc.1203699	http://dx.doi.org/10.1038/sj.onc.1203699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918609				2022-12-28	WOS:000088346500007
J	Vinos, J; Freeman, M				Vinos, J; Freeman, M			Evidence that Argos is an antagonistic ligand of the EGF receptor	ONCOGENE			English	Article						Argos; EGF receptor; antagonist; receptor; tyrosine kinase; Drosophila; growth factor	DROSOPHILA EYE; ACTIVATION; INHIBITION; PATHWAY; LOOP	Argos, the inhibitor of the Drosophila epidermal growth factor (EGF) receptor, remains the only known extracellular inhibitor of this family of receptors in any organism. The functional domain of Argos includes an atypical EGF domain and it is not clear whether it binds to the EGF receptor or if it acts via a distinct receptor to reduce Egfr activity indirectly. Here we present two lines of evidence that strongly suggest that Argos directly interacts with the EGF receptor. First, Argos is unable to inhibit a chimeric receptor that contains an extracellular domain from an unrelated RTK, indicating the need for the EGF receptor extracellular domain. Second, Argos can inhibit the Drosophila EGF receptor even when expressed in human cells, implying that no other Drosophila protein is necessary for inhibition. We also report that Argos and the Drosophila activating ligand, Spitz, can influence mammalian RTK activation, albeit in a cell-type specific manner. This includes the first evidence that Argos can inhibit signalling in mammalian cells, raising the possibility of engineering an effective human EGF receptor/Erbs antagonist.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Freeman, Matthew/0000-0003-0410-5451				Casci T, 1999, CANCER METAST REV, V18, P181, DOI 10.1023/A:1006313122373; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Golembo M, 1996, DEVELOPMENT, V122, P223; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Lohmeyer M, 1997, INT J ONCOL, V10, P677; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Stemerdink C, 1997, DEVELOPMENT, V124, P3787; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f	11	24	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3560	3562		10.1038/sj.onc.1203702	http://dx.doi.org/10.1038/sj.onc.1203702			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918615				2022-12-28	WOS:000088346500013
J	Arlt, DH; Baur, B; Wagner, B; Hoppner, W				Arlt, DH; Baur, B; Wagner, B; Hoppner, W			A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation	ONCOGENE			English	Article						MEN 2; RET-proto-oncogene; additional cysteine 634; ligand independent dimerization	NEOPLASIA TYPE 2A; TYROSINE KINASE; PROTOONCOGENE; GDNF; EXPRESSION; NEURTURIN	Multiple endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited canter syndrome, which involves the triad of MTC, pheochromocytoma, and hypcrparathyridism, Missense mutations in one of sis cysteine codons in the extracellular cysteine-rich domain of the RET proto-oncogene predispose to this disease. These mutations cause ligand-independent constitutive activation of the tyrosine kinase receptor by the formation of disulfide-bonded homodimers. We examined a different type of mutation, which results in an additional cysteine in the cysteine rich domain. A duplication of 9 bp in the first case resulted in an insertion of three amino acids between codon 633 and 634, In the second case a 12 bp duplication in exon 11 results in four additional amino acids between codon 634 and 635. Here we demonstrate that an additional cysteine causes a ligand independent dimerization of the RET receptor in transfected NIH3T3 cells, which results in an activation of the intracellular tyrosine kinase.	Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Neurosci, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Hoppner, W (corresponding author), Univ Hamburg, Inst Hormone & Fertil Res, Grandweg 64, D-22529 Hamburg, Germany.							AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Bongarzone I, 1999, ONCOGENE, V18, P4833, DOI 10.1038/sj.onc.1202848; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FATTORUSO O, 1998, HUM MUTAT S, V1, P167, DOI DOI 10.1002/HUMU.1380110156); Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	19	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3445	3448		10.1038/sj.onc.1203688	http://dx.doi.org/10.1038/sj.onc.1203688			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918602				2022-12-28	WOS:000088198100013
J	Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T				Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T			Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor	ONCOGENE			English	Article						protein kinase; tumor suppressor; cell cycle; mitosis; phosphorylation	MYOTONIC-DYSTROPHY KINASE; CELL-CYCLE; GENE DBF2; ENCODES; SEQUENCE	A novel human protein kinase, designated kpm, was identified and molecularly cloned. The isolated cDNA done had an open reading frame consisting of 1088 amino acid residues with a putative kinase domain located near the carboxy-terminus. Homology search revealed that kpm belongs to a subfamily of serine/threonine protein kinases including warts/lats, a Drosophila tumor suppressor. Among these, kpm is most homologous to, but distinct from, recently reported LATS1, a human homolog of DI Drosophila warts/lats. Northern blot analysis disclosed that kpm is expressed as a 6.0 kb transcript in most of the tissues examined and also as an additional shorter 4.0 kb transcript in testis, Western blotting using polyclonal rabbit anti-kpm antibody detected kpm protein as a band with an apparent M-r of 150 kD. Immune complex kinase assay of HA-tagged kpm showed that kpm had kinase activity and phosphorylated itself in vitro. Studies with synchronized HeLa cells indicated that kpm protein was expressed relatively constantly throughout the cell cycle and underwent significant phosphorylation at mitotic phase. These results suggest that kpm plays a role in cell cycle progression during mitosis and its deletion or dysfunction might be involved in certain types of human cancers.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hori, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Kawaracho, Kyoto 6068507, Japan.							HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KOEFFLER HP, 1980, BLOOD, V56, P265; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; VALLEJO AN, 1995, COLD SPRING HARBOR L; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU TA, 1995, DEVELOPMENT, V121, P1053; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	21	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3101	3109		10.1038/sj.onc.1203659	http://dx.doi.org/10.1038/sj.onc.1203659			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871863				2022-12-28	WOS:000087903900008
J	Lin, YC; Peng, JM; Wang, WB				Lin, YC; Peng, JM; Wang, WB			The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						simian virus 40 (SV40); small t antigen; T/t-common; HER-2/neu; tumor suppressor	E1A GENE-PRODUCTS; SV40 SMALL-T; OVARIAN-CANCER CELLS; SMALL TUMOR-ANTIGEN; RNA-POLYMERASE-II; NEU ONCOGENE; TRANSCRIPTIONAL REPRESSION; PROTEIN PHOSPHATASE-2A; MOLECULAR-CLONING; BREAST-CANCER	Overexpression of HER-2/neu (also known as c-erbB-2) proto-oncogene frequently occurs in many different types of human cancers, including ovarian carcinoma, and is known to enhance tumor metastasis and chemoresistance. Previous studies showed that inhibition of HER-2/neu expression by various agents, such as adenovirus E1A and simian virus 40 large T, can lead to suppression of tumorigenicity of HER-2/neu-overexpressing cancer cells. Here we report that T/t-common, which contains the N-terminal common domain of simian, virus 40 large T and small t antigens, could specifically repress the HER-2/neu promoter. When the coding sequence of T/t-common was stably transfected into the HER-2/neu-overexpressing human ovarian carcinoma SK-OV-3 cells, the expression of HER-2/neu was dramatically reduced by the expression of Tit-common. Accordingly the tumorigenic potential of these T/t-common-expressing clones, including the ability to grow anchorage-independently and the ability to induce tumor in nu/nu mice, was also drastically suppressed. Furthermore, when T/t-common was transiently cotransfected with the activated genomic neu into NIH3T3 cells, the transforming activity of the latter was suppressed by Tit-common in soft-agarose microcolony formation assays. Taken together, these data suggest that Tit-common may act as a transformation suppressor of the HER-2/neu oncogene.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei, Taiwan	National Taiwan University	Wang, WB (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, No 1,Jen Ai Rd,1st Sect, Taipei, Taiwan.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BERCHUCK A, 1990, CANCER RES, V50, P4087; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HARLOW E, 1988, ANTIBODES LAB MANUAL; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kao MC, 1998, ONCOGENE, V16, P547, DOI 10.1038/sj.onc.1201513; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Porras A, 1996, J VIROL, V70, P6902; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; RUBIN H, 1982, CELL, V30, P469, DOI 10.1016/0092-8674(82)90244-6; Rushton JJ, 1997, J VIROL, V71, P5620, DOI 10.1128/JVI.71.7.5620-5623.1997; Sambrook J., 2002, MOL CLONING LAB MANU; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STOKER M, 1968, NATURE, V218, P234, DOI 10.1038/218234a0; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG WB, 1994, J VIROL, V68, P6180, DOI 10.1128/JVI.68.10.6180-6187.1994; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2704	2713		10.1038/sj.onc.1203582	http://dx.doi.org/10.1038/sj.onc.1203582			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851070				2022-12-28	WOS:000087193000006
J	Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD				Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD			Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins	ONCOGENE			English	Article						CBF; CBF beta-SMMHC; AML1-ETO; cdk4; leukemia	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; MURINE MYELOPEROXIDASE; FUSION TRANSCRIPT	Core Binding Factor (CBF) is required for the development of definitive hematopoiesis, and the CBF oncoproteins AML1-ETO, TEL-AML1, and CBF beta-SMMHC are commonly expressed in subsets of acute leukemia. CBF beta-SMMHC slows the G1 to S cell cycle transition in hematopoietic cells, but the mechanism of this effect is uncertain, We have sought to determine whether inhibition of CBF-mediated trans-activation is sufficient to stow proliferation. We demonstrate that activation of KRAB-AML1-ER, a protein containing the AML1 DNA-binding domain, the KRAB repression domain, and the Estrogen receptor ligand binding domain, also slows G1, if its DNA-binding domain is intact, Also, exogenous AML1 overcame CBF beta-SMMHC-induced inhibition of proliferation, Representational difference analysis (RDA) identified cdk4 RNA expression as an early target of KRAB-AML1 activation. Inhibition of CBF activities by KRAB-AML1-ER or CBF beta-SMMHC rapidly reduced endogenous cdk4 mRNA levels, even in cells proliferating at or near control rates as a result of exogenous cdk4 expression, Over-expression of cdk4, especially a variant which cannot bind p16(INK4a) overcame cell cycle inhibition resulting from activation of KRAB-AML1-ER, although cdk4 did not accelerate proliferation when expressed alone. These findings indicate that mutations which alter the expression of G1 regulatory proteins can overcome inhibition of proliferation by CBF oncoproteins.	Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; The Wistar Institute	Friedman, AD (corresponding author), Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Canc Res Bldg,Room 255,1650 Orleans St, Baltimore, MD 21231 USA.				NHLBI NIH HHS [HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; BAE SC, 1993, ONCOGENE, V8, P809; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Herman JG, 1996, CANCER RES, V56, P722; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V88, P5167; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sepehri S, 1997, GENOME RES, V7, P1006, DOI 10.1101/gr.7.10.1006; SMITH IM, 1993, ENERG FUEL, V7, P7, DOI 10.1021/ef00037a003; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	57	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2695	2703		10.1038/sj.onc.1203588	http://dx.doi.org/10.1038/sj.onc.1203588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851069				2022-12-28	WOS:000087193000005
J	Meng, TC; Lee, MS; Lin, MF				Meng, TC; Lee, MS; Lin, MF			Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells	ONCOGENE			English	Article						androgen responsiveness; human prostate cancer; ErbB-2; prostatic acid phosphatase; tyrosine phosphorylation	NEGATIVE BREAST-CANCER; ACID-PHOSPHATASE; FACTOR RECEPTOR; CARCINOMA-CELLS; HORMONAL-THERAPY; MAMMARY-CARCINOMA; ESTROGEN-RECEPTOR; STEROID-HORMONES; ERBB RECEPTORS; POOR-PROGNOSIS	Steroid hormones play key roles in regulating cell proliferation and differentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a Set unknown mechanism even in the presence of functional steroid hormone receptors, We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates,vith a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr le,el, but not the protein level, of ErbB-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases, Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.	Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.		Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; LEE, MING-SHYUE/0000-0002-5884-4535	NCI NIH HHS [CA72274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; Bacus SS, 1996, AM J PATHOL, V148, P549; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BRASS AL, 1995, CANCER RES, V55, P3197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEWINTER JAR, 1990, J PATHOL, V160, P329, DOI 10.1002/path.1711600409; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANGER BO, 1984, ARCH BIOCHEM BIOPHYS, V235, P141, DOI 10.1016/0003-9861(84)90262-5; FOTI AG, 1977, CANCER RES, V37, P4120; Gioeli D, 1999, CANCER RES, V59, P279; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GLAUBER JG, 1992, SEMIN ONCOL, V19, P308; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISAACS JT, 1982, CANCER RES, V42, P5010; JANES PW, 1994, ONCOGENE, V9, P3601; Jensen E V, 1991, Curr Top Pathol, V83, P365; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; LATIL A, 1994, INT J CANCER, V59, P637, DOI 10.1002/ijc.2910590510; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 2000, IN PRESS CELL BIOL I; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; LIU XH, 1993, J CLIN ENDOCR METAB, V77, P1472, DOI 10.1210/jc.77.6.1472; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Lu S, 1997, CANCER RES, V57, P4511; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Marengo SR, 1997, MOL CARCINOGEN, V19, P165; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MILLER JI, 1992, J UROLOGY, V147, P956, DOI 10.1016/S0022-5347(17)37432-3; MURPHY LJ, 1986, CANCER RES, V46, P728; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; QUARMBY VE, 1990, CANCER RES, V50, P735; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; REIF AE, 1973, CANCER-AM CANCER SOC, V31, P689, DOI 10.1002/1097-0142(197303)31:3<689::AID-CNCR2820310331>3.0.CO;2-F; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1; Sandberg A A, 1980, Prog Clin Biol Res, V37, P9; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SCHUURMANS ALG, 1991, J STEROID BIOCHEM, V40, P193, DOI 10.1016/0960-0760(91)90182-5; SCOTT WW, 1980, CANCER-AM CANCER SOC, V45, P1929, DOI 10.1002/cncr.1980.45.s7.1929; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TENNISWOOD M, 1986, PROSTATE, V9, P375, DOI 10.1002/pros.2990090407; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WEISS C, 1990, LEUKEMIA RES, V14, P327, DOI 10.1016/0145-2126(90)90159-7; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; YAM LT, 1974, AM J MED, V56, P604, DOI 10.1016/0002-9343(74)90630-5; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YUAN SX, 1993, CANCER RES, V53, P1304; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386	90	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2664	2677		10.1038/sj.onc.1203576	http://dx.doi.org/10.1038/sj.onc.1203576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851066				2022-12-28	WOS:000087193000002
J	Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A				Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A			CBP/p300 histone acetyl-transferase activity is important for the G1/S transition	ONCOGENE			English	Article						CBP/p300; histone acetyl-transferase; proliferation; E2F; G1/S transition; microinjection	CREB-BINDING PROTEIN; ADENOVIRAL ONCOPROTEIN E1A; SERUM RESPONSE FACTOR; B-MYB TRANSCRIPTION; ACETYLTRANSFERASE ACTIVITY; P300/CBP-ASSOCIATED FACTOR; FUNCTIONAL COLLABORATION; REPRESS TRANSCRIPTION; CELL-DIFFERENTIATION; CHROMATIN DISRUPTION	Transforming viral proteins such as E1A which force quiescent cells into S phase have two essential cellular target proteins, Rb and CBP/p300, Rb regulates the G1/S transition by controlling the transcription factor E2F, CBP/p300 is a transcriptional co-activator with intrinsic histone acetyl-transferase activity. This activity is regulated in a cell cycle dependent manner and shows a peak at the G1/S transition, suggesting a function for CBP/p300 in this crucial step of the cell cycle. Here, we have artificially modulated CBP/p300 levels in individual cells through microinjection of specific antibodies and expression vectors. We show that CBP/p300 is required for cell proliferation and has an essential function during the G1/S transition. Using the same microinjection system and GFP-reporter vectors, we demonstrate that CBP/p300 is essential for the activity of E2F, a transcription factor that controls the G1/S transition. In addition, our results suggest that CBP HAT activity is required both for the G1/S transition and for E2F activity. Thus CBP/p300 seems to be a versatile protein involved in opposing cellular processes, which raises the question of how its multiple activities are regulated.	CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; CNRS, IFC 01, Lab Cytoretrie, F-94801 Villejuif, France; CNRS, UPR 9006, LBME, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Harel-Bellan, A (corresponding author), CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guys Moquet, F-94801 Villejuif, France.		Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015; Cabon, Florence/B-3284-2013	Cabon, Florence/0000-0002-6149-082X; Filleur, Stephanie/0000-0002-3420-5536; Trouche, Didier/0000-0003-1398-6481; Harel-Bellan, Annick/0000-0002-2339-153X				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bennett JD, 1996, ONCOGENE, V13, P1073; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chiarugi V, 1998, ONCOL RES, V10, P55; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1989, Princess Takamatsu Symp, V20, P191; Eckner R, 1996, BIOL CHEM, V377, P685; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Scolnick DM, 1997, CANCER RES, V57, P3693; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smits PHM, 1996, ONCOGENE, V12, P1529; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WEINBERG RA, 1992, CANCER SURV, V12, P43; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	67	111	113	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2430	2437		10.1038/sj.onc.1203562	http://dx.doi.org/10.1038/sj.onc.1203562			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828885				2022-12-28	WOS:000087018400008
J	Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ				Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ			Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas	ONCOGENE			English	Article						seminomas; nonseminomas; carcinoma in situ; 12p; gain	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; MOLECULAR CYTOGENETIC ANALYSIS; IN-SITU HYBRIDIZATION; CARCINOMA-INSITU; TESTIS; IDENTIFICATION; AMPLIFICATION; CANCER; PLOIDY	Overrepresentation of 12p-sequences, mostly due to isochromosome formation, is the only consistent chromosomal alteration found in invasive testicular germ cell tumors of adolescents and young adults (TGCTs), both seminomas and the various histological elenlents of nonseminomas, The biological role of extra 12p in the pathogenesis of this cancer is unclear, and it is also unknown so far, whether it is an early event, i,e,, already present in carcinoma ill situ, or related to invasive growth. Using comparative genomic hybridization (CGH) with DOP-PCR amplified DNA isolated from micro-dissected tumor cells, and double fluorescent in situ hybridization (FISH) on frozen tissue sections, we investigated the presence of overrepresentation of 12p sequences in different development stages of four seminomas and seven nonseminomas, in total 17 invasive components, in addition to the carcinoma in situ of each. CGH demonstrated relative gain of 12p-sequences in all invasive components except one, confirmed by FISH in most samples. In contrast, no gain was found in the carcinoma in situ samples by any of the methods. These findings show that overrepresentation of 12p is not an early event in the development of TGCTs, but relates to invasive growth.	Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Cytochem & Cytometry, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Looijenga, LHJ (corresponding author), Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, FGG EUR Bldg Be,Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019; rosenberg, carla/N-4148-2015	Looijenga, Leendert/0000-0002-8146-1911; rosenberg, carla/0000-0003-3253-4448				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ATKIN NB, 1982, LANCET, V2, P1349; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; GONDOS B, 1993, EUR UROL, V23, P68; JORGENSEN N, 1995, LAB INVEST, V72, P223; KORN MW, 1996, GENE CHROMOSOME CANC, V17, P8; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, CYTOMETRY, V32, P337, DOI 10.1002/(SICI)1097-0320(19980801)32:4<337::AID-CYTO11>3.3.CO;2-9; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; vanEchten J, 1997, CANCER GENET CYTOGEN, V96, P1; VANECHTENARENDS J, 1994, CANCER GENET CYTOGEN, V77, P194; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VORECHOVSKY I, 1989, NEOPLASMA, V36, P697; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; [No title captured]	31	105	109	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5858	5862		10.1038/sj.onc.1203950	http://dx.doi.org/10.1038/sj.onc.1203950			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127816				2022-12-28	WOS:000165563100004
J	Yu, ZK; Geyer, RK; Maki, CG				Yu, ZK; Geyer, RK; Maki, CG			MDM2-dependent ubiquitination of nuclear and cytoplasmic P53	ONCOGENE			English	Article						p53; MDM2; ubiquitination; nuclear export	PROTEIN; DEGRADATION; LOCALIZATION; DOMAIN; COMPLEX; FORMS; HDM2; SITE	Wild-type p53 is stabilized and accumulates in the nucleus of DNA damaged cells. The effect of stabilizing p53 is to inhibit cell growth, either through a G1 cell cycle arrest or apoptotic cell death. MDM2 can inhibit p53 activity, in part, by promoting its rapid degradation through the ubiquitin proteolysis pathway, In the current study, MDM2-mediated degradation of p53 was partially inhibited in cells treated with leptomycin B (LMB), a specific inhibitor of nuclear export. In contrast, levels of ubiquitinated p53 increased in LMB-treated cells, indicating that nuclear export is not required for p53 ubiquitination, To investigate this further, p53 mutants were generated which localize to either the nucleus or cytoplasm, and their susceptibility to MDM2-mediated ubiquitination was assessed. p53 mutants that localized to either the nucleus or the cytoplasm were efficiently ubiquitinated, and their steady-state levels decreased, when coexpressed with MDM2, In addition, an MDM2-mutant that localized to the cytoplasm was able to ubiquitinate and degrade a p53 mutant which was similarly localized in the cytoplasm, Our results indicate that nuclear export is not required for p53 ubiquitination, and that p53 proteins that localize to either the nucleus or cytoplasm can be ubiquitinated and degraded by MDM2.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.							AbouElela S, 1997, CANCER LETT, V117, P23, DOI 10.1016/S0304-3835(97)00196-1; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guerra B, 1998, FEBS LETT, V434, P115, DOI 10.1016/S0014-5793(98)00962-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077	29	87	88	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5892	5897		10.1038/sj.onc.1203980	http://dx.doi.org/10.1038/sj.onc.1203980			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127820				2022-12-28	WOS:000165563100008
J	Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A				Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A			Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling	ONCOGENE			English	Article						Ras; GTPase; oncogene; MAP kinase pathway	GTPASE-ACTIVATING PROTEINS; H-RAS; BINDING-PROTEINS; TRIPHOSPHATE CONFORMATION; STRUCTURAL DIFFERENCES; ESCHERICHIA-COLI; PC12 CELLS; IN-VITRO; P21; DOMAIN	Mutations of Ras with three extra amino acids inserted into the phosphate-binding (P) loop have been investigated both in vitro and in vivo. Such mutants have originally been detected as oncogenes both in the ras and the TC21 genes. Biochemical experiments reveal the molecular basis of their oncogenic potential: the mutants show a strongly attenuated binding affinity for nucleotides, most notably for GDP, leading to a preference for GTP binding. Furthermore, both the intrinsic as web as the GAP-stimulated GTP hydrolysis are drastically diminished. The binding interaction with GAP is reduced, whereas binding to the Ras-binding domain of the downstream effector c-Raf1 is not altered appreciably. Microinjection into PC12 cells shows the mutants to be as potent to induce neurite outgrowth as conventional oncogenic Ras mutants. Unexpectedly, their ability to stimulate the MAP kinase pathway as measured by a reporter gene assay in RK13 cells is much higher than that of the normal oncogenic mutant G12V. This characteristic was attributed to an increased stimulation of c-Raf1 kinase activity by the insertional Ras mutants.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bollag G, 1996, J BIOL CHEM, V271, P32491, DOI 10.1074/jbc.271.51.32491; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ENOMOTO T, 1990, CANCER RES, V50, P6139; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HUANG Y, 1995, ONCOGENE, V11, P1255; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schmidt G, 1996, ONCOGENE, V12, P87; SCHMIDT G, 1996, THESIS RUHR U BOCHUM; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WIEST JS, 1994, ONCOGENE, V9, P2449; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	64	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5367	5376		10.1038/sj.onc.1203909	http://dx.doi.org/10.1038/sj.onc.1203909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103938				2022-12-28	WOS:000165302300008
J	Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP				Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP			Characterization of a novel quiescence responsive element downregulated by v-Src in the promoter of the neuroretina specific QR1 gene	ONCOGENE			English	Article						growth arrest; differentiation; neuroretina; gene expression; oncogene; Maf	ROUS-SARCOMA VIRUS; EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; TRANSCRIPTION FACTOR NRL; ARREST-SPECIFIC GENE; RETINA-SPECIFIC QR1; GROWTH-ARREST; CELL-PROLIFERATION; MAMMALIAN-CELLS; DOWN-REGULATION	The neuroretina is a functional unit of the central nervous system which arises through successive steps of division, growth arrest and differentiation of neuroectodermal precursors. Postmitotic quail neuroretina (QNR) cells are conditionally induced to divide upon infection with temperature sensitive mutants of Rous sarcoma virus (RSV), since QNR cell division can be arrested by either inactivating p60v-Src at the nonpermissive temperature (41 degrees C) or by serum deprivation at 37 degrees C. We are studying the transcriptional control of QR1, a neuroretina specific gene, whose expression is down-regulated in proliferating cells at 37 degrees C and is fully restored when these cells are made quiescent. We previously showed that this quiescence specific upregulation implicates a promoter region named A box, which binds Maf transcription factors. We report the identification of the C box, a second promoter sequence that activates QR1 transcription in non dividing cells. This sequence is able to form two DNA-protein complexes, one of which (C4) is predominantly detected in growth arrested NR cells. We identified the DNA binding site for C4 and described mutations that abolish both C4 binding and promoter activity in quiescent cells. Moreover, we show that a multimerized C box is able to stimulate a heterologous promoter in non dividing cells and constitutes, therefore, a novel quiescence responsive enhancer. Finally, me report that QR1 transcriptional response to cell quiescence requires cooperation between the C box and A box.	CNRS, UMR 146, Inst Curie, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Felder-Schmittbuhl, MP (corresponding author), CNRS, UMR 146, Inst Curie, Batiment 110 Ctr Univ, F-91405 Orsay, France.			PROVOT, SYLVAIN/0000-0003-4087-4450				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Bendik I, 1998, CANCER RES, V58, P626; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goruppi S, 1996, ONCOGENE, V12, P471; Grossi M, 1998, ONCOGENE, V17, P1629, DOI 10.1038/sj.onc.1202090; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MAO PL, 1993, J BIOL CHEM, V268, P8131; McKinnon PJ, 1996, GENOME RES, V6, P1077, DOI 10.1101/gr.6.11.1077; Nelson PS, 1998, CANCER RES, V58, P232; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PEYSSONNAUX C, 2000, IN PRESS MOL CELL BI; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Ring BZ, 2000, DEVELOPMENT, V127, P307; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SIMONNEAU L, 1986, MOL CELL BIOL, V6, P3704, DOI 10.1128/MCB.6.11.3704; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0	58	4	4	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4736	4745		10.1038/sj.onc.1203837	http://dx.doi.org/10.1038/sj.onc.1203837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032024				2022-12-28	WOS:000089528800008
J	Kim, JW; Choi, EJ; Joe, CO				Kim, JW; Choi, EJ; Joe, CO			Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP	ONCOGENE			English	Article						RIP; caspase-8; apoptosis; NF-kappa B activation; I-kappa B kinase	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; DOMAIN KINASE RIP; CONTAINS 2; IKK-ALPHA; PROTEIN; CLEAVAGE; CD95; PHOSPHORYLATION	The two opposite signaling pathways that stimulate NF-kappa B activation and apoptosis are both mediated by tumor necrosis factor receptor 1 (TNFR1) and its cytosolic associated proteins. In this study, we demonstrate that the proteolytic cleavage of receptor interacting protein (RIP) by caspase-8 during TNF-induced apoptosis abrogates the stimulatory role of RIP on TNF-induced NF-kappa B activation. The uncleavable RIPD324A mutant was less apoptotic, but its ability to activate NF-kappa B activation was greater than the wild type counterpart, Ectopic expression of the pro-apoptotic C-terminal fragment of RIP inhibited TNF-induced NF-kappa B activation by suppressing the activity of I-kappa B kinase beta (IKK beta) which phosphorylates I-kappa B, an inhibitor of NF-kappa B, and triggers its ubiquitin-mediated degradation, The C-terminal fragment of RIP also enhanced the association between TNFR1 and death domain proteins including TNFR1 associated death domain (TRADD) and Fas associated death domain (FADD), resulting in the activation of caspase-8 and stimulation of apoptosis, The present study suggest that the C-terminal fragment of RIP produced by caspase-8 activates death-inducing signaling complex (DISC), attenuates NF-kappa B activation, and thereby amplifies the activation of caspase-8 which initiates the downstream apoptotic events.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Cell Death, Seoul 156701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea University	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	39	83	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4491	4499		10.1038/sj.onc.1203796	http://dx.doi.org/10.1038/sj.onc.1203796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002422				2022-12-28	WOS:000089236800006
J	Rytomaa, M; Lehmann, K; Downward, J				Rytomaa, M; Lehmann, K; Downward, J			Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling	ONCOGENE			English	Article						anoikis; apoptosis; Ras; Akt; PKB; Raf	PROTEIN-KINASE B/AKT; CELL-DEATH; EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; BAX; PHOSPHORYLATION; ADHESION; PATHWAY; TRANSFORMATION	Detachment of epithelial cells from extracellular matrix results in induction of apoptosis ('anoikis') which can be blocked by expression of activated Pas or PKB/Akt. Here we show that detachment causes release of cytochrome c from mitochondria in MDCK cells, This is blocked by caspase inhibitors, suggesting a role for caspases upstream of mitochondria in the initiation of anoikis, in accord with the ability of dominant negative FADD to inhibit this form of cell death, Bulk activation of caspase-8 following detachment lags behind cytochrome c release, and is likely the result of a mitochondrial positive feed back loop. Matrix detachment also induces Bax translocation to mitochondria in a caspase-dependent manner. Expression of activated Ras or PKB/Akt blocks all the detectable events on the detachment-induced apoptosis signalling pathway, suggesting that PKB/Akt acts at an early point in the pathway, providing the signal normally generated by matrix attachment. Strong activation of Raf can also protect MDCK cells from detachment induced apoptosis, but this occurs at a point downstream of cytochrome c release from mitochondria, and is clearly distinct from the effect of PKB/Akt.	Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	32	121	124	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4461	4468		10.1038/sj.onc.1203805	http://dx.doi.org/10.1038/sj.onc.1203805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002418				2022-12-28	WOS:000089236800002
J	Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM				Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM			BRCA1 activation of the GADD45 promoter	ONCOGENE			English	Article						GADD45; BRCA1; p53; gene regulation	P53-REGULATED PROTEIN GADD45; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE; OVARIAN-CANCER; CYCLE CHECKPOINT; GENE-EXPRESSION; BREAST; P53; INDUCTION; GROWTH	Breast cancer susceptibility gene BRCA1 has been implicated in the control of gene regulation and such regulated genes are thought to mediate the biological role of BRCA1. Overexpression of BRCA1 induces GADD45, a p53-regulated and stress-inducible gene. However, the molecular mechanism by which BRCA1 induces the expression GADD45 remains unclear. In this report, we have shown that the GADD45 promoter is strongly activated following expression of wild-type BRCA1, In contrast, both the tumor-derived BRCA1 mutants (p1749R and Y1853insA) and truncated BRCA1 mutant protein (Delta 500-1863 BRCA1), which lack transactivation activity, were unable to activate the GADD45 promoter, indicating that the BRCA1-mediated activation of the GADD45 promoter requires normal transcriptional properties of BRCA1. BRCA1 did not induce the c-Jun and c-fos promoters, which rules out a general effect of BRCA1 on other immediate-responsive genes. Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no effect on the induction of the GADD45 promoter by BRCA1, suggesting that activation of the GADD45 promoter by BRCA1 is independent of cellular p53 function. With the 5'-deletion analysis, the BRCA1-responsive element of the GADD45 promoter was mapped at the region from -121 to -75. Disruption of this region resulted in the abrogation of BRCA1 activation of the GADD45 promoter. Taken together, these results demonstrate that the mechanism by which BRCA1 induces GADD45 is mainly through the transactivation of the GADD45 promoter, further demonstrating the evidence that GADD45 acts as one of the BRCA1-regulated genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; NCI, Gene Response Sect, DBS, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Larson JS, 1997, CANCER RES, V57, P3351; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	82	86	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4050	4057		10.1038/sj.onc.1203759	http://dx.doi.org/10.1038/sj.onc.1203759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962562				2022-12-28	WOS:000088825300011
J	Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT				Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT			Redox regulation of p53 during hypoxia	ONCOGENE			English	Article						mitochondria; reactive oxygen species; hydrogen peroxide; apoptosis; cell cycle	INNER MEMBRANE; OXYGEN; MITOCHONDRIA; TUMOR; CARDIOMYOCYTES; PROLIFERATION; METABOLISM; APOPTOSIS; PROTEIN; DEATH	The transcription factor p53 can induce growth arrest or death in cells, Tumor cells that develop mutations in p53 demonstrate a diminished apoptotic potential, which may contribute to growth and tumor metastasis. Cellular levels of p53 are stabilized during hypoxia. The present study tested the hypothesis that reactive oxygen species (ROS) released from mitochondria regulate the cytosolic redox state and are required for the stabilization of p53 protein levels in response to hypoxia. Our results indicate that hypoxia (1.5% O-2) increases mitochondrial ROS generation and increases p53 protein levels in human breast carcinoma MCF-7 cells and in normal human diploid fibroblast IMR-90 cells. MCF-7 cells depleted of their mitochondrial DNA (rho degrees cells) failed to stabilize p53 protein levels during hypoxia. The antioxidant N-acetylcysteine and the Cu/Zn superoxide dismutase inhibitor diethyldithiocarbamic acid abolished the hypoxia-induced increases in ROS and p53 levels. Rotenone, an inhibitor of mitochondrial complex I, and 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate, a mitochondrial anion channel inhibitor, also abolished the increase in ROS signal and p53 levels during hypoxia. The p53-dependent gene p21(WAF1/CIP1) was also induced by hypoxia in both MCF-7 and IMR-90 cells without affecting the growth rate of either cell line. In contrast, both cell lines exhibited increases in p21(WAF1/CIP1) expression and growth arrest after gamma irradiation. Primary chick cardiac myocytes and murine embryonic fibroblasts also showed an increase in p53 protein levels in response to hypoxia without cell death or growth arrest. These results indicate that mitochondria regulate p53 protein levels during hypoxia through a redox-dependent mechanism involving ROS, Despite p53-induction, hypoxia alone does not cause either growth arrest or cell death.	Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Northwestern University; University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Chandel, NS (corresponding author), Northwestern Univ, Dept Med, Div Pulm & Crit Care, Tarry Bldg 14-707,300 E Super St, Chicago, IL 60611 USA.		Rodríguez, Ferran A. A/H-4892-2011	Rodríguez, Ferran A. A/0000-0002-2280-8962; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL35440, HL32646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ballarin C, 1996, J BIOENERG BIOMEMBR, V28, P125, DOI 10.1007/BF02110642; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; BASS DA, 1983, J IMMUNOL, V130, P1910; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Colombini M, 1996, Ion Channels, V4, P169; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; ELDEIRY WS, 1993, CELL, V75, P217; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; JONES DP, 1978, J BIOL CHEM, V253, P4874; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; MISRA HP, 1979, J BIOL CHEM, V254, P1623; Ravi R, 2000, GENE DEV, V14, P34; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P485, DOI 10.1016/0003-9861(79)90375-8	34	142	145	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3840	3848		10.1038/sj.onc.1203727	http://dx.doi.org/10.1038/sj.onc.1203727			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951577				2022-12-28	WOS:000088614300002
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Induction of p21(WAF1) expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; p21(WAF1); protein kinase A; estrogen receptor	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR SP1; SIGNAL-TRANSDUCTION; WAF1/CIP1 GENE; BREAST-CANCER; DNA-BINDING; GROWTH; PHOSPHORYLATION; ACTIVATION; INHIBITION	Although originally synthesized as an anti-estrogen, tamoxifen (Tam) was found to be able to inhibit proliferation of estrogen receptor (ER)-negative cancer cells in vitro. However, the molecular basis of such ER-independent growth inhibition is largely unknown. We have previously demonstrated that Tam induces p21(WAF1) and p27(KIP1) expression in human lung cancer cells which lack ER-alpha and -beta. We found that Tam induced p21(WAF1) expression via transcriptional activation. In order to determine the molecular mechanism responsible for p21(WAF1) induction by Tam, we performed a deletion analysis on the p21(WAF1) promoter. The minimal region in the p21(WAF1) promoter required for Tam-activated induction mas mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site. Our results showed that transcription factor Sp1 and Sp3 bound to this GC-rich region and mutation of Sp1-binding sites dramatically attenuated Tam-induced p21(WAF1) promoter activity. We also tried to elucidate the signaling pathway that mediated the activation of p21(WAF1) by Tam, Inhibition of mitogen-activated protein kinase pathways did not block Tam-induced p21(WAF1). Similarly, protein kinase C inhibitor calphostin C could not suppress Tam-induced p21(WAF1). Conversely, pretreatment of a specific protein kinase A inhibitor H89 significantly attenuated the induction of p21(WAF1) by Tam, Furthermore, PKA activators forskolin and dibutyryl-cAMP activated p21(WAF1) promoter activity and increased p21(WAF1) protein level in lung cancer cells. Taken together, these results demonstrate that Tam activates the p21(WAF1) promoter via Sp1-binding sites and suggest that PKA may be involved in the induction of p21(WAF1) by Tam in ER-negative Lung cancer cells.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Biochem, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, No 100 Shih-Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; ANDREW NC, 1991, NUC ACIDS RES, V19, P6418; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Catzavelos C, 1999, CANCER RES, V59, P684; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; DUHL JL, 1997, PHARMACEUT RES, V14, P186; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Menard S, 2000, CANCER RES, V60, P273; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; White LA, 1997, J NEUROSCI RES, V47, P242, DOI 10.1002/(SICI)1097-4547(19970201)47:3<242::AID-JNR2>3.0.CO;2-I; Yatabe Y, 1998, CANCER RES, V58, P1042; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	48	58	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3766	3773		10.1038/sj.onc.1203715	http://dx.doi.org/10.1038/sj.onc.1203715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949931				2022-12-28	WOS:000088568400009
J	Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF				Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF			The Mom1(AKR) intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64	ONCOGENE			English	Article						Mom1; tumor resistance; Apc; Min mouse; goblet cell; Pla2g2a	FAMILIAL ADENOMATOUS POLYPOSIS; SECRETORY PHOSPHOLIPASE A(2); NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARCINOMA CELL-LINES; LOW-MOLECULAR-WEIGHT; COLON-CANCER CELLS; TRANSGENIC MICE; MURINE MODEL; MIN MOUSE; CHROMOSOME 1P35-36	The Mom1 (Modifier of Min-1) region of distal chromosome 4 was identified during a screen for polymorphic modifiers of intestinal tumorigenesis in Apc(Min/+) mice. Here, we demonstrate that the Mom1(AKR) allele consists of two genetic components. These include the secretory phospholipase Pla2g2a, whose candidacy as a Mom1 resistance modifier has now been tested with several transgenic Lines. A second region, distal to Pla2g2a, has also been identified using fine structure recombinants. Pla2g2a(AKR) transgenic mice demonstrate a modest resistance to tumorigenesis in the small intestine and a ver! robust resistance in the large intestine, Moreover, the tumor resistance in the colon of Pla2g2a(AKR) animals is dosage-dependent, a finding that is consistent with our observation that Pla2g2a is expressed in goblet cells, By contrast, mice carrying the distal Mom1 modifier demonstrate a modest tumor resistance that is confined to the small intestine. Thus. the phenotypes of these two modifier loci are complementary, both in their quantitative and regional effects. The additive effects and tight Linkage of these modifiers may have been necessary for the initial identification of the Mom1 region.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA63677, CA50585, CA07075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Boolbol SK, 1996, CANCER RES, V56, P2556; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; Chiu CH, 1997, CANCER RES, V57, P4267; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dobbie Z, 1997, HUM GENET, V99, P653, DOI 10.1007/s004390050423; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Engle SJ, 1999, CANCER RES, V59, P3379; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fukushima K, 1999, J GASTROENTEROL, V34, P54, DOI 10.1007/s005350050216; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERZOG CR, 1995, ONCOGENE, V11, P1811; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Itoh H, 1999, J CLIN INVEST, V104, P1539, DOI 10.1172/JCI6211; Jacoby RF, 1996, CANCER RES, V56, P710; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Laine VJO, 1999, J IMMUNOL, V162, P7402; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Legare ME, 2000, GENOME RES, V10, P42; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; Moorghen M, 1998, CELL PROLIFERAT, V31, P59, DOI 10.1046/j.1365-2184.1998.00111.x; Morel L, 1999, MAMM GENOME, V10, P176; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Nimmrich I, 1997, HUM GENET, V100, P345, DOI 10.1007/s004390050514; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; PAULUS U, 1993, J CELL SCI, V106, P473; PIAZZA GA, 1995, CANCER RES, V55, P3110; Podolin PL, 1998, MAMM GENOME, V9, P283, DOI 10.1007/s003359900749; Podolin PL, 1997, J IMMUNOL, V159, P1835; POTTER M, 1994, CANCER RES, V54, P969; PRAML C, 1995, CANCER RES, V55, P5504; Praml C, 1998, ONCOGENE, V17, P2009, DOI 10.1038/sj.onc.1202121; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Quesada CF, 1998, JPN J CANCER RES, V89, P392, DOI 10.1111/j.1349-7006.1998.tb00576.x; RAO CV, 1995, CANCER RES, V55, P1464; Rao CV, 1996, CANCER RES, V56, P532; Reddy BS, 1999, CANCER RES, V59, P3387; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Ritland SR, 1999, CARCINOGENESIS, V20, P51, DOI 10.1093/carcin/20.1.51; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 1998, INFLAMM RES, V47, pS112; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yang ZY, 1998, CANCER LETT, V124, P187, DOI 10.1016/S0304-3835(97)00476-X; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	86	90	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3182	3192		10.1038/sj.onc.1203646	http://dx.doi.org/10.1038/sj.onc.1203646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918573				2022-12-28	WOS:000088019200007
J	Maya, R; Oren, M				Maya, R; Oren, M			Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure	ONCOGENE			English	Article						p53; Mdm2; phosphatase; monoclonal antibodies; Western blot	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; GROWTH ARREST; CELL-LINES; IN-VITRO; INDUCTION; DEPHOSPHORYLATION; SIGNALS	Monoclonal antibodies are widely used for the assessment of protein expression levels, protein-protein interactions and protein localization. Phosphorylation of one or more residues within an epitope recognized by a particular antibody may compromise the ability of that antibody to bind the target protein. Inhibition of immunoreactivity by phosphorylation has been reported for many antibody/protein pairs. Here me describe a simple convenient protocol for assessing the effect of phosphorylation on immunoreactivity? employing phosphatase treatment of Western blotted membranes. The efficacy of this protocol is demonstrated for p53 and for Mdm2. This method is useful for obtaining more uniform protein quantification, as well as for rapid assessment of changes in the extent of phosphorylation within a given epitope in response to defined signals.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA-40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39	23	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3213	3215		10.1038/sj.onc.1203658	http://dx.doi.org/10.1038/sj.onc.1203658			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918576				2022-12-28	WOS:000088019200010
J	Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E				Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E			Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b	ONCOGENE			English	Article						Rho GTPases; Rac1; isoform; breast cancer; ductal carcinoma-in-situ; metastasis	GTP-BINDING PROTEIN; RAS TRANSFORMATION; NADPH OXIDASE; GROWTH-FACTOR; CELL-LINES; EXPRESSION; RHO; GTPASES; FAMILY; CDC42	Rac1 is a member of the Ras superfamily of small guanosine triphosphatases (GTPases) that act as molecular switches to control cytoskeletal rearrangements and cell growth. Analogous to Ras, constitutively activating point mutations of Rad cause tumorigenic transformation of cell lines. However, there is no information about whether Rad is also mutated in vivo, After RT-PCR of Rad, several clones of seven benign and 10 malignant breast cancer tissues as well as eight breast cancer cell lines were sequenced. Only single-nucleotide polymorphisms of Rad could be detected, and none of these corresponded to constitutively activating point mutations that have been used in cell lines for transformation. While sequencing Rad in breast tissues, a new Rad isoform with an insertion of 19 codons within the reading frame of Rad close to switch region II was identified and named Rac1b, The Rac1b protein acts like a fast cycling GTPase in GTP binding and hydrolysis assays, In Northern and Western blot experiments both Rad RNA and Rad protein had a significantly higher expression in breast cancer tissues compared to normal breast tissue samples. Immunohistochemical staining of Rad showed weak Rad expression in benign breast disease but high expression level in ductal carcinoma-in-situ, primary breast cancer, and lymph node metastases. In addition, breast tumor cells from patients with recurrent disease had Rad expression at the plasma membrane, suggesting activation of Rad, in patients with aggressive breast cancer.	Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-81675 Munich, Germany; Tech Univ Munich, Klinikum Rechts Isar, Dept Pathol, D-81675 Munich, Germany; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich; Scripps Research Institute; Technical University of Munich	Lengyel, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, Ismaninger Str 22, D-81675 Munich, Germany.		Gerhard, Markus/N-3387-2014; Gerhard, Markus/P-8996-2019; Lengyel, Ernst/D-9220-2014	Gerhard, Markus/0000-0001-9110-3950; Gerhard, Markus/0000-0001-9110-3950; Lengyel, Ernst/0000-0001-8624-1507; Schnelzer, Andreas/0000-0002-5410-3561				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BOS JL, 1989, CANCER RES, V49, P4682; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dickson R B, 1992, Cancer Treat Res, V61, P249; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Krizman DB, 1996, CANCER RES, V56, P5380; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Schiedt K., 1995, ISOLATION ANAL, V1A, P81; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	31	313	323	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3013	3020		10.1038/sj.onc.1203621	http://dx.doi.org/10.1038/sj.onc.1203621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871853	Green Published			2022-12-28	WOS:000087581400008
J	Danial, NN; Rothman, P				Danial, NN; Rothman, P			JAK-STAT signaling activated by Abl oncogenes	ONCOGENE			English	Article						JAK; STAT; v-Abl; BCR-Abl	LYMPHOID-CELL TRANSFORMATION; CHRONIC MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; PRE-B CELLS; BCR-ABL; C-ABL; TYROSINE KINASE; V-ABL; CONSTITUTIVE ACTIVATION	The Abl oncoproteins v-Abl and BCR-Abl can activate member of the signal transducers and activators of transcription (STAT) family of signaling proteins. The mechanisms by which these oncoproteins activate STATs appear to differ, In cells transformed by v-Abl, Janus kinase (JAK) tyrosine kinases are constitutively activated. Tn these cells, the v-Abl oncoprotein and the JAK kinases physically associate. Mapping of the JAK interaction domain in v-Abl demonstrates that amino acids within the carboxyl terminal region of v-Abl bind JAKs through a direct interaction. A mutant of v-Abl lacking this region does not bind or activate JAK 1 in vivo, fails to activate STAT proteins, does not induce cellular proliferation, and is less efficient in cellular transformation. Kinase inactive mutants of JAK 1 inhibit the ability of v-Abl to activate STATs, to induce cytokine-independent proliferation, and to transform bone marrow cells. Interestingly, these effects correlate with defects in the activation of several pathways by v-AbI including Akt, PI3-kinase, STATs, and Ras, These data suggest that Jak kinases may play an important role in v-Abl induced transformation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, Integrated Program Mol Cellular & Biophys Studies, New York, NY 10032 USA	Columbia University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, Integrated Program Mol Cellular & Biophys Studies, 630 168th St, New York, NY 10032 USA.							Banerjee A, 1998, J IMMUNOL, V161, P4611; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DORSCH M, 1996, P NATL ACAD SCI, V93; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FISHER AG, 1993, LEUKEMIA, V7, pS66; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GOGA A, 1995, ONCOGENE, V11, P791; Golub TR, 1996, BBA-REV CANCER, V1288, pM7, DOI 10.1016/0304-419X(96)00015-7; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Henderson YC, 1997, CLIN CANCER RES, V3, P145; HEVEZI P, 1993, ONCOGENE, V8, P2413; Hilbert DM, 1998, ONCOGENE, V17, P2125, DOI 10.1038/sj.onc.1202134; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kanwar VS, 1996, BLOOD, V87, P4911, DOI 10.1182/blood.V87.11.4911.bloodjournal87114911; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; ODA T, 1994, J BIOL CHEM, V269, P22925; Ota J, 1998, BIOCHEM BIOPH RES CO, V252, P779, DOI 10.1006/bbrc.1998.9445; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; Ozaki K, 1998, BLOOD, V92, P4652; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROSENBERG N, 1998, ADV VIRUS RES, V35, P39; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG JYJ, 1984, CELL, V36, P349; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; WeberNordt RM, 1996, BLOOD, V88, P809; WilsonRawls J, 1996, CANCER RES, V56, P3426; YASUNAGA M, 1995, J EXP MED, V182, P315, DOI 10.1084/jem.182.2.315; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	80	111	114	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2523	2531		10.1038/sj.onc.1203484	http://dx.doi.org/10.1038/sj.onc.1203484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851051				2022-12-28	WOS:000087459400008
J	Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U				Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U			Extinction of Rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway	ONCOGENE			English	Article						Rac1; Cdc42Hs; adhesion; apoptosis; p53; MAPK	NF-KAPPA-B; WISKOTT-ALDRICH SYNDROME; CELL-DEATH; SIGNALING PATHWAY; ACTIN-CYTOSKELETON; GTPASE CDC42HS; ONCOGENIC RAS; P53; PROTEIN; KINASE	Apoptosis is a normal physiological process which eliminates cells that do not receive adequate extracellular signals. One of the pathways signalling apoptosis is controlled by the small GTPases of the Rho family, also involved in cell proliferation, differentiation and motility, Another major apoptosis signalling pathway involves the p53 tumour suppressor which is activated by a variety of stress and mediates growth arrest or apoptosis in normal cells. We show here that upon detachment from the extracellular matrix, fibroblasts undergo rapid apoptosis that can be rescued by constitutive activation of Rad and Cdc42Hs GTPases, Conversely, inhibition of Rad and Cdc42Hs efficiently triggers apoptosis in adherent cells. Interestingly, apoptosis is not observed in p53(-/-) cells either cultured in suspension or inhibited for Rad and Cdc42Hs activity. Moreover, Rad and Cdc42Hs extinction in normal cells activates endogenous p53, Using specific inhibitors of MAPK pathways, we demonstrate that, in our experimental system, p38 signals survival, while ERK activity is required for apoptosis, Our data constitute the first demonstration that Rad and Cdc42Hs control pathways that require simultaneous signalling through MAPK ERK and p53 to induce apoptosis.	Inst Genet Mol, CNRS, UMR5535, IFR 24, F-34293 Montpellier 5, France; Ctr Rech Biochim Macromol, CNRS, UPR1086, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Hibner, U (corresponding author), Inst Genet Mol, CNRS, UMR5535, IFR 24, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020; Zugasti, Olivier/P-1352-2017; Roux, Pierre/D-8833-2017; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Zugasti, Olivier/0000-0002-5616-734X; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Donovan FM, 1997, J NEUROSCI, V17, P5316; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dutartre H, 1996, J CELL SCI, V109, P367; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moorman JP, 1996, J IMMUNOL, V156, P4146; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ozes ON, 1999, NATURE, V401, P82; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	35	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2377	2385		10.1038/sj.onc.1203553	http://dx.doi.org/10.1038/sj.onc.1203553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828879				2022-12-28	WOS:000087018400002
J	Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L				Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L			A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts	ONCOGENE			English	Article						CDC25(Mm); signal transduction therapy; fos-luciferase; oncogenes; GEF	TARGETING SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; DISEASE THERAPY; IN-VIVO; PROTEIN; GRB2; EXPRESSION; RECEPTOR; CLONING; FAMILY	Ras proteins are small GTPases playing a pivotal role in cell proliferation and differentiation, Their activation state depends on the competing action of GTPase Activating Proteins (GAP) and Guanine nucleotide Exchange Factors (GEF), A tryptophan residue (Trp1056 in CDC25(Mm)-GEF), conserved in all ras-specific GEFs identified so far has been previously shown to be essential for GEF activity. Its substitution with glutamic acid results in a catalytically inactive mutant, which is able to efficiently displace wild-ty pe GEF from p21(ras) and to originate a stable ras/GEF binary complex due to the reduced affinity of the nucleotide-free ras/GEF complex for the incoming nucleotide, We show here that this 'ras-sequestering property' can be utilized to attenuate ras signal transduction pathways in mouse fibroblasts transformed by oncogenic ras, In fact overexpression of the dominant negative GEF(W1056E), stable transfected cells strongly reduces intracellular ras GTP levels in k-ras transformed fibroblasts. Accordingly, the transfected fibroblasts revert to wild-type phenotype on the basis of morphology, cell cycle and anchorage independent growth. The reversion of the transformed phenotype is accompanied bar DNA endoreduplication, The possible use of dominant negative ras-specific GEFs as a tool to down-regulate tumor growth is discussed.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Ctr Ric Dompe, Laquila, Italy	University of Milano-Bicocca; Dompe	Alberghina, L (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Di Cioccio, Vito/N-1296-2013; Bossù, Paola/E-4832-2014; Vanoni, Marco/AAA-3699-2021; Nacmias, Benedetta/J-5084-2018	Di Cioccio, Vito/0000-0002-8063-9650; Bossù, Paola/0000-0002-1432-0078; Vanoni, Marco/0000-0002-8690-2587; Nacmias, Benedetta/0000-0001-9338-9040; Alberghina, Lilia/0000-0003-1694-931X				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DHIN L, 1999, NATURE, V400, P468; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Downward J, 1997, CURR BIOL, V7, P258; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Guerrero C, 1996, ONCOGENE, V12, P1097; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Levitzki A, 1997, MED ONCOL, V14, P83, DOI 10.1007/BF02990952; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1994, INT J ONCOL, V4, P175; Zippel R, 1996, ONCOGENE, V12, P2697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	49	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2147	2154		10.1038/sj.onc.1203539	http://dx.doi.org/10.1038/sj.onc.1203539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815806				2022-12-28	WOS:000086728000008
J	Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F				Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F			Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation	ONCOGENE			English	Article						adenocarcinoma; epidermal growth factor receptor; mammary gland; transgenic mice; differentiation	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR-ALPHA; TGF-ALPHA; FUNCTIONAL-DIFFERENTIATION; BETA-LACTOGLOBULIN; GENE-EXPRESSION; EGF-RECEPTOR; HUMAN COLON; MICE	The epidermal growth factor receptor (EGFR) is overexpressed in about 48% of human breast cancer tissues. To analyse the role of the EGFR in mammary tumor development me generated transgenic mice expressing the human EGFR under the control of either the MMTV-LTR (MHERc) or the beta-lactoglobulin promoter (BLGHERc), The BLGHERc-transgene was expressed exclusively in the female mammary. gland, whereas the MHERc transgene was expressed more promiscuously in other organs, such as ovary, salivary gland and testis, Female virgin and lactating transgenic mice of both strains have impaired mammary gland development. Virgin EGFR transgenic mice developed mammary epithelial hyperplasias, whereas in lactating animals progression to dysplasias and tubular adenocarcinomas was observed. In both strains the number of dysplasias increased after multiple pregnancies. The transgene expression pattern mas heterogeneous, but generally restricted to regions of impaired mammary gland development. Highest EGFR transgene expression was observed in adenocarcinomas. By using a whole mount organ culture sa stem to study the differentiation potential of the mammary epithelium, we observed a reduced number of fully developed alveoli and a decrease in whey acidic protein expression. Taken together, EGFR overexpression results in a dramatic effect of impaired mammary gland development in vitro as well as in vitro, reducing the differentiation potential of the mammary epithelium and inducing epithelial cell transformation.	Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, D-10117 Berlin, Germany; Schering Res Labs, D-13342 Berlin, Germany; MDC Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Theuring, F (corresponding author), Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, Dorotheen Str 94, D-10117 Berlin, Germany.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ARCHIBALD AL, 1990, P NATL ACAD SCI USA, V87, P5178, DOI 10.1073/pnas.87.13.5178; BANERJEE MR, 1973, IN VITRO CELL DEV B, V9, P129, DOI 10.1007/BF02616011; BARASH I, 1994, TRANSGENIC RES, V3, P141, DOI 10.1007/BF01973981; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BORG A, 1991, ONCOGENE, V6, P137; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1989, ONCOGENE, V4, P831; FAN Z, 1993, CANCER RES, V53, P4322; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; GOLDENRING JR, 1993, REGUL PEPTIDES, V43, P37, DOI 10.1016/0167-0115(93)90405-W; GRAMLICH TL, 1994, AM J CLIN PATHOL, V101, P493; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HARRIS AL, 1987, REGULATORY MECHANISM, P93; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Hinrichs S H, 1991, Princess Takamatsu Symp, V22, P259; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Krane IM, 1996, ONCOGENE, V12, P1781; LEE PPH, 1995, ENDOCRINOLOGY, V136, P1718, DOI 10.1210/en.136.4.1718; LIU TH, 1995, CHINESE MED J-PEKING, V108, P653; Matsui Y., 1990, CELL, V61, P1137; MCCLENAGHAN M, 1995, BIOCHEM J, V310, P637, DOI 10.1042/bj3100637; MULLANEY BP, 1992, MOL ENDOCRINOL, V6, P2103, DOI 10.1210/me.6.12.2103; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; RIVERA EM, 1967, METHODS MAMMAL EMBRY, V31, P442; Salomon D S, 1991, Cancer Treat Res, V53, P107; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; YEE LD, 1989, SEMIN DIAGN PATHOL, V6, P110; YULL F, 1996, TRANSGENIC RES, V6, P7	42	58	61	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2129	2137		10.1038/sj.onc.1203520	http://dx.doi.org/10.1038/sj.onc.1203520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815804				2022-12-28	WOS:000086728000006
J	Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J				Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J			Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization	ONCOGENE			English	Article						p53; cell shape; motility; fibronectin; focal contacts	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; BINDING PROTEIN; BAX GENE; APOPTOSIS; PATHWAY; ARREST; MUTANT	Effects of p53 expression on cell morphology and motility were studied using the derivatives of p53-null 10(1) mouse fibroblasts with tetracycline-regulated expression of exogenous human p53, Induction of p53 expression was accompanied by significant decrease in extracellular matrix (fibronectin) and reduction of matrix fibrils, diminution of the number and size of focal contacts, decrease of cell areas, establishment of more elongated cell shape and alterations of actin cytoskeleton (actin bundles became thinner, their number and size decreased). Expression of His175 and Gln22/Ser23 p53 mutants caused no such effects. To study the influence of p53 expression on cell motility we used wound technique and videomicroscopy observation of single living cells. It was found that induction of p53 expression led to increase of lamellar activity of cell edge, However, in spite of enhanced lamellar activity p53-expressing cells migrated to shorter distance and filled the narrow wound in longer time as compared with their p53-null counterparts. Possible mechanisms of the influence of p53 expression on cell morphology and motility are discussed.	Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia; Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia	Russian Academy of Sciences; Lomonosov Moscow State University	Chumakov, P (corresponding author), Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia.		Kopnin, Boris/R-8240-2019; Chumakov, Peter M/E-7731-2014	Kopnin, Boris/0000-0003-3100-2212; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; BERSHADSKY AD, 1988, CYTOSKELETON, P268; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Dunn G. A., 1986, J CELL SCI, V108, P1659; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Prives C, 1999, J PATHOL, V187, P112; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981	32	37	37	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5826	5830		10.1038/sj.onc.1203944	http://dx.doi.org/10.1038/sj.onc.1203944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126371				2022-12-28	WOS:000165477700016
J	Huang, LL; Sowa, Y; Sakai, T; Pardee, AB				Huang, LL; Sowa, Y; Sakai, T; Pardee, AB			Activation of the p21(WAF1/CIP1) promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites	ONCOGENE			English	Article						SAHA; p31 promoter; Sp1/Sp3	WAF1/CIP1 GENE PROMOTER; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; N-COR; BINDING; REPRESSION; P300; INDUCTION; INDUCERS; HOMOLOG	Suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with high potency in inducing differentiation of cultured murine erythroleukemia cells. We have recently demonstrated that SAHA induces cell cycle arrest and apoptosis in human breast cancer cells, accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21(WAF1/CIP1) via a p53-independent mechanism. In this study, we used p21 gene expression as a model system to elucidate the molecular mechanism(s) underlying SAHA-mediated gene activation. Treatment of human breast cancer cell line MICF7 cells with SAHA induced p21 mRNA as a consequence of an immediate-early gene activation. Moreover, SAHA activated the p21 promoter primarily through two Spl sites located at -82 and -69 relative to the transcription start site. Furthermore, Spl and Sp3 proteins were the major factors binding to the Spl site of the p21 promoter. However, SAHA did not alter their DNA binding activities, suggesting that SAHA mediates p21 promoter activity by a mechanism other than altering the DNA binding activities of Spl and Sp3, Further studies using the GAL4 luciferase assay system demonstrated that both GAL4-Sp1 and GAL4-Sp3 fusion proteins supported SAHA-mediated gene activation from a promoter driven by five GAL4 DNA binding sites, and that GAL4-Sp3 fusion protein,vas suppressive in the absence of SAHA treatment. Collectively, our results suggest that SAHA activates the p21 promoter through the Spl sites, and that both Spl and Sp3 proteins can mediate SAHA-induced gene activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Kyoto Prefectural University of Medicine	Pardee, AB (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA61253] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cohen LA, 1999, ANTICANCER RES, V19, P4999; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	188	193	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5712	5719		10.1038/sj.onc.1203963	http://dx.doi.org/10.1038/sj.onc.1203963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126357				2022-12-28	WOS:000165477700002
J	Irby, RB; Yeatman, TJ				Irby, RB; Yeatman, TJ			Role of Src expression and activation in human cancer	ONCOGENE			English	Review						Src; oncogene; tyrosine kinase; human cancer; metastasis	TYROSINE KINASE-ACTIVITY; HUMAN-COLON-CARCINOMA; PP60C-SRC PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; HUMAN PANCREATIC-CARCINOMA; TUMOR CELL-LINES; C-SRC; HEPATOCELLULAR-CARCINOMA; PREMALIGNANT EPITHELIA	Since the original identification of a transmissible agent responsible for the development of tumors in chickens, non known to be a retrovirus encoding the v-src gene, significant progress has been made in defining the potential functions of its human homolog, SRC, The product of the human SRC gene, c-Src, is found to be over-expressed and highly activated in a wide variety of human cancers. The relationship between Src activation and cancer progression appears to be significant. Moreover, Src may have an influence on the development of the metastatic phenotype, This review discusses the data supporting a role for c-Src as a critical component of the signal transduction pathways that control cancer cell development and growth, and provides the rationale for targeting Src in drug discovery efforts.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yeatman, TJ (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BJELFMAN C, 1990, CANCER RES, V50, P6908; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUMMER J, 1995, ONCOGENE, V11, P1649; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Daigo Y, 1999, CANCER RES, V59, P4222; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; HAAS M, 2000, IN PRESS J BIOL CHEM; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JACOBS C, 1983, CANCER RES, V43, P1696; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Levitzki A, 1996, ANTI-CANCER DRUG DES, V11, P175; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masaki T, 2000, AM J GASTROENTEROL, V95, P837; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; ODAJIMA J, 2000, IN PRESS J BIOL CHEM; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; PENG ZY, 1995, ONCOGENE, V11, P1955; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tokumitsu Y, 2000, J CELL PHYSIOL, V183, P221, DOI 10.1002/(SICI)1097-4652(200005)183:2<221::AID-JCP8>3.0.CO;2-L; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Visser CJT, 1996, LAB INVEST, V74, P2; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	77	654	674	2	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5636	5642		10.1038/sj.onc.1203912	http://dx.doi.org/10.1038/sj.onc.1203912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114744				2022-12-28	WOS:000165659300011
J	MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G				MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G			Identification of a novel human BCL-X promoter and exon	ONCOGENE			English	Article						apoptosis; BCL-X-L; splicing; promoter; transcription	INDUCED APOPTOSIS; BCL-X(L); EXPRESSION; GENE; CANCER; CELLS	BCL-X-L is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-X-L is located in BCL-X exon II and previous analyses have indicated that BCL-X-L RNAs initiate close to the start of exon IT or additionally contain a non-coding first exon (exon IA) spliced to exon TI, Using 5' RACE we have now identified a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon IJ[ in place of exon IA, Exon IB-containing RNAs encoded BCL-X-L and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and mere expressed at significant levels in cell lines derived from ovarian, colon and breast cancers. We identified two TATA-hox sequences upstream of exon TB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identified a powerful new BCL-X promoter and a novel exon that contributes to BCL-X-L expression.	Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Southampton SO16 6YD, Hants, England; Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, Sch Med, London W12 1PG, England	University of Southampton; Imperial College London; Ludwig Institute for Cancer Research	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Ctr Block,Level F, Southampton SO16 6YD, Hants, England.		Johnson, Peter/L-2403-2018; Johnson, Peter/O-3529-2019	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Harigai M, 1996, ONCOGENE, V12, P1369; Krajewska M, 1996, CANCER RES, V56, P2422; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pena JC, 1998, CANCER RES, V58, P2111; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	19	14	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5534	5538		10.1038/sj.onc.1203949	http://dx.doi.org/10.1038/sj.onc.1203949			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114731				2022-12-28	WOS:000165396100014
J	Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15/IL-15R alpha intracellular trafficking in human melanoma cells and signal transduction through the IL-15R alpha	ONCOGENE			English	Article						IL-15; IL-15R alpha; secretion pattern; NF-kappa B; melanoma progression	NF-KAPPA-B; IL-15; RECEPTOR; EXPRESSION; CYTOKINE; PROTEINS; ISOFORMS; PEPTIDES; ALPHA; CHAIN	There are two IL-15 isoforms and eight isoforms for the IL-15R alpha chain whose biological role is poorly understood. Here, we have analysed the intracellular trafficking of IL-15 and IL-15R alpha and tried to shed some light on their function(s), In IL-15/GFP CHO transfectants both IL-15 isoforms show nuclear localization. Two melanoma cell lines (MELP and MELREO) spontaneously expressing the IL-15 isoforms, display different intracellular trafficking of the IL-15/IL-15R alpha complex, In MELP cells only IL-15R alpha is detected inside the nucleus, whereas IL-15 and IL-15R alpha assemble at the cell surface and are internalized, Moreover, the transducing molecule TRAF2 co-immunoprecipitates with IL-15R alpha and may be deflected to TNFRI using anti-IL-15 blocking mAbs and TNF-alpha, By contrast, MELREO cells display IL-15R alpha and IL-15 nuclear localization but only a partial co-localization of these molecules on the cell surface. In these cells, TRAF2 is strongly associated with IL-15R alpha and cannot be deflected by any treatment, Since TRAF2 activates the transcription factor NF-kappaB, IL-15 through IL-15R alpha, could have a role in the control of this pathway. Indeed, anti-IL-15 MaB inhibit the constitutive nuclear localization of NF kappaB and the phosphorylation of its inhibitor I kappa -B alpha, Thus, IL-15R alpha controls NF-KB activation, however differences in the intracellular trafficking of the IL-15 and/or IL-15R alpha suggest a different biological role for this complex in MELP versus MELREO cells.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Ist Nazl Ric Canc, I-16132 Genoa, Italy; DIMI, Fac Med, I-16132 Genoa, Italy; DOCS, Fac Med, F-94800 Villejuif, France; Lab Cytometrie, CNRS, UPS 47, F-94800 Villejuif, France; Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Indiveri, Francesco/AAE-9086-2020; Giron-Michel, Julien/Q-4503-2018; Azzarone, Bruno/AAH-9251-2019; Meazza, Raffaella/AAC-2425-2019	Giron-Michel, Julien/0000-0001-6613-6099; Azzarone, Bruno/0000-0002-5962-3849; Meazza, Raffaella/0000-0003-0242-3157; Ferrini, Silvano/0000-0001-7254-2616; Induveri, Francesco/0000-0002-9280-2232				Alleva DG, 1997, J IMMUNOL, V159, P2941; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Duffey DC, 1999, CANCER RES, V59, P3468; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Hallahan DE, 1998, CANCER RES, V58, P5484; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 1996, ONCOGENE, V12, P2187; Musso T, 1999, BLOOD, V93, P3531; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Shah MH, 1998, NAT MED, V4, P643, DOI 10.1038/nm0698-643a; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393	21	61	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5153	5162		10.1038/sj.onc.1203873	http://dx.doi.org/10.1038/sj.onc.1203873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064452				2022-12-28	WOS:000090124100004
J	Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD				Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD			Complementation of Myc-dependent cell proliferation by cDNA expression library screening	ONCOGENE			English	Article						c-myc; N-myc; myc-null fibroblasts; proliferation; cDNA library	C-MYC; GROWTH; COOPERATION; MECHANISM; ONCOGENES; TARGET	The targeted knockout of the c-myc gene from rat fibroblasts leads to a stable defect in cell proliferation. We used complex cDNA libraries expressed from retroviral vectors and an efficient sorting procedure to rapidly select for cDNAs that can restore the growth rate of c-myc deficient cells, All of the biologically active cDNAs contained either c-myc or N-myc, suggesting that no other cellular genes can effectively bypass the requirement for c-myc in fibroblast proliferation. This approach provides a powerful screening method for cell cycle changes in genetically defined systems.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							ADAMS JM, 1992, CANCER SURV, V15, P119; CORVI R, 1995, CANCER RES, V55, P3471; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	18	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4828	4831		10.1038/sj.onc.1203880	http://dx.doi.org/10.1038/sj.onc.1203880			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039899				2022-12-28	WOS:000089757800004
J	Banelli, B; Casciano, I; Romani, M				Banelli, B; Casciano, I; Romani, M			Methylation-independent silencing of the p73 gene in neuroblastoma	ONCOGENE			English	Article						p73; methylation; neuroblastoma; chromosome 1	DNA METHYLATION; CELL-LINES; EXPRESSION; CANCER; IDENTIFICATION; AMPLIFICATION; SEQUENCES; MUTATION; ALLELE; ASSAY	p73 is a p53 homolog that, in vitro, inhibits cell growth and induce apoptosis, In some tumors p73 is mono-allelically expressed and this raised the possibility that this gene is subjected to imprinting, Silencing of p73 in acute leukemia and in Burkitt's lymphoma occurs in association with the aberrant methylation of the first exon of the gene, We have analysed the methylation pattern of the p73 promoter and of upstream and downstream sequences in neuroblastoma, Our results demonstrate that p73 expression in this tumor is not regulated by methylation. We concluded that it is unlikely that p73 is imprinted in neuroblastoma and that the methylation-dependent silencing of this gene, thus far, is a characteristic of hematologic malignancies.	IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Banelli, Barbara/Y-1151-2019	Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X				Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Baylin SB, 1998, ADV CANCER RES, V72, P141; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Chi SG, 1999, CANCER RES, V59, P2791; Corn PG, 1999, CANCER RES, V59, P3352; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lo Cunsolo C, 1998, CYTOGENET CELL GENET, V82, P199, DOI 10.1159/000015099; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Nomoto S, 1998, CANCER RES, V58, P1380; Peters UR, 1999, CANCER RES, V59, P4233; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REESE MG, 1996, BIOC P 1996 PAC S; Romani M, 1999, ANAL BIOCHEM, V271, P204, DOI 10.1006/abio.1999.4152; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Scaruffi P, 2000, LEUKEMIA, V14, P518, DOI 10.1038/sj.leu.2401698; Toyota M, 1999, CANCER RES, V59, P2307; Zaika AI, 1999, CANCER RES, V59, P3257	27	30	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4553	4556		10.1038/sj.onc.1203807	http://dx.doi.org/10.1038/sj.onc.1203807			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002429				2022-12-28	WOS:000089236800013
J	Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM				Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM			Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha	ONCOGENE			English	Article						FADD; JNK/SAPKs; ATF-2; cJun; APO-1/Fas	TUMOR-NECROSIS-FACTOR; APO-1/FAS LIGAND EXPRESSION; THERAPY-INDUCED APOPTOSIS; HUMAN T-CELLS; FAS LIGAND; SIGNAL-TRANSDUCTION; JNK/SAPK ACTIVITY; ACTIVATION; PROTEIN; STRESS	CD95-L, TNP-alpha and TRAIL are death-inducing ligands (DILs) which may signal apoptosis via crosslinking of their cognate receptors, The present study shows that treatment of cells with agonistic mAB alpha APO-1 (CD95), recombinant TRAIL or TNF-alpha leads to enhanced mRNA and protein expression of each DIL with concomitant death in target cells, Immunoprecipitation of CD95-L protein from supernatant as well as neutralizing antibodies suggest DIL proteins to be cooperatively acting mediators of these cytotoxic activity, Antoamplification of the death signal was blocked in cells with a defect in apoptosis signaling either due to a dysfunctional FADD molecule or to the failure to activate JNK/SAPKs, Phosphorylation and enhanced binding of cJun and ATF-2 to DIL promoters suggest JNK/SAPKs as activators of these transcription factors following death receptor triggering, In consequence, autocrine production of DILs allows the spread of death signals to sensitive target cells.	German Canc Res Ctr, Div Pediat Oncol, D-6900 Heidelberg, Germany; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Univ Ulm, Childrens Hosp, Ulm, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of L'Aquila; Ulm University	Debatin, KM (corresponding author), Univ Kinderklin, Prittwitzstr 43, D-89075 Ulm, Germany.		Böhler, Thomas/AAS-3986-2021; Di Marzio, Luisa/AAF-8052-2021; Cifone, Maria Grazia/ABH-1984-2021; Debatin, Klaus-Michael/J-9704-2014; Cifone, Maria Grazia/I-3750-2019; Posovszky, Carsten/J-5966-2018; Di Marzio, Luisa/H-9969-2012	Di Marzio, Luisa/0000-0002-2518-7188; Debatin, Klaus-Michael/0000-0002-8397-1886; Cifone, Maria Grazia/0000-0002-9923-5445; Posovszky, Carsten/0000-0002-9487-8812; 				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Herr I, 1996, CELL DEATH DIFFER, V3, P299; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Herr I, 1999, INT J CANCER, V80, P417, DOI 10.1002/(SICI)1097-0215(19990129)80:3<417::AID-IJC14>3.3.CO;2-2; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIERNER PA, 1997, J IMMUNOL, V159, P1594; Krammer P H, 1999, Adv Immunol, V71, P163; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MILLERGRAZIANO CL, 1994, SHOCK, V1, P317, DOI 10.1097/00024382-199405000-00001; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Sheikh MS, 1998, CANCER RES, V58, P1593; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	36	36	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4255	4262		10.1038/sj.onc.1203776	http://dx.doi.org/10.1038/sj.onc.1203776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980599				2022-12-28	WOS:000089032900008
J	Mitchell, PJ; Sara, EA; Crompton, MR				Mitchell, PJ; Sara, EA; Crompton, MR			A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK	ONCOGENE			English	Article						BKS; BRK; PH domain; tyrosine kinase; SH2 domain	BREAST-CANCER; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; PH DOMAIN; SRC; PHOSPHORYLATION; MUTATION; ACTIVATION; PP60C-SRC; HOMOLOGY	The brk gene encodes a non-receptor tyrosine kinase that has been found to be overexpressed in approximately two thirds of breast tumours. Using a yeast two-hybrid based screen, we have cloned cDNAs encoding a novel protein, BKS, that is a substrate for the kinase activity of BRK and has the characteristics of an adaptor protein. BKS possesses an N-terminal PH-like domain followed by an SH2-like domain. In co-transfection experiments, high levels of phosphotyrosine were observed on BKS and BRK was found to be associated with BKS, both of which were dependent on the catalytic activity of BRK. The phosphorylation of and association with BKS by BRK was also dependent on the SH2-like domain present within BKS, In addition, BKS recruited an unidentified 100 kDa protein that was also phosphorylated on tyrosine residues in the presence of BRK. We have determined that the BKS protein is expressed in most adult human tissues.	Inst Canc Res, Breakthrough Toby Robinson Canc Res Ctr, Sect Cell Biol & Expt Pathol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mitchell, PJ (corresponding author), UCL, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.		Mitchell, Philip J/F-6393-2013; Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffer PJ, 1998, BIOCHEM J, V335, P1; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUKADA M, 1996, J BIOL CHEM, V271, P30303; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; OKADA M, 1991, J BIOL CHEM, V266, P24249; PATERSON MC, 1991, CANCER RES, V51, P556; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHAFFHAUSEN B, 1995, BIOCHIM BIOPHYS ACTA, V28, P61; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	51	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4273	4282		10.1038/sj.onc.1203775	http://dx.doi.org/10.1038/sj.onc.1203775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980601				2022-12-28	WOS:000089032900010
J	Ge, NL; Rudikoff, S				Ge, NL; Rudikoff, S			Expression of PTEN in PTEN-deficient multiple mgeloma cells abolishes tumor growth in vivo	ONCOGENE			English	Article						multiple myeloma; PTEN; AKT; OPM-2 cells	SUPPRESSOR GENE; FACTOR-I; GERMLINE MUTATIONS; CARCINOMA-CELLS; MYELOMA; INSULIN; BREAST; CANCER; APOPTOSIS; LINES	Biochemical abnormalities associated with the development of multiple myeloma hale been difficult to define especially in terms of demonstrating an irt vivo effect of suspected lesions. Herein, we have identified such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's), In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis, Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56-267, Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis, The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in lon PTEN expressing clones. Importantly, clones expressing high le,els of PTEN failed to produce tumors even at five times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in turner development in a subset of multiple myeloma patients.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 1999, SEMIN HEMATOL, V36, P3; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Boni R, 1998, MELANOMA RES, V8, P300; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FREUND GG, 1994, CANCER RES, V54, P3179; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; GE NL, 2000, IN PRESS BLOOD; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Jelinek DF, 1997, J IMMUNOL, V159, P487; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; Klein B, 1990, Eur Cytokine Netw, V1, P193; KYLE RA, 1992, HEMATOL ONCOL CLIN N, V6, P347, DOI 10.1016/S0889-8588(18)30348-4; LADANYI M, 1992, AM J PATHOL, V141, P949; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Munshi NC, 1999, SEMIN ONCOL, V26, P28; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PORTIER M, 1992, ONCOGENE, V7, P2539; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Risinger JI, 1997, CANCER RES, V57, P4736; Seiden Michael V., 1994, Current Opinion in Oncology, V6, P41, DOI 10.1097/00001622-199401000-00006; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Uddin S, 1996, EXP HEMATOL, V24, P622; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YASUGA Y, 1995, INT J HEMATOL, V62, P91	32	45	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4091	4095		10.1038/sj.onc.1203801	http://dx.doi.org/10.1038/sj.onc.1203801			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962569				2022-12-28	WOS:000088955100002
J	Arapshian, A; Kuppumbatti, YS; Mira-y-Lopez, R				Arapshian, A; Kuppumbatti, YS; Mira-y-Lopez, R			Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells	ONCOGENE			English	Article						DNA methylation; chromatin; bisulfite; 5-azacytidine; trichostatin A	TRANSCRIPTIONAL REGULATION; DNA METHYLATION; CARCINOMA CELLS; IN-VIVO; EXPRESSION; PROMOTER; LINES; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; HETERODIMERS	We investigated the mechanism of retinoic acid receptor (RAR) beta 2 gene silencing in breast cancer cells. Transfection experiments indicated that MCF-7 cells transactivate an exogenous beta 2 promoter (-1470/+156) to the same extent as MTSV1.7 breast epithelial cells, which express endogenous RAR beta 2. This was true even in the context of replicated chromatin, suggesting a cis-acting rather than a trans-acting defect. Cytosine methylation, a cis-acting DNA modification, has been implicated in RAR beta 2 silencing in cancer cells. Upon bisulfite genomic sequencing, we found that 3 CpG sites in the beta 2 RARE region were variably methylated in MCF-7 cells but were not methylated in MTSV1.7 cells or in 2 MDA-MB-231 subclones that differed in RAR beta 2 expression (high in clone A2, low in clone A4). However, the 5'-UTR region was hypermethylated in clone A4 relative to clone A2 cells. Following 5-azacytidine treatment, RA and trichostatin A markedly induced RAR beta 2 expression in MCF-7 cells but not in MDA-MB-231 clone A4 cells. A beta 2 RARE reporter construct in which the methylation-susceptible cytosines in the sense strand were replaced by thymine displayed marked loss of activity in a replicated chromatin-dependent manner. We conclude that cytosine methylation contributes to RAR beta 2 gene silencing in MCF-7 cells and that methylation of the RARE region may be particularly important.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mira-y-Lopez, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [R01 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FERGUSON AT, 1995, CANCER RES, V55, P2279; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIRAYLOPEZ R, 1991, J CELL PHYSIOL, V147, P46, DOI 10.1002/jcp.1041470107; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XC, 1997, CANCER RES, V57, P4992; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; ZHANG XK, 1994, CANCER RES, V54, P5663	30	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4066	4070		10.1038/sj.onc.1203734	http://dx.doi.org/10.1038/sj.onc.1203734			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962564				2022-12-28	WOS:000088825300013
J	Garcia-Guzman, M; Larsen, E; Vuori, K				Garcia-Guzman, M; Larsen, E; Vuori, K			The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; UBIQUITIN-PROTEASOME PATHWAY; SIGNALING COMPLEX-FORMATION; PAPILLARY RENAL CARCINOMAS; SRC-FAMILY KINASES; GRB2 BINDING-SITE; TYROSINE KINASE; T-CELL; PROTOONCOGENE PRODUCT; EGF-RECEPTOR	Hepatocyte growth factor triggers a complex biological program leading to invasive cell growth by activating the c-Met receptor tyrosine kinase. Following activation, Met signaling is elicited via its interactions with SH2- containing proteins, or via the phosphorylation of the docking protein Gab1, and the subsequent interaction of Gab1 with additional SH2-containing effector molecules. We have previously shown that the interaction between phosphorylated Gab1 and the adaptor protein Crk mediates activation of the JNK pathway downstream of Met. We report here that c-Cbl, which is a Gab1-like docking protein, also becomes tyrosine-phosphorylated in response to Met activation and serves as a docking molecule for various SH2-containing molecules, including Crk. We further show that Cbl is similarly capable of enhancing Met-induced JNK activation, and several lines of experimentation suggests that it does so by interacting with Crk. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Taken together, our studies demonstrate a previously unidentified functional role for Cbl in Met signaling and suggest that Met utilizes at least two docking proteins, Gab1 and Cbl, to activate downstream signaling pathways.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA71560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Scaife RM, 2000, J CELL SCI, V113, P215; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	69	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4058	4065		10.1038/sj.onc.1203750	http://dx.doi.org/10.1038/sj.onc.1203750			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962563				2022-12-28	WOS:000088825300012
J	Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI				Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI			Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	ONCOGENE			English	Article						insulin-like growth factor II; p53 mutant; transcriptional activation; hepatocellular carcinoma	X GENE-PRODUCT; FUNCTION MUTATIONS; P4 PROMOTER; TREE SHREWS; VIRUS; EXPRESSION; CELLS; HEPATOCYTES; APOPTOSIS; SITE	Aflatoxin B1 (AFB1) induced mutation of the p53 gene at codon 249 (p53mt249) is critical during the formation of hepatocellular carcinoma (HCC) following hepatitis B virus (HBV) infection. p53mt249 markedly increases insulin-like growth factor II (IGF-II) transcription largely from promoter 4, accumulating the fetal form of IGF-II, Modulation of the transcription factor binding to IGF-II P4 by wild-type p53 and p53mt249 was identified. Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein (Spl or TBP) and protein-protein (Sp1 and TBP) interactions. p53mt249 stimulates transcription factor Spl phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not. Transfection of hepatocytes with p53mt249 impaired induction of apoptosis by the HBV-X protein and TNF-alpha. Therefore, the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes. These results explain the molecular basis for the genesis of HCC by p53mt249 which was found to be induced by a potent mutagen, AFB1.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea; Univ Texas, Ctr Hlth, Dept Mol Biol, Tyler, TX 75710 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARIANI E, 1988, CANCER RES, V48, P6844; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FU XX, 1998, J VIROL, V62, P4322; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSIAO M, 1994, AM J PATHOL, V145, P702; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULLA JE, 1993, CANCER RES, V53, P9; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kim SO, 1996, CANCER RES, V56, P3831; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LUIS P, 1997, SCIENCE, V278, P687; LUSE DS, 1980, CELL, V20, P691, DOI 10.1016/0092-8674(80)90315-3; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, V1; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PERREM K, 1995, ONCOGENE, V11, P1299; SANDEEP RD, 1997, CELL, V91, P231; Shivakumar CV, 1996, ONCOGENE, V13, P323; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su JJ, 1997, EXP MOL MED, V29, P177, DOI 10.1038/emm.1997.27; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Yan RQ, 1996, J CANCER RES CLIN, V122, P289, DOI 10.1007/BF01261405; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YEH FS, 1989, CANCER RES, V49, P2506; Zhang LJ, 1998, DNA CELL BIOL, V17, P125, DOI 10.1089/dna.1998.17.125	35	74	77	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3717	3726		10.1038/sj.onc.1203694	http://dx.doi.org/10.1038/sj.onc.1203694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949925				2022-12-28	WOS:000088568400003
J	Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R				Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R			Gros1, a potential growth suppressor on chromosome 1: its identity to basement membrane-associated proteoglycan, leprecan	ONCOGENE			English	Article						Gros1/leprecan; proteoglycan; tumor suppressor; chomosome 1	IN-SITU HYBRIDIZATION; ALLELIC LOSS; MULTIFUNCTIONAL REGULATOR; MEDIATED SUPPRESSION; BREAST-CANCER; REGION; CARCINOMA; DELETION; DECORIN; HETEROZYGOSITY	By immunoscreening with an antibody raised against a plasma membrane protein, we have cloned a growth suppressor gene, Gros1 and assigned it to short arm of human chromosome 1. Two alternatively spliced forms of the gene encoding 84- and 41-kDa (carboxy-terminus truncated) proteins were cloned. The two transcripts, 4.4 and 2.7 kb, were expressed weakly in most of the human tissues, with a high expression of the smaller transcript in placenta, ovary and testis. Normal human fibroblasts in culture shelved two transcripts, with a higher level of expression of the 4.4 kb transcript. Transformed cells on the other hand showed predominant expression of the 2.7 kb transcript. Two Gros1 transcripts were also detected in most of the mouse tissues. Stable transfection of the mouse cDNA encoding the 85-kDa protein into NIH3T3 cells resulted in their slow growth and reduced colony-forming efficiency. Stable clones expressing antisense RNA on the other hand exhibited higher colony forming efficiency. Wlile our data implied that Gros1 is a novel growth suppressor gene on human chromosome 1, an independent study has recently characterized its rat-homolog as a <(le)under bar>ucine <(pr)under bar>oline-(e) under bar nriched novel basement membrane-associated proteogly<(can)under bar> leprecan. We describe here cloning, expression and biological activity analysis implying that this novel proteoglycan is a potential growth suppressor on chromosome 1p31, frequently altered in many malignancies.	Chugai Res Inst Mol Med, Ibaraki, Osaka 30041, Japan; AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wadhwa, R (corresponding author), Chugai Res Inst Mol Med, 153-2 Nagai, Ibaraki, Osaka 30041, Japan.		Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; ARIYAMA T, 1995, GENOMICS, V25, P114, DOI 10.1016/0888-7543(95)80116-4; Arlt MF, 1996, HUM MOL GENET, V5, P1017, DOI 10.1093/hmg/5.7.1017; Bomme L, 1998, GENE CHROMOSOME CANC, V21, P185, DOI 10.1002/(SICI)1098-2264(199803)21:3<185::AID-GCC2>3.0.CO;2-W; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Caput D, 1997, B CANCER, V84, P1081; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHENG NC, 1995, ONCOGENE, V10, P291; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Di Vinci A, 1998, CANCER-AM CANCER SOC, V83, P415; Fujimoto Y, 1998, Rinsho Byori, V46, P9; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iolascon A, 1997, LEUKEMIA, V11, P359, DOI 10.1038/sj.leu.2400596; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; Lee WC, 1996, CANCER RES, V56, P4297; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Merle B, 1999, J CELL BIOCHEM, V75, P538; MOLEY JF, 1992, CANCER RES, V52, P770; MUNN KE, 1995, ONCOGENE, V10, P1653; NAGAI H, 1995, CANCER RES, V55, P1752; Nakanishi K, 1999, INT J CANCER, V80, P527, DOI 10.1002/(SICI)1097-0215(19990209)80:4<527::AID-IJC8>3.3.CO;2-P; Nash MA, 1999, CANCER RES, V59, P6192; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Perlman EJ, 1996, GENE CHROMOSOME CANC, V16, P15, DOI 10.1002/(SICI)1098-2264(199605)16:1<15::AID-GCC2>3.0.CO;2-6; PRAML C, 1995, ONCOGENE, V11, P1357; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Verbeek MM, 1999, AM J PATHOL, V155, P2115, DOI 10.1016/S0002-9440(10)65529-0; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0	41	29	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3576	3583		10.1038/sj.onc.1203696	http://dx.doi.org/10.1038/sj.onc.1203696			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951563				2022-12-28	WOS:000088568300003
J	Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ				Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ			Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia	ONCOGENE			English	Article						hvpermethylation; APC; gastric cancer	MUTATION CLUSTER REGION; POLYPOSIS-COLI GENE; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETA-CATENIN; CELL-LINES; HYPERMETHYLATION; IDENTIFICATION; CARCINOMA; STOMACH	The adenomatous polyposis coli (APC) tumor suppressor gene is mutationally inactivated in both familial and sporadic forms of colorectal cancers. In addition, hypermethylation of CpG islands in the upstream portion of APC, a potential alternative mechanism of tumor suppressor gene inactivation, has been described in colorectal cancer. Because a subset of both gastric and colorectal cancers display the CpG island methylator phenotype, we hypothesized that epigenetic inactivation of APC was likely to occur in at least some gastric cancers, APC exhibits two forms of transcripts from exons 1A and 1B in the stomach. Therefore, we investigated CpG island methylation in the sequences upstream off sons 1A and 1B, i.e., promoters 1A and 1B, respectively. We evaluated DNAs from 10 gastric cancer cell lines, 40 primary gastric cancers, and 40 matching non-cancerous gastric mucosae, Methylated alleles of promoter 1A were present in 10 (100%) of 10 gastric cancer cell lines, 33 (82.5%) of 40 primary gastric cancers, and 39 (97.5%) of 40 non-cancerous gastric mucosae. In contrast, promoter 1B was unmethylated in all of these same samples, APC transcripts from exon 1A were not expressed in nine of the 10 methylated gastric cancer cell lines, whereas APC transcripts were expressed from exon 1B. Thus, expression from a given promoter correlated well with its methylation status. We conclude that in contrast to the colon, methylation of promoter 1A is a normal el ent in the stomach; moreover, promoter 1B is protected from methylation in the stomach and thus probably does not participate in this form of epigenetic APC inactivation.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Surg, Yamagata 9909585, Japan; Univ Calif Irvine, Irvine Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Yamagata University; Yamagata University; University of California System; University of California Irvine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tsuchiya, T (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA77057, CA85069, CA78843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fleisher AS, 1999, CANCER RES, V59, P1090; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NISHIMURA K, 1995, INT J ONCOL, V7, P587; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OSHIMA M, 1993, CANCER RES, V53, P5589; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; Powell SM, 1996, ONCOGENE, V12, P1953; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sparks AB, 1998, CANCER RES, V58, P1130; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tamura G, 1996, CANCER RES, V56, P612; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681	29	160	169	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3642	3646		10.1038/sj.onc.1203704	http://dx.doi.org/10.1038/sj.onc.1203704			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951570				2022-12-28	WOS:000088568300010
J	Palacios, C; del Arroyo, AG; Silva, A; Collins, MKL				Palacios, C; del Arroyo, AG; Silva, A; Collins, MKL			The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs	ONCOGENE			English	Article						p53; apoptosis; IL-3	DNA-DAMAGING AGENTS; P53-DEPENDENT APOPTOSIS; ANTICANCER AGENTS; C-ABL; LINE; INTERLEUKIN-3; CISPLATIN; PATHWAYS; PROTECTS; STRESS	This report examines the cytotoxicity of chemotherapeutic agents to primary bone marrow-derived IL-3-dependent cells. Such cells derived from p53-null mice were resistant to almost 100-fold higher concentrations of the inhibitors of deoxyribonucleotide synthesis FUdR, methotrexate and hydroxyurea than cells with wild-type p53, In contrast, the cytotoxicity of the DNA damaging agents X-irradiation, cisplatin or bleomycin was p53-independent. The topoisomerase II inhibitor etoposide induced p53-dependent death, which suggests that DNA damage may not be its primary mechanism of cytotoxicity in this cell type. An IL3-dependent cell line which expresses wild-type p53 was used to demonstrate that the ability of cytotoxic drugs to increase p53 expression level does not control their ability to induce p53-dependent loss of clonigenicity. Finally, comparison with a p53-null IL3-dependent cell line was used to show that absence of p53 delays the rate of entry into apoptosis following treatment with either DNA damaging agents or inhibitors of deoxyribonucleotide synthesis. This distinguishes short-term effects of p53 on rate of entry into apoptosis from its role in controlling ultimate cell survival.	Windeyer Inst Med Sci, Dept Immunol, London W1P 6DB, England; CSIC, Ctr Invest Biol, Madrid, Spain	University of London; University College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Collins, MKL (corresponding author), Windeyer Inst Med Sci, Dept Immunol, 46 Cleveland St, London W1P 6DB, England.		Palacios, Carmen/G-7422-2015	Palacios, Carmen/0000-0002-1267-2619				Agami R, 1999, NATURE, V399, P809; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ASCASO R, 1994, EUR J IMMUNOL, V24, P537, DOI 10.1002/eji.1830240307; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Gong JG, 1999, NATURE, V399, P806; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Lamb JR, 1997, NAT MED, V3, P962, DOI 10.1038/nm0997-962; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOIKE JD, 1976, BIOCHEMISTRY-US, V15, P5443, DOI 10.1021/bi00670a004; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OConnor PM, 1997, CANCER RES, V57, P4285; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pritchard DM, 1998, CANCER RES, V58, P5453; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TISHLER RB, 1993, CANCER RES, V53, P2212; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	31	16	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3556	3559		10.1038/sj.onc.1203683	http://dx.doi.org/10.1038/sj.onc.1203683			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918614				2022-12-28	WOS:000088346500012
J	Salimath, B; Marme, D; Finkenzeller, G				Salimath, B; Marme, D; Finkenzeller, G			Expression of the vascular endothelial growth factor gene is inhibited by p73	ONCOGENE			English	Article						vascular endothelial growth factor; p73; p53; promoter; Sp1; leukemia	TUMOR-SUPPRESSOR GENE; INDUCED TRANSCRIPTION; HEMATOPOIETIC-CELLS; HUMAN CANCERS; KINASE-C; P53; ANGIOGENESIS; PROTEIN; DNA; ACTIVATION	Recently, p73, a new member of the p53 family, has been cloned and mapped to chromosome 1p36, a region that is frequently deleted in a variety of human cancers. p73 can activate p53-responsive promoters and induce apoptosis when overexpressed in certain p53-deficient tumor cells, In contrast to p53, analysis of the p73 gene in several human solid tumors did not reveal loss of p73 expression or mutations in the p73 gene, However, transcriptional silencing of the p73 gene by hypermethylation of a CpG island was observed in several leukemias and lymphomas, These lymphoid neoplasms also show increased expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of angiogenesis, To evaluate a possible relationship between p73 status and VEGF expression, we have studied the effect of ectopically expressed p73 on the regulation of the VEGF gene, Our results demonstrate that p73 can down-regulate endogenous VEGF gene expression on mRNA and protein level. This effect is mediated by transcriptional repression of the VEGF promoter and involves the promoter region -85 to -50 bp, containing a cluster of Sp 1 binding sites. Our results suggest a regulatory role for p73 in tumor angiogenesis.	Tumor Biol Ctr, Inst Mol Med, D-79106 Freiburg, Germany; Univ Mysore, Dept Biochem, Mysore 570006, Karnataka, India	University of Mysore	Finkenzeller, G (corresponding author), Tumor Biol Ctr, Inst Mol Med, Breisacher Str 117, D-79106 Freiburg, Germany.							Agami R, 1999, NATURE, V399, P809; Aguayo A, 1999, BLOOD, V94, P3717, DOI 10.1182/blood.V94.11.3717.423k09_3717_3721; Bellamy WT, 1999, CANCER RES, V59, P728; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Corn PG, 1999, CANCER RES, V59, P3352; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussong JW, 2000, BLOOD, V95, P309; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KATOH O, 1995, CANCER RES, V55, P5687; Katoh O, 1998, CANCER RES, V58, P5565; Kawano S, 1999, BLOOD, V94, P1113; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MEKLE C, 1998, GENE THER, V5, P1631; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Sunahara M, 1998, INT J ONCOL, V13, P319; Suzuki K, 1996, CANCER RES, V56, P3004; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	37	63	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2000	19	31					3470	3476		10.1038/sj.onc.1203672	http://dx.doi.org/10.1038/sj.onc.1203672			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918605				2022-12-28	WOS:000088346500003
J	Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K				Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K			Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/Cyclin E complex activation	ONCOGENE			English	Article						Survivin; Cdk; INK4a; p27; cell cycle progression	ANTI-APOPTOSIS GENE; DEPENDENT KINASE INHIBITOR; FAS-MEDIATED APOPTOSIS; TUMOR NECROSIS FACTOR; DEATH FACTOR; RETINOBLASTOMA PROTEIN; IAP GENE; CANCER; P21; EXPRESSION	Survivin is observed uniquely in tumor cells and developmental cells, which undergo either inappropriate or programmed cell growth, In the current study, we investigated the influence of Survivin on cell cycle, Overexpression of Survivin resulted in accelerated S phase shift, resistance to G1 arrest, and activated Cdk2/Cyclin E complex leading Rb phosphorylation, In addition, nuclear translocation of Survivin followed by an interaction with Cdk4 was detected. Interestingly, Survivin nuclear translocation coincided with S phase shift, and prevention of nuclear transport suppressed Survivin nuclear translocation and S phase shift. Further, we also observed that Survivin competitively interacted with the Cdk4/p16(INK4n) complex in a cell free system and in vivo. These results suggest that Survivin initiates the cell cycle entry as a result of nuclear translocation followed by an interaction with Cdk4.	Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Tokyo 1348630, Japan; Mie Univ, Dept Internal Med 1, Sch Med, Tsu, Mie 5148507, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Labs 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 1348630, Japan	Daiichi Sankyo Company Limited; Mie University; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.							Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; LI Y, 1994, ONCOGENE, V9, P2261; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lu CD, 1998, CANCER RES, V58, P1808; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Parry D, 1999, MOL CELL BIOL, V19, P1775; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tamm I, 1998, CANCER RES, V58, P5315; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	48	163	231	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3225	3234		10.1038/sj.onc.1203665	http://dx.doi.org/10.1038/sj.onc.1203665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918579				2022-12-28	WOS:000088019300001
J	Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M				Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M			Cell cycle regulation of the endogenous wild type Bloom's syndrome DNA helicase	ONCOGENE			English	Article						Bloom's syndrome; RecQ 3 '-5 ' DNA helicase; cell cycle; post-translational modifications; cancer predisposition	UBIQUITIN-PROTEASOME PATHWAY; ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BETA-CATENIN; REPLICATION; HOMOLOG; PROTEIN; CLONING; PHOSPHORYLATION; DEGRADATION	Bloom's syndrome (BS) is a rare human autosomal recessive disorder characterized by an increased risk to develop cancer of all types, BS cells are characterized by a generalized genetic instability including a high level of sister chromatid exchanges, BS arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family. We developed polyclonal antibodies specific for the NH2- and COOH-terminal region of BLM, Using these antibodies, we analysed BLM expression during the cell cycle and showed that the BLM protein accumulates to high levels in S phase, persists in G2/M and sharply declines in G1, strongly suggestive of degradation during mitosis, The BLM protein is subject to post-translational modifications in mitosis, as revealed by slow migrating forms of BLM found in both demecolcine-treated cells and in mitotic cells isolated from non-treated asynchronous populations. Phosphatase treatment indicated that phosphorylation events were solely responsible for the appearance of the retarded moieties, a possible signal for subsequent degradation. Together, these results are consistent with a role of BLM in a replicative (S phase) and/or post-replicative (G2 phase) process.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Curie, Lab Radiopathol, CEA, Lab Rech Correspondant,DSV,DRR, F-75005 Paris, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU De Strasbour, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019; Jaulin, Christian/L-9126-2018	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COUX O, 1996, ANNU REV BIOCHEM, V65, P80; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kusano K, 1999, GENETICS, V151, P1027; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LONN U, 1990, CANCER RES, V50, P3141; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MULLER H, 1992, MUTAT RES, V284, P15, DOI 10.1016/0027-5107(92)90021-S; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODMAN TC, 1980, CYTOGENET CELL GENET, V27, P98, DOI 10.1159/000131471; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Walpita D, 1999, P NATL ACAD SCI USA, V96, P5622, DOI 10.1073/pnas.96.10.5622; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHUO S, 1993, J BIOL CHEM, V268, P17754	41	97	100	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2731	2738		10.1038/sj.onc.1203595	http://dx.doi.org/10.1038/sj.onc.1203595			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851073				2022-12-28	WOS:000087318500001
J	Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI				Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI			Disruption of TGF-beta growth inhibition hy oncogenic ras is linked to p27(Kip1) mislocalization	ONCOGENE			English	Article						mislocalization of p27(Kip1); oncogenic Ras; p27(Kip1) partner switching; TGF-beta growth inhibition	CELL-CYCLE ARREST; EPITHELIAL-CELLS; SKI ONCOPROTEIN; CDK INHIBITORS; SMAD PROTEINS; CANCER CELLS; TUMOR-CELLS; C-MYC; RECEPTOR; GENE	Expression of oncogenic Ras in epithelial tumor cells is linked to the loss of transforming growth factor-beta (TGF-beta) anti-proliferative activity, and was proposed to involve inhibition of Smad2/3 nuclear translocation, Here we studied several epithelial cell lines expressing oncogenic N-Ras(K61) and show that TGF-beta -induced nuclear translocation of and transcriptional activation by Smad2/3,were unaffected. In contrast, oncogenic Ras mediated nuclear-to-cytoplasmic mislocalization of p27(Kip1) (p27) and of the cyclin-dependent kinase (CDK) CDK6, but not CDK2, Concomitantly, oncogenic Ras abrogated the ability of p27 and from to CDK6, to enhance its inhibit CDK2 activity. TGF-beta to binding to Inactivation of Ras by a specific antagonist restored the growth inhibitory response to TGF-beta with concurrent normalization of p27 and CDK6 localization. Therefore, the disruption of TGF-beta -mediated growth inhibition by oncogenic Ras appears to be due to lack of inhibition of CDK2, caused by the sequestration of p27 and CDK2 in different subcellular compartments and by the loss of TGF-beta -induced partner switching of p27 from CDK6 to CDK2.	Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Massachusetts Institute of Technology (MIT)	Henis, YI (corresponding author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.			Ehrlich, Marcelo/0000-0002-2352-1808; Henis, Yoav/0000-0002-1408-3877; LIU, XUEDONG/0000-0001-7209-4964				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BOS JL, 1989, CANCER RES, V49, P4682; Catzavelos C, 1999, CANCER RES, V59, P684; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOUCK KA, 1989, ONCOGENE, V4, P19; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LONGSTREET M, 1992, ONCOGENE, V7, P1549; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SP, 1998, CANCER RES, V58, P1730; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	58	54	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5926	5935		10.1038/sj.onc.1203991	http://dx.doi.org/10.1038/sj.onc.1203991			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127824				2022-12-28	WOS:000165563100012
J	Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE				Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE			The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function	ONCOGENE			English	Article						R-Ras; integrin activation; effector binding	NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHOINOSITIDE 3-KINASE; CELLULAR-TRANSFORMATION; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; PUTATIVE EFFECTOR; EPITHELIAL-CELLS; PROTEIN; ACTIVATION; IDENTIFICATION	The closely related small GTP-binding proteins H-Ras and R-Ras have opposing effects on the regulation of integrin cell adhesion receptors, To gain insight into the properties of R-Ras with respect to the regulation of integrin function and interactions with downstream effecters we performed an analysis of R-Ras variants containing mutations in the effector binding domain and C-terminal prenylation site. We found that the activation of the downstream effector PI 3-kinase was sensitive to mutations in the effector binding domain, as was the binding to the effecters, Ral-GDS, Raf-1 and the novel effector Norel, Furthermore, specific mutations in the effector binding loop and C-terminal prenylation motif impaired the ability of R-Ras to regulate integrin function in CHO cells. However, the ability of the R-Ras effector loop mutants to bind, and activate known effecters did not correlate with their ability to regulate integrin function. Thus, the known R-Ras effecters are not critical for regulating integrin activation, at least in CHO cells, Consequently, these studies provide insight into the structural basis of the interactions between R-Ras and its candidate effecters and suggest the existence of novel mechanisms through which this GTPase could regulate cell adhesion.	Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England; Univ Edinburgh, Sch Med, Dept Resp Med, Edinburgh EH8 9AG, Midlothian, Scotland	Scripps Research Institute; Cancer Research UK; University of Edinburgh	Hughes, PE (corresponding author), Scripps Res Inst, Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729	NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; COX AD, 1994, ONCOGENE, V9, P3281; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINASHI T, 2000, IN PRESS J BIOL CHEM; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Takayama S, 1997, Methods Mol Biol, V69, P171; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	38	42	43	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4961	4969		10.1038/sj.onc.1203876	http://dx.doi.org/10.1038/sj.onc.1203876			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042683				2022-12-28	WOS:000089834300003
J	Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP				Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP			Additive effect between NF-kappa B subunits and p53 protein for transcriptional activation of human p53 promoter	ONCOGENE			English	Article						p53; autoregulation; NF-kappa B; transcription factors	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; NUCLEAR-FACTOR; BINDING PROTEIN; DNA-BINDING; GENE-EXPRESSION; OWN TRANSCRIPTION; IN-VITRO; CANCER; CELL	The tumor suppressor p53 plays a pivotal role in the cellular response to DNA damage as it controls DNA repair, cell cycle arrest and apoptosis, We studied the autoregulation of human p53 gene transcription in colon cancer cell lines. Wild-type p53 has been show positively or negatively and probably in a cell-type-specific manner. Indeed, a p53 binding site has been described in the human and murine p53 promoters, but a direct binding of wild-type p53 protein to this site has never been reported. In this study, we demonstrated a transactivation of human p53 pn to autoregulate its own transcription either promoter by wild-type p53 in human colon cancer cells. We identified in the human p53 promoter a novel potential p53-responsive element that binds wildtype p53. Moreover, wild-type p53 protein transactivated a reporter plasmid containing a luciferase gene driven by a minimal promoter harboring this p53 binding site. Finally, as the p53 promoter contains an NF-kappa B binding site, we demonstrated an additive effect when NF-kappa B subunits and p53 protein combined to transactivate the human p53 promoter.	Univ Liege, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium	University of Liege	Merville, MP (corresponding author), Univ Liege, Lab Med Chem & Med Oncol, Pathol B23, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baichwal V. R., 1997, CURR BIOL, V7, P94; Balint E, 1996, CANCER RES, V56, P1648; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAINAUT P, 1993, CANCER RES, V53, P4469; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ravi R, 1998, CANCER RES, V58, P4531; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VAN AD, 1996, SCIENCE, V274, P787; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	49	41	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4787	4794		10.1038/sj.onc.1203831	http://dx.doi.org/10.1038/sj.onc.1203831			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032029				2022-12-28	WOS:000089528800013
J	Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P				Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P			Early events in leukemogenesis in P190Bcr-abl transgenic mice	ONCOGENE			English	Article						oncogenesis; acute leukemia; P190Bcr-abl; cell cycle; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DNA-POLYMERASE-BETA; BCR-ABL ONCOPROTEIN; TYROSINE PHOSPHORYLATION; EXPRESSING P210(BCR/ABL); PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; C-ABL	The activated tyrosine kinase, Bcr-abl, is implicated in a number of hematopoietic malignancies. The exact biological mechanism by which the kinases transforms cells is still not well delineated. Previous data has suggested that the inhibition of apoptosis and the deregulation of cell cycle progression as the result of P210Bcr-abl expression might contribute to leukemogenesis, In vitro systems in which Bcr-Abl is over-expressed have concluded that similar growth regulatory pathways are affected as a result of the expression of both P210 and P190Bcr-abl. Here, we utilized an in vitro P190Bcr-abl leukemia mouse model to dissect the early events that contribute to transformation by this isoform of Bcr-Abl. In this mouse model P190Bcr-abl is expressed as a low but physiologically relevant level in that all mice develop pre-B leukemia lymphomas, We show that cell cycle and apoptotic responses to DNA damage are intact in bone marrow and spleen cells of such animals. We also demonstrate a normal induction of p21(WAF-1/CIP1) in both hematopoietic and non-hematopoietic tissue as a result of genotoxic stress, We suggest that P190Bcr-abl induced transformation is different than that of P210Bcr-abl.	Royal Victoria Hosp, Dept Med, Div Expt Med, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Childrens Hosp Los Angeles, Sect Mol Diag, Div Hematol Oncol, Los Angeles, CA 90027 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Children's Hospital Los Angeles	Laneuville, P (corresponding author), Royal Victoria Hosp, Dept Med, Div Expt Med, Hersey Pavil,H5-21, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Heisterkamp, Nora/C-1698-2012; Laneuville, Pierre/AAH-2293-2021	Heisterkamp, Nora/0000-0003-2769-2273; 	NATIONAL CANCER INSTITUTE [R01CA050248, R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BERGER R, 1993, LEUKEMIA LYMPHOMA, V11, P235, DOI 10.3109/10428199309047892; BLOOMFIELD CD, 1989, ACUTE LYMPHOBLASTIC, P101; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HEISTERKAMP N, 1991, HEMATOL PATHOL, V5, P1; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; TENHOEVE J, 1994, CANCER RES, V54, P2563; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4362	4374		10.1038/sj.onc.1203804	http://dx.doi.org/10.1038/sj.onc.1203804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980612				2022-12-28	WOS:000089271900007
J	Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H				Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H			Detection of PTEN nonsense mutation and psi PTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay	ONCOGENE			English	Article						astrocytoma; glioblastoma; PTEN/MMAC1; psi PTEN; pseudogene	P53 FUNCTIONAL ASSAY; BANNAYAN-ZONANA-SYNDROME; SUPPRESSOR GENE; GLIOBLASTOMA-MULTIFORME; HUMAN GLIOMAS; CELL-LINES; PTEN/MMAC1 MUTATIONS; GERMLINE MUTATIONS; MALIGNANT GLIOMAS; COWDEN-DISEASE	We have developed a new yeast-based assay for the detection of PTEN nonsense mutation, and applied it to a total of 42 astrocytic tumors, The assay utilizes homologous recombination of PCR-amplified PTEN cDNA samples to a yeast vector which expresses an in-frame PTEN::ADE2 chimera protein. An allele of nonsense mutation in the sample PTEN mRNA gives a truncated chimera protein in a yeast cell, resulting in the formation of a red colony, The assay and subsequent sequence analysis demonstrated nonsense mutations as red colonies of more than 10% in one of 10 anaplastic astrocytomas and six of 18 glioblastomas, but none in six pilocytic astrocytomas or in eight astrocytomas, Sequence analysis of white colonies showed one missense mutation in a glioblastoma. Interestingly, four of seven nonsense mutations were frame-shifts due to exon skipping, In addition, pink colonies were found in one of six pilocytic astrocytomas, three of eight astrocytomas, two of 10 anaplastic astrocytomas, and 10 of 18 glioblastomas, Sequence analysis of the pink colonies revealed a sequence similar to those reported as psi PTEN/PTH2. By testing mRNA and genomic DNA, it was found to be a processed pseudogene which was transcribed, The psi PTEN expression was complementary to PTEN mutation, for 14 of 18 glioblastomas showed either PTEN mutation or psi PTEN expression and only one case showed both PTEN mutation and psi PTEN expression (P<0.046), suggesting a pathological role of psi PTEN expression as an alternative to PTEN mutation in glioblastomas.	Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Neurosurg Sect, Dept Neuropathophysiol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Tada, M (corresponding author), Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan.		KOBAYASHI, Hiroyuki/G-8990-2012					AndreuttiZaugg C, 1997, CANCER RES, V57, P3288; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; Bostrom J, 1998, CANCER RES, V58, P29; Cheney IW, 1998, CANCER RES, V58, P2331; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Kleihues P, 1993, HISTOLOGICAL TYPING; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAQUAT LE, 1995, RNA, V1, P453; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsumoto R, 1998, CANCER RES, V58, P609; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Rasheed BKA, 1997, CANCER RES, V57, P4187; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Scala S, 1998, INT J ONCOL, V13, P665; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tada M, 1997, NEUROSURGERY, V40, P393, DOI 10.1097/00006123-199702000-00034; Tada M, 1997, MOL CARCINOGEN, V18, P171, DOI 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.3.CO;2-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; Wang SI, 1997, CANCER RES, V57, P4183; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539	48	17	18	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4346	4353		10.1038/sj.onc.1203795	http://dx.doi.org/10.1038/sj.onc.1203795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980610				2022-12-28	WOS:000089271900005
J	Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J				Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J			Lack of p19(INK4d) in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis	ONCOGENE			English	Article						p19(INK4d); RB pathway; spermatogenesis; carcinoma in situ; testicular germ cell tumours	RETINOBLASTOMA PROTEIN PATHWAY; CARCINOMA IN-SITU; CDK INHIBITORS; DEPENDENT KINASES; TUMORS; CANCER; TESTIS; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS	p19(INK4d) a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) complexes whose ability to phosphorylate the retinoblastoma tumour suppressor (RB) promotes G1/S transition. In contrast to the related p16(INK4a) tumour suppressor, expression patterns of 19(INK4d) in human tissues and tumours remain unknown. As the RE pathway is commonly targeted in cancer, and mouse models suggest a role for p19(INK4d) in spermatogenesis, ne examined the abundance and localization of p19(INK4d) in the human testis, both during normal development and at various stages of germ-cell tumour pathogenesis. Our data show that the p19(INK4d) protein is abundant in spermatocytes of normal human adult testes, whereas virtually no p19(INK4d) is detectable in testicular cancer, including the preinvasive carcinoma ill situ stage. Together with the lack of p19(INK4d) in human foetal germ cells, these results support the concept of foetal origin of the testicular germ-cell tumours, and help better understand the emerging role of the RE pathway in spermatogenesis and tumorigenesis in the human testis.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Growth & Reprod, Rigshosp, Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Rajpert-De Meyts, Ewa/H-6526-2019; Bartek, Jiri/G-5870-2014	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; 				Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; BARKOVA J, 2000, INT J CANCER, V85, P370; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaubert P, 1997, AM J PATHOL, V151, P859; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GRIGOR KM, 1993, EUR UROL, V23, P93; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUSTIN J, 1987, INT J ANDROL, V10, P29, DOI 10.1111/j.1365-2605.1987.tb00162.x; JORGENSEN N, 1995, LAB INVEST, V72, P223; MOSTOFI FK, 1986, GERM CELL TUMOURS, V2, P1; OOSTERHUIS JW, 1993, EUR UROL, V23, P245; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	46	48	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4146	4150		10.1038/sj.onc.1203769	http://dx.doi.org/10.1038/sj.onc.1203769			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962575				2022-12-28	WOS:000088955100008
J	Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG				Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG			p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	ONCOGENE			English	Article						p14arf; p16; mdm2; egfr; brain tumor; tumor suppressor	CELL LUNG-CANCER; HIGH-GRADE GLIOMAS; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; BRAIN-TUMORS; CDK4 AMPLIFICATION; MALIGNANT GLIOMAS; ONCOPROTEIN MDM2; P16(INK4A) GENE; P19(ARF)	P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently: deleted in human tumors, Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci, To examine this question we performed a multigenic analysis on 29 gliomas, We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26, Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis, The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV, either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%), These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and Loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.	CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Univ Hosp, Dept Neuropathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Van Meir, EG (corresponding author), CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; BIERNAT W, 1997, NEUROPATHOL EXP NEUR, V56, P180; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Costello JF, 1997, CANCER RES, V57, P1250; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; DURO D, 1995, ONCOGENE, V11, P21; FRYE RA, 1989, ONCOGENE, V4, P1153; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Gazzeri S, 1998, CANCER RES, V58, P3926; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; HE J, 1994, CANCER RES, V54, P5804; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; Ichimura K, 2000, CANCER RES, V60, P417; JEN J, 1994, CANCER RES, V54, P6353; Kamb A, 1994, Nat Genet, V8, P23; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kleihues P, 1994, Recent Results Cancer Res, V135, P25; LANDERS JE, 1994, ONCOGENE, V9, P2745; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SCHMIDT EE, 1994, CANCER RES, V54, P6321; STONE S, 1995, CANCER RES, V55, P2988; Sure U, 1997, J NEUROPATH EXP NEUR, V56, P782; Teng DHF, 1997, CANCER RES, V57, P5221; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang SI, 1997, CANCER RES, V57, P4183; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	123	124	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3816	3822		10.1038/sj.onc.1203700	http://dx.doi.org/10.1038/sj.onc.1203700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949938				2022-12-28	WOS:000088568400016
J	Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT				Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT			LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis	ONCOGENE			English	Article						LUCA-15; CD95; apoptosis; chromosome 3; jurkat; antisense	FLICE-INHIBITORY PROTEIN; EPSTEIN-BARR VIRUS; INDUCED CELL-DEATH; C-ELEGANS; IMMUNE ESCAPE; LUNG-CANCER; FAS; EXPRESSION; TUMORS; RNA	Using an expression cloning system to discover novel genes involved in apoptosis, we identified a 326 bp bone marrow cDNA fragment (termed Je2) that suppresses, upon transfection, CD95-mediated apoptosis in Jurkat T cells, Sequence homology revealed that Je2, maps to 3p21.3, to an intronic region of the candidate TSG LUCA-15 locus. It represents, in fact, an antisense transcript to the 3'-UTR of two novel splice variants of this gene. Overexpression of sequence representing one of these splice variants (a 2.6 kit cDNA termed Clone 26), inhibited proliferation of Jurkat cells and sensitized them to CD95-mediated apoptosis, This study therefore implicates the LUCA-15 gene locus in the control of apoptosis.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; Keele Univ, Sch Life Sci, Keele ST5 5BG, Staffs, England; Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; CHU Laval, Ctr Rech, Eastern Quebec Peptide Sequencing Facil, Ste Foy, PQ G1V 4G2, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Keele University; University of London; Institute of Cancer Research - UK; Laval University	Sutherland, LC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930; Poirier, Guy/0000-0002-4869-1424	NCRR NIH HHS [M01 RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046778, R01DK046778] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Cook DM, 1996, ONCOGENE, V13, P1789; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Okura T, 1996, J IMMUNOL, V157, P4277; Peltz SW, 1999, J EXP MED, V190, P1729, DOI 10.1084/jem.190.12.1729; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; Sutherland LC, 2000, J IMMUNOL METHODS, V234, P43, DOI 10.1016/S0022-1759(99)00202-1; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Tsuruda K, 1999, LEUKEMIA RES, V23, P159, DOI 10.1016/S0145-2126(98)00158-1; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wei MH, 1996, CANCER RES, V56, P1487; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Williams GT, 1998, TOXICOL LETT, V103, P485, DOI 10.1016/S0378-4274(98)00343-9; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	40	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3774	3781		10.1038/sj.onc.1203720	http://dx.doi.org/10.1038/sj.onc.1203720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949932				2022-12-28	WOS:000088568400010
J	Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ				Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ			Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGF beta RII	ONCOGENE			English	Article						skin carcinogenesis; transforming growth factor beta receptor; transgenic; cell cycle progression; cdk inhibitors; centrosome	GROWTH-FACTOR-BETA; II RECEPTOR GENE; CHEMICAL CARCINOGENESIS; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DOWN-REGULATION; CDK INHIBITOR; MUTATION; MICE; ARREST	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) have been found in various malignant tumors, suggesting that loss of TGF beta signaling plays a causal role in late-stage cancer development, To test whether loss of TGF beta RII is involved in early-stage carcinogenesis, ne have generated transgenic mice expressing a dominant negative TGF beta RII (Delta beta RII) in the epidermis, These mice exhibited an increased susceptibility to chemical carcinogenesis protocols at both early and late stages. In the current study, parameters for cell cycle progression and chromosome instability were analysed in Delta beta RII tumors. Delta beta RII papillomas showed an increased S phase in flow cytometry. Bromodeoxyuridine (BrdU) labeling and mitotic indices in Delta beta RII papillomas also showed a threefold increase compared to papillomas developing in non-transgenic mice, When papillomas further progressed to squamous cell carcinomas (SCC), both control and Delta beta RII SCC showed similar BrdU labeling indices and percentages of S phase cells. However, Delta beta RII SCC cells showed a sixfold increase in the G2/M population. Mitotic indices in Delta beta RII SCC also showed a threefold increase compared to non-transgenic SCC, Consistent with a perturbed cell cycle, Delta beta RII papillomas and SCC showed reduced expression of the TGF beta target genes p15 (INK4b), p21 (WAF-1) and p27 (Kip1), inhibitors of cyclin-dependent kinases (cdks). However, most Delta beta RII papilloma cells exhibited normal centrosome numbers, and Delta beta RII SCC exhibited a similar extent of centrosome abnormalities compared to control SCC (35-40% cells). Most of Delta beta RII SCC exhibited diploid chromosome profiles. These data indicate that inactivation of TGF beta RII accelerates skin tumorigenesis at early stages by the acceleration of loss of cell cycle control, but not by increased chromosome instability.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.				NCI NIH HHS [CA64255, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Go C, 1999, CANCER RES, V59, P2861; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iacopetta BJ, 1998, J PATHOL, V184, P390; Iavarone A, 1997, NATURE, V387, P417; Imai Y, 1998, INT J CANCER, V76, P407, DOI 10.1002/(SICI)1097-0215(19980504)76:3<407::AID-IJC19>3.0.CO;2-7; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SATTERWHITE DJ, 1994, INVAS METAST, V14, P309; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	43	20	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3623	3631		10.1038/sj.onc.1203701	http://dx.doi.org/10.1038/sj.onc.1203701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951568				2022-12-28	WOS:000088568300008
J	Jiang, JG; Gao, B; Zarnegar, R				Jiang, JG; Gao, B; Zarnegar, R			The concerted regulatory functions of the transcription factors nuclear factor-1 and upstream stimulatory factor on a composite element in the promoter of the hepatocyte growth factor gene	ONCOGENE			English	Article						hepatocyte growth factor; NF1; USF; promoter; partial hepatectomy; transcription	FACTOR SCATTER-FACTOR; MAJOR LATE PROMOTER; USF FAMILY; EXPRESSION; PROTEINS; REGION; RECEPTOR; LIVER; DNA; BINDS	Hepatocyte growth factor (HGF) is an important multifunctional cytokine whose gene expression is regulated mainly at the transcriptional level, Previous studies using transgenic mice as well as in vitro analyses showed that a potential regulatory element(s) exists between -260 to -230 bp in the upstream region of the HGF gene promoter. In the present study, me have discovered that this region is a composite site through which members of the nuclear factor 1 (NF1) and upstream stimulatory factor (USF) families bind to and regulate HGF gene transcription. Gel mobility shift and supershift assays revealed that USF and NF1 have high binding affinity for this region and that the binding sites of the two different transcription factor families overlap. Functional studies showed that NF1 suppresses HGF gene promoter activity and that USF has an activating function, We found that the NF1/X and NF1/Red1 isoforms strongly suppressed HGF promoter activity while the NF1/L variant had no obvious effects. USF1, but not USF2, of the USF family stimulated HGF gene promoter activity, More interestingly, during liver regeneration after partial hepatectomy, a process which activates the HGF gene, we noted that the binding activity of USF to the HGF promoter element increased while that of NF1 decreased. These data provide insight into the molecular mechanisms that govern HGF gene transcription.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Virginia Commonwealth University	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.		Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES 06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; Gao B, 1996, MOL CELL BIOL, V16, P5997; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LIU YH, 1994, J BIOL CHEM, V269, P4152; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sirito Mario, 1992, Gene Expression, V2, P231; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	26	13	14	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2786	2790		10.1038/sj.onc.1203581	http://dx.doi.org/10.1038/sj.onc.1203581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851080				2022-12-28	WOS:000087318500008
J	Ma, YY; Wei, SJ; Lin, YC; Lung, JC; Chang, TC; Whang-Peng, J; Liu, JM; Yang, DM; Yang, WK; Shen, CY				Ma, YY; Wei, SJ; Lin, YC; Lung, JC; Chang, TC; Whang-Peng, J; Liu, JM; Yang, DM; Yang, WK; Shen, CY			PIK3CA as an oncogene in cervical cancer	ONCOGENE			English	Article						PIK3CA; p110 alpha; cervical cancer; AKT; PI 3-kinase; 3q26.3	SYNTHASE KINASE 3-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; INTRAEPITHELIAL NEOPLASIA; CYCLIN-E; PATHWAY; CELLS; AKT; D1; TRANSFORMATION	Amplification of chromosome arm 3q is the most consistent aberration in cervical cancer, and is implicated in the progression of dysplastic uterine cervical cells into invasive cancer. The present study employed the 'positional candidate gene' strategy to determine the contribution of PIK3CA, which is located in 3q26.3, in cervical tumorigenesis, PIK3CA is known to be involved in the PI 3-kinase/AKT signaling pathway, which plays an important role in regulating cell growth and apoptosis, The results of comparative genomic hybridization show that the 3q26.3 amplification was the most consistent chromosomal aberration in primary tissues of cervical carcinoma, and a positive correlation between an increased copy number of PIK3CA (detected by competitive PCR) and 3q26.3 amplification was found in tumor tissues and in cervical cancer cell lines. In cervical cancer cell lines harboring amplified PIK3CA, the expression of gene product (p110 alpha) of PIK3CA was increased, and was subsequently associated with high kinase activity. In addition, transformation phenotypes in these lines, including increased cell growth and decreased apoptosis, were found to be significantly affected by the treatment of specific PI 3-kinase inhibitor, suggesting that increased expression of PIK3CA in cervical cancer may result in promoting cell proliferation and reducing apoptosis, These evidences support that PIK3CA is an oncogene in cervical cancer and PIK3CA amplification may be linked to cervical tumorigenesis.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Hlth Res Inst, Canc Res Div, Taipei 115, Taiwan; Natl Def Med Univ, Taipei 100, Taiwan; Chang Gung Mem Hosp, Tao Yuan, Taiwan	Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; National Defense Medical Center; Chang Gung Memorial Hospital	Shen, CY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.		Shen, CY/F-6271-2010	Wei, Sung Jen/0000-0002-9810-9041				Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chu TY, 1999, GENE CHROMOSOME CANC, V24, P127, DOI 10.1002/(SICI)1098-2264(199902)24:2<127::AID-GCC5>3.0.CO;2-8; Clerici M, 1997, J NATL CANCER I, V89, P245, DOI 10.1093/jnci/89.3.245; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ebert AD, 1999, CANCER RES, V59, P4502; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Ku WH, 1997, INT J CANCER, V72, P270, DOI 10.1002/(SICI)1097-0215(19970717)72:2<270::AID-IJC12>3.0.CO;2-K; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Pao CC, 1997, J CLIN ONCOL, V15, P1932, DOI 10.1200/JCO.1997.15.5.1932; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Shah K. V., 1996, FIELDS VIROLOGY; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; Tlsty TD, 1999, NAT GENET, V21, P64, DOI 10.1038/4998; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655	27	363	408	1	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2739	2744		10.1038/sj.onc.1203597	http://dx.doi.org/10.1038/sj.onc.1203597			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851074				2022-12-28	WOS:000087318500002
J	Shuai, K				Shuai, K			Modulation of STAT signaling by STAT-interacting proteins	ONCOGENE			English	Article						STAT-interacting proteins; signal transduction; transcription	INTERFERON-ALPHA; TRANSCRIPTION FACTOR; IFN-GAMMA; TYROSINE PHOSPHORYLATION; DNA-BINDING; RESPONSIVE ELEMENT; NUCLEAR-RECEPTOR; ACTIVATION; GENE; COMPLEX	STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes including immune responses, cell growth and differentiation, cell survival and apoptosis, and oncogenesis. In contrast to many other cellular signaling cascades, the STAT pathway is direct: STATs bind to receptors at the cell surface and translocate into the nucleus where they function as transcription factors to trigger gene activation, However, STATs do not act alone. A number of proteins are found to be associated with STATs, These STAT-interacting proteins function to modulate STAT signaling at various steps and mediate the crosstalk of STATs with other cellular signaling pathways. This article reviews the roles of STAT-interacting proteins in the regulation of STAT signaling.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,10833 LeConte Ave, Los Angeles, CA 90095 USA.							Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bao JX, 1996, ONCOGENE, V12, P2171; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DUTTA A, 1997, KAM REV CELL DEV BIO, V13, P293; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IMAMOTO N, 1995, FEBS LETT, V368, P415; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; LEWIS SE, 1994, J NEUROCHEM, V63, P429; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mohr SE, 1999, GENE, V229, P109, DOI 10.1016/S0378-1119(99)00033-5; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sekimoto T, 1998, CYTOKINE GROWTH F R, V9, P205, DOI 10.1016/S1359-6101(98)00012-4; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	63	280	303	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2638	2644		10.1038/sj.onc.1203522	http://dx.doi.org/10.1038/sj.onc.1203522			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851063				2022-12-28	WOS:000087459400020
J	Wurster, AL; Tanaka, T; Grusby, MJ				Wurster, AL; Tanaka, T; Grusby, MJ			The biology of Stat4 and Stat6	ONCOGENE			English	Review						Stat4; Stat6; T helper cells	NF-KAPPA-B; INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR; GERMLINE EPSILON-PROMOTER; CYTOKINE GENE-EXPRESSION; T-CELL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; IL-4 RECEPTOR; DNA-BINDING; TH2 CELLS	regulators of the proliferation, differentiation and functional capacity of lymphocytes, STATs (signal transducers and activators of transcription) are transcription factors that provide a direct link between the cytokine receptors and cytokine induced gene transcription. Stat6 and Stat4 are two STAT family members that specifically mediate signals that emanate from the IL-4 and IL-12 receptors, respectively, Recently a great deal of progress has been made in understanding the specific roles that Stat6 and Stat4 play in lymphocyte function through in vitro as well as in vivo studies using Stat6 and Stat4-deficient mice. This report will summarize and describe the recent advances made in understanding the activation and regulation of Stat6 and Stat4 as well as their roles in the development of an immune response.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Grusby, MJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.		Tanaka, Takashi/O-8254-2015					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Cho SS, 1996, J IMMUNOL, V157, P4781; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; dePaterHuijsen FL, 1997, IMMUNOL LETT, V57, P47, DOI 10.1016/S0165-2478(97)00044-8; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galon J, 1999, J IMMUNOL, V162, P7256; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hoey T, 1999, Adv Immunol, V71, P145; Holz A, 1999, J IMMUNOL, V163, P5374; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iciek LA, 1997, J IMMUNOL, V158, P4769; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kamogawa Y, 1998, J IMMUNOL, V161, P1074; Kaplan MH, 1998, J EXP MED, V188, P1191, DOI 10.1084/jem.188.6.1191; Kaplan MH, 1998, J IMMUNOL, V160, P1850; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; Karras JG, 1997, J IMMUNOL, V159, P4350; Karras JG, 1996, J IMMUNOL, V157, P39; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Linehan LA, 1998, J IMMUNOL, V161, P302; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Losman JA, 1999, J IMMUNOL, V162, P3770; Lu BF, 1997, J IMMUNOL, V159, P1255; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Messner B, 1997, J IMMUNOL, V159, P3330; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Paul WE, 1997, CIBA F SYMP, V204, P208; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RICHARDS ML, 1994, J IMMUNOL, V152, P3453; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Schaffer A, 1999, J IMMUNOL, V162, P5327; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sherman MA, 1999, J IMMUNOL, V162, P2703; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Sinigaglia F, 1999, IMMUNOL REV, V170, P65, DOI 10.1111/j.1600-065X.1999.tb01329.x; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Wang KS, 1999, J IMMUNOL, V162, P299; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu CY, 1997, J IMMUNOL, V159, P1658; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	103	242	267	2	21	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2577	2584		10.1038/sj.onc.1203485	http://dx.doi.org/10.1038/sj.onc.1203485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851056				2022-12-28	WOS:000087459400013
J	Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I				Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I			Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells	ONCOGENE			English	Article						Met; HGF/SF; dominant negative; tubulogenesis; breast cancer cells	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; HUMAN BREAST-CANCER; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; FACTOR-RECEPTOR; FACTOR/SCATTER FACTOR; TUMOR PROGRESSION; MET/HGF RECEPTOR	Activation of the Met tyrosine kinase growth factor receptor by its ligand HGF/SF has been shown to increase in vitro invasiveness in epithelial cell lines. To study the effect of Met-HGF/SF signaling in breast cancer cells, we transfected met, hgf/sf and dominant negative (DN) forms of met into the poorly differentiated metastatic murine mammary adenocarcinoma cell line DA3, These cells express moderate levels of endogenous Met, which is rapidly phosphorylated in response to HGF/SF treatment. Met+hgf/sf transfection results in significantly increased tumorigenic and metastatic activity in vivo accompanied by reduced tubule formation. DA3 cells transfected with DN forms of Met (DN-DA3) exhibit reduced Met phosphorylation following exposure to HGF/SF, Furthermore, as compared to the parental cells, the DN-DA3 cells exhibit diminished in vitro scattering and invasiveness, while in vitro they display greatly reduced tumorigenicity and spontaneous metastasis, Tumors emanating from DN-DA3 cells injected to BALB/C mice are highly differentiated and display extensive tubule formation. These results suggest that Met-HGF/SF signaling is a determining factor in the delicate balance between differentiation/tubule formation and tumorigenicity-metastasis.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tsarfaty, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.			Tsarfaty, Ilan/0000-0002-5230-7093				ALBINI A, 1987, CANCER RES, V47, P3239; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Clark GM, 1996, DIS BREAST, P461; Cortner J., 1995, V74, P89; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; DENG G, 1994, CANCER RES, V54, P499; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FU YX, 1990, CANCER RES, V50, P227; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lamszus K, 1997, LAB INVEST, V76, P339; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, ONCOGENE, V9, P1507; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Robinson ML, 1995, DEVELOPMENT, V121, P3959; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; YAMASHITA J, 1994, CANCER RES, V54, P1630; YAMASHITA J, 1993, RES COMMUN CHEM PATH, V82, P249; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yao Y, 1996, AM J PATHOL, V149, P1707; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	62	48	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2386	2397		10.1038/sj.onc.1203557	http://dx.doi.org/10.1038/sj.onc.1203557			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828880				2022-12-28	WOS:000087018400003
J	Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G				Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G			HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300	ONCOGENE			English	Article						tax; c-Myb; transrepression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; CREB BINDING-PROTEIN; INDUCED TRANSCRIPTION ACTIVATION; NEGATIVE REGULATORY DOMAIN; NF-KAPPA-B; MESSENGER-RNA; V-MYB; PHOSPHORYLATION SITE; ABERRANT EXPRESSION	The c-Myb proto-oncogene is preferentially expressed in hematopoietic lineages, and highly expressed in several leukemia types. The Human T-cell Leukemia Virus Type I (HTLV-I) is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL), A previous report suggested that Tax, the viral transactivator, is able to suppress the transactivation potential of c-Myb protein by competing for recruitment of CBP, We tested whether such a competition could affect transcription from the c-Myb promoter in Tax expressing T-cells, Using several c-Myb promoter reporter constructs carrying mutations in various regions, we demonstrate that Tax suppression of c-Myb transactivation results in transrepression of the c-Myb promoter through the Myb responsive elements in Jurkat T-cells, The ability of Tax mutants M22, M47 and V89A to interact with the full-length CBP and p300 proteins in vitro, and their ability to repress the c-Myb promoter, was then evaluated. Although both M47 and M22 bind to CBP and p300 to a similar extent, only M47 was able to repress the c-Myb promoter, suggesting that competition for CBP/p300 binding was not the mechanism underlying Tax's effect. This concept was further supported by the fact that the Tax mutant V89A transrepresses the c-Myb promoter efficiently in spite of an impaired binding to CBP and p300, Therefore, Tax-mediated repression of the c-Myb promoter appears to be independent from a direct competition between c-Myb and Tax for recruitment of CBP/p300, Interestingly, a decreased transcription from the endogenous c-Myb promoter was observed in several HTLV-I transformed T-cell lines. Finally, the ability of Tax to directly repress the endogenous c-Myb promoter was demonstrated in a Jurkat cell line stably transfected with a tax gene driven by a cadmium-inducible promoter.	NCI, Div Basic Sci, Basic Res Lab, Bethesda, MD 20814 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20814 USA; NIH, Cellular Oncol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Nicot, C (corresponding author), NCI, Div Basic Sci, Basic Res Lab, 9000 Rockville Pike,Bldg 41,Room C303, Bethesda, MD 20814 USA.			Cereseto, Anna/0000-0003-4453-2597; mahieux, renaud/0000-0002-5129-6804	NATIONAL CANCER INSTITUTE [ZIABC005254, ZIABC005645, Z01BC005254, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CASTRON KM, 1992, J IMMUNOL, V148, P934; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATSUMOTO K, 1994, VIROLOGY, V200, P813, DOI 10.1006/viro.1994.1248; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nicot C, 1997, VIROLOGY, V236, P47, DOI 10.1006/viro.1997.8720; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; NICOT C, IN PRESS BLOOD; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TATEWAKI M, 1995, BLOOD, V86, P3109; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; WATSON RJ, 1988, ONCOGENE, V2, P267; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728	71	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2155	2164		10.1038/sj.onc.1203536	http://dx.doi.org/10.1038/sj.onc.1203536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815807				2022-12-28	WOS:000086728000009
J	Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S				Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S			The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)	ONCOGENE			English	Article						tumor invasion; matrix metalloproteinases; integrins; signal transduction; AP-1 transcription factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; IV COLLAGENASE; GROWTH-FACTOR; E-CADHERIN; IN-VITRO; CELL-ADHESION; EXPRESSION; GELATINASE; INHIBITORS	Overexpression of Integrin Linked Kinase (ILK) in intestinal and mammary epithelial cells results in a highly invasive phenotype, associated with increased levels of expression of the matrix metalloproteinase MMP-9. This increase was at the transcriptional level as determined by MMP-9 promoter-CAT reporter assays. Mutations in the two AP-1 binding sites within the MMP-9 promoter completely inhibited the reporter activity. We have previously shown that ILK inhibits glycogen synthase kinase-3 (GSK-3) activity, Transient transfection of wild-type GSK-3 beta in ILK-overexpressing cells decreased MMP-9 promoter activity and AP-I activity, indicating that ILK can stimulate MMP-9 expression via GSK-3 beta and AP-1 transcription factor, A small molecule inhibitor of the ILK kinase reduced the in vitro invasiveness of ILK-overexpressing cells as well as the invasiveness of several human brain tumor cell lines. Furthermore, both MMP-9 promoter and AP-1 activities mere inhibited by the ILK inhibitor. Invasiveness of ILK-overexpressing cells was also reduced by inhibition of MMP-9. These data demonstrate that ILK can induce an invasive phenotype via AP-1-dependent upregulation of MMP-9.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Kanazawa Univ, Sch Med, Kanazawa, Ishikawa 920, Japan; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Kanazawa University; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Llorens A, 1998, LAB INVEST, V78, P1131; Luo J, 1999, CANCER RES, V59, P3552; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ozes ON, 1999, NATURE, V401, P82; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sato F, 1999, BRIT J CANCER, V80, P1366, DOI 10.1038/sj.bjc.6690530; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Tamaki M, 1997, J NEUROSURG, V87, P602, DOI 10.3171/jns.1997.87.4.0602; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	31	167	176	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5444	5452		10.1038/sj.onc.1203928	http://dx.doi.org/10.1038/sj.onc.1203928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114721				2022-12-28	WOS:000165396100004
J	Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF				Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF			Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; mutant; X protein	TRANSGENIC MICE; HBX PROTEIN; DELETION MUTANTS; GENE PRODUCT; ANTIGEN; DNA; KINASE; PATHOGENESIS; INFECTIONS; APOPTOSIS	The aim of this study was to investigate whether there was a particular hepatitis B virus (HBV) X protein (HBx) mutant associated with Taiwanese patients with hepatocellular carcinoma (HCC). Initially, the entire coding region of HBx gene from the serum samples of 14 Taiwanese patients were sequenced. A novel mutant, HBx-A31, was preferentially found in patients with HCC. Sera from 67 patients with HCC and 100 patients with chronic hepatitis B were thus subjected for codon 31 analysis using a dual amplification created restriction site method. HBx-A31 was detected more frequently in patients with HCC (52% versus 12%; P<0.001) and in patients with liver cirrhosis (44% versus 6%; P<0.001). Site directed mutagenesis experiment revealed that HBx-A31 was less effective in transactivating HBV enhancer I-X promoter complex, less efficient in supporting HBV replication, and less potent in enhancing TNF-alpha induced increment of CPP32/caspase 3 activities in HepG2 cells. In conclusion, a prevalent HBx mutant was identified in Taiwanese patients with hepatocellular carcinoma. Development of this mutant might represent a strategy of the virus to escape immune surveillance and thus contribute to the process of multiple-step hepatocarcinogenesis.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 105, Taiwan; Chang Gung Univ, Sch Med, Taipei 105, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 105, Taiwan.		Liaw, Yun-Fan/B-4305-2009					BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chu CM, 1996, J CLIN MICROBIOL, V34, P1815, DOI 10.1128/JCM.34.7.1815-1818.1996; Dopheide TAA, 1996, J GEN VIROL, V77, P173, DOI 10.1099/0022-1317-77-2-173; DUNSFORD HA, 1990, CANCER RES, V50, P3400; FEITELSON M, 1992, CLIN MICROBIOL REV, V5, P275, DOI 10.1128/CMR.5.3.275-301.1992; FEITELSON MA, 1995, GASTROENTEROLOGY, V108, P1810, DOI 10.1016/0016-5085(95)90144-2; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Greenblatt MS, 1997, CANCER RES, V57, P426; Hsia CC, 1997, BIOCHEM BIOPH RES CO, V241, P726, DOI 10.1006/bbrc.1997.7882; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1994, VIRAL HEPATITIS LIVE, P419; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; OHAKI Y, 1983, CANCER, V51, P822, DOI 10.1002/1097-0142(19830301)51:5<822::AID-CNCR2820510513>3.0.CO;2-C; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Szmuness W, 1978, Prog Med Virol, V24, P40; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG XW, 1995, CANCER RES, V55, P6012; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, HEPATOLOGY, V31, P1318, DOI 10.1053/jhep.2000.7296; Yeh CT, 1997, J VIROL METHODS, V65, P219, DOI 10.1016/S0166-0934(97)02187-3; Yeh CT, 2000, J HEPATOL, V32, P829, DOI 10.1016/S0168-8278(00)80253-6; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	39	63	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5213	5220		10.1038/sj.onc.1203903	http://dx.doi.org/10.1038/sj.onc.1203903			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077437				2022-12-28	WOS:000165059700001
J	Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G			The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site	ONCOGENE			English	Article						Ron; substrate specificity; tumorigenesis; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; KINASE CATALYTIC DOMAIN; INVASIVE GROWTH; RECEPTOR FAMILY; MUTATIONS; ACTIVATION; TRANSFORMATION; GENE; IDENTIFICATION; PROTOONCOGENE	Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y-1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (Ron(M1254T)), but not by other two oncogenic substitutions, Furthermore, Ron(M1254T) lacking the multifunctional docking site retains transforming and metastatic activity, These data reveal that the transforming activity of Ron(M1254T) mutant is dependent on Y-1317 phosphorylation, suggesting a shift in intramolecular substrate specificity. Consistently, a shift of Ron(M1254T) kinase substrate specificity was observed by in vitro peptide phosphorylation assays and in vitro receptor autophosphorylation, The Y-1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways, Our data indicate that the accomplishment of the full oncogenic phenotype of Ron(M1254T) requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y-1317 residue in the tyrosine kinase domain.	Dibit HSR, I-20138 Milan, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dept Med Sci, I-28100 Novara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Dibit HSR, Via Olgettina 58, I-20138 Milan, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; Cilli, Michele/0000-0003-4083-8986; SANTORO, Massimo Mattia/0000-0003-4605-5085				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STENBERG MJE, 1989, NATURE, V339, P587; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5208	5211		10.1038/sj.onc.1203819	http://dx.doi.org/10.1038/sj.onc.1203819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064459	Green Published			2022-12-28	WOS:000090124100011
J	Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J				Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J			Activation of the alpha(2)beta(1) integrin prevents c-erbB2-induced scattering and apoptosis of human mammary epithelial cells in collagen	ONCOGENE			English	Article						epithelial-mesenchymal conversion; E-cadherin; heregulin; morphogenesis; anchorage-independent growth	PHOSPHOINOSITIDE 3-OH KINASE; EPIDERMAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TYROSINE KINASE; CARCINOMA-CELLS; ERBB RECEPTORS; BREAST-CANCER; TUMOR-CELLS; EXPRESSION; ADHESION	Constitutive overexpression of C-erbB2 in the mammary epithelial cell line MTSV1-7 has been shown to result in epithelial-mesenchymal conversion, anchorage-independent growth and loss of organized morphogenesis in collagen. To elucidate the events leading to this drastic change, MTSV1-7 cells and its subclone HB2 (which shows a more strictly epithelial phenotype) were transfected with the hybrid trk-neu receptor consisting of the extracellular domain of the trkA nerve growth factor (NGF) receptor and the transmembrane and cytoplasmic domains of c-erbB2 (neu), In cells expressing this construct, c-erbB2 homodimerization can be mimicked by addition of NGF, In trk-neu transfectants of HB2 cells, modest expression led to increased cell proliferation upon NGF treatment. When clones with higher expression levels were grown in collagen, NGF instead induced cell scattering, diminished viability and dramatically increased apoptosis, Interestingly, both the dissociation of colonies and loss of cell viability could be completely reversed by treatment of the cells with antibodies that activate the adhesive capacity of the alpha(2)beta(1) integrin, Long-term NGF treatment of high-expressing transfectants generated fibroblastic clones displaying a reduced expression of integrin alpha(2) and E-cadherin, and extensive apoptosis in collagen. These results, which indicate that strong c-erbB2 signalling may lead to downregulation and/or inactivation of the alpha(2)beta(1) integrin, promoting apoptosis in collagen, provide one possible explanation to the increased apoptosis frequently seen in early tumour development.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Lab, London SE1 9RT, England	University of Gothenburg; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Baeckstrom, D (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.							Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Alford D, 1998, J CELL SCI, V111, P521; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baasner S, 1996, ONCOGENE, V13, P901; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berdichevsky Feodor, 1994, Molecular and Cellular Differentiation, V2, P255; DEPOTTER CR, 1995, VIRCHOWS ARCH, V426, P107, DOI 10.1007/BF00192631; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Genersch E, 1996, J MOL MED-JMM, V74, P609, DOI 10.1007/s001090050064; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; LAUEROVA L, 1988, HYBRIDOMA, V7, P495, DOI 10.1089/hyb.1988.7.495; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nowak F, 1997, EXP CELL RES, V231, P251, DOI 10.1006/excr.1996.3468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Sambrook J., MOL CLONING LAB MANU; Shak S, 1999, SEMIN ONCOL, V26, P71; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Ye JP, 1996, MOL CELL BIOL, V16, P6178; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	33	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4592	4603		10.1038/sj.onc.1203792	http://dx.doi.org/10.1038/sj.onc.1203792			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030148				2022-12-28	WOS:000089438200005
J	Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M				Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M			Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency	ONCOGENE			English	Article						azacytidine; transforming growth factor-beta; transforming growth factor-beta receptor type I (RI)	COLON-CARCINOMA CELLS; TGF-BETA; O-GLYCOSYLATION; CANCER CELLS; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTIVATION; MECHANISM; GENE	In this report, we describe the mechanism of TGF-beta receptor type I (RI) repression in the CEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-beta response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RT promoter, Protein stability studies after cyclohexamide treatment suggested an increase in the Spl protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Spl expression in Sp1 deficient CEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-beta receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38173, CA 72001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1996, CANCER RES, V56, P2463; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Periyasamy S, 1996, J CELL PHYSIOL, V168, P711, DOI 10.1002/(SICI)1097-4652(199609)168:3<711::AID-JCP24>3.0.CO;2-#; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259	31	30	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4660	4667		10.1038/sj.onc.1203822	http://dx.doi.org/10.1038/sj.onc.1203822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030155				2022-12-28	WOS:000089438200012
J	Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH				Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH			Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector Bak	ONCOGENE			English	Article						apoptosis; Bak; leukemia cells; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; BCL-2 HOMOLOG BAK; CYTOCHROME-C; MYELOID-LEUKEMIA; HL-60 CELLS; TERMINAL DIFFERENTIATION; INHIBITS APOPTOSIS; MESSENGER-RNA; LINE HL-60	We demonstrate that treatment of HCW-2 cells, an apoptotic resistant variant of the human HL-60 promyelocytic leukemia cell line with phorbol-12-myristate acetate (PMA), induced differentiation along the monocytic lineage. During this process there was a dramatic increase in the mitochondrial levels of the apoptosis effector, Bail, due to the stabilization of bak mRNA, which was correlated with the sensitization of HCW-2 cells to respond to the apoptotic effect of staurosporine (STS), Treatment of PMA-differentiated, but not undifferentiated, HCW-2 cells induced processing of Bid, substantial efflux of cytochrome c from mitochondria to the cytosol, activation of caspase-3 and apoptosis, The biological significance of the increased mitochondrial Bak in differentiated HCW-2 cells mas supported by the finding that transient transfection of a bak cDNA into HCW-2 cells conferred sensitivity to STS-triggered apoptosis, as determined ba pro-caspase-3 processing, cytochrome c efflux and DNA fragmentation. Our results suggest that the induction of Bak, upon monocytic differentiation, may he a critical event that regulates the apoptotic sensitivity of differentiated HCW-2 cells.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Howard Univ, Dept Biol, Washington, DC 20059 USA	Brown University; Howard University	Chatterjee, D (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 69 Brown St, Providence, RI 02912 USA.							BENITO A, 1995, AM J PATHOL, V146, P481; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; CAMPANA D, 1993, BLOOD, V81, P1025; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; CHATTERJEE D, 1989, CANCER RES, V49, P3910; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEXTER DL, 1979, CANCER RES, V39, P1020; Doyle GAR, 1997, BIOCHEMISTRY-US, V36, P2492, DOI 10.1021/bi962161e; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HAN ZY, 1994, AM J PATHOL, V145, P423; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Han ZY, 1996, CANCER RES, V56, P1621; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; HSU SY, 1997, P NATL ACAD SCI USA, V95, P4997; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krajewski S, 1996, CANCER RES, V56, P2849; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MINN AJ, 1997, NATURE, V385, P853; MIYASHITA T, 1993, BLOOD, V81, P151; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NAUMOVSKI L, 1994, BLOOD, V83, P2261; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PANTAZIS P, 1994, EUR J HAEMATOL, V53, P135; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; PARK JR, 1994, BLOOD, V84, P440; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; SOLARY E, 1993, BLOOD, V81, P1359; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	4	4	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4108	4116		10.1038/sj.onc.1203757	http://dx.doi.org/10.1038/sj.onc.1203757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962571				2022-12-28	WOS:000088955100004
J	Kostic, C; Shaw, PH				Kostic, C; Shaw, PH			Isolation and characterization of sixteen novel p53 response genes	ONCOGENE			English	Article						p53; transcription; inducible; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; PROGRAMMED CELL-DEATH; SUBTRACTIVE HYBRIDIZATION; P53-INDUCIBLE GENE; TYROSINE KINASE; BINDING-PROTEIN; CANCER-CELLS; DNA-BINDING; G(1) ARREST	The EB-1 cell line is a stable transfectant of EB, a p53 null colon carcinoma cell line, with an inducible promoter controlling expression of a wild type p53 cDNA. The induced p53 is transcriptionally active and gives rise to apoptosis in these cells. Using this cellular model for presence or absence of the transcription factor p53 and transactivated genes, the Suppression Subtractive Hybridization (SSH) technique permitted the isolation of 17 mRNA candidates (GIPs-(G) under bar enes (i) under bar nduced by (p) under bar 53), whose expression appears to be p53-dependent. Identity has been established for nine of the 17 isolated candidates. These are HGFL/MSP, Zap-70, APOBEC2, Ponsin/ SH3P12/CAP/FLAF2, CDCreI2b/H5/PrutI2, Igc, lats 2, cytokeratin 15 and PIG-3 (quinone oxidoreductase). The latter gene is the only GIP previously demonstrated to be p53 regulated. Of the eight remaining GIPs, sis correspond to Unigene clusters. One candidate, GIP #1, is significantly homologous (72% identity) to a chicken zinc finger protein, CTCF, which binds to insulator elements and thus attenuates enhancer cross-talk between physically adjacent promoters. The p53-dependent expression of GIPs was confirmed by dependence of expression upon induction of wt p53 expression in the EB-1 cellular model and by up-regulation following activation of an endogenous wt p53 by treatment with adriamycin.	Univ Lausanne, Inst Pathol, Lausanne, Switzerland	University of Lausanne	Shaw, PH (corresponding author), Univ Lausanne, Inst Pathol, Lausanne, Switzerland.			Kostic, Corinne/0000-0003-1006-9733				ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arah IN, 1998, ANTICANCER RES, V18, P1845; Bacus SS, 1996, ONCOGENE, V12, P2535; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Church DM, 1997, GENOME RES, V7, P787, DOI 10.1101/gr.7.8.787; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collavin L, 1999, ONCOGENE, V18, P5879, DOI 10.1038/sj.onc.1202970; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Han S, 1993, EXS, V65, P81; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; ISHIJIMA SA, 1995, CELL IMMUNOL, V165, P278, DOI 10.1006/cimm.1995.1214; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1996, ANTICANCER RES, V16, P99; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paavola P, 1999, GENOMICS, V55, P122, DOI 10.1006/geno.1998.5612; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Renzing J, 1996, J CELL SCI, V109, P1105; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; TISHLER RB, 1995, CANCER RES, V55, P6021; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Trepel M, 1998, J NEURO-ONCOL, V39, P19, DOI 10.1023/A:1005910323338; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xia F, 1997, MUTAT RES-FUND MOL M, V373, P87, DOI 10.1016/S0027-5107(96)00193-5; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3	80	35	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3978	3987		10.1038/sj.onc.1203747	http://dx.doi.org/10.1038/sj.onc.1203747			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962554				2022-12-28	WOS:000088825300003
J	Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D				Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D			Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells	ONCOGENE			English	Article						TPA; differentiation; caspases	PROTEIN-KINASE-C; ESTER-INDUCED DIFFERENTIATION; SIGNAL-TRANSDUCTION PATHWAY; CYTOCHROME-C; MACROPHAGE DIFFERENTIATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; HL-60 CELLS; RELEASE	Human myeloid leukemia cells respond to 12-tetradecanoylphorbol-13-acetate (TPA) and other activators of protein kinase C (PKC) with the induction of terminal monocytic differentiation, The present studies demonstrate that TPA treatment of U-937 leukemia cells is associated with release of mitochondrial cytochrome c, activation of caspase-3 and induction of internucleosomal DNA fragmentation. By contrast, the TUR cell variant, which is deficient in PKC beta, failed to respond to TPA with release of cytochrome c and induction of the caspase-3 cascade. Moreover, stable overexpression of PKC beta in TUR cells reconstituted sensitivity to TPA-induced cytochrome c release and activation of caspase-3, The results also demonstrate that treatment of cells with the caspase inhibitor z-VAD-fmk blocks both TPA-induced apoptosis and monocytic differentiation, Similar results were obtained in U-937 cells stably expressing the CrmA caspase inhibitor. These findings demonstrate that TPA induces cytochrome c release by a PKC beta-dependent mechanism and that activation of caspase-mediated signaling is required for induction of the differentiated monocytic phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Pandey, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA29431, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; COLLINS SJ, 1987, BLOOD, V70, P1233; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJIKI H, 1984, BIOCHEM BIOPH RES CO, V120, P339, DOI 10.1016/0006-291X(84)91259-2; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HASS R, 1992, CANCER RES, V52, P1445; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; Kim CN, 1997, CANCER RES, V57, P3115; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCFARLANE DE, 1994, J BIOL CHEM, V269, P4327; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STONE RM, 1988, BLOOD, V72, P739; STONE RM, 1988, BLOOD, V72, P208; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG KD, 1994, BLOOD, V83, P490	39	36	37	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3941	3947		10.1038/sj.onc.1203751	http://dx.doi.org/10.1038/sj.onc.1203751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951587	Bronze			2022-12-28	WOS:000088614300013
J	Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ				Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ			G2A is an oncogenic G protein-coupled receptor	ONCOGENE			English	Article						G protein-coupled receptor; Rho; G alpha(12); G alpha(13)	GTP-BINDING PROTEIN; SERUM RESPONSE FACTOR; NUCLEOTIDE EXCHANGE FACTORS; STRESS FIBER FORMATION; MUTANT ALPHA-SUBUNIT; RHO-FAMILY GTPASES; THROMBIN RECEPTOR; RAS TRANSFORMATION; NEOPLASTIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID	G2A is a heptahelical cell surface protein that has recently been described as a potential tumor suppressor, based on its ability to counteract transformation of pre-B cells and fibroblasts by Bcr-Abl, an oncogenic tyrosine kinase, We have isolated cDNAs encoding G2A in the course of screening libraries for clones that cause oncogenic transformation of NIH3T3 fibroblasts, When expressed at high levels in NIH3T3 cells by retroviral transduction, G2A induced a full range of phenotypes characteristic of oncogenic transformation, including loss of contact inhibition, anchorage-independent survival and proliferation, reduced dependence on serum, and tumorigenicity in mice. When expressed by transfection, G2A greatly enhanced the ability of a weakly oncogenic form of Raf-1 to transform NIH3T3 cells. These results demonstrate that G2A is potently oncogenic both on its own and in cooperation with another oncogene, Expression of G2A in fibroblasts and endothelial cells resulted in changes in cell morphology and cytoskeleton structure that were equivalent to those induced by the G protein subunit G alpha(13), Transformation of NIH3T3 cells via G2A expression,vas completely suppressed by co-expression of LscRGS, a GTPase activating protein that suppresses signaling by G alpha(12) and G alpha(13). Hyperactivity of G alpha(12) or G alpha(13) has previously been shown to result in activation of Rho GTPases, G2A expression resulted in activation of Rho, and transformation via G2A was suppressed by a dominant negative form of RhoA, These results indicate that G2A may be directly coupled to G alpha(13), and that it is the activation of this Rho-activating Ga protein which is responsible for the ability of G2A to transform fibroblasts.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4E6, Canada; Onyx Pharmaceut, Richmond, CA 94806 USA	British Columbia Cancer Agency; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.		Karp, Xantha/AAU-9847-2021	Der, Channing/0000-0002-7751-2747; Zohn, Irene/0000-0001-7688-682X; Karp, Xantha/0000-0001-6602-5583; Chrzanowska, Magdalena/0000-0003-4182-2126	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GLUKHOVA MA, 1990, DEV BIOL, V141, P193, DOI 10.1016/0012-1606(90)90114-X; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TORDAI A, 1993, J IMMUNOL, V150, P4876; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	70	53	59	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3866	3877		10.1038/sj.onc.1203731	http://dx.doi.org/10.1038/sj.onc.1203731			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951580				2022-12-28	WOS:000088614300005
J	Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA				Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA			Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles	ONCOGENE			English	Article						woodchuck; hepatocellular carcinoma; hepatitis B virus; N-myc; p53; beta-catenin	WOODCHUCK HEPATITIS-VIRUS; GROWTH-FACTOR-II; C-MYC TRANSGENE; WILD-TYPE P53; LIVER-TUMORS; HEPADNAVIRUS INSERTION; INDUCED CARCINOGENESIS; NUCLEOTIDE-SEQUENCE; CELL-PROLIFERATION; N-MYC2 RETROPOSON	The intronless N-myc2 gene was originally identified as the major target of hepatitis virus insertion in woodchuck liver tumors. Here we report that transgenic mice carrying the N-myc2 gene controlled by woodchuck hepatitis virus (WHV) regulatory sequences are highly predisposed to fiver cancer. In a WHV/N-myc2 transgenic line, hepatocellular carcinomas or adenomas arose in over 70% of mice, despite barely detectable expression of the methylated transgene in liver cells, Furthermore, a transgenic founder carrying unmethylated transgene sequences succumbed to a large liver tumor by the age of two months, demonstrating the high oncogenicity of the woodchuck N-myc2 retroposon, Stabilizing mutations or deletions of beta-catenin were found in 25% of liver tumors and correlated with reduced tumor latency (P<0.05), confirming the important role of beta-catenin activation in MSc-induced tnmorigenesis, The ability of the tumor suppressor gene p53 to cooperate with N-myc2 in liver cell transformation was tested by introducing a p53-null allele into WHV/N-myc2 transgenic mice. The loss of one p53 allele in transgenic animals markedly accelerated the onset of liver cancer (P=0.0001), and most tumors of WHV/N-myc2 p53+/Delta mice harbored either a deletion of the wt p53 allele or a beta-catenin mutation. These findings provide direct evidence that activation of N-myc2 and reduction of p53 levels act synergistically during multistage carcinogenesis in vivo and suggest that different genetic pathways may underlie liver carcinogenesis initiated by a myc transgene.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75015 Paris, France; Hop Beaujon, Lab Anatomopathol, Clichy, France; Univ Paris 05, ICGM, INSERM, U129, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75015 Paris, France.		Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				BLYTH K, 1995, ONCOGENE, V10, P1717; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Bruni R, 1999, VIROLOGY, V257, P483, DOI 10.1006/viro.1999.9678; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; CARTIER N, 1992, ONCOGENE, V7, P1413; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; de la Coste A, 1999, CANCER RES, V59, P5017; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELSON A, 1995, ONCOGENE, V11, P181; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, HEPATOLOGY, V26, P1434; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HSU B, 1995, ONCOGENE, V11, P175; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MURAKAMI H, 1993, CANCER RES, V53, P1719; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nagai H, 1998, HEPATITIS B VIRUS, P182; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Quignon F, 1996, ONCOGENE, V12, P2011; Renard CA, 1998, RES VIROLOGY, V149, P133, DOI 10.1016/S0923-2516(98)80031-9; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsujiuchi T, 1999, CANCER RES, V59, P3904; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996	56	33	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2678	2686		10.1038/sj.onc.1203617	http://dx.doi.org/10.1038/sj.onc.1203617			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851067				2022-12-28	WOS:000087193000003
J	Akira, S				Akira, S			Roles of STAT3 defined by tissue-specific gene targeting	ONCOGENE			English	Article						STAT3; knockout; conditional gene targeting	EMBRYONIC STEM-CELLS; CHRONIC ENTEROCOLITIS; GROWTH-FACTOR; ACTIVATION; TRANSCRIPTION; TYROSINE; MICE; PROLIFERATION; INTERLEUKIN-6; APOPTOSIS	The physiological role of each individual STAT protein is now being examined through the study of 'knockout' (KO) mice, harboring a null allele for the particular gene. In contrast to other STATs deficient mice that are born alive, STAT3-deficient mice die during early embryogenesis, However, the role of STAT3 in adult tissues can be assessed by utilizing the Cre-loxP recombination system to ablate the gene in later life. Analyses of tissue-specific STAT3-deficient mice indicate that STAT3 plays a crucial role in a variety of biological functions including cell growth, suppression and induction of apoptosis, and cell motility.	Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Host Def, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.							Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	32	283	307	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2607	2611		10.1038/sj.onc.1203478	http://dx.doi.org/10.1038/sj.onc.1203478			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851059				2022-12-28	WOS:000087459400016
J	Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T				Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T			Evidence that de novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B	ONCOGENE			English	Article						carcinogenesis; NF-kappa B; apoptosis; TNF-alpha; cycloheximide	RHEUMATOID SYNOVIAL FIBROBLASTS; INDUCED CELL-DEATH; TUMOR PROMOTER; INHIBITION; ACTIVATION; ALPHA; INDUCTION; CANCER; AUROTHIOGLUCOSE; SUPPRESSION	The transcription factor NF-kappa B is a positive transcription factor for a number of genes and has been recognized as an anti-apoptotic regulator. However, the mechanism by which NF-kappa B blocks apoptosis is still controversial. Here, we demonstrate the evidence that NF-kappa B could attenuate the TNF-alpha-induced apoptosis without de novo protein synthesis using human pancreatic cancer cell lines, MIA PaCa-2 and Capan-2, The TNF-alpha-induced apoptosis was blocked by IL-1 beta, a potent inducer of NF-kappa B activation. This inhibitory effect of IL-1 beta was evident when cells were treated with protein synthesis inhibitors such as cycloheximide (CHS). Moreover, NF-kappa B decoy oligonucleotides could not block the anti-apoptotic effect of IL-1 beta at doses sufficient to block the NF-kappa B-dependent transcription induced by IL-1 beta, To confirm the role of NF-kappa B in blocking apoptosis we generated stable cell Lines expressing I kappa B Delta N, a highly stable form of I kappa B alpha, a cytoplasmic inhibitor of NF-kappa B. In these stable transfectants, the antiapoptotic effect of IL-1 beta was totally abolished, indicating that the anti-apoptotic action of IL-1 beta could be ascribed to the NF-kappa B action. These findings show that ne novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B and support the possibility that NF-kappa B could exert its anti-apoptotic action through protein-protein interaction.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; FUJIKI H, 1987, ADV CANCER RES, V49, P223, DOI 10.1016/S0065-230X(08)60799-X; Gilmore TD, 1996, ONCOGENE, V13, P1367; KOMORI A, 1993, CANCER RES, V53, P1982; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suganuma M, 1996, CANCER RES, V56, P3711; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151	33	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2233	2239		10.1038/sj.onc.1203560	http://dx.doi.org/10.1038/sj.onc.1203560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822373				2022-12-28	WOS:000086974100008
J	He, HL; McColl, K; Distelhorst, CW				He, HL; McColl, K; Distelhorst, CW			Involvement of c-Fos in signaling grp78 induction following ER calcium release	ONCOGENE			English	Article						GRP78; c-Fos; calcium; thapsigargin	ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; CA2+-ATPASE INHIBITOR THAPSIGARGIN; UNFOLDED PROTEIN RESPONSE; MOUSE LYMPHOMA-CELLS; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; GLUCOCORTICOID RECEPTOR; DNA-BINDING; IN-VIVO	Release of calcium from the endoplasmic reticulum (ER) signals an increase in transcription of both the early response gene, c-fos, and the late response gene, grp78. We hale used thapsigargin (TG), an ER calcium-ATPase pump inhibitor that induces calcium release from the ER, to investigate the possible involvement of c-Fos, a component of the AP-1 transcription factor, in grp78 induction. Tno cell lines with markedly different responses to TG treatment were employed: the WEHI7,2 mouse lymphoma line in which TG fails to induce grp78, and the MDA-MB-468 mammary epithelial line in which TG induces grp78. In WEHI7,2 cells, TG-induced calcium release triggers a rapid increase in c-fos mRNA, but the level of c-Fos protein decreases due to degradation by the multicatalytic proteasome, C-Fos DeltaC, a proteasome resistant c-Fos mutant with AP-1 activity similar to that of wild type c-Pos, restores grp78 induction in WEHI7.2 cells, detected by both Northern hybridization and a grp78 promoter-luciferase reporter assay. In MDA-MB-468 cells, TG-mediated calcium release induces a sustained elevation of c-Fos protein that precedes grp78 induction. A region of the grp78 promoter containing both ERSE and CORE regions, but missing TRE and CRE regions, is sufficient to mediate induction of reporter luciferase activity, Induction of this reporter was blocked by A-Fos, a dominant negative inhibitor of c-Fos, Also, the induction of grp78-luciferase reporter activity was inhibited by c-fos antisense mRNA. In summary, the findings indicate that c-Fos is involved in signaling grp78 induction following TG treatment, and that grp78 induction is inhibited by proteasome-mediated c-Fos degradation.	Case Western Reserve Univ, Div Hematol Oncol, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Dept Med, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA079806] Funding Source: NIH RePORTER; NCI NIH HHS [CA79806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen LY, 2000, J CELL BIOCHEM, V78, P404, DOI 10.1002/1097-4644(20000901)78:3<404::AID-JCB6>3.0.CO;2-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaina B, 1997, CANCER RES, V57, P2721; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; LODISH HF, 1992, J BIOL CHEM, V267, P12753; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	57	23	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5936	5943		10.1038/sj.onc.1203994	http://dx.doi.org/10.1038/sj.onc.1203994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127825				2022-12-28	WOS:000165563100013
J	MacLaren, A; Clark, W; Gillespie, DAF				MacLaren, A; Clark, W; Gillespie, DAF			v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release	ONCOGENE			English	Article						v-Jun; apoptosis; p53; cytochrome C	MYC-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR-SUPPRESSOR; DEATH; BCL-2; KINASE; FIBROBLASTS; INDUCTION; PROTEASES	v-Jun shares the ability of the Myc, E1A, and E2F oncogenes to both sustain cell cycle progression and promote apoptosis in the absence of mitogenic stimulation. To gain an insight into the mechanism of apoptosis sensitization,,ve examined the possible involvement of key regulatory proteins previously implicated in oncogene-induced cell death during v-Jun-induced apoptosis triggered by serum, withdrawal, We observed that ectopic expression of the anti-apoptotic Bcl-2 protein, or of two downstream effecters of growth factor signalling, v-PI 3-Kinase and v-Src, partially or completely suppressed apoptosis, Apoptosis was also observed in the presence of serum growth factors when endogenous PI3K activity was blocked using the synthetic inhibitor LY294002, further suggesting an important role for PI3-K in cell survival, Cytochrome C was released into the cytosol of apoptotic v-Jun expressing cells, and this release was inhibited by Bcl-2, suggesting an important role for mitochondrial dysfunction in v-Jun induced apoptosis, In contrast, inhibition of Fas signalling using dominant negative FADD did not inhibit apoptosis, nor was there any evidence for accumulation or activation of p53 in v-Jun transformed cells. Consistent with this latter observation, inhibition of p53 function by HPV16 E6 protein had no effect on v-Jun induced cell death. Taken together, these results suggest that mitochondrial dysfunction is an important component of the mechanism through which v-Jun sensitizes cells to apoptosis, but that the apoptotic signals elicited by v-Jun upstream of the mitochondria do not depend on increased levels of p53 activity or Fas signalling.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	MacLaren, A (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kilbey A, 1996, ONCOGENE, V12, P2409; Lenahan MK, 1996, ONCOGENE, V12, P1847; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	47	8	8	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5906	5918		10.1038/sj.onc.1203954	http://dx.doi.org/10.1038/sj.onc.1203954			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127822				2022-12-28	WOS:000165563100010
J	Tagami, S; Eguchi, Y; Kinoshita, M; Takeda, M; Tsujimoto, Y				Tagami, S; Eguchi, Y; Kinoshita, M; Takeda, M; Tsujimoto, Y			A novel protein, RTN-x(S), interacts with both Bcl-x(L) and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity	ONCOGENE			English	Article						RTN-x(S); Bcl-x(L); Bcl-2; endoplasmic reticulum; apoptosis	CYTOCHROME-C; FAMILY PROTEINS; X-L; SUBCELLULAR-LOCALIZATION; BCL-2-BINDING PROTEIN; MITOCHONDRIAL CONTROL; CELL-DEATH; RELEASE; CLONING; APAF-1	Bcl-2 and Bcl-x(L) serve as critical inhibitors of apoptosis triggered by a broad range of stimuli, mainly acting on the mitochondria, We identified two members of the reticulon (RTN) family as Bcl-x(L) binding proteins, i.e,, NSP-C (RTNt-C) and a new family member, RTN-x(S), both of which did not belong to the Bcl-2 family and were predominantly localized on the endoplasmic reticulum (ER). RTN-x(S) interacted with both Bcl-x(L) and Bcl-2, increased the localization of Bcl-xL and Bcl-2 on the ER, and reduced the anti-apoptotic activity of Bcl-xL and Bcl-2. On the other hand, NSP-C interacted only with Bcl-x(L), affected the localization of Bcl-x(L), and reduced Bcl-xL activity, but had no effect on Bcl-2, These results suggest that RTN family proteins can modulate the anti-apoptotic activity of Bcl-x(L) and Bcl-2 by binding with them and can change their localization to the ER.	Osaka Univ, Grad Sch Med, Dept Med Genet, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Med Genet, Biomed Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Kinoshita, Manabu/0000-0001-7923-6902				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	47	150	160	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5736	5746		10.1038/sj.onc.1203948	http://dx.doi.org/10.1038/sj.onc.1203948			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126360				2022-12-28	WOS:000165477700005
J	Dodelet, VC; Pasquale, EB				Dodelet, VC; Pasquale, EB			Eph receptors and ephrin ligands: embryogenesis to tumorigenesis	ONCOGENE			English	Review						receptor tyrosine kinase; tissue patterning; axon guidance; cell segregation; angiogenesis	PROTEIN-TYROSINE KINASE; RETINAL AXON GUIDANCE; CARDIOVASCULAR DEVELOPMENT; TRANSMEMBRANE LIGANDS; MELANOMA PROGRESSION; COMMISSURAL AXONS; MOLECULAR-CLONING; CELL-ADHESION; UP-REGULATION; IN-VITRO	Protein tyrosine kinase genes are the largest family of oncogenes, This is not surprising since tyrosine kinases are important components of signal transduction pathways that control cell shape, proliferation, differentiation, and migration, At 14 distinct members, the Eph kinases constitute the largest family of receptor tyrosine kinases, Although they have been most intensively studied for their roles in embryonic development, increasing evidence also implicates Eph family proteins in cancer. This review will address the recent progress in understanding the function of Eph receptors in normal development and how disregulation of these functions could promote tumorigenesis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; BOHME B, 1993, ONCOGENE, V8, P2857; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Donoghue MJ, 1999, J NEUROSCI, V19, P5967, DOI 10.1523/JNEUROSCI.19-14-05967.1999; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DRESCHER U, 1997, CURR BIOL, V7, pR779; EASTY DJ, 1995, CANCER RES, V55, P2528; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Imondi R, 2000, DEVELOPMENT, V127, P1397; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nikolova Z, 1998, J CELL SCI, V111, P2741; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orsulic S, 2000, J CELL SCI, V113, P1793; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TAKAHASHI H, 1995, ONCOGENE, V11, P879; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Vanderhaeghen P, 2000, NAT NEUROSCI, V3, P358, DOI 10.1038/73929; Vogt T, 1998, CLIN CANCER RES, V4, P791; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zhang JH, 1996, J NEUROSCI, V16, P7182; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	76	247	281	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5614	5619		10.1038/sj.onc.1203856	http://dx.doi.org/10.1038/sj.onc.1203856			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114742				2022-12-28	WOS:000165659300009
J	Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R				Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R			IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE(2) synthesis in Caco-2 human colon carcinoma cells	ONCOGENE			English	Article						IGF-II; IGF-Ir; COX-2; PGE(2); colon cancer	GROWTH-FACTOR-I; ENTEROCYTE-LIKE DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; MESSENGER-RNA EXPRESSION; NF-KAPPA-B; CANCER-CELLS; CYCLOOXYGENASE-2 EXPRESSION; COLORECTAL-CANCER; PROSTAGLANDIN E-2; EPITHELIAL-CELLS	Nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer and this effect is mediated in part through inhibition of type 2 prostaglandin endoperoxide synthase/cyclo-oxygenase (COX-2). In the present study, me demonstrate that COX-2 expression and PGE(2) synthesis are up-regulated by an IGF-II/IGF-I receptor autocrine pathway in Caco-2 colon carcinoma cells. COX-2 mRNA and PGE(2) levels are higher in proliferating cells compared with post-confluent differentiated cells and in cells that constitutively overexpress IGF-II, Up-regulation of COX-2 expression by IGF-II is mediated through activation of IGF-I receptor because: (i) treatment of Caco-2 cells with a blocking antibody to the IGF-I receptor inhibits COX-2 mRNA expression; (ii) transfection of Caco-2 cells with a dominant negative IGF-I receptor reduces COX-2 expression and activity, Also, the blockade of the PI3-kinase, that mediates the proliferative effect of IGF-I receptor in Caco-2 cells, inhibits IGF-II-dependent COX-2 up-regulation and PGE(2) synthesis. Moreover, COX-2 expression and activity inversely correlate with the increase of apoptosis in parental, IGF-II and dominant-negative IGF-I receptor transfected cells. This study suggests that induction of proliferation and tumor progression of colon cancer cells by the IGF-II/IGF-I receptor pathway may depend on the activation of COX-2-related events.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, I-80131 Naples, Italy; II Ateneo Napoli, Dipartimento Internist Clin & Sperimentale, Div Gastroenterol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Acquaviva, AM (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Ricchi, Paolo/J-5140-2019; Zarrilli, Raffaele/F-5067-2012	Ricchi, Paolo/0000-0001-7361-3308; Zarrilli, Raffaele/0000-0003-4191-9032; ACQUAVIVA, Angela Maria/0000-0001-9538-2766				Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; Garrouste FL, 1997, ENDOCRINOLOGY, V138, P2021, DOI 10.1210/en.138.5.2021; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KATO H, 1993, J BIOL CHEM, V268, P2655; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; PINTO M, 1983, BIOL CELL, V47, P323; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; PODOLSKY DK, 1993, AM J PHYSIOL, V264, P179; POMMIER GJ, 1992, CANCER RES, V52, P3182; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ricchi P, 1997, INT J CANCER, V73, P880; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUBIN R, 1995, LAB INVEST, V73, P311; Sheng HM, 1998, CANCER RES, V58, P362; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Zarrilli R, 1999, AM J GASTROENTEROL, V94, P3376, DOI 10.1111/j.1572-0241.1999.03376.x; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zarrilli R, 1999, GASTROENTEROLOGY, V116, P1358, DOI 10.1016/S0016-5085(99)70500-7; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	40	92	96	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5517	5524		10.1038/sj.onc.1203952	http://dx.doi.org/10.1038/sj.onc.1203952			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114729				2022-12-28	WOS:000165396100012
J	Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD				Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD			Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation	ONCOGENE			English	Article						Bcr-Abl; p53; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL LINE; CHRONIC MYELOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; WILD-TYPE P53; BLAST CRISIS; HOMOLOGOUS RECOMBINATION; RETROVIRAL TRANSDUCTION; CLONAL EVOLUTION; PROGENITOR CELLS	Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK), We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Plow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53(null) FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.	Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; UMIST, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Biol Sci, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; University of Manchester; University of Manchester	Spooncer, E (corresponding author), Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England.		Miyan, Jaleel/AAB-1910-2021	Miyan, Jaleel/0000-0002-1835-0143; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; WHETTON, ANTHONY D/0000-0002-1098-3878; Dive, Caroline/0000-0002-1726-8850; Pierce, Andrew/0000-0001-5995-2469				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; FOTI A, 1991, BLOOD, V77, P2441; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lub M, 1996, J LEUKOCYTE BIOL, V59, P648, DOI 10.1002/jlb.59.5.648; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maguer-Satta V, 1998, ONCOGENE, V16, P237, DOI 10.1038/sj.onc.1201533; MASHAL R, 1990, BLOOD, V75, P180; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; METCALF D, 1974, BLOOD, V43, P847, DOI 10.1182/blood.V43.6.847.847; NAKAI H, 1995, BRIT J HAEMATOL, V90, P147, DOI 10.1111/j.1365-2141.1995.tb03393.x; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NAKAI H, 1992, CANCER RES, V52, P6588; PEDERSEN B, 1982, BRIT J HAEMATOL, V51, P339, DOI 10.1111/j.1365-2141.1982.tb02789.x; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROVIRA A, 1995, ANN HEMATOL, V70, P129; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J., MOL CLONING LAB MANU; Seliger B, 1996, EUR J HAEMATOL, V57, P230; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shounan Y, 1996, LEUKEMIA, V10, P1619; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WILLIAMS J, 1995, WILLIAMS HEMATOLOGY	59	29	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5487	5497		10.1038/sj.onc.1203940	http://dx.doi.org/10.1038/sj.onc.1203940			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114726				2022-12-28	WOS:000165396100009
J	Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			Bcl-2 accelerates multistep prostate carcinogenesis in vivo	ONCOGENE			English	Article						bcl-2; prostate cancer; apoptosis; TRAMP; transgenic; androgen	TRANSGENIC MICE; TUMOR-ANTIGEN; T-ANTIGEN; CANCER PROGRESSION; TRAMP MODEL; CELL-DEATH; IN-VIVO; EXPRESSION; GENE; CARCINOMA	The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that express the SV40 early genes (T/t antigens) under probasin control, Prostate size, cell proliferation, apoptosis, and the incidence and latency of tumor formation were evaluated. The double transgenic, probasin-bcl-2 X TRAMP F-1 (BxT) mice exhibited an increase in the wet weight of the prostate, This was associated with an increase in proliferation, attributable to Tit antigens, and a decrease in apoptosis attributable to bcl-2, The latency to tumor formation was also decreased in the BxT mice compared to the TRAMP mice. The incidence of metastases was identical in both the TRAMP and BxT mice, Lastly, the incidence of hormone-independent prostate cancer was reduced in the BxT mice compared to the TRAMP mice. Together, these results demonstrate that bcl-2 can facilitate multistep prostate carcinogenesis in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01, CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759, P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Beham AW, 1998, INT J MOL MED, V1, P953; BERNER A, 1993, BRIT J CANCER, V68, P380, DOI 10.1038/bjc.1993.344; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bruckheimer EM, 2000, ONCOGENE, V19, P2404, DOI 10.1038/sj.onc.1203571; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Eng MH, 1999, UROLOGY, V54, P1112, DOI 10.1016/S0090-4295(99)00297-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Heidenberg HB, 1996, UROLOGY, V48, P971, DOI 10.1016/S0090-4295(96)00365-2; Hsu CX, 1998, J UROLOGY, V160, P1500, DOI 10.1016/S0022-5347(01)62603-X; Johnson MI, 1998, ONCOL REP, V5, P553; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Pettaway C A, 1998, Tech Urol, V4, P35; RAFFO AJ, 1995, CANCER RES, V55, P4438; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; THOMAS DJ, 1993, BRIT J UROL, V72, P778, DOI 10.1111/j.1464-410X.1993.tb16267.x; Westin P, 1997, INT J ONCOL, V10, P113	32	36	36	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5251	5258		10.1038/sj.onc.1203881	http://dx.doi.org/10.1038/sj.onc.1203881			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077442				2022-12-28	WOS:000165059700006
J	Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E				Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E			Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells	ONCOGENE			English	Article						interferon; all-trans retinoic acid; PML; cell cycle; squamous carcinoma cells	PROMYELOCYTIC LEUKEMIA PROTEIN; PRIMARY BILIARY-CIRRHOSIS; CREB BINDING-PROTEIN; LARGE T-ANTIGEN; RETINOIC ACID; NUCLEAR-BODIES; GROWTH-SUPPRESSOR; CDK-INHIBITOR; APL CELLS; TRANSCRIPTIONAL ACTIVATION	Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carcinoma cell Lines (SCC), Examinations of growth-affected cell populations show that SCC lines ME-180 and SiHa treated with IFN-beta undergo a specific slower progression through the S phase that seems to trigger cellular death. In combination treatment RA potentiates IFN-beta effect in SCC ME-180 but not in SiHa cell line, partially resistant to RA antiproliferative action. RA added as single agent affects cell proliferation differently by inducing a slight GI accumulation. The IFN-beta-induced S phase lengthening parallels the increased expression of PML, a nuclear phosphoprotein specifically up-regulated at transcriptional level by IFN, whose overexpression induces cell growth inhibition and tumor suppression. We report that PML up-regulation may account for the alteration of cell cycle progression induced by IFN-beta in SCC by infecting cells with PML-PINCO recombinant retrovirus carrying the PML3 cDNA under the control of the 5' LTR. In fact PML overexpression reproduces the IFN-beta-induced S phase lengthening, These findings provide important insight into the mechanism of tumor suppressing function of PML and could allow PML to be included in the pathways responsible for IFN-induced cell growth suppression.	Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Hop St Louis, CNRS, UPR 9051, F-75010 Paris, France; Univ Perugia, Monteluce Policlin, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Ist Tecnol Biomed, Rome, Italy	Roma Tre University; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Perugia; IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Affabris, E (corresponding author), Univ Roma 3, Dept Biol, Viale G Marconi 446, I-00146 Rome, Italy.		Malorni, Walter/G-5874-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Fiorucci, Gianna/B-3064-2013; Matarrese, Paola/A-4369-2014; CHIANTORE, MARIA VINCENZA/C-2948-2016; Romeo, Giovanna/AAB-2613-2019; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; romeo, giovanna/0000-0002-7638-1001; AFFABRIS, Elisabetta/0000-0001-5142-8144; malorni, walter/0000-0002-1223-7000; matarrese, paola/0000-0001-5477-3752				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DANIEL MT, 1993, BLOOD, V82, P1858; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dyson N, 1999, CURR OPIN GENET DEV, V9, P11, DOI 10.1016/S0959-437X(99)80002-1; Everett RD, 1999, J CELL SCI, V112, P4581; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grignani F, 1998, CANCER RES, V58, P14; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hara E, 1996, MOL CELL BIOL, V16, P859; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kalemkerian G. P., 1996, APOPTOSIS, V1, P11; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lippman SM, 1997, INT J CANCER, V70, P481, DOI 10.1002/(SICI)1097-0215(19970207)70:4<481::AID-IJC20>3.0.CO;2-H; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Matarrese P, 1998, INT J CANCER, V76, P531, DOI 10.1002/(SICI)1097-0215(19980518)76:4<531::AID-IJC15>3.0.CO;2-A; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Qin XQ, 1997, J INTERF CYTOK RES, V17, P355, DOI 10.1089/jir.1997.17.355; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROMEO G, 1996, RETINOIDS TODAY TOMO, V45, P32; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	64	25	27	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5041	5053		10.1038/sj.onc.1203883	http://dx.doi.org/10.1038/sj.onc.1203883			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042692	Green Published			2022-12-28	WOS:000089930100001
J	Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI				Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI			Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; UBF; DNA-binding	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA SUSCEPTIBILITY GENE; TATA-BINDING PROTEIN; III TRANSCRIPTION; CELL-CYCLE; MOLECULAR-CLONING; NEONATAL CARDIOMYOCYTES; LUNG-CANCER; MOUSE P130; P107	We have previously demonstrated that the protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a regulator of transcription by RNA polymerase I (rDNA transcription) by inhibiting UBF-mediated transcription. In the present study, we have examined the mechanism by which Rb represses UBF-dependent rDNA transcription and determined if other Rb-like proteins have similar effects. We demonstrate that authentic or recombinant UBF and Rb interact directly and this requires a functional A/B pocket. DNase footprinting and band-shift assays demonstrated that the interaction between Rb and UBF does not inhibit the binding of UBF to DNA, However, the formation of an UBF/Rb complex does block the interaction of UBF with SL-1, as indicated by using the 48 kDa subunit as a marker for SL-1, Additional evidence is presented that another pocket protein, p130 but not p107, can be found in a complex with UBF, Interestingly, the cellular content of p130 inversely correlated with the rate of rDNA transcription in two physiological systems, and overexpression of p130 inhibited rDNA transcription. These results suggest that p130 may regulate rDNA transcription in a similar manner to Rb.	Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Rothblum, LI (corresponding author), Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.			Hannan, Ross/0000-0002-2166-4493; Hannan, Katherine/0000-0003-4186-8167	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; Farshid M, 1994, J Viral Hepat, V1, P45, DOI 10.1111/j.1365-2893.1994.tb00061.x; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hempel WM, 1996, MOL CELL BIOL, V16, P557; HENSEL CH, 1990, CANCER RES, V50, P3067; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LeCouter JE, 1996, ONCOGENE, V12, P1433; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; XIE WQ, 1992, NUCLEIC ACIDS RES, V20, P1587, DOI 10.1093/nar/20.7.1587	64	105	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4988	4999		10.1038/sj.onc.1203875	http://dx.doi.org/10.1038/sj.onc.1203875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042686				2022-12-28	WOS:000089834300006
J	Zhu, XY; Price-Schiavi, SA; Carraway, KL				Zhu, XY; Price-Schiavi, SA; Carraway, KL			Extracellular regulated kinase (ERK)-dependent regulation of sialomucin complex/rat Muc4 in mammary epithelial cells	ONCOGENE			English	Article						Muc4; ERK; ErbB2; mammary; epithelial; transcript; regulation	GROWTH-FACTOR-I; RECEPTOR TYROSINE KINASE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; PROTEIN-KINASE; MAP KINASE; DUCTAL MORPHOGENESIS; GLYCOPROTEIN COMPLEX; SIGNAL-TRANSDUCTION; CASEIN GENE	Sialomucin complex (SMC, rat Muc4) is a membrane mucin implicated in the protection of epithelia and the metastasis of some tumors. It is a heterodimeric complex, containing a mucin subunit with anti-adhesive activity and a transmembrane subunit with epidermal growth factor-like domains, one of which acts as an intramembrane ligand for ErbB2, Serum, insulin and insulin-like growth factor, but not epidermal growth factor, induce the expression of sialomucin complex in mammary epithelial cells, Induction correlates,vith sustained, but not transient, activation of extracellular-regulated protein kinase (ERK), MEK inhibitor U0126 blocked the induction, while activated MEK-1 transfected into a rat mammary adenocarcinoma cell line induced a sustained activation of ERK and up-regulated SMC/Muc4 expression, Northern and Western blotting indicated that up-regulation occurred concomitantly at the transcript and protein levels, both of which could be blocked by U0126. These results suggest that expression of SMC/Muc4 in mammary epithelial cells is regulated by selected growth factors through an ERK-dependent pathway at the transcript level.	Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, Miami, FL 33101 USA	University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, POB 016960, Miami, FL 33101 USA.				NCI NIH HHS [CA52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J CELL SCI, V99, P407; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Juang SH, 1996, ONCOGENE, V12, P1033; Kleinberg DL, 1998, BREAST CANCER RES TR, V47, P201, DOI 10.1023/A:1005998832636; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; MCNEER RR, 1997, FRONT BIOSCI, V2, P449; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; NICHOLAS KR, 1983, BIOCHIM BIOPHYS ACTA, V763, P309, DOI 10.1016/0167-4889(83)90139-8; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; PROSSER CG, 1987, ENDOCRINOLOGY, V120, P1411, DOI 10.1210/endo-120-4-1411; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; RUAN WF, 1992, P NATL ACAD SCI USA, V89, P10872, DOI 10.1073/pnas.89.22.10872; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VOYTOVICH AE, 1969, P NATL ACAD SCI USA, V63, P213, DOI 10.1073/pnas.63.1.213; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WU K, 1994, J BIOL CHEM, V269, P11950; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	50	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4354	4361		10.1038/sj.onc.1203781	http://dx.doi.org/10.1038/sj.onc.1203781			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980611				2022-12-28	WOS:000089271900006
J	Nieborowska-Skorska, M; Slupianek, A; Skorski, T				Nieborowska-Skorska, M; Slupianek, A; Skorski, T			Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells	ONCOGENE			English	Article						BCR/ABL; signaling; Akt; STAT5	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; DNA-BINDING ACTIVITY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDES; PHILADELPHIA-CHROMOSOME; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED TRANSFORMATION; CONSTITUTIVE ACTIVATION	Our previous study indicated that BCR/ABL SH2 domain and BCR/ABL SH3 domain+SH2 domain complex are required for immediate activation of the phosphatidylinositol-3 kinase PI-3k) --> Akt serine/threonine kinase pathway and of the signal transducer and activator of transcription 5 (STAT5), respectively, in hematopoietic cells. We show here that the defect in activation of PI-3k/Akt by BCR/ABL Delta SH2 mutant (SH2 domain deleted) and of STAT5 by BCR/ABL Delta SH3 + Delta SH2 mutant (SH3 and SH2 domains deleted) is not permanent and both Akt and STAT5 could be 'reactivated' by in vitro culture. This phenomenon was responsible for increased resistance to apoptosis, growth factor-independent proliferation and leukemogenesis in SCID mice. Incubation of cells with BCR/ABL tyrosine kinase inhibitor STI571 abrogated the 're-activation' of Akt or STAT5 by BCR/ABL SH3+SH2 mutants in some clones, in the others Akt and STAT5 activation became independent on BCR/ABL kinase activity. The immediate upstream activators of Akt and STAT5 such as PI-3k and Jak-2 were also activated. In addition, the common beta subunit of IL-3/IL-5/GM-CSF receptor was tyrosine phosphorylated in the clones in which 'reactivation' was dependent on the BCR/ABL kinase activity, These results suggested that 're-activation' of Akt and STAT5, in the absence of functional BCR/ABL SH3+SH2 domains, may be achieved by two different mechanisms: (i) BCR/ABL kinase-dependent activation of alternative pathway(s) and (ii) additional genetic changes stimulating Akt and STAT5 independently of BCR/ABL.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Poznan Tech Univ, Dept Canc Immunol, Sch Med Sci, Great Poland Canc Ctr, PL-60965 Poznan, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Poznan University of Technology; Wielkopolskie Centrum Onkologii	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Anderson SM, 1996, BLOOD, V87, P238; BEDI A, 1994, BLOOD, V83, P2038; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Majewski M, 1999, CANCER RES, V59, P2815; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WilsonRawls J, 1996, CANCER RES, V56, P3426	57	19	19	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4117	4124		10.1038/sj.onc.1203754	http://dx.doi.org/10.1038/sj.onc.1203754			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962572				2022-12-28	WOS:000088955100005
J	Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M				Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M			Detection of spatial localization of Hst-1/Fgf-4 gene expression in brain and testis from adult mice	ONCOGENE			English	Article						Hst-1/Fgf-4; brain; testis; in situ; RT-PCR; adult	FACTOR-LIKE IMMUNOREACTIVITY; FIBROBLAST GROWTH-FACTORS; RAT SERTOLI CELLS; MESSENGER-RNA; SKELETAL-MUSCLE; NERVOUS-SYSTEM; FGF-4; RECEPTOR; MOUSE; HST-1	HST-1, a member of the fibroblast grow th factor (FGF) family (FGF-4), has been shown to be a signaling molecule whose expression is essential for embryonic development. However, HST-1/FGF-4 expression has not been detected or reported in adult tissues so far analysed. To investigate whether there is a possible role of HST-1/FGF-4 in adult stage, we have carried out a highly sensitive RT-PCR analysis of Hst-1/Fgf-4 gene expression in adult mice tissues. Results show Hst-1/Fgf-4 gene expression in the nervous system, intestines, and testis of normal adult mice. In situ hybridization technique was used to localize Hst-1/Fgf-4 gene expression in the cerebellum and testis from 10-week-old mice. Cell type-specific gene expression was detected: Purkinje cells in the cerebellum and Sertoli cells in testis, These findings suggest that the Hst-1/Fgf-4 gene also plays an important role in adult tissues, and may offer insights into the biological significance of HST-1/FGF-4 in cerebellar and testicular functions.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cell Biol, Kodaira, Tokyo 1878502, Japan	National Cancer Center - Japan; Nara Medical University; National Center for Neurology & Psychiatry - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji 5-chome, Tokyo 1040045, Japan.		Osumi, Noriko/T-2823-2019; Ochiya, Takahiro/AAH-7585-2019	Osumi, Noriko/0000-0003-0548-6452; 				BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; Cancilla B, 1998, BIOL REPROD, V58, P1138, DOI 10.1095/biolreprod58.5.1138; Collignon J, 1996, DEVELOPMENT, V122, P509; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; ELHUSSEINI AE, 1994, MOL CELL ENDOCRINOL, V104, P191, DOI 10.1016/0303-7207(94)90122-8; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; GUILLOU F, 1990, CELL TISSUE RES, V260, P395, DOI 10.1007/BF00318642; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HEIKINHEIMO O, 1995, MOL REPROD DEV, V42, P397, DOI 10.1002/mrd.1080420405; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; LEMAGUERESSEBATTISTONI B, 1994, ENDOCRINOLOGY, V135, P2404, DOI 10.1210/en.135.6.2404; MATSUDA S, 1992, NEUROSCIENCE, V50, P99, DOI 10.1016/0306-4522(92)90384-E; MATSUDA S, 1994, NEUROSCIENCE, V59, P651, DOI 10.1016/0306-4522(94)90184-8; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Nakamua S, 1999, GLIA, V28, P53, DOI 10.1002/(SICI)1098-1136(199910)28:1<53::AID-GLIA7>3.0.CO;2-V; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; Ozawa K, 1996, MOL BRAIN RES, V41, P279, DOI 10.1016/0169-328X(96)00108-8; PARANKO J, 1986, DEV BIOL, V117, P35, DOI 10.1016/0012-1606(86)90345-3; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Shamim H, 1999, DEVELOPMENT, V126, P945; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THEILLET C, 1989, ONCOGENE, V4, P915; Todo T, 1998, BRAIN RES, V783, P179, DOI 10.1016/S0006-8993(97)01340-1; TSUDA H, 1989, CANCER RES, V49, P3104; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	45	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3805	3810		10.1038/sj.onc.1203752	http://dx.doi.org/10.1038/sj.onc.1203752			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949936				2022-12-28	WOS:000088568400014
J	Cook, WD; McCaw, BJ				Cook, WD; McCaw, BJ			Accommodating haploinsufficient tumour suppressor genes in Knudson's model	ONCOGENE			English	Review						tumour suppressor; haploinsufficient; p53; p27Kip1	WILD-TYPE P53; MYELOID-LEUKEMIA; RETINOBLASTOMA GENE; MICE LACKING; CELL-CYCLE; CANCER; P27(KIP1); MUTATION; INHIBITOR; TUMORIGENESIS		Royal Melbourne Hosp, Bone Marrow Res Labs, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute	Cook, WD (corresponding author), Royal Melbourne Hosp, Bone Marrow Res Labs, Melbourne, Vic 3050, Australia.							Alexander BJ, 1995, LEUKEMIA, V9, P2009; Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; de la Chapelle A, 1998, CURR OPIN GENET DEV, V8, P298, DOI 10.1016/S0959-437X(98)80085-3; de Wind N, 1998, CANCER RES, V58, P248; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong JT, 1996, CANCER RES, V56, P4387; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHANSSON B, 1994, LEUKEMIA, V8, P953; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNUDSON AG, 1985, CANCER RES, V45, P1437; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kobayashi T, 1999, CANCER RES, V59, P1206; LEVY DB, 1994, CANCER RES, V54, P5953; McClatchey AI, 1998, CURR OPIN GENET DEV, V8, P304, DOI 10.1016/S0959-437X(98)80086-5; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olopade OI, 1996, LEUKEMIA, V10, P669; PEDERSENBJERGAARD J, 1995, BLOOD, V86, P3542, DOI 10.1182/blood.V86.9.3542.bloodjournal8693542; PIETENPOL JA, 1995, CANCER RES, V55, P1206; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Silver A, 1999, GENE CHROMOSOME CANC, V24, P95, DOI 10.1002/(SICI)1098-2264(199902)24:2<95::AID-GCC1>3.3.CO;2-3; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tosi S, 1999, GENE CHROMOSOME CANC, V25, P384, DOI 10.1002/(SICI)1098-2264(199908)25:4<384::AID-GCC11>3.0.CO;2-D; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	51	81	84	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3434	3438		10.1038/sj.onc.1203653	http://dx.doi.org/10.1038/sj.onc.1203653			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918600				2022-12-28	WOS:000088198100011
J	Su, ZZ; Shi, YJ; Fisher, PB				Su, ZZ; Shi, YJ; Fisher, PB			Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells	ONCOGENE			English	Article						cancer progression; promoter analysis; transcriptional regulation	ANCHORAGE-INDEPENDENT GROWTH; TYPE-5 ADENOVIRUS; TUMOR PROMOTERS; BINDING-SITES; TRANSCRIPTION; AP-1; CANCER; INDUCTION; SUPPRESSION; PROTEIN	Cancer is a progressive disease in which a tumor cell temporally develops qualitatively new transformation related phenotypes or a further elaboration of existing transformation associated properties. Subtraction hybridization identified a novel gene associated with transformation progression in mutant adenovirus type 5, H5ts125, transformed rat embryo cells, progression elevated gene-3 (PEG-3). To define the mechanism by which expression of PEG-3 is enhanced as a function of cancer progression a 5'-flanking promoter region of similar to 2.0-kb, PEG-Prom, was Isolated, cloned and characterized. The full-length and various mutated regions of the PEG-From mere linked to a luciferase reporter construct and evaluated for promoter activity during cancer progression. These assays demonstrate a requirement for API and PEA3 sites adjacent to the TATA bos region of PEG-3 in mediating basal promoter activity and the enhanced expression of PEG-3 in progressed H5ts125-transformed rat embryo cells. An involvement of AP1 and PF Lambda 3 in PEG3 regulation was also confirmed by electrophoretic mobility shift assays (EMSA) and transfection studies with cJun and PEA3 expression vectors, Our findings document the importance of both AP1 and PEA3 transcription factors in mediating basal and elevated expression of PEG3 in H5ts125-transformed rat embryo cells displaying an aggressive and progressed cancer phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-15-1501,630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675, R01CA074468] Funding Source: NIH RePORTER; NCI NIH HHS [CA74468, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DeCesare D, 1996, ONCOGENE, V13, P2551; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kang DC, 1998, INT J ONCOL, V13, P1117; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOHN EC, 1995, CANCER RES, V55, P1856; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SU ZZ, 1994, ONCOGENE, V9, P1123; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SU ZZ, 1995, INT J ONCOL, V7, P1279; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	45	42	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3411	3421		10.1038/sj.onc.1203666	http://dx.doi.org/10.1038/sj.onc.1203666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918598				2022-12-28	WOS:000088198100009
J	Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF				Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF			Mlh1 deficiency enhances several phenotypes of Apc(Min/+) mice	ONCOGENE			English	Article						Apc; Mlh1; Min; mutation; tumor	DNA MISMATCH REPAIR; NONPOLYPOSIS COLON-CANCER; INTESTINAL TUMORIGENESIS; MIN MICE; CHROMOSOME SYNAPSIS; MUTANT MICE; MOUSE; GENE; NEOPLASIA; MSH2	Defects in APC and DNA mismatch repair genes are associated with a strong predisposition to colon cancer in humans, and numerous mouse strains with mutations in these genes have been generated. In this report we describe the phenotype of Min/+ Mlh1(-/-) mice. We find that these doubly mutant mice develop more than three times the number of intestinal adenomas compared to Min/+ Mlh1(+/+) or (+/-) mice but that these tumors do not show advanced progression in terms of tumor size or histological appearance. Full length Apc protein was not detected in the tumor cells from Min/+ Mlh1(-/-) mice. Molecular analyses indicated that in many tumors from Min/+ Mlh1(-/-) mice, Apc was inactivated by intragenic mutation. Mlh1 deficiency in Min/+ mice also led to an increase in cystic intestinal crypt multiplicity as well as enhancing desmoid tumorigenesis and epidermoid cyst development. Thus, Mlh1 deficiency influences the somatic events involved in the development of most of the phenotypes associated with the Min mutation.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University	Dove, WF (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.		Dudley, Samuel C/A-7085-2009		NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER; NCI NIH HHS [CA07075, CA63677, CA58085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CLARKE AR, 1995, ONCOGENE, V11, P1913; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gong JG, 1999, NATURE, V399, P806; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEVY DB, 1994, CANCER RES, V54, P5953; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; LUONGO C, 1994, CANCER RES, V54, P5947; Peckham M., 1995, OXFORD TXB ONCOLOGY; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POTTEN CS, 1988, J CELL SCI, P45; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zhang H, 1999, CANCER RES, V59, P3021	42	45	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2774	2779		10.1038/sj.onc.1203574	http://dx.doi.org/10.1038/sj.onc.1203574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851078				2022-12-28	WOS:000087318500006
J	Lee, TA; Farnham, PJ				Lee, TA; Farnham, PJ			Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation	ONCOGENE			English	Article						E2F; Ras; Neu; NIH3T3; transformation; tumor suppressor	MAMMARY EPITHELIAL-CELLS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; DNA-BINDING; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; MEMBRANE-PROTEIN; FAMILY PROTEINS; NEU ONCOGENE; GENE FAMILY	To gain insight into the tumor suppressor properties of E2F1, we investigated growth inhibition by the E2F family of transcription factors using a tissue culture model system, We first show that exogenous E2F expression causes an 80% decrease in NIH3T3 colony formation and activated c-Ha-Ras-mediated focus formation. Inhibition of Ras-mediated transformation was dependent upon E2F DNA binding activity but did not require amino- or carboxy-terminal E2F1 protein interaction domains. Because E2F upregulation has been suggested to be associated with a neoplastic phenotype, it was possible that increased E2F activity would not be inhibitory to previously transformed cells. However, we found that exogenous E2F was also inhibitory to growth of NIH3T3 cells previously transformed by Ras or Neu. Further characterization revealed that exogenous E2F expression is inhibitory at very early times after transfection, causing dramatic losses in transfected cell populations. Interestingly, those few cells which do establish appear to be unaffected by the overexpressed E2F, Therefore, we propose that increased E2F activity may only be tolerated in a subset of cells which have acquired specific alterations that are dominant over E2F-mediated growth inhibition.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA09135, CA07175, CA22484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Maniatis T., 1982, MOL CLONING; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2257	2268		10.1038/sj.onc.1203556	http://dx.doi.org/10.1038/sj.onc.1203556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822376				2022-12-28	WOS:000086974100011
J	Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW				Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW			Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia	ONCOGENE			English	Article						Cdc37; cyclin dependent kinase; chaperone; cancer; transgenic mice	ROUS-SARCOMA VIRUS; CELL-CYCLE MACHINERY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; CDK INHIBITORS; TYROSINE KINASE; FREE SYSTEM; HSP90; P27(KIP1); ARREST	The Cdc37 gene encodes a 50 kDa protein which targets intrinsically unstable oncoprotein kinases such as Cdk4, Raf-1, and src to the molecular chaperone Hsp90, This activity is thought to play an important role in the establishment of signaling pathways controlling proliferation. The budding yeast Cdc37 homolog is required for cell division and mammalian Cdc37 is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation, Here we report that human prostatic tumors, neoplasias and certain pre-malignant lesions display increased Cdc37 expression, suggesting an important and early role for Cdc37 in prostatic transformation. To test the consequences of increased Cdc37 levels, transgenic mice expressing Cdc37 in the prostate were generated, These mice displayed a wide range of growth-related abnormalities including prostatic epithelial cell hyperplasia and dysplasia. These data suggest that the expression of Cdc37 may promote inappropriate proliferation and may be an important early step in the development of human prostate cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Harper, JW (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Harper, Jeffrey/0000-0002-6944-7236	NIGMS NIH HHS [GM54137] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaltomaa S, 1999, PROSTATE, V38, P175; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bangma CH, 1999, SEMIN ONCOL, V26, P422; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Bubendorf L, 1999, CANCER RES, V59, P803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Munoz MJ, 1999, MOL GEN GENET, V261, P242, DOI 10.1007/s004380050963; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sharma P, 1999, ONCOGENE, V18, P5349, DOI 10.1038/sj.onc.1203037; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STEPANOVA L, 2000, IN PRESS MOL CELL BI; Tamboli P, 1998, MODERN PATHOL, V11, P247; THOMPSON T, 1999, COMPREHENSIVE TXB GE; WALSH PC, 1992, CAMPBELLS UROLOGY, V1, P1007; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109	41	67	76	3	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2186	2193		10.1038/sj.onc.1203561	http://dx.doi.org/10.1038/sj.onc.1203561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822368				2022-12-28	WOS:000086974100003
J	Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB				Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB			p21(Waf1/Cip1/Sdi1)-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells	ONCOGENE			English	Article						p21; mitosis; endoreduplication; spindle checkpoint control; senescence	TERMINAL PROLIFERATION ARREST; CYCLIN-DEPENDENT KINASES; NORMAL HUMAN FIBROBLASTS; HUMAN TUMOR-CELLS; REPLICATIVE SENESCENCE; MAMMALIAN-CELLS; INHIBITOR P21; DNA-DAMAGE; EXPRESSION; CHECKPOINT	Induction of a cyclin-dependent kinase inhibitor p21(Wafl/) (Cip1/Sdi1) is an integral part of cell growth arrest associated with senescence and damage response, p21 overexpression from an inducible promoter resulted in senescence-like growth arrest in a human fibrosarcoma cell line. After release from p21-induced growth arrest, cells reentered the cell cycle but displayed growth retardation, cell death and decreased clonogenicity. The failure to form colonies was associated with abnormal mitosis and endoreduplication in the recovering cells and was correlated with the induced level of p21 and the duration of p21 induction. p21 induction was found to inhibit the expression of multiple proteins involved in the execution and control of mitosis, p21-induced depletion of the cellular pools of mitosis-control proteins nas followed by asynchronous resynthesis of such proteins after release from p21, which explains the observed mitotic abnormalities. Genetic destabilization in cells recovering from p21-induced growth arrest may conceivably play a role in carcinogenesis and tumor progression.	Univ Illinois, Dept Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NATIONAL CANCER INSTITUTE [R01CA062099, R37CA040333] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG BD, 1999, CANCER RES, V18, P4808; CHANG BP, 2000, IN PRESS P NATL ACAD; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; GARTEL AL, 1998, INHIBITORS CELL GROW, V20, P43; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hixon ML, 1998, MOL CELL BIOL, V18, P6224, DOI 10.1128/MCB.18.11.6224; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jordan MA, 1996, CANCER RES, V56, P816; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139	41	151	159	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2165	2170		10.1038/sj.onc.1203573	http://dx.doi.org/10.1038/sj.onc.1203573			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815808				2022-12-28	WOS:000086728000010
J	Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE				Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE			The RelA NF-kappa B subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells	ONCOGENE			English	Article						NF-kappa B; RelA; AhR; c-myc oncogene; breast cancer	BREAST-CANCER; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; PROGNOSTIC FACTOR; PROTEIN; DIOXIN; TRANSCRIPTION; ACTIVATION; BINDING; LIGAND; GENE	NF-kappaB/Rel transcription factors regulate many genes involved in control of cellular proliferation, neoplastic transformation, and apoptosis, including the c-myc oncogene, Recently, we have observed that levels of NF-kappaB and aryl hydrocarbon receptor (AhR), which mediates malignant transformation by environmental carcinogens, are highly elevated and appear constitutively active in breast cancer cells. ReI factors have been found to functionally interact with other transcription factors. Here we demonstrate a physical and functional association between the RelA subunit of NF-kappaB and AhR resulting in the activation of c-myc gene transcription in breast cancer cells. RelA and AhR proteins were coimmunoprecipitated from cytoplasmic and nuclear extracts of non-malignant MCF-10F breast epithelial and malignant Hs578T breast cancer cells. In transient cotransfection, RelA and AhR gene products demonstrated cooperation in transactivation of the c-myc promoter, which was dependent on the NF-kappaB elements, and in induction of endogenous c-Myc protein levels. A novel AhR/RelA-containing NF-kappaB element binding complex was identified by electrophoretic mobility shift analysis of nuclear extracts from RelA and AhR co-transfected Hs578T cells. Thus, the RelA and AhR proteins functionally cooperate to bind to NF-kappaB elements and induce c-myc gene expression. These findings suggest a novel signaling mechanism whereby the Ah receptor can stimulate proliferation and tumorigenesis of mammary cells.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Program Res Womens Hlth, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.			Sherr, David/0000-0003-3353-0553	NCI NIH HHS [R01 CA 82742] Funding Source: Medline; NIEHS NIH HHS [1P42ES 07381, R01 ES06086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381, R01ES006086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Dickinson LA, 1999, J BIOL CHEM, V274, P12765, DOI 10.1074/jbc.274.18.12765; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; JAIN S, 1994, J BIOL CHEM, V269, P31518; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PAVELIC ZP, 1991, ANTICANCER RES, V11, P1421; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Robles R, 2000, ENDOCRINOLOGY, V141, P450, DOI 10.1210/en.141.1.450; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Yamaguchi K, 1997, TOXICOL APPL PHARM, V147, P190, DOI 10.1006/taap.1997.8263; Yamaguchi K, 1997, J IMMUNOL, V158, P2165	50	192	203	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5498	5506		10.1038/sj.onc.1203945	http://dx.doi.org/10.1038/sj.onc.1203945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114727				2022-12-28	WOS:000165396100010
J	Mixon, M; Kittrell, F; Medina, D				Mixon, M; Kittrell, F; Medina, D			Expression of Brca1 and splice variant Brca1 Delta 11 RNA levels in mouse mammary gland during normal development and tumorigenesis	ONCOGENE			English	Article						genes; Brca1; breast neoplasms; gene expression	HEREDITARY BREAST-CANCER; DNA-DAMAGE; CELL-CYCLE; MEIOTIC CELLS; IN-VIVO; DIFFERENTIATION; REPAIR; MUTATIONS; TISSUES; GENE	Expression of Brca1 in mouse mammary cancer has yet to be analysed. We use a progressive model of neoplasia based on several mouse epithelial cell lines that represent distinct steps toward the fully tumorigenic state. Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1 Delta 11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary gland through pregnancy and involution, Expression of Brca1 was highest in rapidly proliferating cells. Expression of the full-length Brca1 was detectable in the virgin gland, was slightly elevated in the midpregnant gland, and decreased to levels similar to the age-matched virgin gland in the completely involuted gland, Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1 Delta 11, in tumors higher than those in the hyperplasias. While in disagreement with the observation that Brca1 levels decrease in human breast cancer progression, these patterns support the notion that Brca1 expression is associated with proliferating cells, and suggests that the link with differentiation seen in normal cells can be removed when cells become tumorigenic.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA64255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chen YM, 1996, CANCER RES, V56, P3168; EASTON D, 1993, CANCER SURV, V18, P95; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Husain A, 1998, CANCER RES, V58, P1120; Jiang C, 1997, CARCINOGENESIS, V18, P2085, DOI 10.1093/carcin/18.11.2085; Kainu T, 1996, CANCER RES, V56, P2912; KITTRELL FS, 1992, CANCER RES, V52, P1924; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 1996, CANCER RES, V56, P4578; LYNCH HT, 1994, WORLD J SURG, V18, P21, DOI 10.1007/BF00348188; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Medina D, 1996, Cancer Treat Res, V83, P37; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CANCER RES, V53, P663; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	34	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5237	5243		10.1038/sj.onc.1203905	http://dx.doi.org/10.1038/sj.onc.1203905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077440				2022-12-28	WOS:000165059700004
J	Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J				Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J			Caspase-dependent apoptosis by ectopic expression of E2F-4	ONCOGENE			English	Article						E2F; apoptosis; cell cycle	S-PHASE ENTRY; DIHYDROFOLATE-REDUCTASE GENE; CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; SUBCELLULAR-LOCALIZATION; FAMILY PROTEINS; DNA-SYNTHESIS	E2F is a family of transcription factors which regulates cell cycle and apoptosis of mammalian cells. E2F-1-3 localize in the nucleus, and preferentially bind pRb, while E2F-4 and 5 have no nuclear localization signal and preferentially bind p107/p130. E2F-6 suppresses the transcriptional activity of other E2F proteins. DP-1 and 2 are heterodimeric partners of each E2F protein. Using tetracycline-responsive promoters, here we compared the effects of ectopic expression of E2F-1, DP-I and E2F-4 on cell cycle progression and apoptosis in Chinese hamster cell lines, We found that E2F-4, as well as DP-I and E2F-1, induced growth arrest and caspase-dependent apoptosis, E2F-4 did not have a marked effect on cell cycle progression, while E2P-1 induced DNA synthesis of resting cells and DP-1 arrested cells in G1, Ectopic expression of E2F-4 did not activate E2F-dependent transcription. Our results suggest that expression of E2F-4 at elevated levels induces growth arrest and apoptosis of mammalian cells through a mechanism distinct from E2F-1 and DP-1.	Inst Res & Innovat, Kashiwa, Chiba 2770861, Japan; Univ Vermont, Coll Med, Dept Pathol, S Burlington, VT 05403 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kyoto Prefectural Univ Med, Dept Surg 2, Kamikyo Ku, Kyoto 602, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto Prefectural University of Medicine	Magae, J (corresponding author), Inst Res & Innovat, 1201 Takada, Kashiwa, Chiba 2770861, Japan.				NIGMS NIH HHS [GM54726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BARGOU RC, 1996, J EXP MED, V183, P3; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Magae J, 1999, ONCOGENE, V18, P593, DOI 10.1038/sj.onc.1202345; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHULL S, 1991, J BIOL CHEM, V266, P24398; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	13	13	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4713	4720		10.1038/sj.onc.1203833	http://dx.doi.org/10.1038/sj.onc.1203833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032021				2022-12-28	WOS:000089528800005
J	Varma, H; Conrad, SE				Varma, H; Conrad, SE			Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain	ONCOGENE			English	Article						antiestrogen; breast cancer; cell cycle; pRb; T antigen	LARGE T-ANTIGEN; HUMAN-BREAST-CANCER; SV40 LARGE-T; CARCINOMA-CELLS; SV40-TRANSFORMED CELLS; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; ESTROGEN-RECEPTOR; E-CDK2 ACTIVATION; QUIESCENT CELLS	Proliferation of MCF-7 cells is estrogen dependent and antiestrogen sensitive. In the absence of estrogens or presence of antiestrogens MCF-7 cells arrest in the G(1) phase of the cell cycle, and this arrest is associated with an accumulation of the active, hypophosphorylated form of the retinoblastoma protein (pRb), Because active pRb negatively regulates passage from G(1) to S phase, this suggests that pRb is a crucial target of estrogen action, and that its inactivation might lead to antiestrogen resistance. We tested this hypothesis by expressing viral tumor antigens (T antigens), which bind and inactivate pRb, in MCF-7 cells, and determining the effects on cell proliferation in the presence of antiestrogens. The results of these experiments demonstrate that T antigen expression confers antiestrogen resistance to MCF-7 cells, Using a panel of mutant T antigens, we further demonstrate that the pRb-binding, but not the p53 binding domain is required to confer antiestrogen resistance. Thus, pRb is an important target of estrogen action, and its inactivation can contribute to the development of antiestrogen resistance.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Grad Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Conrad, SE (corresponding author), Michigan State Univ, Dept Microbiol, Giltner Hall, E Lansing, MI 48824 USA.				NCI NIH HHS [CA76647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JJ, 1996, J PATHOL, V180, P65, DOI 10.1002/(SICI)1096-9896(199609)180:1<65::AID-PATH607>3.0.CO;2-C; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; BRUNNER N, 1993, CANCER RES, V53, P3229; Brunner N, 1997, CANCER RES, V57, P3486; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Cole Charles N., 1996, P917; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gao QS, 1996, CANCER RES, V56, P3129; GLUZMAN Y, 1979, COLD SPRING HARB SYM, V44, P293; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Howes SH, 1996, J VIROL, V70, P3581, DOI 10.1128/JVI.70.6.3581-3588.1996; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Johnston SD, 1996, J VIROL, V70, P1191, DOI 10.1128/JVI.70.2.1191-1202.1996; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KATO J, 1993, GENE DEV, V7, P331; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIPPMAN M, 1976, CANCER RES, V36, P4595; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MELORA DB, 1998, PRINCIPLES MOL MED; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OSBORNE CK, 1985, CANCER RES, V45, P584; Pacilio C, 1998, CANCER RES, V58, P871; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WAKELING AE, 1991, CANCER RES, V51, P3867; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	56	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4746	4753		10.1038/sj.onc.1203827	http://dx.doi.org/10.1038/sj.onc.1203827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032025				2022-12-28	WOS:000089528800009
J	von Lintig, FC; Pilz, RB; Boss, GR				von Lintig, FC; Pilz, RB; Boss, GR			Quantitative determination of Rap 1 activation in cyclic nucleotide-treated HL-60 leukemic cells: lack of Rap 1 activation in variant cells	ONCOGENE			English	Article						Rap 1; HL-60; cells; cAMP; cGMP	DEPENDENT PROTEIN-KINASE; CGMP-INDUCED DIFFERENTIATION; HUMAN NEUTROPHILS; BINDING PROTEINS; GENE-EXPRESSION; GROWTH-FACTOR; PHASE-SEPARATION; EXCHANGE PROTEIN; HUMAN-PLATELETS; TRITON X-114	We have previously isolated variant HL-60 cells that are resistant to cGMP-induced differentiation and showed that they are deficient in proteolytic cleavage and/or carboxyl methylation of Rap 1A (J. Biol. Chem. 269, 32155-32161, 1994 and Oncogene 17, 2211-2233, 1998). We have now developed an enzyme-based method for assessing Rap 1 activation which is quantitative and provides a measurement of the per cent of Rap molecules in the active GTP-bound state. Using this method, we show that cAMP and cGMP analogs activate Rap 1 in parental HL-60 cells but not in the variant cells and that H-89, a cAMP-dependent protein kinase inhibitor, has no effect on cAMP-induced Rap 1 activation in parental cells. Thus, cAMP activation of Rap 1 in HL-60 cells is likely through a cAMP-regulated guanine nucleotide exchange factor (cAMP-GEF) and since cAMP does not activate Rap 1 in the variant cells, the data suggest that full post-translational processing of Rap 1 is necessary for cAMP-GEF activation of Rap 1. Activation of Rap 1 by cGMP analogs has not been previously found and suggests possible cross-talk between the NO/cGMP signal transduction pathway and Rap 1 signaling.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA81115] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GANONG BR, 1991, ANAL BIOCHEM, V193, P35, DOI 10.1016/0003-2697(91)90039-V; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; ORITA S, 1993, J BIOL CHEM, V268, P25542; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; PILZ RB, 1994, J BIOL CHEM, V269, P32155; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Scheele JS, 1998, ONCOGENE, V17, P2211, DOI 10.1038/sj.onc.1202137; Scheele JS, 1998, MOL CELL BIOCHEM, V185, P111, DOI 10.1023/A:1006834324419; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMASHIRO S, 1993, LEUKEMIA RES, V17, P129, DOI 10.1016/0145-2126(93)90057-R; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	54	20	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4029	4034		10.1038/sj.onc.1203741	http://dx.doi.org/10.1038/sj.onc.1203741			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962559				2022-12-28	WOS:000088825300008
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the RING finger domain of MDM2 to cell cycle progression	ONCOGENE			English	Article						cell cycle regulation; RING finger domain; p53 degradation; ubiquitination	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; ONCOPROTEIN MDM2; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; IN-VIVO	The MDM2 oncoprotein binds to p53 and abrogates p53-mediated G1 arrest and apoptosis, We show that MDM2 over-expression accelerates cell cycle progression of RPMI2650 cells by overcoming the negative effect of endogenous wild type p53 at the G1/S checkpoint. The interaction with p53 and transcription inhibition are necessary but not sufficient, The RING finger domain of MDM2 is also required for the positive effect of MDM2 on the cell cycle, Surprisingly, several point mutants in the zinc binding sites of the RING finger are fully competent for cell cycle stimulation even though they abolish MDM2-directed degradation of p53 and MDM2 E3-ligase activity. In contrast, alterations in and around the cryptic nucleolar localization sequence (KR motif) inhibit MDM2-mediated cell cycle progression as well as p53 degradation and MDM2 E3 ligase activity, We found that all the RING mutants decrease inhibition of both p53 dependent reporters and endogenous p21(CIP1/WAF1/SDI1). These results indicate that the RING finger of MDM2 has a role in the regulation of the cell cycle that is independent of p53 degradation and endogenous p21(CIP1/WAF1/SDI1) regulation.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu G, 1999, MOL CELL BIOL, V19, P724; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JUVEN T, 1993, ONCOGENE, V8, P3411; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	30	30	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3849	3857		10.1038/sj.onc.1203737	http://dx.doi.org/10.1038/sj.onc.1203737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951578				2022-12-28	WOS:000088614300003
J	Grooteclaes, ML; Frisch, SM				Grooteclaes, ML; Frisch, SM			Evidence for a function of CtBP in epithelial gene regulation and anoikis	ONCOGENE			English	Article						E1a; CtBP; epithelial phenotype; anoikis; E-cadherin	E-CADHERIN EXPRESSION; ZINC-FINGER; CELLULAR PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; NEGATIVE MODULATION; TUMOR PROGRESSION; SUPPRESSOR GENE; BREAST-CANCER; E1A PROTEIN; REPRESSION	Previously, we reported that adenovirus E1a protein behaves as a tumor suppressor in human cells. It apparently functions by transcriptionally inducing an array of epithelial cell adhesion genes, while repressing other cell-type specific genes, thus producing an epithelial phenotype. Concomitantly, the cells become sensitive to anoikis (apoptosis of epithelial cells detached from extracellular matrix), potentially causing tumor suppression. E1a protein interacts with the nuclear acetylases p300, CBP and P/CAF, and also with the co-repressor protein CtBP. In this study, we have determined the role of these interactions in E1a's phenotypic effects on human tumor cells. The results indicate that E1a's interaction with CtBP activates at least three epithelial cell adhesion gene promoters. The E-cadherin repressor appeared to be the CtBP-interacting protein delta EF1/ZEB, which bound the ras-repressible E-boxes of the E-cadherin promoter. The E1a-CtBP interaction also contributed to anoikis-sensitization. E1a's interactions with the nuclear acetylases conferred epithelial morphologies but did not activate epithelial genes. These latter interactions did not sensitize tumor cells to anoikis but nevertheless conferred tumor suppression. These results implicate CtBP as an antagonist of the epithelial phenotype and anoikis, They also indicate a new but undefined role for nuclear acetylases in maintaining the transformed phenotype.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Frisch, SM (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mymryk JS, 1996, ONCOGENE, V13, P1581; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Takagi T, 1998, DEVELOPMENT, V125, P21; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745	51	252	260	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3823	3828		10.1038/sj.onc.1203721	http://dx.doi.org/10.1038/sj.onc.1203721			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949939				2022-12-28	WOS:000088568400017
J	Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH				Nguyen, M; Lee, MC; Wang, JL; Tomlinson, JS; Shao, ZM; Alpaugh, ML; Barsky, SH			The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype	ONCOGENE			English	Article						thrombospondin-l; hypoxia inducible factor-1; angiogenic inhibitors; angiogenic factors	BREAST-CARCINOMA; TUMOR-GROWTH; ENDOTHELIAL-CELLS; INHIBITOR; METASTASIS; CANCER; SERPIN; THROMBOSPONDIN-1; PROLIFERATION; COMPLEMENTARY	Human myoepithelial cells which surround ducts and acini of certain organs such as the breast form a natural border separating epithelial cells from stromal angiogenesis. Myoepithelial cell lines (HMS-1-6), derived from diverse benign myoepithelial tumors, all constitutively express high levels of active angiogenic inhibitors which include TIMP-1, thrombospondin-1 and soluble bFGF receptors but very low levels of angiogenic factors. These myoepithelial cell lines inhibit endothelial cell chemotaxis and proliferation. These myoepithelial cell lines sense hypoxia, respond to low O-2 tension by increased HIF-1 alpha but with only a minimal increase in VEGF and iNOS steady state mRNA levels. Their corresponding xenografts (HMS-X-6X) grow very slowly compared to their non-myoepithelial carcinomatous counterparts and accumulate an abundant extracellular matrix devoid of angiogenesis but containing bound angiogenic inhibitors. These myoepithelial xenografts exhibit only minimal hypoxia but extensive necrosis in comparison to their non-myoepithelial xenograft counterparts. These former xenografts inhibit local and systemic tumor-induced angiogenesis and metastasis presumably from their matrix-bound and released circulating angiogenic inhibitors. These observations collectively support the hypothesis that the human myoepithelial cell (even when transformed) is a natural suppressor of angiogenesis.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon UCLA Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.			DiNome, Maggie/0000-0002-1926-292X	NCI NIH HHS [CA71195, CA83111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R21CA083111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpaugh ML, 1999, CANCER RES, V59, P5079; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P1; Folkman J, 1995, MOL BASIS CANC, P206; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Safarians S, 1996, INT J CANCER, V66, P151, DOI 10.1002/(SICI)1097-0215(19960410)66:2<151::AID-IJC2>3.0.CO;2-1; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; Sternlicht MD, 1996, LAB INVEST, V74, P781; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tobacman JK, 1997, CANCER RES, V57, P2823; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	31	73	75	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3449	3459		10.1038/sj.onc.1203677	http://dx.doi.org/10.1038/sj.onc.1203677			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918603				2022-12-28	WOS:000088346500001
J	Bromberg, J; Darnell, JE				Bromberg, J; Darnell, JE			The role of STATs in transcriptional control and their impact on cellular function	ONCOGENE			English	Article						STAT; growth control; cancer; transcription; signal transduction	GROWTH-FACTOR; INTERFERON-GAMMA; T-CELLS; TARGETED DISRUPTION; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; JAK/STAT PATHWAY; GENE-REGULATION; INFECTED CELLS; DNA-BINDING	The STAT proteins (Signal Transducers and Activators of Transcription), mere identified in the last decade as transcription factors which were critical in mediating virtually all cytokine driven signaling, These proteins are latent in the cytoplasm and become activated through tyrosine phosphorylation which typically occurs through cytokine receptor associated kinases (JAKs) or growth factor receptor tyrosine kinases, Recently a number of non-receptor tyrosine kinases (for example src and abl) have been found to cause STAT phosphorylation, Phosphorylated STATs form homo- or hetero-dimers, enter the nucleus and working coordinately with other transcriptional co-activators or transcription factors lead to increased transcriptional initiation. In normal cells and in animals, ligand dependent activation of the STATs is a transient process, lasting for several minutes to several hours. In contrast, in many cancerous cell lines and tumors, where growth factor dysregulation is frequently at the heart of cellular transformation, the STAT proteins (in particular Stats 1, 3 and 5) are persistently tyrosine phosphorylated or activated. The importance of STAT activation to growth control in experiments using anti-sense molecules or dominant negative STAT protein encoding constructs performed in cell lines or studies in animals lacking specific STATs strongly indicate that STATs play an important role in controlling cell cycle progression and apoptosis, Stat1 plays an important role in growth arrest, in promoting apoptosis and is implicated as a tumor suppressor: while Stats 3 and 5 are involved in promoting cell cycle progression and cellular transformation and preventing apoptosis, Many questions remain including: (I) a better understanding of how the STAT proteins through association with other factors increase transcription initiation; (2) a more complete definition of the sets of genes which are activated by different STATs and (3) how these sets of activated genes differ as a function of cell type. Finally, in the context of many cancers, where STATs are frequently persistently activated, an understanding of the mechanisms leading to their constitutive activation and defining the potential importance of persistent STAT activation in human tumorigenesis remains.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.							ARYA SK, 1985, P NATL ACAD SCI USA, V82, P8691, DOI 10.1073/pnas.82.24.8691; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BARON S, 1992, INT SOC INTERFERON R; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; GUYER NB, 1995, J IMMUNOL, V155, P3472; Holstege FCP, 1999, P NATL ACAD SCI USA, V96, P2, DOI 10.1073/pnas.96.1.2; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; John S, 1999, MOL CELL BIOL, V19, P1910; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PAUCKER K, 1962, VIROLOGY, V17, P324, DOI 10.1016/0042-6822(62)90123-X; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yang E, 1999, MOL CELL BIOL, V19, P5106; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	68	999	1066	3	71	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2468	2473		10.1038/sj.onc.1203476	http://dx.doi.org/10.1038/sj.onc.1203476			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851045				2022-12-28	WOS:000087459400002
J	Kondo, Y; Koga, S; Komata, T; Kondo, S				Kondo, Y; Koga, S; Komata, T; Kondo, S			Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component	ONCOGENE			English	Article						2-5A; antisense; telomerase; prostate cancer; apoptosis	HUMAN TELOMERASE ACTIVITY; MALIGNANT GLIOMA; TARGETING RNA; IN-VITRO; CELLS; INHIBITION; APOPTOSIS; 2-5A; DIFFERENTIATION; CARCINOMA	Prostate cancer is the most common malignancy of elderly men in the United States. Since there is no curative treatment for advanced prostate cancer, exploration of novel modalities of treatment is essential. Telomerase, a ribsnucleoprotein, is detected in the vast majority of prostate cancer, but not in normal or benign prostatic hyperplasin tissues. Thus, telomerase is expected to be a very strong candidate for targeted therapy of prostate cancer. In this study, we synthesized a 19-mer antisense oligonucleotide against the RNA component of human telomerase (hTR) linked to a 2-5A molecule (2-5A-anti-hTR) and examined its cytotoxic effect on prostate cancer cells. The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence. We here show that treatment with 2-5A-anti-hTR in the presence of a cationic liposome reduced cell viability of turner cell lines tested to 9-18% within 6 days, In contrast, normal fibroblast cells mere resistant to the treatment. Its effect was mainly due to induction of apoptosis by activated caspase family members. Furthermore, treatment of subcutaneous tumors in nude mice with 2-SA-anti-hTR significantly suppressed the tumor growth through induction of apoptosis (P < 0.001), The treatment with 2-5A-anti-hTR may be a promising strategy for the treatment modality of prostate cancer with telomerase activity.	CUNY, Mt Sinai Med Ctr, Dept Neurosurg, New York, NY 10029 USA; Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Neurosurg, 1 Gustave L Levy Pl,Box 1136, New York, NY 10029 USA.				NCI NIH HHS [1R01CA80233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, CANCER SURV, V28, P197; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo S, 1996, ONCOGENE, V13, P1279; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Naitoh John, 1998, Cancer Research, V58, P2895; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Sikora K, 1997, BRIT J UROL, V79, P64, DOI 10.1111/j.1464-410X.1997.tb16923.x; Sommerfeld HJ, 1996, CANCER RES, V56, P218; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGO PA, 1995, CA CANC J CLIN, V45, P8030; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	29	80	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2205	2211		10.1038/sj.onc.1203538	http://dx.doi.org/10.1038/sj.onc.1203538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822370				2022-12-28	WOS:000086974100005
J	Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD				Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD			Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAF(II)250 kinase activity	ONCOGENE			English	Article						cyclin D1; Rb; TAF(II)250; kinase	RNA-POLYMERASE-II; SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; HISTONE DEACETYLASE; SP1-MEDIATED TRANSCRIPTION; REPRESSES TRANSCRIPTION; DIFFERENTIAL REGULATION; ESTROGEN-RECEPTOR; INITIATION-FACTOR; RB INTERACTS	The retinoblastoma tumor suppressor protein has been shown to bind directly and inhibit a transcriptionally-important amino-terminal kinase domain of TATA-binding protein-associated factor TAF(II)250. Cyclin D1 also is able to associate! with the amino terminus of TAF(II)250 in a region, cry similar to or overlapping the Rb-binding site. In this study, we ha,le examined whether cyclin D1 affects the functional interaction between Rb and TAF(II)250. We observed that when cyclin D1 is coincubated with Rb and TAF(II)250, the ability of Rb to inhibit TAF(II)250 kinase activity is effectively blocked, However, cyclin D1 by itself has no apparent effect on TAF(II)250 kinase activity. We further found that the Rb-related protein p107 can inhibit TAF(II)250 kinase activity, and this inhibition is likewise alleviated by cyclin D1, Cyclin D1 prevents the kinase-inhibitory effect of an Rb mutant unable to bind to D-type cyclins, indicating that it is acting through its association with TAF(II)250 and not with Rb, However, we found no evidence of TAF(II)250-binding competition between Rb and cyclin D1 in vitro. The adenovirus ELA protein, which also binds to both Rb and TAF(II)250, exhibited a suppressive effect on Rb-mediated kinase inhibition similar to that seen with cyclin D1, Our results suggest a novel means by which cyclin D1 may be able to independently regulate the activity of Rb.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Robbins, PD (corresponding author), Univ New Mexico, Dept Mol Genet & Microbiol, Canc Res Ctr 125, Sch Med, Albuquerque, NM 87131 USA.				PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; Siegert JL, 1999, MOL CELL BIOL, V19, P846; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	51	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5703	5711		10.1038/sj.onc.1203966	http://dx.doi.org/10.1038/sj.onc.1203966			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126356				2022-12-28	WOS:000165477700001
J	Lin, WC; Kao, HW; Robinson, D; Kung, HJ; Wu, CW; Chen, HC				Lin, WC; Kao, HW; Robinson, D; Kung, HJ; Wu, CW; Chen, HC			Tyrosine kinases and gastric cancer	ONCOGENE			English	Review						gastric cancer; protein-tyrosine kinase profile	EPIDERMAL GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; FACTOR-RECEPTOR EXPRESSION; IN-SITU HYBRIDIZATION; CARCINOMA CELL-LINES; K-SAM GENE; C-MET; HELICOBACTER-PYLORI; MESSENGER-RNA; FACTOR-ALPHA	Carcinoma of the stomach is one of the most prevalent cancer types in the world today, Two major forms of gastric cancer are distinguished according to their morphological and clinicopathological classifications (well differentiated/intestinal type and poorly differentiated/diffuse type), characteristics that could also be attributed to the altered expression of different types of oncogenes or tumor suppressor genes. Significant differences exist for gastric cancer incidence comparing people of different ethnic origins, implicating various genetic and epigenetic factors for gastric oncogenesis, There are only a limited number of molecular markers available for gastric cancer detection and prognostic evaluation, among which are tyrosine kinases, There is convincing evidence that tyrosine kinases are involved in oncogenesis and disease progression for many human cancers. Amplifications of certain tyrosine kinases (c-met, k-sam and cr erb2/neu) have been associated with human gastric cancer progression. Alternatively spliced transcripts and enhanced protein-expression levels for some of these tyrosine kinases are correlated,vith clinical outcomes for gastric cancer patients. With advent of high throughput techniques, it is now possible to detect nearly all expressed tyrosine kinases in a single screen. This increases the chance to identify additional tyrosine kinases as predictive markers for gastric cancers. In this article, we will first review the literature data concerning certain tyrosine kinases implicated in gastric carcinogenesis and then summarize more recent work which pro, ide comprehensive tyrosine kinase profiles for gastric cancer specimens and cell lines, Two new gastric cancer molecular markers (tie-1 and mkk4) have been identified through the use of these profiles and demonstrated effective as clinical prognostic indicators.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Univ Calif Davis, Ctr Canc, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Vet Gen Hosp, Dept Surg, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Taipei 115, Taiwan	Academia Sinica - Taiwan; University of California System; University of California Davis; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Lin, WC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.		Lin, Wen-chang/ABH-7976-2020; Kung, Hsing-Jien/C-7651-2013; Lin, Wen-chang/B-3100-2011	Lin, Wen-chang/0000-0003-0194-1745; Lin, Wen-chang/0000-0003-0194-1745				Agus DB, 1999, CANCER RES, V59, P4761; AJANI JA, 1995, WORLD J SURG, V19, P216, DOI 10.1007/BF00308629; Albino A P, 1995, Eur J Surg Oncol, V21, P56, DOI 10.1016/S0748-7983(05)80069-1; Anzai H, 1998, EUR J CANCER, V34, P558, DOI 10.1016/S0959-8049(97)10075-2; BALL M, 1997, NEUROBIOL AGING, V18, P1; BARRANCO SC, 1983, CANCER RES, V43, P1703; Baselga J, 1998, CANCER RES, V58, P2825; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BORLINGHAUS P, 1993, CLIN INVESTIGATOR, V71, P903; Choi JH, 1997, CANCER-AM CANCER SOC, V79, P1879, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1879::AID-CNCR6>3.0.CO;2-B; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coyle WJ, 1999, AM J GASTROENTEROL, V94, P2885, DOI 10.1111/j.1572-0241.1999.01432.x; *DEP HLTH, 2000, LEAD CAUS DEATH CANC; DeRisi J, 1996, NAT GENET, V14, P457; Elitsur Y, 1999, LIFE SCI, V65, P1373, DOI 10.1016/S0024-3205(99)00376-8; Ernst SI, 1998, LAB INVEST, V78, P1633; FILIPE MI, 1995, BRIT J CANCER, V71, P30, DOI 10.1038/bjc.1995.7; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FORMAN D, 1993, LANCET, V341, P1359; Gebhardt F, 1998, BIOCHEM BIOPH RES CO, V247, P319, DOI 10.1006/bbrc.1998.8779; Gospodarowicz Denis, 1989, Critical Reviews in Oncogenesis, V1, P1; Hara T, 1998, LAB INVEST, V78, P1143; Haruma K, 2000, INT J MOL MED, V5, P185; Hashiyama M, 1996, BLOOD, V87, P93; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Hirao T, 1999, CANCER GENE THER, V6, P423, DOI 10.1038/sj.cgt.7700058; HIRONO Y, 1995, ONCOLOGY, V52, P182; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; ILEKIS JV, 1995, MOL REPROD DEV, V41, P149, DOI 10.1002/mrd.1080410205; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ISHII H, 1994, CANCER RES, V54, P518; ITOH H, 1994, CANCER RES, V54, P3237; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jonjic N, 1997, ANTICANCER RES, V17, P3883; Jung T, 1999, EUR J IMMUNOL, V29, P864, DOI 10.1002/(SICI)1521-4141(199903)29:03<864::AID-IMMU864>3.0.CO;2-T; Kaji M, 1996, CANCER GENE THER, V3, P393; KAMEDA T, 1990, CANCER RES, V50, P8002; KAMEDA T, 1992, PATHOL RES PRACT, V188, P37, DOI 10.1016/S0344-0338(11)81153-2; Kang JJ, 1997, METHODS, V13, P437, DOI 10.1006/meth.1997.0549; KARAMERIS A, 1993, PATHOL RES PRACT, V189, P133, DOI 10.1016/S0344-0338(11)80082-8; Kataoka H, 1998, LIFE SCI, V63, P553, DOI 10.1016/S0024-3205(98)00306-3; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KIM SJ, 1995, BIOCHEM BIOPH RES CO, V214, P60, DOI 10.1006/bbrc.1995.2256; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; KIYAMA T, 1992, GASTROENTEROL JPN, V27, P459; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Koizumi H, 1998, PATHOL INT, V48, P93, DOI 10.1111/j.1440-1827.1998.tb03877.x; Kono K, 2000, TUMOR BIOL, V21, P139, DOI 10.1159/000030120; Kuniyasu H, 2000, LANGENBECK ARCH SURG, V385, P69, DOI 10.1007/s004230050248; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lee HR, 1996, ONCOLOGY-BASEL, V53, P192; Lin JS, 1998, J BIOMED SCI, V5, P101, DOI 10.1159/000025319; LIN JT, 1995, CANCER RES, V55, P1428; Lin WC, 1999, CLIN CANCER RES, V5, P1745; Liu SI, 1997, ANTICANCER RES, V17, P3575; LIVINGSTONE JI, 1995, BRIT J CANCER, V72, P976, DOI 10.1038/bjc.1995.445; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masaki T, 2000, AM J GASTROENTEROL, V95, P2135; McCulloch P, 1997, EUR J SURG ONCOL, V23, P304, DOI 10.1016/S0748-7983(97)90669-7; MCCULLOCH PG, 1995, CANCER, V75, P920, DOI 10.1002/1097-0142(19950215)75:4<920::AID-CNCR2820750405>3.0.CO;2-E; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Ming Si-Chun, 1998, Gastric Cancer, V1, P31, DOI 10.1007/s101200050053; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Molina R, 1997, TUMOR BIOL, V18, P188, DOI 10.1159/000218029; MOTOJIMA K, 1994, SURGERY, V115, P349; Nakajima M, 1999, CANCER, V85, P1894; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; OHNISHI Y, 1995, BRIT J CANCER, V71, P969, DOI 10.1038/bjc.1995.187; Okino T, 1999, INT J ONCOL, V15, P709; ONeill AJ, 1997, J PATHOL, V183, P325, DOI 10.1002/(SICI)1096-9896(199711)183:3<325::AID-PATH941>3.0.CO;2-A; Ooi A, 1998, LAB INVEST, V78, P345; Orita H, 1997, HEPATO-GASTROENTEROL, V44, P294; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PERNG CL, 1994, CHUNG HUA I HSUEH TS, V54, P82; Ries L, 2000, SEER CANC STAT REV 1; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Romano M, 1998, J CLIN INVEST, V101, P1604, DOI 10.1172/JCI1174; Saily M, 1999, ANN HEMATOL, V78, P173, DOI 10.1007/s002770050496; Sakurai S, 1999, JPN J CANCER RES, V90, P1321, DOI 10.1111/j.1349-7006.1999.tb00715.x; Santoro E, 1997, HEPATO-GASTROENTEROL, V44, P826; Sanz-Ortega J, 2000, HISTOL HISTOPATHOL, V15, P455, DOI 10.14670/HH-15.455; Sato T, 1997, PATHOL INT, V47, P179, DOI 10.1111/j.1440-1827.1997.tb03737.x; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Sayani F, 2000, BLOOD, V95, P461, DOI 10.1182/blood.V95.2.461; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; Scott CD, 2000, J CELL PHYSIOL, V182, P62, DOI 10.1002/(SICI)1097-4652(200001)182:1<62::AID-JCP7>3.0.CO;2-X; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; SERUCA R, 1995, CANCER GENET CYTOGEN, V82, P140, DOI 10.1016/0165-4608(95)00033-L; SHIMIZU Y, 1991, CANCER RES, V51, P6153; Slesak B, 1998, ANTICANCER RES, V18, P2727; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; SUZUKI S, 1995, BRIT J CANCER, V72, P663, DOI 10.1038/bjc.1995.391; TAHARA E, 1995, CANCER, V75, P1410, DOI 10.1002/1097-0142(19950315)75:6+<1410::AID-CNCR2820751504>3.0.CO;2-O; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Takaishi S, 2000, BIOCHEM BIOPH RES CO, V267, P658, DOI 10.1006/bbrc.1999.2010; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TAKI T, 1985, J BIOCHEM-TOKYO, V98, P887, DOI 10.1093/oxfordjournals.jbchem.a135368; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; Tsugawa K, 1998, ONCOLOGY-BASEL, V55, P475, DOI 10.1159/000011898; TSUGAWA K, 1993, ONCOLOGY, V50, P418; Tsujimoto H, 1997, VIRCHOWS ARCH, V431, P383, DOI 10.1007/s004280050115; Turner JR, 2000, AM J PHYSIOL-GASTR L, V278, pG805, DOI 10.1152/ajpgi.2000.278.5.G805; UCHINO S, 1993, CANCER, V72, P3179, DOI 10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#; Ueda T, 1999, CANCER RES, V59, P6080; Ueda T, 1999, BIOCHEM BIOPH RES CO, V265, P739, DOI 10.1006/bbrc.1999.1735; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vidgren V, 1999, GENE CHROMOSOME CANC, V24, P24, DOI 10.1002/(SICI)1098-2264(199901)24:1<24::AID-GCC4>3.0.CO;2-H; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Wu CW, 1998, ONCOL REP, V5, P817; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Wu CW, 2000, WORLD J SURG, V24, P465, DOI 10.1007/s002689910074; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4; Yasui W, 1999, PATHOL INT, V49, P763, DOI 10.1046/j.1440-1827.1999.00951.x; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; YONEMURA Y, 1991, CANCER RES, V51, P1034; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; YONEMURA Y, 1992, ONCOLOGY, V49, P157; YONEMURA Y, 1991, ANAL CELL PATHOL, V3, P343; YONEMURA Y, 1989, ONCOLOGY, V46, P158; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	144	58	64	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5680	5689		10.1038/sj.onc.1203924	http://dx.doi.org/10.1038/sj.onc.1203924			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114748				2022-12-28	WOS:000165659300015
J	Wang, JYJ				Wang, JYJ			Regulation of cell death by the Abl tyrosine kinase	ONCOGENE			English	Review						Bcr-Abl; retinoblastoma tumor suppressor; ATM; p53; p73	C-ABL; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; IONIZING-RADIATION; BINDING DOMAIN; CYTOCHROME-C; CYCLE ARREST; DNA; ACTIVATION; BCR	The c-abl proto-oncogene encodes a protein tyrosine kinase that is distributed in the nucleus and the cytoplasm of proliferating cells. In the nucleus, c-Abl activity is negatively regulated by the retinoblastoma protein (RB) and positively regulated by DNA damage signals. Activation of the c-Abl kinase by DIVA damage requires the function of ATM, which regulates cell cycle checkpoint, DNA repair and apoptosis in response to DNA damage. Cells lacking c-Abl can activate cell cycle checkpoints and DNA repair, but show defects in apoptosis, The apoptosis defect of c-Abl deficient cells is correlated with a defect in the induction and activation of p73, which is a functional homologue! of the p53 tumor suppressor protein and has pro-apoptotic activity, The inhibition of c-Abl by RE is consistent with RB's ability to block apoptosis; while the activation of c-Abl by ATM is consistent with ATM's ability to activate cell death. The oncogenic Bcr-Abl tyrosine kinase is a potent inhibitor of apoptosis, and it is retained exclusively in the cytoplasm of transformed cells. Interestingly, when Bcr-Abl is trapped inside of the nucleus through a combined disruption of its cytoplasmic retention and its nuclear export, this oncogenic Abl kinase induces apoptosis, Taken together, the current results support a role for the nuclear c-Abl tyrosine kinase in the regulation of apoptosis, Whether the cytoplasmic c-Abl kinase can actively inhibit apoptosis remains to be determined; however, a deliberate retention of c-Abl in the cytoplasm could potentially contribute to the attenuation of apoptosis response.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,0322,Bonner Hall 3326, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA058320, R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [CA43054, CA58320, R37 CA043054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buchdunger E, 1996, CANCER RES, V56, P100; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Dan S, 1999, ONCOGENE, V18, P1277, DOI 10.1038/sj.onc.1202423; David-Cordonnier MH, 1998, BIOCHEMISTRY-US, V37, P6065, DOI 10.1021/bi973030w; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gong JG, 1999, NATURE, V399, P806; Hardin JD, 1996, ONCOGENE, V12, P2669; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Iijima Y, 2000, BLOOD, V95, P2126; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNUDSEN KE, 2000, IN PRESS MOL CELL BI, V20; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Wang JYJ, 2000, CANC DRUG DISC DEV, V5, P303; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	72	224	235	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5643	5650		10.1038/sj.onc.1203878	http://dx.doi.org/10.1038/sj.onc.1203878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114745				2022-12-28	WOS:000165659300012
J	Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA				Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA			Chimeric VEGFRs are activated by a small-molecule dimerizer and mediate downstream signalling cascades in endothelial cells	ONCOGENE			English	Article						VEGF; receptor; angiogenesis; signalling	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR VEGF; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR ENDOTHELIUM; FUNCTIONAL-ANALYSIS; BINDING-SITES; PLC-GAMMA; FLT-1; KDR; TRANSDUCTION	Despite much interest in vascular endothelial growth factor (VEGF) and its receptors (VEGFRs -1 and -2), VEGF-induced signalling cascades remain incompletely defined. Attempts to assign individual responses to a particular receptor have used either transfected cell lines, receptor-specific growth factors or antisense oligonucleotides. Such studies have attributed the majority of VEGF-induced responses to activation of VEGFR-2. As a consequence of poor growth factor-induced VEGFR-1 autophosphorylation however, observations from these studies may instead reflect the relative activation of the two receptors. We have generated novel chimeric VEGF receptors in which the dimerization domain of the B subunit of DNA gyrase is fused to the cytoplasmic domain of VEGFRs -1 and -2. When expressed in porcine aortic endothelial cells, both chimeric VEGFR-1 and -2 autophosphorylate in response to addition of the small-molecule dimerizing agent, coumermycin. Once activated, both receptors induce downstream signalling cascades, exemplified here by the activation of MAPK, PLC gamma and PKB/Akt. Furthermore, we demonstrate that the Y1175 residue of VEGFR-2 is essential for the activation of PLC gamma mediated by this chimeric receptor. In contrast to previous reports which show a limited ability of VEGFR-1 to mediate signalling cascades, we show that once sufficiently activated, VEGFR-1 signals in a similar manner to VEGFR-2 in endothelial cells.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Prigent, SA (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Maxwell, Anthony/0000-0002-5756-6430				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Esser S, 1998, J CELL SCI, V111, P1853; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kume A, 1999, BIOCHEM BIOPH RES CO, V260, P9, DOI 10.1006/bbrc.1999.0859; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	45	17	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5398	5405		10.1038/sj.onc.1203915	http://dx.doi.org/10.1038/sj.onc.1203915			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103941				2022-12-28	WOS:000165302300011
J	Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y				Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y			Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery	ONCOGENE			English	Article						MRP-1/CD9; adenovirus; gene therapy; metastasis	CELL MOTILITY; BREAST-CANCER; TRANSMEMBRANE-4 SUPERFAMILY; TM4SF PROTEINS; POOR-PROGNOSIS; BRAIN-TUMORS; LUNG-CANCER; IN-VIVO; EXPRESSION; THERAPY	Previously we showed that MRP-1/CD9 might prevent tumor metastasis by suppression of cell motility and invasion of tissue barriers. The present study explored the possibility of preventing metastasis of mouse melanoma BL6 by expression of MRP-1/CD9 through gene transfer. A replication-deficient adenovirus vector was used for the in vivo transfer of MRP-1/CD9 cDNA, Intratumor injection of an adenovirus vector (rAd-MRP-1/CD9) expressing MRP-1/CD9 resulted in a 73.7% reduction in the number of pulmonary metastases of mice and the median survival time of mice treated with rAd-MRP-1/CD9 was significantly longer than those treated with the rAd-beta -gal vector (103.2+/-8.5 days vs 71.2+/-5.2 days, P<0.001 respectively). These results support the expression of MRP-1/CD9 through gene transfer as a therapeutic strategy for preventing metastases and prolonging survival, and support the feasibility of gene transfer in a clinically relevant setting.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 5308480, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 5898511, Japan; Kyoto Univ, Dept Urol & Pathol, Kyoto 6068501, Japan	Kitano Hospital; Kitano Hospital; Kindai University (Kinki University); Kyoto University	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 5308480, Japan.							Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; BARNES R, 1991, AM J PATHOL, V139, P245; Bonnekoh B, 1998, J INVEST DERMATOL, V110, P867, DOI 10.1046/j.1523-1747.1998.00221.x; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Cajot JF, 1997, CANCER RES, V57, P2593; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Harris MP, 1996, CANCER GENE THER, V3, P121; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kondo K, 1998, CANCER RES, V58, P2014; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TOH Y, 1994, J BIOL CHEM, V269, P22958; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186	33	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5221	5226		10.1038/sj.onc.1203919	http://dx.doi.org/10.1038/sj.onc.1203919			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077438				2022-12-28	WOS:000165059700002
J	Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R				Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R			CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin	ONCOGENE			English	Article						cisplatin; JNK1; CL100-MKP-1; hVH-5; apoptosis	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; KINASE KINASE KINASE; DNA-DAMAGING AGENTS; C-JUN; MAP KINASE; IN-VIVO; CELL-DEATH; CONDITIONAL EXPRESSION	Treatment of cells with cisplatin induces a sustained activation of the stress activated protein kinase SAPK/JNK and the mitogen-activated protein kinase p38, Activation of JNK by cisplatin is necessary for the induction of apoptosis, Expression of the MAPK phosphatases CL100/MKP-1 and hVH-5 selectively prevents JNK/SAPK activation by cisplatin in a dose dependent fashion and results in protection against cisplatin-induced apoptosis, In contrast, expression of the ERK-specific phosphatase Pyst1 inhibits JNK/SAPK activity only when expressed at very high levels and does not confer protection against cisplatin. Furthermore, expression of a catalytically inactive mutant of CL100 in 293 cells decreases the IC50 for cisplatin and increases the toxicity of transplatin, This effect seems to be mediated by an increase in JNK activity since p38 activity is unaffected. These results suggest that dual-specificity MAPK phosphatases may be candidate drug targets in order to optimize cisplatin based therapeutic protocols.	CSIC, Inst Invest Biomed, UAM, E-28029 Madrid, Spain; Ninewells Hosp, Biomed Res Ctr, Mol Pharmacol Unit, Imperial Canc Res Fund, Dundee DD1 9SY, Scotland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Dundee	Perona, R (corresponding author), CSIC, Inst Invest Biomed, UAM, Arturo Duperier 4, E-28029 Madrid, Spain.		Keyse, Stephen M./B-9575-2009; Sánchez-Pérez, Isabel/R-4107-2016	Keyse, Stephen M./0000-0002-5150-8221; Sánchez-Pérez, Isabel/0000-0002-4829-201X				ALESSI DR, 1993, ONCOGENE, V8, P2015; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Leav I, 1996, LAB INVEST, V75, P361; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	57	120	126	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5142	5152		10.1038/sj.onc.1203887	http://dx.doi.org/10.1038/sj.onc.1203887			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064451				2022-12-28	WOS:000090124100003
J	Basso, J; Briggs, J; Findlay, C; Bos, T				Basso, J; Briggs, J; Findlay, C; Bos, T			Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts	ONCOGENE			English	Article						v-Jun; chicken; binding mutants	MOUSE C-JUN; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; BZIP PROTEINS; TARGET GENE; FOS	Overexpression of v-Jun in chicken embryo fibroblasts (CEF) leads to oncogenic transformation phenotypically characterized by anchorage independent growth and release from contact inhibition (focus formation). The mechanisms involved in this oncogenic conversion however, are not yet clear. Because Jun is a transcription factor, it has been assumed that oncogenic transformation results directly from deregulated AP-1 target gene expression. However, a number of experimental observations in avian cell culture models fail to correlate oncogenesis with AP-I activity suggesting that transformation induced by v-Jun may occur through an indirect mechanism, To test this possibility, we introduced point mutations into the basic DNA binding domain of v-Jun and created mutants that exhibit altered binding specificity, When expressed in CEF, these mutants fail to deregulate three known v-Jun target genes (JTAP-1, apolipoprotein Al,: c-Jun) thus demonstrating in vivo specificity changes, Each of the binding specificity mutants was also tested for its ability to induce oncogenic transformation. Interestingly, expression of these mutants in CEF results in a phenotype indistinguishable from the vector control with respect to growth rate, focus formation and the ability to form colonies in soft agar, These results are consistent with a model requiring direct AP-1 target deregulation as a prerequisite of v-Jun induced cell transformation. With this in mind, we generated a series of additional mutants that retain the ability to bind AP-1 sequence elements, but vary in their oncogenic potential. We demonstrate the use of these mutants to screen v-Jun induced gene targets for a functional role in cell transformation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, T (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; METIVIER C, 1993, ONCOGENE, V8, P2311; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; TOURAY M, 1991, ONCOGENE, V6, P1227; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; VOGT PK, 1990, CANCER BIOL, V1, P27; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206	50	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4876	4885		10.1038/sj.onc.1203863	http://dx.doi.org/10.1038/sj.onc.1203863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039905				2022-12-28	WOS:000089757800010
J	Elliott, K; Ge, K; Du, W; Prendergast, GC				Elliott, K; Ge, K; Du, W; Prendergast, GC			The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program	ONCOGENE			English	Article						transformation; apoptosis; cancer; amphiphysin-like protein/amph1	TUMOR-SUPPRESSOR BIN1; ABL TYROSINE KINASE; INDUCED APOPTOSIS; GENE-EXPRESSION; SCHIZOSACCHAROMYCES-POMBE; MEDIATED ENDOCYTOSIS; AMPHIPHYSIN ISOFORM; EMBRYO FIBROBLASTS; PROSTATE-CANCER; SPLICE VARIANTS	Cell death processes are progressively inactivated during malignant development, in part by loss of tumor suppressors that can promote cell death. The Bin1 gene encodes a nucleocytosolic adaptor protein with tumor suppressor properties, initially identified through its ability to interact with and inhibit malignant transformation by c-Myc and other oncogenes, Bin1 is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma, In this study, we show that Bin1 engages a caspase-independent cell death process similar to type II apoptosis, characterized by cell shrinkage, substratum detachment, vacuolated cytoplasm, and DNA degradation. Cell death induction was relieved by mutation of the BAR domain, a putative effector domain, or by a missplicing event that occurs in melanoma and inactivates suppressor activity. Cells in all phases of the cell cycle were susceptible to death and p53 and Rb were dispensable. Notably, Bin1 did not activate caspases and the broad spectrum caspase inhibitor ZVAD,fmk did not block cell death. Consistent with the lack of caspase involvement, dying cells lacked nucleosomal DNA cleavage and nuclear lamina degradation. Moreover, neither Bcl-2 or dominant inhibition of the Pas pathway had any effect. In previous work, we showed that Bin1 could not suppress cell transformation by SV40 large T antigen. Consistent with this finding, we observed that T antigen suppressed the death program engaged by Bin1, This observation was interesting in light of emerging evidence that T antigen has roles in cell immortalization and human cell transformation beyond Rb and p53 inactivation. In support of a link to c-Myc-induced death processes, AEBSF, a serine protease inhibitor that inhibits apoptosis by c-Myc, potently suppressed DNA degradation by Bin1, Our findings suggest that the tumor suppressor activity of Bin1 reflects engagement of a unique cell death program, We propose that loss of Bin1 may promote malignancy by blunting death penalties associated with oncogene activation.	Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	DuPont; The Wistar Institute	Prendergast, GC (corresponding author), Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA.		Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bowen C, 1998, CANCER RES, V58, P3275; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conzen SD, 1995, ONCOGENE, V11, P2295; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, MOL CELL BIOL, V19, P1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davis RA, 1996, ECONOMET THEOR, V12, P1, DOI 10.1017/S0266466600006423; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harlow E, 1998, ANTIBODIES LAB MANUA; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jenkins RB, 1997, CANCER RES, V57, P524; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEMAITRE JM, 1995, MOL CELL BIOL, V15, P5054; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#	97	84	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4669	4684		10.1038/sj.onc.1203681	http://dx.doi.org/10.1038/sj.onc.1203681			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032017				2022-12-28	WOS:000089528800001
J	Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M				Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M			Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells	ONCOGENE			English	Article						forkhead; FKHR; EGF; breast cancer	PROTEIN-KINASE-B; CAENORHABDITIS-ELEGANS; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; BINDING-SITE; INSULIN; AKT; TRANSLOCATION; LONGEVITY	Akt, when activated by IGF/insulin, can phosphorylate forkhead transcription factors. We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231, After establishing ErbB1, cbl, PI3 kinase and Akt were activated in EGF treated MDA-MB-231, we determined by immunoblot with FKHR antiserum that the electrophoretic mobility of FKHR was retarded after EGF treatment. This mobility retardation was reversible by treatment with alkaline phosphatase, and immunoblot with phospho-Ser(256) FKHR antibody further confirmed phosphorylation on an Akt consensus site after EGF treatment. EGF stimulated FKHR phosphorylation was blocked by the PI3 kinase inhibitor LY294002, and the ErbB1 inhibitor AG1478, FKHR immunoblotting after purification of nuclear and cytoplasmic proteins showed that EGF induced a simultaneous increase of FKHR in the cytoplasm and decrease in the nucleus. This finding was confirmed by immunofluorescence staining. Treatment of cells with pharmacological inhibitors of PI3 kinase or ErbB1 blocked this effect. Thus, these results demonstrate the phosphorylation and nuclear exclusion of FKHR after EGF treatment by a PI3 kinase dependent mechanism, and represent the first report of growth factor regulation of endogenous FKHR localization.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Hosp, Div Res & Dev, San Antonio, TX 78229 USA; Univ Minnesota, Ctr Canc, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Minnesota System; University of Minnesota Twin Cities	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, R01CA074285] Funding Source: NIH RePORTER; NCI NIH HHS [CA74285, CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLASS WF, 1993, J CELL PHYSIOL, V157, P296; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis GD, 1996, CANCER RES, V56, P1457; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	39	73	73	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4574	4581		10.1038/sj.onc.1203825	http://dx.doi.org/10.1038/sj.onc.1203825			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030146				2022-12-28	WOS:000089438200003
J	Fenstermaker, RA; Ciesielski, MJ				Fenstermaker, RA; Ciesielski, MJ			Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; glioma; oncogene; recombination; V(D)J	HUMAN GLIOBLASTOMA CELLS; CONFERS ENHANCED TUMORIGENICITY; CENTRAL-NERVOUS-SYSTEM; EGF-RECEPTOR; TYROSINE KINASE; FACTOR-ALPHA; EXPRESSION; TRANSFORMATION; AMPLIFICATION; RECOMBINATION	The epidermal growth factor receptor (EGFR) gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion mutants (DM). The most common mutant EGFRvIII, which contains a deletion of exons 2-7, is constitutively autophosphorylated and inefficiently do downregulated. Other less common EGFR mRNA species in gliomas contain tandem duplication of exons, which encode the tyrosine kinase (TK) and calcium mediated receptor internalization (CAIN) domains of the molecule. We examined a panel of human malignant gliomas and found one tumor that expressed four related EGFR proteins, including 125-, 140-, 170-, and 180-kDa species. This tumor also contained four EGFR-related mRNA species, including both wild type EGFR and EGFRvIII transcripts. A third transcript contained a deletion of exons 2-7 and 12-13 corresponding to the 125-kDa protein. A fourth transcript contained an in-frame, tandem duplication of exons 2-7 (EGFR,TDM/2-7). The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impaired downregulation, In contrast to the 140-kDa EGFRvIII; however, phosphorylation of the 180-kDa EGFR.TDM/2-7 was strongly induced by ligand, Expression of both deletion and tandem duplication mutants in the same tumor suggests that the mechanisms responsible for DM and TDM formation might be closely related.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-22] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1991, BIOCHEM BIOPH RES CO, V181, P151, DOI 10.1016/S0006-291X(05)81394-4; Bailin T, 1999, MOL CELL BIOL, V19, P4664; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Frederick L, 2000, CANCER RES, V60, P1383; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEBEAU MM, 1986, ADV HUM GENET, V15, P1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TASHIRO S, 1994, ONCOGENE, V9, P1939; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	36	18	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4542	4548		10.1038/sj.onc.1203802	http://dx.doi.org/10.1038/sj.onc.1203802			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002427				2022-12-28	WOS:000089236800011
J	Nakano, K; Balint, E; Ashcroft, M; Vousden, KH				Nakano, K; Balint, E; Ashcroft, M; Vousden, KH			A ribonucleotide reductase gene is a transcriptional target of p53 and p73	ONCOGENE			English	Article						p53; p73; DNA damage; ribonucleotide reductase; p53R2	CELL-CYCLE ARREST; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; TUMOR SUPPRESSION; INDUCE APOPTOSIS; ENDOREDUPLICATION; PROLIFERATION; MUTANTS; CANCER	Many p53-inducible genes have been identified that might play a role in mediating the various downstream activities of p53, We have identified a close relative of ribonucleotide reductase, recently named p53R2, as a p53-inducible gene, and show that this gene is activated by several stress signals that activate a p53 response, including DNA damaging agents and p14(ARF), p53R2 expression was induced by p53 mutants that are defective for the activation of apoptosis, but retain cell cycle arrest function, although no induction of p53R2 was seen in response to p21(WAF1/CIP1)-mediated cell cycle arrest. Several isoforms of the p53 family member p73 were also shown to induce p53R2 expression. Transient ectopic expression of either wild type p53R2 or p53R2 targeted to the nucleus, did not significantly alter cell cycle progression in unstressed cells, The identification of this gene as a p53 target supports a direct role for p53 in DNA repair, in addition to inhibition of growth of damaged cells.	NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Agami R, 1999, NATURE, V399, P809; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gong JG, 1999, NATURE, V399, P806; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	32	191	199	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4283	4289		10.1038/sj.onc.1203774	http://dx.doi.org/10.1038/sj.onc.1203774			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980602				2022-12-28	WOS:000089032900011
J	Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD				Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD			Conformational phenotype of p53 is linked to nuclear translocation	ONCOGENE			English	Article						p53; conformation; subcellular localization	WILD-TYPE P53; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODY; HUMAN NEUROBLASTOMA; DNA-BINDING; PROTEIN; LOCALIZATION; SUPPRESSOR; GENE	P53 is inactivated in tumors by mechanisms other than mutations in the p53 gene itself, To gain insight into the mechanisms by which this inactivation occurs, we chemically mutagenized A1-5 cells expressing high levels of temperature sensitive p53(val135) (tsp53) and selected for clones that were capable of growth at the permissive temperature for p53 activation. We expanded 22 clones (ALTR cells for (A) under bar 1-5 (L) under bar ow (T) under bar emperature (R) under bar esistant) that could grow at the permissive temperature. Most exhibited cytoplasmic sequestration as the mechanism by which p53 was inactivated. We show here that this cytoplasmically sequestered tsp53 protein is maintained in a mutant conformation. Only in clones with nuclear localized p53 is it also expressed in the wild-type conformation suggesting that subcellular localization of tsp53 is important in determining the conformation of the protein. Consistent with this, we show that the changes in conformation of p53 in A1-5 and SK-N-SH cells induced by ionizing radiation also correlate with nuclear translocation of p53, We suggest that nuclear translocation of p53 can result in a change in the conformation from mutant to wild-type but that these may be two separable events.	Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Grad Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, POB 245024,1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McLure KG, 1996, ONCOGENE, V13, P1297; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	42	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4042	4049		10.1038/sj.onc.1203756	http://dx.doi.org/10.1038/sj.onc.1203756			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962561	Bronze			2022-12-28	WOS:000088825300010
J	Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL				Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL			Cyclic AMP activates Ras	ONCOGENE			English	Article						cAMP; Ras; proliferation; thyroid cells	DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; THYROID EPITHELIAL-CELLS; DNA-SYNTHESIS; THYROGLOBULIN EXPRESSION; NEURITE OUTGROWTH; SIGNALING PATHWAY; CAMP; RAP1; INHIBITION	In addition to protein kinase A (PKA), cAMP regulates the activity of cAMP-gated channels and Rap1-specific guanine nucleotide exchange factors, We tested the hypothesis that the targets of cAMP might also include regulators of the Ras protooncogene. In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAMP-mediated pathway that requires Ras activity, interference with Res impairs DNA synthesis stimulated by TSH as well as cAMP elevating agents and analogs, demonstrating that the requirement for Ras lies down-stream of cAMP. Although cAMP stimulates proliferation, microinjection of the purified PKA catalytic subunit failed to do so, suggesting that factors in addition to PKA are required for cAMP-stimulated cell cycle progression. When added to thyroid cells expressing human Ha-Ras, TSH rapidly and markedly increased the proportion of GTP-bound Ras. Ras activity was increased within 1 min of TSH addition, maximal at 5-15 min, and declined to basal levels 30-60 min after hormone treatment. Cyclic AMP elevating agents elicited similar effects on Ras, indicating that TSH activates Ras through a cAMP-mediated pathway. Although cAMP-mediated, Ras activation by TSH and cAMP was independent of PKA activity. Moreover, cAMP-stimulated Ras activation was not impaired by tyrosine kinase inhibitors. These results indicate that cAMP activates targets in addition to PKA in thyroid cells, and that these targets may include regulators of Ras. The ability of cAMP elevating agents to activate Ras in addition to PKA may explain the inability of the PKA catalytic subunit to stimulate DNA synthesis in thyroid cells.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK02494, DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696, K02DK002494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FAGIN JA, 1994, ANNU REV MED, V45, P45; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KOLCH W, 1996, ONCOGENE, V6, P1304; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MUCA C, 1994, ONCOGENE, V9, P3647; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SUAREZ HG, 1991, ONCOGENE, V6, P677; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	45	56	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3609	3615		10.1038/sj.onc.1203680	http://dx.doi.org/10.1038/sj.onc.1203680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951566				2022-12-28	WOS:000088568300006
J	Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y				Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y			Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial calls	ONCOGENE			English	Article						VEGF; Flt-1; KDR; migration; proliferation	PLACENTA GROWTH-FACTOR; FOCAL ADHESION KINASE; DOMAIN-CONTAINING RECEPTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR DOMAIN; CELL-MIGRATION; PHOSPHORYLATION; EXPRESSION	Vascular endothelial growth factor (VEGF) is a principal regulator of vasculogenesis and angiogenesis, VEGF expresses its effects by binding to two VEGF receptors, Flt-1 and KDR, However, properties of FI-l and KDR in the signal transduction of VEGF-mediated effects in endothelial cells (ECs) were not entirely clarified, We investigated this issue by using two newly developed blocking monoclonal antibodies (mAbs) against Flt-1 and KDR, VEGF elicits DKA. synthesis and cell migration of human umbilical, vein endothelial cells (HUVECs). The pattern of inhibition of these effects by two mAbs indicates that DNA. synthesis is preferentially mediated by KDR, In contrast, the regulation of cell migration by VEGF appears to be more complicated. Flt-1 regulates cell, migration through modulating actin reorganization, which is essential for cell motility. a distinct signal is generated by KDR, which influences cell migration by regulating cell adhesion via the assembly of vinculin in focal adhesion plaque and tyrosine-phosphorylation of focal adhesion kinase (FAK) and paxillin.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Sendai, Miyagi 980, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida 194, Japan; Univ Tokyo, Dept Genet, Inst Med Sci, Tokyo, Japan	Tohoku University; Tohoku University; Kyowa Kirin Ltd; University of Tokyo	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan.		Kanno, Shin-ichiro/AAE-4549-2019					Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANAI N, 1986, CANCER RES, V46, P4438; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; SHITARA K, 1987, CANCER RES, V47, P1267; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Zhu ZP, 1998, CANCER RES, V58, P3209; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	39	231	254	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2138	2146		10.1038/sj.onc.1203533	http://dx.doi.org/10.1038/sj.onc.1203533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815805				2022-12-28	WOS:000086728000007
J	Jones, SM; Kazlauskas, A				Jones, SM; Kazlauskas, A			Connecting signaling and cell cycle progression in growth factor-stimulated cells	ONCOGENE			English	Review						PDGF; cell cycle progression; signal transduction	RECEPTOR TYROSINE KINASES; FORKHEAD TRANSCRIPTION FACTOR; FACTOR-BETA-RECEPTOR; SRC FAMILY KINASES; BALB/C 3T3 CELLS; DNA-SYNTHESIS; RESTRICTION POINT; DEPENDENT KINASE; RAS ACTIVITY; PHOSPHATIDYLINOSITOL-3 KINASE	A widely used model system to investigate cell proliferation is stimulation of serum-arrested cells with growth factors. Recent data suggest that there are two waves of growth factor-dependent signaling events required for a proliferative response. One is an acute burst of signaling, which occurs immediately after growth factor stimulation and lasts for 30-60 min. The other occurs in a different time frame (8-12 h post stimulation), and involves activation of cyclin dependent kinases (Cdks), In addition to a general overview of growth factor-dependent signaling,,ve present our 'two wave' hypothesis for how signaling and cell cycle progression are linked.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HELDIN CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, pR79; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JONES S, 2000, UNPUB; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kirschner M W, 1992, Important Adv Oncol, P3; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MORI S, 1993, J BIOL CHEM, V268, P577; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rose DW, 1998, ONCOGENE, V17, P889, DOI 10.1038/sj.onc.1201997; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Schlesinger TK, 1999, BIOCHEM J, V344, P519, DOI 10.1042/0264-6021:3440519; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STILES CD, 1979, J CELL PHYSIOL, V99, P395, DOI 10.1002/jcp.1040990314; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Winston JT, 1996, ONCOGENE, V12, P127; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	100	47	47	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5558	5567		10.1038/sj.onc.1203858	http://dx.doi.org/10.1038/sj.onc.1203858			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114735				2022-12-28	WOS:000165659300002
J	Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V				Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V			The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents	ONCOGENE			English	Article						transgenic mice; p53; hepatocarcinoma; apoptosis; DNA damage	WILD-TYPE P53; LARGE T-ANTIGEN; BREAST-CANCER CELLS; TRANSGENIC MICE; IN-VIVO; GENE-THERAPY; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; DECREASED SENSITIVITY; SPINDLE CHECKPOINT	To analyse the effect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not affect hepatic development, its constitutive expression in tumorigenic livers resulted in a significantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no effect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAg-transformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results confirmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that suppression of dysplastic cells, probably by restoring normal cytokinesis and karyokinesis, and enhancement of apoptosis by means of p53 overexpression were insufficient to counteract or delay the TAg-induced liver tumoral progression.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; JOULIN, Virginie/0000-0003-1091-7819				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allemand I, 1995, ONCOGENE, V11, P2583; Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FAN SJ, 1994, CANCER RES, V54, P5824; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Goto A, 1998, JPN J CANCER RES, V89, P539, DOI 10.1111/j.1349-7006.1998.tb03295.x; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Ju JF, 1998, CLIN CANCER RES, V4, P1315; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan SH, 1998, CANCER RES, V58, P396; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Piovesan B, 1998, ONCOGENE, V17, P2339, DOI 10.1038/sj.onc.1202147; Procopio A, 1998, Monaldi Arch Chest Dis, V53, P241; ROUQUET N, 1995, ONCOGENE, V11, P1061; Seth P, 1997, CANCER GENE THER, V4, P383; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Song KM, 1997, ONCOL RES, V9, P603; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TREMP GL, 1995, GENE, V156, P199, DOI 10.1016/0378-1119(95)00010-4; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	24	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3498	3507		10.1038/sj.onc.1203671	http://dx.doi.org/10.1038/sj.onc.1203671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918608				2022-12-28	WOS:000088346500006
J	Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A				Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A			Mlx, a new Max-Like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?	ONCOGENE			English	Article						bHLHZip; Myc; Max; Rox; cell proliferation	HELIX-ZIPPER PROTEIN; C-MYC; DNA-BINDING; HISTONE DEACETYLASE; GROWTH-FACTOR; CELL-PROLIFERATION; E-BOX; RAS COTRANSFORMATION; OPPOSITE REGULATION; MAMMALIAN-CELLS	The Myc proto-oncogene family members have been identified as the cellular homologs of the transforming oncogene of avian retro viruses. They encode central regulators of mammalian cell proliferation and apoptosis, and they associate with the bHLHZip protein Max to hind specific DNA sequences and regulate the expression of genes important for cell cycle progression. The other family members, Mad1, Mxi1, Mad3, Mad4 and Rox (Mnt) antagonize their activities. The Mads and Ros compete with Myc in heterodimerizing with Max and in binding to the same specific target sequences, These Mads:Max and Rox:Max dimers repress transcription through binding to the mSIN3 corepressor protein and by tethering histone deacetylase-containing complexes to the DNA. In a screen for Rox interactors we isolated Mlx, a bHLHZip protein previously identified in a screen for Mad1 interactors. In the present work we extend the known dimerization partners of Mlx by demonstrating its ability to interact with Rox. Moreover, we show that contrary to previous reports Mlx is able to homodimerize and to bind E-box sequences at low concentration Levels. The possible role of Mlx in an emerging regulatory pathway and acting parallel to the Max driven network is discussed.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Inst Mol Sci, Berkeley, CA 94704 USA; Univ Vita & Salute, Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); The Molecular Sciences Institute; Vita-Salute San Raffaele University	Reymond, A (corresponding author), Telethon Inst Genet & Med, SAn Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		Cairo, Stefano/O-2831-2016; BALLABIO, Andrea/AAL-2672-2020; merla, giuseppe/K-4627-2012	Cairo, Stefano/0000-0002-4725-5970; BALLABIO, Andrea/0000-0003-1381-4604; merla, giuseppe/0000-0001-5078-928X; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM00S01, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Bjerknes M, 1996, GENE, V181, P7, DOI 10.1016/S0378-1119(96)00376-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Eilers M, 1999, MOL CELLS, V9, P1; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HESKETH R, 1997, ONCOGENE TUMOUR SUPP, P1; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li XJ, 1999, JPN J CANCER RES, V90, P740, DOI 10.1111/j.1349-7006.1999.tb00809.x; Lo Nigro C, 1998, GENOMICS, V49, P275; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; REYMOND A, 1995, ONCOGENE, V11, P1173; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Tangir J, 1996, ONCOGENE, V12, P735; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VASTRIK I, 1993, ONCOGENE, V8, P503; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WALKER CW, 1992, ONCOGENE, V7, P2007; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; Zhao Z, 1996, MAMM GENOME, V7, P686, DOI 10.1007/s003359900206	86	59	63	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3266	3277		10.1038/sj.onc.1203634	http://dx.doi.org/10.1038/sj.onc.1203634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918583				2022-12-28	WOS:000088019300005
J	Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P				Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P			Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells	ONCOGENE			English	Article						A2780 ovarian carcinoma; hMLHI silencing; methylation tolerance	OVARIAN-CANCER; DNA-DAMAGE; COLORECTAL-CARCINOMA; ACQUIRED-RESISTANCE; METHYLATING AGENTS; MUTATOR PHENOTYPE; HMLH1 PROMOTER; SENSITIVITY; APOPTOSIS; LINES	The contributions of defective mismatch repair and mutated p53 to cisplatin resistance of human tumor cells were analysed. Mismatch repair defects were not associated with a predictable degree of resistance among several tumor cell Lines. Repair defective variants of the A2780 ovarian carcinoma cell Line which were isolated 62 selection for a methylation tolerant phenotype and did not express the hMLH1 mismatch repair protein, were highly resistant to cisplatin, Their cisplatin resistance was not a simple consequence of the mismatch repair defect. They were members of a drug-naive subpopulation of A2780 in which a silent hMLH1 gene accompanies a mutated p53. Two complementary approaches indicated that each defect contributes to cisplatin resistance independently and to a different extent, Firstly separate introduction of a p53 defect into A2780 cells significantly increased their cisplatin resistance; defective hMLH1 provided less extensive protection. Secondly, azadeoxycytidine reactivation of the silent hMLH1 gene or expression of a transfected hMLH1 cDNA sensitized the doubly hMLH1/p53 deficient cells only slightly to cisplatin, Both approaches indicate that defective p53 status is a major determinant of cisplatin resistance and defective mismatch repair is a minor, and independent, contributor. The data have implications for the development of intrinsic cisplatin resistance.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Ist Super Sanita, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Karran, P (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1995, CANCER RES, V55, P2569; Aquilina G, 1998, CANCER RES, V58, P135; Aquilina G, 2000, CLIN CANCER RES, V6, P671; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, CANCER RES, V59, P538; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Einhorn LH, 1997, CLIN CANCER RES, V3, P2630; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSON SW, 1994, CANCER RES, V54, P5911; KARRAN P, 1993, J BIOL CHEM, V268, P15878; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; [No title captured]	39	103	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3138	3145		10.1038/sj.onc.1203668	http://dx.doi.org/10.1038/sj.onc.1203668			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918568				2022-12-28	WOS:000088019200002
J	Renshaw, MW; Lewis, JM; Schwartz, MA				Renshaw, MW; Lewis, JM; Schwartz, MA			The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin	ONCOGENE			English	Article						Erk2; Ras; signal transduction; extracellular matrix; cell adhesion	FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; GROWTH-FACTOR; V-ABL; SHC; RAS; MIGRATION; INTEGRINS; MOTILITY	Previous work showed that integrin stimulation triggers activation of the c-Abl tyrosine kinase and its transient localization to focal adhesions. We now report that plating cells on fibronectin triggers association of Grb2 with c-Abl, suggesting possible involvement of c-Abl with integrin activation of the MAP kinase pathway. Expression of a kinase-defective c-Abl specifically inhibited the transient induction of Erk2 activity following cell adhesion, Together with the known ability of activated, oncogenic forms of c-Abl to activate Ras and the MAP kinase pathway, these data suggest that c-myc contributes to the integrin induction of MAP kinase activity.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Lewis, Jean/0000-0001-6978-5166; schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [R29 CA74230] Funding Source: Medline; NHLBI NIH HHS [P01 HL57900] Funding Source: Medline; NIGMS NIH HHS [F32 GM18298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074230] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CHANG JH, 1995, METHOD ENZYMOL, V254, P430; CHEN QM, 1994, J BIOL CHEM, V269, P26602; GOGA A, 1995, CELL, V82, P891; Gong JG, 1999, NATURE, V399, P806; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; KAMASHITA I, 1989, ANAL BIOCHEM, V183, P139; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHAO X, 1999, J BIOL CHEM, V272, P18141	30	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3216	3219		10.1038/sj.onc.1203667	http://dx.doi.org/10.1038/sj.onc.1203667			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918577				2022-12-28	WOS:000088019200011
J	Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y				Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y			Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation	ONCOGENE			English	Article						RING finger; ubiquitin ligase; growth essential; cell cycle; SCF complex; apoptosis	NF-KAPPA-B; UBIQUITIN-LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; INDUCED APOPTOSIS; S-PHASE; BCL-2 FAMILY; DEATH; PROTEIN; KINASE; PATHWAY	In an attempt to understand the signaling pathway mediating redox-induced apoptosis, we cloned SAG, an evolutionarily conserved zinc RING finger gene that, when overexpressed, protects cells from apoptosis induced by redox agents. Here we report functional characterization of SAG by the use of yeast genetics approach. Targeted disruption of ySAG, yeast homolog of human SAG, and subsequent tetrad analysis revealed that ySAG is required for yeast viability. Complementation experiment showed that the lethal phenotype induced by the ySAG deletion is fully rescued by wildtype SAG, but not by several hSAG mutants, Complementation experiment has also confirmed that ySAG is essential for normal vegetative growth, rather than being required for sporulation. Furthermore, cell death induced by SAG deletion was accompanied by cell enlargement and abnormal cell cycle profiling with an increased DNA content. Importantly, SAG was found to be the second family member of Rbx (RING box protein) or ROC (Regulator of cullins) or Hrt that is a component of SCF E3 ubiquitin ligase, Indeed, like ROC1/Rbx1/Hrt1, SAG binds to Cull and SAG-Cull complex has ubiquitin ligase activity to promote poly-ubiquitination of E2/ Cdc34. This ligase activity is required for complementation of death phenotype induced by ySAG disruption. Finally, chip profiling of the entire yeast genome revealed induction of several G1/S as well as G2/M checkpoint control genes upon SAG withdrawal. Thus, SAG appears to control cell cycle progression in yeast by promoting ubiquitination and degradation of cell cycle regulatory proteins.	Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI USA	Pfizer; Pfizer	Sun, Y (corresponding author), Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA.			Swaroop, Manju/0000-0002-0576-1664				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boger-Nadjar E, 1998, MOL GEN GENET, V260, P232, DOI 10.1007/s004380050891; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Goh PY, 1999, MOL CELL BIOL, V19, P5512; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; IIDA H, 1984, J CELL BIOL, V99, P199, DOI 10.1083/jcb.99.1.199; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Levine K, 1995, Prog Cell Cycle Res, V1, P101; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MATSUMOTO Y, 1993, YEAST, V9, P929, DOI 10.1002/yea.320090813; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; PRINTEN JA, 1994, GENETICS, V138, P609; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAZER S, 1990, J CELL SCI, V97, P509; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Sun Y, 1997, FEBS LETT, V408, P16, DOI 10.1016/S0014-5793(97)00380-3; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Wyllie A H, 1980, Int Rev Cytol, V68, P251	80	48	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2855	2866		10.1038/sj.onc.1203635	http://dx.doi.org/10.1038/sj.onc.1203635			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851089				2022-12-28	WOS:000087403600007
J	Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M				Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M			Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation	ONCOGENE			English	Article						UV-sensitivity DNA repair; xeroderma pigmentosum; Cockayne syndrome; p53	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; COCKAYNE-SYNDROME CELLS; DNA-REPAIR; P53 RESPONSE; PROTEIN STABILITY; ITALIAN PATIENTS; RNA-POLYMERASE; GENE; TRICHOTHIODYSTROPHY	The apoptotic response and the level of expression of p53 and of three genes transcriptionally activated by p53 (Mdm2, p21 and bar) were investigated in UV-sensitive cells from patients with xeroderma pigmentosum (XP) or Cockayne syndome (CS), These disorders are due to different genetic defects affecting transcription-coupled repair (TCR) and/or global genome repair (GGR), the nucleotide excision repair subpathways which remove UV-induced lesions from the transcribed strand of active genes or from the rest of the genome, respectively. After 20 J/m(2) UV light, normal and GGR-defective XP-C fibroblasts showed rapid increase in p53, late induction of Mdm2 and no evidence of apoptosis even 96 h after irradiation. In contrast, in XP-A (defective in GGR and TCR), CS-A and CS-B (defective only in TCR) fibroblasts, the p53 increase was not followed by Mdm2 induction and the persistence of high levels of p53, due to the lack of its degradation by Mdm2, was associated with the appearance of apoptosis, Besides indicating that the persistence of DNA damage in the transcribed strand of active genes leads to apoptosis, these findings provide the first evidence that the lack of activation of Mdm2 plays a key role in the cascade of events leading to apoptosis.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Ist Ric Farmacol Mario Negri, Dipartimento Oncol, I-20157 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Stefanini, M (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		D'Incalci, Maurizio/AAA-9021-2020	D'Incalci, Maurizio/0000-0001-8784-1360				BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CLAVANNE F, 2000, CANCER RES, V60, P1974; Colella S, 1999, HUM MOL GENET, V8, P935, DOI 10.1093/hmg/8.5.935; CONFORTI G, 1989, BLOOD, V73, P1576; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dumaz N, 1998, CARCINOGENESIS, V19, P1701, DOI 10.1093/carcin/19.9.1701; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leadon SA, 1999, AM J HUM GENET, V64, P1259, DOI 10.1086/302390; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARRIS CN, 1993, P NATL ACAD SCI USA, V90, P7260, DOI 10.1073/pnas.90.15.7260; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEFANINI M, 1986, HUM GENET, V74, P107, DOI 10.1007/BF00282072; STEFANINI M, 1992, MUTAT RES, V273, P119, DOI 10.1016/0921-8777(92)90073-C; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; Stefanini M, 1996, HUM GENET, V97, P418; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	42	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2714	2720		10.1038/sj.onc.1203583	http://dx.doi.org/10.1038/sj.onc.1203583			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851071				2022-12-28	WOS:000087193000007
J	Hirano, T; Ishihara, K; Hibi, M				Hirano, T; Ishihara, K; Hibi, M			Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors	ONCOGENE			English	Review						IL-6; gp130; STAT3; pim; plasmacytoma; Myc	EMBRYONIC STEM-CELLS; DNA-BINDING ACTIVITY; C-MYC GENE; INTERLEUKIN-6 TRANSGENIC MICE; STIMULATING FACTOR-RECEPTOR; LEUKEMIA INHIBITORY FACTOR; ACTIVATED PROTEIN-KINASE; MURINE MYELOID CELLS; COMMON BETA-SUBUNIT; T-CELL	Members of the IL-6 cytokine family are involved in a variety of biological responses, including the immune response, inflammation, hematopoiesis, and oncogenesis by regulating cell growth, survival, and differentiation, These cytokines use gp130 as a common receptor subunit, The binding of ligand to gp130 activates the JAK/STAT signal transduction pathway, where STAT3 plays a central role in transmitting the signals from the membrane to the nucleus. STAT3 is essential for gp130-mediated cell survival and G1 to S cell-cycle-transition signals. Both c-myc and pim have been identified as target genes of STAT3 and together can compensate for STAT3 in cell survival and cell-cycle transition. STAT3 is also required for gp130-mediated maintenance of the pluripotential state of proliferating embryonic stem cells and for the gp130induced macrophage differentiation of Mt cells. Furthermore, STAT3 regulates cell movement, such as leukocyte, epidermal cell, and keratinocyte migration. STAT3 also appears to regulate B cell differentiation into antibody-forming plasma cells. Since the IL-6/gp130/STAT3 signaling pathway is involved in both B cell growth and differentiation into plasma cells it is likely to play a central role in the generation of plasma cell neoplasias.	Osaka Univ, Biomed Res Ctr, Grad Sch Med, Div Mol Oncol C7, Suita, Osaka 5650871, Japan	Osaka University	Hirano, T (corresponding author), Osaka Univ, Biomed Res Ctr, Grad Sch Med, Div Mol Oncol C7, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Besser D, 1999, MOL CELL BIOL, V19, P1401; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CUYPERS HT, 1984, CELL, V37, P141; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FROHLICH KU, 1995, BBA-PROTEIN STRUCT M, V1253, P25, DOI 10.1016/0167-4838(95)00136-I; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Giordano V, 1997, J IMMUNOL, V158, P4097; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303; Hirano T, 1999, BIOCHEM BIOPH RES CO, V260, P303, DOI 10.1006/bbrc.1999.0609; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; Hirano T, 1998, Int Rev Immunol, V16, P249; HIRANO T, 1984, J IMMUNOL, V133, P798; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jaster R, 1999, CELL SIGNAL, V11, P331, DOI 10.1016/S0898-6568(98)00049-7; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; Karras JG, 1997, J EXP MED, V185, P1035, DOI 10.1084/jem.185.6.1035; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kojima H, 1996, ONCOGENE, V12, P547; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kopf M, 1998, J EXP MED, V188, P1895, DOI 10.1084/jem.188.10.1895; KUCHINO Y, 1985, JPN J CANCER RES, V76, P75; Kumanogoh A, 1997, P NATL ACAD SCI USA, V94, P2478, DOI 10.1073/pnas.94.6.2478; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LILLY M, 1992, ONCOGENE, V7, P727; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX JL, 1988, SCIENCE, V239, P25, DOI 10.1126/science.3276001; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; METCALF D, 1989, LANCET, V1, P825; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MurakamiMori K, 1997, J IMMUNOL, V158, P5518; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, J NEUROSCI, V19, P5429; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NORDAN RP, 1987, J IMMUNOL, V139, P813; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; POTTER M, 1985, CURR TOP MICROBIOL, V122, P234; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; Romani L, 1996, J EXP MED, V183, P1345, DOI 10.1084/jem.183.4.1345; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SOVOVA V, 1993, INT J CANCER, V53, P983; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERANISHI T, 1982, J IMMUNOL, V128, P1903; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Thomson AW, 1998, CYTOKINE HDB; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; Wu DY, 1999, DEVELOPMENT, V126, P2021; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yanagisawa M, 1999, NEUROSCI LETT, V269, P169, DOI 10.1016/S0304-3940(99)00447-4; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	161	937	1002	3	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2548	2556		10.1038/sj.onc.1203551	http://dx.doi.org/10.1038/sj.onc.1203551			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851053				2022-12-28	WOS:000087459400010
J	Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD				Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD			The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis	ONCOGENE			English	Article						VHL; von Hippel-Lindau; renal cell carcinoma; apoptosis; UV	BIOLOGICALLY-ACTIVE PRODUCT; CARCINOMA-CELLS; VHL GENE; P53; PHOSPHORYLATION; IDENTIFICATION; INITIATION; INHIBITION; COMPLEX; PATHWAY	The familial cancer syndrome, von Hlippel-Lindau (VHL) disease, characterized by a predisposition to renal cell carcinoma and certain other tumor types, is caused by mutational inactivation of the VHL tumor suppressor gene. Loss of VHL gene function is detected also in the vast majority of sporadic renal cell carcinomas. Previous reports have determined a protective role for VHL in response to serum withdrawal and glucose deprivation, In this study, the effect of UV irradiation on VHL-negative and VHL-positive renal carcinoma cells was examined, VHL-negative 786-O renal carcinoma cells underwent apoptosis following UV irradiation, In contrast, reintroduction of wild-type VHL expression protected 786-O cells from UV-mediated cell death, p53 and Bax levels were equivalent in VHL-negative and VHL-positive 786-O cells. Strikingly, cyclin-dependent kinase? inhibitors p21 and p27 underwent proteasome-dependent degradation in VHL-negative 786-O cells following UV treatment. However, p21 and p27 protein levels were stable in VHL-positive cells. Also, levels of the anti-apoptotic proteins, Bcl-2 and Bcl-xL were elevated in VH L-positive cells, consistent with the protection from apoptotic stimuli, UV treatment led to increased S phase in VHL-negative, but not VHL-positive cells, Thus, following UV irradiation, diminution of p21 and p27 levels resulted in a hyperproliferative state in VHL-negative cells, leading to apoptosis, These results suggest that loss of VHL function promotes apoptosis and may provide selective pressure toward cells that are able to escape apoptosis, leading to tumorigenesis.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Pediat, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Schoenfeld, Alan R./0000-0002-6778-1548	NIDDK NIH HHS [DK 07218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Lu X, 1996, ONCOGENE, V13, P413; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471	28	55	55	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5851	5857		10.1038/sj.onc.1203985	http://dx.doi.org/10.1038/sj.onc.1203985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127815				2022-12-28	WOS:000165563100003
J	Rane, SG; Reddy, EP				Rane, SG; Reddy, EP			Janus kinases: components of multiple signaling pathways	ONCOGENE			English	Review						JAK kinases; STATs; ras; PI3K; CIS/JAB/SOCS/SIS protein family; signal transduction	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; GROWTH-HORMONE RECEPTOR; DNA-BINDING ACTIVITY; JAK-STAT PATHWAYS; SEVERE COMBINED IMMUNODEFICIENCY; INTERLEUKIN-5 TRANSDUCE SIGNALS; DEFECTIVE LYMPHOID DEVELOPMENT; MURINE LEUKEMIA-VIRUS; ERYTHROPOIETIN RECEPTOR	Cytoplasmic Janus protein tyrosine kinases (JAKs) are crucial components of diverse signal transduction pathways that govern cellular survival, proliferation, differentiation and apoptosis, Evidence to date, indicates that JAK kinase function may integrate components of diverse signaling cascades, While it is likely that activation of STAT proteins may be an important function attributed to the JAK kinases, it is certainly not the only function performed by this key family of cytoplasmic tyrosine kinases, Emerging evidence indicates that phosphorylation of cytokine and growth factor receptors may be the primary functional attribute of JAK kinases. The JAK-triggered receptor phosphorylation can potentially be a rate-limiting event for a successful culmination of downstream signaling events. In support of this hypothesis, it has been found that JAK kinase function is required for optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway, the PI3K-AKT pathway and STAT signaling following the interaction of cytokine/interferon receptors with their ligands, Aberrations in JAK kinase activity, that may lead to derailment of one or more of the above mentioned pathways could disrupt normal cellular responses and result in disease states. Thus, over-activation of JAK kinases has been implicated in tumorigenesis, In contrast, loss of JAK kinase function has been found to result in disease states such as severe-combined immunodeficiency. In summary, optimal JAK kinase activity is a critical determinant of normal transmission of cytokine and growth factor signals.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA68239-04] Funding Source: Medline; NIEHS NIH HHS [ES09225-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; ALAM R, 1995, INT ARCH ALLERGY IMM, V107, P226, DOI 10.1159/000236985; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Bates ME, 1996, J IMMUNOL, V156, P711; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bittorf T, 1999, BIOL CHEM, V380, P1201, DOI 10.1515/BC.1999.152; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EDER M, 1994, J BIOL CHEM, V269, P30173; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GIORGETTI-PERALDI S, 1995, EUR J BIOCHEM, V234, P656, DOI 10.1111/j.1432-1033.1995.656_b.x; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARPUR AG, 1992, ONCOGENE, V7, P1347; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JUBINSKY PT, 1993, BLOOD, V81, P587; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOHLHUBER F, 1996, MAMM GENOME, V7, P476; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1997, MOL CELL BIOL, V17, P695; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUGER A, 1991, ONCOGENE, V6, P245; Kumar A, 1996, ONCOGENE, V13, P2009; KUMAR G, 1994, J IMMUNOL, V153, P4436; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIURA O, 1994, BLOOD, V84, P1501; Mizuguchi R, 2000, JPN J CANCER RES, V91, P527, DOI 10.1111/j.1349-7006.2000.tb00977.x; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; RANE SG, 1994, ONCOGENE, V9, P2415; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Riedy MC, 1996, GENOMICS, V37, P57, DOI 10.1006/geno.1996.0520; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROVERA G, 1987, ONCOGENE, V1, P29; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SASAKI A, 2000, J BIOL CHEM, V875, P29293; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tanuma N, 2000, J BIOL CHEM, V275, P28216; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Verbsky JW, 1996, J BIOL CHEM, V271, P13976, DOI 10.1074/jbc.271.24.13976; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; Ward AC, 2000, BLOOD, V95, P19; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yetter D, 1995, Nurs Manage, V26, P60; YIN TG, 1994, J BIOL CHEM, V269, P26614; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZENG YX, 1994, FEBS LETT, V353, P289, DOI 10.1016/0014-5793(94)01065-X; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850	213	343	372	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5662	5679		10.1038/sj.onc.1203925	http://dx.doi.org/10.1038/sj.onc.1203925			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114747				2022-12-28	WOS:000165659300014
J	Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G				Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G			Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway	ONCOGENE			English	Article						epidermal growth factor; prostate cancer; LNCaP; lipogenesis	ONCOGENIC ANTIGEN-519 OA-519; LIPOGENIC GENE-EXPRESSION; PROSTATE-CANCER CELLS; ANDROGEN RECEPTOR; BREAST-CANCER; TRANSGENIC MICE; KINASE PATHWAY; CULTURED-CELLS; MAP KINASE; LINE LNCAP	Increased expression of fatty acid synthase (FAS) is observed in a clinically aggressive subset of various common cancers and interference with FAS offers promising opportunities for selective chemotherapeutic intervention, The mechanisms by which FAS expression is (up)-regulated in these tumors remain, however, largely unknown. Recently we demonstrated that in LNCaP prostate cancer cells FAS expression is markedly elevated by androgens via an indirect pathway involving sterol regulatory element-binding proteins (SREBPs), Here, we also show that growth factors such as EGF are able to stimulate FAS mRNA, protein and activity. Several observations also indicate that the effects of EGF on FAS expression are ultimately mediated by SREBPs, EGF stimulates SREBP-1c mRNA expression and induces an increase in mature nuclear SREBP-1. Moreover, in transient transfection studies EGF stimulates the transcriptional activity of a 178 bp FAS promoter fragment harboring a complex SREBP-binding site. Deletion or mutation of this binding site abolishes these effects and ectopic expression of dominant negative SREBP-1 inhibits FAS expression and induction in intact LNCaP cells, Given the frequent dysregulation of growth factor signaling in cancer and the key role of SREBP-1 in lipid homeostasis, growth factor-induced activation of the SREBP pathway is proposed as one of the mechanisms responsible for upregulation of lipogenic gene expression in a subset of cancer cells.	Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Univ Paris 06, INSERM, U465, Ctr Rech Biomed Cordeliers, Paris, France	KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Swinnen, JV (corresponding author), Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, Herestr 49, B-3000 Louvain, Belgium.		Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077; FOUFELLE, Fabienne/0000-0002-0752-622X; DEBOEL, LUDO/0000-0002-2303-513X				Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1995, EUR UROL, V27, P45; CULIG Z, 1995, WORLD J UROL, V13, P285; CULIG Z, 1996, PROSTATE, V28, P329; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fukazawa H, 2000, CANCER RES, V60, P2104; FURUYA Y, 1997, ANTICANCER RES, V17, P4583; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Hardman W., 1995, Modern Pathology, V8, p90A; Hobisch A, 1998, CANCER RES, V58, P4640; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Putz T, 1999, CANCER RES, V59, P227; Rashid A, 1997, AM J PATHOL, V150, P201; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SHURBAJI MS, 1992, AM J CLIN PATHOL, V97, P686, DOI 10.1093/ajcp/97.5.686; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1998, J STEROID BIOCHEM, V65, P191, DOI 10.1016/S0960-0760(97)00187-8; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; VERHOEVEN G, 1995, INT J ANDROL, V18, P23, DOI 10.1111/j.1365-2605.1995.tb00931.x; Visca P, 1999, CLIN CANCER RES, V5, P4111; Vlad L. D., 1999, Modern Pathology, V12, p70A; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	52	146	158	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5173	5181		10.1038/sj.onc.1203889	http://dx.doi.org/10.1038/sj.onc.1203889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064454				2022-12-28	WOS:000090124100006
J	Gordon, J; Del Valle, L; Otte, J; Khalili, K				Gordon, J; Del Valle, L; Otte, J; Khalili, K			Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice	ONCOGENE			English	Article						JC virus; T-antigen pituitary neoplasia; transgenic animal model	EARLY PROTEIN; HUMAN BRAIN; TUMORS; VIRUS; GENE; P53; ADENOMAS; GROWTH; PATHOGENESIS; PAPOVAVIRUS	In recent years, there has been mounting evidence pointing to the association of polyomaviruses with a wide range of human cancers. The human neurotropic polyomavirus, JCV, infecting greater than 75% of the human population produces a regulators protein named T-antigen which is expressed at the early phase of viral lytic infection and plays a critical role in completion of the viral life cycle, Furthermore, this protein has the ability to transform neural cells in vivo and its expression has been detected in several human neural-origin tumors. To further investigate the oncogenic potential of the JCV early protein in vivo, transgenic mice expressing JCV T-antigen under the control of its own promoter were generated, Nearly 50% of the animals developed large, solid masses within the base of the skull by 1 year of age. Evaluation of the location as well as histological and immunohistochemical data suggest that the tumors arise from the pituitary gland. As T-antigen is known to interact with several cell cycle regulators, the neoplasms were analysed for the presence of the tumor suppressor protein, p53. Immunoprecipitation/Western blot analysis demonstrated overexpression of wild-type, but not mutant p53 within tumor tissue. In addition, co-immunoprecipitation established an interaction between p53 and T-antigen and overexpression of p53 downstream target protein, p21/WAF1, This report describes the analysis of inheritable pituitary adenomas induced by expression of the human polyomavirus. JCV T-antigen in transgenic mice where T-antigen disrupts the p53 pathway by binding to and sequestering mild-type p53, This animal model may serve as a useful tool to further evaluate mechanisms of tumorigenesis by JCV T-antigen.	Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, 1900 N 12th St,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BUCKLEY N, 1994, J CLIN ENDOCR METAB, V79, P1513, DOI 10.1210/jc.79.5.1513; Franks RR, 1996, ONCOGENE, V12, P2573; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gordon J, 1998, DEV BIOL STAND, V94, P93; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HELSETH A, 1992, AM J PATHOL, V140, P1071; KOVACS K, 1983, ATLAS TUMOR PATHOLOG, V10; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Thapar K, 1996, NEUROSURGERY, V38, P765, DOI 10.1227/00006123-199604000-00027; Woloschak M, 1996, CANCER RES, V56, P2493; Zeng YX, 1996, ONCOGENE, V12, P1557; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	27	46	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4840	4846		10.1038/sj.onc.1203849	http://dx.doi.org/10.1038/sj.onc.1203849			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039901				2022-12-28	WOS:000089757800006
J	Iwamoto, T; Senga, T; Naito, Y; Matsuda, S; Miyake, Y; Yoshimura, A; Hamaguchi, M				Iwamoto, T; Senga, T; Naito, Y; Matsuda, S; Miyake, Y; Yoshimura, A; Hamaguchi, M			The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation	ONCOGENE			English	Article						JAB; JAK; STAT; Src; cytokine	CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; CONFERS RESISTANCE; CELLS; PROTEIN; KINASE; GENE; TRANSFORMATION; ASSOCIATION; BINDING	Recently, constitutive activation of JAK kinases (JAKs) and/or signal transducers and activators of transcription (STATs) has been reported in growing numbers of human cancer cells as well as oncogene-transformed cells. JAB/SOCS-1 has been shown to be an intrinsic JAK tyrosine kinase inhibitor and to suppress the cytokine-dependent JAK - STAT pathway. In this report, we investigated the effect of ectopic expression of JAB on v-Src-induced JAK-STAT activation, Forced expression of JAB in v-Src-transformed NIH3T3 cells neither suppressed phosphorylation of STAT3 and JAK1/JAK2 nor blocked STAT3-reporter gene activation. Colony forming assay also showed that JAB did not suppress v-Src-induced transformation of NIH3T3 cells, while dominant negative STAT3 suppressed it. In contrast, JAB could downregulate phosphorylation of STAT1 and STAT3 induced by interferon gamma (IFN gamma,) and interleukin-6 (IL-6) plus soluble IL6 receptor (sIL-6R), respectively. Furthermore, in vitro kinase assay indicated that JAB suppressed hyperactivation of JAK1/JAK2 and JAK1 induced by INF, and IL-6 plus sIL-6R respectively, but not v-Src-induced basal JAK1/JAK2 activity. Nevertheless, both JAK1/JAK2 activated by v-Src and that activated by IL-6 plus sIL-6R could similarly bind JAB. These results clearly demonstrate that JAB distinguishes cytokine-induced JAK-STAT signaling from v-Src-induced one and can not suppress the transformation with v-Src.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Nagoya University; Nagoya University; Kurume University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Yoshimura, Akihiko/K-5515-2013					Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niu GL, 1999, CANCER RES, V59, P5059; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	31	33	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4795	4801		10.1038/sj.onc.1203829	http://dx.doi.org/10.1038/sj.onc.1203829			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032030				2022-12-28	WOS:000089528800014
J	Grotzer, MA; Eggert, A; Zuzak, TJ; Janss, AJ; Marwaha, S; Wiewrodt, BR; Ikegaki, N; Brodeur, GM; Phillips, PC				Grotzer, MA; Eggert, A; Zuzak, TJ; Janss, AJ; Marwaha, S; Wiewrodt, BR; Ikegaki, N; Brodeur, GM; Phillips, PC			Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression	ONCOGENE			English	Article						TRAIL; PNET; medulloblastoma; apoptosis	DRUG-INDUCED APOPTOSIS; LIGAND TRAIL; LEUKEMIA-CELLS; MELANOMA-CELLS; DEATH DOMAIN; APO2 LIGAND; RECEPTOR; FAMILY; GENE; IDENTIFICATION	TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. To characterize the TRAIL death pathway in childhood primitive neuroectodermal brain tumor (PNET), 8 human PNET cell lines were tested for TRAIL-induced apoptosis, TRAIL-sensitivity of the PNET cell lines was correlated with mRNA expression levels of TRAIL, its agonistic (TRAIL-R1, TRAIL-R2) and antagonistic (TRAIL-R3, TRAIL-R4) receptors, cellular FLICE-like inhibitory protein (cFLIP), caspase-3 and caspase-8, Three of 8 PNET cell lines tested were susceptible to TRAIL-induced apoptosis, Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cFLIP, However, all TRAIL-sensitive PNET cell lines expressed caspase-8 mRNA and protein, while none of the five TRAIL-resistant PNET cell lines expressed caspase-8 protein. Treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored mRNA expression of caspase-8 and TRAIL-sensitivity in formerly TRAIL-resistant PNET cells, suggesting that gene methylation inhibits caspase-8 transcription in these cells. We conclude, that loss of caspase-8 mRNA is an important mechanism of TRAIL-resistance in PNET cells. Treatment with recombinant soluble TRAIL, possibly in combination with methyltransferase inhibitors, represents a promising therapeutic approach for PNET that deserves further investigation.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grotzer, MA (corresponding author), Univ Zurich, Childrens Hosp, Steinwiesstr 75, CH-8032 Zurich, Switzerland.		Eggert, Angelika/AAE-6907-2022	Eggert, Angelika/0000-0003-3476-8184; Grotzer, Michael/0000-0002-1154-2732				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; Faderl S, 1999, CLIN CANCER RES, V5, P4041; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, J IMMUNOL, V161, P2833; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura M, 2000, ACTA NEUROPATHOL, V99, P1, DOI 10.1007/PL00007399; PACKER RJ, 1994, J NEUROSURG, V81, P690, DOI 10.3171/jns.1994.81.5.0690; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Phillips TA, 1999, J IMMUNOL, V162, P6053; POLLACK IF, 1994, NEW ENGL J MED, V331, P1500, DOI 10.1056/NEJM199412013312207; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Thomas WD, 1998, J IMMUNOL, V161, P2195; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Weller M, 1998, CANCER LETT, V128, P121, DOI 10.1016/S0304-3835(98)00019-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 1999, CANCER RES, V59, P2747	40	148	154	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4604	4610		10.1038/sj.onc.1203816	http://dx.doi.org/10.1038/sj.onc.1203816			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030149				2022-12-28	WOS:000089438200006
J	Welman, A; Burger, MM; Hagmann, J				Welman, A; Burger, MM; Hagmann, J			Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation	ONCOGENE			English	Article						K-Ras4B; hypervariable domain; positive charge	PROTEIN-KINASE; K-RAS; INDEPENDENT PATHWAYS; ACTIVATE RAF-1; P21 PROTEIN; CAAX MOTIF; BINDING; PRENYLATION; SIGNAL; DOMAIN	The C-terminal hypervariable domain of K-Ras4B targets the protein to the plasma membrane by a combination of positive charge and a hydrophobic signal (farnesyl group), We analysed the contribution of several structural features of the domain: net charge, charge distribution, amino acid sequence and lipid specificity to membrane targetting and function by using artificial 'hypervariable' domains fused to either EGFP or V12K-Ras4B, We found that charge and a lipid residue are sufficient for plasma membrane localization and function of the constitutively active V12K-Ras4B. However, the amount of net charge, charge distribution and the length of the anchoring domain are important, Increasing the net charge and concentrating it close to the C-terminus increases not only the percentage of membrane bound protein, but also shifts the distribution from internal membranes, including the nuclear envelope, to the plasma membrane, While plasma membrane binding is necessary for V12K-Ras4B activity (MAPK activation and focus formation), we found that there are additional restrictions. In particular, mutants with very highly charged domains that bind almost exclusively to the plasma membrane show less transforming potential than expected. In addition, a construct with a short 'hypervariable' domain (7 amino acids) also has decreased transformation activity. These results suggest that specific interactions between K-Ras4B and the plasma membrane are required.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hagmann, J (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							AHUJA HG, 1990, BLOOD, V75, P1684; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOS JL, 1989, CANCER RES, V49, P4682; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Coats SG, 1999, BIOCHEMISTRY-US, V38, P12926, DOI 10.1021/bi9909290; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P; Hagmann J, 1998, J CELL SCI, V111, P2181; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hart KC, 1997, ONCOGENE, V14, P945, DOI 10.1038/sj.onc.1200908; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	46	46	46	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4582	4591		10.1038/sj.onc.1203818	http://dx.doi.org/10.1038/sj.onc.1203818			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030147				2022-12-28	WOS:000089438200004
J	Sun, SY; Yue, P; Lotan, R				Sun, SY; Yue, P; Lotan, R			Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells	ONCOGENE			English	Article						retinoids; CD437; apoptosis; oncogenes; death receptors; prostate cancer	CANCER CELLS; GROWTH ARREST; IN-VIVO; ACID RECEPTORS; MELANOMA-CELLS; LEUKEMIA-CELLS; CDK INHIBITOR; P53; INDUCTION; P21(CIP1/WAF1)	The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces apoptosis in several types of cancer cell. CD437 inhibited the growth of both androgen-dependent and -independent human prostate carcinoma (HPC) cells in a concentration-dependent manner by rapid induction of apoptosis, CD437 was more effective in killing androgen-independent HPC cells such as DU145 and PC-3 than the androgen-dependent LNCaP cells. The caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK blocked apoptosis induced by CD437 in DU145 and LNCaP cells, in which increased caspase-3 activity and PARP cleavage were observed, but not in PC-3 cells, in which CD437 did not induce caspase-3 activation and PARP cleavage. Thus, CD437 can induce either caspase-dependent or caspase-independent apoptosis in HPC cells. CD437 increased the expression of c-Myc, c-Jun, c-Fos, and death receptors DR4, DR5 and Fas. CD437's potency in apoptosis induction in the different cell lines was correlated with its effects on the expression of oncogenes and death receptors, thus implicating these genes in CD437-induced apoptosis in HPC cells. However, the importance and contribution of each of these genes in different HPC cell Lines may vary. Because CD437 induced the expression of DR4, DR5 and Fas, we examined the effects of combining CD437 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas ligand, respectively, in HPC cells. We found synergistic induction of apoptosis, highlighting the importance of the modulation of these death receptors in CD437-induced apoptosis in HPC cells. This result also suggests a potential strategy of using CD437 with TRAIL for treatment of HPC.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 80, Houston, TX 77030 USA.							Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fontana JA, 2000, INT J CANCER, V86, P474, DOI 10.1002/(SICI)1097-0215(20000515)86:4<474::AID-IJC5>3.0.CO;2-Z; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HARRISS DR, 1995, BRIT J UROL, V75, P27; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; ISAACS JT, 1994, SEMIN CANCER BIOL, V5, P391; ISAACS WB, 1991, CANCER RES, V51, P4716; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu XP, 1999, INT J CANCER, V80, P272, DOI 10.1002/(SICI)1097-0215(19990118)80:2<272::AID-IJC17>3.3.CO;2-O; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Preston GA, 1996, MOL CELL BIOL, V16, P211; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Sun SY, 1999, MOL PHARMACOL, V55, P403; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1997, CANCER RES, V57, P4931; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	55	59	62	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4513	4522		10.1038/sj.onc.1203810	http://dx.doi.org/10.1038/sj.onc.1203810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002424				2022-12-28	WOS:000089236800008
J	Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A				Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A			Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control	ONCOGENE			English	Article						phosphatase; tyrosine; proteolysis; MG132; translational regulation; cleavage	V-HA-RAS; TRANSGENIC MICE; MAMMARY-TUMORS; PTP-SIGMA; PROTEASOME; STEP; INITIATION; ISOFORM; CALPAIN; AUG	Two protein forms of tyrosine phosphatase epsilon (PTP epsilon) are known - receptor-like (tm-PTP epsilon) and non receptor-like (cyt-PTP epsilon), with each form possessing unique tissue-specific expression patterns, subcellular localization, and physiological functions. We describe two additional forms of PTP epsilon: protein - p67 and p65, p67 is produced by initiation of translation at an internal initiation codon of PTP epsilon mRNA molecules, while p65 is produced by specific proteolytic cleavage of larger PTP epsilon proteins. Cleavage is inhibited by MG132, but is proteasome-independent. In contrast with full-length tm-PTP epsilon and cyt-PTP epsilon, p67 and p65 are exclusively cytoplasmic, are not phosphorylated by Neu, and do not associate with Grb2 in unstimulated cells. p67 and p65 are catalytically active and can reduce Src-mediated phosphorylation of the Kv2.1 voltage-gated potassium channel, albeit with reduced efficiency which most likely results from their cytoplasmic localization. We also show that full-length cyt-PTP epsilon protein can be found at the cell membrane and in the nucleus and that it is the first 27 residues of cyt-PTP epsilon which determine this localization. p67 and p65 provide mechanisms for removing PTP epsilon activity from the cell membrane, possibly serving to down-regulate PTP epsilon activity there. PTP epsilon emerges as a family of four related proteins whose expression, subcellular localization and most likely physiological roles are subject to complex regulation at the transcriptional, translational and post-translational levels.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Toledano, Hila/0000-0001-9409-7728; Elson, Ari/0000-0001-9808-9135				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; Gurd JW, 1999, J NEUROCHEM, V73, P1990; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; PERETZ A, IN PRESS EMBO J; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	38	43	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4375	4384		10.1038/sj.onc.1203790	http://dx.doi.org/10.1038/sj.onc.1203790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980613				2022-12-28	WOS:000089271900008
J	Laham, LE; Mukhopadhyay, N; Roberts, TM				Laham, LE; Mukhopadhyay, N; Roberts, TM			The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity	ONCOGENE			English	Article						Lck; tyrosine kinase; activation loop; substrate specificity	RECEPTOR TYROSINE KINASE; AFFINITY PHOSPHOTYROSYL PEPTIDE; CRYSTAL-STRUCTURE; PROTEIN-KINASE; SH2 DOMAIN; C-SRC; INSULIN-RECEPTOR; AUTOPHOSPHORYLATION; PHOSPHORYLATION; MUTATION	The activities of Src-family non-receptor tyrosine kinases are regulated by structural changes that alter the orientation of key residues within the catalytic domain. In this study, we investigate the effects of activation loop mutations on regulation of the lymphocyte-specific kinase Lck (p56(lck)). Substitution of 5-7 residues amino terminal to the conserved activation loop tyrosine (Y-394) increases kinase activity and oncogenic potential regardless of regulatory C-terminal tail phosphorylation levels (Y-505), while most mutations in the 13 residues carboxyl to Y-394 decrease kinase activity. Phosphorylation of the C-terminal regulatory tail is carried out by the cytosolic tyrosine kinase Csk and we find that mutations upstream or downstream of Y394 or mutation of Y-394 do not affect the level of Y-505 phosphorylation, In addition, we report that mutations on either side of Y-394 affect substrate specificity in vivo. We conclude that the high degree of conservation across the entire activation loop of Src-family kinases is critical for normal regulation of kinase activity and oncogenicity as well as substrate selection.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Roberts, TM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER; NCI NIH HHS [CA43803-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; CARRERA AC, 1995, ONCOGENE, V10, P2379; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TRAFNY EAM, 1994, PROTEIN SCI, V3, P176; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIL R, 1994, J BIOL CHEM, V269, P22830; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	14	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3961	3970		10.1038/sj.onc.1203738	http://dx.doi.org/10.1038/sj.onc.1203738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962552				2022-12-28	WOS:000088825300001
J	Leung, SY; Yuen, ST; Chan, TL; Chan, ASY; Ho, JWC; Kwan, K; Fan, YW; Hung, KN; Chung, LP; Wyllie, AH				Leung, SY; Yuen, ST; Chan, TL; Chan, ASY; Ho, JWC; Kwan, K; Fan, YW; Hung, KN; Chung, LP; Wyllie, AH			Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation	ONCOGENE			English	Article						microsatellite instability; chromosomal instability; p53 mutation; colon carcinoma; glioma; Turcot's syndrome	COMPARATIVE GENOMIC HYBRIDIZATION; WILD-TYPE P53; MICROSATELLITE INSTABILITY; P53-DEFICIENT MICE; CLINICOPATHOLOGICAL VARIABLES; SECONDARY GLIOBLASTOMAS; GLIOMA PROGRESSION; SOMATIC MUTATIONS; DNA CONTENT; CELL-LINES	We have previously reported high-frequency microsatellite instability (MSI-H) and germ-line mismatch repair gene mutation in patients with unusually young onset of high-grade glioma. Some of these patients developed metachronous MSI-H colorectal cancer and conformed to the diagnosis of Turcot's syndrome. Frameshift mutation of TGF beta RII was present in all the colorectal carcinomas but not in brain tumours. We further characterized the genetic pathways of tumour evolution in these metachronous gliomas and colorectal carcinomas. All MSI-H glioblastomas had inactivation of both alleles of the p53 gene and showed over-expression of the p53 protein while none of the colorectal carcinomas had p53 mutation or protein over-expression. Flow cytometry and comparative genomic hybridization revealed that all glioblastomas were chromosomal unstable with aneuploid DNA content, and with a variable number of chromosomal arm aberrations. In contrast, the colorectal carcinomas had diploid or near-diploid DNA content with few chromosomal arm aberrations. The pattern of chromosomal aberrations in the two organs was different. Loss of 9p was consistently observed in all glioblastomas but not in colorectal carcinomas. Epidermal growth factor receptor amplification was absent in all glioblastomas and colorectal carcinomas. Our results suggest that both the frequency of p53 mutation and its effects differ greatly in the two organs. Following loss of mismatch repair function, p53 inactivation and chromosomal instability are not necessary for development of colorectal carcinoma, but are required for genesis of glioblastoma.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Cambridge	Leung, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Yuen, Siu/K-6311-2014; Chung, Lap Ping/C-4258-2009; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bocker T, 1996, J PATHOL, V179, P15; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CARDER P, 1993, ONCOGENE, V8, P1397; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.0.CO;2-1; Cheng Y, 1999, HUM PATHOL, V30, P1284, DOI 10.1016/S0046-8177(99)90057-6; Cottu PH, 1996, ONCOGENE, V13, P2727; CURTIS LJ, 2000, IN PRESS J PATHOL; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Feeley KM, 1999, J PATHOL, V188, P14, DOI 10.1002/(SICI)1096-9896(199905)188:1<14::AID-PATH323>3.0.CO;2-Q; Forster S, 1998, SURGERY, V123, P13, DOI 10.1067/msy.1998.83304; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Harada K, 1998, CANCER RES, V58, P4694; HARVEY M, 1993, ONCOGENE, V8, P2457; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kleihues P, 1997, BRAIN PATHOL, V7, P1131, DOI 10.1111/j.1750-3639.1997.tb00993.x; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTHE RA, 1993, CANCER RES, V53, P5849; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PURDIE CA, 1994, ONCOGENE, V9, P603; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Schlegel J, 1996, J NEUROPATH EXP NEUR, V55, P81, DOI 10.1097/00005072-199601000-00008; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; TSUKADA T, 1993, ONCOGENE, V8, P3313; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weber RG, 1996, ONCOGENE, V13, P983; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	45	39	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4079	4083		10.1038/sj.onc.1203740	http://dx.doi.org/10.1038/sj.onc.1203740			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962567				2022-12-28	WOS:000088825300016
J	Nowak, R; Sikora, K; Pietas, A; Skoneczna, I; Chrapusta, SJ				Nowak, R; Sikora, K; Pietas, A; Skoneczna, I; Chrapusta, SJ			Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors	ONCOGENE			English	Article						testicular germ cell tumors; telomerase; telomeric length; tumor pathogenesis	BRAIN-TUMORS; CANCER; PATHOGENESIS; MAINTENANCE; EXPRESSION; CARCINOMA; CISPLATIN; TISSUES	Telomere maintenance plays an important role in cell proliferation and tumor survival. Human male germ cells, which carry long telomeres and express telomerase, give rise to a highly heterogeneous group of malignant tumors. We compared telomeric length and telomerase activity between two major histological types of primary testicular germ cell tumors. Fifteen out of 16 seminoma samples revealed telomeric restriction fragment (TRF) length below 13 kb; the remaining seminoma showed a major TRF fraction of 18 kb and a distinct minor fraction of above 23 kb length. In contrast, all 13 samples from nonseminomas showed TRF length greater than or equal to 23 kb, which is similar to that reported in human sperm. Nine out of 11 seminoma specimens and six out of seven nonseminomas studied showed moderate to high telomerase activity, the only telomerase-negative non-seminoma being pure mature teratoma. These results indicate to a major difference in telomeric length between seminomas and nonseminomas, which is apparently unrelated to the presence of telomerase activity, and suggest a germline-like homeostasis of telomeric length is preserved in human nonseminomas.	Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Mol Biol, PL-02781 Warsaw, Poland; Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Pathol, PL-02781 Warsaw, Poland; Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Urol Oncol, PL-02781 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, Lab Expt Pharmacol, PL-02106 Warsaw, Poland	Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Polish Academy of Sciences	Nowak, R (corresponding author), Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Mol Biol, 5 Roentgena St, PL-02781 Warsaw, Poland.		Chrapusta, Stanisław/GLS-1363-2022; Chrapusta, Stanisław/AAA-3076-2020	Chrapusta, Stanislaw Jonatan/0000-0001-5219-8993				Albanell J, 1999, J NATL CANCER I, V91, P1321, DOI 10.1093/jnci/91.15.1321; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Burger AM, 1997, BRIT J CANCER, V75, P516, DOI 10.1038/bjc.1997.90; de Lange T, 1998, CANCER J SCI AM, V4, pS22; Delgado R, 1999, CANCER, V86, P1802, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1802::AID-CNCR23>3.3.CO;2-G; Engelhardt M, 1997, CLIN CANCER RES, V3, P1849; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hiraga S, 1998, CANCER RES, V58, P2117; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KLEIN H, 1993, TEACH SOCIOL, V21, P1, DOI 10.2307/1318846; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; MOSTOFI FK, 1998, WHO INT HISTOLOGICAL, V16, P1; Nowak R, 1997, ONCOL REP, V4, P1099; Nowak R, 1998, CANCER J SCI AM, V4, P148; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oliver R T, 1999, Curr Opin Oncol, V11, P236; Sambrook J., 1989, MOL CLONING, pA1; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; Sano K, 1999, J NEUROSURG, V90, P258, DOI 10.3171/jns.1999.90.2.0258; Sano T, 1998, BRIT J CANCER, V77, P1633, DOI 10.1038/bjc.1998.267; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Wright WE, 1996, DEV GENET, V18, P173; Yasumoto S, 1996, ONCOGENE, V13, P433; Youngren K, 1998, HUM GENET, V102, P640, DOI 10.1007/s004390050755	40	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4075	4078		10.1038/sj.onc.1203746	http://dx.doi.org/10.1038/sj.onc.1203746			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962566				2022-12-28	WOS:000088825300015
J	Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M				Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M			Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15	ONCOGENE			English	Article						Bach2; Maf; non-Hodgkin's lymphoma; CNC family; NF-E2	SMALL MAF PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; LEUCINE ZIPPER PROTEIN; FACTOR NF-E2; FUNCTIONAL-CHARACTERIZATION; BINDING PROTEINS; GENE-EXPRESSION; DNA-BINDING; LONG ARM; FAMILY	The transcription factor Bach2, a member of the BTB-basic region leucine zipper (bZip) factor family, binds to a 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element and the related Maf-recognition element (MARE) by forming homodimers or heterodimers with Maf-related transcription factors. Bach2 regulates transcription by binding to these elements. To understand the function in hematopoiesis, lye isolated a cDNA clone for human Bach2 (BACH2) encoding a protein of 841 amino acid residues with a deduced amino acid sequence having 89.5% identity to mouse homolog, Among human hematopoietic cell lines, BACH2 is expressed abundantly only in some B-lymphocytic cell lines. RT-PCR analysis of hematopoietic cells revealed that BACH2 mRNA is expressed in primary B-cells, Enforced expression of BACH2 in a human Burkitt cell line, RAJI that does not express endogenous BACH2, resulted in marked reduction of clonogenic activity, indicating that BACH2 possesses an inhibitory effect on cell proliferation. By fluorescent in situ hybridization, the BACH2 gene was localized to chromosome 6q15. Because deletion of the long arm of chromosome 6 (6q) is one of the commonest chromosomal alterations in human B-cell lymphoma, we examined for the loss of heterozygosity (LOH) of the BACH2 gene in human B-cell non-Hodgkin's lymphomas (NHL). Among 25 informative cases, five (20%) shelved LOH. These results indicate that BACH2 plays important roles in regulation of B cell development.	Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan; Hirosaki Univ, Fac Sci, Dept Biol, Hirosaki, Aomori 0368563, Japan; Univ Tokyo, Inst Med Sci, Dept Transfus Med & Cell Therapy, Minato Ku, Tokyo 1130033, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Tohoku Univ, Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Oncol, Minato Ku, Tokyo 1130033, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668560, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hirosaki University; Hirosaki University; University of Tokyo; University of Tsukuba; University of Tsukuba; Tohoku University; University of Tokyo; Nagoya University; Tokyo Medical & Dental University (TMDU); University of Tokyo	Ito, E (corresponding author), Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; CALIGARISCAPPIO F, 1985, J CLIN INVEST, V76, P1243, DOI 10.1172/JCI112080; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; HAYASHI Y, 1990, BLOOD, V76, P1626; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IMAI T, 1991, BLOOD, V78, P1969; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Merup M, 1998, BLOOD, V91, P3397, DOI 10.1182/blood.V91.9.3397.3397_3397_3400; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOHLER J, 1995, DEVELOPMENT, V121, P237; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; NAKAO J, 1995, J NEUROCHEM, V64, P2396; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Nishihara M, 1998, EUR J IMMUNOL, V28, P855, DOI 10.1002/(SICI)1521-4141(199803)28:03<855::AID-IMMU855>3.0.CO;2-X; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V91, P9926; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; Oyake T, 1996, MOL CELL BIOL, V16, P6083; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Yoshimatsu T, 1998, HUM GENE THER, V9, P161, DOI 10.1089/hum.1998.9.2-161	48	56	67	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3739	3749		10.1038/sj.onc.1203716	http://dx.doi.org/10.1038/sj.onc.1203716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949928				2022-12-28	WOS:000088568400006
J	Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ				Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ			High level expression of Delta N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?	ONCOGENE			English	Article						p53; p63; p14(ARF); undifferentiated nasopharyngeal carcinoma; NPC	BARR-VIRUS INFECTION; TUMOR-SUPPRESSOR GENE; P16 GENE; POINT MUTATION; MDM2; PROTEIN; P63; LYMPHOMAGENESIS; OVEREXPRESSION; DEGRADATION	Undifferentiated nasopharyngeal carcinoma (NPC) is an epithelial malignancy that is consistently associated with Epstein-Barr virus (EBV) but which very rarely has p53 gene mutations in primary tumours, Since the tumour suppressor p53 is mutated in most human canters or the wild type protein is inactivated in a significant number of the remainder, here we have investigated cellular factors that could compromise p53 function in primary NPC, Twenty-five primary tumours were judged to carry only wild type p53 by SSCP analysis of all exons and sequence determination of exons 4-9, Only one tumour was found to express significant levels of hMdm2 and in 24/25 there were no detectable mutations or deletions in exons 1 beta and 2 of the p14(ARF) gene. However, immunohistochemistry consistently revealed that all the tumour cells express substantial amounts of the p53-related protein p63, Semi-quantitative RT- PCR analysis of mRNA from tumour biopsies showed that the dominant species expressed was invariably the truncated Delta N-isotype. Since this can block p53-mediated transactivation, it is potentially a dominant-negative isoform, In normal nasopharyngeal epithelium the distribution of p63 was restricted to the proliferating basal and suprabasal layers. We suggest that Delta N-p63 is a good candidate as a suppressor of wild type p53 function in these tumours and also that it may prove to be a valuable diagnostic marker for undifferentiated NPC.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of Hong Kong; University of London; London School of Hygiene & Tropical Medicine	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Nicholls, John Malcolm/C-4375-2009	Nicholls, John Malcolm/0000-0001-7217-7444				ALLDRED DC, 1993, J NATL CANCER I, V85, P200; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Gulley ML, 1998, AM J PATHOL, V152, P865; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIN G, 1979, EPSTEIN BARR VIRUS; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lo KW, 1996, CANCER RES, V56, P2721; LO KW, 1992, ANTICANCER RES, V12, P1957; LO KW, 1995, CANCER RES, V55, P2039; McGregor JM, 1997, ONCOGENE, V15, P1737, DOI 10.1038/sj.onc.1201339; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Murono S, 1999, HISTOPATHOLOGY, V34, P432; Niedobitek G, 1996, SEMIN CANCER BIOL, V7, P165, DOI 10.1006/scbi.1996.0023; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARSA R, 1999, J INVEST DERMATOL, V113; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; Rickinson A. B., 1996, FIELDS VIROLOGY; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHEU LF, 1995, HUM PATHOL, V26, P380, DOI 10.1016/0046-8177(95)90137-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	172	189	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3439	3444		10.1038/sj.onc.1203656	http://dx.doi.org/10.1038/sj.onc.1203656			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918601				2022-12-28	WOS:000088198100012
J	Pan, Y; Haines, DS				Pan, Y; Haines, DS			Identification of a tumor-derived p53 mutant with novel transactivating selectivity	ONCOGENE			English	Article						p53; MDM2; p53 target genes	WILD-TYPE P53; CELL-CYCLE ARREST; DNA-BINDING SITE; GENE-EXPRESSION; P53-INDEPENDENT ROLE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TERMINAL DOMAIN; LEUKEMIC-CELLS; TARGET GENES	MDM2 is a p53-responsive molecule that when overexpressed, can alter growth control pathways via p53-dependent and independent mechanisms. We have identified a mutant p53 containing line that expresses high levels of transcripts that are regulated by the p53-responsive promoter of the MDM2 gene. Analysis of cloned product obtained from these tumor cells revealed that they harbor a mutant p53 protein (possessing an Arg to Gin substitution at codon 213) that is a potent transactivator of MDM2 expression. Consistent with this activity, the R213Q mutant was found to have the ability to interact with DIVA sequences located within the MDM2 promoter. In contrast to previously described tumor-derived p53 mutants which retain MDM2 transactivation function and possess partial growth suppressive activity, the R213Q mutant is severely compromised in its ability to induce p53-regulated transcripts that encode for proteins involved in cell-cycle arrest and apoptosis. The R213Q mutant can also be expressed at high levels in stably transfected cells and cells that harbor this mutant possess elevated levels of MDM2 protein. The R213Q mutant was also found to be able to up-regulate MDM2 during a genotoxic stress response. R213Q is the first described tumor-derived p53 mutant that is deficient at up-regulating both cell cycle arrest and apoptotic factors, but is highly proficient at inducing the growth-promoting molecule MDM2.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Haines, DS (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [CA70165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bull EK, 1998, ONCOGENE, V16, P2249, DOI 10.1038/sj.onc.1201757; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DUTHU A, 1992, ONCOGENE, V7, P2161; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pan Y, 1999, CANCER RES, V59, P2064; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	46	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3095	3100		10.1038/sj.onc.1203663	http://dx.doi.org/10.1038/sj.onc.1203663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871862				2022-12-28	WOS:000087903900007
J	Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB				Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB			Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappa B, AP-1, JNK, MAPKK and apoptosis	ONCOGENE			English	Article						anethole; TNF; NF-kappa B; AP-1; JNK; apoptosis	LIPID-PEROXIDATION; TRANSCRIPTION FACTOR; POTENT INHIBITOR; TERMINAL KINASE; COLON-CANCER; ACTIVATION; EUGENOL; CELLS; CHEMOPREVENTION; OVEREXPRESSION	Anethole, a chief constituent of anise, camphor, and fennel, has been shown to block both inflammation and carcinogenesis, but just how these effects are mediated is not known, One possibility is TNF-mediated signaling, which has also been associated with both inflammation and carcinogenesis. In the present report we show that anethole is a potent inhibitor of TNF-induced NF-kappa B activation (an early response) as monitored by electrophoretic mobility shift assay I kappa B alpha phosphorylation and degradation, and NF-kappa B reporter gene expression. Suppresaon of I kappa B alpha phosphorylation and NF-kappa B reporter gene expression induced by TRAF2 and NIK, suggests that anethole acts on I kappa B alpha kinase, Anethole also blocked the NF-kappa B activation induced by a variety of other inflammatory agents. Besides NF-kappa B, anethole also suppressed TNF-induced activation of the transcription factor AP-1, c-jun N-terminal kinase and MAPK-kinase, In addition, anethole abrogated TNF-induced apoptosis as measured by both caspase activation and cell viability. The anethole analogues eugenol and isoeugenol also blocked TNF signaling. Anethole suppressed TNF-induced both lipid peroxidation and ROI generation. Overall, our results demonstrate that anethole inhibits TNF-induced cellular responses,,which mag explain its role in suppression of inflammation and carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Chainy, Gagan B.N./G-7020-2012; Aggarwal, Bharat B/G-3388-2013	Chainy, Gagan/0000-0002-6418-0480				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALHARBI MM, 1995, EUR J CANCER PREV, V4, P307, DOI 10.1097/00008469-199508000-00006; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Bouthillier L, 1996, TOXICOL APPL PHARM, V139, P177, DOI 10.1006/taap.1996.0156; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Budavari S., 1996, MERCK INDEX, P108; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drukarch B, 1997, EUR J PHARMACOL, V329, P259, DOI 10.1016/S0014-2999(97)89187-X; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanna S, 1998, BIOCHEM PHARMACOL, V56, P61, DOI 10.1016/S0006-2952(98)00113-0; KO FN, 1995, BBA-LIPID LIPID MET, V1258, P145; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LUBET RA, 1997, INT J CANCER, P7295; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MANSUY D, 1986, BIOCHEM BIOPH RES CO, V135, P1015, DOI 10.1016/0006-291X(86)91029-6; NAGABABU E, 1994, FREE RADICAL RES, V20, P253, DOI 10.3109/10715769409147521; NAIDU KA, 1995, PROSTAG LEUKOTR ESS, V53, P381, DOI 10.1016/0952-3278(95)90060-8; RAJAKUMAR DV, 1993, BIOCHEM PHARMACOL, V46, P2067, DOI 10.1016/0006-2952(93)90649-H; Reddy BS, 1996, PREV MED, V25, P48, DOI 10.1006/pmed.1996.0017; Reddy BS, 1997, ADV EXP MED BIOL, V400, P931; REDDY BS, 1993, CANCER RES, V53, P3493; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; ROMPELBERG CJM, 1993, FOOD CHEM TOXICOL, V31, P637, DOI 10.1016/0278-6915(93)90046-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SHARMA JN, 1994, PHARMACOLOGY, V49, P314, DOI 10.1159/000139248; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; STOHS SJ, 1986, MECH AGEING DEV, V37, P137, DOI 10.1016/0047-6374(86)90071-0; Suganuma M, 1996, CANCER RES, V56, P3711; TAIRA J, 1992, FREE RADICAL RES COM, V16, P197, DOI 10.3109/10715769209049172; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	40	146	150	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2943	2950		10.1038/sj.onc.1203614	http://dx.doi.org/10.1038/sj.onc.1203614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871845				2022-12-28	WOS:000087544500008
J	Wang, HL; Kurtz, A				Wang, HL; Kurtz, A			Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108	ONCOGENE			English	Article						growth inhibitor; peptide delivery; differentiation; experimental therapy	ACID-BINDING PROTEIN; BOVINE HEART; MAMMARY; CELLS; GENE; CLONING; TISSUE	Mammary derived growth inhibitor (MDGI) is a member of the family of cytoplasmic fatty acid binding proteins (FABPs), which bind hydrophobic ligands such as fatty acids, retinoids, eicosanoids and prostaglandines. MDGI and an 11 amino acid MDGI-derived conserved C-terminal peptide (P108) inhibits growth of normal mammary epithelial cells in tissue and organ culture, but fails to inhibit proliferation of many breast cancer cell Lines in vitro, Here, the effects of peptide P108 on tumor growth of MCF-7, MDA-MB468 and MDA-MB231 human breast cancer cell lines in nude mice were tested. To deliver P108 into tumors, a novel peptide production system was applied for expression and secretion of small bioactive peptides in mammalian cells. Functional differentiation was observed in MCF-7 and MDA-MB468 cells upon P108 expression, In addition, EGF-dependent colony formation in soft agar by MDA-MB468 cells was inhibited by secreted P108, Tumor growth in athymic nude mice was suppressed in all three cell lines tested, Furthermore, P108 expressed by MCF-7/P108 cells caused paracrine tumor growth inhibition of MDA-MB231 cells. These results indicate that breast cancer inhibition by P108 is independent of binding to hydrophobic ligands and is perhaps mediated by interference with EGF-dependent signaling pathways.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Kurtz, A (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, TRB W208,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Kurtz, Andreas/0000-0003-3301-6546				BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BOEHMER F-D, 1988, Journal of Cellular Biochemistry, V38, P199; BOEHMER FD, 1987, J BIOL CHEM, V262, P15137; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRANDT R, 1992, BIOCHEM BIOPH RES CO, V189, P406, DOI 10.1016/0006-291X(92)91573-9; Brandt R, 1998, Prog Mol Subcell Biol, V20, P197; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ERVIN PR, 1989, SCIENCE, V244, P1585, DOI 10.1126/science.2662405; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; Grosse R, 1992, Cancer Treat Res, V61, P69; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; KURTZ A, 1997, BIOCH SOC S, V69, P51; LASSEN D, 1995, EUR J BIOCHEM, V230, P266, DOI 10.1111/j.1432-1033.1995.tb20560.x; LEHMANN W, 1989, BIOMED BIOCHIM ACTA, V48, P143; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; NATARAJAN R, 1998, FRONT BIOSCI, V3, P81; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Phelan CM, 1996, GENOMICS, V34, P63, DOI 10.1006/geno.1996.0241; Phelan CM, 1996, GENOMICS, V36, P377, DOI 10.1006/geno.1996.0481; RYTOMAA T, 1979, MECH AGEING DEV, V9, P471, DOI 10.1016/0047-6374(79)90087-3; SILBERSTEIN G, 1987, SCIENCE, V37, P291; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TREUNER M, 1994, GENE, V147, P237, DOI 10.1016/0378-1119(94)90073-6; VEERKAMP JH, 1995, J CELL BIOL, V127, P1097; VERKAMP J, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P49; YANG Y, 1995, J CELL BIOL, V127, P1097; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2455	2460		10.1038/sj.onc.1203575	http://dx.doi.org/10.1038/sj.onc.1203575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828888				2022-12-28	WOS:000087018400011
J	Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y				Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y			Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia	ONCOGENE			English	Article						erythropoiesis; epo; Fli-1; signal transduction; Friend erythroleukemia	COLONY-STIMULATING FACTOR; MURINE LEUKEMIA-VIRUS; STEM-CELL-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; STAT5 ACTIVATION; DNA-BINDING; F-MULV	We have recently isolated the erythroleukemic cell line, HB60-5 that proliferates in the presence of erythropoietin (Epo) and stem cell factor (SCF), but undergoes terminal differentiation in the presence of Epo alone. Ectopic expression of the ets related transcription factor Fli-1 in these cells resulted in the establishment of the Epo-dependent cell line HB60-ED that proliferates in the presence of Epo, In this study, me utilized these two cell lines to examine the signal transduction pathways that are activated in response to Epo and SCF stimulation, We demonstrate that Epo, but not SCF, phosphorylates STAT-5 in both HB60-5 and HB60-ED cells. Interestingly, SCF activates the Shc/ras pathway in HB60-5 cells while Epo does not. However, both Epo and SCF are capable of activating the Shc/ras pathway in HB60-ED cells, Furthermore, enforced expression of gp55 in HB60-5 cells by means of infection with the Spleen Focus Forming virus-P (SFFV-P), confers Epo independent growth, which is associated with the up-regulation of Fli-1, Activation of the Shc/ras pathway is readily detected in gp55 expressing cells in response to both Epo and SCF, and is associated with a block in STAT-SE tyrosine phosphorylation, These results suggest that STAT-5 activation, in the absence of Shc/ras activation, plays a role in erythroid differentiation. Moreover, Fli-1 is capable of switching Epo-induced differentiation to Epo-induced proliferation, suggesting that this ets factor regulated genes whose products modulate the Epo-Epo-R signal transduction pathway.	Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Immunol, Hlth Network, Arthrit & Immune Disorder Network, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, 2075 Bayview Ave,S Wing, Toronto, ON M4N 3M5, Canada.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVID YB, 1988, ONCOGENE, V3, P179; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Sattler M, 1997, J BIOL CHEM, V272, P10248; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	52	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2296	2304		10.1038/sj.onc.1203590	http://dx.doi.org/10.1038/sj.onc.1203590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822380				2022-12-28	WOS:000086974300004
J	Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J				Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J			c-Myc antagonizes the effect of p53 on apoptosis and p21(WAF1) transactivation in K562 leukemia cells	ONCOGENE			English	Article						myc; p53; leukemia; K562; apoptosis; transactivation	WILD-TYPE P53; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; TEMPERATURE-SENSITIVE MUTANT; CHRONIC MYELOGENOUS LEUKEMIA; GROWTH ARREST; MEDIATED APOPTOSIS; BLASTIC CRISIS; TARGET GENES; CYCLE ARREST	c-myc protooncogene positively regulates cell proliferation and overexpression of c-myc is found in many solid tumors and leukemias, In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional interaction between c-Myc and p53. Using two different methods, we generated K562 transfectant cell lines with conditional expression of either c-Myc or p53. The cells expressed the p53(Vall35) mutant, which adopts a mild-type conformation at 32 degrees C, while c-Myc induction was achieved with a zinc-inducible expression vector. We found that p53 in mild-type conformation induces growth arrest and apoptosis of K562. Expression of c-Myc significantly attenuated apoptosis and impaired the transcriptional activity of D53 on p21(WAF1), fax and cytomegalovirus promoters. The impairment of p21(WAF1) transactivation by c-Myc was confirmed by transfection of a c-Myc-estrogen receptor fusion protein and by induction of c-myc by zinc in transfected cells. Also, p53-mediated up-regulation of p21(WAF1) mRNA protein mere significantly reduced by Myc, while Bas levels were unaffected. Consistently, c- Myc increased cyclin-dependent kinase 2 activity in K562 cells expressing p53 in wild-type conformation These results suggest that c-Myc overexpression may antagonize the pro-apoptotic function of p53, thus providing a molecular mechanism for frequently observed deregulation of c-myc in human cancer.	Hosp Marques de Valdecilla, Serv Hematol, Santander, Spain; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Lund Univ, Dept Hematol, Lund, Sweden	Hospital Universitario Marques de Valdecilla (HUMV); Philipps University Marburg; Lund University	Leon, J (corresponding author), Fac Med, Dept Biol Mol, Santander 39011, Spain.		Ehinger, Mats/H-8457-2016; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Ehinger, Mats/0000-0003-2342-1679; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Alarcon RM, 1996, CANCER RES, V56, P4315; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; AMATI B, 1998, FRONT BIOSCI, V3, pD520; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BI S, 1993, LEUKEMIA, V7, P1840; BLYTH K, 1995, ONCOGENE, V10, P1717; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JACKSON P, 1993, ONCOGENE, V8, P589; Jennings BA, 1998, LEUKEMIA RES, V22, P899, DOI 10.1016/S0145-2126(98)00097-6; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Melo JV, 1996, LEUKEMIA, V10, P751; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PREISLER HD, 1990, EUR J CANCER, V26, P960, DOI 10.1016/0277-5379(90)90620-9; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAYLOR WR, 1992, ONCOGENE, V7, P1383; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trepel M, 1997, LEUKEMIA, V11, P1842, DOI 10.1038/sj.leu.2400824; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WU R, 1988, J EXP MED, V187, P1671; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zeng YX, 1996, ONCOGENE, V12, P1557; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	89	58	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2194	2204		10.1038/sj.onc.1203541	http://dx.doi.org/10.1038/sj.onc.1203541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822369				2022-12-28	WOS:000086974100004
J	Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT				Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT			Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas	ONCOGENE			English	Article						acyl-CoA synthetase; fatty acid; glioma; growth stimulation	PROTEIN; HETEROZYGOSITY; EXPRESSION; REPLICATION; THIOESTERS; TRANSPORT; COENZYME; CLONING; GENOME; ACS2	Acyl-CoA synthetase (ACS) ligates fatty acid and CoA to produce acyl-CoA, an essential molecule in fatty acid metabolism and cell proliferation. ACS5 is a recently characterized ACS isozyme highly expressed in proliferating 3T3-L1 cells. Molecular characterization of the human ACS5 gene revealed that the gene is located on chromosome 10q25.1-q25.2, spans approximately 46 kb, comprises 21 exons and 22 introns, and encodes a 683 amino acid protein, Two major ACS5 transcripts of 2,5-and 3,7-kb are distributed in a wide range of tissues with the highest expression in uterus and spleen. Markedly increased levels of ACS5 transcripts were detected in a glioma line, A172 cells, and primary gliomas of grade IV malignancy,,while ACS5 expression was found to be low in normal brain. Immunohistochemical analysis also revealed strong immunostaining with an anti-ACS5 antibody in glioblastomas. U87MG glioma cells infected with an adenovirus encoding ACS5 displayed induced cell growth on exposure to palmitate, Consistent with the induction of cell growth, the virus infected cells displayed induced uptake of palmitate, These results demonstrate a novel fatty acid-induced glioma cell growth mediated by ACS5.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.			Cho, Yong-Yeon/0000-0003-1107-2651				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERBST RA, 1994, CANCER RES, V54, P3111; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; KARLBOM AE, 1993, HUM GENET, V92, P169; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pizer ES, 1998, CANCER RES, V58, P4611; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E	27	63	67	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5919	5925		10.1038/sj.onc.1203981	http://dx.doi.org/10.1038/sj.onc.1203981			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127823				2022-12-28	WOS:000165563100011
J	Williams, BO; Barish, GD; Klymkowsky, MW; Varmus, HE				Williams, BO; Barish, GD; Klymkowsky, MW; Varmus, HE			A comparative evaluation of beta-catenin and plakoglobin signaling activity	ONCOGENE			English	Article						beta-catenin; plakoglobin; Wnt; LEF/TCF	F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; XENOPUS EMBRYOS; AXIS FORMATION; HEPATOCELLULAR CARCINOMAS; FUNCTIONAL INTERACTION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR	Vertebrates have two Armadillo-like proteins, beta -catenin and plakoglobin. Mutant forms of beta -catenin with oncogenic activity are found in many human tumors, but plakoglobin mutations are not commonly found, In fact, plakoglobin has been proposed to suppress tumorigenesis, To assess differences between beta -catenin and plakoglobin, we compared several of their biochemical properties, After transient transfection of 293T cells with an expression vector encoding either of the two proteins, soluble wild type beta -catenin does not significantly accumulate, whereas soluble wild type plakoglobin is readily detected. As anticipated, beta -catenin is stabilized by the oncogenic mutation S37A; however, the analogous mutation in plakoglobin (S28A) does not alter its half-life. S37A-beta -catenin activates a TCF/LEF-dependent reporter 20-fold more potently than wild type beta -catenin, and similar to5-fold more potently than wild type or S28A plakoglobin. These differences may be attributable to an enhanced affinity of S37A beta -catenin for LEF1 and TCF4, as observed here by immunoprecipitation assays. We show that the carboxyl-terminal domain is largely responsible for the difference in signaling and that the Armadillo repeats account for the remainder of the difference, The relatively weak signaling by plakoglobin and the failure of the S28A mutation to enhance its stability, may explain why plakoglobin mutations are infrequent in malignancies.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Colorado, Boulder, CO 80309 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Boulder	Williams, BO (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; Klymkowsky, Mike/0000-0001-5816-9771	NIGMS NIH HHS [GM54001] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; Barker N, 2000, ADV CANCER RES, V77, P1; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bierkamp C, 1999, DEVELOPMENT, V126, P371; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Carnac G, 1996, DEVELOPMENT, V122, P3055; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dale TC, 1998, BIOCHEM J, V329, P209; Denk C, 1997, CANCER LETT, V120, P185, DOI 10.1016/S0304-3835(97)00308-X; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Gradl D, 1999, MOL CELL BIOL, V19, P5576; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kolligs FT, 2000, GENE DEV, V14, P1319; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ogawa K, 1999, CANCER RES, V59, P1830; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wahl JK, 1996, J CELL SCI, V109, P1143; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHURINSKY J, 2000, IN PRESS MOL CELL BI; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2; [No title captured]	87	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5720	5728		10.1038/sj.onc.1203921	http://dx.doi.org/10.1038/sj.onc.1203921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126358				2022-12-28	WOS:000165477700003
J	Furge, KA; Zhang, YW; Vande Woude, GF				Furge, KA; Zhang, YW; Vande Woude, GF			Met receptor tyrosine kinase: enhanced signaling through adapter proteins	ONCOGENE			English	Review						receptor tyrosine kinase; signal transduction; c-Met; hepatocyte growth factor/scatter factor; HGF/SF	HEPATOCYTE GROWTH-FACTOR; GRB2 BINDING-SITE; ANCHORAGE-INDEPENDENT GROWTH; KIDNEY-CELLS REQUIRES; SCATTER FACTOR; C-MET; DOCKING PROTEIN; FACTOR/SCATTER FACTOR; FACTOR HGF; SOMATIC MUTATIONS	The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses, The ligand for Met is hepatocyte growth factor/scatter factor (HGF/SF) and while normal HGF/SF-Met signaling is required for embryonic development, abnormal Met signaling has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. Following ligand binding and autophosphorylation, Met transmits intercellular signals using a unique multisubstrate docking site present within the C-terminal end of the receptor, The multisubstrate docking site mediates the binding of several adapter proteins such as Grb2, SH-IC, Crk/CRKL, and the large adapter protein Gab1, These adapter proteins in turn recruit several signal transducing proteins to form an intricate signaling complex, Analysis of how these adapter proteins bind to the Met receptor and what signal transducers they recruit have led to more substantial models of HGF/SF-Met signal transduction and have uncovered new potential pathways that may be involved into Met mediated tumor cell invasion and metastasis.	Van Andel Res Inst, Grand Rapids, MI 49503 USA	Van Andel Institute	Vande Woude, GF (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.							Aberger F, 1997, BIOCHEM BIOPH RES CO, V231, P191, DOI 10.1006/bbrc.1996.5944; Aoki S, 1996, J BIOCHEM-TOKYO, V120, P961; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cottage A, 1999, FEBS LETT, V443, P370, DOI 10.1016/S0014-5793(99)00011-3; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FALETTO DL, 1992, ONCOGENE, V7, P1149; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; Gherardi E, 1997, CIBA F SYMP, V212, P84; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Gonzatti-Haces M, 1986, Princess Takamatsu Symp, V17, P221; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huff JL, 1996, ONCOGENE, V12, P299; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOMADA M, 1993, ONCOGENE, V8, P2381; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumoto K, 1993, EXS, V65, P225; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park WS, 1999, CANCER RES, V59, P307; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Shimizu T S, 1995, Int J Urol, V2, P257, DOI 10.1111/j.1442-2042.1995.tb00468.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sonnenberg E, 1993, EXS, V65, P381; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1985, J CELL SCI, V77, P209; STREIT A, 1995, DEVELOPMENT, V121, P813; Tanyi J, 1999, Pathol Oncol Res, V5, P187, DOI 10.1053/paor.1999.0219; THERY C, 1995, DEV GENET, V17, P90, DOI 10.1002/dvg.1020170110; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; Wallenius VR, 1997, MAMM GENOME, V8, P661, DOI 10.1007/s003359900533; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG Y, 1995, J CELL BIOL, V131, P1; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	119	349	400	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5582	5589		10.1038/sj.onc.1203859	http://dx.doi.org/10.1038/sj.onc.1203859			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114738				2022-12-28	WOS:000165659300005
J	Sweeney, C; Carraway, KL				Sweeney, C; Carraway, KL			Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage	ONCOGENE			English	Review						ErbB receptor; tyrosine kinase; EGF-like ligands; ligand discrimination	EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; ERYTHROPOIETIN RECEPTOR; BREAST-CANCER; KINASE; DIMERIZATION; ACTIVATION; NETWORK; TRANSDUCTION; DOMAIN	The four members of the ErbB family of receptor tyrosine kinases (RTKs) mediate a variety of cellular responses to epidermal growth factor (EGF)-like growth factors, and serve as a model for the generation of both diversity and specificity in RTK signaling. Previous studies indicate that receptor-receptor interactions figure prominently in signaling through ErbB receptors, In addition to a role in receptor kinase activation, ligand-induced ErbB receptor homo- and heterodimerization is thought to account for the diversity of biological responses stimulated by EGF-like growth factors. Since each receptor has the potential to couple to different complements of signaling pathways, EGF-like ligands specify cellular response by dictating which pairs of receptors become activated. More recently evidence has been uncovered for ligand discrimination by individual ErbB receptor dimers; receptors appear to realize which ligand is binding and differentially respond through autophosphorylation site usage. These observations indicate that ligand stimulation of RTKs is not generic, and point to another layer in the ErbB signal diversification mechanism. The mechanistic implications of ligand discrimination are discussed.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sweeney, C (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Room 1018,330 Brookline Ave, Boston, MA 02215 USA.		Mieszkowska, Magdalena/O-6753-2017		NCI NIH HHS [CA71702] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LONARDO F, 1990, New Biologist, V2, P992; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Otsuka T, 2000, MOL CELL BIOL, V20, P2055, DOI 10.1128/MCB.20.6.2055-2065.2000; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shak S, 1999, SEMIN ONCOL, V26, P71; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9	50	74	76	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5568	5573		10.1038/sj.onc.1203913	http://dx.doi.org/10.1038/sj.onc.1203913			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114736				2022-12-28	WOS:000165659300003
J	Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR				Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR			Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation	ONCOGENE			English	Article						BRK; breast cancer; epithelial cells; EGF; erbB3; PI 3-kinase	EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GASTROINTESTINAL-TRACT; RECEPTOR FAMILY; PROTEIN-KINASE; GENE; TUMORS	A high proportion of human breast cancers, in contrast with normal mammary tissue, express the intracellular tyrosine kinase BRK, BRK expression enhances the mitogenic response of mammary epithelial cells to epidermal growth factor, and conferment of a proliferative advantage through this mechanism may account for the frequent elevation of BRK expression in tumours, Here we report that BRK expression in mammary epithelial cells, at pathologically relevant levels, results in an enhanced phosphorylation of the epidermal growth factor receptor-related receptor erbB3 in response to epidermal growth factor. As a consequence, erbB3 recruits increased levels of phosphoinositide 3-kinase, and this is associated with a potentiated activation of Akt, This effect of BRK on the regulation of phosphoinositide 3-kinase and Akt activity may account for BRK's ability to enhance mammary cell mitogenesis, and raises the possibility that breast tumours expressing BRK may acquire a resistance to pro-apoptotic signals.	Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ London Imperial Coll Sci Technol & Med, CRC Labs, Sch Med, London W12 0NN, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of London; Royal Holloway University London; Imperial College London; MRC Laboratory Molecular Biology; University of Reading	Crompton, MR (corresponding author), Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.			Fry, Michael/0000-0001-8518-1370				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	89	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5471	5476		10.1038/sj.onc.1203931	http://dx.doi.org/10.1038/sj.onc.1203931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114724				2022-12-28	WOS:000165396100007
J	Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R				Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R			p27(kip1)-independent cell cycle regulation by MYC	ONCOGENE			English	Article						CDK-inhibitors; cell cycle; retinoblastoma protein; c-Myc oncogene	C-MYC; RESPONSIVE GENES; KINASE-ACTIVITY; PROTEIN; TUMORIGENESIS; EXPRESSION; E2F; IDENTIFICATION; SEQUESTRATION; INDUCTION	MYC transcription factors are potent stimulators of cell proliferation. It has been suggested that the CDK-inhibitor p27(kip1) is a critical G1 phase cell cycle target of c-MYC. We show here that mouse embryo fibroblasts deficient for both p27(kip1) and the related p21(cip1) are still responsive to stimulation by c-MYC and can be arrested in G1 by a dominant negative mutant of c-MYC. This growth arrest can be overruled by ectopic expression of E2F or adenovirus E1A, but not by a mutant of E1A defective for binding to retinoblastoma family proteins. We show that fibroblasts with a genetic disruption of all three retinoblastoma family members (pRb, p107 and p130) are unresponsive to a dominant negative c-MYC mutant. These data indicate that p27(kip1) is not the only rate limiting cell cycle target of c-MYC and suggest that regulation of E2F is also essential for c-MYC's mitogenic activity.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	27	25	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4822	4827		10.1038/sj.onc.1203879	http://dx.doi.org/10.1038/sj.onc.1203879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039898	Green Published			2022-12-28	WOS:000089757800003
J	Bruey, JM; Paul, C; Fromentin, A; Hilpert, S; Arrigo, AP; Solary, E; Garrido, C				Bruey, JM; Paul, C; Fromentin, A; Hilpert, S; Arrigo, AP; Solary, E; Garrido, C			Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo	ONCOGENE			English	Article						small heat shock protein; colon carcinoma; apoptosis; tumorigenesis	HEAT-SHOCK-PROTEIN; COLON-CANCER-CELLS; NECROSIS-FACTOR-ALPHA; CONFLUENCE-DEPENDENT RESISTANCE; SMALL STRESS PROTEINS; ACTIN POLYMERIZATION; PROTECTIVE ACTIVITY; REGRESSIVE TUMORS; TNF-ALPHA; PHOSPHORYLATION	HSP27 form oligomeric structures up to 800 Kda, In cultured cells, the equilibrium between small and large oligomers shifted towards smaller oligomers when phosphorylated on serine residues. To further explore HSP27 structural organization and its repercussion in HSP27 antiapoptotic and tumorigenic properties, we transfected colon cancer REG cells with wild type HSP27 and two mutants in which the phosphorylatable serine residues have been replaced by alanine (to mimic the non phosphorylated protein) or aspartate (to mimic the phosphorylated protein). In growing cells, wild type and alanine mutant formed small and large oligomers and demonstrated antiapoptotic activity while aspartate mutant only formed small multimers and had no antiapoptotic activity, In a cell-free system, only large oligomeric structures interfered with cytochrome c-induced caspase activation, thereby inhibiting apoptosis, The inability of the aspartate mutant to form large oligomers and to protect tumor cells from apoptosis was overcome by growing the cells in vivo, either in syngeneic animals or nude mice, These observations were reproduced by culturing the cells at confluence in vitro, In conclusion (1) large oligomers are the structural organization of HSP27 required for its antiapoptotic activity and (2) cell-cell contacts induce the formation of large oligomers, whatever the status of phosphorylatable serines, thereby increasing cell tumorigenicity.	Fac Med & Pharm, INSERM U517, F-21000 Dijon, France; Univ Lyon 1, CNRS, UMR 5534, F-69622 Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Garrido, C (corresponding author), Fac Med & Pharm, INSERM U517, 7 Blvd Jeanne Arc, F-21000 Dijon, France.		Garrido, Carolina/GWM-5557-2022; Paul, Catherine/F-8376-2019; Garrido, carmen/G-1633-2018	Garrido, carmen/0000-0003-1368-1493; Paul, Catherine/0000-0002-7657-5535; Solary, Eric/0000-0002-8629-1341				ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Beresford PJ, 1998, J IMMUNOL, V161, P161; CAIGNARD A, 1985, INT J CANCER, V36, P373; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; HOUT J, 1991, CANCER RES, V51, P5245; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTIN F, 1983, INT J CANCER, V32, P623, DOI 10.1002/ijc.2910320517; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MEHLEN P, 1994, EUR J BIOCHEM, V221, P321; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PELLETIER H, 1990, CANCER RES, V50, P6626; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9	41	126	129	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4855	4863		10.1038/sj.onc.1203850	http://dx.doi.org/10.1038/sj.onc.1203850			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039903				2022-12-28	WOS:000089757800008
J	Bryckaert, M; Guillonneau, X; Hecquet, C; Perani, P; Courtois, Y; Mascarelli, F				Bryckaert, M; Guillonneau, X; Hecquet, C; Perani, P; Courtois, Y; Mascarelli, F			Regulation of proliferation-survival decisions is controlled by FGF1 secretion in retinal pigmented epithelial cells	ONCOGENE			English	Article						FGF1; proliferation; apoptosis; ERK2; retinal pigmented epithelial cells	FIBROBLAST-GROWTH-FACTOR; HUMAN BREAST-CANCER; ACTIVATED PROTEIN-KINASE; FACTOR-I; MAP KINASE; EXTRACELLULAR-MATRIX; NUCLEAR-LOCALIZATION; NEUROTROPHIC FACTORS; PROMOTES APOPTOSIS; CARCINOMA-CELLS	Fibroblast growth factor 1 (FGF1) induces proliferation and differentiation in a wide variety of cells of mesodermal and neuroectodermal origin. FGF1 has no 'classical' signal sequence to direct its secretion, and there has been considerable debate concerning FGF1 secretion and its role in the biological activities of FGF1, We investigated the effects of FGF1 secretion and the signalling induced by signal peptide (SP)-containing FGF1 and SP-less FGF1, on the proliferation and the apoptosis in retinal pigmented epithelial (RPE) cells, Primary RPE cell cultures were transfected with FGF1 (FGF1 cells) and SP-FGF1 (SP-FGF1 cells) cDNAs. SP-FGF1 cells secreted large amount of FGF1 and actively proliferated, whereas FGF1 and control cells did not. Secreted FGF1 induced short-term activation of both FGFR1 and ERK2, which were required for cell proliferation, In contrast, SP-FGF1 cells stopped secreting FGF1 and died rapidly, if cultured in the absence of serum. Surprisingly, FGF1 cells, but not control cells, secreted FGF1 and were resistant to apoptosis induced by serum depletion, Secreted FGF1 induced long-term activation of FGFR1 and ERK2, which was necessary to induce a constant and high level of Bcl-x production, and to induce cell survival in FGF1 cells. Downregulation of ERK2 and Bcl-x increased apoptosis, Thus, the proliferation and survival activities of FGF1 depend on the secretion of FGF1 which is determined by the cell culture conditions. Cell proliferation was SP-dependent, whereas cell survival was not. The signal peptide controls the level and duration, 'whispering or shouting', of ERK2 activation cells which determines FGF1 biological function and may have important implications for anti-degenerative and antiproliferative treatments.	Assoc Claude Bernard, CNRS, INSERM U450, F-75016 Paris, France; IFR Circulat, INSERM U348, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM U450, 29 Rue Wilhem, F-75016 Paris, France.		guillonneau, xavier/AAF-9495-2021; Mascarelli, Frederic/L-8916-2018; Guillonneau, xavier/E-3995-2017	guillonneau, xavier/0000-0001-7379-3935; Guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ananyeva NM, 1997, ARTERIOSCL THROM VAS, V17, P445, DOI 10.1161/01.ATV.17.3.445; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUDOUIN C, 1993, OPHTHALMIC RES, V25, P52, DOI 10.1159/000267221; BLAM SB, 1988, ONCOGENE, V3, P129; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRADSHAW RA, 1990, PROG BRAIN RES, V86, P157; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARENC JP, 1993, J BIOL CHEM, V268, P5600; DENNIS PA, 1990, J CELL PHYSIOL, V144, P84, DOI 10.1002/jcp.1041440112; Desire L, 1998, DEV DYNAM, V212, P63, DOI 10.1002/(SICI)1097-0177(199805)212:1<63::AID-AJA6>3.0.CO;2-0; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fenig E, 1999, J CANCER RES CLIN, V125, P556, DOI 10.1007/s004320050316; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Guillonneau X, 1996, J CELL PHYSIOL, V166, P170, DOI 10.1002/(SICI)1097-4652(199601)166:1<170::AID-JCP19>3.0.CO;2-J; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; Guillonneau X, 2000, DEV DYNAM, V217, P24, DOI 10.1002/(SICI)1097-0177(200001)217:1<24::AID-DVDY3>3.0.CO;2-C; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; HER JH, 1991, NUCLEIC ACIDS RES, V19, P37; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Hjelmeland L M, 1988, Birth Defects Orig Artic Ser, V24, P87; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Karsan A, 1997, AM J PATHOL, V151, P1775; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; LEWIS GP, 1992, J NEUROSCI, V12, P3968; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; MASCARELLI F, 1989, EMBO J, V8, P2265, DOI 10.1002/j.1460-2075.1989.tb08351.x; MASON I, 1994, CURR BIOL, V4, P1158, DOI 10.1016/S0960-9822(00)00263-3; Mishima K, 1998, MODERN PATHOL, V11, P886; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ren GY, 2000, JPN J OPHTHALMOL, V44, P308, DOI 10.1016/S0021-5155(00)00149-0; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SATO Y, 1988, J CELL BIOL, V107, P1129; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yazlovitskaya EM, 1999, MOL CARCINOGEN, V25, P14, DOI 10.1002/(SICI)1098-2744(199905)25:1<14::AID-MC2>3.0.CO;2-V; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	72	20	22	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4917	4929		10.1038/sj.onc.1203872	http://dx.doi.org/10.1038/sj.onc.1203872			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039909				2022-12-28	WOS:000089757800014
J	Gregory, MA; Xiao, QR; Cornwall, GA; Lutterbach, B; Hann, SR				Gregory, MA; Xiao, QR; Cornwall, GA; Lutterbach, B; Hann, SR			B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation	ONCOGENE			English	Article						B-Myc protein; tissue-specific expression; phosphorylation; ubiquitin; growth inhibition	C-MYC; DIFFERENTIAL EXPRESSION; NEOPLASTIC-CELLS; ONCOGENE FAMILY; TARGET GENES; IN-VIVO; PROTEINS; MOUSE; PHOSPHORYLATION; TRANSFORMATION	The myc family of genes plays an important role in several cellular processes including proliferation, apoptosis, differentiation, and transformation. B-myc, a relatively new and largely unstudied member of the myc family, encodes a protein that is highly homologous to the N-terminal transcriptional regulatory domain of c-Myc, Here, we show that high level B-myc expression is restricted to specific mouse tissues, primarily hormonally-controlled tissues, with the highest level of expression in the epididymis, We also report the identification of the endogenous B-Myc protein from mouse tissues. Like other Myc family proteins, B-Myc is a short-lived nuclear protein which is phosphorylated on residues Ser-60 and Ser-68, Rapid proteolysis of B-Myc occurs via the ubiquitin-proteasome pathway. Finally, we found that overexpression of B-Myc significantly slows the growth of Rat la fibroblasts and COS cells suggesting B-Myc functions as an inhibitor of cellular proliferation.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Vanderbilt University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, MCN C-2310, Nashville, TN 37232 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD033903, R01HD033903] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA078888, R01CA047399] Funding Source: NIH RePORTER; NCI NIH HHS [CA47399, CA78888] Funding Source: Medline; NICHD NIH HHS [HD33903] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASKER C, 1989, ONCOGENE, V4, P1523; ASKER CE, 1995, ONCOGENE, V11, P1963; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Domashenko AD, 1997, MOL REPROD DEV, V47, P57, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;57::AID-MRD8&gt;3.0.CO;2-P; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; Kjerfve, 1988, HYDRODYNAMICS ESTUAR, P31; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OHagan RC, 1996, ONCOGENE, V13, P1323; PANNO JP, 1993, COMP BIOCHEM PHYS B, V104, P649, DOI 10.1016/0305-0491(93)90191-7; PULVERER BJ, 1994, ONCOGENE, V9, P59; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEMSEI I, 1989, ONCOGENE, V4, P465; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4886	4895		10.1038/sj.onc.1203851	http://dx.doi.org/10.1038/sj.onc.1203851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039906				2022-12-28	WOS:000089757800011
J	Chappell, SA; LeQuesne, JPC; Paulin, FEM; deSchoolmeester, ML; Stoneley, M; Soutar, RL; Ralston, SH; Helfrich, MH; Willis, AE				Chappell, SA; LeQuesne, JPC; Paulin, FEM; deSchoolmeester, ML; Stoneley, M; Soutar, RL; Ralston, SH; Helfrich, MH; Willis, AE			A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation	ONCOGENE			English	Article						c-myc; multiple myeloma; internal ribosome; entry segment; translation initiation	FACTOR MESSENGER-RNA; ALTERNATIVE TRANSLATION; CELL-GROWTH; SITE; PROTEIN; CONTAINS; INITIATION; SEGMENT	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) (Nanbru ct nl,, 1997; Stoneley ct al., 1998) and thus c-myc protein synthesis can be initiated by a cap-independent as well as a cap-dependent mechanism (Stoneley ct al., 2000), In cell lines derived from patients with multiple myeloma (RIM) there is aberrant translational regulation of c-myc and this correlates with a C-T mutation in the c-myc-IRES (Paulin ct nl,, 1996), RNA derived from the mutant IRES displays enhanced binding of protein factors (Paulin ct nl,, 1998), Here we show that the same mutation is present in 42% of bone marrow samples obtained from patients with MM, but was not present in any of 21 controls demonstrating a strong correlation between this mutation and the disease. In a tissue culture based assay, the mutant version of the c-myc-IRES was more active in all cell types tested, but showed the greatest activity in a cell line derived from a patient with MM. Our data demonstrate that a single mutation in the c-myc-IRES is sufficient to cause enhanced initiation of translation via internal ribosome entry and represents a novel mechanism of oncogenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Univ Glasgow, Western Infirm, Dept Haematol, Glasgow G11 6NT, Lanark, Scotland	University of Leicester; University of Aberdeen; University of Glasgow	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Willis, Anne/0000-0002-1470-8531				AUSEBEL RM, 1987, CURRENT PROTOCOLS MO; Bernstein J, 1997, J BIOL CHEM, V272, P9356; CHOCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARTINEZSALAS E, 1993, J VIROL, V67, P3748; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; PELICCI P, 1986, P NATL ACAD SCI USA, P2984; ROSS J, 1995, MICROBIOL REV, V59, P16; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SUMEGI J, 1985, INT J CANCER, V36, P367; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WEST MJ, 1995, ONCOGENE, V13, P2515	29	117	123	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4437	4440		10.1038/sj.onc.1203791	http://dx.doi.org/10.1038/sj.onc.1203791			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980620				2022-12-28	WOS:000089271900015
J	Girnita, L; Girnita, A; Wang, M; Meis-Kindblom, JM; Kindblom, LG; Larsson, O				Girnita, L; Girnita, A; Wang, M; Meis-Kindblom, JM; Kindblom, LG; Larsson, O			A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells	ONCOGENE			English	Article						EWS/FLI-1; bFGF; cell growth; Ewing's sarcoma	FACTOR-I RECEPTOR; NEUROECTODERMAL TUMOR; FUSION PROTEIN; INSULIN; TRANSLOCATION; GLYCOSYLATION; TRANSFORMATION; PROLIFERATION; EXPRESSION; TARGET	The EWS/FLI-1 fusion gene is characteristic of most cases of Ewing's sarcoma and has been shown to be crucial for tumor transformation and cell growth. In this study we demonstrate a drastic down-regulation of the EWS/FLI-1 protein, and a growth arrest, following serum depletion of Ewing's sarcoma cells. This indicates that growth factor circuits may be involved in regulation of the fusion gene product. Of four different growth factors tested, basic fibroblast growth factor (bFGF) was found to be of particular significance. In fact, upon treatment of serum-depleted cells with bFGF, expression of the EWS/FLI-1 protein and growth of the Ewing's sarcoma cells were restored. In addition, a bFGF-neutralizing antibody, which was confirmed to inhibit FGF receptor (FGFR) phosphorylation, caused downregulation of EWS/FLI-1. Experiments using specific cell cycle blockers (thymidine and colcemide) suggest that EWS/FLI-1 is directly linked to bFGF stimulation, and not indirectly to cell proliferation. We also demonstrated expression of FGFRs in several tumor samples of Ewing's sarcoma, Taken together, our data suggest that expression of FGFR is a common feature of Ewing's sarcoma and, in particular, that the bFGF pathway may be important for the maintenance of a malignant phenotype of Ewing's sarcoma cells through up-regulating the EWS/FLI-1 protein.	Karolinska Hosp, Dept Oncol & Pathol Cellular & Mol Tumor Pathol, CCK, SE-17176 Stockholm, Sweden; Sahlgrens Univ Hosp, Musculoskeletal Tumor Ctr, Dept Pathol, S-41345 Gothenburg, Sweden	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital	Larsson, O (corresponding author), Karolinska Hosp, Dept Oncol & Pathol Cellular & Mol Tumor Pathol, CCK, R8-04, SE-17176 Stockholm, Sweden.		Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Carlberg M, 1996, J BIOL CHEM, V271, P17453, DOI 10.1074/jbc.271.29.17453; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DOYLE JW, 1993, J CELL PHYSIOL, V155, P171, DOI 10.1002/jcp.1041550122; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAMMELTOFT S, 1991, PEPTIDE HORMONE ACTI, P1; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HOFBAUER S, 1993, EUR J CANCER, V29A, P241, DOI 10.1016/0959-8049(93)90183-G; HORI A, 1991, CANCER RES, V51, P6180; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; KULL FC, 1983, J BIOL CHEM, V258, P6561; Scotlandi K, 1996, CANCER RES, V56, P4570; TAKAHASHI H, 1998, JAPAN J UROL, V89, P836; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; Wang M, 1999, EXP CELL RES, V246, P38, DOI 10.1006/excr.1998.4280; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910	22	46	51	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4298	4301		10.1038/sj.onc.1203755	http://dx.doi.org/10.1038/sj.onc.1203755			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980604				2022-12-28	WOS:000089032900013
J	Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y				Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y			Cell-cell adhesion-mediated tyrosine phosphorylation of nectin-2 delta, an immunoglobulin-like cell adhesion molecule at adherens junctions	ONCOGENE			English	Article						cell-cell adhesion; cadherin; nectin; Src; tyrosine phosphorylation	POLIOVIRUS RECEPTOR GENE; CADHERIN-CATENIN COMPLEX; EPIDERMAL GROWTH-FACTOR; SIMPLEX VIRUS TYPE-1; SRC FAMILY KINASES; BETA-CATENIN; BINDING PROTEIN; COMPLEMENTARY-DNA; N-CADHERIN; PHOSPHATASE	We have recently found a novel functional unit of cell-cell adhesion at cadherin-based adherens junctions, consisting of at least nectin, an immunoglobulin-like cell adhesion molecule, and afadin, an actin filament-binding protein which connects nectin to the actin cytoskeleton. Among the members of the nectin family, we have found here that nectin-2 delta is tyrosine-phosphorylated in response to cell-cell adhesion. Expression of E-cadherin induced tyrosine phosphorylation of nectin-2 delta, while disruption of cell-cell adhesion by an anti-E-cadherin antibody reduced the tyrosine phosphorylation of nectin-2 delta. An inhibitor specific for Src family kinase or expression of Csk reduced tyrosine phosphorylation of nectin-2 delta. In addition, Src kinase tyrosine phosphorylates the recombinant cytoplasmic region of nectin-2 delta in vitro. The major tyrosine phosphorylation site of nectin-2 delta was Tyr(505) in the cytoplasmic region, because the mutant nectin-2 delta, of which Tyr(505) was replaced by Phe, showed a loss of tyrosine phosphorylation in vivo and in vitro. These results, together with our recent observations, indicate that the cadherin-catenin system and the nectin-afadin system are closely connected to each other. The cadherin-mediated cell-cell adhesion system may link to the activation of a Src family kinase, that is, at least in part, responsible for the tyrosine phosphorylation of the cytoplasmic region of nectin-2 delta.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Nakanishi, Hiroyuki/0000-0002-9765-0266; Kawabe, Hiroshi/0000-0001-5650-8696				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OKADA M, 1991, J BIOL CHEM, V266, P24249; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4022	4028		10.1038/sj.onc.1203744	http://dx.doi.org/10.1038/sj.onc.1203744			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962558				2022-12-28	WOS:000088825300007
J	Schulte, AM; Malerczyk, C; Cabal-Manzano, R; Gajarsa, JJ; List, HJ; Riegel, AT; Wellstein, A				Schulte, AM; Malerczyk, C; Cabal-Manzano, R; Gajarsa, JJ; List, HJ; Riegel, AT; Wellstein, A			Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site	ONCOGENE			English	Article						pleiotrophin; HERV-E.PTN; promoter; Sp1; choriocarcinoma	TRANSCRIPTION FACTORS SP1; AFFIN REGULATORY PEPTIDE; HUMAN SALIVARY; MESSENGER-RNA; FACTOR GENE; ADULT-RAT; SP-FAMILY; CELLS; CANCER; ACTIVATION	Germ line insertion of a human endogenous retrovirus-like element (HERV-E.PTN) into the growth factor pleiotrophin (PTN) gene generated a phylogenetically new promoter driving the expression of functional HERV-PTN fusion transcripts. Here we show by in situ hybridization, that HERV-PTN fusion transcripts are expressed in malignant trophoblasts (i.e. choriocarcinoma) and in the proliferative and in the invasive trophoblasts of gestational trophoblastic tissue. Additionally, a 1.9 kb fragment of the HERV-derived PTN promoter was analysed which has strong activity when transiently transfected into choriocarcinoma JEG-3 cells in contrast to HeLa cells. Deletion of the retrovirally-derived promoter portion abolished its activity and an enhancer (+443 to +486) was identified in this region. Electrophoretic mobility shift and supershift experiments identified a Spl binding site in this enhancer and site specific mutation of this site abolished its activity in choriocarcinoma cells. Sp1 overexpression in Drosophila SL2 cells showed that the enhancer activity is mediated via Sp1 binding in vivo. Furthermore, mutation of the Sp1 binding site reduced the activity of a promoter test fragment in choriocarcinoma cells by 80%. Our result shows that a retroviral Sp1 binding site in the PTN promoter is important for the expression of growth factor pleiotrophin in human choriocarcinoma cells.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Schulte, AM (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Res Bldg Room E312,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOEHLEN P, 1991, GROWTH FACTORS, V4, P97; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICRISTOFANO A, 1995, NUCLEIC ACIDS RES, V23, P2823, DOI 10.1093/nar/23.15.2823; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; GATTONICELLI S, 1986, P NATL ACAD SCI USA, V83, P6127, DOI 10.1073/pnas.83.16.6127; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.0.CO;2-M; Herbst H, 1996, AM J PATHOL, V149, P1727; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHANSEN T, 1989, GENE, V79, P259, DOI 10.1016/0378-1119(89)90208-4; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LEISER R, 1994, EXP CLIN ENDOCRINOL, V102, P122, DOI 10.1055/s-0029-1211275; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIU AY, 1991, CANCER RES, V51, P4107; Loewer Roswitha, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P5177; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; Patience C, 1997, TRENDS GENET, V13, P116, DOI 10.1016/S0168-9525(97)01057-3; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RABSON AB, 1983, NATURE, V306, P604, DOI 10.1038/306604a0; SAMUELSON LC, 1990, MOL CELL BIOL, V10, P2513, DOI 10.1128/MCB.10.6.2513; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Schulte AM, 1998, J VIROL, V72, P6065, DOI 10.1128/JVI.72.7.6065-6072.1998; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Silverberg SG, 1992, ATLAS TUMOR PATHOL, P219; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Wilkinson D. A., 1994, RETROVIRIDAE, P465; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387	50	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					3988	3998		10.1038/sj.onc.1203742	http://dx.doi.org/10.1038/sj.onc.1203742			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962555				2022-12-28	WOS:000088825300004
J	Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A				Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A			High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model	ONCOGENE			English	Article						jun; fos; ATF-2; mouse skin; AP-1; carcinogenesis	DNA-BINDING ACTIVITY; HA-RAS; CYCLIN D1; V-JUN; TRANSCRIPTIONAL ACTIVATION; CHEMICAL CARCINOGENESIS; CELLULAR-TRANSFORMATION; HETERODIMER FORMATION; ONCOGENE ACTIVATION; IN-VITRO	Analysis of the functions of AP-1 transcription factor in cellular systems has shown its key role as a mediator of oncogenic signals. The employment of suitable animal model systems greatly facilitates the study of changes in the composition and activity of the AP-1 complex. Here, we have analysed the quantitative and qualitative changes of AP-1 at different stages of carcinogenesis in mouse skin cell lines, derived from tumours induced by chemical mutagens. The findings of this study suggest that elevated AP-1 DNA binding and transactivation activity characterize the carcinoma cell lines, most notably the highly malignant spindle carcinomas. In addition, increased amounts and post-translational modifications of c-Jun, Fra-1, Fra-2 and ATF-2 proteins account for a high percentage of the increased AP-1 activity. Remarkably, high levels of phosphorylated ATF-2 protein were detected in malignant cell lines, indicating a novel role of ATF-2 in tumour progression. c-Jun and ATF-2 proteins are phosphorylated by highly active JNK kinases present in tumour cells. Finally, our results indicate distinct functions for different AP-1 components in the promotion and progression of mouse skin tumours.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece; Onyx Pharmaceut, Richmond, CA 94806 USA; CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	National Hellenic Research Foundation; Beatson Institute; University of California System; University of California San Francisco	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, GR-11635 Athens, Greece.			Gillespie, David/0000-0002-6338-0544; Linardopoulos, Spiros/0000-0002-6600-400X				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURLEY SK, 1994, CURR OPIN STRUC BIOL, V4, P3, DOI 10.1016/S0959-440X(94)90053-1; BURNS PA, 1991, ONCOGENE, V6, P2363; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRUDA MC, 1994, ONCOGENE, V9, P2537; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	65	85	92	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4011	4021		10.1038/sj.onc.1203732	http://dx.doi.org/10.1038/sj.onc.1203732			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962557				2022-12-28	WOS:000088825300006
J	Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L				Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L			pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels	ONCOGENE			English	Article						tumor suppressor; retinoblastoma protein; p107; E2F; growth suppression	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; GROWTH SUPPRESSION; TRANSCRIPTION FACTORS; FAMILY MEMBERS; MICE LACKING; MUSCLE-CELLS; IN-VIVO; PROTEIN	A key difference among the three structurally similar pRB family members is that only pRB is a tumor suppressor. Identification of distinctive functional differences between pRB and p107/p130 therefore holds promise for a better understanding of the tumor suppression mechanisms of pRB, Enigmatically, pRB and p107 have been shown to have indistinguishable growth suppression activities when studied in the pRB-deficient Saos-2 cell system. In this study, we discovered that, when expressed at physiologically relevant levels, pRB and p107 had distinctive effects in causing growth suppression, pRB induced cellular p130 levels while p107 repressed them, p107, but not pRB, blocked cells inside S phase in addition to G1 arrest. In contrast, no qualitative differences were identified in their abilities to repress the expression of a set of suspected pRB/E2F repression target genes. These results indicate that pRB and p107 possess different growth suppression effects, despite the fact that they have similar E2F repression effects.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhu, L (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-519, Bronx, NY 10461 USA.							Ausubel FA, 1990, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLBRINIK D, 1996, GENE DEV, V10, P1633; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARPER JW, 1993, CELL, V75, P805; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tiemann F, 1998, EMBO J, V17, P1040, DOI 10.1093/emboj/17.4.1040; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3878	3887		10.1038/sj.onc.1203722	http://dx.doi.org/10.1038/sj.onc.1203722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951581				2022-12-28	WOS:000088614300006
J	Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S				Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S			The retinoblastoma protein is an essential mediator that links the interferon-inducible 204 gene to cell-cycle regulation	ONCOGENE			English	Article						Ifi 204; antiproliferative activity; cell cycle; retinoblastoma proteins	ANTIPROLIFERATIVE ACTIVITY; HIN-200 FAMILY; 3T3 CELLS; INHIBITION; P202; TRANSCRIPTION; PRB; EXPRESSION; INDUCTION; CLUSTER	We have previously demonstrated that overexpression of p204, a member of the Ifi 200 gene family, inhibits growth, delays G0/G1 progression into S phase, and impairs E2F-mediated transcriptional activity. In this study, we show that p204 directly binds the retinoblastoma protein (pRb) in vivo to exert its activity. Transient p204 overexpression in Rb+/+ mouse embryo fibroblasts (MEF) inhibits cell proliferation, but does not affect cell growth in MEF derived from Rb-/- mice. Two human cell lines, Saos2 and C33A, bearing an inactive pRb, but not primary human embryo fibroblasts, are resistant to the p204 antiproliferative activity. p204 contains two 200 amino acid motifs, designated as type a or b domains, each containing a canonical Rb binding motif (LXCXE). When dominant-negative mutants at the Rb binding motif were transfected in Rb+/+ MEF, p204 lost its ability to inhibit cell growth, delay cell transition from G1 to S phase, and impair DNA synthesis. Moreover p204 overexpression in Rb+/+ MEF led to a significant decrease of both DHFR and PCNA proteins, two S phase markers. BS contrast, this effect was not observed when Rb+/+ MEF were transfected with a p204 mutated at both Rb binding sites. Finally, overexpression of the LXCXE p204 mutant rendered Rb+/+ MEF resistant to the IFN-alpha antiproliferative activity, in comparison to the untransfected Rb+/+ MEF. As expected, Rb-/- cells were unsensitive to the IFN-alpha induced growth inhibition. Taken as a whole, these results suggest that (i) p204 contributes to the IFN-alpha antiproliferative activity and (ii) the primary target of p204 leading to efficient G1 arrest as web as to blockade of DNA replication from G1 phase is the pRb regulatory system.	CNR, Immunogenet & Expt Oncol Ctr, I-10126 Turin, Italy; Med Sch Novara, Dept Med Sci, Novara, Italy; Med Sch Torino, Dept Publ Hlth & Microbiol, Turin, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Eastern Piedmont Amedeo Avogadro	Landolfo, S (corresponding author), CNR, Immunogenet & Expt Oncol Ctr, Via Santan 9, I-10126 Turin, Italy.		Azzimonti, Barbara/K-3550-2016; De Andrea, Marco/J-5253-2012; Gribaudo, Giorgio/A-8872-2011	Azzimonti, Barbara/0000-0001-6364-6595; De Andrea, Marco/0000-0002-3188-5783; Gribaudo, Giorgio/0000-0002-1583-9146; Gariglio, Marisa/0000-0002-5187-0140				Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; BREJM A, 1999, BRIT J CANCER, V80, P38; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; Demaeyer E., 1988, INTERFERONS OTHER RE; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gariglio M, 1998, J LEUKOCYTE BIOL, V64, P608, DOI 10.1002/jlb.64.5.608; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; GARIGLIO M, 1994, EUR J BIOCHEM, V221, P731, DOI 10.1111/j.1432-1033.1994.tb18786.x; GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022-1759(95)00170-F; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Min W, 1996, MOL CELL BIOL, V16, P359; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	48	61	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3598	3608		10.1038/sj.onc.1203697	http://dx.doi.org/10.1038/sj.onc.1203697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951565				2022-12-28	WOS:000088568300005
J	Lin, TS; Mahajan, S; Frank, DA				Lin, TS; Mahajan, S; Frank, DA			STAT signaling in the pathogenesis and treatment of leukemias	ONCOGENE			English	Article						STAT; cytokines; cancer; leukemia; therapy	CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW TRANSPLANTATION; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; BCR-ABL; INTERFERON-GAMMA; MYELOID-LEUKEMIA; MONOCLONAL-ANTIBODY	Leukemias continue to cause significant mortality in adults and children, and the use of standard cytotoxic chemotherapy has reached a therapeutic plateau, Thus, there is great interest in treatments directed against inappropriately activated cell signaling pathways which stimulate the uncontrolled growth of neoplastic cells. Increasing evidence suggests that the STAT signaling cascade may be one target of these therapies. Signal transducer and activator of transcription (STAT) proteins are critical in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. Constitutive STAT activation is present in many malignancies and has been especially well characterized in acute and chronic leukemias. While STAT activation is a common characteristic of leukemias, the specific pattern of activated STATs and the manner by which STAT activation occurs vary with each disease. STAT tyrosine phosphorylation can occur through inappropriate Jak activation or by direct activation of an oncoprotein such as Bcr/Abl, and STAT serine phosphorylation may play an important role in leukemias as well. Thus, the STAT signaling pathway is an attractive target for therapeutic intervention, and strategies designed to inhibit STAT activation and STAT mediated gene transcription may play an important role in the next generation of anti-leukemia therapies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA079547] Funding Source: NIH RePORTER; NCI NIH HHS [CA79547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Frank DA, 1996, LEUKEMIA, V10, P1724; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; Frank DA, 1999, MOL MED, V5, P432; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Holland JF, 1997, CANC MED; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILAND H, 1995, POLYCYTHEMIA VERA MY, P292; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KAWANO F, 1985, CANCER-AM CANCER SOC, V55, P851, DOI 10.1002/1097-0142(19850215)55:4<851::AID-CNCR2820550424>3.0.CO;2-J; KLEIN B, 1991, BLOOD, V78, P1198; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; NAJEAN Y, 1994, BRIT J HAEMATOL, V86, P233, DOI 10.1111/j.1365-2141.1994.tb03289.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Palmer Alyson M., 1997, Blood, V90, p178A; RABINOWE SN, 1993, BLOOD, V82, P1366; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Thiesing JT, 1999, BLOOD, V94, p100A; VERWILGHEN R L, 1987, Blood Reviews, V1, P34, DOI 10.1016/0268-960X(87)90017-8; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xia Z, 1998, CANCER RES, V58, P3173; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	52	200	226	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2496	2504		10.1038/sj.onc.1203486	http://dx.doi.org/10.1038/sj.onc.1203486			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851048				2022-12-28	WOS:000087459400005
J	Zeidler, MP; Bach, EA; Perrimon, N				Zeidler, MP; Bach, EA; Perrimon, N			The roles of the Drosophila JAK/STAT pathway	ONCOGENE			English	Article						hopscotch; unpaired; stat92E; ommatidia; segmentation; polarity	SIGNAL-TRANSDUCTION; JAK; EYE; KINASE; GENE; STAT; MELANOGASTER; ACTIVATION; HOPSCOTCH; POLARITY	The JAK/STAT signal transduction pathway has been conserved throughout evolution such that true structural and functional homologues of components originally identified in vertebrate systems are also present in the model genetic system Drosophila melanogaster. In addition to roles during larval hematopoiesis reminiscent of the requirement for this pathway in mammalian systems, the JAK/STAT pathway in Drosophila is also involved in a number of other developmental events. Recent data has demonstrated further roles for the JAK/STAT pathway in the establishment of sexual identity via the early embryonic expression of Sex lethal. the segmentation of the embryo via the control of pair rule genes including even skipped and the establishment of polarity within the adult compound eye via a mechanism that includes the four jointed gene, Use of the powerful genetics in the model organism Drosophila may identify new components of the JAK/STAT pathway, define new roles for this pathway, and provide insights into the function of this signal transduction system. Here we review the roles of STAT and its associated signaling pathway during both embryonic and adult stages of Drosophila development and discuss future prospects for the identification and characterization of novel pathway components and targets.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Zeidler, Martin/E-6209-2010	Bach, Erika/0000-0002-5997-4489; Zeidler, Martin/0000-0003-2942-1135; Perrimon, Norbert/0000-0001-7542-472X				Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Chou TB, 1996, GENETICS, V144, P1673; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Heberlein U, 1998, DEVELOPMENT, V125, P567; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Juni N, 1996, GENETICS, V143, P1257; LIU X, 1999, SCIENCE, V285, pA167; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Luo H, 1999, DEV BIOL, V213, P432, DOI 10.1006/dbio.1999.9390; Mathey-Prevot B, 1998, CELL, V92, P697, DOI 10.1016/S0092-8674(00)81396-3; Mesilaty-Gross S, 1999, GENE, V231, P173, DOI 10.1016/S0378-1119(99)00053-0; Mohr SE, 1999, GENE, V229, P109, DOI 10.1016/S0378-1119(99)00033-5; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; VENDEROSA FJ, 1954, GENETICS, V39, P999; VILLANO JL, 1995, DEVELOPMENT, V121, P2767; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Williams JG, 1999, TRENDS BIOCHEM SCI, V24, P333, DOI 10.1016/S0968-0004(99)01443-7; Wolff Tanya, 1993, P1277; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	38	119	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2598	2606		10.1038/sj.onc.1203482	http://dx.doi.org/10.1038/sj.onc.1203482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851058				2022-12-28	WOS:000087459400015
J	Yuan, ZQ; Sun, M; Feldman, RI; Wang, G; Ma, XL; Jiang, C; Coppola, D; Nicosia, SV; Cheng, JQ				Yuan, ZQ; Sun, M; Feldman, RI; Wang, G; Ma, XL; Jiang, C; Coppola, D; Nicosia, SV; Cheng, JQ			Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer	ONCOGENE			English	Article						Akt; PI 3-kinase; signal transduction; ovarian cancer	RAC PROTEIN-KINASE; V-HA-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; GROWTH-FACTORS; CELL-SURVIVAL; ONCOGENE; PHOSPHORYLATION; AMPLIFICATION	We previously demonstrated that AKT2, a member of protein kinase B family, is activated by a number of growth factors via Pas and PI 3-kinase signaling pathways. Here we report the frequent activation of AKT2 in human primary ovarian cancer and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase (P1 3-kinase)/Akt pathway. In vitro AKT2 kinase assay analyses in 91 ovarian cancer specimens revealed elevated levels of AKT2 activity (>3-fold) in 33 cases (36.3%). The majority of tumors displaying activated AKT2 were high grade and stages III and IV. Immunostaining and Western blot analyses using a phospho-ser-473 Akt antibody that detects the activated form of AKT2 (AKT2 phosphorylated at serine-474) confirmed the frequent activation of AKT2 in ovarian cancer specimens, Phosphorylated AKT2 in tumor specimens localized to the cell membrane and cytoplasm but not the nucleus. To address the mechanism of AKT2 activation, we measured in vitro PI 3-kinase activity in 43 ovarian cancer specimens, including the 33 cases displaying elevated AKT2 activation, High levels of PI 3-kinase activity were observed in 20 cases, 15 of which also exhibited AKT2 activation. The remaining five cases displayed elevated AKT1 activation. Among the cases with elevated AKT2, but not PI 3-kinase activity (18 cases), three showed down-regulation of PTEN protein expression. Inhibition of PI 3-kinase/AKT2 by wortmannin or LY294002 induces apoptosis in ovarian cancer cells exhibiting activation of the PI 3-kinase/AKT2 pathway. These findings demonstrate for the first time that activation of AKT2 is a common occurrence in human ovarian cancer and that PI 3-kinase/Akt pathway may be an important target for ovarian cancer intervention.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA077935, R29CA077935] Funding Source: NIH RePORTER; NCI NIH HHS [CA77935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liu AX, 1998, CANCER RES, V58, P2973; McMenamin ME, 1999, CANCER RES, V59, P4291; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Obata K, 1998, CANCER RES, V58, P2095; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	39	319	373	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2324	2330		10.1038/sj.onc.1203598	http://dx.doi.org/10.1038/sj.onc.1203598			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822383				2022-12-28	WOS:000086974300007
J	Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK				Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK			A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region	ONCOGENE			English	Article						B-CLL; genomic sequence; transcript map; 13q14; gene annotation	CHROMOSOME-ABNORMALITIES; D13S25 LOCUS; L1 ELEMENT; GENE; INSERTION; TRANSLOCATION; BREAKPOINT; PROTEINS; CLONING; CONTIG	Extensive analysis of tumors has demonstrated homozygous and heterozygous deletions in chromosome region 13q14.3 in B-cell chronic lymphocytic leukemia (B-CLL), suggesting the site of a tumor suppressor gene. Since previous searches for this gene have not yielded any viable candidates, we now present the sequence of the BACs which span the minimally deleted approximately 650 kb region between markers D13S319 and D13S25, This sequence has allowed us to create the definitive transcription map for the region which reveals 93 ESTs and 12 Unigene clusters in this region. Using gene prediction programs, a further 19 potential genes are also identified. The genes show an asymmetrical distribution throughout the region with most of them clustering at the extreme ends. This sequencing effort provides for the definitive structure of the B-CLL deletion region and the identification of the vast majority of the potential candidate genes. Of all the genes identified, only three have homologies to known genes: two LL repeat genes and rabbit epididymal protein 52, This 13q14.3 sequence provides the final substrate from which to characterize the B-CLL tumor suppressor gene.	Cleveland Clin Fdn, Ctr Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Pan, Huaqin/0000-0002-7166-108X; Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [R01CA074190] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001604, R01HG000313] Funding Source: NIH RePORTER; NCI NIH HHS [CA74190] Funding Source: Medline; NHGRI NIH HHS [HG00313, HG01604] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bezieau S, 1998, GENOMICS, V52, P369, DOI 10.1006/geno.1998.5464; BIENZ N, 1993, BRIT J HAEMATOL, V85, P819, DOI 10.1111/j.1365-2141.1993.tb03233.x; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; BouygeMoreau I, 1997, GENOMICS, V46, P183, DOI 10.1006/geno.1997.5008; Brandon CI, 1999, THERIOGENOLOGY, V52, P863, DOI 10.1016/S0093-691X(99)00178-8; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHAPMAN RM, 1994, ONCOGENE, V9, P1289; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; ESCUDIER SM, 1993, BLOOD, V81, P2702; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; Hawthorn LA, 1998, ANN HUM GENET, V62, P401, DOI 10.1046/j.1469-1809.1998.6250401.x; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; IULIUSSON G, 1988, CANCER, V62, P500; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KILLIAN GJ, 1993, BIOL REPROD, V49, P1202, DOI 10.1095/biolreprod49.6.1202; Kooy R F, 1994, Eur J Hum Genet, V2, P228; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; PITTMAN S, 1983, CANCER GENET CYTOGEN, V9, P355, DOI 10.1016/0165-4608(83)90084-5; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROE BA, 1996, DNA ISOLATION SEQUEN; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; XU Y, 1994, 2 INT C INT SYST MOL	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5772	5780		10.1038/sj.onc.1203978	http://dx.doi.org/10.1038/sj.onc.1203978			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126364				2022-12-28	WOS:000165477700009
J	Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME				Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME			Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant	ONCOGENE			English	Article						p53 germline mutation; transdominance; gain-of-function; turner penetrance; mouse brain tumor model	EPIDERMAL GROWTH-FACTOR; LI-FRAUMENI-SYNDROME; SRC TRANSGENIC MICE; MALIGNANT PROGRESSION; GERMLINE MUTATIONS; SUPPRESSOR GENE; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; V-SRC	p53-germline mutations located in the core DNA-binding domain have been associated with a more dominant tumor penetrance especially for breast cancer and brain tumors. We previously reported an unusual accumulation of CNS turners associated with a unique p53 germline mutation, Y236 Delta (deletion of codon 236). To test whether this tissue-specific tumor predisposition reflects a gain-of-function activity of Y236 Delta, we generated transgenic mice expressing Y236 Delta in astrocytes using the regulatory elements of the glial fibrillary acidic protein (G-FAP) gene. After transplacental exposure to N-ethyl-N-nitrosourea (25mg/kg BW) brain tumors developed in 18% (7/39) of GFAP-Y236 Delta transgenic p53(+/-) mice, while in p53(+/-) mice the incidence was 28% (11/40) (P > 0.3). However, the mean tumor latency for GFAP-Y236 Delta /p53(+/-) mice was significantly shorter than for p53(+/-) mice, with 19.9 weeks vs 31.6 weeks (P = 0.039), respectively. Taken together, cell specific expression of Y236 Delta results in an acceleration of tumor progression but does not confer a higher tumor penetrance. Conceivably, the transdominant effect of Y236 Delta provided a growth advantage early in the progression of neoplastic cells, since the endogenous p53 wild-type allele was lost in all brain tumors independent of the genotype. This reflects well observations from human astrocytic neoplasms with p53 mutations.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Hosp, Inst Pathol, CH-1011 Lausanne, Switzerland; Univ Hosp, Div Neuropathol, CH-1011 Lausanne, Switzerland	University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015; Aguzzi, Adriano/A-3351-2008	Hegi, Monika/0000-0003-0855-6495; Aguzzi, Adriano/0000-0002-0344-6708				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Chene P, 1999, INT J CANCER, V82, P17, DOI 10.1002/(SICI)1097-0215(19990702)82:1<17::AID-IJC4>3.0.CO;2-6; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENLINGER RH, 1974, INT J CANCER, V13, P559, DOI 10.1002/ijc.2910130416; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRASER H, 1971, J PATHOL, V103, P266, DOI 10.1002/path.1711030410; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hegi ME, 2000, CANCER RES, V60, P3019; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Hermanson M, 1996, CANCER RES, V56, P164; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ichimura K, 1996, ONCOGENE, V13, P1065; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 1997, AM J PATHOL, V150, P1; Kleihues P, 2000, PATHOLOGY GENETICS T; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; LUONGO C, 1994, CANCER RES, V54, P5947; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marino S, 2000, GENE DEV, V14, P994; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MUCKE L, 1991, NEW BIOL, V3, P465; Oda H, 1997, CANCER RES, V57, P646; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; VONDEIMLING A, 1992, CANCER RES, V52, P2897; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5329	5337		10.1038/sj.onc.1203941	http://dx.doi.org/10.1038/sj.onc.1203941			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103934				2022-12-28	WOS:000165302300004
J	Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG				Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG			PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition	ONCOGENE			English	Article						hRad9; hHus1; PCNA; DNA damage; cell-cycle checkpoints	CELL NUCLEAR ANTIGEN; CHECKPOINT CONTROL GENE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; POLYMERASE-DELTA; HUMAN HOMOLOG; PROTEIN-PCNA; CYCLE; REPAIR; RAD1	The hHus1 and several hRad proteins are involved in the control of DNA integrity checkpoints, although the mechanisms underlying these processes are unknown. Using a yeast two-hybrid system to detect protein-protein interactions, we found that human proliferating cell nuclear antigen (PCNA), a protein known to function in both DNA replication and repair, interacts with the human checkpoint-related protein Hus1 (hHus1). In human skin fibroblast cells, exposure to ionizing radiation of hydroxyurea triggers translocation of hHus1 from the cytosol to the nucleus, where it associates with PCNA as well as another checkpoint protein, hRad9. This nuclear translocation and the complex formation or hHus1 with PCNA and hRad9 correlate closely with changes in cell cycle distribution in response to radiation exposure. These results suggest that this multi-protein complex may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Imgenex Corp, San Diego, CA 92121 USA	Columbia University	Wang, HG (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Wu, Chun-Fang/0000-0002-4973-2021	NATIONAL CANCER INSTITUTE [R01CA072694, R01CA082197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NCI NIH HHS [CA72694, CA82197] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 1999, MOL CELL BIOL, V19, P1136; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Nojima H, 1997, Hum Cell, V10, P221; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x	35	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5291	5297		10.1038/sj.onc.1203901	http://dx.doi.org/10.1038/sj.onc.1203901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077446				2022-12-28	WOS:000165059700010
J	Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P				Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P			Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells	ONCOGENE			English	Article						hTERT; p53; Sp1; telomerase	CATALYTIC SUBUNIT HTERT; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; BREAST-CANCER; DNA-BINDING; MUTANT P53; LIFE-SPAN; C-MYC; PROTEIN	The p53 tumor suppressor protein inhibits the formation of tumors through induction of cell cycle arrest and/or apoptosis, In the present study we demonstrated that p53 is also a powerful inhibitor of human telomerase reverse transcriptase (hTERT), a key component for telomerase, Activation of either exogenous temperature-sensitive (ts) p53 in BL41 Burkitt lymphoma cells or endogenous wild type (wt) p53 at a physiological level in MCF-7 breast carcinoma cells triggered a rapid downregulation of hTERT mRNA expression, independently of the induction of the p53 target gene p21, Co-transfection of an hTERT promoter construct with wt p53 but not mutant p53 in HeLa cells inhibited the hTERT promoter activity. Furthermore, the activation of the hTERT promoter in Drosophila Schneider SL2 cells was completely dependent on the ectopic expression of Sp1 and was abrogated by wt p53, Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex. Since activation of telomerase, widely observed in human tumor cell lines and primary tumors, is a critical step in tumorigenesis, wt p53-triggered inhibition of hTERT/telomerase expression may reflect yet another mechanism of p53-mediated tumor suppression. Our findings provide new insights into both the biological function of p53 and the regulation of hTERT/telomerase expression.	Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Radiumhemmet, Dept Oncol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem, SE-10405 Stockholm, Sweden; Linkoping Univ, Fac Hlth Sci, SE-58185 Linkoping, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University; Linkoping University	Xu, DW (corresponding author), Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, L8-03, SE-17176 Stockholm, Sweden.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Chen, Zhiguo/0000-0003-1508-510X; Zaid, Ahmed/0000-0002-1063-2883; Selivanova, Galina/0000-0002-8698-4332; Xu, Dawei/0000-0003-3141-4524				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Loveday RL, 1999, INT J CANCER, V84, P516, DOI 10.1002/(SICI)1097-0215(19991022)84:5<516::AID-IJC12>3.0.CO;2-Y; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OKAN I, 1995, ONCOGENE, V11, P1027; PERREM K, 1995, ONCOGENE, V11, P1299; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SOUSSI T, 1990, ONCOGENE, V5, P945; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang QJ, 1998, CANCER RES, V58, P5762; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu X, 1999, BRIT J CANCER, V80, P453, DOI 10.1038/sj.bjc.6690378; Xu D, 1996, LEUKEMIA, V10, P1354; XU D, 1999, BRIT J CANCER, V80, P453; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x	47	205	224	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5123	5133		10.1038/sj.onc.1203890	http://dx.doi.org/10.1038/sj.onc.1203890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064449				2022-12-28	WOS:000090124100001
J	Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS				Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS			Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis	ONCOGENE			English	Article						hepatocellular adenoma; hepatocellular carcinoma; c-myc; p53; mouse	CELL-CYCLE CONTROL; GROWTH-FACTOR-ALPHA; C-MYC; HEPATOCELLULAR-CARCINOMA; S-PHASE; MICE; CANCER; TRANSCRIPTION; EXPRESSION; APOPTOSIS	Deregulation of E2F transcriptional control has been implicated in oncogenic transformation. Consistent with this idea, we recently demonstrated that during hepatocarcinogenesis in c-myc/TGF alpha double transgenic mice, there is increased expression of E2F-1 and E2F-2, as well as induction of putative E2F target genes. Therefore, we generated transgenic mice expressing E2F-1 under the control of the albumin enhancer/promoter to test the hypothesis that E2F family members may contribute to liver tumor development. Overexpression of E2F-1 resulted in mild but persistent increases in cell proliferation and death during postnatal liver growth, and no increases in hepatic regenerative growth in response to partial hepatectomy. Nevertheless, from 2 months postnatally E2F-1 transgenic mice exhibited prominent hepatic histological abnormalities including preneoplastic foci adjacent to portal tracts and pericentral large cell dysplasia. From 6 to 8 months onward, there was an abrupt increase in the number of neoplastic nodules ('adenomas') with 100% incidence by 10 months. Some adenomas shelved evidence of malignant transformation, and two of six mice killed at IZ months showed trabecular hepatocellular carcinoma. Endogenous c-myc was up-regulated in the early stages of E2F-1 hepatocarcinogenesis, whereas p53 was overexpressed in the tumors, suggesting that both E2F-1-mediated proliferation and apoptosis are operative but at different stages of hepatocarcinogenesis. In conclusion, E2F-1 overexpression in the liver causes dysplasia and tumors and suggests a cooperation between E2F-1 and c-myc oncogenes during liver oncogenesis.	NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, 37 Convent Dr MSC4255,Bldg 37,Room 3C28, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005750] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COHEN C, 1986, CANCER, V57, P1535, DOI 10.1002/1097-0142(19860415)57:8<1535::AID-CNCR2820570816>3.0.CO;2-8; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEPHINHO RA, 1991, ADV CANCER RES, V57, P1; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Factor VM, 1997, HEPATOLOGY, V26, P1434; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Guy CT, 1996, MOL CELL BIOL, V16, P685; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higgins GM, 1931, ARCH PATHOL, V12, P186; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI H, 1993, CANCER RES, V53, P1719; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; NEVINS JR, 1992, SCIENCE, V258, P424; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROUNBEHIER R, 2000, P AM ASSOC CANC RES, V41, P394; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHERR C, 1994, CELL, V79, P551; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	122	126	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5054	5062		10.1038/sj.onc.1203885	http://dx.doi.org/10.1038/sj.onc.1203885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042693				2022-12-28	WOS:000089930100002
J	Georgopoulos, NT; Proffitt, JL; Blair, GE				Georgopoulos, NT; Proffitt, JL; Blair, GE			Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins	ONCOGENE			English	Article						human papillomavirus; E7; MHC class I; TAP1; LMP2; transcriptional repression	CERVICAL CARCINOMAS; DOWN-REGULATION; CELL-LINE; EXPRESSION; TRANSACTIVATION; IDENTIFICATION; NEOPLASIA; ANTIGEN; CANCER; E1A	We have examined the possibility that the E7 proteins of the high-risk human papillomavirus (HPV) type 16 and 18 and the oncogenic adenovirus (Ad) type 12 E1A protein share the ability to down-regulate the expression of components of the antigen processing and presentation pathway, as a common strategy in the evasion of immune surveillance during the induction of cell transformation. Expression of the HPV 18 E7 oncoprotein, like Ad 12 E1A, resulted in repression of the major histocompatibility complex (MHC) class I heavy chain promoter, as well as repression of a bidirectional promoter that regulates expression of the genes encoding the transporter associated with antigen processing subunit 1 (TAP1) and a proteasome subunit, low molecular weight protein 2 (LMP2), HPV 16 E7 also caused a reduction in class I heavy chain promoter activity, however it did not have any significant effect on the activity of the bidirectional promoter. Interestingly, expression of the low-risk I-IPV 6b E7 protein resulted in an increase in MHC class I heavy chain promoter activity, while repressing the TAP1/LMP2 promoter, Interference with the class I pathway could also explain the ability of low-risk HPVs in inducing benign lesions.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Blair, GE (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Georgopoulos, Nik/0000-0002-6330-4947				ACKRILL AM, 1988, ONCOGENE, V3, P483; ARENDS MJ, 1993, HUM PATHOL, V24, P432, DOI 10.1016/0046-8177(93)90093-V; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; Bartholomew Jennifer, 1995, P233, DOI 10.1017/CBO9780511525339.010; Blair GE, 1998, SEMIN VIROL, V8, P387, DOI 10.1006/smvy.1997.0140; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; BYRD PJ, 1982, J GEN VIROL, V60, P279, DOI 10.1099/0022-1317-60-2-279; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COX JT, 1995, BAILLIERE CLIN OB GY, V9, P1, DOI 10.1016/S0950-3552(05)80357-8; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DERY CV, 1987, ONCOGENE, V2, P15; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HERRMANN CH, 1987, ONCOGENE, V2, P25; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; Rey O, 2000, J VIROL, V74, P4912, DOI 10.1128/JVI.74.10.4912-4918.2000; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Stern PL, 1996, ADV CANCER RES, V69, P175, DOI 10.1016/S0065-230X(08)60863-5; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; WILCZYNSKI SP, 1993, HUM PATHOL, V24, P96, DOI 10.1016/0046-8177(93)90068-R; WILCZYNSKI SP, 1988, VIROLOGY, V166, P624, DOI 10.1016/0042-6822(88)90539-9; Williams DB, 1996, TRENDS CELL BIOL, V6, P267, DOI 10.1016/0962-8924(96)10020-9; Zwerschke W, 2000, ADV CANCER RES, V78, P1	40	110	112	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4930	4935		10.1038/sj.onc.1203860	http://dx.doi.org/10.1038/sj.onc.1203860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039910				2022-12-28	WOS:000089757800015
J	Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S				Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S			Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase-8; caspase-9; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C RELEASE; DEATH RECEPTORS; NEUROBLASTOMA-CELLS; MEDIATED APOPTOSIS; LEUKEMIA-CELLS; WILD-TYPE; ACTIVATION; BCL-2; MITOCHONDRIA	Caspase-8 plays an essential role in apoptosis triggered by death receptors, Through the cleavage of Bid, a proapoptotic Bcl-2 member, it further activates the mitochondrial cytochrome c/Apaf-1 pathway. Because caspase-8 can be processed also by anticancer drugs independently of death receptors, we investigated its exact role and order in the caspase cascade. We show that in Jurkat cells either deficient for caspase-8 or overexpressing its inhibitor c-FLIP apoptosis mediated by CD95, but not by anticancer drugs was inhibited. In the absence of active caspase-8, anticancer drugs still induced the processing of caspase-9, -3 and Bid, indicating that Bid cleavage does not require caspase-8, Overexpression of Bcl-x(L) prevented the processing of caspase-8 as well as caspase-9, -6 and Bid in response to drugs, but was less effective in CD95-induced apoptosis, Similar responses were observed by overexpression of a dominant-negative caspase-9 mutant, To further determine the order of caspase-8 activation, we employed MCF7 cells lacking caspase-3, In contrast to caspase-9 that was cleaved in these cells, anticancer drugs induced caspase-8 activation only in caspase-3 transfected MCF7 cells. Thus, our data indicate that, unlike its proximal role in receptor signaling, in the mitochondrial pathway caspase-8 rather functions as an amplifying executioner caspase.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-7000 Stuttgart, Germany; Univ Tubingen, Dept Radiat & Oncol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; University of Stuttgart; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Wajant, Harald/A-3020-2017; Schulze-Osthoff, Klaus/N-9025-2013	Wajant, Harald/0000-0002-2005-3949; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tolomeo M, 1998, CELL DEATH DIFFER, V5, P735, DOI 10.1038/sj.cdd.4400406; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	58	229	234	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4563	4573		10.1038/sj.onc.1203824	http://dx.doi.org/10.1038/sj.onc.1203824			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030145				2022-12-28	WOS:000089438200002
J	Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K				Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K			The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner	ONCOGENE			English	Article						Bmx; IL-3; G-CSF; PI-3K; differentiation; apoptosis	PLECKSTRIN HOMOLOGY DOMAIN; BRUTON TYROSINE; PHOSPHOINOSITIDE 3-KINASE; B-LYMPHOCYTES; PH-DOMAIN; RECEPTOR; TEC; BTK; CELLS; FAMILY	Cytoplasmic protein tyrosine kinases play crucial roles in signaling, ia a variety of cell surface receptors, The Bmx tyrosine kinase, a member of the Tec family, is expressed in hematopoietic cells of the granulocytic and monocytic lineages. Here we show that Bmx is catalytically activated by interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) receptors, Activation of Ems required phosphatidylinositol 3-kinase (PI-3K) as demonstrated by the ability of PI-3K inhibitors to block the activation signal. A green fluorescent protein (GFP) tagged Bmx nas translocated to cellular membranes upon co-expression of a constitutively active form of PI-3K, further indicating a role for PI-3K in signaling upstream of Ems. The expression of wild type Bmx in 32D myeloid progenitor cells resulted in apoptosis in the presence of G-CSF, while cells expressing a kinase dead mutant of Bmx differentiated into mature granulocytes. However, Bmx did not modulate IL-3-dependent proliferation of the cells. These results demonstrate distinct effects of Ems in cytokine induced proliferation and differentiation of myeloid cells, and suggest that the stage specific expression of Ems is critical for the differentiation of myeloid cells.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Helsinki 00029, Finland; Tampere Univ, Tampere 33014, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Saharinen, Pipsa I/C-9601-2016; Alitalo, Kari K/J-5013-2014	Saharinen, Pipsa I/0000-0003-2652-0584; Alitalo, Kari K/0000-0002-7331-0902				Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BOGGS DANE R., 1967, SEMINAR HEMATOL, V4, P359; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Dentelli P, 1999, J IMMUNOL, V163, P2151; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GIBSON S, 1993, BLOOD, V82, P1561; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Hunter MG, 1998, J IMMUNOL, V160, P4979; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miyajima A, 1999, INT J HEMATOL, V69, P137; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; QUI Y, 1998, P NATL ACAD SCI USA, V95, P3644; Saharinen P, 1997, BLOOD, V90, P4341; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; SOMMERS CL, 1995, ONCOGENE, V11, P245; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Venkataraman C, 1998, J IMMUNOL, V160, P3322; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687	51	36	36	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4151	4158		10.1038/sj.onc.1203763	http://dx.doi.org/10.1038/sj.onc.1203763			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962576				2022-12-28	WOS:000088955100009
J	Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P				Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P			Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation	ONCOGENE			English	Article						embryoid bodies; FGF signaling; epithelial differentiation; Akt/PKB; PLC gamma-1	PHOSPHOLIPASE C-GAMMA; PHOSPHOINOSITIDE 3-KINASE; STEM-CELLS; PROTEIN-KINASE; MOUSE EMBRYOS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; TARGETED DISRUPTION; MESODERM INDUCTION; VISCERAL ENDODERM; CELLULAR-SURVIVAL	The role of FGF signaling in early epithelial differentiation was investigated in ES (embryonic) stem) cell derived embryoid bodies. A dominant negative fibroblast growth factor receptor (FGFR) mutation was created by stably introducing into ES cells an Fgfr2 cDNA, truncated in its enzymatic domains. These cells failed to differentiate into cystic embryoid bodies. No epithelial differentiation and cavitation morphogenesis could be observed, in the mutant, although its rate of cell proliferation remained unchanged. This phenotype was associated with a significant decrease in the activation of Akt/PKB and PLC gamma-1, as compared to the wild type, while the activation of MAPK/Erk was less affected, Requirement for PL 3-kinase signaling in embryoid body differentiation was demonstrated by specific inhibitors, Akt/PKB activation was abrogated by wortmannin in short-term experiments. In long-term cultures Ly294002 inhibited the differentiation of ES cells into embryoid bodies. Our data demonstrate that for early epithelial differentiation FGF signaling is required through the PI 3-kinase-Akt/ PKB pathway.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lonai, P (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Eswarakumar, Jacob/0000-0003-0784-0507; Eswarakumar, V.P./0000-0001-7941-8714				Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; Barbacci E, 1999, DEVELOPMENT, V126, P4795; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chai N, 1998, DEV BIOL, V198, P105, DOI 10.1016/S0012-1606(98)80031-6; CONLON RA, 1992, METHOD ENZYMOL, V225, P361; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Cross MJ, 2000, J CELL SCI, V113, P643; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Duncan SA, 1997, DEVELOPMENT, V124, P279; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRIEDMAN HM, 1982, CANCER RES, V42, P4683; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Hogan B, 1994, MANIPULATING MOUSE E; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rappolee DA, 1998, MOL REPROD DEV, V51, P254, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;254::AID-MRD4&gt;3.0.CO;2-O; RAZ V, 1991, ONCOGENE, V6, P753; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	49	104	113	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3750	3756		10.1038/sj.onc.1203726	http://dx.doi.org/10.1038/sj.onc.1203726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949929				2022-12-28	WOS:000088568400007
J	Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM				Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM			Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death	ONCOGENE			English	Article						Pim-1kinase; genotoxin-induced apoptosis	INHIBITS APOPTOSIS; C-MYC; IONIZING-RADIATION; GENE-EXPRESSION; TRANSGENIC MICE; MYELOID CELLS; BONE-MARROW; ACTIVATION; DIFFERENTIATION; ERYTHROPOIETIN	The hematopoietic cell S/T kinase Pim-1 was originally discovered as a target of murine leukemia provirus integration, and when expressed at increased levels is predisposing to lymphomagenesis. Recently, Pim-1 has been shown to enhance the activities of p100, c-Myb and cdc25a, and in part this might explain reported effects on mitogenesis. In the context of cytokine withdrawal, Pim-1 also can attenuate programmed cell death (PCD). Cytokine withdrawal, however, alters signaling pathways and can complicate the dissection of mitogenic vs apoptotic responses. To better study possible effects of Pim-1 on PCD, a hematopoietic cell model was developed in which proliferation was supported efficiently by SCF plus EPO in the absence of endogenous Pim-1 gene expression. This was provided by factor-dependent FDCW2 cells that express endogenous and functional c-Kit, and were transfected stably with truncated Epo receptor form mutated at a Y343 STAT5 binding site. In proliferating cells, exogenously expressed Pim-1 was observed to efficiently inhibit PCD as induced by either Co-60 or adriamycin, and the dose-dependent nature of this effect was established in several independent clones, By comparison, effects of exogenous Pim-1 on mitogenesis were nominal. In addition, in cell fractionation studies an estimated 25% of M-r 34 000 Pim-1 (but not M-r 44 000 Pim-1) was present in nuclear extracts. Thus, Pim-1 efficiently buffers hematopoietic progenitor cells against death as induced by several clinically important apoptotic agents, and may directly target nuclear effecters.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Program Immunobiol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 115 Henning Bldg, University Pk, PA 16802 USA.				NHLBI NIH HHS [HLR0144491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG RY, 1979, BIOCHEMISTRY-US, V18, P2069, DOI 10.1021/bi00577a035; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1993, J IMMUNOL, V151, P621; Joneja B, 1997, BLOOD, V90, P3533, DOI 10.1182/blood.V90.9.3533; KLEIN AK, 1985, RADIAT RES, V101, P332, DOI 10.2307/3576399; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Xu J, 1999, MOL CELL BIOL, V19, P12; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561	43	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3684	3692		10.1038/sj.onc.1203684	http://dx.doi.org/10.1038/sj.onc.1203684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951575				2022-12-28	WOS:000088568300015
J	He, YW; Armanious, MK; Thomas, MJ; Cress, WD				He, YW; Armanious, MK; Thomas, MJ; Cress, WD			Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region	ONCOGENE			English	Article						E2F; E2F-3; retinoblastoma; cell cycle	C-MYC PROTEINS; TRANSCRIPTION FACTORS E2F-1; FIBROBLAST GROWTH-FACTOR; DNA-BINDING SITE; S-PHASE ENTRY; CELL-CYCLE; IN-VIVO; NUCLEAR-LOCALIZATION; FAMILY MEMBERS; REGULATING TRANSCRIPTION	We have identified a novel form of the full-length E2F-3 protein that we term E2F-3B, In contrast to full-length E2F-3, which is expressed only at the G1/S boundary, E2F-3B is detected throughout the cell cycle with peak levels in GO where it is associated with Rb, Transfection and in vitro translation experiments demonstrate that a protein identical to E2F-3B in size and iso-electric point is produced from the E2F-3 mRNA via the use of an alternative translational start site, This alternative initiation codon was mapped hy mutagenesis to codon 102, an ACG codon, Mutation of the ACC codon at position 102 abolished E2F-3B expression, whereas the conversion of ACG 102 to a consensus ATG led to the expression of a protein indistinguishable from E2F-3B, Given these results, E2F-3B is missing 101 N-terminal amino acids relative to full-length E2F-3. This region includes a moderately conserved sequence of unknown function that is present only in the growth-promoting E2F family members, including E2F-1, 2 and full-length E2F-3. These observations make E2F-3B the first example of an E2F gene giving rise to two different protein species and also suggest that E2F-3 and E2F-3B may have opposing roles in cell cycle control.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen KE, 1997, J CELL SCI, V110, P2819; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOYD L, 1993, P NATL ACAD SCI USA, V90, P9164, DOI 10.1073/pnas.90.19.9164; BUCK V, 1995, ONCOGENE, V11, P31; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COLIGAN J, CURRENT PROTOCOLS PR; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HANN SR, 1995, ADV EXP MED BIOL, V375, P107; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Magae J, 1996, J CELL SCI, V109, P1717; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	79	67	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3422	3433		10.1038/sj.onc.1203682	http://dx.doi.org/10.1038/sj.onc.1203682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918599				2022-12-28	WOS:000088198100010
J	Liu, SL; Rand, A; Kelm, RJ; Getz, MJ				Liu, SL; Rand, A; Kelm, RJ; Getz, MJ			The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in fibroblasts	ONCOGENE			English	Article						tissue factor; adenovirus EIA; retinoblastoma tumor suppressor; pRB; p107; AP-1	GROWTH-FACTOR-BETA; SERUM-STIMULATED FIBROBLASTS; TUMOR-SUPPRESSOR PROTEIN; CREB BINDING-PROTEIN; C-FOS; TRANSCRIPTION FACTOR; CELL-GROWTH; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; EXPRESSION	Serum-stimulation of quiescent mouse fibroblasts results in transcriptional activation of tissue factor (TF), the cellular initiator of blood coagulation. This requires the rapid entry of c-Fos into specific AP-1 DNA-binding complexes and can be strongly inhibited by the adenovirus E1A 12S gene product. In this study, we utilized a panel of E1A mutants deficient in cellular protein binding to analyse the molecular basis for E1A inhibition of a minimal, c-Fos-dependent TF promoter/reporter construct in mouse AKR-2B fibroblasts, Mutations which impaired binding of the retinoblastoma tumor suppressor protein family members pRB, p107, and p130 relieved E1A-mediated inhibition of transcription in response to serum-stimulation or c-Fos overexpression. Inhibition was restricted to the G(0) to G(1) transition, consistent with the specificity of E1A for hypophosphorylated forms of RE proteins. Although E1A mutants deficient in CBP/p300 binding retained the ability to inhibit TF transcription, deletion of the aminoterminal portion of the CBP/p300 interaction domain was required to permit rescue of TF promoter activity by coexpression of pRB, Moreover, ectopic p107 could effectively substitute for pRB in relieving E1A-mediated repression. In primary mouse embryo fibroblasts, activity of the minimal AP(-/-) dependent TF promoter was suppressed in Rb-/- cells compared to parallel Rb+/- and Rh+/+ transfectants, Ectopic expression of either PRB or p107 markedly enhanced TF promoter activity in Rh-/- fibroblasts. Collectively, these data imply that pRB and p107 can cooperate with c-Fos to activate TF gene transcription in fibroblasts and suggest a requirement for another, as yet unidentified, E1A-binding protein.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA	Mayo Clinic	Kelm, RJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Tumor Biol, Rochester, MN 55905 USA.				NCI NIH HHS [T32 CA09441, CA76083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076083, T32CA009441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BISPHOPRIC NH, 1997, J BIOL CHEM, V272, P20584; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Felts SJ, 1997, ONCOGENE, V14, P1679, DOI 10.1038/sj.onc.1201006; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Giannini G, 1997, J BIOL CHEM, V272, P5313, DOI 10.1074/jbc.272.8.5313; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1992, SCIENCE, V258, P424; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REDDY JC, 1995, J BIOL CHEM, V270, P29976; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vrana JA, 1996, CANCER RES, V56, P5063; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	57	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3352	3362		10.1038/sj.onc.1203675	http://dx.doi.org/10.1038/sj.onc.1203675			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918592				2022-12-28	WOS:000088198100003
J	Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J				Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J			IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7	ONCOGENE			English	Article						Ewing's sarcoma; interferon-beta; IRF-1; apoptosis; caspase-7	I INTERFERON RECEPTOR; NECROSIS-FACTOR-ALPHA; KINASE INHIBITOR P21; REGULATORY FACTOR-I; SIGNALING PATHWAY; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; GROWTH-INHIBITION; P53 MUTATIONS; HUMAN TUMORS	Four human cell lines derived from Ewing's sarcoma, EW-7, EW-1, COH and ORS, were investigated to establish the effects of human recombinant interferon-alpha 2a and human recombinant interferon-beta on cell proliferation and apoptosis, All four cell lines were much more sensitive to the antiproliferative effects of IFN-beta than of IFN-alpha. Analysis of the early signals triggered by IFN-alpha and IFN-beta demonstrated that the two IFNs were similarly effective in inducing tyrosine phosphorylation of the Jak-1 and Tyk-2 kinases and the transcription factors Stat-1 and Stat-2, Interestingly, an additional rapid phosphorylation of Stat-1 on serine was observed after IFN-beta treatment, with concomitant activation of p38 mitogen-activated protein kinase, In these cells, Stat-1 Ser727 phosphorylation in response to IFN-beta was found to be impaired by p38 MAPkinase inhibitor (SB203580). IFN-beta induced the formation of the Interferon Stimulated Gene Factor 3 complex more efficiently than IFN-alpha, as well as sustained induction of IRF-1, which may account for its greater induction of 2'5'oligo(A)synthetase and greater inhibition of cell proliferation. IFN-beta, but not IFN-alpha, induced apoptosis in wild-type p53 EW-7 and COH cell lines, but not in the mutated p53 EW-1 or ORS cell lines. The apoptosis induced by IFN-beta in EW-7 and COH cell lines appeared to be mediated by IRF-1 and involved the activation of caspase-7, Ectopic expression of IRF-1 induced apoptosis in all four cell lines which correlated with the activation of caspase-7 and,vith the downregulation of the Bcl-2 oncoprotein, as observed for IFN-beta-induced apoptosis in parental EW-7 and COH cell lines.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; McGill Univ, Lady Davis Inst Res, Montreal, PQ H3T 1E2, Canada; Inst Curie, INSERM, U509, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Lady Davis Institute; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sanceau, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Borden, 1998, Oncologist, V3, P198; BRAILLY RA, 1993, MOL CELL BIOL, V14, P3230; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMARCO F, 1995, J GEN VIROL, V76, P445, DOI 10.1099/0022-1317-76-2-445; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grumbach IM, 1999, J INTERF CYTOK RES, V19, P797, DOI 10.1089/107999099313659; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hadida F, 1999, HUM GENE THER, V10, P1803, DOI 10.1089/10430349950017482; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Horowitz Marc E., 1997, P831; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Marcelli M, 1998, CANCER RES, V58, P76; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MICHALEVICZ R, 1988, LEUKEMIA RES, V12, P845, DOI 10.1016/0145-2126(88)90038-0; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROKLIN OW, 1996, CANCER RES, V58, P5870; Rosolen A, 1997, MODERN PATHOL, V10, P55; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sacchi S, 1998, J CLIN ONCOL, V16, P882, DOI 10.1200/JCO.1998.16.3.882; Salmeron J, 1999, LIVER, V19, P275, DOI 10.1111/j.1478-3231.1999.tb00049.x; SALVESEN G, 1997, CELL, V91, P433; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	70	98	101	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3372	3383		10.1038/sj.onc.1203670	http://dx.doi.org/10.1038/sj.onc.1203670			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918594				2022-12-28	WOS:000088198100005
J	Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G				Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G			PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27(kip1)	ONCOGENE			English	Article						PTEN; thyroid cancer; growth suppression; AKT; p27(kip1)	TUMOR-SUPPRESSOR; COWDEN-DISEASE; GLIOBLASTOMA CELLS; PROSTATE-CANCER; GENE; MUTATION; PTEN/MMAC1; SURVIVAL; PROTEIN; PKB/AKT	The dual-specificity phosphatase PTEN/MMAC1/TEP1 has recently been identified as the tumor suppressor gene most frequently mutated and/or deleted in human tumors. Germline mutations of PTEN give rise to Cowden Disease (CD), an autosomal dotninantly-inherited cancer syndrome which predisposes to increased risk of developing breast and thyroid tumors. However, PTEN mutations have rarely been detected in sporadic thyroid carcinomas. In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened. However, we report that PTEN expression is reduced both at the mRNA and at the protein level - in five out of eight tumor-derived cell Lines and in 24 out of 61 primary tumors. In most cases, decreased PTEN expression is correlated with increased phosphorylation of the P-TEN-regulated protein kinase Akt/PKB. Moreover, we demonstrate that PTEN may act as a suppressor of thyroid cancerogenesis as the constitutive re-expression of PTEN into two different thyroid tumor cell lines markedly inhibits cell growth. PTEN-dependent inhibition of BrdU incorporation is accompanied by enhanced expression of the cyclin-dependent kinase inhibitor p27(kip1) and can be overcome by simultaneous co-transfection of an excess p27(kip1) antisense plasmid Accordingly, in a subset of thyroid primary carcinomas and tumor-derived cell Lines, a striking correlation between PTEN expression and the level of p27(kip1) protein was observed, In conclusion, our findings demonstrate that inactivation of PTEN may play a role in the development of sporadic thyroid carcinomas and that one key target of PTEN suppressor activity is represented by the cyclin-dependent kinase inhibitor p27(kip1).	Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, I-80131 Naples, Italy; Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Magna Groecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, Via S Pansini 5, I-80131 Naples, Italy.		Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Fusco, Alfredo/0000-0003-3332-5197				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dahia PLM, 1997, CANCER RES, V57, P4710; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Eng C, 1998, INT J ONCOL, V12, P701; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Scala S, 1998, INT J ONCOL, V13, P665; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	35	128	143	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3146	3155		10.1038/sj.onc.1203633	http://dx.doi.org/10.1038/sj.onc.1203633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918569				2022-12-28	WOS:000088019200003
J	Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A				Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A			Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue	ONCOGENE			English	Article						human papilloma-virus (HPV); E7; ubiquitin; proteolysis; N-terminus	TRANSGENIC MICE; END RULE; TYPE-16; PROTEIN; EXPRESSION; GENE; E6; TRANSFORMATION; CONJUGATION; CELLS	The E7 oncoprotein of the high risk human papillomavirus type 16 (HPV-16), which is etiologically associated with uterine cervical cancer, is a potent immortalizing and transforming agent, It probably exerts its oncogenic functions by interacting and altering the normal activity of cell cycle control proteins such as p21(WAF1), p27(KIP1) pRb, transcriptional activators such as TBP and AP-1, and metabolic regulators such as M2-pyruvate kinase (M2-PK), Here we show that E7 is a short-lived protein and its degradation both in vitro and in vivo is mediated by the ubiquitin-proteasome pathway. interestingly; ubiquitin does not attach to any of the two internal Lysine residues of E7, Substitution of these residues with Arg does not affect the ability of the protein to be conjugated and degraded; in contrast, addition of a MSc tag to the N-terminal but not to the C-terminal residue, stabilizes the protein. Also, deletion of the first If amino acid residues stabilizes the protein in cells, Taken together, these findings strongly suggest that, like MyoD and the Epstein Barr Virus (EBV) transforming Latent Membrane Protein 1 (LMP1), the first ubiquitin moiety is attached linearly to the free N-terminal residue of E7, Additional ubiquitin moieties are then attached to an internal Lys residue of the previously conjugated molecule, The involvement of E7 in many diverse and apparently unrelated processes requires tight regulation of its function and cellular level, which is controlled in this case by ubiquitin-mediated proteolysis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-30196 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-30196 Haifa, Israel; Univ Cologne, Fak Med, Inst Biochem, D-50931 Cologne, Germany; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Cologne; Weizmann Institute of Science; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, POB 9649,Efron St, IL-30196 Haifa, Israel.		高, 雨莉/HGU-8187-2022; Ciechanover, Aaron J/C-9166-2017; Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Oren, Moshe/0000-0003-4311-7172				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Boyer SN, 1996, CANCER RES, V56, P4620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HU TH, 1995, INT J ONCOL, V6, P167; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; MUNGER K, 1989, J VIROL, V63, P4417; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	39	149	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5944	5950		10.1038/sj.onc.1203989	http://dx.doi.org/10.1038/sj.onc.1203989			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127826				2022-12-28	WOS:000165563100014
J	Cizeau, J; Ray, R; Chen, G; Gietz, RD; Greenberg, AH				Cizeau, J; Ray, R; Chen, G; Gietz, RD; Greenberg, AH			The C-elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3-and caspase-independent mechanism	ONCOGENE			English	Article						ceBNIP3; BNIP3; cell death; CED-9; BH3 domain	PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; BH3 DOMAIN; GENETIC-CONTROL; PROTEIN; MITOCHONDRIAL; APOPTOSIS; HOMOLOG; BNIP3; NIP3	We have studied ceBNIP3, the orthologue of BNIP3 in C, elegans. Sequence analysis reveals that the different domains of BNIP3 have been conserved throughout evolution. ceBNIP3 contains a C-terminal transmembrane (TM) domain, a conserved domain (CD) of 19 amino acids, a BCL-2 homology-3 (BH3)-like domain and a PEST sequence. ceBNIP3 is expressed primarily as a 25 kDa monomer and a 50 kDa homodimer, After transfection, ceBNIP3 protein is rapidly degraded through a ubiquitin-dependent pathway by the proteasome. Like BNIP3, the TM domain of ceBNIP3 mediates the localization of the protein to mitochondria and is also necessary for homodimerization and cell death in mammalian cells. Neither the putative BH3 domain nor conserved domain is necessary for killing. ceBNIP3 protein interacts with CED-9 and BCL-X-L, but unlike other pro-apoptotic BCL-2 family members, the BH3-like domain does not participate in dimerization, The ceBNIP3 TM domain mediates interaction with both CED-9 and BCL-XL. ceBNIP3 interacts with CED-3 but co-expression of CED-3 and ceBNIP3 does not significantly enhance induction of cell death in the presence or absence of CED-4, ceBNIP3 kills mammalian cells by a caspase-independent mechanism. In conclusion, we find that although ceBNIP3 interacts with CED-9 and CED-3 it kills by a BH3- and caspase-independent mechanism.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Fac Med, Dept Biochemn & Med Genet, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Greenberg, AH (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5453	5463		10.1038/sj.onc.1203929	http://dx.doi.org/10.1038/sj.onc.1203929			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114722				2022-12-28	WOS:000165396100005
J	Pettersson, K; Delaunay, F; Gustafsson, JA				Pettersson, K; Delaunay, F; Gustafsson, JA			Estrogen receptor beta acts as a dominant regulator of estrogen signaling	ONCOGENE			English	Article						ER alpha; ER beta; heterodimerization; agonists; antagonists	NUCLEAR HORMONE RECEPTORS; MESSENGER-RNA EXPRESSION; BREAST-CANCER; PROMOTER-CONTEXT; ER-BETA; GLUCOCORTICOID RECEPTOR; CELL-TYPE; ALPHA; TRANSCRIPTION; HETERODIMERS	The physiological effects of estrogens are mediated by two intracellular transcription factors, the estrogen receptors (ERs), that regulate transcription of target genes through binding to specific DNA target sequences. Here we describe alterations in cellular responses to different ER agonists and to the anti-estrogenic compound tamoxifen resulting from co-expression of the two ERs in transient co-transfection experiments. Our results demonstrate that ER beta can act as a negative or positive dominant regulator of ER activity. This is manifested through reduced transcriptional activity at low concentrations of estradiol (E-2); increased antagonistic effects of tamoxifen on E-2 stimulated activity; and enhanced agonistic action of the phytoestrogenic compound genistein, Furthermore, using chimeric proteins lacking the N-terminal activation function 1 (AF-1), we show that the differential responses of ER alpha and ER beta to different agonists and antagonists are primarily dictated by inherent differences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is influenced by ER alpha AF-1, but not ER beta AF-1, The ER alpha AF-1 activity appears to be modulated upon co-expression of both ERs, The alterations in transcriptional activity resulting from co-expression of ER alpha and ER beta are probably due to the formation of alpha/beta heterodimeric complexes, This study demonstrates that co-localization and subsequent heterodimerization of ER alpha and ER beta may result in receptor activity distinct from that of ER homodimers.	Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Pettersson, K (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.			Delaunay, Franck/0000-0003-4927-1701				Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Ciocca DR, 1997, TRENDS ENDOCRIN MET, V8, P313, DOI 10.1016/S1043-2760(97)00122-7; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dotzlaw H, 1999, CANCER RES, V59, P529; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FORMAN BM, 1995, ANN NY ACAD SCI, V761, P29, DOI 10.1111/j.1749-6632.1995.tb31366.x; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HILLIER SG, 1989, J MOL ENDOCRINOL, V2, P39, DOI 10.1677/jme.0.0020039; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Leygue E, 1998, CANCER RES, V58, P3197; Li X, 1997, NEUROENDOCRINOLOGY, V66, P63, DOI 10.1159/000127221; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Sasano H, 1999, J CLIN ENDOCR METAB, V84, P781, DOI 10.1210/jc.84.2.781; Speirs V, 1999, CANCER RES, V59, P525; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	39	305	315	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4970	4978		10.1038/sj.onc.1203828	http://dx.doi.org/10.1038/sj.onc.1203828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042684				2022-12-28	WOS:000089834300004
J	Kawabe, T; Tsuyama, N; Kitao, S; Nishikawa, K; Shimamoto, A; Shiratori, M; Matsumoto, T; Anno, K; Sato, T; Mitsui, Y; Seki, M; Enomoto, T; Goto, M; Ellis, NA; Ide, T; Furuichi, Y; Sugimoto, M				Kawabe, T; Tsuyama, N; Kitao, S; Nishikawa, K; Shimamoto, A; Shiratori, M; Matsumoto, T; Anno, K; Sato, T; Mitsui, Y; Seki, M; Enomoto, T; Goto, M; Ellis, NA; Ide, T; Furuichi, Y; Sugimoto, M			Differential regulation of human RecQ family helicases in cell transformation and cell cycle	ONCOGENE			English	Article						RecQ helicase; cell transformation; immunoblotting; genomic stability	ROTHMUND-THOMSON-SYNDROME; EPSTEIN-BARR-VIRUS; SV40-TRANSFORMED HUMAN FIBROBLASTS; WERNER-SYNDROME PROTEIN; ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BLOOM-SYNDROME CELLS; DNA HELICASE; GENOMIC INSTABILITY; HUMAN HOMOLOG	Three human RecQ DNA helicases, WRN, BLM and RTS, are involved in the genetic disorders associated with genomic instability and a high incidence of cancer. RecQL1 and RecQL5 also belong to the human RecQ helicase family, but their correlation with genetic disorders, if any, is unknown. We report here that in human B cells transformed by Epstein-Barr virus (EBV), human fibroblasts and umbilical endothelial cells transformed by simian virus 40, the expression of WRN, BLM, RTS and RecQL1 was sharply up-regulated. In B cells this expression was stimulated within 5-40 h by the tumor promoting agent phorbol myristic acetate (PMA). Interestingly, RecQL5 beta, an alternative splicing product of RecQL5 with a nuclear localization signal, is expressed in resting B cells without significant modulation of its synthesis by EBV or PMA, suggesting it has a role in resting cells. We also roughly determined the number of copies per cell for the five RecQ helicase in B cells. In addition, levels of the different RecQ helicases are modulated in different ways during the cell cycle of actively proliferating fibroblasts and umbilical endothelial cells. Our results support the view that the levels of WRN, BLM, RTS and RecQL1 are differentially upregulated to guarantee genomic stability in cells that are transformed or actively proliferating.	AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan; Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Tohoku Univ, Mol Cell Biol Lab, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; Tokyo Metropolitan Otsuka Hosp, Dept Rheumatol, Toshima Ku, Tokyo 1700005, Japan; Mem Sloan Kettering Canc Ctr, Lab Canc Susceptibil, Dept Human Genet, New York, NY 10021 USA	Hiroshima University; National Institute of Advanced Industrial Science & Technology (AIST); Tohoku University; Memorial Sloan Kettering Cancer Center	Furuichi, Y (corresponding author), AGENE Res Inst, 200 Kajiwara, Kamakura, Kanagawa 2470063, Japan.							ABB J, 1979, J IMMUNOL, V122, P1639; AMANUMA K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P336, DOI 10.1016/S0167-4889(97)90009-4; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; BERTOGLIO JH, 1983, J IMMUNOL, V131, P2279; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLEVERS HC, 1985, J IMMUNOL, V135, P3827; Cooper MP, 2000, GENE DEV, V14, P907; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; EGELER RM, 1992, CANCER, V70, P683, DOI 10.1002/1097-0142(19920801)70:3<683::AID-CNCR2820700324>3.0.CO;2-C; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Goto M, 1999, HUM GENET, V105, P301, DOI 10.1007/s004390051105; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IDE T, 1983, EXP CELL RES, V143, P343, DOI 10.1016/0014-4827(83)90060-5; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lindor NM, 1996, CLIN GENET, V49, P124; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; MILLER G, 1990, VIROLOGY, P1921; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; SALK D, 1985, ADV EXP MED BIOL, V190, P541; Schulz VP, 1996, HUM GENET, V97, P750; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tada S, 1996, CELL STRUCT FUNCT, V21, P123, DOI 10.1247/csf.21.123; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; TAHARA H, 1995, ONCOGENE, V10, P835; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YAMAGUCHI N, 1975, J VIROL, V15, P1297, DOI 10.1128/JVI.15.6.1297-1301.1975; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	60	105	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4764	4772		10.1038/sj.onc.1203841	http://dx.doi.org/10.1038/sj.onc.1203841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032027				2022-12-28	WOS:000089528800011
J	Narayan, S; Wilson, SH				Narayan, S; Wilson, SH			Kinetic analysis of Sp1-mediated transcriptional activation of the human DNA polymerase beta promoter	ONCOGENE			English	Article						Sp1; beta-pol promoter; in vitro transcription; kinetic analysis	PROTEIN-PROTEIN INTERACTIONS; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL-ANALYSIS; II TRANSCRIPTION; TFIID COMPLEX; SP1; INITIATOR; CLONING	In the present studies, we have examined the effect of Spl on the activation of the human DNA polymerase beta (beta-pol), a TATA-less promoter. A HeLa cell nuclear extract (NE) based in vitro runoff transcription system of core beta-pol promoter human DNA (p beta P8) three-step kinetic model of transcription initiation were used to describe the kinetic effect of Spl. The results showed that distal Spl-binding sites in the core beta-pol promoter are important for transcriptional activation of the p beta P8 promoter. A detailed kinetic analysis showed that Spl stimulates the activity of the p beta PS promoter through distal Spl-binding sites by increasing the amount of recruitment, instead of stimulating the apparent rate of RPc assembly (k(1)), There was no significant effect of Sp1 on the apparent rate of open complex (RP0) formation (k(2)) Or on the apparent rate of promoter clearance (k(3)) Of the p beta P8 promoter. These studies define the kinetic mechanisms by which Spl may regulate the rate of transcript formation of the p beta P8 promoter, and these results may have implications for Spl regulation of TATA-less promoters.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, POB 100232, Gainesville, FL 32610 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA77721] Funding Source: Medline; NIEHS NIH HHS [ES06492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, R01ES006492, ZIAES050159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HE F, 1996, BIOCHEMISTRY-US, V35, P1776; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 2000, BIOCHEMISTRY-US, V39, P818, DOI 10.1021/bi9912701; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; Yean D, 1996, NUCLEIC ACIDS RES, V24, P2723, DOI 10.1093/nar/24.14.2723; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	44	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4729	4735		10.1038/sj.onc.1203823	http://dx.doi.org/10.1038/sj.onc.1203823			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032023				2022-12-28	WOS:000089528800007
J	Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J				Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J			Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development	ONCOGENE			English	Article						erbB2; EGFr; erbB3; skin; carcinogenesis	GROWTH-FACTOR-RECEPTOR; TREATED MOUSE EPIDERMIS; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ALTERED EXPRESSION; NEU-ONCOGENE; CELL-LINE; TGF-ALPHA; CANCER; OVEREXPRESSION	The erbB family of receptor tyrosine kinases, which consists of the epidermal growth factor receptor (EGFr/erbB1), erbB2 (neu), erbB3 and erbB4, has been shown to be important for both normal development as well as neoplasia. The expression of rat erbB2 was targeted to the basal layer of mouse epidermis with the bovine keratin 5 promoter. Overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with >90% incidence by 6 months. Analysis of several proliferationl differentiation markers indicated that erbB2 overexpression led to epidermal hyperproliferation and a possible delay in epidermal differentiation. Transgenic mice were also hypersensitive to the proliferative effects of the skin tumor promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA) and were more sensitive to two-stage carcinogenesis. Elevations in EGFr and erbB2 protein as well as erbB2:EGFr and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgenic mice. Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. These results indicate an important role for erbB2 signaling in epidermal growth, development and neoplasia.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Ciemat Inst, Dept Cell & Mol Biol, Madrid 28040, Spain	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	DiGiovanni, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.				NCI NIH HHS [CA16672, CA76520] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1989, SKIN TUMORS EXPT CLI, V11, P227; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanni J, 2000, CANCER RES, V60, P1561; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ELDRIDGE SR, 1990, CARCINOGENESIS, V4, P281; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Hogan B, 1994, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; MOLLOY CJ, 1987, CANCER RES, V47, P4674; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Riese DJ, 1996, ONCOGENE, V12, P345; SAMBROOK J, 1994, MOL CLONING LAB MAN; SCHLESSINGER J, 1992, NEURON, V9, P389; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TOFTGARD R, 1985, CANCER RES, V45, P5845; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WOOD DP, 1991, J UROLOGY, V146, P1398, DOI 10.1016/S0022-5347(17)38123-5; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YOKOTA J, 1986, LANCET, V1, P765; YUSPA S, 1994, J INVEST DERMATOL, V103, P908; YUSPA SH, 1994, CANCER RES, V54, P1178; [No title captured]	60	76	76	2	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4243	4254		10.1038/sj.onc.1203778	http://dx.doi.org/10.1038/sj.onc.1203778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980598				2022-12-28	WOS:000089032900007
J	Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T				Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T			The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins	ONCOGENE			English	Article						G-protein-coupled receptor; mitogenic signaling; multiple signaling; neuropeptides	GROWTH-FACTOR RECEPTOR; STRESS FIBER FORMATION; PHOSPHOLIPASE C-BETA; ACTIVATED G-PROTEINS; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; MEMBRANE DEPOLARIZATION; NEUROENDOCRINE PEPTIDE; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING	Neuropeptides like galanin produced and released by small cell lung cancer (SCLC) cells are considered principal mitogens in these tumors. We identified the galanin receptor type 2 (GALR2) as the only galanin receptor expressed in H69 and H510 cells. Photoaffinity labeling of G proteins in H69 cell membranes revealed that GALR2, activates G proteins of three subfamilies: G(q), G(i), and G(12). In H-69 cells, galanin-induced Ca2+ mobilization was pertussis toxin-insensitive. While phorbol ester-induced extracellular signal-regulated kinase (ERK) activation required protein kinase C (PKC) activity, preincubation of 1169 cells with the PKC-inhibitor GF109203X had no effect on galanin-dependent ERK activity. A rise of the intracellular calcium concentration was necessary and sufficient to mediate galanin-induced ERK activation, In support of Gi coupling, stimulation of GALR2 expressed in HEK293 cells inhibited isoproterenol-induced cAMP accumulation and raised cAMP levels in COS-7 cells when coexpressed with a chimeric G alpha(S)-G alpha(i) protein. In 1169 cells, galanin activated the monomeric GTPase RhoA and induced stress fiber formation in Swiss 3T3 cells expressing GALR2, Thus, we provide the first direct evidence that in SCLC the mitogenic neuropeptide galanin, interacting with GALR2, simultaneously activates multiple classes of G proteins and signals through the Gq phospholipase C/calcium sequence and a G(12)/Rho pathway.	Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; Univ Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Philipps University Marburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.			Grosse, Robert/0000-0002-3380-5273; Gohla, Antje/0000-0002-7442-1487				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BEDECS K, 1995, INT J BIOCHEM CELL B, V27, P337, DOI 10.1016/1357-2725(95)00008-D; Beekman A, 1998, CANCER RES, V58, P910; BEPLER G, 1988, J CANCER RES CLIN, V114, P235, DOI 10.1007/BF00405828; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bloomquist BT, 1998, BIOCHEM BIOPH RES CO, V243, P474, DOI 10.1006/bbrc.1998.8133; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1985, LIFE SCI, V37, P105, DOI 10.1016/0024-3205(85)90413-8; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pang L, 1998, J NEUROCHEM, V71, P2252; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SETHI T, 1991, CANCER RES, V51, P1674; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, CANCER RES, V56, P5758; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Tokman MG, 1997, CANCER RES, V57, P1785; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VIALLET J, 1990, J CLIN INVEST, V86, P1904, DOI 10.1172/JCI114923; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; Wang SK, 1998, DRUG NEWS PERSPECT, V11, P458; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	71	94	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4199	4209		10.1038/sj.onc.1203777	http://dx.doi.org/10.1038/sj.onc.1203777			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980593				2022-12-28	WOS:000089032900002
J	Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J				Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J			Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8	ONCOGENE			English	Article						Ewing tumors; p53; caspase S; transcription; early phase; apoptosis; PIG-3; TRAIL	IRRADIATION-INDUCED APOPTOSIS; TEMPERATURE-SENSITIVE MUTANT; ZINC-FINGER PROTEIN; BCL-X-L; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; HUMAN P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS	To dissect the p53-dependent apoptotic pathway events following induction of temperature sensitive (ts) p53val138 were studied in a Ewing tumor cell line. Transcriptional deregulation of p53 targets first observable after 1 h at 32 degrees C preceded activation of caspases and the break-down of mitochondrial respiratory activity. Activation of caspases was first observed 4 h after p53 induction. Using peptide inhibitors we identified activation of caspase 8 upstream of caspases-9 and -3. Although the caspase 8 specific inhibitor z-IETD.fmk did not affect translocation of BAX to the mitochondrial membrane and cytochrome C release it almost completely blocked cleavage of the prototype caspase substrate PARP and DNA fragmentation while enforcing mitochondrial depolarization and production of reactive oxygene species (ROS). Activation of caspase 8 did not involve death-domain receptor signaling. Expression of BCL2 only partially suppressed caspase activation but blocked apoptosis, Replacement of the N-terminus of p53val138 by the related VP16 transactivation domain created a ts p53 with a tanscriptional activity indistinguishable from p53val138 until the time of caspase activation. However, the VP16-p53 fusion failed to trigger caspases and subsequent induction of the ROS producing gene pig3 paralleled by complete loss of apoptotic activity. These results indicate that p53-dependent transcriptional deregulation, triggering of the caspase cascade and the mitochondrial break-down occur in a timely ordered sequence coordinated by the genuine p53 amino terminus and suggest caspase 8 and PIG3 as key regulatory elements in this process.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Vienna, Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital; University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Kovar, Heinrich/0000-0001-6873-9109				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD SC, 1990, CANCER RES, V50, P38; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sheikh MS, 1998, CANCER RES, V58, P1593; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Theis S, 1997, INT J CANCER, V71, P858; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	59	32	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4096	4107		10.1038/sj.onc.1203780	http://dx.doi.org/10.1038/sj.onc.1203780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962570				2022-12-28	WOS:000088955100003
J	Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S				Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S			The polo-like kinase Plx1 prevents premature inactivation of the APC(Fizzy)-dependent pathway in the early Xenopus cell cycle	ONCOGENE			English	Article						Plx1; cyclin; APC/cyclosome; microcystin; phosphatase	ANAPHASE-PROMOTING COMPLEX; AMPHIBIAN EGGS; CHROMOSOME SEGREGATION; INTERPHASE EXTRACTS; MEIOTIC METAPHASE; MITOTIC CYCLINS; OKADAIC ACID; M-PHASE; MITOSIS; PROTEOLYSIS	Members of the polo-like family of protein kinases have been involved in the control of APC (anaphase-promoting complex) during the cell cycle, Set how they activate APC is not understood in any detail. In Xenopus oocytes, Cati-dependent degradation of cyclin B associated with release from arrest at second meiotic metaphase was demonstrated to require the polo-like kinase Plx1. The aim of the present study mas to examine, beyond Ca2+-dependent resumption of meiosis, the possible role of Plx1 in the control of cyclin degradation during the early mitotic cell cycle, Plx1 was found to be dispensable for MPF to turn on the cyclin degradation machinery, However, it is required to prevent premature inactivation of the APC-dependent proteolytic pathway. Microcystin suppresses the requirement for Plx1 in both Ca2+-dependent exit from meiosis, associated with degradation of both cyclin B and A downstream of CaMK2 activation, and prevention of premature APC(Fizzy) inactivation in the early mitotic cell cycle, These results are consistent with the view that Plx1 antagonizes an unidentified microcystin-sensitive phosphatase that inactivates APC(Fizzy).	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Galas, S (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Galas, Simon/X-1312-2019; labbe, jean-claude/B-2277-2009; CASTRO, ANNA/F-4350-2010	Galas, Simon/0000-0002-1717-1266; CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				Abrieu A, 1998, J CELL SCI, V111, P1751; Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brown KD, 1996, J CELL SCI, V109, P961; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	44	19	22	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3782	3790		10.1038/sj.onc.1203724	http://dx.doi.org/10.1038/sj.onc.1203724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949933				2022-12-28	WOS:000088568400011
J	Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M				Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M			SCF beta-TRCP and phosphorylation dependent ubiquitination of I kappa B alpha catalyzed by Ubc3 and Ubc4	ONCOGENE			English	Article						I kappa B alpha; NF kappa B; SCF beta-TRCP; cullin; ubiquitin	F-BOX PROTEIN; LIGASE COMPLEX; ENZYME CDC34; HUMAN CUL-1; CELL-CYCLE; DEGRADATION; CATENIN; FAMILY; PATHWAY; SKP1	NF kappa B is an important transcriptional regulator of multiple pro-inflammatory genes. In non-stimulated cells NF kappa B is anchored in the cytoplasm via the inhibitory protein I kappa B alpha. Following exposure to diverse proinflammatory signals (e.g. TNF alpha, IL1, LPS) various signal transduction cascades are initiated converging on the I kappa B kinase (IKK). IKK phosphorylates I kappa B alpha on serines 32 and 36 signaling the inhibitory protein for ubiquitin-mediated degradation. The SCFbeta-TRCP complex is the ubiquitin ligase responsible for mediating phosphorylation dependent ubiquitination of I kappa-B alpha. Here we reconstitute phosphorylation dependent ubiquitination of I kappa B alpha using recombinant components. Our results suggest that the cullin specificity of the SCF complex may reflect its ability to associate with Rbx1, We demonstrate specific ubiquitination of I kappa B alpha by Ubc3 and Ubc4 in a phosphorylation and SCFbeta-TRCP dependent manner and that both are capable of associating with the SCFbeta-TRCP complex isolated from human cells. Finally, we show that Ubc4 is in excess to Ubc3 in THP.1 cells and 19 times more efficient in catalyzing the reaction, suggesting that Ubc4 is the preferentially used Ubc in this reaction in vivo. Our results also suggest that ubiquitin is transferred directly from the Ubc to phospho-I kappa B alpha in a SCFbeta-TRCP dependent reaction.	Mitotix Inc, Cambridge, MA 02139 USA; DuPont Pharmaceut Co, Wilmington, DE 19880 USA	DuPont	Caligiuri, M (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600,Suite 622, Cambridge, MA 02139 USA.			Strack, Peter/0000-0003-4042-0416				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P93; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Vuillard L, 1999, FEBS LETT, V455, P311, DOI 10.1016/S0014-5793(99)00895-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	37	36	39	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3529	3536		10.1038/sj.onc.1203647	http://dx.doi.org/10.1038/sj.onc.1203647			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918611				2022-12-28	WOS:000088346500009
J	Skalski, V; Lin, ZY; Choi, BY; Brown, KR				Skalski, V; Lin, ZY; Choi, BY; Brown, KR			Substrate specificity of the p53-associated 3 '-5 ' exonuclease	ONCOGENE			English	Article						p53; 3 '-5 ' exonuclease; mismatches; DNA double-strand breaks	DNA-REPLICATION FIDELITY; C-TERMINAL DOMAIN; P53 CORE DOMAIN; WILD-TYPE; 3'-TO-5' EXONUCLEASE; POLYMERASE-ALPHA; N-TERMINUS; PROTEIN; REPAIR; DAMAGE	p53 exhibits 3'-5' exonuclease activity and the significance of this biochemical function is currently not defined. In order to gain information about the potential role(s) of this exonuclease activity, recombinant and wild-type human p53 was examined for excision of nucleotides from defined synthetic DNA substrates. p53 removes nucleotides threefold faster from single-strand DNA than from DNA duplexes, exhibits a 1.5-fold preference for 3'-terminals of DNA that contain a single nucleotide mispair (mismatch) as compared to correctly paired DNA and efficiently excises nucleotides from 3'-ends of blunt and cohesive (staggered) DNA double-strand breaks, The p53 exonuclease is predominantly non-processive on DIVA which is 17 nucleotides long (or shorter) and processive on the longer 30-mers, The processivity of nucleotide excision is decreased in the presence of 50 mM potassium phosphate and eliminated when full-length p53 is replaced with the core domain, comprised of amino acids 82-292, Photoaffinity labeling indicates that (1) p53 monomers, rather than dimers, bind to single-strand forms of these oligomers; (2) complexes between p53 and 30-mers are more stable than those formed with 17-mers, The stability of these complexes determines processivity during nucleotide removal and modulates the 3'-5' exonuclease activity of p53. The relevance of substrate specificity of the p53 exonuclease to DNA repair is discussed.	Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Skalski, V (corresponding author), Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Brown, Kevin/0000-0002-5514-2538				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BELYAKOVA NV, 1993, EUR J BIOCHEM, V217, P493, DOI 10.1111/j.1432-1033.1993.tb18269.x; BRYANT PE, 1994, INT J RADIAT BIOL, V66, P597, DOI 10.1080/09553009414551681; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Chuang YYE, 1999, CANCER RES, V59, P3073; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARPER JW, 1993, CELL, V75, P805; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLESNIKOV VA, 1981, FEBS LETT, V132, P101, DOI 10.1016/0014-5793(81)80437-1; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LALUMIERE M, 1995, BACULOVIRUS EXPRESSI, P161; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLAS AL, 1994, MOL CELL BIOL, V14, P170; NISHINO H, 1995, ONCOGENE, V11, P263; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pelicano H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P28; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Rogers S G, 1980, Methods Enzymol, V65, P201; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Shevelev IV, 1996, MUTAT RES-FUND MOL M, V352, P51, DOI 10.1016/0027-5107(95)00230-8; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TARUNINA M, 1993, ONCOGENE, V8, P3165; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; ZU L, 1999, BIOCHEM BIOPH RES CO, V259, P262	47	28	29	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3321	3329		10.1038/sj.onc.1203649	http://dx.doi.org/10.1038/sj.onc.1203649			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918588				2022-12-28	WOS:000088019300010
J	Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L			Unique carboxyl-terminal sequences of wild type and alternatively spliced variant forms of transforming growth factor-alpha precursors mediate specific interactions with ErbB4 and ErbB2	ONCOGENE			English	Article						TGF-alpha variants; ErbBs; protein interaction; CHO cells	SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; PROTGF-ALPHA; NEU PROTOONCOGENE; VALINE RESIDUES; PDZ DOMAINS; PROTEIN; BETACELLULIN; MEMBRANE; COEXPRESSION	We have previously reported that the human transforming growth factor-alpha (TGF-alpha) gene encodes three forms of TGF-alpha precursors, designated wild type (WT), variant I (VaI), and variant II (VaII), derived from alternative splicing, The two carboxyl-terminal valine residues of WT are replaced by 5 (GCRLY) or 4 (ATLG) amino acids in VaI or VaII, respectively. When overexpressed in Chinese hamster ovary (CHO) cells, VaI and VaII, but not WT, support autonomous growth, We detected tyrosine phosphorylation of ErbB2 in the absence of serum, in CHO cells expressing WT, VaI, or VaII, but not in mock transfectants. These observations prompted us to investigate possible interactions between the ErbBs and the TGF-alpha precursors in CHO cells. All TGF-alpha precursors mere found to co-immunoprecipitate with the ErbBs. but with different specificity, WT co-immunoprecipitated with ErbB4, but not with ErbB1, ErbB2, or ErbB3, VaI and VaII co-immunoprecipitated with ErbB2, but not with ErbB1, ErbB3, or ErbB4. Confocal fluorescent microscopy analysis demonstrated that WT, VaI. and VaII all distribute equally to the cell surface while, as expected, a WT mutant lacking the tno C-terminal value residues does not. Point and deletion mutants involving the unique carboxyl-terminal residues of WT, Val and VaII, indicated that the interactions between the three TGF-alpha precursors and the ErbBs were mediated by their carboxyl-terminal regions, which constitute distinct protein-binding motifs, A chimera of the intracellular domain of WT TGF-alpha linked to exogenous transmembrane and extracellular domains retained both the cell surface distribution and the specific interaction with ErbB4 of full-length WT, confirming that this interaction is mediated by the C-terminus of the TGF-a precursor. While interactions of WT and variant TGF-alpha with the ErbBs all result in ErbB2 activation, they produce different biological consequences, suggesting that the various TGF-alpha precursors differentially modulate ErbB signaling.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER; NCI NIH HHS [CA62094] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LEE DC, 1995, PHARMACOL REV, V47, P51; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; NAKAMURA T, 1994, GENE, V140, P251, DOI 10.1016/0378-1119(94)90553-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Urena JM, 1999, J CELL SCI, V112, P773; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; Xu XZ, 1999, ONCOGENE, V18, P5554, DOI 10.1038/sj.onc.1203091; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3172	3181		10.1038/sj.onc.1203645	http://dx.doi.org/10.1038/sj.onc.1203645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918572				2022-12-28	WOS:000088019200006
J	Frost, V; Sinclair, AJ				Frost, V; Sinclair, AJ			p27(KIP1) is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis	ONCOGENE			English	Article						p27KIP1; apoptosis; caspase; z-VAD-fmk; EBV	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; GROWTH-FACTOR-BETA; CYCLE ARREST; MDM2 ONCOPROTEIN; ACTIVATION; CLEAVAGE; PROTEIN; RAPAMYCIN; DEATH	The cyclin-dependent kinase inhibitor p27(KIP1) is a crucial component of the mammalian restriction point, and as such is subject to multiple regulatory mechanisms. It has recently been shown that the abundance of p27(KIP1) is also regulated during apoptosis; p27K'P' is cleaved by a Z-VAD-fmk-sensitive caspase during apoptosis induced by growth factor deprivation in endothelial cells, and also following exposure of myeloid leukaemia cells to etoposide. Here, we investigate p27(KIP1) regulation in B- and T-lymphoid cells undergoing apoptosis, We observe that p27(KIP1) is down-regulated following exposure to a variety of apoptotic stimuli including an agonistic anti-Fas antibody, cycloheximide and etoposide. Further investigation revealed the existence of two different routes of p27K'P' regulation in lymphoid cells undergoing apoptosis. The first pathway is utilized by lymphoid cells stimulated through Fas, is abrogated in a caspase-8-deficient T-cell line, and is blocked by the caspase inhibitors z-VAD-fmk and Boc-D-fmk. In contrast, the loss of p27(KIP1) in cells exposed to cycloheximide and etoposide occurs in the absence of caspase-8 or any z-VAD-fmk- or Boc-D-fmk-sensitive caspase activities. Thus the down-regulation of p27(KIP1) is a common occurrence in lymphoid cells undergoing apoptosis but, depending on the apoptotic trigger, this can be affected by two different mechanisms.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Frost, V (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MENEZES J, 1975, BIOMEDICINE, V22, P276; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	35	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3115	3120		10.1038/sj.onc.1203657	http://dx.doi.org/10.1038/sj.onc.1203657			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871865				2022-12-28	WOS:000087903900010
J	Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M				Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M			Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia	ONCOGENE			English	Article						chromosome 14q32; T-cell leukemia; TML1; TCL1; MTCP-1; translocation	ATAXIA-TELANGIECTASIA; LOCUS; TRANSLOCATIONS; RECEPTOR; NEOPLASIA; PATIENT; REVEALS; SUBUNIT; GROWTH; 14Q11	A region on chromosome 14q32.1 is often involved in chromosomal translocations and inversions with one of the T-cell receptor loci in T-cell lymphoproliferative diseases. The breakpoints of the different rearrangements segregate into two clusters; a cluster due to inversion on the centromeric side and a cluster due to simple balanced translocations on the telomeric side. If the target gene activated by these different types of chromosomal rearrangements is the same, the gene must be localized between the two clusters of breakpoints in a region of around 160 kb, Within this breakpoint cluster region, we isolated two genes; namely, TCL1 and TML1/TCL1b genes. In the course of characterizing the TML1 gene, we further identified a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus. The TCL6 gene expressed at least 11 isoforms through very complex alternative-splicing, including splicing with the TML1 gene. Those isoforms encode at least five open reading frames (ORFs) with no homology to known sequences. The localization of the proteins corresponding to these ORF was determined by fusing green fluorescence protein at the carboxyl terminal of each ORF. ORF141 and ORF72 were observed in the cytoplasmic region, while ORF105, ORF119, and ORF163 were predominantly localized in the nuclear region. Since the TCL6 gene was expressed in T-cell leukemia carrying a t(14;14) (q11;q32.1) chromosome translocation and was not expressed in normal T-cells (just like the TML1 and TCL1 genes), it is also a candidate gene potentially involved in leukemogenesis.	Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan; IDI IRCCS, Res Labs, I-00167 Rome, Italy	University of Toyama; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Isobe, M (corresponding author), Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan.		Russo, Giandomenico/K-9566-2016	Russo, Giandomenico/0000-0002-7718-9687				BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; Goswami S, 1998, J NEUROCHEM, V71, P1837; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KANZAKI T, 1992, CANCER, V69, P1034, DOI 10.1002/1097-0142(19920215)69:4<1034::AID-CNCR2820690434>3.0.CO;2-E; KUBONISHI I, 1991, AM J HEMATOL, V37, P179, DOI 10.1002/ajh.2830370309; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1985, NATURE, V316, P549, DOI 10.1038/316549a0; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; SMITH SD, 1989, BLOOD, V73, P2182; STEM MH, 1996, PATHOL BIOL PARIS, V44, P689; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	20	37	38	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2796	2802		10.1038/sj.onc.1203604	http://dx.doi.org/10.1038/sj.onc.1203604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851082				2022-12-28	WOS:000087318500010
J	Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M				Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M			Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment	ONCOGENE			English	Article						melanoma; metastasis; apoptosis; transcriptional regulation	ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; WILD-TYPE P53; HUMAN MELANOCYTES; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; INDUCED APOPTOSIS; DOWN-REGULATION; C-KIT; CELLS	Activating transcription factor-1 (ATF-1) and cAMP-responsive element (CRE)-binding protein (CREB) have been implicated in cAMP and Ca2+-induced transcriptional activation. The expression of the transcription factors CREB and ATF-1 is upregulated in metastatic melanoma cells. However, how overexpression of ATF-1/CREB contributes to the acquisition of the metastatic phenotype remains unclear. Here, the effect of disrupting ATF-1 activity was investigated using intracellular expression of an inhibitory anti-ATF-1 single chain antibody fragment (ScFv), Intracellular expression of ScFv anti-ATF-1 in MeWo melanoma cells caused significant reduction in CRE-dependent promoter activation. In addition, expression of ScFv anti-ATF-1 in melanoma cells suppressed their tumorigenicity and metastatic potential in nude mice. ScFv anti-ATF-1 rendered the melanoma cells susceptible to thapsigargin-induced apoptosis in vitro and caused massive apoptosis in tumors transplanted subcutaneously into nude mice, suggesting that ATF-1 and its associated proteins act as survival factor for human melanoma cells. This is the first report to demonstrate the potential of ScFv anti-ATF-1 as an inhibitor of tumor growth and metastasis of solid tumor in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Texas System; UTMD Anderson Cancer Center; University of Nebraska System; University of Nebraska Medical Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404	NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER; NCI NIH HHS [CA76098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; Bussfeld D, 1997, IMMUNOBIOLOGY, V198, P291, DOI 10.1016/S0171-2985(97)80049-6; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Grim J, 1996, AM J RESP CELL MOL, V15, P348, DOI 10.1165/ajrcmb.15.3.8810638; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; ISHIKAWA M, 1988, CANCER RES, V48, P665; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; KOPF AW, 1995, CANCER-AM CANCER SOC, V75, P684, DOI 10.1002/1097-0142(19950115)75:2+<684::AID-CNCR2820751411>3.0.CO;2-B; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LIU F, 1993, J BIOL CHEM, V268, P6714; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; RADINSKY R, 1994, ONCOGENE, V9, P1877; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGH RK, 1995, CANCER RES, V55, P3669; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILE RG, 1994, CANCER RES, V54, P6228; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	53	57	60	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2721	2730		10.1038/sj.onc.1203569	http://dx.doi.org/10.1038/sj.onc.1203569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851072				2022-12-28	WOS:000087193000008
J	Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F				Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F			ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin	ONCOGENE			English	Article						angiogenesis; endothelium; adhesion; transcription	BINDING-SITES; PLASMINOGEN-ACTIVATOR; TRANSGENIC MICE; GENE PROMOTER; CHICK-EMBRYO; DNA-BINDING; TRANSCRIPTION; C-ETS-1; GROWTH; PROTEIN	Ets1 is a transcription factor expressed in endothelial cells during angiogenesis but its target genes and function in blood vessel formation are still unknown. We have over-expressed Ets1 as a tagged protein in brain capillary endothelial cells and in 3T3 fibroblasts using a retroviral vector. Over-expression of Ets1 reduced by nearly half cell density at confluence of endothelials but not of fibroblasts, As density at confluence is controlled in part by cadherins, this growth arrest could be due to the up-regulation of these cell contact molecules. Indeed, Ets1 increased the expression of the endothelial-specific VE-cadherin without affecting N-cadherin expression levels. In parallel, both dominant negative mutant of Ets members and an Ets1 anti-sense oligonucleotide inhibited VE-cadherin expression in endothelial cells, Ets1 bound to two Ets-binding sites located in the proximal region of the VE-cadherin promoter. Mutation of these sites abolished Ets1-induced transactivation of the promoter. The present work is the first demonstration of a function of Ets1 in the regulation of a specific endothelial marker based on its endogenous gene and protein expression.	Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, F-59021 Lille, France; CEA, Lab Transgenese & Differenciat Cellulaire, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CEA	Soncin, F (corresponding author), Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009; Huber, Philippe/C-7971-2019	SONCIN, Fabrice/0000-0001-6312-0673; Huber, Philippe/0000-0002-4153-7694; Lelievre, Etienne/0000-0003-0452-1578				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; COFFER P, 1994, ONCOGENE, V9, P911; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER RJ, 1991, ONCOGENE, V6, P2249; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OKA T, 1991, ONCOGENE, V6, P2077; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; QUEVA C, 1993, ONCOGENE, V8, P2511; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1990, ONCOGENE, V5, P1761; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Telo P, 1998, J BIOL CHEM, V273, P17565, DOI 10.1074/jbc.273.28.17565; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	51	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2438	2446		10.1038/sj.onc.1203563	http://dx.doi.org/10.1038/sj.onc.1203563			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828886				2022-12-28	WOS:000087018400009
J	Baserga, R				Baserga, R			The contradictions of the insulin-like growth factor 1 receptor	ONCOGENE			English	Review						insulin-like growth factor 1 receptor; differentiation; cell size; cytoskeleton; transformation	GROWTH-FACTOR-I; FOCAL ADHESION KINASE; DOMINANT-NEGATIVE MUTANT; PROSTATE-CANCER CELLS; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSFORMING ACTIVITIES; SIGNALING PATHWAYS; ANTISENSE RNA; CONSTITUTIVE EXPRESSION	In recent years, the type I insulin-like growth factor receptor (IGF-IR) has emerged as a receptor that plays a very important role in the growth of cells, both in vivo and in vitro. The ability of the IGF-IR to induce mitogenesis and to promote survival of cells against a variety of apoptotic agents is well documented. Somewhat less known are other functions of the ICF-IR, like its ability to induce differentiation, to regulate cell size and to affect the organization of the cytoskeleton of cells. This review will focus on these lesser known functions of the IGF-IR, At the same time, we will emphasize how the IGF-IR can send contradictory signals, which depend on different domains of the receptor and the availability of downstream transducing molecules.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 56309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; Baserga R, 1999, CONT ENDOCRINOL, V17, P329; BASERGA R, 1985, BIOL CELL REPRODUCTI, P251; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brown G, 1999, EXP CELL RES, V253, P511, DOI 10.1006/excr.1999.4660; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Carson JP, 1999, CANCER RES, V59, P1449; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Davies MA, 1999, CANCER RES, V59, P2551; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; Hongo A, 1996, ONCOGENE, V12, P1231; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lee CT, 1996, CANCER RES, V56, P3038; Leventhal PS, 1999, CONT ENDOCRINOL, V17, P425; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu Q, 1998, J IMMUNOL, V160, P1393; Liu XD, 1998, CANCER RES, V58, P5432; LONG L, 1995, CANCER RES, V55, P1006; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Navarro M, 1997, ENDOCRINOLOGY, V138, P5210, DOI 10.1210/en.138.12.5210; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Soon L, 1999, MOL CELL BIOL, V19, P3816; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steller MA, 1996, CANCER RES, V56, P5087; Stewart CEH, 1996, J CELL PHYSIOL, V169, P23, DOI 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; SURMACZ E, 1987, MOL CELL BIOL, V7, P657, DOI 10.1128/MCB.7.2.657; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VALENTINIS B, 2000, IN PRESS J BIOL CHEM; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Werner H, 1999, CONT ENDOCRINOL, V17, P63; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	109	208	225	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5574	5581		10.1038/sj.onc.1203854	http://dx.doi.org/10.1038/sj.onc.1203854			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114737				2022-12-28	WOS:000165659300004
J	Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM				Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM			Inhibition of farnesyltransferase increases TGF beta type II receptor expression and enhances the responsiveness of human cancer cells to TGF beta	ONCOGENE			English	Article						farnesyltransferase inhibitors; Ras; transforming growth factor beta; tumor growth and transformation	GROWTH-FACTOR-BETA; TRANSFORMED THYROID-CELLS; FAMILY MEDIATOR SMAD1; GTP-BINDING PROTEIN; K-RAS; SIGNALING PATHWAYS; TRANSGENIC MICE; H-RAS; N-RAS; EPITHELIAL-CELLS	Several small GTPases of the Ras superfamily have been shown to antagonize TGF beta signaling in human tumor cell lines. Some of these GTPases are post-translationally modified by farnesylation, a lipid modification catalyzed by farnesyltransferase and required for the proteins to attach to membranes and to function. In this study, we investigated the effect of the farnesyltransferase inhibitor FTI-277 on TGF beta -regulated cell growth and transcription. Treatment of the human pancreatic tumor cell line, Panc-1, with FTI-277 enhanced the ability of TGF beta to inhibit both anchorage-dependent and -independent tumor cell growth. FTI-277 also enhanced the ability of TGF beta to induce transcription, as measured by p3TP-lux reporter activity and collagen synthesis. The enhancement of TGF beta responses by FTI-277 correlated with the stimulation of transcription and protein expression of type II TGF beta receptor (T beta RII). Consequently, FTI-277-treated cells exhibited a higher level of TGF beta binding to its receptor. Thus, inhibition of protein farnesylation stimulates T beta RII expression, which leads to increased TGF beta receptor binding and signaling as well as inhibition of tumor cell growth and transformation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CARMICHAEL J, 1987, CANCER RES, V47, P936; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Choi SE, 1999, CELL SIGNAL, V11, P71, DOI 10.1016/S0898-6568(98)00033-3; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; FILMUS J, 1992, ONCOGENE, V7, P521; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Kim YS, 1999, ARCH PHARM RES, V22, P1, DOI 10.1007/BF02976427; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kohl NE, 1999, ANN NY ACAD SCI, V886, P91, DOI 10.1111/j.1749-6632.1999.tb09404.x; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lobell RB, 1998, CANCER METAST REV, V17, P203, DOI 10.1023/A:1006018922878; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mangues R, 1998, CANCER RES, V58, P1253; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MunozAntonia T, 1996, CANCER RES, V56, P4831; Norgaard P, 1999, ANN NY ACAD SCI, V886, P265, DOI 10.1111/j.1749-6632.1999.tb09432.x; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Omer CA, 2000, CANCER RES, V60, P2680; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SERRA R, 1992, CELL GROWTH DIFFER, V3, P693; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHAO J, 1995, CANCER RES, V55, P6181; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	70	19	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5525	5533		10.1038/sj.onc.1203920	http://dx.doi.org/10.1038/sj.onc.1203920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114730				2022-12-28	WOS:000165396100013
J	Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J				Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J			Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers	ONCOGENE			English	Article						p73; monoallelic expression; inflammatory breast carcinoma	TUMOR-SUPPRESSOR GENE; P53; MUTATION; OVEREXPRESSION; PROTEIN; NEUROBLASTOMA; CARCINOMA; DELETION	The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted. To study whether p73 was associated with breast carcinogenesis, loss of heterozygosity (LOH), allele expression and transcript levels were assessed in 59 BC, including 39 BC presenting no inflammatory symptoms (NBC) and 20 inflammatory BC (IBC). IBC is a rare but aggressive form of cancer with a very Door prognosis. Normal breast epithelium (BE) and lymphocytes from patients were used as controls. StyI polymorphism generating GC and/or AT alleles was used to select 22 heterozygous patients, p73 LOH was significantly higher in IBC than in NBC [five of eight cases (62%) versus two of 14 cases (14%); Fisher's exact test, P = 0.05]. p73 was biallelically expressed in all BE. In contrast, 12 of 16 (75%) BC were monoallelically expressed, showing that allele silencing was significantly associated with breast carcinogenesis (P = 0.012), AT being the preferential silent allele (10 out of 12 tumours). p73 mRNA levels in NBC and IBC were two- and threefold lower than in BE, respectively, suggesting that decreased expression could be related to tumour aggressiveness. In conclusion, LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Anatomopathol, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Chirurg, F-94800 Villejuif, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Sanofi-Aventis; Sanofi France	Benard, J (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, Rue Camille Desmoulins, F-94800 Villejuif, France.		Laurent, Zelek/F-2906-2017	Laurent, Zelek/0000-0001-7455-2009				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BEAHRS OH, 1992, AM JOINT COMMITTEE C, P149; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIECHE I, 1994, CANCER RES, V54, P4274; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; PETER M, 1992, INT J CANCER, V52, P544, DOI 10.1002/ijc.2910520408; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SHITTOOR SR, 1998, BREAST COMPREHENSIVE, V2, P1260; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257	22	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5413	5418		10.1038/sj.onc.1203914	http://dx.doi.org/10.1038/sj.onc.1203914			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103943				2022-12-28	WOS:000165302300013
J	Gouble, A; Morello, D				Gouble, A; Morello, D			Synchronous and regulated expression of two AU-binding proteins, AUF1 and HuR, throughout murine development	ONCOGENE			English	Article						AU-rich element; c-myc mRNA; murine development; hnRNP proteins; mRNA turnover	MESSENGER-RNA STABILITY; RICH ELEMENT; NEUROGENIC CELLS; TRANSGENIC MICE; ELAV PROTEINS; GENE; IDENTIFICATION; DEGRADATION; GROWTH; PURIFICATION	The AUF1 (hnRNPD) and HuR (ELAV-like) proteins, potential trans-acting factors for regulated mRNA decay, bind in vitro to A+U-rich elements (AREs) found in the 3' untranslated region (3' UTR) of many labile transcripts. In an effort to determine whether these trans-acting factors are likely to play a role in embryogenesis, we have analysed their expression during mouse development both at the mRNA and protein levels. We show that AUF1 and HuR are expressed at all the developmental stages analysed from day 8.5 of embryonic development to adulthood. Expression levels are dynamic, varying between tissues and developmental stages. However, a strong positive correlation between AUF1 and HuR protein levels was observed in all examined tissues. Finally, we compared AUF1 and HuR expression with accumulation of one common target mRNA, c-myc. The similar spatio-temporal distribution of these proteins and of c-myc mRNA is in agreement with a potential concerted role in ARE-mediated control of mRNA stability.	Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Morello, D (corresponding author), Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 4, France.							Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENICS T, 1994, J BIOL CHEM, V269, P5377; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perron M, 1999, MECH DEVELOP, V84, P139, DOI 10.1016/S0925-4773(99)00056-8; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	51	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5377	5384		10.1038/sj.onc.1203910	http://dx.doi.org/10.1038/sj.onc.1203910			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103939				2022-12-28	WOS:000165302300009
J	Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H				Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H			Age-dependent spontaneous mutagenesis in Xpc mice defective in nucleotide excision repair	ONCOGENE			English	Article						nucleotide excision repair; Hprt; mutation; cancer; transgenic mice	DNA-REPAIR; INCREASED SUSCEPTIBILITY; PYRIMIDINE DIMERS; DHFR GENE; DAMAGE; ACCUMULATION; MUTATIONS; APOPTOSIS; INDUCTION; P53	DNA damages caused by cellular metabolites and environmental agents induce mutations, that may predispose to cancer. Nucleotide excision repair (NER) is a major cellular defence mechanism acting on a variety of DNA lesions. Here, we show that spontaneous mutant frequencies at the Hplt gene increased 30-fold in T-lymphocytes of 1 year old Xpc(-/-) mice, possessing only functional transcription-coupled repair (TCR), Hprt mutant frequencies in Xpa(-/-) and Csb(-/-) mice that both have a defect in this NER subpathway, remained low during ageing. In contrast to current models, the elevated mutation rate in Xpc(-/-) mice does not lead to an increased tumour incidence or premature ageing.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, NL-2333 AL Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA; Natl Inst Publ Hlth & Environm, RIVM, Hlth Effects Res Lab, Dept Carcinogenesis Mutagenesis & Genet, NL-3720 BA Bilthoven, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Netherlands National Institute for Public Health & the Environment	Vrieling, H (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		van der Horst, Gijsbertus TJ/E-3661-2015; Vrieling, Harry/ABC-8068-2020	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Vrieling, Harry/0000-0002-3034-2664				Ananthaswamy HN, 1999, ONCOGENE, V18, P7395, DOI 10.1038/sj.onc.1203147; BERG RJW, 2000, IN PRESS CANC RES; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Cheo DL, 2000, CANCER RES, V60, P1580; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KURAOKA I, 2000, IN PRESS P NATL ACAD; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 1996, ONCOGENE, V13, P823; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Odagiri Y, 1998, NAT GENET, V19, P116, DOI 10.1038/468; Reis AM, 2000, CANCER RES, V60, P1571; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TATES AD, 1994, MUTAT RES-FUND MOL M, V309, P299, DOI 10.1016/0027-5107(94)90106-6; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANOOSTEN M, 2000, IN PRESS P NATL ACAD; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; WIJNHOVEN SWP, 2000, IN PRESS CANC RES; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	28	52	53	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5034	5037		10.1038/sj.onc.1203844	http://dx.doi.org/10.1038/sj.onc.1203844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042691				2022-12-28	WOS:000089834300011
J	Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W				Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W			p55CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase	ONCOGENE			English	Article						spindle checkpoint; cell cycle; protein kinase; mitosis	CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; KINETOCHORE LOCALIZATION; PROTEIN-KINASE; BUDDING YEAST; CELLS; P55CDC; MITOSIS; CDC20; GENE; MAD2	Eukaryotic cells have evolved a mechanism that delays the progression of mitosis until condensed chromosomes are properly positioned on the mitotic spindle. We have been studying genes that regulated the spindle checkpoint in human cells. Enforced expression of human BUBR1, but not a BUBR1 mutant allele, enhances accumulation of mitotic cells. Yeast two-hybrid system and GST-pull-down analyses show that p55CDC/hCdc20, a protein known to link spindle checkpoint components such as MAD2 to anaphase promoting complex (APC), interacts with BUBR1, In addition, p55CDC is capable of pulling down BUBR1 in sf-9 cells infected with both p55CDC and His6-BUBR1 recombinant baculoviruses but not in the cells infected with p55CDC baculoviruses or with the baculoviral vector alone. Moreover, immunoprecipitation followed by Western blot analyses confirmed that native p55CDC is associated with BUBR1 in HeLa cells. Spindle checkpoint activation by nocodazole treatment enhances the association between p55CDC and His6-BUBR1, In nocodazole-arrested mitotic cells, both CDC16 and hyperphosphorylated CDC27, two APC components, preferentially associate with His6-BUBR1 resins, but not the control resins, Furthermore, BUBR1 phosphorylates p55CDC in vitro, and the phosphorylation of p55CDC by BUBR1 appears to be correlated with spindle checkpoint activation. Together, our studies strongly suggest that BUBR1 may target APC via p55CDC.	Amer Hlth Fdn, Valhalla, NY 10595 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat & Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90024 USA; Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA	American Health Foundation; Amgen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; University of Cincinnati	Dai, W (corresponding author), Amer Hlth Fdn, 1 Dana Rd, Valhalla, NY 10595 USA.			Sakamoto, Kathleen/0000-0003-0494-8838	NATIONAL CANCER INSTITUTE [R13CA074299] Funding Source: NIH RePORTER; NCI NIH HHS [CA74299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bin OY, 1998, CELL GROWTH DIFFER, V9, P877; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Donadelli R, 1998, BIOCHEM BIOPH RES CO, V246, P881, DOI 10.1006/bbrc.1998.8713; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	25	52	52	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4557	4562		10.1038/sj.onc.1203803	http://dx.doi.org/10.1038/sj.onc.1203803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030144				2022-12-28	WOS:000089438200001
J	de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP				de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP			STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-degendent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						G-CSF; STAT3; p27(Kip1); neutrophilic differentiation; survival	DISTINCT CYTOPLASMIC REGIONS; G-CSF RECEPTOR; TRANSCRIPTION FACTOR; ACTIVATION; STAT3; PROLIFERATION; GENE; GROWTH; SIGNALS; INVOLVEMENT	The signal transducer and activator of transcription (STAT) proteins have been implicated in cytokine-regulated proliferation, differentiation and cell survival. Granulocyte colony-stimulating factor (G-CSF), a regulator of granulocytic differentiation, induces a robust and sustained activation of STAT3. Here, we show that introduction of dominant negative (DN) forms of STAT3 interferes with G-CSF-induced differentiation and survival in murine 32D cells, G-CSF induces expression of the cyclin-dependent kinase (cdk) inhibitor p27(Kip1) (but not p21(Cip1)), which is completely blocked by DN-STAT3. The ability of tyrosine-to-phenylalanine substitution mutants of the G-CSF receptor to activate STAT3 strongly correlated with their capacity to induce p27 expression and their ability to mediate differentiation and survival, suggesting a causal relationship between STAT3 activation, p27 expression and the observed cellular responses. We identified a putative STAT binding site in the promoter region of p27 that showed both STAT3 binding in electrophoretic mobility shift assays and functional activity in luciferase reporter assays, Finally, we studied G-CSF-induced responses in primary bone marrow and spleen cells of p27-deficient mice. Compared with wildtype, myeloid progenitors from p27-deficient mice showed significantly increased proliferation and reduced differentiation in response to G-CSF. These findings indicate that STAT3 controls myeloid differentiation, at least partly, via upregulation of p27(Kip1).	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Dr Daniel Den Hoed Canc Ctr, Dept Hematol, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Touw, IP (corresponding author), Erasmus Univ, Inst Hematol, Room H Ee 13-14,POB 1738, NL-3000 DR Rotterdam, Netherlands.			Ward, Alister/0000-0001-7945-7975				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; Dong F, 1998, J IMMUNOL, V161, P6503; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICOLA NA, 1987, INT J CELL CLONING, V5, P1, DOI 10.1002/stem.5530050102; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	46	110	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3290	3298		10.1038/sj.onc.1203627	http://dx.doi.org/10.1038/sj.onc.1203627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918585				2022-12-28	WOS:000088019300007
J	Robertson, H; Hime, GR; Lada, H; Bowtell, DDL				Robertson, H; Hime, GR; Lada, H; Bowtell, DDL			A Drosophila analogue of v-Cbl is a dominant-negative oncoprotein in vivo	ONCOGENE			English	Article						cbl; oncogene; Drosophila; ubiquitin; endocytosis; EGFR	GROWTH-FACTOR RECEPTOR; C-CBL; EGF RECEPTOR; TYROSINE KINASE; SH3 DOMAIN; MEDIATED ENDOCYTOSIS; HORMONE RECEPTOR; CELL-DEATH; T-CELLS; PROTEIN	Cells rely on the ability to receive and interpret external signals to regulate growth, differentiation, and death. Positive transduction of these signals to the cytoplasm and nucleus has been extensively characterized, and genetic studies in Drosophila have made major contributions to the understanding of these pathways, Less well understood, but equally important, are the mechanisms underlying signal down-regulation. Here me report biochemical and genetic characterization of the Drosophila homologue of c-Cbl, a negative regulator of signal transduction with ubiquitin-protein ligase activity. A new isoform of D-Cbl, D-CblL, has been identified that contains SH3-binding and UBA domains previously reported to he absent. Genetic analysis demonstrates that Dv-cbl, analogous to the mammalian v-cbl oncogene, is a dominant negative mutation able to enhance signalling from the Drosophila Egfr and cooperate with activating mutations in the sevenless pathway to produce melanotic tumours, In addition, our data show genetic and biochemical links between D-Cbl and proteins involved in endocytosis and ubiquitination, suggesting that v-Cbl may exert its oncogenic effect by enhancing receptor signalling as a consequence of suppressing receptor endocytosis.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Bowtell, DDL (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.		Bowtell, David/H-1007-2016; Hime, Gary/B-7162-2015	Bowtell, David/0000-0001-9089-7525; Hime, Gary/0000-0003-4732-3184				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Feldmann P, 1999, MOL CELL BIOL, V19, P1928; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Karim FD, 1998, DEVELOPMENT, V125, P1; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MASUI H, 1991, CANCER RES, V51, P6170; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rorth P, 1998, DEVELOPMENT, V125, P1049; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wieschaus E., 1986, P199; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	58	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3299	3308		10.1038/sj.onc.1203624	http://dx.doi.org/10.1038/sj.onc.1203624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918586				2022-12-28	WOS:000088019300008
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation	ONCOGENE			English	Article						myeloid; c-myc; p53; differentiation; apoptosis	LEUKEMIA INHIBITORY FACTOR; TERMINAL DIFFERENTIATION; GROWTH-INHIBITION; DEATH; EXPRESSION; BCL-2; GENE; PROTOONCOGENES; REGULATORS; ARREST	Previously we have shown that deregulated expression of c-myc in M1 myeloid leukemic cells blocked IL-6-induced differentiation and its associated growth arrest; however, the cells proliferated at a significantly reduced rate compared to untreated cells. The basis for the increased doubling time of IL-6-treated M1myc cells was found to be due to the induction of a p53-independent apoptotic pathway. The apoptotic response was not completely penetrant; in the same population of cells both proliferation and apoptosis were continuously ongoing, Down-regulation of Bcl-2 was insufficient to account for the apoptotic response, since deregulated expression of Bcl-2 delayed, but did not block, the onset of apoptosis, Furthermore, our results indicated that the IL-6-induced partial hypophosphorylation of the retinoblastoma gene product (Rb), observed in M1myc cells, was not responsible for the apoptotic response. Finally, the findings in M1 cells were extended to myeloid cells derived from the bone marrow of wild type and p53-deficient mice, where the deregulated expression of c-myc was also shown to block terminal differentiation and induce apoptosis independent of p53, These findings provide new insights into how myc participates in the neoplastic process, and how additional mutations can promote more aggressive tumors.	Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [IROI CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Eilers M, 1999, MOL CELLS, V9, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAWLEY RG, 1994, ANN NY ACAD SCI, V716, P327, DOI 10.1111/j.1749-6632.1994.tb21724.x; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	44	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2967	2977		10.1038/sj.onc.1203638	http://dx.doi.org/10.1038/sj.onc.1203638			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871848				2022-12-28	WOS:000087581400003
J	Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ				Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ			The chicken c-Jun 5 ' untranslated region directs translation by internal initiation	ONCOGENE			English	Article						c-Jun; translation; internal initiation; 5 ' UTR	RIBOSOME ENTRY SITE; CAP-DEPENDENT TRANSLATION; EUKARYOTIC MESSENGER-RNAS; NF-KAPPA-B; BINDING-PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; 5'-UNTRANSLATED REGION; TRANSCRIPTION FACTORS; SECONDARY STRUCTURE	The 5' untranslated region (UTR) of the chicken c-jun message is exceptionally GC rich and has the potential to form a complex and extremely stable secondary structure. Because stable RNA secondary structures can serve as obstacles to scanning ribosomes, their presence suggests inefficient translation or initiation through alternate mechanisms. We have examined the role of the c-jun 5' UTR with respect to its ability to influence translation both in vitro and in vivo. We find, using rabbit reticulocyte lysates, that the presence of the c-jun 5' UTR severely inhibits translation of both homologous and heterologous genes in vitro. Furthermore, translational inhibition correlates with the degree of secondary structure exhibited by the 5' UTR, Thus, in the rabbit reticulocyte lysate system, the c-jun 5' UTR likely impedes ribosome scanning resulting in inefficient translation. In contrast to our results in vitro, the c-jun 5' UTR does not inhibit translation in a variety of different cell lines suggesting that it may direct an alternate mechanism of translational initiation in vivo, To distinguish among the alternate mechanisms, we generated a series of bicistronic expression plasmids, Our results demonstrate that the downstream cistron, in the bicistronic gene, is expressed to a much higher level when directly preceded by the c-jun 5' UTR, In addition, inhibition of ribosome scanning on the bicistronic message, through insertion of a synthetic stable hairpin, inhibits translation of the first cistron but does not inhibit translation of the cistron downstream of the c-jun 5' UTR, These results are consistent with a model by which the c-jun message is translated through cap independent internal initiation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUKH A, 1990, J IMMUNOL, V144, P4835; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; deQuinto SL, 1997, J VIROL, V71, P4171; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Diamond DA, 1999, J BIOL CHEM, V274, P16959, DOI 10.1074/jbc.274.24.16959; DUTTON CM, 1993, NUCLEIC ACIDS RES, V21, P2953, DOI 10.1093/nar/21.12.2953; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gilby KL, 1997, MOL BRAIN RES, V48, P87, DOI 10.1016/S0169-328X(97)00085-5; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hadman M, 1996, ONCOGENE, V12, P135; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, RNA, V1, P985; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Martinez-Salas E, 1999, CURR OPIN BIOTECH, V10, P458, DOI 10.1016/S0958-1669(99)00010-5; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NISHIMURA T, 1988, ONCOGENE, V3, P659; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sella O, 1999, MOL CELL BIOL, V19, P5429; Sickinger S, 1999, BIOL CHEM, V380, P1217, DOI 10.1515/BC.1999.154; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TOURAY M, 1991, ONCOGENE, V6, P1227; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zuker M., 1999, V70, P11	69	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2836	2845		10.1038/sj.onc.1203601	http://dx.doi.org/10.1038/sj.onc.1203601			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851087				2022-12-28	WOS:000087403600005
J	Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A				Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A			Altered natural killer cell differentiation in CD34(+) progenitors from chronic myeloid leukemia patients	ONCOGENE			English	Article						IL-15; IL-15R; chronic myeloid leukemia; NK cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; INTERLEUKIN-2 RECEPTOR; INTERFERON-GAMMA; HUMAN MONOCYTES; IL-2 RECEPTOR; EXPRESSION; ACTIVATION; IDENTIFICATION; TRANSFORMATION	IL-15 and SCF fail to induce NK differentiation and proliferation of CD34(+) hematopoietic progenitors from chronic myeloid leukemia patients in contrast to normal stem cells although, both normal and leukemic CD34(+) cells display comparable expression of c-kit or IL-15 receptor subunits, Interestingly, confocal microscopy analysis revealed that leukemic and most normal CD34(+) cells produce and secrete IL-15, as shown by its trafficking through the Golgi apparatus and early endosomes, However, only leukemic progenitors express the membrane bound IL-15, Colocalization and internalization of IL-15R beta/gamma c and IL-15R alpha/gamma c complexes indicated that IL-15 was specifically uptaken by leukemic progenitors. We also demonstrated that in both normal and leukemic progenitors, the signaling kinase Jak3 is constitutively pre-associated with the gamma c chain. Anti-IL-15 neutralizing mAb treatment resulted in downregulation of gamma c chain and disruption of gamma c/Jak3 interaction in normal but had no effect in leukemic progenitors. Our results suggest the existence in both normal and leukemic CD34(+) cells of a constitutive production of a bioactive IL-15 that does not lead to NK differentiation and further indicate that membrane bound IL-15 and constitutive activation of gamma c are hallmarks of leukemic progenitors.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Hematol, F-94805 Villejuif, France; Hop Paul Brousse, INSERM 506, F-94807 Villejuif, France; CHU Lille, Serv Hematol, F-59037 Lille, France; Lab Cytometrie, CNRS, UPS 47, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS)	Caignard, A (corresponding author), Inst Gustave Roussy, INSERM, U487, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Chouaib, Salem/F-7939-2016; Castagna, L/ABC-7613-2021; Azzarone, Bruno/AAH-9251-2019; Caignard, Anne/F-8159-2013; Giron-Michel, Julien/Q-4503-2018	Azzarone, Bruno/0000-0002-5962-3849; Caignard, Anne/0000-0001-9923-6045; Giron-Michel, Julien/0000-0001-6613-6099; Castagna, Luca/0000-0002-6239-7387				Alleva DG, 1997, J IMMUNOL, V159, P2941; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; Carayol G, 1998, EUR J IMMUNOL, V28, P1991, DOI 10.1002/(SICI)1521-4141(199806)28:06<1991::AID-IMMU1991>3.0.CO;2-7; Carella AM, 1999, BLOOD, V93, P1534, DOI 10.1182/blood.V93.5.1534.405a05_1534_1539; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Cervantes F, 1996, BLOOD, V87, P2476, DOI 10.1182/blood.V87.6.2476.bloodjournal8762476; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Frassoni F, 1999, BRIT J HAEMATOL, V104, P538, DOI 10.1046/j.1365-2141.1999.01201.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANTARJIAN HM, 1993, BLOOD, V82, P691; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Meazza R, 1996, ONCOGENE, V12, P2187; Mingari MC, 1997, EUR J IMMUNOL, V27, P1374, DOI 10.1002/eji.1830270612; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Musso T, 1999, BLOOD, V93, P3531; NOWELL PC, 1960, SCIENCE, V132, P1497; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; VERFAILLIE C, 1990, BLOOD, V76, P401; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	29	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2758	2766		10.1038/sj.onc.1203584	http://dx.doi.org/10.1038/sj.onc.1203584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851076				2022-12-28	WOS:000087318500004
J	Decker, T; Kovarik, P				Decker, T; Kovarik, P			Serine phosphorylation of STATs	ONCOGENE			English	Article						STAT; signal transduction; phosphorylation; MAP kinase	ACTIVATED PROTEIN-KINASE; INTERFERON-GAMMA; IFN-GAMMA; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; SUBSTRATE RECOGNITION; GENE-EXPRESSION; ALPHA; P38	Tyrosine phosphorylation regulates the dimerization of STATs as an essential prerequisite for the establishment of a classical JAK-STAT signaling path. However, most vertebrate STATs contain a second phosphorylation site within their C-termini, The phosphorylated residue in this case is a serine contained within a P(M)SP motif, and in the majority of situations its mutation to alanine alters transcription factor activity. This review addresses recent advances in understanding the regulation of STAT serine phosphorylation, as well as the kinases and other signal transducers implied in this process. The biochemical and biological consequences of STAT serine phosphorylation are discussed.	Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	Vienna Biocenter (VBC)	Decker, T (corresponding author), Vienna Bioctr, Inst Microbiol & Genet, Dr Bohr Gasse 9, A-1030 Vienna, Austria.		Kovarik, Pavel/D-1184-2014	Kovarik, Pavel/0000-0003-2956-0944; Decker, Thomas/0000-0001-9683-0620				Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Gotoh A, 1996, BLOOD, V88, P138; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Park C, 1999, NUCLEIC ACIDS RES, V27, P4191, DOI 10.1093/nar/27.21.4191; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHURINGA JJ, 2000, IN PRESS BIOCH J; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Stoiber D, 1999, J IMMUNOL, V163, P2640; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; VISCONTI R, 2000, UNPUB; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	74	687	709	2	22	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2628	2637		10.1038/sj.onc.1203481	http://dx.doi.org/10.1038/sj.onc.1203481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851062				2022-12-28	WOS:000087459400019
J	Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo	ONCOGENE			English	Article						prostate; bcl-2; bax; apoptosis; androgen	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; REGULATED EXPRESSION; ANDROGEN-ABLATION; CANCER; APOPTOSIS; ANTIGEN; GENE	Prostatic glandular epithelial cells undergo apoptosis in response to androgen-deprivation. The molecular determinants of androgen-responsiveness in these cells are incompletely understood. Recent evidence suggests that bcl-2 gene family members mag be important in this context, We used the probasin promoter to target a human bcl-2 transgene specifically to the prostate in order to assess its impart on conferring resistance to androgen withdrawal in, otherwise sensitive, prostatic glandular epithelial cells in vivo, We examined the contribution of bax to mediating androgen-responsiveness in prostatic glandular epithelial cells using hair knockout mice, The histologic appearance of the prostates from probasin-bcl-2 transgenic mice or bax(-/-) mice did not differ from those of control littermates. There was no evidence of hyperplastic or neoplastic growth, There was no difference between probasin bcl-2 transgenic mice, bax(-/-) mice, and control littermates in steady-state levels of apoptosis, Following castration our findings suggest that both bax and bcl-2 may each contribute to the androgen-responsiveness of prostatic glandular epithelial cells. It is apparent from these results, however, that bax is not required to mediate cell death in prostatic glandular epithelial cells following castration. A comparison between the apoptotic indices in the ventral prostate from the probasin-hcl-2 and bax(-/-) mice following castration suggests that the presence of bcl-2 may be a more important indicator of androgen-sensitivity than a deficiency of bax.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE PP, 1995, ENDOCRINOLOGY, V136, P4368, DOI 10.1210/en.136.10.4368; Beham AW, 1998, INT J MOL MED, V1, P953; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bruckheimer EM, 1999, SEMIN ONCOL, V26, P382; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; COLOMBEL M, 1993, AM J PATHOL, V143, P390; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pang S, 1997, CANCER RES, V57, P495; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; RAFFO AJ, 1995, CANCER RES, V55, P4438; Schorr K, 1999, CANCER RES, V59, P2541; TUNN S, 1989, PROSTATE, V15, P263, DOI 10.1002/pros.2990150307; Westin P, 1997, INT J ONCOL, V10, P113; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	31	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2404	2412		10.1038/sj.onc.1203571	http://dx.doi.org/10.1038/sj.onc.1203571			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828882				2022-12-28	WOS:000087018400005
J	Yasuda, M; Chinnadurai, G				Yasuda, M; Chinnadurai, G			Functional identification of the apoptosis effector BH3 domain in cellular protein BNIP1	ONCOGENE			English	Article						BNIP1; BH3 domain; apoptosis; heterodimerization	INTERACTING PROTEIN; E1B 19K; BCL-2; DEATH; DISTINCT; SEQUENCE; NIP3; BAK	BCL-2 family proteins play a central role in apoptosis regulation in mammals and in C. elegans. Mammalian cellular and viral anti-apoptosis proteins such as BCL-2 and E1B-19K interact with several cellular proteins. Some of these interacting proteins promote apoptosis and belong to the BCL-2 family. Certain BCL-2 family pro-apoptotic proteins such as BAX and BAK share extensive sequence homology with BCL-2. In contrast, certain pro-apoptotic proteins such as BIK and BID share a single death effector domain, BH3, with other BCL-2 family proteins. By mutational analysis, we show that one of the cellular proteins, BNIP1 (previously Nip-1), that interacts with BCL-2 family anti-apoptosis proteins is a 'BH3 alone' pro-apoptotic protein. Transient transfection of BNIP1 induces a moderate level of apoptosis, Deletions of the N-terminal 32 amino acid region and the C-terminal tl aas-membrane domain did not significantly affect pro-apoptotic activity. In contrast, deletions encompassing a region containing a motif similar to the BH3-domain abrogated the apoptotic activity. Substitution of BNIP1 BH3 domain for the corresponding sequence in BAX efficiently restored the apoptotic activity of BAX, establishing the functional identity of the BH3 domain of BNIP1. The N-terminal deletions of BNIP1 (that retain the BH3 domain) enhanced the level of interaction with BCL-X-L. Mutants containing the BH3 deletions were still able to heterodimerize with BCL-X-L while mutants lacking both the N-terminal region and the BH3 domain were unable to heterodimerize, suggesting that BNIP1 may bind to BCL-XL via two different binding motifs.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-73803, CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Han J, 1996, MOL CELL BIOL, V16, P5857; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X	18	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2363	2367		10.1038/sj.onc.1203565	http://dx.doi.org/10.1038/sj.onc.1203565			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822388				2022-12-28	WOS:000086974300012
J	Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G				Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G			Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants	ONCOGENE			English	Article						caffeine; DNA; Double Strand Breaks (DSB); repair; homologous recombination; non-homologous end joining	IRRADIATED HELA-CELLS; DOUBLE-STRAND BREAKS; RADIATION-SENSITIVE MUTANT; INDUCED CHROMOSOMAL-ABERRATIONS; INDUCED G2 DELAY; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; CHO-CELLS; PROTEIN-KINASE	The radiosensitizing effect of caffeine has been associated with the disruption of multiple DNA damage-responsive cell cycle checkpoints, but several lines of evidence also implicate inhibition of DNA repair. The role of DNA repair inhibition in caffeine radiosensitization remains uncharacterized, and it is unknown which repair process, or lesion, is affected. We show that a radiosensitive cell line, mutant for the RAD51 homolog XRCC2 and defective in homologous recombination repair (HRR), displays significantly diminished caffeine radiosensitization that can be restored by expression of XRCC2, Despite the reduced radiosensitization, caffeine effectively abrogates checkpoints in S and G2 phases in XRCC2 mutant cells indicating that checkpoint abrogation is not sufficient for radiosensitization, Another radiosensitive line, mutant for XRCC3 and defective in HRR, similarly shows reduced caffeine radiosensitization, On the other hand, a radiosensitive mutant (irs-20) of DNA-PKcs with a defect in non-homologous end-joining (NHEJ) is radiosensitized by caffeine to an extent comparable to wild-type cells. In addition, rejoining of radiation-induced DNA DSBs, that mainly reflects NHEJ, remains unaffected by caffeine in XRCC2 and XRCC3 mutants, or their wild-type counterparts. These observations suggest that caffeine targets steps in HRR but not in NHEJ and that abrogation of checkpoint response is not sufficient to explain radiosensitization, Indeed, immortalized fibroblasts from AT patients show caffeine radiosensitization despite the checkpoint defects associated with ATM mutation. We propose that caffeine radiosensitization is mediated by inhibition of stages in DNA DSB repair requiring HRR and that checkpoint disruption contributes by allowing these DSBs to transit into irreparable states. Thus, checkpoints may contribute to genomic stability by promoting error-free HRR.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England	Jefferson University	Iliakis, G (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,Rm B-1, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P30CA056036, R01CA042026] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA42026, P30-CA56036] Funding Source: Medline; PHS HHS [56706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Bebb DG, 1998, MUTAT RES-FUND MOL M, V401, P27, DOI 10.1016/S0027-5107(97)00214-5; BEETHAM KL, 1982, RADIAT RES, V91, P199, DOI 10.2307/3575827; BEETHAM KL, 1984, RADIAT RES, V100, P104, DOI 10.2307/3576526; BEETHAM KL, 1986, RADIAT RES, V107, P272, DOI 10.2307/3576814; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; Dibiase SJ, 2000, CANCER RES, V60, P1245; DOMON M, 1969, RADIAT RES, V39, P207, DOI 10.2307/3572642; FABRE F, 1972, MOL GEN GENET, V117, P153, DOI 10.1007/BF00267612; FAN SJ, 1995, CANCER RES, V55, P1649; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; FURCINITTI PS, 1993, RADIAT RES, V95, P197; GARATTINI S, 1993, CAFFEINE COFFEE HLTH, P1; GENTNER NE, 1981, MOL GEN GENET, V181, P283, DOI 10.1007/BF00425598; GENTNER NE, 1978, MOL GEN GENET, V167, P43, DOI 10.1007/BF00270320; GRIFFITHS TD, 1978, INT J RADIAT BIOL, V33, P493, DOI 10.1080/09553007814550401; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HANSSON K, 1984, HUM GENET, V67, P329, DOI 10.1007/BF00291363; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY AN, 1994, MUTAT RES, V304, P203, DOI 10.1016/0027-5107(94)90212-7; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; ILIAKIS G, 1983, RADIAT RES, V95, P87, DOI 10.2307/3576074; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEHMANN AR, 1972, BIOPHYS J, V12, P1316, DOI 10.1016/S0006-3495(72)86165-4; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOPRIENO N, 1973, MUTAT RES, V21, P275; LOPRIENO N, 1974, MUTAT RES, V26, P83, DOI 10.1016/S0027-5107(74)80038-2; LOPRIENO N, 1971, MOL GEN GENET, V110, P348, DOI 10.1007/BF00438276; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; MURNANE JP, 1980, NATURE, V285, P326, DOI 10.1038/285326a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; MUSK SRR, 1991, RADIAT RES, V125, P262, DOI 10.2307/3578108; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NASIM A, 1974, MOL GEN GENET, V132, P13, DOI 10.1007/BF00268226; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; PAINTER RB, 1980, J MOL BIOL, V143, P289, DOI 10.1016/0022-2836(80)90191-6; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PAWLAK AL, 1990, MUTAT RES, V230, P197, DOI 10.1016/0027-5107(90)90057-B; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; POWELL SN, 1995, CANCER RES, V55, P1643; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rowley R, 1999, GENETICS, V152, P61; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shinomiya N, 1997, CYTOMETRY, V27, P365, DOI 10.1002/(SICI)1097-0320(19970401)27:4<365::AID-CYTO8>3.3.CO;2-F; SIEDE W, 1985, RADIAT ENVIRON BIOPH, V24, P1, DOI 10.1007/BF01212648; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; STACKHOUSE MA, 1994, INT J RADIAT BIOL, V65, P571, DOI 10.1080/09553009414550661; STACKHOUSE MA, 1993, RADIAT RES, V136, P250, DOI 10.2307/3578618; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TATSUMI K, 1979, J MOL BIOL, V135, P435, DOI 10.1016/0022-2836(79)90445-5; TAYLOR YC, 1993, INT J RADIAT BIOL, V64, P57, DOI 10.1080/09553009314551111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; TIMSON J, 1977, MUTAT RES, V47, P1, DOI 10.1016/0165-1110(77)90016-1; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WANG H, 2000, UNPUB; Wang SW, 1999, J CELL SCI, V112, P927; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZAMPETTIBOSSELER F, 1985, MUTAT RES, V143, P251, DOI 10.1016/0165-7992(85)90089-2; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	100	92	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5788	5800		10.1038/sj.onc.1203953	http://dx.doi.org/10.1038/sj.onc.1203953			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126366				2022-12-28	WOS:000165477700011
J	Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH				Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH			Up-regulation of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function	ONCOGENE			English	Article						von Hippel-Lindau (VHL) tumor suppressor; gene; hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha; protein stability; renal clear cell carcinoma cell lines	ENDOTHELIAL GROWTH-FACTOR; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; MESSENGER-RNA; FACTOR-I; FACTOR 1-ALPHA; ALPHA-SUBUNIT; FACTOR-1-ALPHA; ACTIVATION; EXPRESSION	Hypoxia induces transcription of a range of physiologically important genes including erythropoietin and vascular endothelial growth factor. The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits, HLF-1 alpha shares 48 per cent identity with the recently identified HIF-2 alpha protein that is also stimulated by hypoxia, In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2 alpha. mRNA in stromal cells of the tumors. Mutations of the VHL tumor suppressor gene are associated with a variety of tumors such as renal clear cell carcinomas (RCC), In this study, we analysed the expression of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in a range of VHL wildtype and VHL deficient RCC cell lines. In the presence of functional VHL protein, HIF-1 alpha mRNA levels are elevated, whereas HIF-2 alpha mRNA expression is increased only in cells lacking a functional VHL gene product. On the protein levels, however, in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1 alpha and HIF-2 alpha proteins under normoxic conditions. Moreover, immunohistochemical analyses of RCCs and hemangioblastomas demonstrate up-regulation of HIF-1 alpha and HIF-2 alpha in the tumor cells. The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1 alpha and HIF-2 alpha proteins.	Univ Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany; Univ Freiburg, Sch Med, Neuroctr, D-79106 Freiburg, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Univ Cologne, Ctr Mol Biol & Med, D-50931 Cologne, Germany	University of Erlangen Nuremberg; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Cologne	Plate, KH (corresponding author), Univ Erlangen Nurnberg, Dept Neuropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.			Brauch, Hiltrud/0000-0001-7531-2736; Acker, Till/0000-0001-6357-7227				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Glavac D, 1996, HUM GENET, V98, P271, DOI 10.1007/s004390050206; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NEUMANN HPH, 1995, BRAIN PATHOL, V5, P181, DOI 10.1111/j.1750-3639.1995.tb00592.x; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PLATE KH, 1993, CANCER RES, V53, P5822; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	38	304	319	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5435	5443		10.1038/sj.onc.1203938	http://dx.doi.org/10.1038/sj.onc.1203938			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114720				2022-12-28	WOS:000165396100003
J	Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P				Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P			Aberrant p27(Kip1) promoter methylation in malignant melanoma	ONCOGENE			English	Article						p27; Kip1; tumor suppressor; malignant melanoma; cell cycle; haploinsufficiency; methylation; cyclin-dependent kinase inhibitor	KINASE INHIBITOR P27; CELL LUNG-CANCER; CDK INHIBITORS; BREAST-CANCER; FREQUENT LOSS; GENE; CYCLE; HETEROZYGOSITY; EXPRESSION; MUTATION	p27(Kip1) is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27(Kip1) protein expression are found in a variety of human carcinomas, and p27(Kip1) expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27(Kip1) expression is reduced or lost during tumorigenesis remains unclear, Specific alterations of the p27(Kip1) gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27(Kip1) in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma, Dense methylation of a CpG island in the promoter region of p27(Kip1) was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27(Kip1) methylation is associated with transcriptional silencing in situ, Cell lines with p27(Kip1) methylation showed retention of the wild-type allele and detectable p27(Kip1) protein whose abundance was reduced compared with normal melanocytes, Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27(Kip1) silencing in malignant melanoma, which would support a role for p27(Kip1) haploinsuffciency in human cancer.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	thor Straten, Per/0000-0002-4731-4969				Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECKER HJH, 1990, CANCER GENET CYTOGEN, V46, P135, DOI 10.1016/0165-4608(90)90021-2; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Guldberg P, 1997, CANCER RES, V57, P3660; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738	26	55	64	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5111	5115		10.1038/sj.onc.1203891	http://dx.doi.org/10.1038/sj.onc.1203891			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042700				2022-12-28	WOS:000089930100009
J	Ma, Y; Geerdes, DW; Vogt, PK				Ma, Y; Geerdes, DW; Vogt, PK			Oncogenic transformation by the FOX protein Qin requires DNA binding	ONCOGENE			English	Article						Qin; BF-1 oncogenic transformation; winged helix domain/forkhead box; DNA binding; transcriptional repression	TRANSCRIPTION FACTORS; CEREBRAL HEMISPHERES; FORK HEAD; EXPRESSION; FAMILY; BF-1; DOMAINS; RETINA; BRAIN	Some functions of the Qin oncoprotein are not dependent on DNA binding, In order to test the requirement for DNA binding in Qin-induced oncogenic transformation, site directed mutations were introduced in the winged helix (WH) DNA binding domain of the Qin protein, In cellular Qin (c-Qin), the glycine at position 233 was either deleted or substituted with the amino acids aspartic acid, alanine, glutamic acid, asparagine, proline or lysine, The same position carries aspartic acid in the viral Qin protein (v-Qin), The adjacent residues, threonine 232 and lysine 234, were separately mutated to proline, Several additional amino acid substitutions believed to be involved in DNA contacts were introduced at the following c-Qin positions: asparagine 189, histidine 193, serine 196 or arginine 236, Most of the substitutions reduced DNA binding of Qin, one mutation, H193A, completely abolished DNA binding, and another mutation, T232P, increased DNA binding affinity, Mutant H193A failed to transform chicken embryo fibroblasts (CEF), all other mutants, even those showing minimal DNA binding, retained oncogenicity for CEF, The efficiencies of focus formation induced by these mutant proteins in cell culture were not significantly different from that of wild type, However, the rate of focus development and the size of foci induced by the Qin mutants were greater with strong DNA binders than with weak DNA binders, Transdominant negative constructs consisting of the winged helix domain of c-Qin or v-Qin interfered with focus formation induced by full length Qin proteins, These results suggest that DNA binding is a prerequisite for transformation by Qin, and strong DNA binding is related to accelerated transformation in CEF.	Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 79616, CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079616, R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Dou CL, 1999, CEREB CORTEX, V9, P543, DOI 10.1093/cercor/9.6.543; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Kaestner KH, 2000, GENE DEV, V14, P142; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	16	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4815	4821		10.1038/sj.onc.1203834	http://dx.doi.org/10.1038/sj.onc.1203834			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039897				2022-12-28	WOS:000089757800002
J	Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M				Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M			Identification of an RNA element that confers post-transcriptional repression of connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) gene: Similarities to retroviral RNA-protein interactions	ONCOGENE			English	Article						CTGF; angiogenesis; chondrocyte; HIV-1 Rev; 3 '-UTR	ANCHORAGE-INDEPENDENT GROWTH; VASCULAR ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VIVO; CAP-BINDING-PROTEIN; MESSENGER-RNAS; FACTOR-BETA; NEGATIVE REGULATOR; NUCLEAR EXPORT; LINE HCS-2/8; REV PROTEIN	The repressive effect of the 3'-untranslated region (3'-UTR) in human connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) mRNA on gene expression had been demonstrated in our previous study. Here, we identified a minimal RNA element in the 3'-UTR, which acts as a cis-acting element of structure-anchored repression (CAESAR). Deletion analyses of the 3'-UTR led us to minimize the element of 84 bases at the junction of the coding region and the 3'-UTR. The minimized RNA segment is predicted, and actually capable of forming a stable secondary structure in vitro. Mutational analyses disclosed a significant relationship between the predicted structure and repressive effect. The utility of CAESAR as a post-transcriptional regulatory element was represented by the fact that steady-state mRNA levels were not affected by CAESAR linked in cis, while protein levels from such a chimeric gene were markedly reduced. Of note, the CAESAR sequence exerted no effect, when it was placed upstream of the promoter. Finally, RNA gel electromobility-shift analyses demonstrated a nuclear factor that interacts with the folded CAESAR. Taken together, it was uncovered that CAESAR of ctgf is a novel post-transcriptional structured RNA regulatory element, probably acting through direct interactions with a nuclear factor as observed in retroviral RNA elements with certain proteins.	Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Ctr Human Virol,Div Infect Dis, Philadelphia, PA 19107 USA	Okayama University; Jefferson University	Takigawa, M (corresponding author), Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, 2-5-1 Shikata Cho, Okayama 7008525, Japan.		Kondo, Seiji/I-4332-2017; Kondo, Seiji/ABD-3982-2020	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Eguchi, Takanori/0000-0002-3297-6126	PHS HHS [A143876] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; ENOMOTO M, 1992, BIOL REGULATION CHON, P321; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GILMAN M, 1987, CURRENT PROTOCOLS MO; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hattori T, 1998, BIOCHEM BIOPH RES CO, V245, P679, DOI 10.1006/bbrc.1998.8505; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kubo M, 1998, BRIT J DERMATOL, V139, P192; KUBOTA S, 1995, FEBS LETT, V375, P31, DOI 10.1016/0014-5793(95)01166-C; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Naveh-Many T, 1999, J BONE MINER RES, V14, pS167; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Ogbourne S, 1998, BIOCHEM J, V331, P1; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sterling K, 1996, MOL PHARMACOL, V49, P329; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TAKIGAWA M, 1989, CANCER RES, V49, P3996; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; ZHU J, 1994, JPN J CANCER RES, V85, P364, DOI 10.1111/j.1349-7006.1994.tb02368.x	51	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4773	4786		10.1038/sj.onc.1203835	http://dx.doi.org/10.1038/sj.onc.1203835			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032028				2022-12-28	WOS:000089528800012
J	Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R				Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R			AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14)	ONCOGENE			English	Article						t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukaemogenesis	DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; TRANSLOCATION; PROTEIN; FUSION; REARRANGEMENTS; INVOLVEMENT; BREAKPOINT; PRODUCTS	In haematopoietic malignancies the MLL gene, located on chromosome 11q23, is frequently disrupted by chromosome rearrangement, generally resulting in fusion to various partner genes. We have previously reported a t(11;15)(q23;q14) in a case of acute myeloblastic leukaemia. Here, we report the cloning of a novel MLL partner, AF15q14, at chromosome 15q14, In this translocation, the breakpoint occurred in exon 8 of MLL and exon 10 of AF15q14. The normal AF15q14 transcripts of approximately 8.5 kb in size, are expressed in different tumoral cell lines, in variety of normal tissues, and in all the foetal tissues tested. Sequencing of AF15q14 cDNA revealed a putative open reading frame of 1833 amino acids that had no homology with any other known protein. The C-terminal end of the putative AF15q14 contained a bipartite nuclear localization site. The translocation t(11;15) preserved the open reading frame between MLL and the 3' end of AF15q14. The contribution of AF15q14 to the fusion protein was only 85 amino acids, Immunofluorescence staining experiments with expression vectors encoding these 85 amino acids confirmed the functionality of the predicted nuclear localization site.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Fac Med Nord, Lab Biochim & Biol Mol, F-13916 Marseille, France; IBCP, UMR 5086, F-69367 Lyon 07, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France.		HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Deléage, Gilbert/F-7163-2010	Deléage, Gilbert/0000-0003-1939-1614				Archimbaud E, 1998, LEUKEMIA, V12, P25, DOI 10.1038/sj.leu.2400853; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Fidanza V, 1996, CANCER RES, V56, P1179; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2326; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; HUNGER SP, 1993, BLOOD, V81, P3197; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; Rogaia D, 1997, CANCER RES, V57, P799; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; RUBNITZ JE, 1994, BLOOD, V84, P570; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	21	37	42	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4446	4450		10.1038/sj.onc.1203789	http://dx.doi.org/10.1038/sj.onc.1203789			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980622				2022-12-28	WOS:000089271900017
J	Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A				Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A			Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP Kinase activation in IL-2-dependent Kit 225 T lymphocytes	ONCOGENE			English	Article						cell cycle; lymphocyte; IL-2; cdk2; MAP kinase; nuclear localization	CELL-CYCLE CONTROL; PROTEIN-KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; G(1)/S TRANSITION; GROWTH-FACTORS; GENE-PRODUCT; IN-VIVO; S-PHASE; PHOSPHORYLATION	Cell proliferation is controlled by cdk2 which in association with cyclin E and a regulates G1/S transition and S phase progression. cdk2 activation is dependent on its localization in the nucleus where regulatory mediators are found, We report that activation of cdk2 is associated with the formation of cdk2/MAP kinase complexes, cdk2 associates with both inactive and activated MAP Kinase. Prevention of MAP Kinase activation ba the MEK inhibitor PD98059 inhibits both activation and nuclear localization of cdk2 and S phase entry. These findings indicate that the nuclear translocation of cdk2 is associated with the formation of molecular complexes containing active MAP Kinase and is dependent on MAP Kinase activation.	IPSC, INSERM U131, F-92140 Clamart, France; Claude Bernard Res Ctr, F-92140 Clamart, France; IPSC, INSERM U355, F-92140 Clamart, France; Fac Pharm Chatenay Malabry, INSERM U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), IPSC, INSERM U131, 32 Rue des Carnets, F-92140 Clamart, France.							ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HORI T, 1987, BLOOD, V70, P1069; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Prosperi E, 1997, EUR J HISTOCHEM, V41, P161; Reed SI, 1997, CANCER SURV, V29, P7; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAIEB J, 1995, J IMMUNOL, V155, P5623; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	54	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4184	4189		10.1038/sj.onc.1203761	http://dx.doi.org/10.1038/sj.onc.1203761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962581				2022-12-28	WOS:000088955100014
J	Bies, J; Feikova, S; Bottaro, DP; Wolff, L				Bies, J; Feikova, S; Bottaro, DP; Wolff, L			Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases	ONCOGENE			English	Article						c-Myb; proteolysis; phosphorylation; 26S proteasome; Ser/Thr phosphatases	NEGATIVE REGULATORY DOMAIN; INDUCED TRANSCRIPTION ACTIVATION; DNA-BINDING DOMAIN; KAPPA-B-ALPHA; V-MYB; PHOSPHORYLATION SITE; PROTEASOME PATHWAY; ONCOGENIC ACTIVATION; TRANS-ACTIVATION; TERMINAL REGION	The c-myb proto-oncogene encodes a nuclear phosphoprotein that plays a crucial role in normal hematopoiesis. It is a short-lived transcription factor rapidly degraded by the 26S proteasome, Although it has been shown that instability determinants reside in its carboxyl terminus, the molecular mechanism of c-Myb degradation is unknown, Here, we report the first evidence that phosphorylation plays a role in targeting the protein to the proteasome, Inhibition of cellular serine/threonine protein phosphatase activity by okadaic acid resulted in hyperphosphorylation of c-Myb and extremely rapid turnover, The hyperphosphorylation resulted in a protein with altered properties that was indicative of conformational changes. Its mobility on gel electrophoresis was altered as well as its recognition by specific monoclonal antibody, The altered hyperphosphorylated protein still bound to DNA with an affinity similar to that of the hypophosphorylated form, Phosphorylation of three previously identified sites, serines 11, 12, and 528, does not appear to be involved in the proposed changes in conformation or stability, However, phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased c-Myb phosphorylation mainly on threonine residues that correlated with other okadaic acid-induced alterations of c-Myb, These findings indicate that Ser/Thr phosphatases prevent conformational changes that may play an important role in controlled degradation of c-Myb.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Canc Res Inst, Mol Virol Lab, Bratislava 83392, Slovakia; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	NATIONAL CANCER INSTITUTE [Z01BC008952] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAI P, 1996, GENE DEV, V10, P28; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dubendorff JW, 1999, ONCOGENE, V18, P3452, DOI 10.1038/sj.onc.1202679; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KRIEG J, 1995, ONCOGENE, V10, P2221; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; WON KA, 1996, EMBO J, V15, P182	44	26	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2846	2854		10.1038/sj.onc.1203613	http://dx.doi.org/10.1038/sj.onc.1203613			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851088				2022-12-28	WOS:000087403600006
J	Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A				Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A			The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways	ONCOGENE			English	Article						Rgr; oncogene; exchange factor; Ral; signal transduction	NUCLEOTIDE EXCHANGE FACTORS; TERNARY COMPLEX FACTORS; C-FOS PROMOTER; NIH 3T3 CELLS; DISSOCIATION STIMULATOR; INCREASING COMPLEXITY; SIGNAL-TRANSDUCTION; BINDING PROTEIN-1; MAMMALIAN-CELL; GTPASES	The effects of the 5'-truncated Rgr oncogene, previously shown specific guanine exchange factor for Ral in vitro, in stimulating proliferation, cell transformation and gene expression were investigated. We have established TetRgr cell lines in which expression of Rgr can be inhibited by the presence of tetracycline in the medium. Using this system, we show that Rgr overexpressing cells are morphologically transformed and grow in a disorganized manner. At the transcriptional level, Rgr enhances the activity of the serum response element and c-Jun. Rgr induces phosphorylation of ERKs, p38 and JNK kinases, and increases the levels of the GTP-bound forms of Ral and Ras. I:as activation could account for the broad spectra of effects displayed by Rgr. The important role of these pathways is confirmed by experiments in which the transcriptional activation events can be blocked by dominant negative versions of Ras, Ral and Rho. Among all the Rgr-induced pathways, the Ras-Raf-MEK-ERK cascade is essential for the transforming properties of Rgr. Additional analysis has shown that the activation of this pathway by Rgr is not due to a feed back mechanism mediated by the Grb2 adaptor protein.	NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU Med Ctr, Dept Pathol, New York, NY 10016 USA.		Malumbres, Marcos/E-8834-2011; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA050434, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36327, CA 50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 1999, MOL CELL BIOL, V19, P1731; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mangues R, 1998, CANCER RES, V58, P1253; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Murai H, 1997, J BIOL CHEM, V272, P10483; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	53	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2745	2757		10.1038/sj.onc.1203586	http://dx.doi.org/10.1038/sj.onc.1203586			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851075	Bronze			2022-12-28	WOS:000087318500003
J	Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z				Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z			Differential modulation of paclitaxel-mediated apoptosis by p21(Waf1) and p27(Kip1)	ONCOGENE			English	Article						paclitaxel; chemoresistance; cell cycle; p21(Waf1); p27(Kip1)	TAXOL-INDUCED APOPTOSIS; CELL-CYCLE ARREST; P34(CDC2) KINASE; DNA-REPLICATION; CARCINOMA-CELLS; PROTEIN-KINASE; G(2)-M ARREST; CANCER CELLS; M-PHASE; PHOSPHORYLATION	The impact of the cyclin dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) on paclitaxel-mediated cytotoxicity was investigated in RKO human colon adenocarcinoma cells with the ecdysone-inducible expression of p21(Waf1) or p27(Kip1). Ectopic expression of p27(Kip1) arrested cells at G1 phase, whereas p21(Waf1) expression arrested cells at G1 and G2, Expression of p21(Waf1) after paclitaxel treatment produced much greater resistance to paclitaxel than did expression of p27(Kip1). We attributed this difference to the additional block at G2 induced by p21(Waf1), which prevented cells from entering M phase and becoming paclitaxel susceptible. Expression of p21(Waf1) inhibited p34cdc2 activity and markedly reduced paclitaxel-mediated mitotic arrest, from 87.5 to 23%, In contrast, p27(Kip1) expression also inhibited p34cdc2 but reduced mitotic arrest only slightly, from 87.4 to 74.5%, We concluded that the G2 block produced by p21(Waf1), but not by p27(Kip1), contributed to their unequal modulation of sensitivity to paclitaxel-mediated apoptosis in RKO cells, and there is no causal relationship between paclitaxel-mediated cytotoxicity and elevation of p34cdc2 activity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA16672, CA68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amato SF, 1998, CANCER RES, V58, P241; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Frankel A, 1997, CANCER RES, V57, P2388; Haldar S, 1996, CANCER RES, V56, P1253; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Ibrado AM, 1997, CANCER RES, V57, P1109; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rakovitch E, 1999, INT J RADIAT ONCOL, V44, P1119, DOI 10.1016/S0360-3016(99)00109-1; ROWINSKY EK, 1997, SEMIN ONCOL S19, V24, P1; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; van Bree C, 1999, J CANCER RES CLIN, V125, P549, DOI 10.1007/s004320050315; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wu XP, 1996, ONCOGENE, V12, P1397; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	33	59	62	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2423	2429		10.1038/sj.onc.1203546	http://dx.doi.org/10.1038/sj.onc.1203546			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828884				2022-12-28	WOS:000087018400007
J	Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP				Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP			An N-terminal p14(ARF) peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo	ONCOGENE			English	Article						p53 tumour suppressor; Mdm2; p14(ARF); ubiquitination; protein stability; transcriptional activation	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; NUCLEAR EXPORT; DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; MAMMALIAN-CELLS; STABILIZES P53; HUMAN SARCOMAS	The p53 tumour suppressor protein is down-regulated by the action of Mdm2, which targets p53 for rapid degradation by the ubiquitin-proteasome pathway. The p14(ARF) protein is also a potent tumour suppressor that acts by binding to Mdm2 and blocking Mdm2-dependent p53 degradation and transcriptional silencing, We have screened a series of overlapping synthetic peptides derived from the p14(ARF) protein sequence and found that a peptide corresponding to the first 20 amino acids of ARF (Peptide 3) could bind human Mdm2, The binding site for Peptide 3 on Mdm2 was determined by deletion mapping and lies adjacent to the binding site of the anti-Mdm2 antibody 2A10, which on microinjection into cells can activate p53-dependent transactivation of a reporter plasmid, To determine whether Peptide 3 could similarly activate p53, we expressed a fusion of green fluorescent protein and Peptide 3 in MCF7 and U-2 OS cells and were able to demonstrate induction of p53 protein and p53-dependent transcription. Peptide 3 was able to block in vitro ubiquitination of p53 mediated by Mdm2, Small peptides which are sufficient to block degradation of p53 could provide therapeutic agents able to restore p53-dependent cell death pathways in tumours that retain wild-type p53 expression.	Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9TS, Fife, Scotland	University of Dundee; University of St Andrews	Lane, DP (corresponding author), Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, WTB-MSI Bldg,Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Hay, Ronald T/F-9338-2011	Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MAKI CG, 1996, CANCER RES, V56, P2694; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; VOJTESEK B, 1993, J CELL SCI, V105, P607; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	65	227	238	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2312	2323		10.1038/sj.onc.1203593	http://dx.doi.org/10.1038/sj.onc.1203593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822382				2022-12-28	WOS:000086974300006
J	Boutillier, AL; Trinh, E; Loeffler, JP				Boutillier, AL; Trinh, E; Loeffler, JP			Caspase-dependent cleavage of the retinoblastoma protein is an early step in neuronal apoptosis	ONCOGENE			English	Article						apoptosis; cerebellar neuron; retinoblastoma protein; caspase; CPP32	CEREBELLAR GRANULE NEURONS; ICE-LIKE PROTEASE; TUMOR-SUPPRESSOR PROTEIN; CELL-DEATH; ICE/CED-3 PROTEASE; SIGNALING PATHWAY; MDM2 ONCOPROTEIN; FAMILY PROTEINS; GENE-PRODUCT; DEGRADATION	Rb-deficient embryos (Rb-/-) show abnormal degeneration of neurons and die at mid-gestation, suggesting that RE may protect against apoptosis. Having previously shown that cyclin D1 accumulates during K+-induced apoptosis of granule neurons, we chose to investigate the role of RB under these conditions. We show that RB is cleaved in its C-terminus during the onset of neuronal apoptosis. Caspase 3-like activity increases following K+ deprivation and the time course correlates with RB cleavage and apoptosis, Although the use of a specific caspase 3-like inhibitor (z-DEBD.fmk) delays RB cleavage and reduces DNA fragmentation, data implicate other caspases in these processes. However K+ deprivation induces a gradual production of the active p20 subunit of caspase 3 (CPP32) that coincides with RB disappearance at the cellular level. Nuclear detection of a transfected HA-tagged caspase cleavage-resistant RB mutant (DEAG/D to DEAA/D) revealed a significant decrease in apoptosis of neurons expressing the RB mutant (less than 5%) relative to the wild type form of RB (40%) during K+ deprivation. Taken together, these data show that caspase-dependent cleavage of RB is an early permissive step of the apoptosis-inducing signaling pathway in neurons, They indicate a major role of RB in neuronal protection.	CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), CNRS, UMR 7519, 21 Rue Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Armstrong RC, 1997, J NEUROSCI, V17, P553; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DOU QP, 1998, FRONT BIOSCI, V3, P419; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GALLO V, 1987, J NEUROSCI, V7, P2203; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KONDO S, 1995, ONCOGENE, V10, P2001; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Lynch T, 1997, MOL PSYCHIATR, V2, P227, DOI 10.1038/sj.mp.4000242; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulz JB, 1996, J NEUROSCI, V16, P4696; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; Sohm F, 1999, ONCOGENE, V18, P2762, DOI 10.1038/sj.onc.1202634; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	56	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2171	2178		10.1038/sj.onc.1203532	http://dx.doi.org/10.1038/sj.onc.1203532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822366				2022-12-28	WOS:000086974100001
J	Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM				Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM			The isoform-specific stretch of hSos1 defines a new Grb2-binding domain	ONCOGENE			English	Article						hSos1; isoforms; Grb2; SH3 domains	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; SRC HOMOLOGY-3 DOMAINS; RAS SIGNALING PATHWAY; SH3 DOMAINS; FACTOR SON; SH3-LIGAND INTERACTIONS; STRUCTURAL BASIS; ADAPTER PROTEIN	hSos1 isoform II, defined by the presence of a 15 amino acid stretch in its carboxy-terminal region, exhibits higher Grb2 affinity than hSos1 isoform I. In this study, we investigated the cause for this difference and observed that, in addition to the four currently accepted Grb2-binding motifs, a number of additional, putative SH3-minimal binding sites (SH3-MBS) could be identified. The isoform II-specific 15 amino acid stretch contained one of them, Indeed, me demonstrated by site-directed mutagenesis that these SH3-MBS were responsible for the Grb2 interaction, and we found that C-terminal fragments of the two hSos1 isoforms (lacking the four cannonical Grb2-binding motifs, but containing the SH3-minimal binding sites) were able to bind Grb2, with the isoform II fragment showing higher Grb2 affinity than the corresponding isoform I fragment. Furthermore, we provide evidence that C-terminal truncated mutants of either hSos1 isoform, containing only the SH3-minimal binding sites, were able to originate in vivo stable complexes with Grb2, Although, Grb2-binding remains higher in both full-length isoforms, compared to the C-terminal truncated mutants, these mutants were also able to activate Ras, supporting a potential role of this C-terminal region as negative modulator of Sos1 activity. These findings document the existence of a new, functional, SH3-minimal binding site located in the specific stretch of hSos1 isoform II which may be responsible for the increased Grb2 affinity of this isoform in comparison to isoform I, and for the physiological properties differences between both isoforms, Moreover, these SH3-minimal binding sites may be sufficient to attain stable and functional hSos1-Grb2 complexes.	Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Instituto de Salud Carlos III; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain.		Rojas, José M./AAA-3354-2021; Rojas, José M/D-3718-2018	Rojas, José M./0000-0002-7547-2825; Rojas, José M/0000-0002-5383-3482; Zarich, Natasha/0000-0003-1058-6191				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rojas JM, 1996, ONCOGENE, V12, P2291; Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	57	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5872	5883		10.1038/sj.onc.1203955	http://dx.doi.org/10.1038/sj.onc.1203955			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127818				2022-12-28	WOS:000165563100006
J	Jhiang, SM				Jhiang, SM			The RET proto-oncogene in human cancers	ONCOGENE			English	Review						RET; papillary thyroid carcinomas; MEN 2; signal transduction	RECEPTOR TYROSINE KINASE; PAPILLARY THYROID CARCINOMAS; NEOPLASIA TYPE 2A; RET/PTC1 ONCOGENE; CELL LINE; TRANSGENIC MICE; HIGH PREVALENCE; TRANSFORMING ACTIVITY; TARGETED EXPRESSION; SIGNAL-TRANSDUCTION	The activation of the RET proto-oncogene contributes to the development of human cancers in two different ways. Somatic rearrangements of RET with a variety of activating genes, which contribute to unscheduled expression and constitutive dimerization of the chimeric RET/PTC oncoproteins in thyroid follicular cells, are frequently found in radiation-induced papillary thyroid carcinomas. Germ-line mutations, mainly point mutations, that lead to constitutive activation of RET tyrosine kinase activity are responsible for the development of the inherited cancer syndrome, multiple endocrine neoplasia type 2, There appears to be a correlation between specific types of RET mutation and clinical phenotypes of the cancers involved. The biological effects and the signaling pathways induced by different forms of RET activation have been investigated in a variety of cultured cells as well as in genetically engineered animal models. The identification of RET mutations in most MEN 2 families (95%) has translated into improved care for MEN 2 patients. However, further investigation of the signaling pathways contributing to tumorigenesis in relevant tissues will eventually help us to develop no, el strategies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as the sporadic cancers relevant to MEN 2 disease.	Ohio State Univ, Dept Cell Biol & Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Cell Biol & Physiol, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060074, R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Asai N, 1999, BIOCHEM BIOPH RES CO, V255, P587, DOI 10.1006/bbrc.1999.0237; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bartsch DK, 2000, EXP CLIN ENDOCR DIAB, V108, P128, DOI 10.1055/s-2000-5806; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BOND JA, 1994, ONCOGENE, V9, P281; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8; Giannini R, 2000, INT J ONCOL, V16, P485; GRIECO D, 1995, ONCOGENE, V11, P113; Ito S, 1997, CANCER RES, V57, P2870; ITOH F, 1989, Tumor Research, V24, P1; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1992, ONCOGENE, V7, P1331; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRIJGER RR, 2000, J PATHOL, V191, P264; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Powell DJ, 1998, CANCER RES, V58, P5523; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; ROMANO A, 1994, ONCOGENE, V9, P2923; Sagartz JE, 1997, LAB INVEST, V76, P307; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Soares P, 1998, J PATHOL, V185, P71; Tallini G, 1998, CLIN CANCER RES, V4, P287; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; TSUZUKI T, 1995, ONCOGENE, V10, P191; Uchino S, 1999, JPN J CANCER RES, V90, P1231, DOI 10.1111/j.1349-7006.1999.tb00701.x; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512	71	219	249	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5590	5597		10.1038/sj.onc.1203857	http://dx.doi.org/10.1038/sj.onc.1203857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114739				2022-12-28	WOS:000165659300006
J	Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH				Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH			Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells	ONCOGENE			English	Article						Src; IR; IGFR; MAPK; PI3K; transformation	FACTOR-I RECEPTOR; ACTIVATED PROTEIN-KINASE; AVIAN-SARCOMA VIRUS; C-SRC; TYROSINE KINASES; STAT3 ACTIVATION; ONCOGENIC ROS; V-SRC; GENE; TUMOR	There have been few studies on the specific signaling pathways involved in the transformation of epithelial cells by oncogenic protein tyrosine kinases. Here we investigate the requirement of MAP (MAPK) and phosphatidylinositol 3-(PI3K) kinases in the transformation of rat intestinal epithelial (RIE) cells by oncogenic forms of insulin receptor (gag-IR), insulin-like growth factor-1 receptor (gag-ICFR), and v-Src. MAPK is not significantly activated in cells transformed by gag-IR and gag-IGFR but is activated in v-Src transformed cells. Treatment with PD98059, a MEK inhibitor, at concentrations where MAPK activity was reduced below the basal level showed that MAPK is partially required for the monolayer growth of parental and transformed RIE cells. However, MAPK is not essential for the focus forming ability of the three oncogene-transformed cells. It is also not necessary for the colony forming ability of gag-IR- and gag-IGFR-, but is partially required for v-Src-transformed cells. PI3K is significantly activated in all three oncogene transformed RIE cells. LY294002, a PI3K inhibitor, potently inhibited monolayer growth of all three oncogene-transformed cells. However, at concentrations of LY294002 where activated forms of Akt, a downstream component of the PI3K pathway, were undetectable, colony and focus forming abilities of the v-Src-RIE cells were only slightly affected whereas those of gag-IR/IGFR-RIE cells were greatly inhibited. These results were confirmed using a different pharmacological inhibitor, wortmannin, and a dominant negative form of PI3K, Delta p85. Similarly, rapamycin, known to inhibit p70S6 kinase, a downstream component of the PI3K-Akt pathway, also inhibited gag-IR/IGFR-induced, but not v-Src-induced, focus and colony formation. We conclude that the MAPK and PI3K signaling pathways are differentially required for transformation of RIE cells by oncogenic IR and IGFR versus Src and the pattern of requirements is different from that of fibroblast transformation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; AMFO K, 1995, ONCOGENE, V11, P351; BASERGA R, 1995, CANCER RES, V55, P249; BECK EP, 1994, GYNECOL ONCOL, V53, P196, DOI 10.1006/gyno.1994.1115; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chan JLK, 1997, J BIOL CHEM, V272, P146; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GARCIA R, 1991, ONCOGENE, V6, P1983; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Greulich H, 1996, ONCOGENE, V12, P1689; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Ligon AH, 1998, J NEUROVIROL, V4, P217, DOI 10.3109/13550289809114521; LIN X, 1997, CANCER RES, V57, P2402; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPA V, 1993, CANCER RES, V53, P3736; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P894, DOI 10.1016/S0006-291X(05)80870-8; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TAKEYA T, 1982, J VIROL, V44, P1; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YASHIRO T, 1989, ACTA ENDOCRINOL-COP, V121, P112, DOI 10.1530/acta.0.1210112; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	55	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5385	5397		10.1038/sj.onc.1203911	http://dx.doi.org/10.1038/sj.onc.1203911			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103940				2022-12-28	WOS:000165302300010
J	Benistant, C; Chapuis, H; Roche, S				Benistant, C; Chapuis, H; Roche, S			A specific function for phosphatidylinositol 3-kinase alpha (p85 alpha-p110 alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85 alpha-p110 beta) in de novo DNA synthesis of human colon carcinoma cells	ONCOGENE			English	Article						phosphatidylinositol 3-kinase; intracellular signalling; carcinoma; DNA synthesis; apoptosis	PHOSPHOINOSITIDE 3-OH KINASE; SIGNALING PATHWAY; LYSOPHOSPHATIDIC-ACID; CATALYTIC SUBUNIT; ACTIVATION; PROTEIN; GAMMA; RAS; TRANSFORMATION; CANCER	We have previously shown an important function of phosphatidylinositol 3-kinase (PI3K)alpha(p85 alpha-p110 alpha) and PI3K beta (p85-alpha-p110 beta) for DNA synthesis induced by various mitogens in non transformed fibroblasts and we now report a specific role of these enzymes in human colon cancer cell growth. Using antibodies specific to p110 alpha and to p110 beta catalytic subunits, increase in PI3K alpha and PI3K beta activities,vas detected in 15/19 human tumour biopsies relative to adjacent normal mucosa of human colon and bladder. Increase in such activities was also observed in adenocarcinoma cell lines CaCo2, CO115, HCT 116, LS 174T and WiDr relative to nontransformed fibroblasts. Maximal PI3K alpha activity was observed for LS 174T and PI3K beta activity for WiDr cells. This was partly correlated with an increase in p110 alpha and p110 beta protein levels both in some primary tumours and established cell lines, suggesting that PI3K overexpression is involved in enzymatic deregulation. Functional consequence of such activation was assessed by a microinjection approach. An injection of neutralizing antibody specific to p110 beta in WiDr, HCT116 and CO 115 cells inhibited de novo DNA synthesis, whereas antibodies specific to p110 gamma had no effect. Neutralizing antibodies specific to p110 alpha induced apoptosis, a response that was reverted by treating cells with the caspase inhibitor z-VAD-fmk. However anti-p110 beta and anti-p110 gamma antibodies did not affect cell survival, We concluded that PI3K alpha and PI3K beta play important roles in human colon cancer cell growth with a specific function for PI3K beta in de novo DNA synthesis and an involvement of PI3K alpha in cell survival.	CRBM, CNRS, UPR 1086, F-34293 Montpellier 05, France; Ctr Hosp Univ, Dept Anathomopathol, Nimes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Nimes	Roche, S (corresponding author), CRBM, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier 05, France.		Benistant, Christine/M-5771-2018	roche, serge/0000-0003-3413-3859				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Moore SM, 1998, CANCER RES, V58, P5239; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	35	128	162	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5083	5090		10.1038/sj.onc.1203871	http://dx.doi.org/10.1038/sj.onc.1203871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042696				2022-12-28	WOS:000089930100005
J	Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J				Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J			Expression of protein tyrosine phosphatase alpha (RPTP alpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo	ONCOGENE			English	Article						tyrosine phosphatase; c-Src; PTP; breast cancer; tumor marker	DOWN-REGULATION; MAMMARY-TUMORS; C-SRC; SIGNAL-TRANSDUCTION; PROGNOSTIC FACTOR; TRANSGENIC MICE; FACTOR RECEPTOR; NEU ONCOGENE; PTP-ALPHA; IN-VIVO	Tyrosine phosphorylation is controlled by a balance of tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), Whereas the contribution of PTKs to breast tumorigenesis is the subject of intense scrutiny, the potential role of PTPs is poorly known. RPTP alpha is implicated in the activation of Src family kinases, and regulation of integrin signaling, cell adhesion, and growth factor responsiveness. To explore its potential contribution to human neoplasia, we surveyed RPTPa protein levels in primary human breast cancer. We found RPTPa levels to vary widely among tumors, with 29% of cases manifesting significant overexpression, High RPTP alpha protein levels correlated significantly with low tumor grade and positive estrogen receptor status. Expression of RPTP alpha in breast carcinoma cells led to growth inhibition, associated with increased accumulation in G(0) and G(1), and delayed tumor growth and metastasis. To our knowledge, this is the first example of a study correlating expression level of a specific bona fide PTP with neoplastic disease status in humans.	Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Gen Surg Breast Unit B, I-20133 Milan, Italy; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; New York University; New York University	Menard, S (corresponding author), Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019; Tagliabue, Elda/B-9377-2017	Agresti, Roberto/0000-0003-4700-1951; Tagliabue, Elda/0000-0001-9877-2903	NCI NIH HHS [R29 CA68365, 5R21 CA66229-04, P30CA16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA066229, P30CA016087, R29CA068365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BARKER KT, 1995, ONCOGENE, V10, P569; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; ELSON A, 1995, P NATL ACAD SCI USA, V92, P12335; ELSTON CW, 1984, AUST NZ J SURG, V54, P11, DOI 10.1111/j.1445-2197.1984.tb06677.x; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lollini PL, 1998, INT J CANCER, V77, P937, DOI 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OTTENHOFFKALFF AE, 1995, BREAST CANCER RES TR, V33, P245, DOI 10.1007/BF00665949; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PEREIRA H, 1995, HISTOPATHOLOGY, V27, P219, DOI 10.1111/j.1365-2559.1995.tb00213.x; Petrone A, 2000, J CELL SCI, V113, P2345; PIZAO PE, 1992, BRIT J CANCER, V66, P660, DOI 10.1038/bjc.1992.333; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SILVESTRINI R, 1985, CANCER, V56, P1982, DOI 10.1002/1097-0142(19851015)56:8<1982::AID-CNCR2820560816>3.0.CO;2-I; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1996, J BIOL CHEM, V271, P28026; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; *UICC, 1997, ILL GUID TNM PTNM CL; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHAI YF, 1993, CANCER RES, V53, P2272; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	63	69	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4979	4987		10.1038/sj.onc.1203869	http://dx.doi.org/10.1038/sj.onc.1203869			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042685				2022-12-28	WOS:000089834300005
J	Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E				Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E			High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis	ONCOGENE			English	Article						HTLV; leukemogenesis; adult T cell leukemia; genetic instability	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; FRENCH-WEST-INDIES; EPSTEIN-BARR-VIRUS; LEUKEMIA-LYMPHOMA; TAX PROTEIN; SEMIQUANTITATIVE ANALYSIS; POLYCLONAL INTEGRATION; STERCORALIS INFECTION; PERIPHERAL-BLOOD	Adult T cell leukemia (ATLL) develops in 3-5% of HTLV-1 carriers after a long period of latency during which a persistent polyclonal expansion of HTLV-1 infected lymphocytes is observed in all individuals. This incubation period is significantly shortened in HTLV-1 carrier with Strongyloides stercoralis (Ss) infection, suggesting that Ss could be a cofactor of ATLL, As an increased T cell proliferation at the asymptomatic stage of HTLV-1 infection could increase the risk of malignant transformation, the effect of Ss infection on infected T lymphocytes was assessed in vivo in HTLV-1 asymptomatic carriers. After real-time quantitative PCR, the mean circulating HTLV-1 proviral load was more than five times higher in HTLV-1 carriers with stongyloidiasis than in HTLV-1+ individuals without Ss infection (P < 0,009), This increased proviral load was found to result from the extensive proliferation of a restricted number of infected clones, i,e, from oligoclonal expansion, as evidenced by the semiquantitative amplification of HTLV-1 flanking sequences. The positive effect of Ss on clonal expansion was reversible under effective treatment of strongyloidiasis in one patient with parasitological cure whereas no significant modification of the HTLV-1 replication pattern was observed in an additional case with strongyloidiasis treatment failure. Therefore, Ss stimulates the oligoclonal proliferation of HTLV-1 infected cells in HTLV-1 asymptomatic carriers in vivo, This is thought to account for the shortened period of latency observed in ATLL patients with strongyloidiasis.	Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, F-69373 Lyon 08, France; Inst Rech Canc Lille, INSERM, Unite 524, Lille, France; Inst Pasteur Guyane, Cayenne, France; CHU Ft France, Serv Hematol Biol, Martinique, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Univ Mons, Serv Biol Mol, B-7000 Mons, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Martinique; UNICANCER; Centre Oscar Lambret; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Mons	Wattel, E (corresponding author), Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.		mortreux, franck/M-5944-2014; mortreux, franck/T-4564-2019	mortreux, franck/0000-0002-4840-021X; mortreux, franck/0000-0002-4840-021X				Agape P, 1999, J ACQ IMMUN DEF SYND, V20, P394, DOI 10.1097/00042560-199904010-00011; ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; ARAKAKI T, 1992, J TROP MED HYG, V95, P210; ARAKAKI T, 1992, TROP MED PARASITOL, V43, P199; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; de-The G, 1985, IARC Sci Publ, P165; DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617; deThe G, 1997, ANN MED INTERNE, V148, P357; DEVAULT GA, 1990, REV INFECT DIS, V12, P653; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FACER CA, 1989, ADV CANCER RES, V53, P33; FUJII M, 1991, ONCOGENE, V6, P1023; GELBER M, 1996, HAREFUAH, V130, P13; Gelber Moshe, 1996, Harefuah, V130, P90; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GORDON SM, 1994, J AM ACAD DERMATOL, V31, P255, DOI 10.1016/S0190-9622(94)70158-X; Goyal SB, 1998, SOUTHERN MED J, V91, P768, DOI 10.1097/00007611-199808000-00016; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hayashi J, 1997, AM J TROP MED HYG, V56, P71, DOI 10.4269/ajtmh.1997.56.71; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; LAGRENADE L, 1990, LANCET, V336, P1345; Leclercq I, 1998, BRIT J HAEMATOL, V101, P500, DOI 10.1046/j.1365-2141.1998.00743.x; Leclercq I, 1999, BRIT J HAEMATOL, V105, P743, DOI 10.1046/j.1365-2141.1999.01389.x; MASSEY AC, 1990, VA MED Q, V117, P31; MATSUMOTO T, 1990, CLIN EXP IMMUNOL, V81, P207, DOI 10.1111/j.1365-2249.1990.tb03319.x; Mattos K, 1993, Arq Neuropsiquiatr, V51, P134; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MOCHIZUKI M, 1994, BRIT J OPHTHALMOL, V78, P149, DOI 10.1136/bjo.78.2.149; MOLBAK K, 1994, J INFECT DIS, V169, P581, DOI 10.1093/infdis/169.3.581; NAKANE S, 1988, J PHARM PHARMACOL, V40, P1, DOI 10.1111/j.2042-7158.1988.tb05139.x; NEWTON RC, 1992, AM J MED, V92, P202, DOI 10.1016/0002-9343(92)90113-P; Nonaka D, 1998, AM J TROP MED HYG, V59, P535, DOI 10.4269/ajtmh.1998.59.535; OHSHIMA K, 1991, CANCER RES, V51, P4639; OSAME M, 1986, LANCET, V1, P1031; Pagliuca A, 1999, BRIT J HAEMATOL, V105, P1, DOI 10.1111/j.1365-2141.1999.01401.x; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PHELPS KR, 1991, AM J MED SCI, V302, P224, DOI 10.1097/00000441-199110000-00006; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SATO K, 1991, ARTHRITIS RHEUM, V34, P714, DOI 10.1002/art.1780340612; SHERMAN MP, 1995, ARTHRITIS RHEUM, V38, P690, DOI 10.1002/art.1780380518; SHIMAMOTO Y, 1994, BLOOD, V84, P853; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	67	103	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4954	4960		10.1038/sj.onc.1203870	http://dx.doi.org/10.1038/sj.onc.1203870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042682				2022-12-28	WOS:000089834300002
J	Kikuchi, M; Miki, T; Kumagai, T; Fukuda, T; Kamiyama, R; Miyasaka, N; Hirosawa, S				Kikuchi, M; Miki, T; Kumagai, T; Fukuda, T; Kamiyama, R; Miyasaka, N; Hirosawa, S			Identification of negative regulatory regions within the first exon and intron of the BCL6 gene	ONCOGENE			English	Article						BCL6; B-cell lymphoma; silencer element	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; B-CELL LYMPHOMA; SOMATIC HYPERMUTATION; 5'-NONCODING REGION; TRANSCRIPTIONAL REPRESSION; 3Q27 TRANSLOCATION; MUTATIONS; SEQUENCE; DELETIONS	Chromosomal translocations involving BCL6 gene are frequent in human B-cell lymphomas, Chromosomal breaks preferentially occur within a 3-kb region containing the first exon and intron, Recent reports have revealed that internal deletions or point mutations also are common in this region, suggesting that structural alteration of this region may be a crucial event in the development of lymphomas, In this study, we identified two regions in the BCL6 gene that negatively regulate BCL6 expression, One region, ES, is located within the first exon between nucleotides +472 and +543, and a second region, IS, is located between +783 and +918 of the first intron, A consensus nucleotide sequence for the binding of the BCL6 protein itself was found within the ES region. An electrophoretic mobility shift assay and a co-transfection experiment using a BCL6 expression vector showed that transcription of the BCL6 gene was negatively regulated by the BCL6 gene product. The IS region which is included in the regions commonly deleted in B-cell lymphomas had a silencer activity. Structural alterations of these two regions may play roles in the deregulated expression of the BCL6 gene in B-cell lymphomas.	Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Sch Allied Hlth Sci, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Capello D, 1997, BRIT J HAEMATOL, V99, P168, DOI 10.1046/j.1365-2141.1997.3573171.x; Cattoretti G., 1997, Blood, V90, p175A; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Gaidano G, 1997, BLOOD, V89, P3755; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; Liang R, 1998, CANCER GENET CYTOGEN, V102, P110, DOI 10.1016/S0165-4608(97)00353-1; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1999, BRIT J HAEMATOL, V105, P274; Nakamura Y, 1996, LEUKEMIA, V10, P658; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	22	43	43	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4941	4945		10.1038/sj.onc.1203864	http://dx.doi.org/10.1038/sj.onc.1203864			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039912				2022-12-28	WOS:000089757800017
J	Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A				Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A			MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression	ONCOGENE			English	Article						chemokine; MGSA/GRO; Ras; AP-I; melanocytes; transformation	GROWTH-STIMULATORY ACTIVITY; PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAY; TISSUE DISTRIBUTION; CANCER-CELLS; SKIN TUMORS; KAPPA-B; C-FOS; ALPHA; BETA	The MGSA/GRO protein is endogenously expressed in almost 70% of the melanoma cell lines and tumors, but not in normal melanocytes. We have previously demonstrated that over-expression of human MGSA/GRO alpha, beta or gamma in immortalized murine melanocytes (melan-a cells) enables these cells to form tumors in SCID and nude mice. To examine the possibility that the MGSA/GRO effect on melanocyte transformation requires expression of other genes, differential display was performed. One of the mRNA's identified in the screen as overexpressed in MGSA/GRO transformed melan-a clones was the newly described M-Ras or R-Ras3 gene, a member of the Ras gene superfamily, Over-expression of MGSA/GRO upregulates M-Ras expression at both the mRNA and protein levels, and this induction requires an intact glutamine-leucine-arginine (ELR)-motif in the MGSA/ GRO protein. Western blot examination of Ras expression revealed that K- and N-Ras proteins are also elevated in MGSA/GRO-expressing melan-a clones, leading to an overall increase in the amount of activated Ras, MGSA/GRO-expressing melan-a clones exhibited enhanced AP-1 activity. The effects of MGSA/GRO on AP-I activation could be mimicked by over-expression of wild-type M-Ras or a constitutively activated M-Ras mutant in control melan-a cells as monitored by an API-luciferase reporter, while expression of a dominant negative M-Ras blocked AP-1-luciferase activity in MGSA/GRO-transformed melan-a clones. In the in vitro transformation assay, over-expression of M-Ras mimicked the effects of MGSA/GRO by inducing cellular transformation in control melan-a cells, while over-expression of dominant negative M-Ras in MGSA/ GRO alpha-expressing melan-a-6 cells blocked transformation. These data suggest that MGSA/GRO-mediated transformation requires Ras activation in melanocytes.	Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA; VA Med Ctr, Nashville, TN 37232 USA; Chiba Univ, Dept Biol, Chiba, Japan	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Chiba University	Richmond, A (corresponding author), Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [R01 CA034590-19, CA56704, CA 68485, P30 CA068485, R01 CA034590, R01 CA034590-17, R01 CA056704-07, R01 CA034590-18, R01 CA056704-08] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FUJIMOTO J, 1995, J STEROID BIOCHEM, V55, P25, DOI 10.1016/0960-0760(95)00145-P; GEISER T, 1993, J BIOL CHEM, V268, P15419; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KURDOWSKA A, 1994, CYTOKINE, V6, P124, DOI 10.1016/1043-4666(94)90033-7; Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MANGUES R, 1992, ONCOGENE, V7, P2073; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rennekampff HO, 1997, ARCH DERMATOL RES, V289, P204, DOI 10.1007/s004030050181; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rutberg SE, 1997, MOL CARCINOGEN, V20, P88, DOI 10.1002/(SICI)1098-2744(199709)20:1<88::AID-MC10>3.0.CO;2-5; Sadhu C, 1998, J IMMUNOL, V160, P5622; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Shattuck-Brandt RL, 1997, DNA SEQUENCE, V7, P379, DOI 10.3109/10425179709034060; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	56	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4647	4659		10.1038/sj.onc.1203820	http://dx.doi.org/10.1038/sj.onc.1203820			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030154	Green Accepted			2022-12-28	WOS:000089438200011
J	Miller, MA; Malik, IA; Shenk, MA; Steele, RE				Miller, MA; Malik, IA; Shenk, MA; Steele, RE			The Src/Csk regulatory circuit arose early in metazoan evolution	ONCOGENE			English	Article						evolution; metazoan; Src; Csk; protein-tyrosine kinase; Cnidaria	PROTEIN-TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; YEAST; GENE; HYDRA; EXPRESSION; IDENTIFICATION; HOMOLOG; CSK; DNA	We have identified a gene encoding a member of the Csk family of non-receptor protein-tyrosine kinases (PTKs) in the early-diverging metazoan Hydra. In situ hybridization analysis of the distribution of RNA from the Hydra Csk gene indicates that it is expressed in most of the epithelial cells of the adult polyp and in gametogenic cells. Comparison of the expression pattern of Hydra Csk with that of STK, the Hydra Src gene orthologue, reveals that the two genes are largely co-expressed. Such co-expression is consistent with a role for Hydra Csk in regulation of STK activity. This possibility was tested directly by co-expressing Hydra Csk with STK in yeast. Co-expression suppressed the growth inhibition seen when STK alone is expressed in yeast. Suppression was dependent on the presence of the putative regulatory tyrosine in the carboxyl-terminal tail of STK. Phosphotyrosine immunoblot analysis confirmed that expression of Csk resulted in suppression of STK kinase activity. Taken together these data indicate that the regulatory circuit involving Src and Csk PTKs was established prior to the divergence of the phylum Cnidaria from the rest of the metazoans.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dev Biol Ctr, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Steele, RE (corresponding author), Univ Calif Irvine, Dept Biol Chem, 240D Med Sci I, Irvine, CA 92697 USA.			Miller, Michael/0000-0003-4872-7121				BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHAN TA, 1994, ONCOGENE, V9, P1253; COOPER JA, 1987, ONCOGENE RES, V1, P297; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Grens A, 1995, DEVELOPMENT, V121, P4027; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LIU HP, 1992, GENETICS, V132, P665; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; OTTILIE S, 1992, ONCOGENE, V7, P1625; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SIKORSKI RS, 1989, GENETICS, V122, P19; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; Steele RE, 1999, GENE, V239, P91, DOI 10.1016/S0378-1119(99)00373-X; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; Swofford D., 1998, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	31	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3925	3930		10.1038/sj.onc.1203714	http://dx.doi.org/10.1038/sj.onc.1203714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951585				2022-12-28	WOS:000088614300011
J	Wang, WL; Healy, ME; Sattler, M; Verma, S; Lin, J; Maulik, G; Stiles, CD; Griffin, JD; Johnson, BE; Salgia, R				Wang, WL; Healy, ME; Sattler, M; Verma, S; Lin, J; Maulik, G; Stiles, CD; Griffin, JD; Johnson, BE; Salgia, R			Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571	ONCOGENE			English	Article						small cell lung cancer; c-Kit and stem cell factor; STI 571; signal transduction in lung cancer; cell motility	C-KIT; BCR-ABL; EXPRESSION; COEXPRESSION; PAXILLIN	Small cell lung cancer (SCLC) is an aggressive cancer characterized by several autocrine growth mechanisms including stem cell factor and its receptor c-Kit, In order to arrive at potentially new and novel therapy for SCLC, we have investigated the effects of the tyrosine kinase inhibitor, STI 571, on SCLC cell lines. It has been previously reported that STI 571 does not only inhibit cellular Abl tyrosine kinase activity but also the PDGF receptor and c-Kit tyrosine kinases at similar concentrations (approximately 0.1 mu M). There is no expression of the PDGF-receptor, and the Abl kinase is not activated by SCLC, but over 70% of SCLC contain the c-Kit receptor. Utilizing this preliminary data, we have determined that three (NCI-H69, NCI-H146 and NCI-H209) of five (including NCI-H82 and NCI-H249) SCLC cell lines had detectable c-Kit receptors and were inhibited in growth and viability at concentrations 1-5 mu M of STI 571 after 48 h of treatment. The SCLC cell lines, NCI-H69, NCI-H146 and NCI-H209, showed a dose-response (tested between 0.1-10 mu M) inhibition of tyrosine phosphorylation of c-git as well as in vitro kinase activity (at 5 mu M) of c-Kit in response to STI 571, STI 571 inhibited cell motility, as assessed by time-lapsed video microscopy, within 6 h of STI 571 treatment (5 mu M). STI 571 also decreased intracellular levels of reactive oxygen species (ROS) by at least 60%, at a concentration (5 mu M) that also inhibited cell growth. Cell cycle analysis of STI 571 responsive cells showed that cells were generally slowed in G2/M phase, but there was no arrest at G1/S, A downstream phosphorylation target of c-Kit, Akt, was not phosphorylated in response to stem cell factor in the presence of STI 571, These data imply that STI 571 inhibits growth of SCLC cells through a mechanism that involves inactivation of the tyrosine kinase c-Kit, The effectiveness of STI 571 in this study suggests this drug may be useful in a clinical trial, for patients with SCLC.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Salgia, R (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Dana 530C,44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NCI NIH HHS [CA75348-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buchdunger E, 1996, CANCER RES, V56, P100; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Druker BJ, 1999, BLOOD, V94, p368A; FERRY D, 2000, P AN M AM SOC CLIN, V19, pA3; HIBI K, 1991, ONCOGENE, V6, P2291; JOHNSON BE, 1995, LUNG CANCER-J IASLC, V12, pS5, DOI 10.1016/S0169-5002(10)80014-5; Krystal GW, 1996, CANCER RES, V56, P370; PLUMMER H, 1993, CANCER RES, V53, P4337; Salgia R, 1998, BLOOD, V92, p487A; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1999, BLOOD, V94, P4233; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 1999, CANCER J SCI AM, V5, P63	23	214	230	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3521	3528		10.1038/sj.onc.1203698	http://dx.doi.org/10.1038/sj.onc.1203698			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918610				2022-12-28	WOS:000088346500008
J	Kim, SH; Forman, AP; Mathews, MB; Gunnery, S				Kim, SH; Forman, AP; Mathews, MB; Gunnery, S			Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR	ONCOGENE			English	Article						PKR; breast cancer; translation; p58; eIF2B	TETRATRICOPEPTIDE REPEAT PROTEIN; SYNTHESIS INITIATION-FACTOR; RNA-BINDING PROTEIN; NF-KAPPA-B; MALIGNANT TRANSFORMATION; CELLULAR INHIBITOR; EXPRESSION; APOPTOSIS; PATHWAY; P68	PKR is a double-stranded (ds) RNA activated protein kinase whose expression is induced by interferon. Activated PKR phosphorylates its cellular substrate, eIF2, an essential initiation factor of translation. Prior evidence from a murine model system suggested that PKR may act as a tumor suppressor, but the evidence from human tumors is equivocal. To study PKR function in human breast cancer, PKR activity was measured in mammary carcinoma cell lines and nontransformed mammary epithelial cell lines. If PKR functioned as a tumor suppressor in this system, its activity would be higher in nontransformed cells than in carcinoma cells. On the contrary, PKR autophosphorylation and the phosphorylation of its substrate, the v.-subunit of eLF2, is 7 - 40-fold higher in lysates prepared from breast carcinoma cell lines than in those from nontransformed epithelial cell lines. Correspondingly, a larger proportion of eIF2 alpha is present in a phosphorylated state in carcinoma cell lines than in nontransformed cell lines. Protein synthesis is not inhibited by the high eIF2 alpha phosphorylation in carcinoma cells, probably because they contain higher levels of eIF2B, the initiation factor that is inhibited by eIF2 alpha phosphorylation, The dramatically lower PKR activity in nontransformed cell lines is partially due to lower PKR protein levels (2-4-fold) as well as to the presence of a PKR inhibitor. The nontransformed cells contain P58, a known cellular inhibitor of PKR that physically interacts with PKR and may be responsible for the low PKR activity in these cells. Taken together, these observations call into question the role of PKR as a tumor suppressor and suggest a positive regulatory role of PKR in growth control of breast cancer cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gunnery, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Basu S, 1997, CANCER RES, V57, P943; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Beretta L, 1996, ONCOGENE, V12, P1593; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Harlow E, 1998, ANTIBODIES LAB MANUA; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Shimada A, 1998, CANCER RES, V58, P4434; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	41	94	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3086	3094		10.1038/sj.onc.1203632	http://dx.doi.org/10.1038/sj.onc.1203632			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871861				2022-12-28	WOS:000087903900006
J	Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW				Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW			DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma	ONCOGENE			English	Article						carcinogenesis; drug resistance; p53; genetic instability; SOS-repair	HOMOLOGOUS RECOMBINATION; BREAK REPAIR; PROTEIN; CELLS; RESISTANCE; RADIATION; SPHEROIDS; GENES; P53	Molecular processes that could contribute to differences in chemo- and radioresistance include variations in DNA repair mechanisms. In mammalian cells, the product of the rad51 gene mediates DNA repair via homologous recombination. We describe that in contrast to conventional monolayer cell systems Rad51 protein accumulates to high-levels in three-dimensional cell culture models as well as in orthotopic xeno-transplants of human pancreatic cancer cells. Strikingly, over-expression of wild-type Rad51 was also found in 66% of human pancreatic adenocarcinoma tissue specimens. Functional analysis revealed that Rad51 over-expression enhances survival of cells after induction of DNA double strand breaks. These data suggest that perturbations of Rad51 expression contribute to the malignant phenotype of pancreatic cancer.	Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, D-23538 Lubeck, Germany; Univ Kiel, Inst Pathol, Clin Gen & Thorac Surg, D-24105 Kiel, Germany	University of Lubeck; University of Kiel	Sturzbecher, HW (corresponding author), Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Kalthoff, Holger/B-1618-2010					Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Buchhop S, 1996, HYBRIDOMA, V15, P205, DOI 10.1089/hyb.1996.15.205; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Desoize B, 1998, ANTICANCER RES, V18, P4147; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Israel L, 1996, J THEOR BIOL, V178, P375, DOI 10.1006/jtbi.1996.0033; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kloppel GES, 1996, HISTOLOGICAL TYPING; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Ohnishi T, 1998, BIOCHEM BIOPH RES CO, V245, P319, DOI 10.1006/bbrc.1998.8440; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Strauss BS, 1998, GENETICS, V148, P1619; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanagisawa T, 1998, ORAL ONCOL, V34, P524, DOI 10.1016/S1368-8375(98)00045-1	20	167	175	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2791	2795		10.1038/sj.onc.1203578	http://dx.doi.org/10.1038/sj.onc.1203578			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851081				2022-12-28	WOS:000087318500009
J	Bowman, T; Garcia, R; Turkson, J; Jove, R				Bowman, T; Garcia, R; Turkson, J; Jove, R			STATs in oncogenesis	ONCOGENE			English	Review						STAT; oncogenes; tyrosine kinases; serine kinases; cell transformation; human cancer; cancer therapy	GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; HEMATOPOIETIC-CELL LINES; PROTEIN-TYROSINE KINASE; HUMAN BREAST-CANCER; CYTOKINE SIGNAL-TRANSDUCTION; AMINO-ACID SUBSTITUTION; PERIPHERAL-BLOOD CELLS; PIM-1 TRANSGENIC MICE; CONSTITUTIVE ACTIVATION	Since their discovery as key mediators of cytokine signaling, considerable progress has been made in defining the structure-function relationships of Signal Transducers and Activators of Transcription (STATs), In addition to their central roles in normal cell signaling, recent studies have demonstrated that diverse oncoproteins can activate specific STATs (particularly Stall and Stat5) and that constitutively-activated STAT signaling directly contributes to oncogenesis, Furthermore, extensive surveys of primary tumors and cell lines derived from tumors indicate that inappropriate activation of specific STATs occurs with surprisingly high frequency in a wide variety of human cancers. Together, these findings provide compelling evidence that aberrant STAT activation associated with oncogenesis is not merely adventitious but instead contributes to the process of malignant transformation. These studies are beginning to reveal the molecular mechanisms leading to STAT activation in the context of oncogenesis, and candidate genes regulated by STATs that may contribute to oncogenesis are being identified. Recent studies suggest that activated STAT signaling participates in oncogenesis by stimulating cell proliferation and preventing apoptosis, This review presents the evidence for critical roles of STATs in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT signaling.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Besser D, 1999, MOL CELL BIOL, V19, P1401; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buard A, 1998, CANCER RES, V58, P840; BURDELYA L, 2000, UNBUB; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CUYPERS HT, 1984, CELL, V37, P141; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; DEGROOT RP, 2000, UNPUB; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; EPLINGBURNETTE PK, 2000, UNPUB; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Frank DA, 1996, LEUKEMIA, V10, P1724; Frank DA, 1999, MOL MED, V5, P432; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GARCIA RA, 2000, UNPUB; Gollob JA, 1999, J IMMUNOL, V162, P4472; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grimley PM, 1998, BLOOD, V91, P3017, DOI 10.1182/blood.V91.8.3017.3017_3017_3027; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KELLER ET, 1995, J IMMUNOL, V154, P4091; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KRAKER AJ, 2000, UNPUB; KRUGER A, 1991, ONCOGENE, V6, P245; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Kuwahara M, 1999, DIS ESOPHAGUS, V12, P116, DOI 10.1046/j.1442-2050.1999.00034.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Murakami Y, 1998, J CELL PHYSIOL, V175, P220, DOI 10.1002/(SICI)1097-4652(199805)175:2<220::AID-JCP12>3.0.CO;2-C; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Niu GL, 1999, CANCER RES, V59, P5059; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Okuda K, 1996, ONCOGENE, V13, P1147; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OSHIRO MM, 2000, UNPUB; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pindzola JA, 1998, PATHOL RES PRACT, V194, P685; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sartor CI, 1997, CANCER RES, V57, P978; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; SINIBALDI D, 2000, UNPUB; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sparrow LE, 1998, AM J DERMATOPATH, V20, P255, DOI 10.1097/00000372-199806000-00006; STACEY DW, 1991, ONCOGENE, V6, P2297; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Puijenbroek AAFL, 1999, EXP CELL RES, V251, P465, DOI 10.1006/excr.1999.4576; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WANG YH, 2000, IN PRESS ONCOGENE; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WeberNordt RM, 1996, BLOOD, V88, P809; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Xu XL, 1998, CANCER RES, V58, P2832; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Yu CL, 1997, J IMMUNOL, V159, P5206; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; ZHANG Q, 2000, P NATL ACAD SCI US; Zhang Y.P, 2000, UNPUB; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	177	1538	1730	3	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2474	2488		10.1038/sj.onc.1203527	http://dx.doi.org/10.1038/sj.onc.1203527			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851046				2022-12-28	WOS:000087459400003
J	Doucet, C; Jasmin, C; Azzarone, B				Doucet, C; Jasmin, C; Azzarone, B			Unusual interleukin-4 and-13 signaling in human normal and tumor lung fibroblasts	ONCOGENE			English	Article						lung fibroblasts; myofibroblasts; IL-4/IL-13; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; CELLS; TRANSDUCTION; IL-13; CHAIN; EXPRESSION; PATHWAYS; INVOLVEMENT	IL-4 and IL-13 act on human lung fibroblasts through specific receptors differing in their composition. Indeed, the gammac chain is constitutively expressed in tumor lung myofibroblast but not in normal cells, Here, we have analysed the signal transduction induced by IL-4 and IL-13 in both cell types, in order to better understand the molecular mechanisms underlying tumor stromal development. The IL-4R alpha chain is constitutively phosphorylated and pre-associated with the JAK1 protein in both cell types. In normal cells, we detected the activation of the classic IRS-2 or JAK1/STAT6 pathways, the phosphorylation of JAK2, while Tyk2 was constitutively phosphorylated and not modified by both cytokines, In addition to these pathways, in lung tumor myofibroblasts, IL-4 and IL-13 induced the phosphorylation of JAK3 and increased the phosphorylation of Tyk2, Interestingly, in both cell types IL-4 and IL-13 triggered an unusual pattern of STAT1 and STAT3 activation. These events probably correspond to a tissue-specific signaling important for the immunoregulatory functions of airways fibroblasts, Indeed, the inflammatory-like pattern of STATs signaling triggered by IL-4 and IL-13 in these cells may favor the homing of inflammatory and/or metastatic cells. In lung myofibroblasts, these properties could be modified through the different pattern of JAK activation.	Hop Paul Brousse, INSERM U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM U506, 16 Av PV Couturier, F-94807 Villejuif, France.		Azzarone, Bruno/AAH-9251-2019	Azzarone, Bruno/0000-0002-5962-3849				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Aringer M, 1999, IMMUNOLOGIST, V7, P139; AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; Brouty-Boye D, 2000, EUR J IMMUNOL, V30, P914, DOI 10.1002/1521-4141(200003)30:3<914::AID-IMMU914>3.0.CO;2-D; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Chen XH, 1997, J BIOL CHEM, V272, P6556, DOI 10.1074/jbc.272.10.6556; Chuang LM, 1997, BIOCHEM BIOPH RES CO, V235, P317, DOI 10.1006/bbrc.1997.6771; Chuang LM, 1996, J BIOCHEM-TOKYO, V120, P111; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; PAUL WE, 1991, BLOOD, V77, P1859; ROLLING C, 1995, ONCOGENE, V10, P1757; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SAPPINO AP, 1990, LAB INVEST, V63, P144; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SIRONI M, 1994, BLOOD, V84, P1913; SMEZBERTLING C, 1995, J BIOL CHEM, V270, P966; Smith RS, 1997, AM J PATHOL, V151, P317; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda K, 1996, J IMMUNOL, V157, P3220; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	38	31	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5898	5905		10.1038/sj.onc.1203933	http://dx.doi.org/10.1038/sj.onc.1203933			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127821				2022-12-28	WOS:000165563100009
J	Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J				Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J			Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;16)	ONCOGENE			English	Article						translin; liposarcoma; translocation; mobility-shift assay	CHROMOSOMAL TRANSLOCATIONS; TOPOISOMERASE-II; RECOMBINATION; PROTEIN; FUSION; REPAIR; MECHANISM; LEUKEMIA; ENDS	Myxoid and round-cell liposarcomas share the translocation t(12;16)(q13;p11) creating the TLS-CHOP fusion gene as a common genetic alteration. We previously reported several unique characteristics of genomic sequences around the breakpoints in the TLS and CHOP loci, and among them was the presence of consensus recognition motifs of Translin, a protein that associates with chromosomal translocations of lymphoid neoplasms. We further extended our search for Translin binding motifs in sequences adjacent to breakpoints and investigated,whether Translin binds to these sequences in vitro by mobility-shift assay. Computer-assisted search found sequences highly homologous (>70%) with Translin binding motifs adjacent to the breakpoints in 10 out of 11 liposarcomas,vith the TLS-CHOP fusion genes. All of 13 oligonucleotides corresponding to the putative binding sequences in these cases bind to Hela cell extract and also recombinant Translin protein, although the binding affinity of each motif showed considerable differences. The DNA-protein complex formation was inhibited by non-labeled competitor or anti-Translin antibody, suggesting the specificity of the complex formation. Considering the high incidence and specific binding property, the presence of Translin binding motif may be one of the important determinants for the location of breakpoints in the TLS and CHOP gents in liposarcomas.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Kyoto 6068507, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 6068507, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan	Kyoto University; Kyoto University; Kyoto University; National Institute of Infectious Diseases (NIID)	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.							AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; Badge RM, 2000, HUM MOL GENET, V9, P1239, DOI 10.1093/hmg/9.8.1239; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kasai M, 1997, J BIOL CHEM, V272, P11402; Obata K, 1999, GENE CHROMOSOME CANC, V25, P6, DOI 10.1002/(SICI)1098-2264(199905)25:1<6::AID-GCC2>3.3.CO;2-D; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	18	24	26	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5821	5825		10.1038/sj.onc.1203943	http://dx.doi.org/10.1038/sj.onc.1203943			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126370	Green Submitted			2022-12-28	WOS:000165477700015
J	Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C				Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C			TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin	ONCOGENE			English	Article						TTC4; malignant melanoma; sequencing analysis	TETRATRICOPEPTIDE REPEAT MOTIFS; HUMAN PROTEIN; CELL-LINES; PROGRESSION; IDENTIFICATION; CYTOGENETICS; EXPRESSION; HOMOLOG	A novel candidate tumor suppressor gene, TTC4, on chromosome 1p31 has been described recently. Since aberrations in this region have been detected in malignant melanoma, we investigated DNA of paraffin-embedded sections from 16 typical naevi, 19 atypical naevi, 32 primary melanomas (15 superficial spreading melanomas, 17 nodular melanomas) and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis for mutations in all exons of TTC4. Tumors comprised a wide range of thickness (Breslow index) and Clark levels. No mutations could be detected in typical or atypical naevi, but we found se, cn different point mutations in the tumor samples, sis of them causing an amino acid change. Ten melanoma samples belonging to nine patients showed one or more of these mutations. In detail, in sis of 25 metastases, in two of 17 nodular melanomas and in two of 15 superficial spreading melanomas point mutations could be detected, In two cell lines, a loss of a whole exon could be demonstrated and in one cell line we found a point mutation. In addition, three polymorphisms were found. Our findings indicate that TTC4 may participate in the pathogenesis of malignant melanomas of the skin.	Univ Greifswald, Inst Forens Med, D-17489 Greifswald, Germany; Univ Greifswald, Dept Dermatol, D-17489 Greifswald, Germany; Univ Greifswald, Inst Pathol, D-17489 Greifswald, Germany; Cleveland Clin Fdn, Ctr Mol Genet, Cleveland, OH USA	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Cleveland Clinic Foundation	Poetsch, M (corresponding author), Univ Greifswald, Inst Forens Med, Kuhstr 30, D-17489 Greifswald, Germany.			Cowell, John/0000-0002-2079-5950				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Heim S., 1995, CANC CYTOGENETICS CH, V2nd; HONORE B, 1992, J BIOL CHEM, V267, P8485; Isfort RJ, 1997, ONCOGENE, V15, P1797, DOI 10.1038/sj.onc.1201535; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Poetsch M, 1998, LAB INVEST, V78, P883; Poetsch M, 1999, VIRCHOWS ARCH, V435, P105, DOI 10.1007/s004280050406; POETSCH M, 2000, IN PRESS CANC GENET; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SIRACKY J, 1982, NEOPLASMA, V29, P661; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Su GF, 2000, INT J MOL MED, V5, P197; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; Zhang H, 1999, PROTEIN SCI, V8, P1658, DOI 10.1110/ps.8.8.1658	21	11	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5817	5820		10.1038/sj.onc.1203961	http://dx.doi.org/10.1038/sj.onc.1203961			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126369				2022-12-28	WOS:000165477700014
J	Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M				Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M			A role for FAK in the concanavalin A-dependent secretion of matrix metalloproteinase-2 and-9	ONCOGENE			English	Article						matrix metalloproteinase; MMP-2; MMP-9; FAK; concanavalin A; signal transduction	FOCAL ADHESION KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; C-RAS; COLLAGENASE; ACTIVATION; CANCER; INVASION; FIBROBLASTS	To study the signaling pathway critical for the secretion of matrix metalloproteinases (MMPs), we examined the role of focal adhesion kinase (FAK) in Concanavalin A (Con A)-stimulated cells, We established a cell line in which FAK gene was conditionally inducible by use of EAR-nub fibroblasts and the tetracycline repression system. In this cell line, FAK expression was undetectable in the presence of tetracycline but induced within 1 day by the removal of the drug. We found that FAK expression augmented the Con A-dependent secretion of MMP-9 and MMP-2, In contrast, proteolytic activation of MMP-2 by Con A-treatment did not require FAK expression. In addition, activation of MMP-secretion and tyrosine phosphorylation of FAK by Con A, but not the proteolytic activation of MMP-2, required attachment of the cells to the extracellular matrix. Taken together, our results suggest that the FAK signaling pathway play a pivotal role in the secretion of MMPs.	Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan	Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			AMIN, ARM/0000-0001-9144-2960				BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3053; HURUM S, 1982, BIOCHEM BIOPH RES CO, V107, P357, DOI 10.1016/0006-291X(82)91712-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kataoka M, 1996, INT J ONCOL, V8, P773; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIOTTA LA, 1986, CANCER RES, V46, P1; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Shibata K, 1997, CANCER RES, V57, P5416; Shibata K, 1998, CANCER RES, V58, P900; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S	17	75	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5539	5542		10.1038/sj.onc.1203932	http://dx.doi.org/10.1038/sj.onc.1203932			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114732				2022-12-28	WOS:000165396100015
J	Thomas, A; Giesler, T; White, E				Thomas, A; Giesler, T; White, E			p53 mediates Bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway	ONCOGENE			English	Article						Cdc42; p53; Bcl-2; JNK1; PAK1; apoptosis	SIGNAL-TRANSDUCTION PATHWAY; WISKOTT-ALDRICH SYNDROME; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; E1B 19K PROTEIN; P53-DEPENDENT APOPTOSIS; ACTIN CYTOSKELETON; RHO-GTPASES; ION-CHANNEL; BAX GENE	A member of the small G protein family, cdc42, was isolated from a screen undertaken to identify p53-inducible genes during apoptosis in primary baby rat kidney (BRK) cells transformed with E1A and a temperature-sensitive mutant p53 using a PCR-based subtractive hybridization method. Cdc42 is a GTPase that belongs to the Rho/Rac subfamily of Ras-like GTPases, In response to external stimuli, Cdc42 is known to transduce signals to regulate the organization of the actin cytoskeleton, induce DNA synthesis in quiescent fibroblasts, and promote apoptosis in neuronal and immune cells. In this study, we have demonstrated that cdc42 mRNA and protein were up-regulated in the presence of wild-type p53 in BRK cells, followed by cytoplasmic to plasma membrane translocation of Cdc42, Overexpression of Cdc42 in the presence of a dominant-negative mutant p53 induced apoptosis rapidly, indicating that Cdc42 functions downstream of p53, Furthermore, stable expression of a dominant-negative mutant of Cdc42 partially inhibited p53-mediated apoptosis, The Bcl-2 family members Bcl-x(L), and the adenovirus protein E1B 19K, inhibited Cdc42-mediated apoptosis, whereas Bcl-2 did not. We provide evidence that PAK1 and JNK1 may play a role downstream of Cdc42 to transduce its apoptotic signal. Cdc42/PAK1 activates JNK1-induced phosphorylation of Bcl-2, thereby inactivating its function, and that a phosphorylation resistant mutant (Bcl-2S70,87A,T56,74A) gains the ability to inhibit Cdc42- and p53-mediated apoptosis, Thus, one mechanism by which p53 promotes apoptosis is through activation of Cdc42 and inactivation of Bcl-2.	Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	White, E (corresponding author), HHMI, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MCGLADE CJ, 1989, VIROLOGY, V168, P119, DOI 10.1016/0042-6822(89)90410-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muraoka M, 1996, ONCOGENE, V12, P1565; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG W, 1997, J BIOL CHEM, V222, P24819; Zhao RB, 2000, GENE DEV, V14, P981; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	67	91	94	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5259	5269		10.1038/sj.onc.1203895	http://dx.doi.org/10.1038/sj.onc.1203895			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077443				2022-12-28	WOS:000165059700007
J	Shimizu, T; Awai, N; Takeda, K				Shimizu, T; Awai, N; Takeda, K			Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells	ONCOGENE			English	Article						leukemia; differentiation; CDK; p27; p18	DEPENDENT KINASE INHIBITOR; RETINOIC ACID; CYCLE ARREST; MYELOID-LEUKEMIA; P21; P27(KIP1); INDUCTION; P18(INK4C); MEDIATOR; CLONING	We previously reported that all-trans retinoic acid (ATRA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) synergistically induced granulocytic differentiation in human myeloblastic leukemia ML-1 cells. The combination of these agents also suppressed DNA-synthesis. In the present study, we investigated the suppression of cyclin dependent kinase (CDK) activities resulting in G1 arrest in differentiated ML-1 cells. We show that treatment of ML-1 cells with ATRA plus GM-CSF results in G1 arrest and suppression of CDK activities, Protein levels of the G1 CDKs were essentially unchanged during this time, However, we observed an increase in CDK2-bound p27 and CDK4-bound pig, and a decrease in CDK6-bound cyclin D3, These results suggest that complex regulation of CDKs play a key role in Ct arrest of ML-l after treatment with ATRA and GM-CSF, We also showed that an increase in CDK2-bound p27 and CDK4-bound p18 are caused by treatment with ATRA and a decrease in CDK6-bound cyclin D3 is induced synergistically by treatment with both reagents. Furthermore, we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in p27 binding to CDK2 is due to a novel mechanism.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan	Tokyo University of Science	Takeda, K (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oka Y, 1997, ANTICANCER RES, V17, P1951; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Saito Y, 1999, ANTICANCER RES, V19, P1069; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu T, 1999, LEUKEMIA RES, V23, P901, DOI 10.1016/S0145-2126(99)00106-X; Singh SP, 1998, CANCER RES, V58, P1730; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; TAKEDA K, 1982, CANCER RES, V42, P5152; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TAKEI M, 1984, BIOCHEM BIOPH RES CO, V124, P100, DOI 10.1016/0006-291X(84)90922-7; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4640	4646		10.1038/sj.onc.1203821	http://dx.doi.org/10.1038/sj.onc.1203821			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030153				2022-12-28	WOS:000089438200010
J	Petrocelli, T; Slingerland, J				Petrocelli, T; Slingerland, J			UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35	ONCOGENE			English	Article						UVB; cell cycle; checkpoint; DNA damage; Cdc25A	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3-BETA; DNA-DAMAGE CHECKPOINT; D-DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; TYROSINE PHOSPHORYLATION; FISSION YEAST; INHIBITORY PHOSPHORYLATION; ULTRAVIOLET-IRRADIATION; PHASE PROGRESSION	The activation of cell cycle checkpoints in response to genotoxic stressors is essential for the maintenance of genomic integrity. Although most prior studies of cell cycle effects of UV irradiation have used UVC, this UV range does not penetrate the earth's atmosphere. Thus, we have investigated the mechanisms of ultraviolet B (UVB) irradiation-induced cell cycle arrest in biologically relevant target cell type, the early stage human melanoma cell line, WM35. Irradiation of WM35 cells with UVB resulted in arrests throughout the cell cycle: at the G1/S transition, in S phase and in G2. G1 arrest was accompanied by increased association of p21 with cyclin E/cdk2 and cyclin A/cdk2, increased binding of p27 to cyclin E/cdk2 and inhibition of these Kinases, A loss of Cdc25A expression was associated with an increased inhibitory phosphotyrosine content of cyclin and cyclin A-associated cdk2 and may also contribute to G1 arrest following UVB irradiation. The association of Cdc25A with 14-3-3 was increased by UVB, Reduced cyclin D1 protein and increased binding of p21 and p27 to cyclin D1/cdk4 complexes were also observed. The loss of cyclin D1 could not be attributed to inhibition of either MAPK or PI3K/PKB pathways, since both were activated by UVB. Cdc25B levels fell and the remaining protein showed an increased association with 14-3-3 in response to UVB, Losses in cyclin B1 expression and an increased binding of p21 to cyclin B1/cdk1 complexes also contributed to inhibition of this kinase activity, and G2/M arrest.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Res Bldg,S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARKER D, 1995, CANCER RES, V55, P4041; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Florenes VA, 1996, ONCOGENE, V13, P2447; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pedley J, 1996, ONCOGENE, V13, P1335; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrocelli T, 1996, ONCOGENE, V12, P1387; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; REED SI, 1994, J CELL SCI, P69; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	82	23	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4480	4490		10.1038/sj.onc.1203808	http://dx.doi.org/10.1038/sj.onc.1203808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002421				2022-12-28	WOS:000089236800005
J	Kang, BS; French, OG; Sando, JJ; Hahn, CS				Kang, BS; French, OG; Sando, JJ; Hahn, CS			Activation-dependent degradation of protein kinase C eta	ONCOGENE			English	Article						protein kinase C; down-regulation; proteolysis; phorbol ester; ubiquitin; proteasome	MOUSE THYMOMA CELLS; DOWN-REGULATION; EXPRESSION VECTORS; COUPLED RECEPTOR; UP-REGULATION; BETA-II; PHOSPHORYLATION; APOPTOSIS; INACTIVATION; PATHWAY	Prolonged activation of protein kinase Cs (PKCs) by long-term treatment of cells with phorbol ester tumor promoters down-regulates the expression of many PKCs, To investigate the molecular mechanisms involved in the down-regulation of PKC eta, we expressed the novel PKCs eta and theta and various mutant forms in baby hamster kidney cells. Upon overexpression, constitutively active PKC eta, but not wild type or kinase-dead PKC eta, underwent rapid degradation to generate several lower molecular weight polypeptides. When co-expressed with active kinases, kinase-dead PKC eta with a pseudosubstrate site mutation designed to give an active conformation was dawn-regulated while the wild type PKC eta was not. These results suggest requirements for kinase activity and an active conformation for down-regulation of PKC eta. Treatment with the proteasome inhibitors N-Ac-Leu-Leu-norleucinal and lactacystin led to accumulation of PKC eta proteolytic products and potentially ubiquitinated forms, While wild type PKC eta localizes mostly to the detergent-soluble fraction of the cell, a significant portion of full-length constitutively active PKC eta and of kinase-dead, active conformation PKC eta were found in the detergent-insoluble fraction. Several proteolytic fragments of constitutively active PKC eta also were found in the detergent insoluble fraction. These full-length and proteolytic fragments of PKC eta in the detergent-insoluble fraction accumulated further in the presence of proteasome inhibitors. These data suggest that active conformation PKC eta accumulates in the detergent-insoluble compartment, is degraded by proteolysis in the presence of kinase activity, and that the cleavage products undergo further degradation via ubiquitin-mediated degradation in the proteasome.	Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Box MR4-4012, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM54572, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HONG DH, 1995, BBA-MOL CELL RES, V1267, P45, DOI 10.1016/0167-4889(95)00024-M; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Moorman JP, 1996, J IMMUNOL, V156, P4146; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Resnick MS, 1997, CANCER RES, V57, P2209; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9	37	32	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4263	4272		10.1038/sj.onc.1203779	http://dx.doi.org/10.1038/sj.onc.1203779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980600				2022-12-28	WOS:000089032900009
J	Reddy, TR; Xu, WD; Wong-Staal, F				Reddy, TR; Xu, WD; Wong-Staal, F			General effect of Sam68 on Rev/Rex regulated expression of complex retroviruses	ONCOGENE			English	Article						Sam68; HTLV-1; EIA V; Rev-MS2; transactivation	INFECTIOUS-ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; NUCLEAR EXPORT SIGNALS; HIV-1 REV PROTEIN; I REX; MESSENGER-RNA; LEPTOMYCIN-B; TYPE-1 REV; VIRAL-RNA; IDENTIFICATION	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, C-terminal deletion mutants of Sam68 exhibit a transdominant negative phenotype in HIV replication. We now report that Sam68 also enhances the activities of Rev-like proteins of other complex retroviruses (e.g. HTLV-1 and EIAV) on their respective RNA targets. Furthermore, we demonstrate that Sam68 can function alone as well as synergize with Rev-MS2 and/or Rex-MS2 chimeric proteins on expression mediated by the corresponding RRE-MS2 fusion RNA element. Additionally, dominant negative mutants of Sam68 also repressed the synergistic activation of Sam68 with Rex, E-Rev, and/or Rev-MS2/ Rex-MS2 on their corresponding RNA targets. Thus, Sam68 may play an important role in the post-transcriptional regulation of all complex retroviruses.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; FELBER B K, 1989, New Biologist, V1, P318; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; LEWIS N, 1990, J VIROL, V64, P1690, DOI 10.1128/JVI.64.4.1690-1697.1990; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MARTARANO L, 1994, J VIROL, V68, P3102, DOI 10.1128/JVI.68.5.3102-3111.1994; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535	24	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4071	4074		10.1038/sj.onc.1203749	http://dx.doi.org/10.1038/sj.onc.1203749			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962565				2022-12-28	WOS:000088825300014
J	Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM				Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM			Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs)	ONCOGENE			English	Article						apoptosis; erbB; EGFR; phosphoinositide-3-OH kinase (PI3-K); SHP2; Signal-Regulatory Proteins (SIRPs)	EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE SHP-2; CONFERS ENHANCED TUMORIGENICITY; PHOSPHORYLATED 100-KDA PROTEIN; SRC HOMOLOGY-2 DOMAINS; TUMOR-SUPPRESSOR PTEN; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GLIOMA-CELLS; ERBB FAMILY	Several growth factors and cytokines, including EGF, are known to induce tyrosine phosphorylation of Signal Regulatory Proteins (SIRPs). Consistent with the idea that increased phosphorylation activates SIRP function, we overexpressed human SIRP alpha 1 in U87MG glioblastoma cells in order to examine how SIRP alpha 1 modulates EGFR signaling pathways. Endogenous EGFR proteins are overexpressed in U87MG cells and these cells exhibit survival and motility phenotypes that are influenced by EGFR kinase activity. Overexpression of the SIRP alpha 1 cDNA diminished EGF-induced phosphoinositide-3-OH kinase (PI3-K) activation in U87MG cells. Reduced EGF-stimulated activation of PI3-K was mediated by interactions between carboxyl terminus of SIRP alpha 1 and the Src homology-2 (SH2)-containing phosphotyrosine phosphatase, SHP2. SIRP alpha 1 overexpression also reduced the EGF-induced association between SHP2 and the p85 regulatory subunit of PI3-K. Inhibition of transformation and enhanced apoptosis following gamma-irradiation were observed in SIRP alpha 1-overexpressing U87MG cells, and enhanced apoptosis was associated with reduced levels of bcl-x(L) protein. Furthermore, SIRP alpha 1-overexpressing U87MG cells displayed reduced cell migration and cell spreading that was mediated by association between SIRP alpha 1 and SHP2. However, SIRP alpha 1-overexpressing U87MG clonal derivatives exhibited no differences in cell growth or levels of mitogen-activated protein kinase (MAPK) activation. These data reveal a pathway that negatively regulates EGFR-induced PI3-K activation in glioblastoma cells and involves interactions between SHP2 and tyrosine phosphorylated SIRP alpha 1. These results also suggest that negative regulation of PI3-K pathway activation by the SIRP family of transmembrane receptors may diminish EGFR-mediated motility and survival phenotypes that contribute to transformation of glioblastoma cells.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Ctr, Philadelphia, PA 19104 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Univ Penn, Sch Med, Abramson Family Canc Inst, Philadelphia, PA 19104 USA; Philadelphia Vet Adm Med Ctr, Dept Surg Neurosurg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Max Planck Society; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 502 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coggeshall KM, 1999, IMMUNOL RES, V19, P47, DOI 10.1007/BF02786476; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Davies MA, 1998, CANCER RES, V58, P5285; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Okada N, 1996, BIOCHEM BIOPH RES CO, V229, P607, DOI 10.1006/bbrc.1996.1851; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan M, 1999, CANCER RES, V59, P1620; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959	70	56	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3999	4010		10.1038/sj.onc.1203748	http://dx.doi.org/10.1038/sj.onc.1203748			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962556				2022-12-28	WOS:000088825300005
J	Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R				Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R			The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain	ONCOGENE			English	Article						tumor suppressor; PDZ; protein tyrosine phosphatase	TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; BETA-CATENIN; GENE-PRODUCT; FUNCTIONAL INTERACTION; GUANYLATE KINASES; MOLECULAR-CLONING; CELL-MIGRATION; IN-VITRO; PHOSPHORYLATION	Mutations of the tumor suppressor protein APC (Adenomatous Polyposis Coli) are linked to familiar and sporadic human colon cancer. Here we describe a novel interaction between the APC protein and the protein tyrosine phosphatase PTP-BL carrying five PDZ protein-protein interaction domains. Exclusively, the second PDZ domain (PDZ2) of PTP-BL is binding to the extreme C-terminus of the APC protein, as determined by yeast two-hybrid studies. Using surface plasmon resonance analysis we established a dissociation constant (K-D) of 8.1 x 10(-9) M. We find that a naturally occurring splice insertion of five amino acids (PDZ2b) abolishes its binding affinity to the APC protein. The in vivo interaction between PTP-BL and the APC protein was shown by coprecipitation experiments in transfected COS cells. Furthermore, in cultured epithelial Madine Carnine Kidney cells the subcellular colocalization was demonstrated for the nucleus and also for the tips of cellular extensions, The interaction of the APC protein with a protein tyrosine phosphatase may indirectly modulate the steady state levels of tyrosine phosphorylations of associated proteins, such as beta-catenin playing a major role in the regulation of cell division, migration and cell adhesion.	Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Biophys Analyt, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Tumorgenet, D-44227 Dortmund, Germany	Ruhr University Bochum; Max Planck Society; Max Planck Society	Erdmann, KS (corresponding author), Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany.		Leßmann, Volkmar/E-8125-2013; Heumann, Rolf/ABB-9675-2021; Eulenburg, Volker/B-7263-2013; Heumann, Rolf/AAK-4390-2020; Eulenburg, Volker/B-7263-2013	Leßmann, Volkmar/0000-0002-6863-323X; Heumann, Rolf/0000-0003-4364-2655; Eulenburg, Volker/0000-0002-4878-5746; Eulenburg, Volker/0000-0001-6314-566X				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cuppen E, 1999, FEBS LETT, V459, P291, DOI 10.1016/S0014-5793(99)01191-6; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Goold RG, 1999, J CELL SCI, V112, P3373; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Midgley CA, 1997, J PATHOL, V181, P426; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Niethammer M, 1996, J NEUROSCI, V16, P2157; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Tseng HC, 1999, P NATL ACAD SCI USA, V96, P9503, DOI 10.1073/pnas.96.17.9503	57	74	74	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3894	3901		10.1038/sj.onc.1203725	http://dx.doi.org/10.1038/sj.onc.1203725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951583	Green Submitted			2022-12-28	WOS:000088614300008
J	Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA				Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA			The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway	ONCOGENE			English	Article						genomic instability; Ras; thyroid cancer; MAP kinase	SPINDLE ASSEMBLY CHECKPOINT; THYROTROPIN RECEPTOR GENE; TOPOISOMERASE II-ALPHA; XENOPUS EGG EXTRACTS; NIH 3T3 CELLS; PROTEIN-KINASE; PAPILLARY CARCINOMAS; CANCER-CELLS; METASTATIC ABILITY; MAMMALIAN-CELLS	Activating mutations of RAS are thought to be early events in the evolution of thyroid follicular neoplasms, We used a doxycycline-inducible expression system to explore the acute effects of H-RAS(V12) on genomic stability in thyroid PCCL3 cells, At 2-3 days (first or second cell cycle) there was a significant increase in the frequency of micronucleation, Treatment of cells with YVAD-CHO inhibited RAS-induced apoptosis, but had no effect on micronucleation, The effects of H-RAS(V12) were mediated by activation of MAPK, as treatment with PD98059 at concentrations verified to selectively inhibit MEK1 reduced the frequency of prevalence of cells with micronuclei. In addition, doxycycline-inducible expression of a constitutively active MEK1, but not of a mutant RAC1, mimicked the effects of H-RAS(V12). The effects of H-RAS(V12) on genome destabilization were apparent even though the sequence of p53 in PCCL3 cells was confirmed to be wild-type. Acute activation of H-RAS(V12) evoked a proportional increase in both CREST negative and CREST positive micronuclei, indicating that both clastogenic and aneugenic effects were involved. H-RAS(V12) and activated MEK1 also induced centrosome amplification, and chromosome misalignment, Evidence that acute expression of constitutively activated RAS destabilizes the genome of PCCL3 cells is consistent with a mode of tumor initiation in which this oncogene promotes phenotypic progression by predisposing to large scale genomic abnormalities.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.			Shirokawa, Jill/0000-0001-5669-1478; ELISEI, ROSSELLA/0000-0002-5333-9257; Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, F32CA069711, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA69711, CA50706, CA72597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov YE, 1997, CANCER RES, V57, P1690; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Porcellini A, 1997, J MOL MED-JMM, V75, P567, DOI 10.1007/s001090050141; Powell DJ, 1998, CANCER RES, V58, P5523; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; SHIROKAWA J, 1999, 81 ANN M END SOC JUN; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; THACKER J, 1985, MUTAT RES, V150, P431, DOI 10.1016/0027-5107(85)90140-X; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WANI MA, 1994, CANCER RES, V54, P2504; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; WOESSNER RD, 1990, CANCER RES, V50, P2901; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	54	143	149	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3948	3954		10.1038/sj.onc.1203723	http://dx.doi.org/10.1038/sj.onc.1203723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951588				2022-12-28	WOS:000088614300014
J	Andersson, ML; Vennstrom, B				Andersson, ML; Vennstrom, B			A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site	ONCOGENE			English	Article						thyroid hormone; receptor; P75(gag-v-erbA); corepressor; response element	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-SEQUENCE SPECIFICITY; C-ERBA; ERYTHROID-DIFFERENTIATION; BINDING DOMAIN; COREPRESSOR SMRT; A GENE; P-BOX; PROTEIN	The v-erbA oncoprotein (P75(gag-v-erbA)) can repress thyroid hormone receptor induced transcriptional activation of target genes. A central question is hom hormone responsive elements in a target gene determine the transcriptional regulation mediated by P75(gag-v-erbA). We addressed this with receptors chimeric between P75(gag-v-erbA) and thyroid hormone receptor (TR) by testing their regulatory activities on thyroid hormone response elements (TREs) differing in the sequence of the consensus core recognition motif AGGTCA. We report here that enhances, TR dependent transcriptional activation is conferred by P75(gag-v-erbA) when the thymidine in the half site recognition motif is exchanged for an adenosine. The enhancement mas independent of the DNA binding region of P75(gag-v-erbA), whereas increased expression of corepressor abolished the enhancing effect, The data indicate that the enhancement results from an impaired DNA binding by the oncoprotein combined with an effective scavenging of corepressors. Our data thus suggest the P75(gag-v-erbA) indirectly can contribute to enhancement of thyroid hormone induced gene expression.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Vennstrom, B (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.		Andersson Lendahl, Monika/ABE-5981-2021	Andersson Lendahl, Monika/0000-0002-5690-8515				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Baniahmad A, 1998, MOL ENDOCRINOL, V12, P504, DOI 10.1210/me.12.4.504; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1993, FASEB J, V7, P904, DOI 10.1096/fasebj.7.10.8102105; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE Y, 1993, J BIOL CHEM, V268, P2021; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAWAZ Z, 1995, P NATL ACAD SCI USA, V92, P11691, DOI 10.1073/pnas.92.25.11691; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RASCLE A, 1994, ONCOGENE, V9, P2853; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schmidt S, 1998, NUCLEIC ACIDS RES, V26, P1191, DOI 10.1093/nar/26.5.1191; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1991, CELL, V65, P1; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; YEN PM, 1992, J BIOL CHEM, V267, P3565; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	53	4	4	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3563	3569		10.1038/sj.onc.1203692	http://dx.doi.org/10.1038/sj.onc.1203692			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951561	Bronze			2022-12-28	WOS:000088568300001
J	Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F				Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F			Human endothelial cells expressing polyoma middle T induce tumors	ONCOGENE			English	Article						hemangioma; middle T; endothelial cells; polyomavirus; human	OPPORTUNISTIC VASCULAR TUMORS; KAPOSIS-SARCOMA; GROWTH-FACTOR; KINASE-ACTIVITY; SRC FAMILY; NUDE-MICE; IN-VITRO; ANTIGEN; ONCOGENE; TRANSFORMATION	The middle T oncogene of murine polyomavirus (PymT) rapidly transforms and immortalizes murine embryonic endothelial cells (EC), leading to the formation of vascular tumors in newborn mice, by recruitment of host, non-transformed EC. These tumors are reminiscent of human vascular tumors like cavernous hemangioma, Kaposi's sarcoma or those characterizing Kasabach-Merrit syndrome. Here we investigate the in vitro and in vivo behavior of human primary umbilical cord vein EC expressing PymT. While PymT has been unable to transform human fibroblasts in earlier experiments or controls done here, mT expressing EC (PymT-EC) derived by infection with pLX-PymT retrovirus induce hemangiomas in nu/nu mice. These tumors contain not only human cells but also recruited mouse EC as shown by the presence of human and murine CD31 positive EC. In vitro analysis shows that PymT-EC retain endothelial specific markers like CD31, Von Willebrand factor, and VE-cadherin, and reach the confluence without signs of overgrowth. They are also responsive to vascular endothelial growth factor-A. However, their proliferation rate is increased. The balance between urokinase-type plasminogen activator and plasminogen activator inhibitor-1 is modified; RNA and catalytic activity for the former are elevated while PAI-1 RN4 is reduced. In contrast with murine model, where the PymT EC cells become immortal, the effects induced by PymT in human EC are transient. After 12-15 passages, human PymT EC stop proliferating, assume a senescent phenotype, and lose the ability to induce hemangiomas, At the same time both the amount of middle T protein and the level of activation of pp60(c-src) lower.	IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Genet Biol & Biochem, I-10100 Turin, Italy; European Inst Oncol, Dept Expt Oncol, I-20100 Milan, Italy	University of Turin; IRCCS European Institute of Oncology (IEO)	Bussolino, F (corresponding author), IRCC, Strada Prov 142,Km 3-95, I-10060 Turin, Italy.		Lanfrancone, Luisa/AAC-8671-2019; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Lanfrancone, Luisa/0000-0002-4523-3815; PRIMO, Luca/0000-0002-1294-0441; Bussolino, Federico/0000-0002-5348-1341				AGUZZI A, 1991, ONCOGENE, V6, P113; Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BEATTIE GM, 1982, P NATL ACAD SCI-BIOL, V79, P3033, DOI 10.1073/pnas.79.9.3033; Biancone L, 1999, J IMMUNOL, V162, P5263; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong QG, 1996, INT J CANCER, V65, P700, DOI 10.1002/(SICI)1097-0215(19960301)65:5<700::AID-IJC23>3.0.CO;2-9; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; FIORELLI V, 1995, J CLIN INVEST, V95, P1723, DOI 10.1172/JCI117849; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GHIGO D, 1995, J EXP MED, V181, P9, DOI 10.1084/jem.181.1.9; Giraudo E, 1996, J IMMUNOL, V157, P2618; GOLDENBERG DM, 1981, SCIENCE, V212, P65, DOI 10.1126/science.7209521; GOLDENBERG DM, 1982, P NATL ACAD SCI-BIOL, V79, P2389, DOI 10.1073/pnas.79.7.2389; GROSS L, 1983, ONCOGENIC VIRUSES, V2, P737; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HOLMAN PS, 1994, J VIROL, V68, P668, DOI 10.1128/JVI.68.2.668-673.1994; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LEVY JA, 1983, LANCET, V2, P78; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTESANO R, 1993, J CELL SCI, V105, P1013; Muhlner U, 1999, ONCOGENE, V18, P4200, DOI 10.1038/sj.onc.1203014; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SARTOR O, 1993, J BIOL CHEM, V268, P21014; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN BS, 1987, J VIROL, V61, P1221, DOI 10.1128/JVI.61.4.1221-1225.1987; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TARABOLETTI G, 1993, CANCER RES, V53, P3812; TRATTNER A, 1993, CANCER-AM CANCER SOC, V72, P1779, DOI 10.1002/1097-0142(19930901)72:5<1779::AID-CNCR2820720543>3.0.CO;2-M; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	56	24	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3632	3641		10.1038/sj.onc.1203708	http://dx.doi.org/10.1038/sj.onc.1203708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951569				2022-12-28	WOS:000088568300009
J	Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI				Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI			RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; confluence; cell cycle	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA GENE-PRODUCT; UPSTREAM BINDING-FACTOR; FACTOR-TIF-IA; FACTOR UBF; INITIATION-FACTOR; CARDIOMYOCYTE HYPERTROPHY; NEONATAL CARDIOMYOCYTES; C-FOS; PROMOTER	When 3T6 cells are confluent, they withdraw from the cell cycle. Concomitant with cell cycle arrest significant reduction in RNA polymerase I transcription (80% decrease at 100% confluence) is observed. In the present study, we examined mechanism(s) through which transcription of the ribosomal genes is coupled to cell cycle arrest induced by cell density. Interestingly with an increase in cell density (from 3-43% confluence), a significant accumulation in the cellular content of hyperphosphorylated Rb was observed. As cell density increased further, the hypophosphorylated form of Rb became predominant and accumulated in the nucleoli, Co-immunoprecipitation experiments demonstrated there was also a significant rise in the amount of hypophosphorylated Rb associated with the rDNA transcription factor UBF, This increased interaction between Rb and UBF correlated with the reduced rate of rDNA transcription. Furthermore, overexpression of recombinant Rb inhibited UBF-dependent activation of transcription from a cotransfected rDNA reporter in either confluent or exponential cells. The amounts or activities of the rDNA transcription components we examined did not significantly change with cell cycle arrest. Although the content of PAF53, a polymerase associated factor was altered marginally (decreased 38%), the time course and magnitude of the decrease did not correlate with the reduced rate of rDNA transcription. The results presented support a model wherein regulation of the binding of UBF to Rb and, perhaps the cellular content of PAF53, are components of the mechanism through which cell cycle and rDNA transcription are linked.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Massachusetts Gen Hosp, Ctr Canc, Dept Mol Oncol, Charlestown, MA 02129 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Massachusetts General Hospital	Rothblum, LI (corresponding author), Penn State Univ, Coll Med, Sigfried & Janet Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.			Hannan, Katherine/0000-0003-4186-8167; Hannan, Ross/0000-0002-2166-4493; Kennedy, Brian/0000-0002-5754-1874	NIDDK NIH HHS [DK13499, DK15658] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658, R01DK013499, R37DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts B., 1994, MOL BIOL CELL; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HANNAN KM, 1999, UNPUB ONCOGENE; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; HANNAN RD, 1995, CARDIOVASC RES, V30, P501, DOI 10.1016/S0008-6363(95)00095-X; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hempel WM, 1996, MOL CELL BIOL, V16, P557; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MAUCK JC, 1973, P NATL ACAD SCI USA, V70, P2819, DOI 10.1073/pnas.70.10.2819; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAULE MR, 1994, TRANSCRIPTION MECH R; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P190, DOI 10.1002/j.1460-2075.1994.tb06248.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	52	68	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3487	3497		10.1038/sj.onc.1203690	http://dx.doi.org/10.1038/sj.onc.1203690			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918607				2022-12-28	WOS:000088346500005
J	Bemark, M; Neuberger, MS				Bemark, M; Neuberger, MS			The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line	ONCOGENE			English	Article						somatic hypermutation; immunoglobulin genes; c-MYC	HEAVY-CHAIN LOCUS; RNA-POLYMERASE-II; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; CHROMOSOME-TRANSLOCATION; B-CELLS; TRANSCRIPTION; MUTATION; REGION; ACTIVATION	Burkitt's lymphomas harbour chromosomal translocations bringing c-MYC into the vicinity of one of the immunoglobulin gene loci. Point mutations have been described within c-MYC in several Burkitt's lymphomas and it has been proposed that translocation into the Ig loci might have transformed c-MYC into a substrate for the antibody hypermutation mechanism. Here we test this hypothesis by exploiting a Burkitt's lymphoma line (Ramos) that,ve have previously shown to hypermutate its immunoglobulin genes constitutively, We find that, during in vitro culture, Ramos mutates the c-MYC allele that is translocated into the IgH locus whilst leaving the untranslocated c-MYC and other control genes essentially unaffected. The mutations are introduced downstream of the c-MYC transcription start with the pattern of substitutions being characteristic of the antibody hypermutation mechanism; the mutation frequency is 2-3-fold lower than for the endogenous functional IgH allele, Thus chromosomal translocations involving the Ig loci may not only contribute to transformation by deregulating oncogene expression but could also act by potentiating subsequent oncogene hypermutation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bemark, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; JOHNSTON JM, 1991, BLOOD, V78, P2419; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; PARHAM P, 1998, IMMUNOL REV; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rada C, 1997, EUR J IMMUNOL, V27, P3115, DOI 10.1002/eji.1830271206; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tumas-Brundage K, 1996, Semin Immunol, V8, P141, DOI 10.1006/smim.1996.0018; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; Wagner SD, 1996, INT IMMUNOL, V8, P701, DOI 10.1093/intimm/8.5.701; Wagner SD, 1996, ANNU REV IMMUNOL, V14, P441, DOI 10.1146/annurev.immunol.14.1.441; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YELAMOS J, 1995, NATURE, V376, P225; ZAJECKAYE M, 1988, SCIENCE, V240, P1776	48	42	44	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3404	3410		10.1038/sj.onc.1203686	http://dx.doi.org/10.1038/sj.onc.1203686			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918597				2022-12-28	WOS:000088198100008
J	Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC				Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC			Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis	ONCOGENE			English	Article						caveolin; c-myc; apoptosis; prostate cancer	IN-SITU HYBRIDIZATION; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; UP-REGULATION; CHROMOSOMAL-ANOMALIES; BREAST-CANCER; TARGET GENES; EXPRESSION; GROWTH; TRANSCRIPTION	accent data indicating that overexpression of caveolin-1 as well as c-myc are relatively. common features of advanced prostate cancer prompted us to test for potential cooperative interactions between caveolin-1 and c-myc that would be consistent with malignant progression. We used the well-characterized Rat1AmycER(TM) cells to show that the caleolin-1 gene is down-regulated at the level of transcription by c-myc. BS maintaining relatively high levels of caveolin-1 with an adenoviral vector or in stably transfected clones we show; that caveolin-1 can suppress c-myc-induced apoptosis, Further we established human prostate cancer cell lines with the mycER(TM) construct and show that clones with increased caveolin-1 are more resistant to myc-induced apoptosis and have increased capacity for growth in soft agar when c-myc is activated.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Calgary	Thompson, TC (corresponding author), Baylor Coll Med, Scott Dept Urol, 6560 Fannin St,Suite 2100, Houston, TX 77030 USA.		Johnston, Randal/B-9247-2009		NCI NIH HHS [P50-CA58204, CA50588, R0-1 CA68814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204, R01CA050588, R01CA068814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bubendorf L, 1999, CANCER RES, V59, P803; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Jenkins RB, 1997, CANCER RES, V57, P524; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qian JQ, 1997, MODERN PATHOL, V10, P1113; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shinoura N, 1999, CANCER RES, V59, P4119; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; THOMPSON TC, 1999, EMERGING THERAPEUTIC, V3, P337; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Vairo G, 1996, ONCOGENE, V13, P1511; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	121	124	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3256	3265		10.1038/sj.onc.1203654	http://dx.doi.org/10.1038/sj.onc.1203654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918582				2022-12-28	WOS:000088019300004
J	Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F				Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F			Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines	ONCOGENE			English	Article						anti-cancer drug; FTI; Cdk inhibitor; apoptosis	FARNESYL-PROTEIN TRANSFERASE; CYCLIN-DEPENDENT KINASES; RAS-TRANSFORMED CELLS; TRANSGENIC MICE; SELECTIVE-INHIBITION; CYTOCHROME-C; TUMOR-CELLS; GROWTH; DEATH; ACTIVATION	Farnesyltransferase inhibitor (FTI) induces apoptosis of transformed cells. This involves changes in mitochondria, including decrease of mitochondrial membrane potential and the release of cytochrome c, The released cytochrome c then induces events leading to the activation of caspase-3, In this study, we report that purine derivative cyclin-dependent kinase (Cdk) inhibitors, roscovitine and olomoucine, dramatically enhance this FTI-induced apoptosis of human cancer cell lines. We noticed the synergy between Cdk inhibitors and FTI through our screen to identify compounds that enhance FTI-induced apoptosis of promyelocytic leukemic cell line HL-60, The Cdk inhibitors by themselves do not induce apoptosis at the concentrations used, Roscovitine synergizes with FTI to release cytochrome c from mitochondria, In addition, we detected synergistic effects of FTI and roscovitine to inhibit hyperphosphorylation of retinoblastoma protein. Enhancement of FTI-induced apoptosis by roscovitine is not unique to HL-60 cells, since similar synergy was observed with a leukemic cell line CEM and a prostate cancer cell line LNCaP, In LNCaP cells, in addition to roscovitine and olomoucine, phophatidylinositol 3-kinase (PI 3-kinase) inhibitor, LY294002, was effective in enhancing FTI-induced apoptosis, However, the effects of roscovitine appear to be distinct from those of LY294002, since roscovitine did not affect Akt activity while LY294002 significantly decreased the activity of Akt, Our finding of the synergy between FTI and Cdk inhibitor is significant for understanding the mechanism of action of FTI as well as for clinical use of FTI.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA.			Edamatsu, Hironori/0000-0002-1335-4217	NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DER CJ, 1996, ANTI-CANCER DRUG, V7, P165; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Du W, 1999, CANCER RES, V59, P4208; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; Hung WC, 1998, INT J ONCOL, V12, P137; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Liu M, 1998, CANCER RES, V58, P4947; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; NAGASU T, 1995, CANCER RES, V55, P5310; Norgaard P, 1999, CLIN CANCER RES, V5, P35; OKADA T, 1994, J BIOL CHEM, V269, P3563; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Strickland CL, 1999, J MED CHEM, V42, P2125, DOI 10.1021/jm990030g; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	100	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3059	3068		10.1038/sj.onc.1203625	http://dx.doi.org/10.1038/sj.onc.1203625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871858				2022-12-28	WOS:000087903900003
J	Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T				Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T			Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer	ONCOGENE			English	Article						paclitaxel; p53; tubulin; drug resistance; human cancer	ANTICANCER-DRUG; P53-EXPRESSING ADENOVIRUS; GENOMIC INSTABILITY; HUMAN-CELLS; GENE; TAXOL; SENSITIVITY; CHECKPOINT; EXPRESSION; APOPTOSIS	The efficacy of anticancer therapy is limited by the development of drug resistance. While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed. In this study me examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired P-tubulin mutations which impair paclitaxel's interaction with tubulin, In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive. Two of the resistant sublines expressed high levels of transcriptionally inactive p53 protein, each with a distinct point mutation in codons 236 and 239 of the DNA binding domain. The third subline presented a novel p53 pseudo-null phenotype as a result of markedly decreased wt p53 mRNA expression, Introduction of ectopic wt p53 had no effect on PTX sensitivity in both parental and resistant cells, while it induced p21(WAF1/CIP1), demonstrating an intact p53 pathway, While PTX resistance is primarily conferred by the tubulin mutations, the loss of functional p53 observed in all clones, suggests that this loss may facilitate the development of resistance potentially by providing a clonal advantage which promotes the isolation of paclitaxel resistant cells.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Giannakakou, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X				Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1998, J CLIN ENDOCR METAB, V83, P2516, DOI 10.1210/jc.83.7.2516; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Debernardis D, 1997, CANCER RES, V57, P870; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAVRE PA, 1995, CANCER RES, V55, P4420; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KASTAN MB, 1991, CANCER RES, V51, P6304; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIYASHITA T, 1995, CELL, V80, P293; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OConnor PM, 1997, CANCER RES, V57, P4285; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	33	60	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3078	3085		10.1038/sj.onc.1203642	http://dx.doi.org/10.1038/sj.onc.1203642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871860	Green Submitted			2022-12-28	WOS:000087903900005
J	Reddy, TR				Reddy, TR			A single point mutation in the nuclear localization domain of Sam68 blocks the Rev/RRE-mediated transactivation	ONCOGENE			English	Article						Sam68; nuclear localization signal; RRE-mediated transactivation; HIV-1 inhibition	RNA-BINDING PROTEIN; KH DOMAIN; HIV-1 REV; SRC; MITOSIS; REPLICATION; GENE	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, we have shown that the C-terminal deletion mutants of Sam68 act with a transdominant negative phenotype in HIV replication, Previously, an Arginine429 mutation within the C-terminal domain of Sam68 has been reported to be critical for the localization of Sam68 in the nucleus. However, these studies were done in the context of truncated protein in which C-terminal amino acids 420-443 of Sam68 were fused to GFP. In contrast, we now report that the full length Sam68 protein having the same mutation (Arginine429 --> Alanine) is completely localized in the nucleus while another Sam68 (Proline439-->Arginine) mutant is found in the cytoplasm. The localization of these Sam68 mutant proteins also correlates,vith their function in RRE-mediated reporter gene expression, i.e. Sam68 mutant protein that is localized in the cytoplasm failed to enhance RRE-mediated transactivation. Furthermore, we demonstrate that Sam68 P439-->R inhibited the transactivation of RRE-mediated gene expression by both wild type Sam68 and Rev. These results indicate that the proline residue at position 439 unlike arginine at position 429, mag play a critical role in targeting Sam68 protein to nucleus. We propose that these negative dominant mutants of Sam68 may have potential as anti-viral agents to combat AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30AI36214-06] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0	15	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3110	3114		10.1038/sj.onc.1203637	http://dx.doi.org/10.1038/sj.onc.1203637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871864				2022-12-28	WOS:000087903900009
J	Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M				Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M			Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis	ONCOGENE			English	Article						H-ras mutant; skin papilloma; chemical carcinogenesis	CHEMICAL CARCINOGENESIS; MALIGNANT PROGRESSION; ANIMAL-MODEL; KI-RAS; ACTIVATION; INITIATION; ONCOGENES; MICE; MUTAGENESIS; MUTATIONS	To clarify the role of the H-Ras in vivo, we generated H-ras null mutant mice by gene targeting. In spite of the importance of the Ras in cell proliferation and differentiation, H-ras null mutant mice grew normally and were fertile. The oldest H-ras mutant mice grew to be more than 30 months old. We used the H-ras deficient mice to study the importance of the H-ras and other ras genes in the development of skin tumors induced by initiation with 7,12-dimethylbenz(a)anthracene (DMBA) followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), We showed that H-ras null mutant mice develop approximately six times less papillomas compared with wild-type littermates after 20 weeks of TPA treatment. While all papillomas examined (17 out of 17) in wild-type mice have mutations of H-ras at codon 61, 13 (62%) out of 21 papillomas in H-ras null mutant mice have mutations of K-vas gene at codon 12, 13, or 61 and another eight (38%) papillomas have no mutations in these codons of K-ras or N-ras genes. This suggests that the activation of H-ras gene is critical in the wild-type mice, but the activation of K-ras gene can replace the H-ras activation in the initiation step of skin tumor development in the H-ras deficient mice.	Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, Tokyo 1088638, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Core Res Evolut Sci & Technol, Tokyo 1088639, Japan; Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Cell Biol, Fukuoka 8128582, Japan; Med Ctr Canc & Cardiovasc Dis, Osaka 5378511, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2440804, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo; Kyushu University; RIKEN	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088638, Japan.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; zhong wei, he gui/0000-0002-3066-3564; Aiba, Atsu/0000-0002-8192-0778; Ichise, Taeko/0000-0002-1441-1463				BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROOKES P, 1988, MOL CARCINOGEN, V1, P82, DOI 10.1002/mc.2940010203; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HECKER E, 1982, CARCINOGENESIS COMPR; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANAM S, 1992, CANCER RES, V52, P3347; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	26	103	104	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2951	2956		10.1038/sj.onc.1203600	http://dx.doi.org/10.1038/sj.onc.1203600			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871846				2022-12-28	WOS:000087581400001
J	Herrington, J; Smit, LS; Schwartz, J; Carter-Su, C				Herrington, J; Smit, LS; Schwartz, J; Carter-Su, C			The role of STAT proteins in growth hormone signaling	ONCOGENE			English	Review						growth hormone (GH); STAT proteins; tyrosines	ACUTE-PHASE RESPONSE; PROMOTED TYROSYL PHOSPHORYLATION; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; ACID-LABILE SUBUNIT; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MESSENGER-RIBONUCLEIC-ACID; MAMMARY-GLAND DEVELOPMENT; DEPENDENT NUCLEAR IMPORT; I GENE-TRANSCRIPTION	Growth hormone (GH) has long been known to be the body's primary regulator of body growth and a regulator of metabolism, yet the mechanisms by which GH regulates the transcription of specific genes required for these processes are just now being delineated. GH binding to its receptor recruits and activates the receptor-associated JAK2 that in turn phosphorylates tyrosines within itself and the GH receptor. These tyrosines form binding sites for a number of signaling proteins, including members of the family of signal transducers and activators of transcription (STAT), Among the known signaling molecules for GH, STAT proteins play a particularly prominent role in the regulation of gene transcription. This paper will review what is currently understood about which STAT proteins are regulated by GH, how they are regulated by GH, the GH-dependent genes they regulate, and discuss current theories about how GH-activated STAT signaling is regulated, Particular attention will be given to the novel role that STAT5 plays in sexually dimorphic gene expression in the liver as determined by the secretory pattern of GH and the role of STAT5 in body growth.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [R01-DK54222, R01 DK034171, R01 DK046072, R01 DK054222, R01-DK34171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054222, R01DK034171, R01DK046072] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASPLIN CM, 1989, J CLIN ENDOCR METAB, V69, P239, DOI 10.1210/jcem-69-2-239; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Benbassat C, 1999, ENDOCRINOLOGY, V140, P3073, DOI 10.1210/en.140.7.3073; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; Boisclair YR, 1996, P NATL ACAD SCI USA, V93, P10028, DOI 10.1073/pnas.93.19.10028; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; DAI J, 1994, ENDOCRINOLOGY, V135, P1066, DOI 10.1210/en.135.3.1066; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; EILERS A, 1995, MOL CELL BIOL, V15, P3579; ENBERG B, 1994, J MOL ENDOCRINOL, V12, P39, DOI 10.1677/jme.0.0120039; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fain JN, 1999, BIOCHEM BIOPH RES CO, V263, P201, DOI 10.1006/bbrc.1999.1302; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; Freeth JS, 1998, ENDOCRINOLOGY, V139, P20, DOI 10.1210/en.139.1.20; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; HERRINGTON J, 2000, IN PRESS J BIOL CHEM; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ISGAARD J, 1988, ENDOCRINOLOGY, V122, P1515, DOI 10.1210/endo-122-4-1515; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; JOHNSON RJ, 1988, J ENDOCRINOL, V119, P101, DOI 10.1677/joe.0.1190101; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Le Stunff C, 1998, ENDOCRINOLOGY, V139, P859, DOI 10.1210/en.139.3.859; LECAM A, 1994, J BIOL CHEM, V269, P21532; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meton I, 1999, FEBS LETT, V444, P155, DOI 10.1016/S0014-5793(99)00064-2; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; PETER MA, 1993, ENDOCRINOLOGY, V133, P2624, DOI 10.1210/en.133.6.2624; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RAZ R, 1994, J BIOL CHEM, V269, P24391; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Simar-Blanchet AE, 1998, MOL ENDOCRINOL, V12, P391, DOI 10.1210/me.12.3.391; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SMIT LS, 1999, HDB PHYSL, V5, P445; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; STOFEGA MR, 2000, UNPUB J BIOL CHEM; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1993, J BIOL CHEM, V268, P3573; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINER LM, 1990, J CLIN ENDOCR METAB, V70, P1678, DOI 10.1210/jcem-70-6-1678; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	166	215	225	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2585	2597		10.1038/sj.onc.1203526	http://dx.doi.org/10.1038/sj.onc.1203526			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851057	Green Published			2022-12-28	WOS:000087459400014
J	Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM				Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM			PKC-delta is an apoptotic lamin kinase	ONCOGENE			English	Article						apoptosis; nuclear lamina; PKC-delta	PROTEIN-KINASE; C-DELTA; PROTEOLYTIC ACTIVATION; NUCLEAR TRANSLOCATION; HL-60 CELLS; PHOSPHORYLATION; ALPHA; DYNAMICS; SITES; DEATH	Protein kinase C-delta is activated during apoptosis, following proteolytic cleavage by caspase 3. Furthermore, overexpression of the catalytic kinase fragment of PKC-delta induces the nuclear phenotype associated with apoptosis, though the molecular basis of this effect has not been determined. In these studies we have examined the role of PKC-delta in the disassembly of the nuclear Lamina at apoptosis. The nuclear lamina is disassembled during mitosis and apoptosis and mitotic disassembly involves hyperphosphorylation of lamin proteins by mitotic lamin kinases. During apoptosis, lamin proteins are degraded by caspase 6 and the contribution made by phosphorylation has not been proven. We show here that protein kinase C-delta co-localized with lamin B during apoptosis and activation of PKC-delta by caspase 3 was concomitant with lamin B phosphorylation and proteolysis. Inhibition of PKC-delta delayed lamin proteolysis, even in the presence of active caspase 6, whilst inhibitors of mitotic lamin kinases were without effect. In addition recombinant human PKC-delta was able to phosphorylate lamin B in vitro suggesting that its actions are direct and not via an intermediary kinase. We propose that PKC-delta is an apoptotic lamin kinase and that efficient lamina disassembly at apoptosis requires both lamin hyperphosphorylation and caspase mediated proteolysis.	Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England; Queensland Inst Med Res, Brisbane, Qld 4006, Australia	University of Birmingham; QIMR Berghofer Medical Research Institute	Lord, JM (corresponding author), Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England.		Watters, Dianne J/E-6007-2010; Gough, Michael/AAY-3419-2020; Sallis, Rosemary/H-4241-2014	Watters, Dianne J/0000-0002-2555-5825; Gough, Michael/0000-0002-5575-0074; Lord, Janet/0000-0003-1030-6786				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVANS CA, 1995, J CELL SCI, V108, P2591; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOZAK P, 1995, J CELL SCI, V108, P635; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Mikulits W, 1997, DNA CELL BIOL, V16, P849, DOI 10.1089/dna.1997.16.849; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; WHELAN RDH, 1998, EMBO J, V14, P6148; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yazaki T, 1996, MOL PHARMACOL, V50, P236; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	31	190	193	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2331	2337		10.1038/sj.onc.1203555	http://dx.doi.org/10.1038/sj.onc.1203555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822384				2022-12-28	WOS:000086974300008
J	Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD				Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD			Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability	ONCOGENE			English	Article						mismatch repair; hPMS2; colon cancer; MNNG; HPRT	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; CARCINOMA CELL-LINES; TUMOR-CELLS; NUCLEAR EXTRACTS; DEFICIENCY; DEFECTS; HYPERMUTABILITY; HETERODIMER; PHENOTYPES	Inactivation of DIVA-mismatch repair underlies the genesis of microsatellite unstable (MSI) colon cancers. hPMS2 is one of several genes encoding components of the DNA-mismatch repair complex, and germline hPMS2 mutations have been found in a fem kindreds with hereditary nonpolyposis colorectal carcinoma (HNPCC), in whom hereditary MSI colon cancers develop. Ho tr ever, mice bearing null hPMS2 genes do not develop colon cancers and hPMS2 mutations in sporadic human colon cancers have not been described, Here we report that in Vaco481 colon cancer the hPMS2 gene is inactivated by somatic mutations of both hPMS2 alleles, The cell line derived from this tumor is functionally deficient in DNA mismatch repair. This deficiency can be biochemically complemented by addition of a purified hMLH1-hPMS2 (hMutL alpha) complex, The hPMS2 deficient Vaco481 cancer cell line demonstrates microsatellite instability, an elevated HPRT gene mutation rate, and resistance to the cytotoxicity of the alkylator MNNG. We conclude that somatic inactivation of hPMS2 can play a role in development of sporadic MSI colon cancer expressing the full range of cancer phenotypes associated with inactivation of the mismatch repair system.	Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; Duke University; Howard Hughes Medical Institute; Duke University	Markowitz, SD (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA.			Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [R01 CA67409, R01 CA 70788] Funding Source: Medline; NIGMS NIH HHS [R01 GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, R01CA070788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinz JM, 1999, CARCINOGENESIS, V20, P215, DOI 10.1093/carcin/20.2.215; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; Umar A, 1997, CANCER RES, V57, P3949	35	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2249	2256		10.1038/sj.onc.1203568	http://dx.doi.org/10.1038/sj.onc.1203568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822375				2022-12-28	WOS:000086974100010
J	Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW				Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW			Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion	ONCOGENE			English	Article						transcription; AP-1; invasion	ONCOGENE-INDUCED TRANSFORMATION; DOMINANT-NEGATIVE MUTANT; C-JUN; CELL-TRANSFORMATION; PROTO-ONCOGENE; TUMOR INVASION; DNA-BINDING; IN-VITRO; MORPHOLOGICAL TRANSFORMATION; NEOPLASTIC TRANSFORMATION	The transcription factor AP-1 (activator protein-1) is required for transformation by many oncogenes, which function upstream of it in the growth factor-ras signal transduction pathway. Previously, we proposed that one role of AP-1 in transformation is to regulate the expression of a multigenic invasion programme. As a test of this proposal we sought to identify AP-1 regulated genes based upon their differential expression in 208F rat fibroblasts transformed by FBR-v-fos (FBR), and to determine if they functioned in the invasion programme. Subtracted cDNA libraries specific for up- or down-regulated genes in FBRs compared to 208Fs were constructed and analysed. Northern analysis revealed that the cDNAs in both libraries represented differentially expressed genes. Nucleic acid sequence analysis of randomly selected cDNA clones from each library coupled with searches of nucleic acid and amino acid sequence databases determined that many of the cDNAs represented proteins that function in various aspects of the invasion process. Functional analysis of one the down-regulated genes, TSC-36/follistatin-related protein (TSC-36/Frp), which has not previously been associated with invasion, demonstrated that its expression in FBRs inhibited in vitro invasion. These results support the proposal that AP-1 in transformed cells regulates a multigenic invasion programme.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ozanne, BW (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Stapleton, Genevieve/0000-0002-7493-5277				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bardelli A, 1997, CIBA F SYMP, V212, P133; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guang RJ, 2000, CANCER RES, V60, P749; HAJNAL A, 1993, CANCER RES, V53, P4670; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOOSS KU, 1995, ONCOGENE, V10, P603; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim S, 1996, ONCOGENE, V12, P1043; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Liang P, 1997, Methods Mol Biol, V85, P3; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lutfiyya LL, 1998, GENETICS, V150, P1377; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RIGBY PWJ, 1984, PHILOS T ROY SOC B, V307, P347, DOI 10.1098/rstb.1984.0138; SAEZ E, 1995, CANCER RES, V55, P6196; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOH Y, 1994, J BIOL CHEM, V269, P22958; Treinies I, 1999, MOL CELL BIOL, V19, P321; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WERNERT N, 1994, CANCER RES, V54, P5683; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WICK M, 1992, ONCOGENE, V7, P859; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	95	61	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5348	5358		10.1038/sj.onc.1203927	http://dx.doi.org/10.1038/sj.onc.1203927			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103936				2022-12-28	WOS:000165302300006
J	Xiao, GT; Sun, SC				Xiao, GT; Sun, SC			Activation of IKK alpha and IKK beta through their fusion with HTLV-I Tax protein	ONCOGENE			English	Article						I kappa B kinase; HTLV-I Tax; NF-kappa B; T-cell activation	NF-KAPPA-B; T-CELL LEUKEMIA; TRANSFORMING PROTEIN; KINASE COMPLEX; VIRUS TYPE-1; GAMMA; IDENTIFICATION; COMPONENT; REPEAT; MEKK1	Human T-cell leukemia virus type I (HTLV-I) Tax protein persistently stimulates the activity of I kappaB kinase (IKK), resulting in constitutive activation of the transcription factor NF-kappaB. Tax activation of IKK requires physical interaction of this viral protein with the IKK regulatory subunit, IKK gamma. The Tax/IKK gamma interaction allows Tax to engage the IKK catalytic subunits, IKK alpha and IKK beta, although it remains unclear whether this linker function of IKK gamma is sufficient for supporting the Tax-specific IKK activation. To address this question, we have examined the sequences of IKK gamma required for modulating the Tax/IKK signaling. We demonstrate that when fused to Tax, a small N-terminal fragment of IKK gamma, containing its minimal IKK alpha/beta -binding domain, is sufficient for bringing Tax to and activating the IKK catalytic subunits, Disruption of the IKK alpha/beta -binding activity of this domain abolishes its function in modulating the Tax/IKK signaling. We further demonstrate that direct fusion of Tax to IKK alpha and IKK beta leads to activation of these kinases. These findings suggest that the IKK gamma -directed Tax/TKK association serves as a molecular trigger for IKK activation.	Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; XIAO G, 2000, IN PRESS J BIOL CHEM; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	30	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5198	5203		10.1038/sj.onc.1203894	http://dx.doi.org/10.1038/sj.onc.1203894			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064457				2022-12-28	WOS:000090124100009
J	Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M				Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M			Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells	ONCOGENE			English	Article						sFRP; Wnt signaling; migration; MMP-2; beta-catenin; malignant glioma	CADHERIN-CATENIN COMPLEX; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; FACTOR RECEPTOR; IN-VITRO; TYROSINE-PHOSPHATASE; SPEMANN ORGANIZER; CARCINOMA-CELLS; CD95 LIGAND; MIGRATION	Cellular resistance to multiple proapoptotic stimuli and invasion of surrounding brain tissue by migrating tumor cells are main obstacles to an effective therapy for human malignant glioma. Here, we report that the Wnt family of embryonic differentiation genes modulate growth of malignant glioma cells in vitro and in ville and inhibit cellular migration in vitro. sFRPs (soluble Frizzled-related proteins) are soluble proteins that bind to Wnt and interfere with Wnt signaling. We find that sFRP-1 and sFRP-2 are produced by the majority of longterm and ex vivo malignant glioma cell lines. Glioma cells that ectopically express sFRPs exhibit increased clonogenicity and enhanced resistance to serum starvation. In contrast, sFRPs do not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines, CD95 (Fas/APO-1) ligand (CD95L) or Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL), or various cytotoxic drugs. sFRP-2 strongly promotes the growth of intracranial glioma xenografts in nude mice. In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of beta-catenin. Thus, sFRPs promote survival under non-supportive conditions and inhibit the migration of glioma cells. We suggest that the regulation of these cellular processes involves expression of MMP-2: and tyrosine phosphorylation of beta-catenin. These data support a function for Wnt signaling and its modulation by sFRPs in the biology of human gliomas.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; LXR Biotechnol Inc, Richmond, CA 94804 USA	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Platten, Michael/F-2902-2013	Platten, Michael/0000-0002-4746-887X; Weller, Michael/0000-0002-1748-174X				Amberger VR, 1998, CANCER RES, V58, P149; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; APODACA G, 1990, CANCER RES, V50, P2322; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dennis S, 1999, J CELL SCI, V112, P3815; Deryugina EI, 1997, J CELL SCI, V110, P2473; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Friedlander DR, 1996, CANCER RES, V56, P1939; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Jawhari AU, 1999, J PATHOL, V187, P155, DOI 10.1002/(SICI)1096-9896(199901)187:2<155::AID-PATH193>3.0.CO;2-E; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu D, 1997, LAB INVEST, V77, P557; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; MERZAK A, 1994, CANCER RES, V54, P3988; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Ogawa K, 1999, CANCER RES, V59, P1830; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; Platten M, 2000, BIOCHEM BIOPH RES CO, V268, P607, DOI 10.1006/bbrc.2000.2176; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Roth W, 2000, BRAIN PATHOL, V10, P223, DOI 10.1111/j.1750-3639.2000.tb00256.x; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WELLER M, 1995, CANCER RES, V55, P2936; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yamamoto M, 1996, CANCER RES, V56, P384; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zurawel RH, 1998, CANCER RES, V58, P896	49	140	148	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4210	4220		10.1038/sj.onc.1203783	http://dx.doi.org/10.1038/sj.onc.1203783			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980594				2022-12-28	WOS:000089032900003
J	Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J				Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J			Isolation and characterization of the human A-myb promoter: regulation by NF-Y and Sp1	ONCOGENE			English	Article						myb; promoter; Sp1; NF-Y	CELL-CYCLE REGULATION; TRANSCRIPTION FACTOR; B-MYB; GENE-EXPRESSION; IN-VIVO; C-MYB; BURKITTS-LYMPHOMA; MUSCLE CELLS; CLASS-II; BINDING	The A-myb transcription factor shows a restricted tissue distribution and is cell cycle regulated. Furthermore its deregulation has profound effects on the growth and/or differentiation of the cells in which it is normally expressed. We have therefore characterized its promoter. A 12 kb genomic clone was isolated that comprises the first exon, part of the first intron as well as upstream regulatory sequences. Multiple transcription start sites have been identified which operate in both B lymphocytes and epithelial cells and the upsteam region was shown to have promoter, activity. The boundaries of the minimal promoter region (-183-14), of a positive upstream (-538-183) and a negative downstream regulatory region (NRE) (+83+374) have been defined. The NRE is promoter- and orientation-independent but position specific. The A-myb minimal promoter is GC-rich, does not contain any TATA box but has a functional CCAAT box. The! CCAAT box and minimal promoter is highly conserved in the corresponding murine sequence, The CCAAT box efficiently binds the NF-Y complex and its mutation decreases basal promoter activity by 50%, Two Sp1 binding sites are present upstream from the CCAAT box which can bind Sp1 and contribute to A-myb promoter activity by 70 and 30%, respectively. The two Sp1 sites and CCAAT box together contribute to over 80% of A-myb basal promoter activity and are therefore the major regulatory elements. Finally, we show that the promoter is cell cycle regulated and that the SP1 and CCAAT elements are required for S phase induction.	Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, I-20157 Milan, Italy; Univ Milan, Dept Genet & Biol Microorganisms, I-20133 Milan, Italy; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Imperial College London; Ludwig Institute for Cancer Research	Introna, M (corresponding author), Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, Via Eritrea 62, I-20157 Milan, Italy.		Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; FOOS G, 1994, ONCOGENE, V9, P2481; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huet X, 1996, MOL CELL BIOL, V16, P3789; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Latham KE, 1996, ONCOGENE, V13, P1161; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; METTUS RV, 1994, ONCOGENE, V9, P3077; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Saville MK, 1998, ADV CANCER RES, V72, P109; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wells J, 1996, MOL CELL BIOL, V16, P634; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	53	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3931	3940		10.1038/sj.onc.1203730	http://dx.doi.org/10.1038/sj.onc.1203730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951586				2022-12-28	WOS:000088614300012
J	Sumner, R; Crawford, A; Mucenski, M; Frampton, J				Sumner, R; Crawford, A; Mucenski, M; Frampton, J			Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor	ONCOGENE			English	Article						c-Myb; knockout; definitive haemopoiesis; megakaryocytes; foetal liver	HEMATOPOIETIC-CELLS; STEM-CELLS; FACTOR GATA-2; YOLK-SAC; V-MYB; DIFFERENTIATION; KIT; EXPRESSION; APOPTOSIS; MOUSE	The c-Myb transcriptional regulator is crucial to the development and functioning of haemopoietic cells, so much so that mouse embryos homozygous for an inactivated c-myb allele die from anaemia at about day 15 of gestation. BS analysing c-myb(-/-) chimaeras we show that no mature cells of any lymphoid or myeloid lineage can be detected in adult haemopoietic tissues. This demonstrates that the effects of c-myb ablation on haemopoiesis are cell autonomous and correlates with an absence in the c-myb(-/-) foetal liver of uni- and multilineage CFUs. Indeed, CFU assays performed on E8.5 yolk sac cells revealed that haemopoietic progenitors are already defective at this st-age. However, although cells expressing high levels of c-Kit were absent, we could detect a high proportion of CD34(+) CD45(+) cells in the c-myb(-/-) foetal liver. Examination of chimaeric embryos revealed that c-myb(-/-) donor-derived CD34(+)/Kit(+) cells, representing committed definitive progenitors, initially populated the foetal liver, but are unable to expand like wild type progenitors. Our results showing no megakaryocytic CFUs and a reduction in the absolute numbers of megakargocytes in the c-myb(-/-) foetal liver also refute early suggestions that megakaryopoiesis is unaffected by the absence of c-Myb.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; John Radcliffe Hosp, Biomed Serv, Oxford OX3 9DS, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; University of Oxford; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.							Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Bernex F, 1996, DEVELOPMENT, V122, P3023; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Hogan B, 1994, MANIPULATING MOUSE E; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Krause DS, 1998, EXP HEMATOL, V26, P1086; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 1996, CURR TOP MICROBIOL, V211, P79; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MATSUMURA G, 1989, J ANAT, V167, P181; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; OGAWA M, 1993, DEVELOPMENT, V117, P1089; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	28	81	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3335	3342		10.1038/sj.onc.1203660	http://dx.doi.org/10.1038/sj.onc.1203660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918590				2022-12-28	WOS:000088198100001
J	Brenner, KA; Corbett, SA; Schwarzbauer, JE				Brenner, KA; Corbett, SA; Schwarzbauer, JE			Regulation of fibronectin matrix assembly by activated Ras in transformed cells	ONCOGENE			English	Article						Ras; fibronectin; matrix assembly	CHICK-EMBRYO FIBROBLASTS; FOCAL ADHESION KINASE; FIBRO-SARCOMA CELLS; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTEGRIN ACTIVATION; CYCLE PROGRESSION; GROWTH-FACTOR	Fibronectin extracellular matrix plays a critical role in the microenvironment of cells. Loss of this matrix frequently accompanies oncogenic transformation, allowing changes in cell growth, morphology, and tissue organization. The HT1080 human fibrosarcoma cell lint is deficient in formation of fibronectin match fibrils but assembly can be induced by the glucocorticoid dex-amethasone, Here we show that fibronectin assembly can also be restored by stimulation of alpha(5)beta(1) integrin with activating antibody or with Mn2+ suggesting that integrin activity is reduced in these cells. While dexamethasone promoted actin stress fiber formation, actin filaments remained cortical following Mn2+ treatment shelving that the dexamethasone effect is not due solely to cytoskeletal changes. HT1080 cells have one activated allele of N-ras and PD98059 inhibition of signaling from Ras through ERK increased fibronectin matrix accumulation. Conversely, the p38 MAP kinase inhibitor SB203580 blocked induction of matrix and increased ERK phosphorylation, Thus, two MAP kinase pathways contribute to the control of integrin-mediated fibronectin assembly, ERK activity and fibronectin assembly were linked in three different ras-transformed cell Lines but not in SV40- or RSV-transformed cells indicating that oncogenic Ras uses a distinct mechanism to down-regulate cell-fibronectin interactions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Schwarzbauer, Jean/0000-0003-1012-7593				AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FURCHT LT, 1979, CANCER RES, V39, P2077; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRENZ H, 1993, J CELL SCI, V105, P739; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423; HYNES RO, 1975, VIROLOGY, V64, P492, DOI 10.1016/0042-6822(75)90126-9; HYNES RO, 1977, J SUPRAMOL STR CELL, V7, P397, DOI 10.1002/jss.400070311; Hynes RO, 1990, FIBRONECTINS; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; KOHNO M, 1985, J BIOL CHEM, V260, P1771; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MEYER M, 1991, J BIOL CHEM, V266, P8230; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Moustakas A, 1999, J CELL SCI, V112, P1169; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sottile J, 1998, J CELL SCI, V111, P2933; Stice Ligaya L., 1999, Frontiers in Bioscience, V4, pD72, DOI 10.2741/Stice; STONE KR, 1974, VIROLOGY, V58, P86, DOI 10.1016/0042-6822(74)90143-3; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; YAMADA KM, 1990, CANCER RES, V50, P4485; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	63	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3156	3163		10.1038/sj.onc.1203626	http://dx.doi.org/10.1038/sj.onc.1203626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918570				2022-12-28	WOS:000088019200004
J	Brown, A; Browes, G; Mitchell, M; Montano, X				Brown, A; Browes, G; Mitchell, M; Montano, X			c-abl is involved in the association of p53 and trk A	ONCOGENE			English	Article						c-abl; phosphorylation; p53 and trk A association; c-abl and trk A association	NERVE GROWTH-FACTOR; WILD-TYPE P53; TYROSINE KINASE-ACTIVITY; DNA-DAMAGE; PC12 CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; GENOTOXIC STRESS; PROTEIN-BINDING	The p53 tumour suppressor phosphoprotein associates with proteins involved in DNA replication, transcription, cell cycle machinery and regulation of its own expression, Recently it has been shown that p53 can also bind to trk A tyrosine kinase which is the receptor for nerve growth factor (NGF). This study demonstrates that p53 appears to associate with trk A via c-abl, Endogenous c-abl was detected when the trk A and p53 complex was immunoprecipitated from lysates of NGF stimulated NIH3T3 cells expressing trk A or NIH3T3 cells expressing trk A and a temperature sensitive p53 (val 135), Endogenous c-abl and trk A association was observed in NGF stimulated p53 negative fibroblasts transfected with trk A alone; suggesting that c-abl can independently bind to trk A in the absence of p53. Interestingly, association between endogenous p53 and trk A was not detected in NGF stimulated abl negative fibroblasts transfected with trk A or when these cells were exposed to gamma radiation, This result suggests that p53 preferentially binds to trk A in the presence of c-abl and that p53 and trk A do not appear to associate directly even if p53 is activated and its levels increased by gamma radiation, Overall, these data suggest that c-abl is possibly acting as an adaptor or bridge between p53 and trk A.	Newcastle Univ, Sch Med, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England	Newcastle University - UK; Cancer Research UK	Montano, X (corresponding author), Newcastle Univ, Sch Med, Canc Res Unit, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							Agami R, 1999, NATURE, V399, P809; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; GOGA A, 1995, ONCOGENE, V11, P791; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATTIONI T, 1995, ONCOGENE, V10, P1325; MICHALOWITZ D, 1990, CELL, V620, P671; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZERRAHN J, 1992, ONCOGENE, V7, P1371	62	18	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3032	3040		10.1038/sj.onc.1203619	http://dx.doi.org/10.1038/sj.onc.1203619			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871855				2022-12-28	WOS:000087581400010
J	Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B				Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B			Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src	ONCOGENE			English	Article						MET; c-Src; papillary renal cancer	FACTOR SCATTER FACTOR; PAPILLARY RENAL CARCINOMAS; TYROSINE KINASE RECEPTOR; ROUS-SARCOMA VIRUS; C-SRC; PROTOONCOGENE PRODUCT; ACTIVATING MUTATIONS; CELL CARCINOMA; RON RECEPTOR; GROWTH	We recently described germline and somatic mutations in the MET gene associated with papillary renal carcinoma type 1, MET mutation M1268T was Located in a codon highly conserved among receptor tyrosine kinases, and homologous to the codon mutated in multiple endocrine neoplasia type 2B, and many cases of sporadic medullary carcinoma of the thyroid gland (Ret M918T), Ret M918T and MET M1268T have previously been shown to be highly active in mouse NIH3T3 transformation assays, and to change the substrate specificity of the kinase. We studied the mechanism of transformation mediated by MET M1268T by analysing a clone, F4, derived from NIH3T3 cells transformed by MET M1268T, In contrast to NIH3T3 cells, F4 cells grew in suspension in tissue culture, and rapidly formed tumors in nude mice. We found that c-Src was constitutively bound to MET proteins in F4 cells, and that Src kinase activity was elevated. Transfection of dominant negative Src constructs into F4 cells eliminated the ability of F4 cells to grow in suspension culture and retarded the growth of F4 cells in vivo. The ability of transfected dominant negative Src constructs to inhibit the growth of F4 cells correlated with the inhibition of phosphorylation of paxillin and focal adhesion kinase, Transfection of dominant negative Src constructs into F4 cells had no effect on Grb2 binding or PLC gamma phosphorylation, The results suggest that c-Src participates in the tumorigenic phenotype induced in NIH3T3 cells by MET M1268T by signaling through focal adhesion kinase and paxillin.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Zbar, B (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bentz M, 1996, CYTOGENET CELL GENET, V75, P17, DOI 10.1159/000134448; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WEEMINK PAO, 1995, J BIOL CHEM, V270, P2264; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; ZHU H, 1994, J BIOL CHEM, V269, P29943	31	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2996	3002		10.1038/sj.onc.1203628	http://dx.doi.org/10.1038/sj.onc.1203628			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871851				2022-12-28	WOS:000087581400006
J	Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R				Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R			IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation	ONCOGENE			English	Article						insulin-like growth factor; IGF-I receptor; prostate cancer; PTEN; IRS-I	GROWTH-FACTOR-I; DOMINANT-NEGATIVE MUTANT; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; INSULIN-RECEPTOR; TUMOR-GROWTH; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; TYROSINE PHOSPHORYLATION; ALPHA-V-BETA-3 INTEGRIN; BINDING-PROTEINS	LNCaP prostatic cancer cells are characterized by having a PTEN mutation, low levels of type 1 insulin-like growth factor receptor (IGF-IR) and no IRS-1, one of the major substrates of the IGF-IR, The absence of IRS-1, an activator of PI3-kinase, is compensated in these cells by the mutation in PTEN, an inhibitor of PI3-kinase, However, IGF-IR signaling in the absence of IRS-1 can cause cell differentiation and growth arrest. We hypothesized that these three characteristics may not be unrelated, specifically that, together, they may favor the metastatic spread of prostatic cancer cells without decreasing their growth potential. In support of this hypothesis, we report here that: (1) IRS-1 expression increases cell adhesion and decreases cell motility; (2) over-expression of the IGF-IR, in the absence of IRS-1, causes growth arrest and (3) a combination of TGF-IR and IRS-1 restores the transformed phenotype of LNCaP cells. These findings suggest a mechanism by which prostatic cancer cells can achieve metastatic potential without interfering with their growth potential.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Jefferson University; Ludwig Institute for Cancer Research	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.			Furnari, Frank/0000-0003-1909-4361	NCI NIH HHS [CA 78890, CA 53484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484, P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Baserga Renato, 1999, V17, P329; Bright RK, 1997, CANCER RES, V57, P995; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CARSON JP, 1999, CANCER RES, V59, P49; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Dunn SE, 1998, CANCER RES, V58, P3353; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GLEAVE ME, 1992, CANCER RES, V52, P1598; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Huynh H, 1998, CANCER RES, V58, P215; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Soos G, 1997, ANTICANCER RES, V17, P4253; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; THALMANN GN, 1994, CANCER RES, V54, P2577; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, RECENT PROG HORM RES, V53, P119; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	48	76	76	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2687	2694		10.1038/sj.onc.1203587	http://dx.doi.org/10.1038/sj.onc.1203587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851068				2022-12-28	WOS:000087193000004
J	Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC				Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC			High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma	ONCOGENE			English	Article						cancer; maspin; protease inhibitor; tumor suppressor	CANCER CELLS; GENE MASPIN; NECK-CANCER; HEAD; OVEREXPRESSION; SUPPRESSOR; SERPIN; P53; AMPLIFICATION; MUTATION	Maspin, a member of the serpin family of protease inhibitors, is known to have tumor-suppressor functions, However, the association between its expression level and survival has not been demonstrated in human cancer. Using the immunohistochemical technique to examine the expression levels of maspin in 44 cases of oral squamous cell carcinoma (SCC), we found that 66% of the cases expressed low to intermediate levels of maspin and 34% of the cases expressed high levels of maspin, We further examined maspin protein expression in a series of sis SCC cell lines from the head and neck, and found that all but one expressed low or no maspin protein. We also compared the clinicopathological features of the oral SCC cases with the maspin expression level, and found that high maspin expression was associated with the absence of lymph node metastasis, More importantly,,ve showed that higher maspin expression was significantly associated with better rates of overall survival, suggesting that high maspin expression may be a favorable prognostic marker for oral SCC.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Shanghai Second Med Univ, Peoples Hosp 9, Dept Oral Pathol, Shanghai, Peoples R China; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Wayne State University	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BERENSON JR, 1989, ONCOGENE, V4, P1111; FIELD JK, 1989, ONCOGENE, V4, P1463; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SOMERS KD, 1992, CANCER RES, V52, P5997; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Umekita Y, 1997, CANCER LETT, V113, P87, DOI 10.1016/S0304-3835(97)04600-4; WATLING DL, 1992, HEAD NECK-J SCI SPEC, V14, P437, DOI 10.1002/hed.2880140603; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, CANCER RES, V46, P414; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	17	129	139	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2398	2403		10.1038/sj.onc.1203535	http://dx.doi.org/10.1038/sj.onc.1203535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828881				2022-12-28	WOS:000087018400004
J	Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H				Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H			Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers	ONCOGENE			English	Article						Smad; transforming growth factor-beta; lung cancer; growth inhibition; oligomerization	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR SMAD4; IN-VIVO ALTERATIONS; TGF-BETA; SIGNAL-TRANSDUCTION; DNA-BINDING; DPC4 GENE; RECEPTOR	Smad family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities. The loss of sensitivity to TGF-beta is frequent in human lung cancers and inactivation of Smad family members are thought to play important roles in disruption of TGF-beta signaling. In the study presented here, we characterized the biological and biochemical functions of six Smad2 and Smad4 mutants, which we previously identified in human lung cancers. All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription. Transcriptional activation of plasminogen activator inhibitor type 1 (PAI-1) was impaired in four of the six mutants due to the defects in homo- and/or hetero-oligomerization with wild-type Smads, In contrast, the remaining two Smad mutants showed a modest reduction in the PAI-1 transcriptional activation and apparently retained the ability to oligomerize with wild-type Smads, Significant loss of growth inhibition and Smad/hFAST-1-mediated transcriptional activation by all of the six mutants suggested that Smad mutants are indeed functionally impaired Smad mutations and may play a role in lung tumorigenesis, Moreover, the present findings suggest that in addition to the impairment in the homo- and/or hetero-oligomerization, there may be an alternative mechanism producing disruption of TGF-beta signaling, involving hFAST-1-or possibly other transcriptional cofactor(s)-mediated transcriptional activation.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagatake M, 1996, CANCER RES, V56, P2718; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	35	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2305	2311		10.1038/sj.onc.1203591	http://dx.doi.org/10.1038/sj.onc.1203591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822381				2022-12-28	WOS:000086974300005
J	De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N				De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N			Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts	ONCOGENE			English	Article						TGF alpha; amphiregulin; cripto; colon carcinoma; antisense	MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-A; FACTOR-ALPHA; IMMUNOHISTOCHEMICAL DETECTION; ANTISENSE OLIGONUCLEOTIDES; ANTITUMOR-ACTIVITY; COLORECTAL TUMORS; FACTOR FAMILY; CANCER CELLS; AMPHIREGULIN	A majority of human colon carcinomas coexpress the epidermal growth factor (ECF)-related peptides transforming growth factor alpha (TGF alpha), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGF alpha. AR and CR, We screened the EGF-related (AS MBOs) for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. Tbe MBOs that showed a high in vitro efficacy were then used for in vitro experiments. TGF alpha, AR and CR AS MBOs were able to inhibit the growth of CEO tumor xenografts in nude mice in a dose-dependent manner. Furthermore, the AS MBOs were able to specifically inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more significant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO, Finally, tumors from mice treated with TGF alpha, AR and CR AS MBOs showed a significant reduction of microvessel count, as compared with tumors from untreated mice or from mire treated with a single AS MBO, These data suggest that combinations of AS oligonucleotides directed against different growth factors might represent a novel, experimental therapy approach of colon carcinomas.	ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy; ITN Fdn Pascale, Anim Fac, I-80131 Naples, Italy; Anat Pathol ULSS 3, I-36061 Bassano Del Grappa, VI, Italy; ITN Fdn, Anat Patol, I-80131 Naples, Italy; Univ Naples Federico II, Dip Endocrinol & Oncol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; NCI, LTIB, Tumor Growth Factor Sect, NIH, Bethesda, MD 20892 USA	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Normanno, N (corresponding author), ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy.		De Luca, Antonella/J-8737-2016; losito, Nunzia/Y-6339-2018; Casamassimi, Amelia/AAD-2816-2020; Normanno, Nicola/AAT-1107-2021	De Luca, Antonella/0000-0001-5762-447X; losito, Nunzia/0000-0001-9045-0328; Casamassimi, Amelia/0000-0002-6010-4261; Ciardiello, Fortunato/0000-0002-3369-4841; Normanno, Nicola/0000-0002-7158-2605; Arra, Claudio/0000-0003-3162-2091	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Ebert AD, 1999, CANCER RES, V59, P4502; Fontanini G, 1998, CLIN CANCER RES, V4, P241; GAGLIARDI G, 1994, INT J ONCOL, V4, P865; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MODRELL B, 1992, GROWTH FACTORS, V7, P195; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Normanno N, 1996, CLIN CANCER RES, V2, P601; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; Qi C., 1994, BRIT J CANCER, V69, P19896; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; STROMBERG K, 1994, INT J GYNECOL PATHOL, V13, P342, DOI 10.1097/00004347-199410000-00008; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325	37	52	53	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5863	5871		10.1038/sj.onc.1203979	http://dx.doi.org/10.1038/sj.onc.1203979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127817	Bronze			2022-12-28	WOS:000165563100005
J	Krosl, J; Sauvageau, G				Krosl, J; Sauvageau, G			AP-1 complex is effector of Hox-induced cellular proliferation and transformation	ONCOGENE			English	Article						Hox; Pbx; AP-1; proliferation; transformation	HEMATOPOIETIC-CELLS CAUSES; BONE-MARROW CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENES; MAMMARY-GLAND; CLUSTER GENES; GROWTH-FACTOR; FRA-1 GENE; EXPRESSION; PROTEIN	Hox gene products, initially characterized as master regulators of embryonic patterning, are also required for proper functioning of adult tissues. There is also a growing body of evidence that links Hox proteins to regulation of cellular proliferation/transformation. However, the underlying molecular mechanisms of Hox-associated transformation and tissue growth have yet to be elucidated. Using a well established model system for studying changes in cellular proliferation induced by Hoxb4, we show that AP-I activity is markedly increased in Hoxb4-transduced cells due to significant upregulation of Jun-B and Fra-1 protein levels, Furthermore, we also show that the specific changes in AP-1 protein expression are necessary for the proliferation effects induced by Hoxb4, and that these changes converge to increase levels of cyclin D1, a known integrator of proliferation signals. Our observations thus link Hox gene products with key elements of the cell cycle machinery.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amato SF, 1996, J IMMUNOL, V157, P146; Asahara H, 1999, MOL CELL BIOL, V19, P8219; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; CILLO C, 1994, INVAS METAST, V14, P38; COFFER P, 1994, ONCOGENE, V9, P911; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; HERBER, 1994, ONCOGENE, V9, P2105; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Mamo A, 1999, BLOOD, V94, p250A; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	39	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5134	5141		10.1038/sj.onc.1203897	http://dx.doi.org/10.1038/sj.onc.1203897			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064450				2022-12-28	WOS:000090124100002
J	Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT				Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT			Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells	ONCOGENE			English	Article						mutant p53; protein stability; teniposide resistance; ionizing radiation	DNA TOPOISOMERASE-II; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; IN-VIVO; GENE-EXPRESSION; UP-REGULATION; BAX GENE; MDM2; BINDING; BCL-2	We examined p53 protein stability and DNA damage-induced p53-dependent responses in a human leukemic CEM cell line and two teniposide-resistant sublines, CEM/VM-1 and CEM/VM-1-5 (similar to 40 and 400-fold resistant to teniposide, respectively). Although all cell lines contain the same p53 mutations at codons 175 (Arg-->His) and 248 (Arg-->Gln), the constitutive levels of p53 were progressively increased with the resistance of the cells to teniposide, By pulse-chase experiments, we found that the half-lives of mutant p53 protein were approximately 12, 17, and >30 h in CEM, CEM/VM-1, and CEM/VM-1-5 cells, respectively. The prolonged half-lives of p53 in these cells is consistent with the fact that the protein harbors the indicated mutations. Of note, however, is the fact that the increased p53 protein half-lives in the two drug-resistant cell lines corresponds to a proportional decrease in MDM2 protein levels but an increase in p53-MDM2 binding interactions. This suggests that MDM2-mediated p53 degradation may be altered in our leukemic cell lines. The DNA damage-induced p53 response is fully functional in the drug-sensitive CEM cells containing a mutant p53, but this pathway is attenuated in the drug-resistant cells. Specifically, while the mutant p53 was phosphorylated at serine-15 in response to ionizing radiation in all these cell lines, mutant p53 induction in response to teniposide or ionizing radiation and induction of the p53-target genes, p21 and GADD45 only occurred in the drug-sensitive CEM cells. As assessed by MTT cytotoxicity assay, CEM cells were also significantly more sensitive to ionizing radiation, compared to the drug-resistant cell lines, and this correlated with p53 induction. Collectively, these results suggest that changes in constitutive mutant p53 protein levels, p53-MDM2 binding interactions, and altered regulation of the DNA damage-inducible p53-dependent pathway may play a role in drug- and radiation-responsiveness in these cells.	Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, Chicago, IL 60607 USA; Hiroshima Univ, Dept Surg Oncol, Minami Ku, Hiroshima 7348553, Japan; Fukuoka Dent Coll Hosp, Dept Gen Surg, Fukuoka 81401, Japan; St Jude Childrens Res Hosp, Dept Cell & Gene Therapy, Memphis, TN 38101 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hiroshima University; Fukuoka Dental College (FDC); St Jude Children's Research Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, 900 S Ashland Ave, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NCI NIH HHS [CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHEN M, 1993, CANCER RES, V53, P5946; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DANKS MK, 1993, CANCER RES, V53, P1373; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM RS, 1994, CANCER RES, V54, P4958; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; KWOK TT, 1994, CANCER RES, V54, P2834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARK DJ, 1994, ONCOGENE, V9, P1899; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TISHLER RB, 1993, CANCER RES, V53, P2212; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Wang QJ, 1998, CANCER RES, V58, P5762; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	51	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5010	5019		10.1038/sj.onc.1203865	http://dx.doi.org/10.1038/sj.onc.1203865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042688				2022-12-28	WOS:000089834300008
J	Vial, E; Perez, S; Castellazzi, M				Vial, E; Perez, S; Castellazzi, M			Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors	ONCOGENE			English	Article						v-Jun; Fra2; ATF2; Maf; AP1; SPARC promoter; chick embryo fibroblasts; cell transformation	RAT EMBRYO FIBROBLASTS; C-JUN; CELLULAR-TRANSFORMATION; NEOPLASTIC PROGRESSION; OSTEONECTIN PROMOTER; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; CYSTEINE SPARC; AP-1 FUNCTION; BONE-CELLS	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a down-regulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA, Alteration in SPARC expression has been repeatedly reported in human cancers of various origin, and is thought to contribute to the remodeling of the extracellular matrix during neoplastic progression, Transcriptional control of SPARC is poorly understood, We show here that (i) v-Jun-mediated repression of the endogenous SPARC gene is enhanced by Fra2 but alleviated by ATF2, Fra2 and ATF2 being the two major partners of v-Jun in the transformed cells; (ii) high basal activity as well as repression by v-Jun and modulation by Fra2 and ATF2 is restricted to a small proximal fragment (-124/+16) of the chicken SPARC promoter; (iii) the activity of this minimal promoter is modulated by all the AP1 family members known in chickens (c-Jun and JunD; c-Fos and Fra2; ATF2; c-Maf, MafA, and MafB), Taken together these data demonstrate that, at least in avian primary cells, SPARC expression is under the control of the AP1 transcription factor. Further studies with the minimal (-124/+16) promoter fragment are needed to understand how this control takes place at the molecular level.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN T, 1990, VIROLOGY, V1, P317; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; Gao MH, 1996, CANCER RES, V56, P4229; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Hafner M, 1995, MATRIX BIOL, V14, P733, DOI 10.1016/S0945-053X(05)80016-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kilbey A, 1996, ONCOGENE, V12, P2409; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NOMURA S, 1989, J BIOL CHEM, V264, P12201; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; SAGE H, 1984, J BIOL CHEM, V259, P3993; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; YOUNG MF, 1989, J BIOL CHEM, V264, P450	48	32	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5020	5029		10.1038/sj.onc.1203867	http://dx.doi.org/10.1038/sj.onc.1203867			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042689	Bronze			2022-12-28	WOS:000089834300009
J	Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG				Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG			Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation	ONCOGENE			English	Article						TSHR gene; mouse fibroblasts; transformation; pathways	HUMAN THYROTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; ALPHA-1B-ADRENERGIC RECEPTOR; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; GERMLINE MUTATIONS; THYROID CARCINOMAS; KINASE-A; RAS	Constitutive activating mutations of the TSHR gene, have been detected in about 30 per cent of hyperfunctioning human thyroid adenomas and in a minority of differentiated thyroid carcinomas. The mutations activating the TSHR gene(s) in the thyroid carcinomas, were located at the codon 623 changing an Ala to a Ser (GCC-->TCC) or in codon 632 changing a Thr to Ala or Ile (ACC-->GCC or ACC-->ATC). In order to study if the constitutively activated TSHR gene(s) has played a role in the determination of the malignant phenotype presented by these tumors, we investigated: (1) the transforming capacity after transfection of mouse 3T3 cells, of a TSHR cDNA activated by an Ala-->Ser mutation in codon 623 or an Thr-Ile mutation in codon 632 and (2) the pathway(s) eventually responsable(s) for the malignant phenotype of the cells transformed by these constitutively activated TSHR cDNAs, Our results show that (1) the TSHRM623 or(M632) cDNAs give rise to 3T3 clones presenting a fully neoplastic phenotype (growth in agar and nude mouse tumorigenesis); this phenotype was weaker in the cells transformed by the 632 cDNA; (2) suggest that the fully transformed phenotype of our 3T3 cells, may be the consequence of the additive effect of the activation of at least two different pathways: the cAMP pathway through G(alpha s) and the Ras dependent MAPK pathway through G(beta gamma) and PI3K and (3) show that the PI3K isoform playing a key role as an effector in the MAPK pathway activation in our 3T3-transformed cells is PI3K gamma. Signaling from PI3K gamma to MAPK appears to require in our murine cellular system a tyrosine kinase (still not characterized), Shc, Grb2, Sos, Ras and Raf. It is proposed that the constitutively activated TSHR genes detected in the thyroid carcinomas, may have played an oncogenic role, participating in their development through these two pathways.	Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, F-94801 Villejuif, France; Univ Cantabria, Fac Med, Dept Mol Biol, Santander 39011, Spain; Univ Catanzaro, Dip Med Sperimentale & Clin, Cattedra Endocrinol, I-88100 Catanzaro, Italy; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	Universidad de Cantabria; Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Suarez, HG (corresponding author), Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, 7 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DUMONT JE, 1989, METABOLIC BASIS INHE, P555; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Fournes B, 1998, ONCOGENE, V16, P985, DOI 10.1038/sj.onc.1201626; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHELIN S, 1991, ONCOGENE, V196, P314; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; Spambalg D, 1996, J CLIN ENDOCR METAB, V81, P3898, DOI 10.1210/jc.81.11.3898; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; VAN BT, 1995, NATURE, V376, P781	38	15	16	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4896	4905		10.1038/sj.onc.1203852	http://dx.doi.org/10.1038/sj.onc.1203852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039907				2022-12-28	WOS:000089757800012
J	Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB				Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB			Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human Galectin-8 related gene	ONCOGENE			English	Article						prostate; genomic structure; chromosomal localization; 1q42-43; SEM	BINDING PROTEIN GALECTIN-3; SURFACE-EPITOPE MASKING; ANIMAL LECTINS; CELL-ADHESION; SUPPRESSOR GENE; T-CELLS; EXPRESSION; GROWTH; CANCER; DIFFERENTIATION	The galectin family of proteins has been associated with several diverse cellular processes. More than 30 years since the discovery of the first member, precise biological functions for the family as a whole, or for individual members has pro, cn elusive. The isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination,with expression screening. It appears that PCTA-1 expression is almost ubiquitous in normal human tissues and could alter in specific contests such as transformation or metastasis. Multiple expression isoforms of PCTA-1 at the mRNA level are observed. PCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer. We have determined the genomic structure of PCTA-1 to account for the several observed isoforms, performed expression analysis to determine distribution in normal and transformed contests at the RNA and protein level and conducted over-expression studies to determine effects on cellular phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,603 W 168th St, New York, NY 10032 USA.		Roberts, Terry/A-8211-2014					Akahani S, 1997, CANCER RES, V57, P5272; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bassen R, 1999, ANTICANCER RES, V19, P5429; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1997, CANCER, V80, P776; Chadli A, 1997, J NEUROCHEM, V68, P1640; Chammas R, 1996, BRAZ J MED BIOL RES, V29, P1141; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; Cortegano I, 1998, J IMMUNOL, V161, P385; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Ellerhorst J, 1999, INT J ONCOL, V14, P217; FEICHTINGER W, 1989, HUM GENET, V83, P145, DOI 10.1007/BF00286707; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gillenwater A, 1996, HEAD NECK-J SCI SPEC, V18, P422, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.3.CO;2-S; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; Greenhalgh CJ, 1999, MOL BIOCHEM PARASIT, V98, P285, DOI 10.1016/S0166-6851(98)00167-4; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hebert E, 1996, CR ACAD SCI III-VIE, V319, P871; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0; Hughes D, 1997, DRUG DISCOV TODAY, V2, P2, DOI 10.1016/S1359-6446(97)81331-1; Iglesias MM, 1998, GLYCOBIOLOGY, V8, P59, DOI 10.1093/glycob/8.1.59; INOHARA H, 1995, CANCER RES, V55, P3267; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kaltner H, 1998, ACTA ANAT, V161, P162; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Lu Y, 1998, BIOL CHEM, V379, P1323, DOI 10.1515/bchm.1998.379.11.1323; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; Maldonado CA, 1999, INVEST OPHTH VIS SCI, V40, P2971; Maquoi E, 1997, PLACENTA, V18, P433, DOI 10.1016/S0143-4004(97)80044-6; Mehul B, 1997, J CELL SCI, V110, P1169; MURTY VVVS, 1994, CANCER RES, V54, P3983; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Puch S, 1999, UROLOGY, V53, P848, DOI 10.1016/S0090-4295(98)00619-0; Remmelink M, 1999, J CANCER RES CLIN, V125, P275, DOI 10.1007/s004320050274; RINI JM, 1995, CURR OPIN STRUC BIOL, V5, P617, DOI 10.1016/0959-440X(95)80053-0; Sahraoui YH, 1996, J CELL BIOCHEM, V62, P529, DOI 10.1002/(SICI)1097-4644(19960915)62:4<529::AID-JCB10>3.0.CO;2-A; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; SHEN RQ, 1994, J NATL CANCER I, V86, P91, DOI 10.1093/jnci/86.2.91; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WELCH DR, 1994, ONCOGENE, V9, P255; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	64	46	49	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4405	4416		10.1038/sj.onc.1203767	http://dx.doi.org/10.1038/sj.onc.1203767			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980616				2022-12-28	WOS:000089271900011
J	Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR				Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR			Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways	ONCOGENE			English	Article						p53; cdk; ionizing; radiation; DRB; Roscovitine	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; NORMAL HUMAN FIBROBLASTS; DNA-BINDING FUNCTION; RNA-POLYMERASE-II; WILD-TYPE P53; PROTEIN-KINASE; IONIZING-RADIATION; MOUSE FIBROBLASTS	High level activation of p53-dependent transcription occurs following cellular exposure to genotoxic damaging agents such as UV-C, while ionizing radiation damage does not induce a similarly potent induction of p53-dependent gene expression. Reasoning that one of the major differences between UV-C and ionizing radiation damage is that the latter does not inhibit general transcription, we attempted to reconstitute p53-dependent gene expression in ionizing irradiated cells by co-treatment with selected transcription inhibitors that alone do not activate p53. p53-dependent transcription can be dramatically enhanced by the treatment of ionizing irradiated cells with low doses of DRB, which on its own does not induce p53 activity, The mechanism of ionizing radiation-dependent activation of p53-dependent transcription using DRB is more likely due to inhibition of gene transcription rather than prolonged DNA damage, as the non-genotoxic and general transcription inhibitor Roscovitine also synergistically activates p53 function in ionizing irradiated cells, These results identify two distinct signal transduction pathways that cooperate to fully activate p53-dependent gene expression: one responding to lesions induced by ionizing radiation and the second being a kinase pathway that regulates general RNA Polymerase it activity.	Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Photobiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209; Gibbs, Neil K./0000-0003-2311-2489				ABARZUA P, 1995, CANCER RES, V55, P3490; Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLAYDES J, 2000, STRESS RESPONSES MET; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hardmeier R, 1997, P NATL ACAD SCI USA, V94, P7572, DOI 10.1073/pnas.94.14.7572; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Hughes PE, 1997, NEUROREPORT, V8, pR5; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin Martin F., 1999, Cancer Research, V59, P3845; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Reavy HJ, 1997, PHOTOCHEM PHOTOBIOL, V66, P368, DOI 10.1111/j.1751-1097.1997.tb03160.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; YAMADA T, 1994, SEMICOND SCI TECH, V9, P775, DOI 10.1088/0268-1242/9/5S/102; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	75	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3829	3839		10.1038/sj.onc.1203773	http://dx.doi.org/10.1038/sj.onc.1203773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951576				2022-12-28	WOS:000088614300001
J	Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A				Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A			Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size	ONCOGENE			English	Article						cell cycle; mitosis; G2/M; c-myc; endoreplication; checkpoints	P53-MEDIATED TRANSCRIPTIONAL ACTIVITY; GROWTH-FACTOR-BETA; NORMAL HUMAN SKIN; TERMINAL DIFFERENTIATION; WILD-TYPE; IN-VITRO; EPIDERMAL-KERATINOCYTES; MALIGNANT PROGRESSION; MURINE KERATINOCYTES; INVOLUCRIN SYNTHESIS	p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies, One of its transcriptional targets is MDM2, which in turn down-regulates p53, The role of the p53/MDM2 regulatory loop upon genotoxic stress is well documented, but less is known about its role in normal tissue homeostasis. We have explored this pathway during the different transitions of the human epidermal differentiation programme and after isolating stem cells, transit amplifying cells or differentiating cells from epidermis, Maximum expression of p53 was found in proliferating keratinocytes. A striking and transient induction of MDM2 and a down-modulation of p53 characterized the transition from proliferation to differentiation in primary human keratinocytes. These changes were delayed in late differentiating carcinoma cells, and were clearly different in suspended primary fibroblasts. Interestingly, these changes correlated with an increase in cell size, at the time of irreversible commitment to differentiation. Induction of MDM2 was also associated with suppression of proliferation in normal, or hyperproliferative, psoriatic epidermis, Moreover, both proteins were induced as keratinocytes mere driven to leave the stem cell compartment by c-Myc activation, Overall, our results show a critical regulation of the p53/MDM2 pathway at the epidermal transition from proliferation to differentiation.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Hop St Louis, Inst Rech Peau, INSERM, U532, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gandarillas, A (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.							ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BURNHAM JC, 1993, B HIST MED, V67, P1; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Di Leonardo A, 1997, CANCER RES, V57, P1013; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GANDARILLAS A, IN PRESS ONCOGENE; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; HALL PA, 1993, ONCOGENE, V8, P203; Hannuksela-Svahn A, 1999, ACTA DERM-VENEREOL, V79, P195; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN R, 1989, BLOOD, V74, P1196; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; JONES MA, 1973, PERSPECT AM HIST, V7, P3; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laktionov PP, 1999, NUCLEIC ACIDS RES, V27, P2315, DOI 10.1093/nar/27.11.2315; LAVKER RM, 1983, J INVEST DERMATOL S, V81, P121; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCKAY IA, 1995, CLIN DERMATOL, V13, P105, DOI 10.1016/0738-081X(95)93817-8; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MILS V, 1994, DIFFERENTIATION, V58, P77, DOI 10.1046/j.1432-0436.1994.5810077.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLES JP, 1993, ONCOGENE, V8, P583; MOSNER J, 1994, ONCOGENE, V9, P3321; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigro JM, 1997, CANCER RES, V57, P3635; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OLSON DC, 1993, ONCOGENE, V8, P2353; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Peled A, 1996, ONCOGENE, V13, P1677; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Prives C, 1999, J PATHOL, V187, P112; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Sidransky D, 1996, ANNU REV MED, V47, P285; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	93	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3693	3705		10.1038/sj.onc.1203695	http://dx.doi.org/10.1038/sj.onc.1203695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949923				2022-12-28	WOS:000088568400001
J	Odaka, R; Mally, A; Elliot, LT; Meyers, S				Odaka, R; Mally, A; Elliot, LT; Meyers, S			Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8)	ONCOGENE			English	Article						ETO; nuclear localization signal; nuclear import; subnuclear structure	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; GRANULOCYTIC DIFFERENTIATION; FUSION PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; GENE; AML1; T(8-21)	ETO (MTG8) was first described due to its involvement in the (8;21) translocation frequently observed in acute myeloid leukemias. In the t(8;21) the AML1 gene on chromosome 21 is fused to ETO on chromosome 8. The resultant hybrid protein is comprised of the DNA, binding domain of AML-1 and the majority of ETO. This study examines the subnuclear distributions of ETO, AML-1B and AML-1/ETO proteins fused to green fluorescence protein in living cells using fluorescence microscopy. Further, we identified a 40 amino acid portion of ETO (amino acids 241-280) that was sufficient to cause nuclear import of green fluorescent protein. Mutational analysis demonstrated that lysine 265 and/or arginine 266 were required for nuclear impart of ETO, but that the surrounding basic residues were not critical, ETO interacted with the nuclear import proteins importin-alpha and beta in vitro, and mutations in ETO that abolish nuclear localization also abolished the in vitro interaction with importin-alpha and beta. These data suggest that ETO enters the nucleus via an importin-mediated pathway. additionally, ETO and AMIL-1/ETO co-localized to punctate nuclear bodies distinct from those containing promyelocytic leukemia protein. Nuclear body formation was dependent upon a region of ETO N-terminal to the nuclear localization signal. Thus, ETO and AML-1/ ETO reside in potentially novel subnuclear compartments.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Feist Weiler Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, F7-36,1501 Kings Highway, Shreveport, LA 71130 USA.		Odaka, Yoshinobu/AAY-6918-2021	Odaka, Yoshinobu/0000-0003-3966-5475	NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1995, TRENDS CELL BIOL, V5, P189, DOI 10.1016/S0962-8924(00)88991-6; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; DETHE H, 1991, CELL, V66; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOHLER MS, 1997, FEBS LETT, V417, P107; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LENNY N, 1995, ONCOGENE, V11, P1761; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1995, MOL CELL BIOL, V15, P1947; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NIWAKAWAKITA M, 1995, GENOMICS, V29, P755, DOI 10.1006/geno.1995.9941; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROWLEY JD, 1984, CANCER RES, V44, P3159; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Speck NA, 1999, CANCER RES, V59, p1789S; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Takeda S, 1997, CYTOGENET CELL GENET, V76, P87, DOI 10.1159/000134521; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Welch K, 1999, MOL CELL BIOL, V19, P8400; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	63	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3584	3597		10.1038/sj.onc.1203689	http://dx.doi.org/10.1038/sj.onc.1203689			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951564				2022-12-28	WOS:000088568300004
J	Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA				Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA			Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis	ONCOGENE			English	Article						ErbB receptors; heregulin beta 1; VEGF; cell proliferation; HUVEC	NEU DIFFERENTIATION FACTOR; RECEPTOR TYROSINE KINASES; NIH 3T3 CELLS; PERMEABILITY FACTOR; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; BREAST-CANCER; MESSENGER-RNA; FACTOR VEGF; MAP KINASE	The interaction between the erbB tyrosine kinase receptors and their ligands plays an important role in tumor growth via the regulation of autocrine and paracrine loops. We report the effect of heregulin beta 1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor. We demonstrate that heregulin beta 1 induces VEGF secretion in most cancer cell lines, while no significant effect was observed in normal human mammary and bronchial primary cells. Overexpression of erbB-2 receptor results in induction of the basal level of VEGF and exposure to heregulin further enhances VEGF secretion. This is associated with increased VEGF mRNA expression. In contrast, VEGF induction is significantly decreased in a T47D cell line where erbB-2 is functionally inactivated. Conditioned media from heregulin-treated cancer cells, but not from normal cells, stimulates endothelial cell proliferation; this paracrine stimulation is inhibited by co-exposure to a specific VEGF neutralizing antibody, Furthermore, heregulin-mediated angiogenesis is observed in the in vivo CAM assay. This study reports the first evidence of VEGF regulation by heregulin in cancer cells.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Pharmacol Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1P1, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1T8, Canada; Hotel Dieu Montreal, Ctr Rech, Montreal, PQ H2W 1T8, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Friedrich Miescher Institute for Biomedical Research; Universite de Montreal; Universite de Montreal; Universite de Montreal	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room 523,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROWN LF, 1997, EXS, V79, P233; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Claffey KP, 1996, CANCER RES, V56, P172; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; Feleszko W, 1999, INT J CANCER, V81, P560, DOI 10.1002/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Im SA, 1999, CANCER RES, V59, P895; Jannot CB, 1996, ONCOGENE, V13, P275; Joukov V, 1996, EMBO J, V15, P290; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARTE BM, 1995, ONCOGENE, V10, P167; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Melnyk O, 1999, J UROLOGY, V161, P960, DOI 10.1016/S0022-5347(01)61829-9; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NOGUCHI M, 1993, CANCER RES, V53, P2035; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Pluda JM, 1997, SEMIN ONCOL, V24, P203; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Rossler J, 1999, INT J CANCER, V81, P113; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tan M, 1997, CANCER RES, V57, P1199; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246; YU DH, 1994, CANCER RES, V54, P3260; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhang K, 1996, J BIOL CHEM, V271, P3884	78	192	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2000	19	31					3460	3469		10.1038/sj.onc.1203685	http://dx.doi.org/10.1038/sj.onc.1203685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918604				2022-12-28	WOS:000088346500002
J	Almog, N; Goldfinger, N; Rotter, V				Almog, N; Goldfinger, N; Rotter, V			p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53	ONCOGENE			English	Article						p53; alternative splicing; C-terminus	WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DNA-BINDING; IONIZING-RADIATION; SINGLE STRANDS; MYELOID CELLS; MOUSE P53; DOMAIN	It is now well accepted that the p53 C-terminus plays a central role in controlling the activity of the wild-type molecule. In our previous studies, we observed that a C-terminally altered p53 protein (p53AS), generated by an alternative spliced p53 mRNA, induces an attenuated p53-dependent apoptosis, compared to that induced by the regularly spliced form (p53RS). In the present study we analysed the interrelationships between these two physiological variants of wild-type p53, and found that in cells co-expressing both forms, in contrast to the expected additive effect on the induction of apoptosis, p53AS inhibits apoptosis induced by p53RS, This inhibitory effect is specific for p53-dependent apoptosis and was not evident in a p53-independent apoptotic pathway induced by growth factor deprivation. Furthermore, the expression of p53AS in transiently transfected cells caused both inhibition of apoptosis and inhibition of the p53RS-dependent transactivation of a number of p53 target genes. These results suggest that expression of an alternatively spliced p53 form may serve as an additional level in controlling the complexity of p53 function by the C-terminal domain.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Flaman JM, 1996, ONCOGENE, V12, P813; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1997, CURR BIOL, V7, P144; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko JL, 1996, GENE DEV, V10, P1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Miner Z, 1997, NUCLEIC ACIDS RES, V25, P1319, DOI 10.1093/nar/25.7.1319; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROTTGER J, 1994, COSPAR COLL, V5, P29; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAULIAN E, 1995, ONCOGENE, V10, P671; Shaw P, 1996, ONCOGENE, V12, P921; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zhou XL, 1999, CANCER RES, V59, P843	74	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3395	3403		10.1038/sj.onc.1203673	http://dx.doi.org/10.1038/sj.onc.1203673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918596				2022-12-28	WOS:000088198100007
J	Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI				Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI			Hepatitis B virus-X protein upregulates the expression of p21(waf1/cip1) and prolongs G1 -> S transition via a p53-independent pathway in human hepatoma cells	ONCOGENE			English	Article						hepatitis B virus-X; p21(waf1/cip1); cyclin-dependent kinase inhibitor; hepatocellular carcinoma; p53	ETS GENE FAMILY; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; ONCOGENIC ACTIVITY; TRANSACTIVATOR-X; MAMMALIAN-CELLS; WAF1/CIP1 GENE; LEUKEMIC-CELLS	Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclin-dependent kinases, The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types, We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line, In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21(wafl/cipl), increased binding of p21(wafl/cipl) with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone HI and induced the activation of a p21 promoter reporter construct, By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between -1185 and -1482, relative to the transcription start site, Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21(wafl/cipl). AS a consequence, there is an increased chance of acquisition of mutations which can enhance the genesis of hepatomas, Our results also emphasize the chemotherapeutic potential of p21(wafl/cipl) inhibitors, particularly in the HBV-X infected hepatoma which lacks functional p53.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorospe M, 1996, CANCER RES, V56, P475; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANA X, 1995, ONCOGENE, V11, P211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang BS, 1996, MOL CELL BIOL, V16, P538; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	52	67	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3384	3394		10.1038/sj.onc.1203674	http://dx.doi.org/10.1038/sj.onc.1203674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918595				2022-12-28	WOS:000088198100006
J	Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF				Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF			Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization	ONCOGENE			English	Article						p14ARF; nucleolar localization; hdm2; p53	MELANOMA-PRONE FAMILIES; CELL-CYCLE ARREST; GERMLINE MUTATIONS; NUCLEAR EXPORT; INK4A LOCUS; P53 PROTEIN; MDM2; P19(ARF); GENE; P16(INK4A)	The INK4a/ARF locus encodes two distinct tumour suppressors, p16(INK4a) and p14ARF, that regulate cell cycle progression via the pRB and p53 pathways, respectively, The ARF protein inhibits hdm2 activity, leading to the stabilization of the p53 tumour suppressor and cell cycle inhibition, The amino-terminal domain of human p14ARF and of the mouse homologue, p19ARF, is sufficient for these effects, This domain is also sufficient for the nucleolar localization of the mouse ARF protein. In contrast, we show that the human ARF protein requires two arginine rich domains, one in the amino- and the other in the carboxy-terminus, for nucleolar targeting. The amino-terminal nucleolar-targeting domain of p14ARF is also important for ARF-hdm2 binding and cell cycle inhibition, The carboxy-terminal p14ARF nucleolar localization domain lies within the shared INK4a/ARF exon 2, and is mutated in a small number of melanoma-prone kindreds, The INK4a/ARF exon2-mutations could affect the function of both the p16(INK4a) and p14ARF tumour suppressors.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney	Rizos, H (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lee JY, 1997, BIOCHEM BIOPH RES CO, V237, P667, DOI 10.1006/bbrc.1997.7212; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parry D, 1996, MOL CELL BIOL, V16, P3844; Piccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	89	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2978	2985		10.1038/sj.onc.1203629	http://dx.doi.org/10.1038/sj.onc.1203629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871849				2022-12-28	WOS:000087581400004
J	Bernardi, R; Liebermann, DA; Hoffman, B				Bernardi, R; Liebermann, DA; Hoffman, B			Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation	ONCOGENE			English	Article						cdc25A; cell cycle; differentiation; myc; proteasome; protein degradation; ubiquitin	MYELOBLASTIC-LEUKEMIA CELLS; C-MYC; PROTEIN-DEGRADATION; G(1)/S TRANSITION; DEPENDENT KINASES; S-PHASE; PHOSPHATASE; PROTEOLYSIS; ACTIVATION; DEPHOSPHORYLATION	Members of the cdc25 family are protein phosphatases that play pivotal roles in cell cycle progression. Cdc25A has been shown to be a critical regulator of the G1/S transition of mammalian cells and to be a myc-target gene with oncongenic properties. We investigated the regulation of cdc25A during terminal differentiation using myeloblastic leukemia M1 cells, that can be induced to undergo differentiation into macrophages by interleukin-6 (IL-6) treatment. In this report it is shown that cdc25A protein is degraded by the ubiquitin-proteasome machinery in both terminally differentiating and cycling cells. Cdc25A was found to have two major peaks of accumulation during cell cycle progression, one in G1 and the other in S/G2, Evidence was obtained that degradation of cdc25A by the ubiquitin-proteasome machinery in terminally differentiating myeloid cells is accelerated compared to cycling cells, Moreover, deregulated expression of c-myc in M1 cells, which had been previously shown to block terminal differentiation, was also found to block IL-6 induced degradation of cdc25A.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336	NCI NIH HHS [1RO1CA51168, 1RO1CA4316] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dick LR, 1997, J BIOL CHEM, V272, P182; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Lammer C, 1998, J CELL SCI, V111, P2445; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vigo E, 1999, MOL CELL BIOL, V19, P6379	42	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2447	2454		10.1038/sj.onc.1203564	http://dx.doi.org/10.1038/sj.onc.1203564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828887				2022-12-28	WOS:000087018400010
J	Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M				Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M			Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts	ONCOGENE			English	Article						human papillomaviruses; E7 protein; apoptosis; S phase; pRb destabilization	CELL-CYCLE REGULATION; ABL TYROSINE KINASE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; ONCOPROTEIN MDM2; LENS DEVELOPMENT; ADENOVIRUS E1A; STABILIZES P53; GROWTH ARREST	The HPV16 E7 oncoprotein neutralizes several cell cycle checkpoints, favouring the entry of quiescent cells into S phase, This activity is mediated in part by association of E7 with the pocket proteins and consequent activation of E2F transcription factors. In addition, HPV16 E7 protein is able to promote apoptosis, In this study we demonstrate that the ability to induce apoptosis is a common property of E7s belonging to both benign and malignant HPV types. The E7-induced apoptosis is mediated by inactivation of pRb, whilst neutralization of the other two pRB-related proteins, p107 and 130, is not sufficient to trigger apoptosis, Moreover, we show that certain point mutations in the conserved region 1 (CRI) of HPV16 E7 abolish the induction of apoptosis without altering the ability to stimulate S phase. Thus, these two E7-mediated cellular events, apoptosis and S phase entry, can be separated in immortalized rodent fibroblasts. Our findings demonstrate that the E7-mediated pRb destabilization is not required for its ability to drive quiescent cells into S phase and to induce apoptosis, Finally, expression of E7 proteins in NIH3T3, which lack a functional p19(ARF), does not lead to p53 accumulation, indicating that the E7 impacts upon additional cellular pathways to promote apoptosis.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Imperial Canc Res Fund, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boyer SN, 1996, CANCER RES, V56, P4620; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HU TH, 1995, INT J ONCOL, V6, P167; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	58	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2277	2285		10.1038/sj.onc.1203570	http://dx.doi.org/10.1038/sj.onc.1203570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822378				2022-12-28	WOS:000086974300002
J	Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR				Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR			Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix	ONCOGENE			English	Article						cervical cancer; FGFR; oncogene	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; ACTIVATING MUTATIONS; HUMAN-PAPILLOMAVIRUS; RAS GENE; ACHONDROPLASIA; ONCOGENE; CANCER; T(4/14)(P16.3,Q32); OVEREXPRESSION	Germline mutations of the gene encoding human fibroblast growth factor receptor 3 (FGFR3) have been shown to be responsible for several related autosomal dominant forms of syndromic craniosynostosis and short limb dwarfism. Somatic activating mutations of FGFR3 were recently reported to occur in three of 12 (25%) uterine cervical carcinomas and nine of 26 (35%) bladder carcinomas, suggesting that constitutive activation of FGFR3 may be an important mechanism underlying the development and/or progression of these common epithelial malignancies. In order to investigate further a possible role for FGFR3 mutations in cervical carcinogenesis, we performed sequence-based mutational analysis of FGFR3 in 51 primary cervical carcinomas and seven cervical carcinoma-derived cell lines. The regions analysed (exons 7, 10, 13, 15, and 19) encompassed all previously described FGFR3 mutations. A single nucleotide substitution at codon 249, predicting a serine to cysteine amino acid substitution (S249C) in the FGFR3 extracellular domain, was identified in one primary tumor. Only wild type FGFR3 alleles were identified in the remaining tumors and cell lines. The S249C mutation is the only FGFR3 mutation described to date in cervical carcinomas. These findings suggest that while activating mutations of FGFR3 occur in cervical cancer, they may not be as common as initially reported.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Philippines, Philippine Gen Hosp, Dept Med, Clin Epidemiol Unit, Manila, Philippines; Hosp Llobregat, Inst Catala Oncol, Serv Epidemiol & Registre Canc, E-08907 Barcelona, Spain; Int Agcy Res Canc, F-69372 Lyon 08, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Philippines System; University of the Philippines Manila; Catalan Institute of Oncology; University of Barcelona; World Health Organization; International Agency for Research on Cancer (IARC)	Cho, KR (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4301 MSRBIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012	Cho, Kathleen/0000-0003-0500-9998; BOSCH JOSE, FRANCESC XAVIER/0000-0002-7172-3412	NATIONAL CANCER INSTITUTE [R29CA064466] Funding Source: NIH RePORTER; NCI NIH HHS [CA64466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER VV, 1988, J SURG ONCOL, V39, P225, DOI 10.1002/jso.2930390403; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IKEGAWA S, 1995, HUM GENET, V96, P309; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Katsumata N, 1998, ENDOCR J, V45, pS171, DOI 10.1507/endocrj.45.Suppl_S171; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; MITRA AB, 1994, CANCER RES, V54, P637; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIOU G, 1988, ONCOGENE, V3, P329; RIOU GF, 1990, ANTICANCER RES, V10, P1225; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WONG YF, 1995, CANCER LETT, V95, P29, DOI 10.1016/0304-3835(95)03857-S; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493	31	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5543	5546		10.1038/sj.onc.1203934	http://dx.doi.org/10.1038/sj.onc.1203934			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114733				2022-12-28	WOS:000165396100016
J	Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL				Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL			Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line	ONCOGENE			English	Article						p21; Caco-2; promoter; Sp1; Sp3	MEDIATED NEURONAL DIFFERENTIATION; HISTONE DEACETYLASE INHIBITOR; REPRESS TRANSCRIPTION; BINDING-SITES; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; PROMOTER ACTIVITY; CYCLE REGULATION; FAMILY MEMBERS; PC12 CELLS	The CDK inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, and its expression is induced during terminal differentiation in vitro and in vivo. Expression of p21 is controlled at the transcriptional level by both p53-dependent and -independent mechanisms. Our previous studies established that p21 is expressed in the Caco-2 adenocarcinoma cell line, and its expression is induced by a p53-independent mechanism during differentiation of these cells, Here we have found that transcription of p21 in Caco-2 cells is controlled primarily by the transcription factors Sp1 and Sp3 through two Spl binding sites, Sp1-1 and Sp1-2 located between -119 and -114 bp and between -109 and -104 bp of the p21 promoter, respectively, Spl and Sp3 binding to the p21 promoter increased during Caco-2 cell differentiation, while the absolute level of Spl did not change and the absolute level of Sp3 increased approximately twofold. Transfection experiments in the SL2 Drosophila cell line that lacks endogenous Sp3 activity demonstrated that Spl transactivates the p21 promoter primarily through the Sp1-2 site, while Sp3 acts through the Spl-l site, In these cells Sp3 is a stronger transactivator of the p21 promoter than Spl, Our data suggest that induction of p21 transcription during Caco-2 differentiation is modulated by Sp1/Sp3 interactions with the p21 promoter.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048836, R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056283, R01 DK056283-05, DK48836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Billon N, 1996, ONCOGENE, V13, P2047; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; JIANG HP, 1994, ONCOGENE, V9, P3397; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINTO M, 1983, BIOL CELL, V47, P323; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Wildhage I, 1999, ENDOCRINOLOGY, V140, P624, DOI 10.1210/en.140.2.624; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zhang YG, 1999, J BIOL CHEM, V274, P12367, DOI 10.1074/jbc.274.18.12367; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	62	70	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5182	5188		10.1038/sj.onc.1203900	http://dx.doi.org/10.1038/sj.onc.1203900			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064455				2022-12-28	WOS:000090124100007
J	Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM				Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM			A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line	ONCOGENE			English	Article						drug resistance; p53 mutations; apoptotic genes; T-lymphoblastoid cells	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONALLY ACTIVE P53; PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; MUTANT P53; BAX GENE; PHOSPHORYLATION; CHEMOTHERAPY; GROWTH; CANCER	The p53 protein accumulates rapidly through posttranscriptional mechanisms following cellular exposure to DNA damaging agents and is also activated as a transcription factor leading to growth arrest or apoptosis, Phosphorylation of p53 occurs after DNA damage thereby modulating its activity and impeding the interaction of p53 with its negative regulator oncogene Mdm2. The serines 15 and 37 present in the amino terminal region of p53 are phosphorylated by the DNA-dependent protein kinase (DNA-PK) in response to DNA damage, In order to verify if specific p53 mutations occur in the multi-drug resistance phenotype, we analysed the p53 gene in two T-lymphoblastoid cell lines, CCRF-CEM and its multi-drug-resistant clone CCRF-CEM VLB100, selected for resistance to vinblastine sulfate and cross-resistant to other cytotoxic drugs, Both cell lines showed two heterozygous mutations in the DNA binding domain at codons 175 and 248. The multi-drug resistant cell line, CCRF-CEM VLB100, showed an additional mutation that involves the serine 37 whose phosphorylation is important to modulate the protein activity in response to DNA damage, The effects of these mutations on p53 transactivation capacity were evaluated, The activity of p53 on pro-apoptotic genes expression in response to DNA damage induced by (-irradiation, was affected in the vinblastine (VLB) resistant cell line but not in CCRF-CEM sensitive cell Line resulting in a much reduced apoptotic cell death of the multi-drug resistant cells.	IOR, CNR, Ist Citomorfol Normale & Patol, I-40136 Bologna, Italy; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Lab Cell Odontostomatol & Maxillofacciali, I-80131 Naples, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Int Inst Genet & Biophys, Genome Res & Sequencing Lab, I-80125 Naples, Italy; Wistar Inst Anat & Biol, Dept Mol Oncol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; IOR, Lab Cell Biol & Electron Microscopy, I-40136 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); The Wistar Institute; Jefferson University	Cinti, C (corresponding author), IOR, CNR, Ist Citomorfol Normale & Patol, Via Barbiano 1-10, I-40136 Bologna, Italy.		Claudio, Pier Paolo/AAW-7282-2021; Paggi, Marco G./K-3494-2018; Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; Halazonetis, Thanos/D-7923-2011	Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; Howard, Candace/0000-0001-6537-3551; Cinti, Caterina/0000-0001-8049-0369				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CIANFRIGLIA M, 1991, INT J CANCER, V49, P394, DOI 10.1002/ijc.2910490314; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPER ML, 1994, J CELL SCI, P13; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAYR GA, 1995, CANCER RES, V55, P2410; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MEEK DW, 1997, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MIYASHITA T, 1995, CELL, V80, P293; MOYRET C, 1994, ONCOGENE, V9, P1739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OITVAI ZN, 1993, CELL, V74, P609; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Righetti SC, 1996, CANCER RES, V56, P689; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Shelling AN, 1997, LANCET, V349, P744, DOI 10.1016/S0140-6736(05)60195-X; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TISHLER RB, 1995, CANCER RES, V55, P6021; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5098	5105		10.1038/sj.onc.1203848	http://dx.doi.org/10.1038/sj.onc.1203848			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042698				2022-12-28	WOS:000089930100007
J	Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y				Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y			Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC	ONCOGENE			English	Article						gelsolin; VDAC; apoptosis	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; REGULATORY PROTEIN; BAX; MEMBRANE; FAMILY; PLASMA; GENE	Gelsolin is a Ca2+-dependent actin-regulatory protein that modulates actin assembly and disassembly, and is believed to regulate cell motility through modulation of the actin network. Gelsolin was also recently suggested to be involved in the regulation of apoptosis: human gelsolin (hGsn) has anti-apoptotic activity, whereas mouse gelsolin (mGsn) exerts either proapoptotic or anti-apoptotic activity depending on different cell types. Here, we studied the basis of anti-apoptotic activity of hGsn, We showed that both endogenous and overexpressed hGsn has anti-apoptotic activity, that depends on its C-terminal half. We also found that hGsn and its C-terminal half but not mGsn could prevent apoptotic mitochondrial changes such as Delta psi loss and cytochrome c release in isolated mitochondria to a similar extent as Bcl-x(L), indicating that hGsn targets the mitochondria to prevent apoptosis via its C-terminal half. In the same way as anti-apoptotic Bcl-xL, which we recently found to prevent apoptotic mitochondrial changes by binding and closing the voltage-dependent anion channel (VDAC), hGsn and its C-terminal half inhibited the activity of VDAC on liposomes through direct binding in a Ca2+-dependent manner. These results suggest that hGsn inhibits apoptosis by blocking mitochondrial VDAC activity.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Suita, Osaka 5650871, Japan; JST, CREST, Suita, Osaka, Japan; Hokkaido Univ, Inst Med Genet, Div Canc Gene Regulat, Kita Ku, Sapporo, Hokkaido, Japan	Osaka University; Japan Science & Technology Agency (JST); Hokkaido University	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita H, 1997, EUR J BIOCHEM, V248, P834, DOI 10.1111/j.1432-1033.1997.00834.x; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Rappaport L, 1998, MOL CELL BIOCHEM, V184, P101, DOI 10.1023/A:1006843113166; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	145	148	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4807	4814		10.1038/sj.onc.1203868	http://dx.doi.org/10.1038/sj.onc.1203868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039896				2022-12-28	WOS:000089757800001
J	Walter, AO; Seghezzi, W; Korver, W; Sheung, J; Lees, E				Walter, AO; Seghezzi, W; Korver, W; Sheung, J; Lees, E			The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation	ONCOGENE			English	Article						mitotic kinase; phosphorylation; degradation; cell cycle	CHROMOSOME SEGREGATION REGULATORS; CAENORHABDITIS-ELEGANS EMBRYOS; HUMAN PROTEIN-KINASE; POLO-LIKE KINASES; CELL-CYCLE; DROSOPHILA-AURORA; BUDDING YEAST; M-PHASE; CHECKPOINT; CENTROSOME	Aurora2 is a cell cycle regulated serine/threonine protein kinase which is overexpressed in many tumor cell lines. We demonstrate that Aurora2 is regulated by phosphorylation in a cell cycle dependent manner. This phosphorylation occurs on a conserved residue, Threonine 288, within the activation loop of the catalytic domain of the kinase and results in a significant increase in the enzymatic activity. Threonine 288 resides within consensus motif for the cAMP dependent kinase and can be phosphorylated by PKA in vitro. The protein phosphatase 1 is shown to dephosphorylate this site in vitro, and in vivo the phosphorylation of T288 is induced by okadaic acid treatment. Furthermore, we show that the Aurora2 kinase is regulated by proteasome dependent degradation and that Aurora2 phosphorylated on T288 may be targeted for degradation during mitosis, Our experiments suggest that phosphorylation of T288 is important for regulation of the Aurora2 kinase both for its activity and its stability.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lees, E (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.							Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; CHAN CSM, 1993, GENETICS, V135, P677; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Morgan DO, 1996, NATURE, V382, P295, DOI 10.1038/382295a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Page AM, 1997, CANCER SURV, V29, P133; Pfleger CM, 2000, GENE DEV, V14, P655; Roghi C, 1998, J CELL SCI, V111, P557; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Straight AF, 1997, CURR BIOL, V7, pR613, DOI 10.1016/S0960-9822(06)00315-0; TAKAI A, 1992, BIOCHEM J, V284, P539, DOI 10.1042/bj2840539; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	41	225	233	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4906	4916		10.1038/sj.onc.1203847	http://dx.doi.org/10.1038/sj.onc.1203847			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039908				2022-12-28	WOS:000089757800013
J	Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M				Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M			Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor	ONCOGENE			English	Article						RET; GDNF; SHC; CREB; NF-kappa B	MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; DOCKING SITE; INDEPENDENT MECHANISMS; TRANSDUCTION PATHWAYS; SYMPATHETIC NEURONS; RECEPTOR COMPLEX; KINASE; NEURTURIN; SURVIVAL	Glial cell line derived neurotrophic factor (GDNF) signals through a multicomponent receptor complex consisting of RET receptor tyrosine kinase and a member of GDNF family receptor alpha (GPR alpha). Recently, it was shown that tyrosine 1062 in RET represents a binding site for SHC adaptor proteins and is crucial for both RAS/mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways. In the present study, we characterized how these two pathways diverge from tyrosine 1062, using human neuroblastoma and primitive neuroectodermal tumor cell lines expressing RET at high levels. In response to GDNF stimulation, SHC bound to GAB1 and GRB2 adaptor proteins as well as RET, and SHC and GAB1 were highly phosphorylated on tyrosine. The complex formation consisting of SHC, GAB1 and GRB2 was almost abolished by replacement of tyrosine 1062 in RET with phenylalanine. Tyrosine-phosphorylated GAB1 was also associated with p85 subunit of PI3-K, resulting in PI3-K and AKT activation, whereas SHC-GRB2-SOS complex was responsible for the RAS/ERK signaling pathway. These results suggested that the RAS and PI3K pathways activated by GDNF bifurcate mainly through SHC bound to tyrosine 1062 in RET. Furthermore, using luciferase reporter-gene assays, we found that the RAS/ERK and PI3-K signaling pathways are important for activation of CREB and NF-kappa B in GDNF-treated cells, respectively.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014; Takahashi, Masahide/AAN-4770-2020	Kumi, Kawai/0000-0002-7772-2605; Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Feng L, 1999, NEUROSCIENCE, V93, P265, DOI 10.1016/S0306-4522(99)00129-3; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Heuckeroth RO, 1999, NEURON, V22, P253, DOI 10.1016/S0896-6273(00)81087-9; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rossi J, 1999, NEURON, V22, P243, DOI 10.1016/S0896-6273(00)81086-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Soler RM, 1999, J NEUROSCI, V19, P9160; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909	48	182	188	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4469	4475		10.1038/sj.onc.1203799	http://dx.doi.org/10.1038/sj.onc.1203799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002419				2022-12-28	WOS:000089236800003
J	Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N				Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein	ONCOGENE			English	Article						endogenous retroviruses; germ cell tumor; spermatogenesis	ACID RECEPTOR-ALPHA; OPEN READING FRAMES; PLZF-RAR-ALPHA; RETINOIC ACID; GERM-CELL; HISTONE DEACETYLASE; TROPHOBLASTIC TUMORS; FUSION PARTNERS; HTDV/HERV-K; TRANSLOCATION	Human endogenous retrovirus sequences (HERVs) reside in the genomes of primates and humans for several million years, The majority of HERVs is non-coding but a limited set is intact and can express proteins, We have recently identified an almost intact HERV-K(HML-2) provirus on chromosome 7 and have documented that most patients with germ cell tumors (GCTs) display antibodies directed against proteins of HERV-K(HML-2), To address whether these proteins merely represent tumor markers or contribute to neoplastic transformation, we examined the transforming potential of various HERV sequences and studied physical interactions between HERV and cellular proteins by yeast two-hybrid and biochemical assays. cORF, a protein encoded by the C-terminal open reading frame within the cnv gene, supports tumor growth in nude mice and associates with the promyelocytic leukemia zinc finger protein (PLZF), The interaction domains map between amino acid residues 21 and 87 of cORF, and between residues 245 and 543 of PLZF, PLZF is critical for spermatogenesis in mice. Abnormal spermatogenesis or maturation of gonocytes is thought to predispose humans to the development of germ cell tumors. Thus, cORF of human endogenous retroviruses may contribute to tumor development by interfering,vith processes during spermatogenesis that involve PLZF.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	Saarland University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.		Mayer, Jens/B-8506-2013; Mayer, Jens/P-4777-2019	Mayer, Jens/0000-0002-1090-5765; Mayer, Jens/0000-0002-1090-5765; Boese, Annette Sophia/0000-0002-5166-7425				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hawe N., 1996, Blood, V88, p291A; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heimdal K, 1997, BRIT J CANCER, V75, P1084, DOI 10.1038/bjc.1997.185; Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x; Herbst H, 1996, AM J PATHOL, V149, P1727; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; Mayer J, 1997, CYTOGENET CELL GENET, V78, P1, DOI 10.1159/000134614; Mayer J, 1997, CYTOGENET CELL GENET, V79, P157, DOI 10.1159/000134709; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MUELLERLANTZSCH N, 1993, AIDS RES HUM RETROV, V9, P343, DOI 10.1089/aid.1993.9.343; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	41	98	103	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4328	4336		10.1038/sj.onc.1203794	http://dx.doi.org/10.1038/sj.onc.1203794			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980608				2022-12-28	WOS:000089271900003
J	Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T				Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T			The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase	ONCOGENE			English	Article						BRCA2; protein kinase; phosphorylation	GENE; RAD51; ACETYLTRANSFERASE; IDENTIFICATION; INTERACT; MOUSE; BINDS; JNK	A substantial proportion of familiar breast cancers have mutations within the BRCA2 gene. The product of this gene has been implicated in DNA repair and in the regulation of transcription. We have previously identified at the amino-terminus of BRCA2 a transcriptional activation domain whose importance is highlighted by the presence of predisposing mutations and in-frame deletions in breast cancer families. This activation domain shows sequence similarity to a region of c-Jun which has been defined as a binding site for the c-Jun N-terminal kinase, Here, we show that the analogous region in BRCA2 is also a binding site for a cellular kinase, although this kinase is distinct from JNK, The BRCA2 associated enzyme Is able to phosphorylate residues within the BRCA2 activation domain. Consistent with this observation, we find that the activation domain of BRCA2 is phosphorylated in vivo. Our results indicate that the BRCA2 activation domain possesses a binding site for a kinase that may regulate BRCA2 activity by phosphorylation.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Addenbrookes Hosp, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; May GHW, 1999, GENE CHROMOSOME CANC, V25, P407, DOI 10.1002/(SICI)1098-2264(199908)25:4<407::AID-GCC16>3.0.CO;2-I; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nordling M, 1998, CANCER RES, V58, P1372; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	19	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4441	4445		10.1038/sj.onc.1203793	http://dx.doi.org/10.1038/sj.onc.1203793			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980621				2022-12-28	WOS:000089271900016
J	Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA				Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA			F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21(WAF1/CIP1) degradation	ONCOGENE			English	Article						p21(WAF1/CIP1); p53; G1 and G2 arrests; teratocarcinoma F9; gamma-irradiation	RADIATION-INDUCED APOPTOSIS; WILD-TYPE P53; DNA-DAMAGE; TERATOCARCINOMA CELLS; SPINDLE DISRUPTION; TRANSFORMED-CELLS; RETINOIC ACID; STEM-CELLS; DIFFERENTIATION; CHECKPOINT	We studied the ability of F9 teratocarcinoma cells to arrest in G1/S and G2/M checkpoints after gamma-irradiation, Wild-type p53 protein was rapidly accumulated in F9 cells after gamma-irradiation, however, this was followed not by a G1/S arrest but by a short and reversible delay of the cell cycle in G2/M. In order to elucidate the reasons of the lack of G1/S arrest in F9 cells, we investigated the expression of p53 downstream target Cdk inhibitor p21(WAF1/CIP1). In spite of p53-dependent activation of p21(WAF1/CIP1) gene promoter and p21(WAF1/CIP1) mRNA accumulation upon irradiation, the p21(WAF1/CIP1) protein was not detected by either immunoblot or immunofluorescence techniques. However, the cells treated with a specific proteasome inhibitor lactacystin revealed the p21(WAF1/CIP1) protein both in non-irradiated and irradiated cells. Therefore we suggest that p21(WAF1/CIP1) protein is degraded by a proteasome-dependent mechanism in F9 cells and the lack of G1/S arrest after gamma-irradiation is due to this degradation. We also examined the expression and activity of cell cycle regulatory proteins: G1- and G2-cyclins and cyclin-dependent kinases, In the absence of functional p21(WAF1/CIP1) inhibitor, the activity of G1 cyclin/Cdk complexes was insufficiently inhibited to cause a G1 arrest, whereas a decrease of cdc2 and cyclin B1-associated kinase activities was enough to contribute to a reversible G2 arrest following gamma-irradiation. After gamma-irradiation, the majority of F9 cells undergo apoptosis implying that wt-p53 likely triggers pro-apoptotic gene expression in DNA damaged cells. Elimination of defected cells might ensure maintenance of genome integrity in the remaining cell population.	Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, Tikhoretsky 4, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017; Malashicheva, Anna/K-2649-2014	Malashicheva, Anna/0000-0002-0820-2913				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARDER P, 1993, ONCOGENE, V8, P1397; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 1998, CANCER RES, V58, P396; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANGLEY RE, 1995, RADIAT RES, V144, P90, DOI 10.2307/3579240; LANGLEY RE, 1993, RADIAT RES, V136, P320, DOI 10.2307/3578543; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Malashicheva A B, 1998, Tsitologiia, V40, P14; Mayo LD, 1996, ONCOGENE, V13, P2315; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Orlovskaya E. I., 1997, Molekulyarnaya Biologiya (Moscow), V31, P224; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERREAULT J, 1993, J CELL PHYSL, V156, P189; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P2261; SLEIGH MJ, 1992, BIOESSAYS, V14, P769, DOI 10.1002/bies.950141109; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	43	27	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3858	3865		10.1038/sj.onc.1203736	http://dx.doi.org/10.1038/sj.onc.1203736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951579				2022-12-28	WOS:000088614300004
J	Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA				Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA			Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine	ONCOGENE			English	Article						apoptosis; bcl-w; 5-fluorouracil; gamma-radiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; GASTROINTESTINAL-TRACT; CELL-SURVIVAL; MICE; EXPRESSION; P53; PROLIFERATION; INHIBITION; FAMILY; CRYPTS	The potential role of the bcl-2 relative bcl-w as a physiological regulator of apoptosis in intestinal epithelia has been investigated, Immunoblots for bcl-w with new monoclonal antibodies revealed that it was expressed in the small intestine and colon, among other murine tissues, as well as in six: human tumour cell lines of epithelial origin, including two colon carcinoma lines, To assess whether bcl-w regulates either spontaneous or damage-induced apoptosis in the small intestine or colon, apoptosis in intestinal crypts of bcl-w -/- and wild-type mice,vas quantified microscopically on a cell positional basis. Spontaneous apoptosis within crypt epithelia was not significantly increased by loss of bcl-w, in either the small intestine or midcolon. However, after treatment with the cytotoxic drug 5-fluorouracil or with gamma-radiation, the bcl-w-null animals exhibited substantially more apoptosis than their wild-type counterparts in both tissues. The greatest enhancement of apoptosis attributable to the absence of bcl-w (up to sixfold) occurred in the small intestine, Hence, bcl-w is an important determinant of damage-induced apoptosis in intestinal epithelia, and unlike bcl-2, which regulates only colonic apoptosis, plays a major role In small intestinal epithelium.	Christie Hosp NHS Trust, Paterson Inst, CRC, Dept Epithelial Biol, Manchester M20 9BX, Lancs, England; Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Walter & Eliza Hall Institute	Pritchard, DM (corresponding author), Univ Liverpool, Dept Med, 5th Floor UCD Bldg,Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.		Adams, Jerry M/E-1199-2013	Print, Cristin/0000-0001-8345-7812; Pritchard, David Mark/0000-0001-7971-3561; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA 43540, CA80188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Gibson L, 1996, ONCOGENE, V13, P665; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178	19	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3955	3959		10.1038/sj.onc.1203729	http://dx.doi.org/10.1038/sj.onc.1203729			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951589				2022-12-28	WOS:000088614300015
J	Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV				Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV			Different impact of p53 and p21 on the radiation response of mouse tissues	ONCOGENE			English	Article						p53; p21; apoptosis; radiation; proliferation; mouse tissues	CELL-CYCLE ARREST; INDUCED APOPTOSIS; P53-DEFICIENT MICE; DISTINCT PATTERNS; P53-INDEPENDENT APOPTOSIS; INTESTINAL EPITHELIUM; IONIZING-RADIATION; GAMMA-IRRADIATION; HUMAN SKIN; IN-VIVO	Mammalian tissues differ dramatically in their sensitivity to genotoxic stress, although the mechanisms determining these differences remain largely unknown. To analyse the role of p53 and p21 in determination of tissue specificity to DNA damage in vivo, we compared the effects of gamma radiation on DNA synthesis on whole-body sections of wild type, p53-deficient and p21-deficient mice, ii dramatic reduction in C-14-thymidine incorporation after gamma irradiation was observed in the majority of rapidly proliferating tissues of wild type and p21(-/-) but not in p53(-/-) mice, confirming the key role of p53 in determination of tissue response to genotoxic stress vivo and suggesting that p53-mediated inhibition of DNA synthesis does not depend on p21, Rapid radiation induced p53-dependent apoptosis was mapped to the areas of high levels of p53 mRNA in radiation sensitive tissues analysed (white pulp in the spleen and bases of crypts in small intestine), indicating that p53 regulation at the mRNA level is a determinant of cellular sensitivity to genotoxic stress. High p53 mRNA expression is inherited as a recessive trait in cell-cell hybrids suggesting the involvement of a negative control mechanism in the regulation of p53 gene expression.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; CLARKE AR, 1994, ONCOGENE, V9, P1767; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	41	97	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3791	3798		10.1038/sj.onc.1203717	http://dx.doi.org/10.1038/sj.onc.1203717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949934				2022-12-28	WOS:000088568400012
J	Shtrichman, R; Sharf, R; Kleinberger, T				Shtrichman, R; Sharf, R; Kleinberger, T			Adenovirus E4orf4 protein interacts with both B alpha and B ' subunits of protein phosphatase 2A, but E4orf4-induced apoptosis is mediated only by the interaction with B alpha	ONCOGENE			English	Article						protein phosphatase 2A (PP2A); adenovirus E4orf4 protein; apoptosis	CATALYTIC SUBUNIT; REGULATORY SUBUNITS; TRANSFORMED-CELLS; EARLY REGION-4; CORE ENZYME; PP2A; PHOSPHORYLATION; BINDING; KINASE; IDENTIFICATION	Adenovirus E4orf4 protein is a multifunctional viral regulator, which is involved in down regulation of virally-modulated signal transduction, in control of alternative splicing of viral mRNAs? and in induction of apoptosis in transformed cells. It has been previously shown that E4orf4 interacts with protein phosphatase 2A through the phosphatase B alpha subunit. It was further shown that PP2A is required for performing the various E4orf4 functions. We report here that E4orf4 interacts with multiple isoforms of the PP2A-B' subunit, as well as with B alpha. We map the interaction sites of the B subunits on E4orf4 and show that they overlap but are not identical. We identify a dominant negative E4orf4 mutant, which disrupts the PP2A holoenzyme. We show that induction of apoptosis by E4orf4, which we previously reported to require the interaction with B alpha, is not affected by the interaction with B'. Our results suggest that the interaction of E4orf4 with various PP2A subpopulations may mediate the different E4orf4 functions.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinberger, T (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, POB 9649, IL-31096 Haifa, Israel.							AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Harlow E., 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256	48	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3757	3765		10.1038/sj.onc.1203705	http://dx.doi.org/10.1038/sj.onc.1203705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949930				2022-12-28	WOS:000088568400008
J	Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM				Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM			Cross-talk between the proto-oncogenes Met and Ron	ONCOGENE			English	Article						Met; Ron; cross talk; scatter factors; tyrosine kinase	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; SIGNAL-TRANSDUCTION; MEDIATED TRANSFORMATION; GASTRIC-CARCINOMA; MET/HGF RECEPTOR	Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase receptors encoded by the proto-oncogenes MET and RON. Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Roll, and Vice ver sn. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). The transphosphorylation specifically takes place for the receptor subfamily, as it is not observed between Met or Ron and ErbB1, ErbB2 or TrkA. Cross-linking experiments show that non-covalent Met-Roll complexes are present on the cell surface, before ligand-induced dimerization. Go-expression of a kinase inactive Ron receptor with naturally-occurring oncogenic Met mutants suppresses the transforming phenotype, suggesting a dominant negative role for the inefficient kinase partner. These data show that, while specific for their ligands, scatter factor receptors cross-talk and cooperate in intracellular signaling.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Follenzi, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		Comoglio, Paolo/G-6323-2011; Gual, Philippe/P-9833-2019	Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Banu N, 1996, J IMMUNOL, V156, P2933; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blechman JM, 1995, ANN NY ACAD SCI, V766, P344, DOI 10.1111/j.1749-6632.1995.tb26685.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FALETTO DL, 1992, ONCOGENE, V7, P1149; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GAUDINO G, 1995, ONCOGENE, V11, P2527; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Michieli P, 1996, ONCOGENE, V12, P775; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; TARTARE S, 1991, FEBS LETT, V295, P219, DOI 10.1016/0014-5793(91)81422-5; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Westermark B, 1989, CURR OPIN CELL BIOL, V1, P279, DOI 10.1016/0955-0674(89)90101-4; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	73	153	157	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3041	3049		10.1038/sj.onc.1203620	http://dx.doi.org/10.1038/sj.onc.1203620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871856				2022-12-28	WOS:000087903900001
J	Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y				Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y			Two actions of frabin: direct activation of Cdc42 and indirect activation of Rac	ONCOGENE			English	Article						frabin; Rac; Cdc42; filopodia; lamellipodia; membrane ruffles	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; EXPRESSION CLONING; PROTEIN-KINASE; RHO; CYTOSKELETON; GTPASES; GENE; DBL; FILOPODIA	Frabin is an actin filament-binding protein which shows GDP/GTP exchange activity specific for Cdc42 small G protein and induces filopodium-like microspike formation and c-Jun N-terminal kinase (JNK) activation presumably through the activation of Cdc42. Frabin has one actin filament-binding (FAB) domain, one Dbl homology (DH) domain, first pleckstrin homology (PH) domain adjacent to the DH domain, one cysteine-rich FYVE domain, and second PH domain from the N-terminus to the C-terminus in this order. Different domains of frabin are involved in the microspike formation and the JNK activation, and the association of frabin with the actin cytoskeleton through the FAB domain is necessary for the microspike formation, but not for the JNK activation. We have found here that frabin induces the formation of not only filopodium-like microspikes but also lamellipodium-like structures in NIH3T3 and L fibroblasts. We have analysed the mechanism of frabin in these two actions and found that frabin induces filopodium-like microspike formation through the direct activation of Cdc42 and lamellipodium-like structure formation through the Cdc42-independent indirect activation of Pac small G protein. The FAB domain of frabin in addition to the DH domain and the first PH domain is necessary for the filopodium-like microspike formation, but not for the lamellipodium-like structure formation. The FYVE domain and the second PH domain in addition to the DH domain and the first PH domain are necessary for the lamellipodium-like structure formation. We show here these two actions of frabin in the regulation of cell morphology.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Onishi M, 1996, EXP HEMATOL, V24, P324; PASTERIS NG, 1994, CELL, V79, P669; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	21	54	57	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3050	3058		10.1038/sj.onc.1203631	http://dx.doi.org/10.1038/sj.onc.1203631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871857				2022-12-28	WOS:000087903900002
J	Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P				Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P			Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration	ONCOGENE			English	Article						pancreatic cancer; Ras; MAPK; signal transduction; growth factors	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CANCER CELLS; FACTOR RECEPTOR; FACTOR-ALPHA; N-RAS; MAMMALIAN-CELLS; BINDING DOMAIN; HUMAN-COLON; HA-RAS	Human ductal adenocarcinoma of the pancreas frequently carry activating point mutations in the K-ras protooncogene. We have anal! sed the activity of the Ras-Raf-MEK-MAPK cascade in the human pancreatic carcinoma cell line PANC-1 carrying an activating K-ras mutation. Serum-starved cells and cells grown in medium with serum did not show constitutively activated c-Raf, MEK-1, or p42 MAPK. Stimulation bf cells with epidermal growth factor (EGF) or fetal calf serum (FCS) resulted in activation of N-Ras, but not K-Ras, as well as activation of c-Raf, MEK-1, and p42 MAPK. Preincubation of serum-starved cells with MEK-1 inhibitor PD98059 abolished EGF- and FCS-induced MAPK activation, identifying MEK as the upstream activator of MAPK. PANC-1 cells exhibited marked serum-dependence of anchorage-dependent and -independent cell growth as well as cell migration. EGF, alone or in combination with insulin and transferrin, did not induce cell proliferation of serum-starved PANC-1 cells, indicating that activation of MAPK alone was not sufficient to induce cell proliferation, FCS-induced DNA synthesis was inhibited by 40% by the MEK-1 inhibitor. On the other hand, treatment with either FCS or EGF alone resulted in marked, MEK-dependent increase of directed cell migration. Collectively, our results show that the activating K-ras mutation in PANC-1 cells does not result in constitutively increased Raf-MEK-MAPK signaling. Signal transduction via the Ras-Raf-MEK-MAPK cascade is maintained in these cells and is required for growth factor-induced cell proliferation and directed cell migration.	Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany	Ulm University; Ulm University	Giehl, K (corresponding author), Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany.							AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; Brat DJ, 1997, AM J PATHOL, V150, P383; Buard A, 1996, INT J CANCER, V67, P539, DOI 10.1002/(SICI)1097-0215(19960807)67:4<539::AID-IJC13>3.0.CO;2-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALDAS C, 1995, INT J PANCREATOL, V18, P1; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; COX AD, 1995, METHOD ENZYMOL, V255, P195; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FREEDMAN RR, 1995, MENOPAUSE, V2, P163; Friess H, 1996, J MOL MED-JMM, V74, P35, DOI 10.1007/BF00202070; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GILLESPIE J, 1993, BRIT J CANCER, V68, P1122, DOI 10.1038/bjc.1993.491; Grewe M, 1999, CANCER RES, V59, P3581; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Longnecker DS, 1998, PANCREAS, V17, P323, DOI 10.1097/00006676-199811000-00001; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; Moepps B, 1999, GENOMICS, V60, P199, DOI 10.1006/geno.1999.5901; Okada S, 1998, PANCREAS, V16, P349, DOI 10.1097/00006676-199804000-00023; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RODRIGUEZ VP, 1997, CELL, V89, P457; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, J BIOL CHEM, V267, P24796; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUMI S, 1994, PANCREAS, V9, P657, DOI 10.1097/00006676-199409000-00018; TAN MH, 1986, CANCER INVEST, V4, P15, DOI 10.3109/07357908609039823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271	63	99	105	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2930	2942		10.1038/sj.onc.1203612	http://dx.doi.org/10.1038/sj.onc.1203612			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871844				2022-12-28	WOS:000087544500007
J	Sato, H; Ogata, H; De Luca, LM				Sato, H; Ogata, H; De Luca, LM			Annexin V inhibits the 12-O-tetradecanoylphorbol-13-acetate-induced activation of Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of Shc in MCF-7 cells	ONCOGENE			English	Article						annexin V; MAPK; TPA; signal transduction; PKC	BREAST-CANCER CELLS; PROTEIN-KINASE; CARCINOMA-CELLS; MAP KINASE; RAF-1 KINASE; C ACTIVITY; IN-VITRO; RAS; EXPRESSION; PHOSPHORYLATION	Annexin V is a Ca2+-dependent phospholipid binding protein. Although it has been shown to inhibit protein kinase C (PKC) in cell-free systems, its role in the intact cell is unclear, A stable,MCF-7 human breast cancer cell overexpression system was established to investigate the function of annexin V, In these cells, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced phosphorylation and kinase activity of ERK1/2 were suppressed. Morphological changes induced by TPA were reduced by annexin V overexpression as well as by the pan-PKC inhibitor, bisindolylmaleimide I, and by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor, PD98059, TPA-induced MEK1/2 and Raf-l phosphorylation were reduced in these cells, The TP,S-enhanced active Ras, and its association with Raf-1, were reduced. TPA treatment of MCF-7 cells caused an increased association of She with Grb2, However, this increased association was prevented in the annexin V-overexpressors. p21(WAF/CIPI) is responsible for inhibition of cell cycle progression in MICF-7 cells. TPA induced the expression of p21(WAF/CIPI) to a greater extent in MCF-7 parent and control plasmid cells than in annexin V overexpressors, PD98059 inhibited this increase, suggesting that TPA upregulation of p21(WAF/CIPI) occurs via the MEK pathway, and that annexin V overexpression blunts it, This work shows that annexin V overexpression suppresses the TPA-induced Ras/ERK; signaling by inhibiting at/or upstream of She, possibly through the inhibition of PkCs.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	De Luca, LM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA.							ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buckland AG, 1998, BBA-LIPID LIPID MET, V1391, P367, DOI 10.1016/S0005-2760(98)00026-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COMERA C, 1989, J CELL BIOCHEM, V40, P361, DOI 10.1002/jcb.240400312; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KARUBE A, 1995, GYNECOL ONCOL, V58, P295, DOI 10.1006/gyno.1995.1233; KATO S, 1988, EXP CELL RES, V179, P31, DOI 10.1016/0014-4827(88)90345-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MENAPACE L, 1987, BIOCHEM BIOPH RES CO, V148, P1295, DOI 10.1016/S0006-291X(87)80274-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RAYNAL P, 1993, BIOCHEM J, V292, P759, DOI 10.1042/bj2920759; ROTHHUT B, 1995, EUR J BIOCHEM, V232, P865; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Shibata S, 1997, GYNECOL ONCOL, V66, P217, DOI 10.1006/gyno.1997.4746; SHIBATA S, 1992, J BIOCHEM-TOKYO, V112, P552, DOI 10.1093/oxfordjournals.jbchem.a123937; SHIBATA S, 1992, TOHOKU J EXP MED, V166, P479, DOI 10.1620/tjem.166.479; SOZERI O, 1992, ONCOGENE, V7, P2259; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Utsumi T, 1992, Nihon Sanka Fujinka Gakkai Zasshi, V44, P793; VALETTE A, 1987, CANCER RES, V47, P1615; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WINKELSTEIN A, 1986, EXP HEMATOL, V14, P1023; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	27	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2904	2912		10.1038/sj.onc.1203615	http://dx.doi.org/10.1038/sj.onc.1203615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871841				2022-12-28	WOS:000087544500004
J	Kotenko, SV; Pestka, S				Kotenko, SV; Pestka, S			Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes	ONCOGENE			English	Review						cytokines; interleukin-10; interferons; receptors; IFN-8; IFN-alpha	INTERFERON-GAMMA RECEPTOR; HUMAN-TISSUE FACTOR; PROTEIN-TYROSINE KINASE; COAGULATION-FACTOR VIIA; ALPHA-BETA RECEPTOR; CRYSTAL-STRUCTURE; IFN-GAMMA; ERYTHROPOIETIN RECEPTOR; GROWTH-HORMONE; INTRACELLULAR DOMAIN	Cells of the immune system communicate with each other to initiate, establish and maintain immune responses. The communication occurs through cell-to-cell contact or through a variety of intercellular mediators that include cytokines, chemokines, growth factors and hormones. In the case of cytokines, the signal is transmitted from the outside to the inside of a cell through cell surface receptors specific for each cytokine, At this step the signal is also decoded and amplified: ligand binding causes recruitment and/or activation of numerous cytoplasmic proteins. One cytokine can activate number of signal transduction pathways leading to regulation of a wide array of biological activities, One of these pathways, the Jak-Stat pathway, is briefly reviewed here with respect to the class II cytokine receptors, Signal transduction through receptors for interferons Type I (IFN-alpha, IFN-beta, IFN-omega) and Type II (IFN-gamma), and interleukin 10 (IL-10) is described in detail. In addition, a complex between tissue factor (TF) and coagulation factor VIIa, and two new receptors related to the class II cytokine receptor family are discussed.	Canc Inst New Jersey, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pestka, S (corresponding author), Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.				NATIONAL CANCER INSTITUTE [P30CA072720, R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46465, 1P30-CA72720] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Arduini RM, 1999, PROTEIN SCI, V8, P1867, DOI 10.1110/ps.8.9.1867; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carmeliet P, 1998, INT J BIOCHEM CELL B, V30, P661, DOI 10.1016/S1357-2725(97)00121-0; CARSON SD, 1985, SCIENCE, V229, P991, DOI 10.1126/science.4023720; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cunningham MA, 1999, BLOOD, V94, P3413, DOI 10.1182/blood.V94.10.3413.422k24_3413_3420; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KEMPNER ES, 1986, METHOD ENZYMOL, V119, P255; Kirchhofer D, 1996, CURR OPIN BIOTECH, V7, P386, DOI 10.1016/S0958-1669(96)80112-1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LIU Y, 1994, J IMMUNOL, V152, P1821; LOK S, 1999, Patent No. 5965704; LOK S, 1999, Patent No. 5945511; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MOORE D, 1993, ADDICT RES, V1, P11; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Muthukumaran G, 1997, J BIOL CHEM, V272, P4993, DOI 10.1074/jbc.272.8.4993; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Novelli F, 1996, J IMMUNOL, V157, P1935; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; PESTKA S, 1983, J BIOL CHEM, V258, P9706; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; POLLACK BP, 2000, UNPUB; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; Reboul J, 1999, GENOME RES, V9, P242; RUI H, 1994, J BIOL CHEM, V269, P5364; Sakatsume M, 1996, J IMMUNOL, V156, P4160; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SKRENTA H, 1996, EUR CYTOKINE NETW, V7, P622; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIYAMA T, 1995, HUM GENET, V95, P99; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; USACHEVA A, 2000, UNPUB; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	112	168	194	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2557	2565		10.1038/sj.onc.1203524	http://dx.doi.org/10.1038/sj.onc.1203524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851054				2022-12-28	WOS:000087459400011
J	Wang, X; Weng, LP; Yu, Q				Wang, X; Weng, LP; Yu, Q			Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR	ONCOGENE			English	Article						PTPase; tyrosine phosphorylation; growth factor	EPIDERMAL GROWTH-FACTOR; MOTOR AXON GUIDANCE; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; KINASES; CELLS; SIGMA; OVEREXPRESSION; ASSOCIATION	LAR is a widely expressed receptor-like protein tyrosine phosphatase that is implicated in regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors, Genetic studies revealed that LAR regulates neuron axon path finding in Drosophila and mammary gland epithelial cell differentiation in mice. The molecular mechanism underlying the tissue specific function of LAR has not been clearly understood. We investigated the role and mechanism of LAR in peptide growth factors EGF and FGF signaling in human tissue culture cells in which the expression of LAR is under the control of an inducible promoter. We found that although both EGF and FGF induce activation of mitogen-activated protein kinase (MAPK), LAR only inhibits FGF-induced MAPK activation. LAR does not interact directly with the peptide growth factor receptors, since the ligand-induced autophosphorylation of growth factor receptors was not affected by induction of LAR, The specific effect of LAR on FGF-induced MAPK activation appeared to be mediated by specific inhibition of the phosphorylation of two signal transducers that act downstream of the FGF receptor, FRS2 and a 180 kDa protein, and by prevention of their interaction with the adaptor protein GRB2, In contrast, LAR selectively inhibited the epidermal growth factor (EGF)-induced phosphorylation of p130(CAS) and the formation of the complex between p130(CAS) and GRB2 but this effect did not influence the activation of MAPK by EGF, These data suggest that LAR and similar receptor-like protein tyrosine phosphatases may contribute to the regulation of transmembrane signaling by selectively inhibiting the tyrosine phosphorylation of specific signal transducers that act downstream of the plasma membrane-associated tyrosine kinases, The consequent inhibition of the Formation of signaling complexes by these proteins may contribute to the specificity of the signals generated by specific peptide growth factors as well as extracellular matrix proteins.	Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Ctr Pulm, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Yu, Q (corresponding author), Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA.				NHLBI NIH HHS [R01 HL 54044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 1997, J BIOL CHEM, V272, P448; AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; KATSURA H, 1995, DEV DYNAM, V204, P89, DOI 10.1002/aja.1002040111; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YU Q, 1992, ONCOGENE, V7, P1051; Zinn K, 1998, CURR BIOL, V8, pR725, DOI 10.1016/S0960-9822(98)70459-2	38	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2346	2353		10.1038/sj.onc.1203558	http://dx.doi.org/10.1038/sj.onc.1203558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822386				2022-12-28	WOS:000086974300010
J	Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM				Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM			The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3 ' kinase	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); HGF/SF; c-Met; breast cancer; adriamycin (doxorubicin)	C-MET RECEPTOR; SCATTER FACTOR; CELL-DEATH; TUMOR-SUPPRESSOR; EXPRESSION; SURVIVAL; BRCA1; AKT; PHOSPHORYLATION; ACTIVATION	Scatter factor (SF) [aka, hepatocyte growth factor (HGF)] (designated HGF/SF) is a multifunctional cytokine that stimulates tumor cell invasion and angiogenesis. We recently reported that HGF/SF protects epithelial and carcinoma cells against cytotoxicity from DNA-damaging agents and that HGF/SF-mediated cytoprotection was associated with up-regulation of the anti-apoptotic protein Bcl-X-L in cells exposed to adriamycin, We now; report that in addition to blocking apoptosis, HGF/SF markedly enhances the repair of DNA strand breaks caused by adriamycin or gamma radiation. Constitutive expression of Bcl-X-L in MDA-MB-453 breast cancer cells not only simulated the HGF/SF-mediated chemoradioresistance, but also enhanced the repair of DNA strand breaks, The ability of HGF/SF to induce both chemoresistance and DNA repair was inhibited by wortmannin, suggesting that these activities of HGF/SF are due, in part, to a phosphatidylinositol-3'-kinase (PI3K) dependent signaling pathway. Consistent with this finding, HGF/SF induced the phosphorylation of c-Akt (protein kinase-B), a PI3K substrate implicated in apoptosis inhibition; and an expression vector encoding a dominant negative kinase inactive Akt partially but significantly inhibited HGF/SF-mediated cell protection and DNA repair. These findings suggest that HGF/SF activates a cell survival and DNA repair pathway;ay that involves signaling through PI3K and c-Akt and stabilization of the expression of Bcl-X-L and they implicate Bcl-X-L in the DNA repair process.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Rockville Ctr, Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Mercy Med Ctr, New York, NY 11570 USA; Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Neurosci, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Oncol, Baltimore, MD 21205 USA	Northwell Health; Yeshiva University; Memorial Sloan Kettering Cancer Center; Kennedy Krieger Institute; Johns Hopkins University; Kennedy Krieger Institute; Kennedy Krieger Institute	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS CA32148] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032148] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Husain A, 1998, CANCER RES, V58, P1120; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KOLIK G, 1997, MOL CELL BIOL, V17, P1595; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Packham G, 1996, ONCOGENE, V13, P461; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rodriguez C, 1996, J CELL PHYSIOL, V166, P387, DOI 10.1002/(SICI)1097-4652(199602)166:2<387::AID-JCP17>3.0.CO;2-8; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SATTLER MM, 1996, NATURE, V382, P335; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shao NS, 1996, ONCOGENE, V13, P1; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; STOKER M, 1987, NATURE, V327, P238; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao Y, 1996, AM J PATHOL, V149, P1707; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	47	140	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2212	2223		10.1038/sj.onc.1203566	http://dx.doi.org/10.1038/sj.onc.1203566			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822371				2022-12-28	WOS:000086974100006
J	Bjorge, JD; Jakymiw, A; Fujita, DJ				Bjorge, JD; Jakymiw, A; Fujita, DJ			Selected glimpses into the activation and function of Src kinase	ONCOGENE			English	Review						Src; tyrosine kinase; protein tyrosine phosphatases; oncogene; cancer; cellular localization	PROTEIN-TYROSINE-PHOSPHATASE; AVIAN-SARCOMA VIRUS; FOCAL ADHESION KINASE; DEPENDENT DNA-POLYMERASE; HIGHLY SPECIFIC ANTIBODY; GENE-PRODUCT RECOGNIZES; CELL-CYCLE PROGRESSION; GAP-ASSOCIATED PROTEIN; AMINO-ACID-SEQUENCE; C-SRC	Since the discovery of the v-src and c-src genes and their products, much progress has been made in the elucidation of the structure, regulation, localization, and function of the Src protein. Src is a non-receptor protein tyrosine kinase that transduces signals that are involved in the control of a variety of cellular processes such as proliferation, differentiation, motility, and adhesion. Src is normally maintained in an inactive state, but can be activated transiently during cellular events such as mitosis, or constitutively by abnormal events such as mutation (i.e, v-Src and some human cancers). Activation of Src occurs as a result of disruption of the negative regulatory processes that normally suppress Src activity, and understanding the various mechanisms behind Src activation has been a target of intense study. Src associates with cellular membranes, in particular the plasma membrane, and endosomal membranes. Studies indicate that the different subcellular localizations of Src could be important for the regulation of specific cellular processes such as mitogenesis, cytoskeletal organization, and/or membrane trafficking. This review will discuss the history behind the discovery and initial characterization of Src and the regulatory mechanisms of Src activation, in particular, regulation by modification of the carboxyterminal regulatory tyrosine by phosphatases and kinases, Its focus will then turn to the different subcellular localizations of Src and the possible roles of nuclear and perinuclear targets of Src, Finally, a brief section will review some of our present knowledge regarding Src involvement in human cancers.	Univ Calgary, Dept Biochem & Mol Biol, Canc Biol Res Grp, Med Ctr, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Canc Biol Res Grp, Med Ctr, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Jakymiw, Andrew/0000-0001-6431-8753				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BJORGE JD, 2000, IN PRESS J BIOL CHEM; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CANTLEY LC, 1994, J CELL SCI, P121; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chappel J, 1997, J CELL BIOCHEM, V67, P432, DOI 10.1002/(SICI)1097-4644(19971215)67:4<432::AID-JCB2>3.0.CO;2-T; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1995, J VIROL, V69, P1699, DOI 10.1128/JVI.69.3.1699-1713.1995; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FANG KS, 1994, J BIOL CHEM, V269, P14056; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; Furuyama N, 2000, BIOCHEM BIOPH RES CO, V272, P116, DOI 10.1006/bbrc.2000.2698; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; Gondran P, 1999, ONCOGENE, V18, P2547, DOI 10.1038/sj.onc.1202598; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Guitard E, 1998, BIOCHEM BIOPH RES CO, V245, P562, DOI 10.1006/bbrc.1998.8374; Hamaguchi I, 1996, BIOCHEM BIOPH RES CO, V224, P172, DOI 10.1006/bbrc.1996.1003; HANAFUSA H, 1965, VIROLOGY, V25, P248, DOI 10.1016/0042-6822(65)90203-5; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; HENDERSON D, 1987, EXP CELL RES, V168, P411, DOI 10.1016/0014-4827(87)90013-9; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Jabado N, 1997, J IMMUNOL, V158, P94; Jabado N, 1998, J IMMUNOL, V161, P2798; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON TM, 2000, IN PRESS J BIOL CHEM; JOHO RH, 1975, P NATL ACAD SCI USA, V72, P4772, DOI 10.1073/pnas.72.12.4772; Joukov V, 1997, BIOCHEM J, V322, P927, DOI 10.1042/bj3220927; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAI MMC, 1973, P NATL ACAD SCI USA, V70, P2266, DOI 10.1073/pnas.70.8.2266; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lang V, 1999, J IMMUNOL, V162, P7224; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LIN PH, 1995, ONCOGENE, V10, P401; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LIU XQ, 1993, ONCOGENE, V8, P1119; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MARTIN GS, 1971, P NATL ACAD SCI USA, V68, P2739, DOI 10.1073/pnas.68.11.2739; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKAMURA H, 1994, ONCOGENE, V9, P2293; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; PARKER RC, 1981, P NATL ACAD SCI-BIOL, V78, P5842, DOI 10.1073/pnas.78.9.5842; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PENG ZY, 1995, ONCOGENE, V11, P1955; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; PURCHIO AF, 1978, P NATL ACAD SCI USA, V75, P1567, DOI 10.1073/pnas.75.3.1567; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; RENDU F, 1989, BLOOD, V73, P1545; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROBINSON WS, 1967, P NATL ACAD SCI USA, V58, P825, DOI 10.1073/pnas.58.3.825; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKANO S, 1994, ONCOGENE, V9, P1155; Samokhvalov I, 1997, BIOCHEM MOL BIOL INT, V43, P115; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHALLOWAY D, 1981, CELL, V24, P531, DOI 10.1016/0092-8674(81)90344-5; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P194, DOI 10.1006/abbi.1997.0156; TAKEUCHI S, 2000, IN PRESS J BIOL CHEM; TAKEYA T, 1982, J VIROL, V44, P1; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1990, ONCOGENE RES, V5, P305; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; TANAKA T, 1984, VIROLOGY, V133, P202, DOI 10.1016/0042-6822(84)90440-9; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; VOGT PK, 1966, VIROLOGY, V30, P368, DOI 10.1016/0042-6822(66)90115-2; VOGT PK, 1971, VIROLOGY, V46, P939, DOI 10.1016/0042-6822(71)90092-4; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WANG L, 1975, J VIROL, V16, P1051, DOI 10.1128/JVI.16.4.1051-1070.1975; Wang L H, 1975, Bibl Haematol, P542; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YANG Q, 1993, J BIOL CHEM, V268, P6622; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu WJ, 1998, ONCOGENE, V17, P565, DOI 10.1038/sj.onc.1201979	236	323	330	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5620	5635		10.1038/sj.onc.1203923	http://dx.doi.org/10.1038/sj.onc.1203923			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114743				2022-12-28	WOS:000165659300010
J	Robinson, DR; Wu, YM; Lin, SF				Robinson, DR; Wu, YM; Lin, SF			The protein tyrosine kinase family of the human genome	ONCOGENE			English	Review						tyrosine kinase; human genome; receptor; non-receptor; mouse; ortholog	SIGNAL-TRANSDUCTION; EPH RECEPTORS; NEUROTROPHIN RECEPTORS; CAENORHABDITIS-ELEGANS; RET PROTOONCOGENE; NERVOUS-SYSTEM; TRK FAMILY; GROWTH; GENE; DOMAIN	As the sequencing of the human genome is completed by the Human Genome Project, the analysis of this rich source of information will illuminate many areas in medicine and biology. The protein tyrosine kinases are a large multigene family with particular relevance to many human diseases, including cancer. A search of the human genome for tyrosine kinase coding elements identified several novel genes and enabled the creation of a nonredundant catalog of tyrosine kinase genes. Ninety unique kinase genes can be identified in the human genome, along with five pseudogenes. Of the 90 tyrosine kinases, 58 are receptor type, distributed into 20 subfamilies. The 32 nonreceptor tyrosine kinases can be placed in 10 subfamilies. Additionally, mouse orthologs can be identified for nearly all the human tyrosine kinases, The completion of the human tyrosine kinase family tree provides a framework for further advances in biomedical science.	Univ Calif Davis, Ctr Canc, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA	University of California System; University of California Davis	Robinson, DR (corresponding author), Univ Calif Davis, Ctr Canc, Sch Med, Dept Biol Chem, 4645 2nd Ave, Sacramento, CA 95817 USA.		Lin, Su-Fang/B-2666-2010	Lin, Su-Fang/0000-0001-8706-2439	NCI NIH HHS [R0I CA82073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Cole PA, 1999, PHARMACOL THERAPEUT, V82, P219, DOI 10.1016/S0163-7258(98)00046-1; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; Crosby AE, 1999, SUICIDE LIFE-THREAT, V29, P131; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Danilkovitch A, 1999, J LEUKOCYTE BIOL, V65, P345, DOI 10.1002/jlb.65.3.345; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hallbook F, 1999, CURR OPIN NEUROBIOL, V9, P616, DOI 10.1016/S0959-4388(99)00011-2; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holder N, 1999, DEVELOPMENT, V126, P2033; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Klambt C, 2000, CURR BIOL, V10, pR388, DOI 10.1016/S0960-9822(00)00485-1; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; Ladanyi M, 2000, AM J PATHOL, V157, P341, DOI 10.1016/S0002-9440(10)64545-2; Ladanyi M, 1997, CANCER SURV, V30, P59; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lee HY, 1998, MOL CELLS, V8, P401; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; Lucini C, 1999, NEUROSCI LETT, V261, P163, DOI 10.1016/S0304-3940(99)00011-7; Maglott DR, 2000, NUCLEIC ACIDS RES, V28, P126, DOI 10.1093/nar/28.1.126; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; Mason I, 2000, Pharm Acta Helv, V74, P261, DOI 10.1016/S0031-6865(99)00048-5; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Muller WEG, 1999, GENE, V238, P179, DOI 10.1016/S0378-1119(99)00226-7; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Neubauer A, 1997, LEUKEMIA LYMPHOMA, V25, P91, DOI 10.3109/10428199709042499; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Park SK, 1996, J BIOCHEM, V119, P235; Partanen J, 1999, CURR TOP MICROBIOL, V237, P159; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Popovici C, 1999, GENOME RES, V9, P1026, DOI 10.1101/gr.9.11.1026; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Pruitt KD, 2000, TRENDS GENET, V16, P44, DOI 10.1016/S0168-9525(99)01882-X; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rikke BA, 2000, MOL BIOL EVOL, V17, P671, DOI 10.1093/oxfordjournals.molbev.a026346; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sakuma M, 1997, ZOOL SCI, V14, P941, DOI 10.2108/zsj.14.941; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Serfas MS, 1998, ONCOGENE, V17, P3435, DOI 10.1038/sj.onc.1202266; Shurin MR, 1998, CYTOKINE GROWTH F R, V9, P37, DOI 10.1016/S1359-6101(97)00035-X; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsai JY, 1996, SCIENCE, V271, P1432, DOI 10.1126/science.271.5254.1432; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; Veikkola T, 2000, CANCER RES, V60, P203; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Walchli S, 2000, GENE, V253, P137, DOI 10.1016/S0378-1119(00)00275-4; Weiner HL, 2000, CANCER INVEST, V18, P544, DOI 10.3109/07357900009012194; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; White JA, 1997, GENOMICS, V45, P468, DOI 10.1006/geno.1997.4979; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Yeung CH, 1998, J REPROD FERTIL, P137	114	773	826	3	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5548	5557		10.1038/sj.onc.1203957	http://dx.doi.org/10.1038/sj.onc.1203957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114734				2022-12-28	WOS:000165659300001
J	Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J				Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J			Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells	ONCOGENE			English	Article						senescence; cell cycle; Cdc25A; p15(INK4B); cyclin E-cdk2; HMEC	GROWTH-FACTOR-BETA; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; CDK INHIBITORS; DNA-SYNTHESIS; G(1)/S TRANSITION; DEPENDENT KINASES; PROTEIN-KINASE; GENE STATUS	Replicative senescence may be an important tumor suppressive mechanism for human cells. We investigated the mechanism of cell cycle arrest at senescence in human mammary epithelial cells (HMECs) that have undergone a period of 'self-selection', and as a consequence exhibit diminished p16(INK4A) levels. As HMECs approached senescence, the proportion of cells with a 2N DNA content increased and that in S phase decreased progressively. Cyclin D1-cdk4, cyclin E-cdk2 and cyclin A-cdk2 activities were not abruptly inhibited, but rather diminished steadily with increasing population age. In contrast to observations in fibroblast, p21(Cip1) was not increased at senescence in HMECs. There was no increase in p27(Kip1) levels nor in KIP association with targets cdks. While p15(INK4B) and its binding to both cdk4 and cdk6 increased with increasing passage, some cyclin D1-bound cdk4 and cdk6 persisted in senescent cells, whose inhibition could not be attributed to p15(INK4B). The inhibition of cyclin E-cdk2 in senescent HMECs was accompanied by increased inhibitory phosphorylation of cdk2, in association with a progressive loss of Cdc25A. Recombinant Cdc25A strongly reactivated cyclin E-cdk2 from senescent HMECs suggesting that reduction of Cdc25A contributes to cyclin E-cdk2 inhibition and G1 arrest at senescence. Although ectopic expression of Cdc25A failed to extend the lifespan of HMECs, the exogenous Cdc25A appeared to lack activity in these cells, since it neither shortened the G1-to-S phase interval nor activated cyclin E-cdk2. In contrast, in the breast cancer-derived MCF-7 line, Cdc25A overexpression increased both cyclin E-cdk2 activity and the S phase fraction. Thus, mechanisms leading to HMEC immortalization may involve not only the re-induction of Cdc25A expression, but also activation of this phosphatase.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, Toronto, ON M4N 3M5, Canada; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Mitotix Inc, Cambridge, MA 02139 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, S-238,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA-24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024844, R37CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRENNER AJ, 1998, IN PRESS ONCOGENE; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Enders GH, 1996, ONCOGENE, V12, P1239; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gasparotto D, 1997, CANCER RES, V57, P2366; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERMAN JG, 1995, CANCER RES, V55, P4525; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P440; Kim IY, 1996, ENDOCRINOLOGY, V137, P991, DOI 10.1210/en.137.3.991; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nijjar T, 1999, CANCER RES, V59, P5112; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Reznikoff CA, 1996, CANCER RES, V56, P2886; Roberts L, 1998, FORSCH KOMPLEMENTMED, V5, P82, DOI 10.1159/000057115; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Sandhu C, 2000, CANCER RES, V60, P2616; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2392; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wong DJ, 1997, CANCER RES, V57, P2619; YAMASHITA M, 1992, DEV BIOL, V1, P8; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	71	41	46	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5314	5323		10.1038/sj.onc.1203908	http://dx.doi.org/10.1038/sj.onc.1203908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103932	Green Published			2022-12-28	WOS:000165302300002
J	Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF				Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF			A novel germ line juxtamembrane Met mutation in human gastric cancer	ONCOGENE			English	Article						gastric cancer; germ line; juxtamembrane Met mutation	HEPATOCYTE GROWTH-FACTOR; PAPILLARY RENAL CARCINOMAS; SCATTER FACTOR; TYROSINE KINASE; FACTOR RECEPTOR; C-MET; EPITHELIAL-CELLS; PROTOONCOGENE PRODUCT; SOMATIC MUTATIONS; TUMORIGENICITY	Activating mutations in the Met receptor tyrosine kinase, both germline and somatic, have been identified in human papillary renal cancer. Here we report a novel germline missense Met mutation, P1009S, in a patient with primary gastric cancer. The dosage of the mutant Met DNA was elevated in the tumor when compared to its matched normal DNA. Therefore, as with hereditary renal papillary cancer, the mutant Met allele may also be selectively duplicated in the tumor. Different from previously reported Met mutations, which occur in the tyrosine kinase domain, this missense mutation is located at the juxtamembrane domain, and is not constitutively activated. However, following treatment with HGF/SF, the P1009S mutant Met protein, expressed in NIH3T3 cells, displays increased and persistent tyrosine phosphorylation compared to the wild-type Met. Importantly, these cells also form colonies in soft agar, and are highly tumorigenic in athymic nude mice. A second nucleotide change in this region of Met, T1010I, was found in a breast cancer biopsy and a large cell lung cancer cell line. Although this previously reported 'polymorphism' did not stimulate NIH3T3 cell growth in soft agar, it was more active than the wild-type Met in the athymic nude mice tumorigenesis assay, suggesting that it may have effects on tumorigenesis. Met has been shown to be highly expressed in human gastric carcinoma cell lines, and our results raise the possibility that activating missense Met mutations could contribute to tumorigenesis of gastric cancer.	Van Andel Res Inst, Grand Rapids, MI 49503 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Ajou Univ, Sch Med, Dept Surg, Paldal Gu, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem, Paldal Gu, Suwon 442749, South Korea; Norfolk & Norwich Healthcare NHS Trust, Norwich, Norfolk, England; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Div Intramural Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), Van Andel Res Inst, 333 Bostwick,NE, Grand Rapids, MI 49503 USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Cho, Hyeseong/0000-0002-4672-8887	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLUSCI S, 1994, ONCOGENE, V9, P1091; Blair D G, 1983, Prog Clin Biol Res, V119, P79; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldas C, 1999, J MED GENET, V36, P873; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; FALETTO DL, 1992, ONCOGENE, V7, P1149; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Higashio K, 1993, EXS, V65, P351; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kanda H, 1993, Nihon Rinsho, V51, P380; Matturri L, 1998, ANTICANCER RES, V18, P2819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PONZETTO C, 1991, ONCOGENE, V6, P553; RAO PH, 1993, DIAGN MOL PATHOL, V2, P264, DOI 10.1097/00019606-199312000-00006; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tanyi J, 1999, Pathol Oncol Res, V5, P187, DOI 10.1053/paor.1999.0219; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	47	276	292	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4947	4953		10.1038/sj.onc.1203874	http://dx.doi.org/10.1038/sj.onc.1203874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042681				2022-12-28	WOS:000089834300001
J	Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD				Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD			C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines	ONCOGENE			English	Article						C-erbB-2; fascin; breast cancer; cell motility; actin	BETA-CATENIN; TYROSINE PHOSPHORYLATION; SELECTIVE-INHIBITION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; NEU ONCOGENE; IN-VIVO; EXPRESSION; METASTASIS; KINASE	The over-expression of c-erbS-2/ HER-2, a receptor tyrosine kinase, correlates with poor prognosis in patients with breast and ovarian cancer. In the human breast cancer cell line, MDA-MB-435, c-erbB-2 overexpression results in increased chemoinvasion and higher metastatic properties in nude mice. I-ion ever, the mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear. We have determined that over-expression of c-erbB-2 in MDA-MB-435 cells, and in some additional breast cancer cell lines, is associated with graphic increases in mRNA and protein levels of the actin bundling protein fascin, Heightened fascin expression has been observed in other systems to result in greatly increased cell motility, and indeed, our work employing semi-automated time-lapse microscopy demonstrates that MDA-MB-435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics and locomotion, while visualization of bundled microfilaments within fixed cells revealed enhanced formation of dendritic-like processes, microspikes and other dynamic actin based structures. To address the means by which c-erbB-2 over-expression might result in elevated fascin levels, we identified multiple perfect match TCF and NF-kappa B consensus sites in fascin's promoter and first intron,which appeared consistent with the greater endogenous transcriptional activities of TCF and NF-kappa B in c-erbB-2 over-expressing MDA-MB-435 cells. While such transcriptional modulation may occur in the context of the intact gene/chromatin, subsequent tests using reporter constructs did not support involvement of these signaling pathways. In conclusion, highly increased fascin levels were observed in MDA-MB-435 over-expressing c-erbB-2, likely contributing to these cells' altered actin dynamics, and increased cell motility and malignancy. Studies in progress aim to discern the means by which c-erbB-2 over-expression leads to transcriptional activation of the fascin gene.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Plast Surg, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM052112, R01 GM 52112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; Aljada A, 1999, J CLIN ENDOCR METAB, V84, P3386, DOI 10.1210/jc.84.9.3386; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CANO RJ, 1992, BIOTECHNIQUES, V12, P264; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; DECORTE V, 1994, J CELL SCI, V107, P405; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; del Peso L, 1997, ONCOGENE, V15, P3047; DHALIWAL MK, 1990, ANTICANCER RES, V10, P113; DICKASON RR, 1995, J IMMUNOL METHODS, V185, P237, DOI 10.1016/0022-1759(95)00119-U; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GROTHEY A, 2000, BR J CANC, V88; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hung MC, 1999, SEMIN ONCOL, V26, P51; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klapper LN, 2000, ADV CANCER RES, V77, P25; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kzhyshkowska JG, 1996, IMMUNOL LETT, V53, P101, DOI 10.1016/S0165-2478(96)02625-9; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Montross WT, 2000, J CELL SCI, V113, P1759; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; PELES E, 1992, J BIOL CHEM, V267, P12266; Pinkus GS, 1997, AM J PATHOL, V150, P543; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SEGATTO O, 1993, ONCOGENE, V8, P2105; Shibata T, 1996, ONCOGENE, V13, P883; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 1997, CANCER RES, V57, P1199; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; VAN AD, 1996, SCIENCE, V274, P787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	51	97	114	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4864	4875		10.1038/sj.onc.1203838	http://dx.doi.org/10.1038/sj.onc.1203838			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039904				2022-12-28	WOS:000089757800009
J	Modi, S; Kubo, A; Oie, H; Coxon, AB; Rehmatulla, A; Kaye, FJ				Modi, S; Kubo, A; Oie, H; Coxon, AB; Rehmatulla, A; Kaye, FJ			Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer	ONCOGENE			English	Article						RB; RBL1/p107; RBL2/p130; SV40; mesothelioma	CARCINOMA CELL-LINES; RETINOBLASTOMA PROTEIN; DIFFERENTIAL EXPRESSION; MALIGNANT MESOTHELIOMA; GROWTH SUPPRESSION; SIMIAN VIRUS-40; DNA-SEQUENCES; P107; SIMIAN-VIRUS-40; E2F	Mutational inactivation of the RE-related gene RBL2/ p130 has been reported as a common and important prognostic factor in human lung cancer. To examine the role of the RE-related gene family in lung cancer we analysed the protein expression of the RE gene in cell Lines obtained from 83 patients with small cell lung cancer (SCLC) and 114 patients with non-SCLC that included 21 novel lung tumor samples. While we detected five new SCLC with mutant RE expression (RB inactivation in 75/83; 90.4%), we did not detect any RE mutations in the new non-SCLC cell lines (RB inactivation in 13/114 non-SCLC and mesothelioma; 11.4%), In addition, we detected expression of a full-length RBL1/p107 and RBL2/p130 species in every sample tested (RBL1 or RBL2 inactivation in 0/69) and confirmed that both RE-related gene products retain functional binding activity to the E1A viral oncoprotein. Since expression of SV40 Large T antigen (Tag) has been reported in a subset of human lung tumors where it may inactivate RBL1 and RBL2, we also examined mesothelioma and non-mesothelioma lung tumors for Tag expression. Although we detected a faint 85 kDa protein species using specific anti-Tag antibodies, this signal migrated slightly faster than Tag extracted from Cos7 cells and did not exhibit binding activity to the RE or RBL1 proteins, Finally, we subjected 11 lung cancer cell lines to nucleotide sequencing and did not detect mutations within the C-terminal RBL2 exons 19-22 as recently reported. While the RB/p16 tumor suppressor pathway is targeted for mutations in 100% of lung cancers, mutational inactivation of the related RBL1 and RBL2 genes is a rare event.	Natl Naval Med Ctr, Med Branch, Bethesda, MD 20889 USA; NCI, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA	Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Natl Naval Med Ctr, Med Branch, Bldg 8,Room 5101, Bethesda, MD 20889 USA.		kaye, frederic/E-2437-2011					Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG JQ, 1994, CANCER RES, V54, P5547; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eberhard D, 1999, CANCER RES, V59, p1716S; Eberhard D, 1999, CANCER RES, V59, p1724s; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HOWARD CM, 1998, J NATL CANCER I, V90, P123; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KRATZKE RA, 1994, ONCOGENE, V9, P1321; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; YOKOTA J, 1988, ONCOGENE, V3, P471; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	36	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4632	4639		10.1038/sj.onc.1203815	http://dx.doi.org/10.1038/sj.onc.1203815			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030152				2022-12-28	WOS:000089438200009
J	Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C				Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C			Correct binding of viral X protein to UVDDB-p127 cellular protein is critical for efficient infection by hepatitis B viruses	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA binding protein; virus-host interaction; therapeutic target	NUCLEOTIDE-SEQUENCE; GENE PRODUCT; IN-VIVO; REPLICATION; MUTATIONS; CELLS	A fully effective treatment of chronic human hepatitis B virus (I-IBV) infection is still missing and HBV remains the first etiological agent of liver cancer. Although the viral regulatory X protein is essential for infection, its mode of action remains obscure, due the lark of an in vitro infection system. In the accompanying study, we showed the functional importance of interaction between X and the host protein UVDDB-p127, in the transactivation and apoptotic properties of the viral protein, Here, we addressed the biological role of X-UVDDB interaction in the infectious process using a genetic approach in the woodchuck virus closely related to HBV. We show that (i) mutations in X, which markedly affect UVDDB-binding, also abolished productive infection in woodchucks, (ii) in the few cases where mutant viruses led to infection, compensatory mutations had occurred in the X gene of the viral progeny, which restored correct UVDDB-binding. We conclude that efficient viral replication in vivo requires proper X-UVDDB interaction. The interaction may thus provide a novel therapeutic target for the treatment of hepatitis B.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France; Cornell Univ, Coll Vet Med, Dept Clin Sci, Vet Med Ctr C2 005, Ithaca, NY 14853 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Krogsgaard K, 1998, J VIRAL HEPATITIS, V5, P389, DOI 10.1046/j.1365-2893.1998.00118.x; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Wei Y, 1998, J VIROL, V72, P6608, DOI 10.1128/JVI.72.8.6608-6613.1998; Zoulim F, 1998, J HEPATOL, V29, P151, DOI 10.1016/S0168-8278(98)80191-8; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	21	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4427	4431		10.1038/sj.onc.1203770	http://dx.doi.org/10.1038/sj.onc.1203770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980618				2022-12-28	WOS:000089271900013
J	Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS				Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS			The conserved PI3 ' K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila	ONCOGENE			English	Article						Drosophila; PKB; PI3K; PTEN; cell size; cell survival	PROTEIN-KINASE B/AKT; B C-AKT; PHOSPHOINOSITIDE 3-KINASE; GROWTH; TRANSFORMATION; ACTIVATION; APOPTOSIS; DEATH	Akt (or PKB) is an oncogene involved in the regulation of cell survival. Akt is regulated by phosphatidylinositol 3-OH kinase (P13'K) signaling and has shown to be hyperactivated through the loss of the PTEN tumor suppressor. In Drosophila, insulin signaling as studied using the Drosophila IRS-4 homolog (Chico) has been shown to be a crucial regulator of cell size. We have studied Drosophila Akt (Dakt1) and have shown that it is also involved in the regulation of cell size. Furthermore me have performed genetic epistasis tests to demonstrate that in Drosophila, PI3'K, PTEN and Akt comprise a signaling cassette that is utilized during multiple stages of development. In addition, we show that this signaling cassette is also involved in the regulation of cell survival during embryogenesis. This study therefore establishes the evolutionary conservation of this signaling pathway in Drosophila.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Expt Therapeut,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Electron Microscopy Unit, Toronto, ON M5S 1A8, Canada; Amgen Res Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Manoukian, AS (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Stambolic, Vuk/0000-0001-8853-3239				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ANJELKOVIC M, 1996, P NATL ACAD SCI USA, V93, P5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CULLEN CF, 1991, TISSUE CELL, V23, P29, DOI 10.1016/0040-8166(91)90064-Z; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Huang H, 1999, DEVELOPMENT, V126, P5365; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehner CF, 1999, NAT CELL BIOL, V1, pE129, DOI 10.1038/12961; MANOUKIAN AS, 1997, MRNA FORMATION FUNCT, P361; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	29	149	153	9	22	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3971	3977		10.1038/sj.onc.1203739	http://dx.doi.org/10.1038/sj.onc.1203739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962553				2022-12-28	WOS:000088825300002
J	Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR				Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR		UK Canc Cytogenetics Grp	Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes	ONCOGENE			English	Article						chromosome 20; tumour suppressor genes; myeloproliferative disorders; myelodysplastic syndromes	MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; MOLECULAR ANALYSIS; HUMAN GENOME; LEUKEMIA; MAP; REFINEMENT; LIBRARIES; SEGMENT; YEAST	Deletion of the long arm of chromosome 20 represents the most common chromosomal abnormality associated with the myeloproliferative disorders (MPDs) and is also found in other myeloid malignancies including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Previous studies have identified a common deleted region (CDR) spanning approximately 8 Mb. We have now used G-banding, FISH or microsatellite PCR to analyse 113 patients with a 20q deletion associated with a myeloid malignancy. Our results define a new MPD CDR of 2.7 Mb, an MDS/AML CDR of 2.6 Mb and a combined 'myeloid' CDR of 1.7 Mb, We have also constructed the most detailed physical map of this region to date - a bacterial clone map spanning 5 Mb of the chromosome which contains 456 bacterial clones and 202 DNA markers. Fifty-one expressed sequences were localized within this contig of which 37 lie within the MPD CDR and 20 within the MDS/AML CDR, Of the 16 expressed sequences (sis genes and 10 unique ESTs) within the 'myeloid' CDR, five were expressed in both normal bone marrow and purified CD34 positive cells. These data identify a set of genes which are both positional and expression candidates for the target gene(s) on 20q.	Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Sangor Ctr, Hinxton CB10 1SA, Cambs, England; St Vincents Hosp, Victorian Canc Cytogenet Serv, Fitzroy, Vic 3065, Australia	University of Cambridge; Wellcome Trust Sanger Institute; St Vincent's Hospital Melbourne	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.		Deloukas, Panos/B-2922-2013; huntly, brian JP/E-6725-2014	Deloukas, Panos/0000-0001-9251-070X; huntly, brian JP/0000-0003-0312-161X; Green, Anthony/0000-0002-9795-0218; Hunt, Adrienne/0000-0002-1227-0310				Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V87, P1561, DOI 10.1182/blood.V87.4.1561.bloodjournal8741561; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; BENCH AJ, 1998, MYELOPROLIFERATIVE D, P819; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BERNARDI G, 1993, GENE, V135, P57, DOI 10.1016/0378-1119(93)90049-9; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1993, CANCER GENET CYTOGEN, V68, P60, DOI 10.1016/0165-4608(93)90075-W; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S; HOLLINGS PE, 1994, GENE CHROMOSOME CANC, V11, P21, DOI 10.1002/gcc.2870110105; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KRALOVICS R, 1998, MYELOPROLIFERATIVE D, P803; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; LEBEAU MM, 1985, P NATL ACAD SCI USA, V82, P6692; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MITELMAN F, 1995, CATALOG CHROMOSOME A; MORRIS CM, 1989, BLOOD, V74, P1768; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NACHEVA E, 1995, CANCER GENET CYTOGEN, V82, P9, DOI 10.1016/0165-4608(94)00286-K; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; ROSS MT, 1997, GENOME MAPPING, P165; ROULSTON D, 1993, BLOOD, V82, P3424; Saville MK, 1998, ADV CANCER RES, V72, P109; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	39	127	132	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3902	3913		10.1038/sj.onc.1203728	http://dx.doi.org/10.1038/sj.onc.1203728			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10952764				2022-12-28	WOS:000088614300009
J	Rodriguez, MI; Finbow, ME; Alonso, A				Rodriguez, MI; Finbow, ME; Alonso, A			Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation	ONCOGENE			English	Article						papillomavirus; receptors; membrane proteins; vacuolar H+-ATPase; endosomes; recycling	PORE-FORMING PROTEIN; EPITHELIAL-CELL LINE; BOVINE PAPILLOMAVIRUS; TRANSFORMING PROTEIN; TYPE-16 DNA; GENE-EXPRESSION; ONCOPROTEIN; KERATINOCYTES; SITE; COMMUNICATION	Human papillomavirus type 16 E5 protein (HPV16 E5) upregulates ligand-mediated activation of the epidermal growth factor receptor (EGFR) in transfected human keratinocytes. HPV16 E5 binds to the 16 kDa proteolipid (subunit c) of the vacuolar H+-ATPase (16K), responsible for endosomal acidification, and this binding has been suggested to be responsible for increased recycling of the EGFRs, Using mutant deletions we show here that amino acids 53-78, but not 79-83 are necessary for binding to the 16K proteolipid, EGF treatment of cells expressing wild type or mutants of the E5 protein show that deletion of the last carboxy terminal 5 amino acids results in loss of ES-mediated EGFR overactivation, Thus, our results show that the binding capacity of HPV16 E5 to 16K can be dissociated from the effect of the viral protein on EGFR activation.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Helmholtz Association; German Cancer Research Center (DKFZ); Beatson Institute	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld-242, D-69120 Heidelberg, Germany.		García, Isabel Rodríguez/AAG-2211-2019; Rodríguez, Isabel/L-9327-2013	García, Isabel Rodríguez/0000-0001-7213-1411; Rodríguez, Isabel/0000-0001-7213-1411				ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; DURST M, 1987, ONCOGENE, V1, P251; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FINBOW ME, 1991, MOL CARCINOGEN, V4, P441, DOI 10.1002/mc.2940040605; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NEAL MA, 1995, J INVEST DERMATOL, V105, P668; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PIM D, 1992, ONCOGENE, V7, P27; PIRISI L, 1987, J VIROL, V57, P572; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	38	51	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3727	3732		10.1038/sj.onc.1203718	http://dx.doi.org/10.1038/sj.onc.1203718			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949926				2022-12-28	WOS:000088568400004
J	Fu, SL; Waha, A; Vogt, PK				Fu, SL; Waha, A; Vogt, PK			Identification and characterization of genes upregulated in cells transformed by v-Jun	ONCOGENE			English	Article						v-Jun; oncogenic transformation; transcriptional activation; transcriptional targets	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; LIM DOMAIN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; TRANSACTIVATION DOMAIN; LEUCINE ZIPPER; MESSENGER-RNAS	The transcription factor Jun (c-Jun) functions as a recipient of extracellular growth signals and converts them into patterns of gene expression. An oncogenic variant of c-Jun was isolated from the acutely transforming retrovirus ASV17, Overexpression of this viral Jun (v-Jun) induces transformation of chicken embryo fibroblasts (CEF) in culture and fibrosarcomas in chickens. v-Jun is constitutively active form of c-Jun and transforms cells presumably by deregulating the expression of specific target genes. In this report, we describe six genes whose transcripts are upregulated in v-Jun-transformed CEF, Three of these genes show homology to known mammalian genes, to MAP kinase phosphatase 2 (MKP-2), to reversion-induced LIM protein (RIL) and to cytokine-inducible SH2-containing protein (CIS), Northern blot analysis, using CEF infected with various Jun mutants or an estrogen-regulatable Jun chimera, revealed distinct induction patterns of individual targets by v-jun, The chicken RIL homolog showed an expression pattern tightly correlated with the activity of v-Jun, Its expression is also transformation-dependent, suggesting a role for this gene in v-Jun transformation, The newly identified v-Jun targets can serve as molecular markers in the v-Jun transformation process.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DeRisi J, 1996, NAT GENET, V14, P457; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIESS M, 1995, ONCOGENE, V10, P61; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; NEIL JC, 1981, P NATL ACAD SCI-BIOL, V78, P1906, DOI 10.1073/pnas.78.3.1906; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; TSUCHIE H, 1989, ONCOGENE, V4, P1281; USUI H, 1994, J NEUROSCI, V14, P4915; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vogt P K, 1981, Haematol Blood Transfus, V26, P424; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	57	28	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3537	3545		10.1038/sj.onc.1203691	http://dx.doi.org/10.1038/sj.onc.1203691			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918612				2022-12-28	WOS:000088346500010
J	Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y				Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y			p51A (TAp63 gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation	ONCOGENE			English	Article						p51; p63; p53; p21(wafI); Bax; DNA damage	TEMPERATURE-SENSITIVE MUTANT; KINASE C-ABL; MUTATIONAL ANALYSIS; IONIZING-RADIATION; APOPTOTIC RESPONSE; IN-VIVO; GENE; P63; PHOSPHORYLATION; PROLIFERATION	p51A, or TAp63 gamma, a translation product of gene p51, or p63, was identified as a homolog of p53 in its primary structure and transactivating function. p53 plays a decision-making role in inducing either cell cycle arrest or apoptosis in response to DNA damage, and thereby preserves genome integrity of living cells, To compare the biological activities between p51A and p53, cell lines with low-level, constitutive expression of each protein were obtained by cDNA transfection of mouse erythroleukemic cells. Production of p51A with an apparent molecular mass of 57-kilodalton (kD) accompanied induction of p21(wafl) and appearance of hemoglobin-producing cells. After DNA-damaging treatment either with ultraviolet light (UV) irradiation or with actinomycin D, the p51A protein accumulated in time courses corresponding to those of wild-type p53, and caused an increase in the hemoglobin-positive cell count. In contrast, p53-accumulated cells underwent apoptosis without exhibiting the feature of erythroid differentiation, The mode of p21(wafl) and Bax-alpha upregulations varied between p51A- and p53-expressing cells and between the types of DNA damage. These results suggest the possibility that p51A induces differentiation under genotoxic circumstances. There may be cellular factors that control p51A protein stability and transactivating ability.	Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1138510, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan.		井川, 俊太郎/L-5911-2015					Agami R, 1999, NATURE, V399, P809; AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hagiwara K, 1999, CANCER RES, V59, P4165; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimada A, 1999, CANCER RES, V59, P2781; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	34	84	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3126	3130		10.1038/sj.onc.1203644	http://dx.doi.org/10.1038/sj.onc.1203644			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871867				2022-12-28	WOS:000087903900012
J	Broome, MA; Courtneidge, SA				Broome, MA; Courtneidge, SA			No requirement for Src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen	ONCOGENE			English	Article						p53; PDGF; mitogenesis; Src	EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; SH3 DOMAIN; CELLS; TRANSDUCTION; GENE; P53	A growing body of literature suggests that the ubiquitously expressed Src family kinases (Src, Fyn and Yes) are required for agents such as platelet-derived growth factor (PDGF) to stimulate DNA synthesis. Yet Klinghoffer and colleagues recently presented evidence that fibroblasts derived from mice null for Src, Fyn and Yes responded normally to PDGF (Klinghoffer et al,, 1999, EMBO J,, 18: 2459-2471), What is the reason for this discrepancy? We noted that Klinghoffer ef al, (1999) used SV40 large T antigen (largeT) to facilitate derivation of cell lines from the embryos. We therefore tested the effect of largeT on PDGF receptor signaling, We found that expression of largeT overcame the inhibitory effects of interfering forms of both Ras (N17Ras) and Src (SrcK-). Furthermore, injection of SrcK- or the cst.1 antibody (which inhibits Src, Fyn and Yes) failed to inhibit PDGF-stimulated DNA synthesis in NIH3T3 cells expressing dominant negative p53, and fibroblasts derived from p53 null embryos. These data suggest firstly that caution should be used in interpretation of experiments conducted in cell lines expressing largeT, and secondly that the role of Src family kinases in growth factor signaling may be to oppose the effects of negative growth regulators such as p53.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	15	42	43	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2867	2869		10.1038/sj.onc.1203608	http://dx.doi.org/10.1038/sj.onc.1203608			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851090				2022-12-28	WOS:000087403600008
J	Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T				Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T			Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway	ONCOGENE			English	Article						Aurora2; degradation; anaphase-promoting complex; ubiquitin-proteasome pathway	CHROMOSOME SEGREGATION; CELL-CYCLE; IN-VIVO; YEAST; PROTEOLYSIS; EXPRESSION; BINDING; IPL1; TRANSFORMATION; LOCALIZATION	Human Aurora2 was originally identified by its close homology to yeast IPL1 and fly aurora, which are key regulators of chromosome segregation and a family of serine/threonine kinases, Here we demonstrate that the Aurora2 protein is degraded rapidly after G2/M phase release in mammalian cells. Aurora2 protein has a rapid turnover rate with a half-life of approximately 2 h, Tn eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of unstable proteins, The treatment of mammalian cells with proteasome inhibitors blocks Aurora2 degradation. Furthermore, Aurora2 is polyubiquitinated in vivo and in vitro using anaphase-promoting complex (APC), These results demonstrate that Aurora2 protein is turned over through the APC-ubiquitin-proteasome pathway.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Fukui Med Sch, Dept Surg 1, Fukui 9101193, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Nagoya University; University of Fukui; Tokyo University of Pharmacy & Life Sciences	Urano, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai-machi, Nagoya, Aichi 4660065, Japan.			Urano, Takeshi/0000-0003-3383-3554				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Maki CG, 1996, CANCER RES, V56, P2649; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; URANO T, 1993, ONCOGENE, V8, P1371; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANAI A, 1997, ONCOGENE, V14, P2493; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	30	126	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2812	2819		10.1038/sj.onc.1203609	http://dx.doi.org/10.1038/sj.onc.1203609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851084				2022-12-28	WOS:000087403600002
J	Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G				Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G			Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells	ONCOGENE			English	Article						DNA base excision repair; BRCA2; DNA ligation; abasic sites; uracil	BREAST-CANCER SUSCEPTIBILITY; LIGASE-III; POLYMERASE-BETA; IN-VITRO; PANCREATIC CARCINOMAS; MAMMALIAN-CELLS; RADIATION; MUTATIONS; COMPLEX; XRCC1	The brest cancer predisposing genes BRCA1 and BRCA2 appear to be involved in DNA repair. In particular, the sensitivity of BRCA2-deficient mouse embryonic fibroblasts to ionizing radiation and the demonstrated interaction of the BRCA2 protein with Rad51, a major factor in recombinational repair, indicate that BRCA2 is important for double strand break repair. The human BRCA2-deficient human cell line Capan-1, whilst being sensitive to ionizing radiation, is also sensitive to the alkylating agent methymethanesulfonate, The major lesions induced by this agent are methylated bases which are removed primarily by the base excision repair (BER) pathway. We have investigated the efficiency of BER in Capan-1 cells by an in vitro assay in which plasmid substrates containing a single lesion are repaired by mammalian cell extracts. In comparison to the control cell lines BxPC-3, T24 and MCF7, Capan-1 cells exhibited a reduced rate of DNA ligation during both the single-nucleotide insertion and PCNA-dependent pathways of BER, The reduced rate of DNA ligation exhibited by Capan-1 cell extracts was complemented by addition of bacteriophage T4 DNA ligase or human DNA ligase III, BXCA2-mutant Capan-1 cells may possess reduced DNA ligase activity during BER.	Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Manchester, Sch Biol Sci, AstraZeneca Lab Cell & Mol Biol, Manchester M13 9PT, Lancs, England	University of Genoa; IRCCS AOU San Martino IST; AstraZeneca; University of Manchester	Frosina, G (corresponding author), Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Bogliolo, Massimo/J-1631-2019; Caldecott, Keith/S-4245-2019; Frosina, Guido/Z-2382-2019	Frosina, Guido/0000-0002-6717-5097; Bogliolo, Massimo/0000-0001-8240-7784; Caldecott, Keith/0000-0003-4255-9016	Telethon [E.0728] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Frosina G, 1999, METH MOL B, V113, P301; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Goggins M, 1996, CANCER RES, V56, P5360; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Livingston DM, 1997, JAMA-J AM MED ASSOC, V277, P1476; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Morimatsu M, 1998, CANCER RES, V58, P3441; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; REDSTON MS, 1994, CANCER RES, V54, P3025; Schutte M, 1997, CANCER RES, V57, P3126; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Yuan SSF, 1999, CANCER RES, V59, P3547	32	19	19	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5781	5787		10.1038/sj.onc.1203951	http://dx.doi.org/10.1038/sj.onc.1203951			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126365				2022-12-28	WOS:000165477700010
J	Al-Obeidi, FA; Lam, KS				Al-Obeidi, FA; Lam, KS			Development of inhibitors for protein tyrosine kinases	ONCOGENE			English	Review						protein tyrosine kinase; inhibitors; preclinical studies; clinical studies; cancer therapy; drug development	GROWTH-FACTOR-RECEPTOR; STRUCTURE-BASED DESIGN; ATP-BINDING-SITE; IN-VIVO; C-SRC; PHASE-I; MONOCLONAL-ANTIBODY; SUBSTRATE-SPECIFICITY; SELECTIVE INHIBITOR; PEPTIDE INHIBITOR	In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed, The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes, Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases, Some of these inhibitors are highly potent and selective, Several are currently undergoing clinical trials for a number of diseases such as cancer.	Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA; Selectide Corp, Tucson, AZ 85737 USA	University of California System; University of California Davis; University of California System; University of California Davis; Sanofi-Aventis	Lam, KS (corresponding author), Univ Calif Davis, Ctr Canc, Div Hematol Oncol, 4501 X St, Sacramento, CA 95817 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Al-Obeidi FA, 1998, BIOPOLYMERS, V47, P197, DOI 10.1002/(SICI)1097-0282(1998)47:3<197::AID-BIP2>3.0.CO;2-H; Alfaro-Lopez J, 1998, J MED CHEM, V41, P2252, DOI 10.1021/jm9707885; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Boschelli Diane H., 1999, Drugs of the Future, V24, P515, DOI 10.1358/dof.1999.024.05.858622; BOTFIELD MC, 1995, ANNU REP MED CHEM, V30, P227, DOI DOI 10.1016/S0065-7743(08)60937-9; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Braunwalder AF, 1996, ANAL BIOCHEM, V234, P23, DOI 10.1006/abio.1996.0044; Braunwalder AF, 1996, ANAL BIOCHEM, V238, P159, DOI 10.1006/abio.1996.0269; Bridges AJ, 1999, CURR MED CHEM, V6, P825; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; Cassinelli G, 2000, BIOCHEM PHARMACOL, V59, P1539, DOI 10.1016/S0006-2952(00)00278-1; Chen CL, 1999, J CLIN PHARMACOL, V39, P1248, DOI 10.1177/00912709922012051; CIARDIELLO F, 2000, P AM ASSOC CANC RES, V41, P3075; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; COOK PW, 1992, CANCER RES, V52, P3224; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; Eckhardt SG, 1999, J CLIN ONCOL, V17, P1095, DOI 10.1200/JCO.1999.17.4.1095; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; Ferry DR, 1996, CLIN CANCER RES, V2, P659; Floyd CD, 1999, PROGR MED CHEM, V36, P91, DOI 10.1016/S0079-6468(08)70046-8; Fong TAT, 1999, CANCER RES, V59, P99; FRY DW, 1994, PEPTIDES, V15, P951, DOI 10.1016/0196-9781(94)90057-4; Fry DW, 1996, ANNU REP MED CHEM, V31, P151, DOI 10.1016/S0065-7743(08)60455-8; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Gazit A, 1996, J MED CHEM, V39, P4905, DOI 10.1021/jm960225d; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iwata K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P633; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; LAM KS, 1995, INT J PEPT PROT RES, V45, P587; Lam KS, 1997, ANTI-CANCER DRUG DES, V12, P145; Lee TR, 2000, J MED CHEM, V43, P1173, DOI 10.1021/jm990462r; Lei WD, 1999, ANTICANCER RES, V19, P221; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Losiewicz MD, 1999, BIOCHEM PHARMACOL, V57, P281, DOI 10.1016/S0006-2952(98)00293-7; Lou Q, 1996, BIOORGAN MED CHEM, V4, P677, DOI 10.1016/0968-0896(96)00063-6; Lou Q, 1997, CANCER RES, V57, P1877; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lunney EA, 1997, J AM CHEM SOC, V119, P12471, DOI 10.1021/ja971794t; LUNNEY EA, 1997, Patent No. 9712903; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; McLeod HL, 1996, BRIT J CANCER, V74, P1714, DOI 10.1038/bjc.1996.620; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MILKIEWICZ KL, 2000, ACS NAT M WASH DC; Millauer B, 1996, CANCER RES, V56, P1615; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Niu JK, 1997, J BIOL CHEM, V272, P1493, DOI 10.1074/jbc.272.3.1493; Niu JK, 1997, J AM CHEM SOC, V119, P3844, DOI 10.1021/ja970037s; O'Donnell A, 1999, EUR J CANCER, V35, pS282, DOI 10.1016/S0959-8049(99)81554-8; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PALMER BD, 1995, J MED CHEM, V38, P58, DOI 10.1021/jm00001a011; Palmer BD, 1997, J MED CHEM, V40, P1519, DOI 10.1021/jm960789h; PARKER YW, 1997, 3 ANN C SOC BIOM SCR; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PETRAKIS KS, 1987, J AM CHEM SOC, V109, P2831, DOI 10.1021/ja00243a050; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; POSNER I, 1994, MOL PHARMACOL, V45, P673; Powell TJ, 1999, BRIT J DERMATOL, V141, P802, DOI 10.1046/j.1365-2133.1999.03152.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rewcastle GW, 1998, J MED CHEM, V41, P742, DOI 10.1021/jm970641d; Rewcastle GW, 1996, J MED CHEM, V39, P918, DOI 10.1021/jm950692f; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; RUGGERI UT, 1989, TRENDS PHARMACOL SCI, V10, P218; Sausville EA, 1998, CANCER CHEMOTH PHARM, V42, pS54, DOI 10.1007/s002800051080; Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Seethalal R, 1997, ANAL BIOCHEM, V253, P210, DOI 10.1006/abio.1997.2365; Shakespeare W, 2000, P NATL ACAD SCI USA, V97, P9373, DOI 10.1073/pnas.97.17.9373; Showalter HDH, 1997, J MED CHEM, V40, P413, DOI 10.1021/jm960689b; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smaill JB, 1999, J MED CHEM, V42, P1803, DOI 10.1021/jm9806603; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stahura FL, 1999, J MOL GRAPH MODEL, V17, P1, DOI 10.1016/S1093-3263(99)00015-7; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Strawn LM, 1996, CANCER RES, V56, P3540; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Sun L, 2000, J MED CHEM, V43, P2655, DOI 10.1021/jm9906116; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Theodorescu D, 1998, INT J CANCER, V78, P775, DOI 10.1002/(SICI)1097-0215(19981209)78:6<775::AID-IJC16>3.0.CO;2-G; Toledo LM, 1999, CURR MED CHEM, V6, P775; Traxler P, 1999, J MED CHEM, V42, P1018, DOI 10.1021/jm980551o; Traxler PM, 1996, J MED CHEM, V39, P2285, DOI 10.1021/jm960118j; Twaddle GM, 1999, J SURG ONCOL, V70, P83, DOI 10.1002/(SICI)1096-9098(199902)70:2<83::AID-JSO4>3.0.CO;2-L; Uckun FM, 1999, CLIN CANCER RES, V5, P3906; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vincent P. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P117; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; WEN X, 2000, P AM ASSOC CANC RES, V41, P2052; Woodburn J. R., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P633; WOODBURN JR, 2000, P AM ASSOC CANC RES, V41, P2552; Wu JJ, 1996, LETT PEPT SCI, V3, P309, DOI 10.1007/BF00127665; WU JJ, 1997, AM ASS CANC RES P, V38, P443; Wu JZJ, 1998, BIOORG MED CHEM LETT, V8, P2279, DOI 10.1016/S0960-894X(98)00413-2; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu XL, 1996, BIOCHEM PHARMACOL, V52, P527, DOI 10.1016/0006-2952(96)00303-6; YE F, 2000, ACS NAT M WASH DC; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	125	98	107	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5690	5701		10.1038/sj.onc.1203926	http://dx.doi.org/10.1038/sj.onc.1203926			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114749				2022-12-28	WOS:000165659300016
J	Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT				Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT			Interaction of the retinoblastoma protein (pRb) with the catalytic subunit of DNA polymerase delta (p125)	ONCOGENE			English	Article						DNA polymerase delta; retinoblastoma; cyclin dependent kinase; cell cycle	LARGE-T-ANTIGEN; TRANSCRIPTION FACTOR; REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; BINDING PROTEIN; E1A PROTEINS; RB; PRODUCT; CYCLINS; GENE	The retinoblastoma gene product (pRb) interacts with many cellular proteins to function in the control of cell division, differentiation, and apoptosis, Several pRb binding proteins complex with pRb through an amino acid sequence called the LXCXE motif, The catalytic subunit of DNA polymerase delta (p125) contains a LXCXE motif, To further study the biochemical function of this polymerase, we sought to determine if p125 interacts with pRb, Experiments using GST-pRb fusion proteins showed that p125 from breast epithelial (MCF10A) cell extracts associates with pRb. In addition, GST-p125 fusion proteins bound pRb from the same cell extracts. The pRb that associated with GST-p125 was largely unphosphorylated, Coimmunoprecipitation experiments using cell cycle synchronized cells revealed that p125 and pRb form a complex predominantly during G(1) phase, the phase during which pRb is mostly unphosphorylated. In vitro phosphorylation of GST-pRb by the cyclin dependent kinases reduced the ability of p125 to associate with GST-pRb, Addition of the LXCXE containing protein SV40 large T antigen to GST-pRb blocks the ability of p125 to associate with pRb, suggesting that it may be through a LXCXE sequence by which p125 interacts with pRb, Finally, in vitro polymerase assays demonstrate that GST-pRb fusion protein stimulates DNA polymerase delta activity.	Pace Univ Pleasantville, Dept Biol Sci, Pleasantville, NY 10570 USA; New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY USA	Pace University; New York Medical College; University of Rochester	Krucher, NA (corresponding author), Pace Univ Pleasantville, Dept Biol Sci, 861 Bedford Rd, Pleasantville, NY 10570 USA.				NHGRI NIH HHS [NIHGM31973] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; JONES RE, 1990, J BIOL CHEM, V265, P12782; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MO J, 2000, BIOCHEMISTRY-US, V39, P2745; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DH, 1988, MOL CELL BIOL, V8, P3883; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561	36	8	8	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5464	5470		10.1038/sj.onc.1203930	http://dx.doi.org/10.1038/sj.onc.1203930			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114723				2022-12-28	WOS:000165396100006
J	Brachat, A; Pierrat, B; Brungger, A; Heim, J				Brachat, A; Pierrat, B; Brungger, A; Heim, J			Comparative microarray analysis of gene expression during apoptosis-induction by growth factor deprivation or protein kinase C inhibition	ONCOGENE			English	Article						apoptosis; microarray; interleukin-3; protein kinase C; staurosporine	PROGRAMMED CELL-DEATH; NF-KAPPA-B; TRANSCRIPTION FACTOR; PROTEOLYTIC ACTIVATION; MEDIATED APOPTOSIS; MOUSE SKIN; IN-VIVO; T-CELLS; SURVIVAL; RECEPTOR	The transcriptional response of mouse pro-B cells to two different apoptotic stimuli was investigated. First, interleukin3 (IL-3) deprivation was used to trigger programmed cell death in IL-3 dependent FL5.12 cells, Alternatively, cells were treated with the protein kinase C (PKC) inhibitor staurosporine, The temporal pattern of gene expression was followed with cDNA microarrays, covering over 8700 different mouse cDNA sequences corresponding to approximately 7900 unique genes. Messenger RNA levels of 315 genes mere found to be regulated by more than twofold upon IL-3 removal, while 125 genes reacted to staurosporine treatment. Cross-comparison revealed an intersection of 34 genes similarly regulated in both pathways and thus representing candidates for common apoptosis regulators, For many expressed sequence tags (ESTs) our data suggest for the first time functions in the control of apoptosis, stress response or the cell cycle. IL-3 removal led to the repression of genes required for proliferation and to the induction of genes, linked to apoptotic and signaling pathways. Staurosporine caused predominantly activation of genes, some of which had previously been described to be involved in inflammation. Our findings indicate that cellular responses to both apoptotic stimuli influence various physiological pathways which had not previously been known to be linked.	Novartis Pharma AG, Mol & Cellular Biol Senior Sci Expert Lab, CH-4002 Basel, Switzerland; Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis; Novartis	Heim, J (corresponding author), Novartis Pharma AG, Mol & Cellular Biol Senior Sci Expert Lab, K-125-13-16, CH-4002 Basel, Switzerland.			Brachat, Arndt/0000-0001-5768-3429				BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BLANDINO G, 1995, ONCOGENE, V10, P731; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Galvin JP, 1999, J IMMUNOL, V162, P5345; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; GUPTA AK, 1988, J INVEST DERMATOL, V91, P486, DOI 10.1111/1523-1747.ep12476635; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hartigan J., 1975, CLUSTERING ALGORITHM; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hisaeda H, 1997, J IMMUNOL, V159, P2375; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INGLIS JD, 1991, GENE, V106, P213, DOI 10.1016/0378-1119(91)90201-L; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kataoka M, 1997, J BIOL CHEM, V272, P18209, DOI 10.1074/jbc.272.29.18209; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; KHANNA KK, 1993, ONCOGENE, V8, P3307; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lentsch AB, 1999, CLIN CHEM LAB MED, V37, P205, DOI 10.1515/CCLM.1999.038; Li FZ, 1999, CANCER RES, V59, P3143; LOTSCHER E, 1990, NUCLEIC ACIDS RES, V18, P7153, DOI 10.1093/nar/18.23.7153; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIYASHITA T, 1995, CELL, V80, P293; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MOOLENAAR WH, 1990, CIBA F SYMP, V150, P99; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Oliver FJ, 1996, BIOCHEM J, V316, P421, DOI 10.1042/bj3160421; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; Reynolds NJ, 1997, ARCH DERMATOL RES, V289, P540, DOI 10.1007/s004030050236; Rickers A, 1999, EUR J BIOCHEM, V261, P269, DOI 10.1046/j.1432-1327.1999.00273.x; Rosenfeld ME, 1998, SEMIN REPROD ENDOCR, V16, P249, DOI 10.1055/s-2007-1016285; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Simpkins C, 1998, J SURG RES, V75, P30, DOI 10.1006/jsre.1997.5241; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu YQ, 1999, CYTOKINE, V11, P523, DOI 10.1006/cyto.1998.0436; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang H, 1999, INT J ONCOL, V14, P113; Zhang HC, 1996, PROSTATE, V29, P69; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	79	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5073	5082		10.1038/sj.onc.1203882	http://dx.doi.org/10.1038/sj.onc.1203882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042695				2022-12-28	WOS:000089930100004
J	Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS				Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS			Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner	ONCOGENE			English	Article						tumor; angiogenesis; oncogenes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; K14-HPV16 TRANSGENIC MICE; CERVICAL-CARCINOMA CELLS; FACTOR MESSENGER-RNA; FACTOR RECEPTOR; PERMEABILITY FACTOR; FACTOR EXPRESSION; HUMAN KERATINOCYTES; SUPPRESSOR GENE; DNA-BINDING	Like other types of pre-malignant lesions and carcinoma, angiogenesis is associated with high-grade cervical dysplasia and with invasive squamous carcinoma of the cervix, Vascular endothelial cell growth factor (VEGF) is known to be one of the most important inducers of angiogenesis and is upregulated in carcinoma of the cervix, Human Papilloma Virus 16 (HPV-16) has been etiologically linked to human cervical cancer, and the major oncogenic proteins encoded by the viral genome, E6 and E7, are involved in the immortalization of target cells, Because several oncogenes including mutant ras, EGF receptor, ErbB2/Her2, c-myc and v-src upregulate VEGF expression, we asked whether HVP-16 E6 oncoprotein could act in a similar fashion. We found that HPV-16 E6-positive cells generally express high levels of VEGF message. Furthermore, co-expression of the VEGF promoter-Luc (luciferase) reporter gene with E6 in both human keratinocytes and mouse fibroblast showed that E6 oncoprotein upregulates VEGF promoter activity, and does so in a p53 independent manner. An E6 responsive region which comprises four Sp-1 sites, between -194 and -50 bp of the VEGF promoter, is also necessary for constitutive VEGF transcription, Taken together, our results suggest the possibility that the HPV oncoprotein E6 may contribute to tumor angiogenesis by direct stimulation of the VEGF gene.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Int Ctr Genet Engn & Biotechnol, Vaccine Div, Havana 10600, Cuba; Int Ctr Genet Engn & Biotechnol, Div Pharmaceut, Havana 10600, Cuba; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; McMaster Univ, Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8W 1C3, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; McMaster University	Kerbel, RS (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bequet-Romero, Monica/M-3356-2017	Bequet-Romero, Monica/0000-0003-0351-857X	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BenBassat H, 1997, CANCER RES, V57, P3741; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DERYNCK R, 1987, CANCER RES, V47, P707; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FAN Z, 1993, CANCER RES, V53, P4637; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herrington CS, 1999, J PATHOL, V189, P1; Hove MGM, 1999, J REPROD MED, V44, P493; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIESER A, 1994, ONCOGENE, V9, P963; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; Mazure NM, 1996, CANCER RES, V56, P3436; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUNGER K, 1989, J VIROL, V63, P4417; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; PARK NH, 1995, ONCOGENE, V10, P2145; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Petit AMV, 1997, AM J PATHOL, V151, P1523; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Ravi R, 2000, GENE DEV, V14, P34; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SIF S, 1993, ONCOGENE, V8, P2501; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stoler MH, 2000, INT J GYNECOL PATHOL, V19, P16, DOI 10.1097/00004347-200001000-00004; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tokumo K, 1998, GYNECOL ONCOL, V68, P38, DOI 10.1006/gyno.1997.4876; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Webster NJG, 1996, CANCER RES, V56, P2781; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WOODWORTH CD, 1988, CANCER RES, V48, P4620; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	82	159	176	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4611	4620		10.1038/sj.onc.1203817	http://dx.doi.org/10.1038/sj.onc.1203817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030150	Bronze			2022-12-28	WOS:000089438200007
J	Shimizu, S; Shinohara, Y; Tsujimoto, Y				Shimizu, S; Shinohara, Y; Tsujimoto, Y			Bax and Bcl-x(L) independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator	ONCOGENE			English	Article						ANT; VDAC; Bax; mitochondria; yeast	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; ADP/ATP CARRIER; PROTEASE CASCADE; BCL-2; EXPRESSION; MEMBRANE; PROTEINS; CHANNEL; FAMILY	Mitochondria play an essential role in apoptosis by releasing apoptogenic molecules such as cytochrome c and AlF, and some caspases, which are all regulated by Bcl-2 family proteins. Pro-apoptotic Pas and Bah have been shown to induce cytochrome c release and loss of membrane potential (Delta psi) leading to AIF release in the isolated mitochondria. We have previously shown that Bas and Bah open the voltage-dependent anion channel (VDAC) allowing cytochrome c to pass through the channel, and Bcl-x(L) closes the channel. However, it has been reported that it is adenine nucleotide translocator (ANT) with which Bax/Bcl-x(L) interacts that modulate the channel activity. Here, we investigated the role of ANT and VDAC in the changes of isolated mitochondria triggered by Bas and by chemicals that induce permeability transition (PT), In rat and yeast mitochondria, Bas did not affect the ADP/ATP exchange activity of ANT. VDAC-deficient but not ANT-deficient feast mitochondria showed resistance to cytochrome c release, Delta psi loss, and swelling caused by Bas and PT inducers. Bcl-x(L) showed similar inhibition of all these changes in ANT-deficient and wild type yeast mitochondria, Furthermore, Bas induces cytochrome c release in wild type yeast cells but not VDAC1-deficient yeast cells. These data indicate that VDAC, but not ANT, is essential for apoptotic mitochondrial changes. The data also indicate that Bcl-xL acid Bas possess an ability to regulate mitochondrial membrane permeability independently of other Bcl-2 family members.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci, Osaka, Japan	Osaka University; Tokushima University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLANCHLYDYSON E, 1997, MOL CELL BIOL, V17, P5727; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; KLINGENBERG M, 1994, BBA-BIOENERGETICS, V1187, P241, DOI 10.1016/0005-2728(94)90119-8; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	39	134	143	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4309	4318		10.1038/sj.onc.1203788	http://dx.doi.org/10.1038/sj.onc.1203788			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980606				2022-12-28	WOS:000089271900001
J	Koga, H; Deppert, W				Koga, H; Deppert, W			Identification of genomic DNA sequences bound by mutant p53 protein (Gly(245)-> Ser) in vivo	ONCOGENE			English	Article						mutant p53; CHIP; PCR-EMSA; microinjection; repetitive DNA elements	CROSS-LINKING; BINDING; TRANSCRIPTION; ELEMENTS; GENE; MUTATIONS; REGIONS; COMPLEX; MURINE	Mutant p53 proteins were shown to exert complex DNA-interactions interactions in vitro, like binding to MAR-DNA, but so far it is unknown whether such interactions also occur in vivo. Therefore we analysed the binding of mutant (mut) p53 (Gly(245)-->Ser) in Onda 11 glioma cells to cellular DNA in vivo, using p53-specific chromatin immunoprecipitation (CHIP) after in vivo cross-linking of mut p53 to genomic DNA with cisplatin, We identified genomic DNA fragments to which mut p53 (Gly(245)-->Ser) could be cross-linked in vivo. Purified recombinant mut p53 (Gly(245)-->Ser) was able to bind specifically to such elements in PCR-EMSA in vitro, supporting the idea that this mut p53 protein interacts with genomic DNA in vivo. The genomic DNA fragments identified are vastly different in sequence, but display as a common feature a high likelihood to adopt a non B-DNA conformation. Therefore we propose that structural determinants within these DNA elements are important for their interaction with mut p53 (Gly(245)-->Ser) in vivo.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; Bode J, 1995, INT REV CYTOL, V162A, P389; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLOROS J, 1995, BIOCHEM J, V305, P583, DOI 10.1042/bj3050583; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HERNANDEZBOUSSA.T, 1999, IARC SCI PUBL, V146, P43; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Koga H, 1996, Noshuyo Byori, V13, P1; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel SK, 1998, CANCER RES, V58, P3004; Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; WEISSKER SN, 1992, ONCOGENE, V7, P1921; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Zhang SJ, 1996, JPN J CANCER RES, V87, P900, DOI 10.1111/j.1349-7006.1996.tb02118.x	31	30	30	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4178	4183		10.1038/sj.onc.1203745	http://dx.doi.org/10.1038/sj.onc.1203745			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962580	Bronze			2022-12-28	WOS:000088955100013
J	Ronchini, C; Capobianco, AJ				Ronchini, C; Capobianco, AJ			Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation	ONCOGENE			English	Article						notch; hormone inducible activity; phosphorylation; CBF-1; nuclear localization	HUMAN ESTROGEN-RECEPTOR; CELL-FATE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; IN-VIVO; CONDITIONAL TRANSFORMATION; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; FUSION PROTEINS	Notch genes encode a family of evolutionarily conserved transmembrane receptors that are involved in many distinct cellular processes such as differentiation, proliferation and apoptosis. Notch function has been shown to be required both during development and in adult life. Moreover, several studies on spontaneous human tumors and in experimental models demonstrate that three of the four mammalian Notch genes can act as oncogenes. The mechanism by which Notch proteins induce neoplastic transformation is not known. In order to determine the early signaling events mediated by Notch during cellular transformation we constructed several inducible alleles of Notch(ic) by fusing portions of Notch(ic) to the hormone-binding domain of the estrogen receptor. Here we show that Notch(ic)-ER chimeras are conditionally activated by 4-Hydroxytamoxifen (OHT) in a dose-dependent manner. Clonal RKE cell lines expressing Notch(ic)-ER chimeras display hormone-dependent transformation in vitro. Transformation mediated by Notch(ic)-ER is reversible and chronic stimulation is necessary for the maintenance of the transformed phenotype. In response to hormone activation Notch(ic)-ER chimeras become hyperphosphorylated and accumulate in the nuclear of the cell; indicating that both phosphorylation and nuclear localization are required for Notch transforming activity.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Capobianco, AJ (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Ronchini, Chiara/K-3935-2013	Ronchini, Chiara/0000-0003-3908-4021; Capobianco, Anthony/0000-0002-3706-6797	NATIONAL CANCER INSTITUTE [R01CA083736] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 83736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; ECCLES SA, 1994, INVAS METAST, V14, P337; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FuentesPanana EM, 1998, J VIROL, V72, P693; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grignani F, 1998, CANCER RES, V58, P14; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lofts F J, 1992, Cancer Treat Res, V61, P161; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; NYE JS, 1994, DEVELOPMENT, V120, P2421; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; STIFANI S, 1992, NAT GENET, V2, P343, DOI 10.1038/ng1292-343a; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vigo E, 1999, MOL CELL BIOL, V19, P6379; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	57	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3914	3924		10.1038/sj.onc.1203719	http://dx.doi.org/10.1038/sj.onc.1203719			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951584				2022-12-28	WOS:000088614300010
J	Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J				Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J			In vitro differentiation of c-myb(-/-) ES cells reveals that the colony forming capacity of unilineage macrophage precursors and myeloid progenitor commitment are c-Myb independent	ONCOGENE			English	Article						c-Myb; knockout; ES cell differentiation; haemopoietic progenitors	MULTIPLE HEMATOPOIETIC LINEAGES; EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR GATA-1; MICE LACKING; ERYTHROID DEVELOPMENT; YOLK-SAC; GENE; LEUKEMIA; MOUSE; MEGAKARYOCYTE	Mice homozygous for an inactivated c-myb allele exhibit embryonic (primitive) blood formation but die at about day 15 of gestation because of a failure to generate adult (definitive) haemopoiesis. Recently, it has been shown that commitment to definitive haemopoiesis does occur in vivo, but that some point in the subsequent development towards the differentiated lineages is compromised. Here we have asked whether it is possible to demonstrate this same distinction between the development of primitive and definitive haemopoiesis during the in vivo differentiation of c-myb null ES cells, and whether this can be used to define more precisely at which developmental stage the absence of c-Myb blocks the adult haemopoietic lineages. We investigated the kinetics of progenitor formation and commitment to differentiation using a combination of colony forming assays and analysis of RNA and surface antigen expression. Primitive unilineage macrophage and erythroid precursor commitment could develop in the absence of c-Myb. No precursors characteristic of definitive haemopoiesis were detected; nevertheless, we could show the expression of programme of transcription and surface antigens which is consistent with the appearance of definitive progenitors blocked at an early multipotential stage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; Saint James's University Hospital; University of Leeds; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Elwood NJ, 1998, BLOOD, V91, P3756; Faust N, 1997, EXP HEMATOL, V25, P432; FAUST N, 1994, DNA CELL BIOL, V13, P901, DOI 10.1089/dna.1994.13.901; Frampton J, 1997, MOL B INT U, P287; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LONG MW, 1981, BLOOD, V58, P1032; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V12, P123; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palis J, 1999, DEVELOPMENT, V126, P5073; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; TAKAHASHI K, 1989, J LEUKOCYTE BIOL, V45, P87, DOI 10.1002/jlb.45.2.87; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WILES MV, 1991, DEVELOPMENT, V111, P259; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	43	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3343	3351		10.1038/sj.onc.1203661	http://dx.doi.org/10.1038/sj.onc.1203661			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918591				2022-12-28	WOS:000088198100002
J	Ivanov, VN; Ronai, Z				Ivanov, VN; Ronai, Z			p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappa B activity and Fas expression	ONCOGENE			English	Article						p38; stress kinases; NF-kappa B; UV-irradiation; radiation resistance; TNF	NECROSIS-FACTOR-ALPHA; TERMINAL KINASE JNK; SIGNAL-TRANSDUCTION; LIGAND EXPRESSION; MAP KINASE; T-CELLS; TRANSCRIPTIONAL REGULATION; ACTIVATION; INHIBITION; PROMOTER	Identifying mechanisms that underlie the resistance of human melanoma to radiation and chemotherapy is expected to assist in developing new strategies for the treatment of this tumor type. We recently demonstrated that through up-regulation of TNF alpha, ATF2 increases the resistance of late stage melanoma cells to apoptosis induced by UV-irradiation, In elucidating the role of ATF2 kinases, we now demonstrate that ASK1/MKK6/p38 elicits suppression of Fas expression. ASK1/p38 downregulates the expression of a Fas via NF-kappa B/SP1 site on the Fas promoter. Deletion or mutation of NF-kappa B/SP1 within the Fas promoter abrogates p38 effect. ASK1/p38 silences the Fas promoter by inhibition of I kappa B alpha phosphorylation - thereby limiting NF-kappa B activity. Forced expression of a dominant negative form of p38 (p38-ASP) or treatment with p38 pharmacological inhibitor, SB203580, increases NF-kappa B activity, Fas expression and the levels of UVC-induced apoptosis in late stage melanoma cells. Inhibition of p38 activity also restored NF-kappa B activity and Fas expression in early-phase melanoma cells, suggesting that p38 elicited suppression of Fas expression is not restricted to late phase melanoma, Identifying p38-mediated down-regulation of Fas expression illustrates a novel regulatory pathway by which ASK1/MKK6/p38 alters the degree and nature of the UV-induced apoptosis of melanoma cells.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cain BS, 1999, J SURG RES, V83, P7, DOI 10.1006/jsre.1998.5548; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh S, 1999, J IMMUNOL, V162, P7434; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOGUCHI K, 1999, J BIOL CHEM, V274, P32850; Ozes ON, 1999, NATURE, V401, P82; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Schafer PH, 1999, J IMMUNOL, V162, P659; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	60	108	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3003	3012		10.1038/sj.onc.1203602	http://dx.doi.org/10.1038/sj.onc.1203602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871852	Green Published			2022-12-28	WOS:000087581400007
J	Thullberg, M; Bartek, J; Lukas, J				Thullberg, M; Bartek, J; Lukas, J			Ubiquitin/proteasome-mediated degradation of p19(INK4d) determines its periodic expression during the cell cycle	ONCOGENE			English	Article						INK4 family; p19(INK4d); cyclin D; CDK4; ubiquitin/proteasome-dependent degradation; retinoblastoma protein	DEPENDENT KINASES CDK4; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; INHIBITOR P27; LUNG-CANCER; INK4 FAMILY; TGF-BETA; S-PHASE; P16(INK4A)	Assembly and activity of the proto-oncogenic cyclin D/ CDK4(6) complexes, the major driving force of G1 phase progression, is negatively regulated by a family of INK4 CDK inhibitors p16(INK4a), p15(INK4b), p18(INK4c), and p19(INK4d). Expression of the INK4 family members is controlled at the transcriptional level, through differential response to environmental and intracellular signals such as cytokines, oncogenic overload, or cellular senescence. Here we show that the periodic oscillation of the p19(INK4d) protein during the cell cycle is determined by the ubiquitin/proteasome-dependent mechanism, allowing the protein abundance to follow the changes in its mRNA expression. Within the INK4 family, this regulatory mode appears restricted to p19(INK4d) whose ubiquitination was dependent on the integrity of lysine 62, and binding to CDK4. These results highlight unexpected differences among the INK4 inhibitors, and suggest how p19(INK4d) may help regulate the rate of cyclin D/CDK4(6) complex formation, and thereby timely progression through the mammalian cell division cycle.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark	Danish Cancer Society	Lukas, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, CANCER RES, V56, P5475; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Esposito V, 1997, CANCER RES, V57, P3381; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lukas C, 1999, HYBRIDOMA, V18, P225, DOI 10.1089/027245799315871; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pavey S, 1999, CANCER RES, V59, P4185; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Welcker M, 1996, ONCOGENE, V13, P419; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	47	48	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2870	2876		10.1038/sj.onc.1203579	http://dx.doi.org/10.1038/sj.onc.1203579			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851091				2022-12-28	WOS:000087403600009
J	Lin, JX; Leonard, WJ				Lin, JX; Leonard, WJ			The role of Stat5a and Stat5b in signaling by IL-2 family cytokines	ONCOGENE			English	Review						IL-2 family cytokines; Jak kinases; Stat5; signal transduction; phosphorylation; gene regulation	RECEPTOR-BETA-CHAIN; HUMAN INTERLEUKIN-2 RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; T-CELL PROLIFERATION; PROTEIN-TYROSINE-PHOSPHATASE; DNA-BINDING ACTIVITY; JAK-3 JANUS KINASE; MICE LACKING JAK3; P70 S6 KINASE; GAMMA-CHAIN	The activation of Stat5 proteins (Stat5a and Stat5b) is one of the earliest signaling events mediated by IL-2 family cytokines, allowing the rapid delivery of signals from the membrane to the nucleus. Among STAT family proteins, Stat5a and Stat5b are the two most closely related STAT proteins. Together with other transcription factors and co-factors, they regulate the expression of the target genes in a cytokine-specific fashion. In addition to their activation by cytokines, activities of Stat5a and Stat5b, as well as other STAT proteins, are negatively controlled by CIS/SOCS/SSI family proteins. The outcome of Stat5 activation in regulating expression of target genes varies, depending upon the complexity of the promoter region of target genes and the other signaling pathways that are activated by each cytokine as well. Here, we mainly focus on the IL2-/IL-2 receptor system, as it is one of the best-studied systems that depend on Stat5-mediated signals, We will summarize what we have learned about the molecular mechanisms of how Stat5 is activated by IL-2 family cytokines from in vitro biochemical studies as well as the role that is played by Stat5 in each of the cytokine signaling pathways from in vivo gene-targeting analyses.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252,9000 Rockville Pike, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022					Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Ascherman DP, 1997, J BIOL CHEM, V272, P8704, DOI 10.1074/jbc.272.13.8704; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2; BALLARD D W, 1989, New Biologist, V1, P83; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Corry DB, 1999, NATURE, V402, pB18; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; Eicher DM, 1998, J IMMUNOL, V161, P5430; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Friedrich K, 1999, INT IMMUNOL, V11, P1283, DOI 10.1093/intimm/11.8.1283; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gadina M, 1999, J IMMUNOL, V162, P2081; Gadina M, 1998, J IMMUNOL, V160, P4657; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; John S, 1999, MOL CELL BIOL, V19, P1910; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lischke A, 1998, J BIOL CHEM, V273, P31222, DOI 10.1074/jbc.273.47.31222; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MERIDA I, 1991, J IMMUNOL, V147, P2202; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pericle F, 1997, J IMMUNOL, V159, P2580; Pericle F, 1998, J IMMUNOL, V160, P28; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROMAN D, 1990, New Biologist, V2, P642; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, ONCOGENE, V13, P247; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; VanParijs L, 1997, J IMMUNOL, V158, P3738; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waldmann T, 1998, Int Rev Immunol, V16, P205, DOI 10.3109/08830189809042995; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yu CR, 1996, J IMMUNOL, V157, P126; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZHU XY, 1994, J BIOL CHEM, V269, P5518; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	158	271	291	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2566	2576		10.1038/sj.onc.1203523	http://dx.doi.org/10.1038/sj.onc.1203523			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851055				2022-12-28	WOS:000087459400012
J	Seidel, HM; Lamb, P; Rosen, J				Seidel, HM; Lamb, P; Rosen, J			Pharmaceutical intervention in the JAK/STAT signaling pathway	ONCOGENE			English	Article						JAK; STAT; mimics; antagonists; cytokine	RECOMBINANT HUMAN ERYTHROPOIETIN; RESONANCE ENERGY-TRANSFER; GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE; DNA-BINDING; T-CELLS; FLUORESCENCE POLARIZATION; TARGETED DISRUPTION; ASSAY TECHNOLOGIES; INTERFERON-GAMMA	Many cytokines exert their effect via the JAK/STAT signal transduction pathway, Due to the medical relevance of many of these cytokines, they are being exploited, either directly, or through antagonists, as therapeutics for a variety of serious diseases. Currently, these therapeutics consist almost entirely of protein products, with all of their attendant drawbacks, Delineation of the signaling mechanisms for the cytokines, however, has allowed the design and implementation of a variety of cell-based and biochemical screens for small molecule mimics or antagonists of these cytokines, Several successful assays will be described along with the advantages of each type of assay, Use of assays of this type should make it possible to discover numerous small molecule cytokine modulators with significant utility in the clinic.	Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Ligand Pharmaceuticals	Rosen, J (corresponding author), Ligand Pharmaceut Inc, 10275 Sci Ctr Dr, San Diego, CA 92121 USA.							Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Ahmed T, 1992, J Clin Apher, V7, P129, DOI 10.1002/jca.2920070306; Baselga J, 1998, CANCER RES, V58, P2825; Braunwalder AF, 1996, ANAL BIOCHEM, V234, P23, DOI 10.1006/abio.1996.0044; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIRALT S, 1995, SEMIN HEMATOL, V32, P152; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HOOFNAGLE JH, 1990, J HEPATOL, V11, pS100, DOI 10.1016/0168-8278(90)90173-O; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kolb A, 1997, HIGH THROUGHPUT SCRE, P345; Lamb P, 1998, DRUG DISCOV TODAY, V3, P122, DOI 10.1016/S1359-6446(97)01157-4; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Lindsay KL, 1999, J HEPATOL, V31, P232, DOI 10.1016/S0168-8278(99)80408-5; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177; NEMUNAITIS J, 1988, BLOOD, V72, P834; Panitch H S, 1995, Mult Scler, V1 Suppl 1, pS17; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RACKER E, 1991, METHOD ENZYMOL, V200, P107; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Silverman L, 1998, CURR OPIN CHEM BIOL, V2, P397, DOI 10.1016/S1367-5931(98)80015-X; Sittampalam GS, 1997, CURR OPIN CHEM BIOL, V1, P384, DOI 10.1016/S1367-5931(97)80078-6; SPIELBERGER RT, 1992, LEUKEMIA, V6, P142; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; STONE WJ, 1988, AM J MED SCI, V296, P171, DOI 10.1097/00000441-198809000-00005; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Trieu VN, 2000, BIOCHEM BIOPH RES CO, V267, P22, DOI 10.1006/bbrc.1999.1905; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 1999, J IMMUNOL, V162, P3897; WeIte K, 1987, J EXP MED, V165, P941; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Whitty A, 1999, CHEM BIOL, V6, pR107, DOI 10.1016/S1074-5521(99)80034-9; Wu PG, 1997, ANAL BIOCHEM, V249, P29, DOI 10.1006/abio.1997.2158	67	71	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2645	2656		10.1038/sj.onc.1203550	http://dx.doi.org/10.1038/sj.onc.1203550			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851064				2022-12-28	WOS:000087459400021
J	Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I			The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	ENHANCER-BINDING-PROTEIN; HUMAN MYELOID-LEUKEMIA; ADIPOCYTE DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RETINOIC ACID; C/EBP-ALPHA; GENE	The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human Liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1 alpha (EF1 alpha) promoter to all tissues, The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-specific genes and a concordant block in the differentiation program, We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high Levels of the adipocyte regulatory protein PPAR gamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPAR gamma expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. This establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the first in vivo evidence for a link between a fusion gene created by a chromosomal translocation and a solid tumor.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, E-37008 Salamanca, Spain; Univ Salamanca, Serv Radiodiagnost, E-37008 Salamanca, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Edificio Dept,Avda Campo Charro S-N, Salamanca 37007, Spain.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014; Gutierrez-Adan, Alfonso/A-1485-2014	Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1R01CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BENNETT JH, 1995, J CLIN PATHOL, V48, P950, DOI 10.1136/jcp.48.10.950; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	44	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2413	2422		10.1038/sj.onc.1203572	http://dx.doi.org/10.1038/sj.onc.1203572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828883				2022-12-28	WOS:000087018400006
J	Hotti, A; Jarvinen, K; Siivola, P; Holtta, E				Hotti, A; Jarvinen, K; Siivola, P; Holtta, E			Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases	ONCOGENE			English	Article						apoptosis; ATM (ataxia telangiectasia mutated); caspases; c-Myc; mitochondria; p53	CYCLE CHECKPOINT PATHWAY; ATAXIA-TELANGIECTASIA; CELL-CYCLE; DNA-DAMAGE; IONIZING-RADIATION; CYTOCHROME-C; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; PROTEIN-KINASE; WILD-TYPE	The mechanism(s) of c-Myc transcription factor-induced apoptosis is still obscure. The activation of c-Myc has been found to lead into the processing/activation of caspases (caspase-3), but the significance of this for the cell demise is debatable, Here we report that several targets of caspases (PKC delta, MDM2, PARP, replication factor C, 70 kDa UlsnRNP, fodrin and lamins) are cleaved during c-Myc-induced apoptosis in Rat-1 MycER(TM) cells, indicating an important role for caspases in the apoptotic process. We further found that the ATM (ataxia telangiectasia mutated) - protein is a novel key substrate of caspases, In in vitro assays, purified recombinant ATM protein was found to be cleaved by the effector caspases 3 and 7, The functional significance of the ATM cleavage is supported by the finding that ectopic expression of ATM protected in part against apoptosis, We also show that c-Myc-induced apoptosis involves loss of mitochondrial transmembrane potential, release of cytochrome c from mitochondria into the cytosol and subsequent processing of caspase-9, The cleavage of caspase-9 is, hone, er, minimal and a much later event than the processing/activation of caspase-3, suggesting that it is not the apical caspase, Evidence is provided that there is, nevertheless, an upstream caspase(s) regulating the functions of caspase-3 and mitochondria, Additionally, it mas found that p53 becomes upregulated, together,vith its transcriptional targets MDM2 and p21, upon c-Myc induction, but this occurs also at a later time than the activation of caspase-3.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki	Holtta, E (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2354	2362		10.1038/sj.onc.1203567	http://dx.doi.org/10.1038/sj.onc.1203567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822387				2022-12-28	WOS:000086974300011
J	Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL				Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL			The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium	ONCOGENE			English	Article						neoplasia; nerve growth factor receptor; papillary thyroid carcinoma; RET/PTC; transgenic mice; TRK-T1	CHERNOBYL REACTOR ACCIDENT; COILED-COIL DOMAIN; PAPILLARY CARCINOMAS; RET/PTC1 ONCOGENE; RET REARRANGEMENT; TRANSGENIC MICE; TARGETED EXPRESSION; MOLECULAR-GENETICS; HIGH PREVALENCE; ACTIVATION	Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examined, Although, the majority of thyroid specific translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described, One such translocation, TRK=T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region), To determine if TRK-TI expression can cause thyroid cancer in vivo, we developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid. Immunohistochemical analysis of TRK=T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium. In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma. Furthermore, all transgenic mice examined greater than 7 months of age developed thyroid hyperplasia and/or carcinoma. These data support the conclusion that TRK-T1 is oncogenic iii vivo and contributes to the neoplastic transformation of the thyroid.	Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Inst Nazl Tumori, Div Expt Oncol A, Milan, Italy; Univ Naples, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Cantanzaro, Italy	Jefferson University; Jefferson University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA.		Greco, Angela/C-1953-2017; Portella, Giuseppe/AFU-6826-2022	Greco, Angela/0000-0003-2994-0349; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769	NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER; NCI NIH HHS [CA21124, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Beimfohr C, 1999, INT J CANCER, V80, P842, DOI 10.1002/(SICI)1097-0215(19990315)80:6<842::AID-IJC7>3.0.CO;2-Z; Bongarzone I, 1998, CLIN CANCER RES, V4, P223; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; HOGAN B, 1986, MANIPULATING MOUSE E; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Portella G, 1999, ONCOL RES, V11, P421; Powell DJ, 1998, CANCER RES, V58, P5523; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Rochefort P, 1996, ONCOGENE, V12, P111; ROSAI J, 1990, TUMORS THYROID GLAND; Sagartz JE, 1997, LAB INVEST, V76, P307; Santoro M, 1996, ONCOGENE, V12, P1821; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	28	82	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5729	5735		10.1038/sj.onc.1203922	http://dx.doi.org/10.1038/sj.onc.1203922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126359				2022-12-28	WOS:000165477700004
J	Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL				Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL			Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions	ONCOGENE			English	Article						osteopontin; promoter; transcriptional regulation; malignant astrocytoma; astrocytes; glioma	C-MYC; GENE-EXPRESSION; IN-VIVO; NEOPLASTIC TRANSFORMATION; EXTRACELLULAR-MATRIX; MESSENGER-RNA; CELLS; VITRONECTIN; MECHANISM; CLONING	Synthesis of cell attachment proteins and cytokines, such as osteopontin (OPN), can promote tumor cell remodeling of the extracellular matrix into an environment that promotes tumor cell attachment and migration, We investigated the transcriptional regulation of OPN in the U-251MG and U-87MG human malignant astrocytoma cell lines. Deletion and mutagenesis analyses of the OPN promoter region identified a proximal promoter clement (-24 to -94 relative to the transcription initiation site) that is essential for maintaining high levels of OPN expression in the tumor cells. This clement, designated RE-1, consists of two cis-acting elements, RE-la (-55 to -86) and RE-lb (-22 to -45), which act synergistically to regulate the activity of the OPN promoter, Gel shift assays using nuclear extracts of U-251MG cells demonstrated that RE-la contains binding sites for transcription factors Spl, the glucocorticoid receptor, and the E-box-binding factors, whereas RE-lh contains a binding site for the octamer motif-binding protein (OCT-1/OCT-2), Inclusion of antibodies directed toward Myc and OCT-1 in the gel shift assays indicated that Myc and OCT-1 participate in forming DNA-protein complexes on the RE-la and RE-lb elements, respectively. Our results identify two previously unrecognized elements in the OPN promoter that act synergistically to promote upregulation of OPN synthesis by tumor cells but are regulated by different transcription factors.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Oita Med Univ, Dept Pathol, Oita 87955, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Oita University	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 19th St S, Birmingham, AL 35294 USA.				NCI NIH HHS [CA59958, CA75682] Funding Source: Medline; NINDS NIH HHS [NS 34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, R01CA075682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; Broaddus WC, 1997, NEUROSURGERY, V41, P908, DOI 10.1097/00006123-199710000-00027; BROWN LF, 1994, AM J PATHOL, V145, P610; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHANG PL, 1993, CANCER RES, V53, P2217; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; GARDNER HAR, 1994, ONCOGENE, V9, P2321; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GLADSON CL, 1995, J CELL SCI, V108, P947; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Manji SS, 1998, J CELL PHYSIOL, V176, P1; NODA M, 1988, J BIOL CHEM, V263, P13916; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SAITOH Y, 1995, LAB INVEST, V72, P55; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1995, J BIOL CHEM, V270, P28471; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; Stein GS, 1999, J CELL BIOCHEM, P24; SU LC, 1995, ONCOGENE, V10, P2163; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	39	53	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5801	5809		10.1038/sj.onc.1203917	http://dx.doi.org/10.1038/sj.onc.1203917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126367				2022-12-28	WOS:000165477700012
J	Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M				Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M			A possible role for centrosome overduplication in radiation-induced cell death	ONCOGENE			English	Article						centrosome; ionizing radiation; multinucleated cells; mitotic cell death; apoptosis; p21(Waf1/Cip1)	TERMINAL PROLIFERATION ARREST; PANCREATIC-CANCER CELLS; HAMSTER OVARY CELLS; TUMOR-CELLS; GENOMIC INSTABILITY; DNA-SYNTHESIS; CYCLE ARREST; P53; APOPTOSIS; DAMAGE	Radiotherapy plays a key role in the treatment of many tumors; however, the precise mechanisms responsible for radiation-induced cell death remain uncertain. We have reported previously that ionizing radiation induces centrosome overduplication in human tumor cells. The present study was designed to elucidate a possible link between centrosome dysregulation and radiation-induced cell death. Exposure to 10 Gy gamma -radiation resulted in a substantial increase in cells containing an abnormally high number of centrosomes in a variety of cell lines derived from different types of human solid tumors. These aberrant centrosomes contribute to the assembly of multipolar spindles, thereby causing an unbalanced division of chromosomes and mitotic cell death characterized by the appearance of multi- or micronucleated cells. An extensive analysis of a panel of 10 tumor cell lines revealed a positive correlation between the fraction of cells with multiple centrosomes and the fraction with these nuclear abnormalities after irradiation. When the centrosome overduplication was blocked by enforced expression of p21(Waf1/Cip1), the radiation-induced lethality was drastically rescued. Taken together, these results indicate that centrosome overduplication may be a critical event leading to mitotic failure and subsequent cell death following exposure to ionizing radiation.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 8128582, Japan; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19017 USA	Kyushu University; Kyushu University; Jefferson University	Mizumoto, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318				BAE IS, 1995, CANCER RES, V55, P2387; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lock RB, 1996, CANCER RES, V56, P4006; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDonald E, 1996, CANCER RES, V56, P2250; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Sablina AA, 1998, J CELL SCI, V111, P977; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sato N, 1999, CLIN CANCER RES, V5, P963; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Ueno H, 1997, ANN NY ACAD SCI, V811, P401, DOI 10.1111/j.1749-6632.1997.tb52020.x; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang L, 1999, CANCER LETT, V142, P129, DOI 10.1016/S0304-3835(99)00107-X	47	82	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5281	5290		10.1038/sj.onc.1203902	http://dx.doi.org/10.1038/sj.onc.1203902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077445				2022-12-28	WOS:000165059700009
J	Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW				Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW			Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; VEGF; bax; bcl-2; MAPK/ERK	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; ACID-INDUCED APOPTOSIS; CYTOCHROME-C; CELL-DEATH; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; EXPRESSION; ACTIVATION; RELEASE	Low oxygen and nutrient depletion play critical roles in tumorigenesis, but little is known about how they interact to produce tumor survival and tumor malignancy. In the present study, we investigated the mechanism underlying hypoxia-modulated apoptosis of serum-deprived HepG2 cells, Our results showed that hypoxia blocked the apoptosis, which was accompanied with decreased Bax/ Bcl-2 ratio, inhibited cytochrome c release, and reduced caspase-3 activity. More importantly, increased expressions of VEGF and its receptor-2 (KDR) under hypoxic/ serum-deprived condition suggest that VEGF may act as a survival factor in a self-promoting manner. Data were further supported by results that recombinant human VEGF (rhVEGF) suppressed the serum deprivation-induced apoptosis, and anti-VEGF neutralizing antibody block anti-apoptotic activity of hypoxia, In addition, inhibitors of receptor tyrosine kinase blocked anti-apoptosis of hypoxia, Our study further showed that rhVEGF or hypoxia induced ERK phosphorylation in serum-deprived cells, and that a specific inhibitor of MAPK/ERK, PD98059 eliminated the anti-apoptotic activity of rhVEGF or hypoxia by increasing Bax/Bcl-2 ratio and caspase-3 activity. Our data led us to conclude that induction of ERK phosphorylation and decrease of Bax/Bcl-2 ratio by rhVEGF implies that hypoxia-induced VEGF prevents apoptosis of serum-deprived cells by activating the MAPK/ERK pathway. Taken together, we propose that hypoxia enhances survival of nutrient-depleted tumor cells by reducing susceptibility to apoptosis, which consequently leads to tumor malignancy.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Seoul Natl Univ, WHO, Collaborat Ctr Phys Culture & Aging Res Hlth Prom, Seoul 110799, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea	Pusan National University; Seoul National University (SNU); World Health Organization; Pusan National University	Kim, KW (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.							ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bae SK, 1998, CANCER LETT, V126, P97, DOI 10.1016/S0304-3835(97)00538-7; Baek JH, 1996, J BIOCHEM MOL BIOL, V29, P68; Baek JH, 1997, INT J CANCER, V73, P725, DOI 10.1002/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.3.CO;2-T; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DOLBEARE F, 1994, METHOD CELL BIOL, V41, P297; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gotz ME, 1999, J NEUROSCI RES, V56, P420; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hockel M, 1996, CANCER RES, V56, P4509; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; Kim KW, 1998, CANCER RES, V58, P348; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Rempel A, 1996, CANCER RES, V56, P2468; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Satoh T, 1996, BRAIN RES, V733, P9, DOI 10.1016/0006-8993(96)00527-6; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; WANG TTY, 1995, CANCER RES, V55, P2487; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Younes M, 1996, CANCER RES, V56, P1164	48	151	168	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4621	4631		10.1038/sj.onc.1203814	http://dx.doi.org/10.1038/sj.onc.1203814			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030151				2022-12-28	WOS:000089438200008
J	Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A				Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A			TGF beta(1) represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation	ONCOGENE			English	Article						TGF beta; EGF; ERK2; proliferation control	GROWTH-FACTOR-BETA; RAS-BINDING DOMAIN; TGF-BETA; PROTEIN-KINASE; EPITHELIAL-CELLS; CANCER-CELLS; MAP KINASE; I RECEPTOR; NUCLEAR TRANSLOCATION; SIGNALING PATHWAYS	Transforming growth factor beta (TGF beta) is a tumor suppressor acting as inhibitor of cell cycle progression of epithelial cells. We show that treatment of the pancreatic carcinoma cell lines PANC-1 and BxPC-3 with TGF beta(1) inhibits both growth factor-induced activation of the extracellular signal-regulated kinase 2 (ERK2) and translocation of the kinase to the nucleus. TGF beta(1) causes a concentration-dependent reduction of cell proliferation in both cell lines, By measuring ERK activation, we can show that TGF beta(1) is able to repress ERK activation induced by mitogenic stimuli such as EGF, This inhibitory effect of TGF beta(1) is not mediated by suppression of Ras or c-Raf-1 activation, but mediated by TGF beta(1)-induced activation of a serine-threonine phosphatase, as demonstrated by inhibition of phosphatases by treatment with okadaic acid. Results obtained in the Smad4-deficient pancreatic carcinoma cell line BxPC-3, demonstrate that TGF beta(1)-induced growth inhibition is mediated by a Smad4-independent prevention of ERK2 activation. In contrast to the effects of TGF beta(1) on epithelial cells, mesenchymal NIH3T3 fibroblasts exhibit elevated ERK2 activation and increased cell proliferation in response to TGF beta(1) treatment, Smad4-independent phosphatase-mediated inhibition of mitogen-activated ERK2 represents a novel effector pathway contributing to suppression of epithelial pancreatic carcinoma cell proliferation by TGF beta(1), in addition to the well-known Smad-induced tumor suppressor activity of TGF beta.	Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-89070 Ulm, Germany	Ulm University; Ulm University	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Liu JH, 1999, ONCOGENE, V18, P269, DOI 10.1038/sj.onc.1202263; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Menke A, 1999, BBA-MOL CELL RES, V1449, P178, DOI 10.1016/S0167-4889(99)00011-7; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; Roberts AB, 1990, GROWTH FACTORS, V2, P135, DOI 10.3109/08977199009071500; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	50	70	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4531	4541		10.1038/sj.onc.1203806	http://dx.doi.org/10.1038/sj.onc.1203806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002426				2022-12-28	WOS:000089236800010
J	Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L				Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L			Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53	ONCOGENE			English	Article						exonuclease; fidelity control; homologous recombination; mismatch correction; strand exchange	DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; NUCLEOTIDE EXCISION-REPAIR; MOUSE L-CELLS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MUTANT P53; GENETIC-RECOMBINATION; TRANSACTIVATION ACTIVITY; REPLICATION FIDELITY	Our previous work (Dudenhoffer et al., 1999) unveiled a link between the capacity of p53 to regulate homologous recombination processes and to specifically bind to heteroduplex junction DNAs. Here, we show that p53 participates in ternary complex formation after preassembly of nucleoproteins, consisting of the human recombinase hRad51 and junction DNA, The cancer-related mutant p53(273H), which is defective in inhibiting recombination processes, displays a reduced capacity to associate with hRad51-DNA complexes, even under conditions which support DNA-binding, This suggests that hRad51-p53 contacts play a role in targeting p53 to heteroduplex joints and indicates an involvement in recombination immediately following hRad51-mediated strand transfer. To study the initial phase of strand exchange, when heteroduplex joints arise, we applied oligonucleotide based strand transfer assays. We observed that hRad51 stimulates exonucleolytic DNA degradation by p53, when it generates strand transfer intermediates. In agreement with this observation, artificial 3-stranded junction DNAs, designed to mimic nascent recombination intermediates, were found to represent preferred exonuclease substrates, especially when comprising a mismatch within the heteroduplex part. From our data, we propose a model according to which, p53-dependent correction of DNA exchange events is triggered by high-affinity binding to joint molecules and by stabilizing contacts with hRad51 oligomers.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Grosse Frank, 1993, V16, P95; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Kawamura M, 1996, ONCOGENE, V12, P2361; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PARK DJ, 1994, ONCOGENE, V9, P1899; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH ML, 1995, ONCOGENE, V10, P1053; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tang W, 1999, CANCER RES, V59, P2562; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2476; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wiesmuller L, 1996, J VIROL, V70, P737; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	96	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4500	4512		10.1038/sj.onc.1203809	http://dx.doi.org/10.1038/sj.onc.1203809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002423				2022-12-28	WOS:000089236800007
J	Holcik, M; Yeh, C; Korneluk, RG; Chow, T				Holcik, M; Yeh, C; Korneluk, RG; Chow, T			Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death	ONCOGENE			English	Article						IAP; radiation induced cell death; IRES; translation	CANCER; SURVIVIN; GENE; THERAPY	Inhibitory regulators of apoptosis play a critical role in the responsiveness of tumour cells to cytotoxic agents. The X-linked inhibitor of apoptosis protein (XIAP) is a member of a novel family of Inhibitor of Apoptosis (IAP) proteins. Here we show that acute lon dose ionizing irradiation results in the translational upregulation of XIAP that correlates with an increased resistance to radiation in non-small cell lung carcinoma. This upregulation is mediated by an internal ribosome binding mechanism, ia an IRES element located within a XIAP 5' UTR. Transient overexpression of XIAP rendered human carcinoma cells resistant to low dose gamma-irradiation. By contrast, the antisense targeting of XIAP resulted in increased cell death following irradiation advocating a distinct role for XIAP in radiation resistant phenotype of human cancers.	Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Apoptogen Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1A4, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; McGill University	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Holcik, Martin/A-9768-2008; Holcik, Martin/AAC-6660-2019; Holcik, Martin/E-5372-2011	Holcik, Martin/0000-0002-1922-5299; 				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Withers HR, 1999, CANCER RES, V59, p1676S; Yount GL, 1998, CANCER RES, V58, P3819; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	20	217	233	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4174	4177		10.1038/sj.onc.1203765	http://dx.doi.org/10.1038/sj.onc.1203765			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962579				2022-12-28	WOS:000088955100012
J	Panigone, S; Debernardi, S; Taya, Y; Fontanella, E; Airoldi, R; Delia, D				Panigone, S; Debernardi, S; Taya, Y; Fontanella, E; Airoldi, R; Delia, D			pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide	ONCOGENE			English	Article						HPR; pRb; cell cycle	CANCER CELL-LINES; DEPENDENT KINASE-ACTIVITY; BREAST-CARCINOMA CELLS; RETINOIC ACID RECEPTOR; RETINOBLASTOMA PROTEIN; GROWTH-INHIBITION; CYCLE PROGRESSION; APOPTOSIS; PHOSPHORYLATION; RETINAMIDE	The cancer chemopreventive synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR) can inhibit the growth and induce apoptosis of tumor cells. In this study we analysed the growth suppressive effect of HPR on human breast cancer cell lines in vitro and the role of the retinoblastoma protein (pRb) in this response. Treatment of MCF7, T47D and SKBR3 for 24-48 h with 3 mu M HPR, a concentration attainable in vivo, resulted in growth inhibition and marked dephosphorylation of pRb involving Ser(612), Thr(821), Ser(795) and Ser(780), target residues for cyclin-dependent kinase 2 (Cdk2) the former two, and Cdk4 the latter two. Interestingly, this dephosphorylation of pRb occurred in S-G2-M phase cells, as revealed by experiments on cells fractionated by FACS according to the cell cycle phase, hence suggesting that the retinoid interferes with the regulation of pRb phosphorylation, The in vitro phosphorylation of a GST-pRb recombinant substrate by Cdk2 immunocomplexes from MCF7, T47D and SKBR3 was markedly suppressed after HPR treatment, whereas that by Cdk4 complexes was suppressed in T47D and SKBR3 but not in MCF7, The steady-state levels of Cdk2, Cdk4 and Cyclin A proteins were unaffected by HPR, while those of Cyclin D1 were significantly reduced in all three cell lines. Interestingly, Cyclin D1 downregulation by HPR correlated with transcriptional repression, but not with enhanced proteolysis of Cyclin D1 typically elicited by other retinoids, Collectively, our data suggest that the antiproliferative activity of HPR arises from its capacity to maintain pRb in a de-phosphorylated growth-suppressive status in S-G2/M, possibly through Cyclin D1 downregulation and inhibition of pRb-targeting Cdks.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Natl Canc Ctr, Res Inst, Div Biol, Mol Biol Lab,Chuo Ku, Tokyo 1040045, Japan	Fondazione IRCCS Istituto Nazionale Tumori Milan; National Cancer Center - Japan	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.							Adams PD, 1999, MOL CELL BIOL, V19, P1068; Angoli D, 1996, BIOCHEM BIOPH RES CO, V229, P681, DOI 10.1006/bbrc.1996.1863; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Brooks SC, 1996, BLOOD, V87, P227; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P3659; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Louvet C, 1996, BRIT J CANCER, V74, P394, DOI 10.1038/bjc.1996.371; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARIOTTI A, 1994, J NATL CANCER I, V86, P1245, DOI 10.1093/jnci/86.16.1245; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McCormick DL, 1996, CARCINOGENESIS, V17, P2513, DOI 10.1093/carcin/17.11.2513; Moon Richard C., 1994, P573; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; PIENTA KJ, 1993, CANCER RES, V53, P224; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLLARD M, 1991, CANCER RES, V51, P3610; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	44	29	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4035	4041		10.1038/sj.onc.1203743	http://dx.doi.org/10.1038/sj.onc.1203743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962560				2022-12-28	WOS:000088825300009
J	Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F				Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F			Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA	ONCOGENE			English	Article						nuclear export; RNA helicase A; Sam68; Tap; RRE; CTE	CONSTITUTIVE TRANSPORT ELEMENT; HIV-1 REV PROTEIN; MESSENGER-RNA; NUCLEAR EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; BINDING; IDENTIFICATION; EXPRESSION; SEQUENCES; SIGNAL	Unlike cellular mRNA, retroviral mRNA bypasses the tight coupling of the splicing and nuclear export steps to allow the export of intron-containing viral RNA transcripts to the cytoplasm. Two distinct nuclear export pathways for retroviral mRNA have been described: a CRM-1 dependent pathway mediated by the HIV-1 Rev protein and the Rev Response Element (RRE), and a CRM-1 independent pathway mediated by the Constitutive Transport Element (CTE) of type D retroviruses. Two CTE-binding proteins, RNA helicase A (RHA) and Tap, have been implicated in the nuclear export of CTE-containing RNA. Recently, we reported that expression of RRE-containing RNA could also be mediated by a cellular protein, Sam68, independently of Rev. Here we report evidence that Sam68, RHA and Tap cooperate in the nuclear export of both CTE- and RRE-containing RNA. RHA binds to Sam68 and to Tap both in vivo and in vitro. Over-expression of Sam68 activates both RRE-and CTE-regulated reporter gene expression in human cells and in quail cells in the presence of human lap. This activation was competitively inhibited by the nuclear transport domain (NTD) of RHA and a transdominant negative mutant of Tap. Conversely, the activation of CTE by Tap in quail cells was inhibited by a transdominant mutant of Sam68 and NTD. We propose that both HIV and type D retroviruses may access the same constitutive RNA nuclear export path tray involving RHA, Tap and Sam68, even though HIV also utilizes the Rev protein for more efficient nuclear export, it is likely that this constitutive export pathway is also used by cellular mRNA, but at a different interface with the splicing process.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014		NIGMS NIH HHS [GM56089] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bear J, 1999, MOL CELL BIOL, V19, P6306; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; EMST RK, 1997, MOL CELL BIOL, V17, P135; Fornerod M, 1997, CELL, V90, P1051; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; SOLOMIN L, 1990, J VIROL, V64, P6010, DOI 10.1128/JVI.64.12.6010-6017.1990; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhang SS, 1999, J CELL SCI, V112, P1055; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	34	72	72	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3570	3575		10.1038/sj.onc.1203676	http://dx.doi.org/10.1038/sj.onc.1203676			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951562				2022-12-28	WOS:000088568300002
J	Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F				Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F			Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: The role of the chromatin structure and AP-1 composition	ONCOGENE			English	Article						chemokines; human papillomaviruses; cervical cancer; somatic cell hybrids; tumorigenicity	NF-KAPPA-B; CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN PAPILLOMAVIRUS INFECTION; JE GENE; HELA-CELLS; HYBRIDS; ALPHA; EXPRESSION; GROWTH; DNA	The expression of the monocyte-chemoattractant-protein-1 (MCP-1) is closely linked with a non-tumorigenic phenotype in somatic cell hybrids made between the human papillomavirus type 18 (HPV 18) positive cervical carcinoma cell line HeLa and normal human fibroblasts, In contrast, MCP-1 transcription is absent in tumorigenic segregants derived from the same hybrids or in parental HeLa cells. Selectivity of MCP-1 transcription, which is regulated at the le, el of initiation of transcription, is mainly based on differences in the location and extension of DNAse I-hypersensitive regions (DHSR) at both ends of the gene, While TNF-alpha only moderately increases the sensitivity of pre-existing 5'-DHSRs, a 3'-end DHSR became strongly induced exclusively in non-malignant hybrids, DNA sequencing showed that the 3'-DHSR coincides with an additional AP-1 site located approximately 600 bp downstream of the polyadenylation site. Analyses of AP-1 composition revealed that MCP-1 is only expressed in those cells where jun-family members were mainly heterodimerized with the fos-related protein fra-1. In contrast, in tumorigenic cells the 1:1 ratio between jun and fra-1 is disturbed and the MCP-1 gene is no longer expressed. Hence, alterations in the heterodimerization pattern of AP-1 and its selective accessibility to opened chromatin may represent a novel regulatory pathway in the regulation of chemokines in malignant and non-malignant HPV-positive cells.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Genomforsch & Bioinformat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALTMANN A, 1994, INTERVIROLOGY, V37, P180, DOI 10.1159/000150376; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; Kleine-Lowinski K, 1999, INT J CANCER, V82, P6, DOI 10.1002/(SICI)1097-0215(19990702)82:1<6::AID-IJC2>3.0.CO;2-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Majewski S., 1996, PAPILLOMAVIRUS REPOR, V7, P143; MEHRABIAN M, 1991, GENOMICS, V9, P200, DOI 10.1016/0888-7543(91)90239-B; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ozbun MA, 1996, J VIROL, V70, P5437, DOI 10.1128/JVI.70.8.5437-5446.1996; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Rosl F, 1999, CONT CANC RES, P207; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1989, MOL CARCINOGEN, V2, P72, DOI 10.1002/mc.2940020205; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; SOTO U, 2000, IN PRESS INT J CANC; SPINILLO A, 1993, GYNECOL ONCOL, V48, P210, DOI 10.1006/gyno.1993.1035; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P1094, DOI 10.1111/j.1471-0528.1987.tb02296.x; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	38	38	41	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3235	3244		10.1038/sj.onc.1203643	http://dx.doi.org/10.1038/sj.onc.1203643			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918580				2022-12-28	WOS:000088019300002
J	Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV				Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV			Genetic dissection of c-myc apoptotic pathways	ONCOGENE			English	Article						IL-3; cDNA microarrays; interferon-gamma; max	IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; TRANSACTIVATION DOMAIN; LUNG-CARCINOMA; DNA-BINDING; CELL-GROWTH; PROTEIN; MAX; EXPRESSION	All biological functions mediated by the c-myc oncoprotein require an intact transactivation domain (TAD). We compared TAD mutants for their ability to promote apoptosis of 32D myeloid cells in response to interleukin-3 (IL-3) deprivation and exposure to chemotherapeutic drugs, and to activate ornithine decarboxylase, an endogenous c-myc target. Different sub-regions of the TAD were required to mediate each function. cDNA microarrays were then used to identify multiple c-myc-regulated transcripts, some of which were also modulated by IL-3 or cytotoxic drugs, as well as by specific sub-regions of the TAD. Several of the c-myc-regulated transcripts had also been previously identified as targets for IFN-gamma. The functional consequences of their deregulation were manifested by a marked sensitivity of c-myc-overexpressing cells to IFN-gamma-mediated apoptosis, Our results establish that several well-characterized functions of c-myc are separable and correlate with the expression of a novel group of target genes, some of which also mediate the apoptotic action of IFN-gamma.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Program Mol Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barr LF, 1998, CANCER RES, V58, P5537; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bonfil RD, 1998, ONCOL RES, V10, P15; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIJIMOTOOCHIAI S, 1995, GLYCOBIOLOGY, V5, P443, DOI 10.1093/glycob/5.4.443; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Okochi H, 1997, BRIT J DERMATOL, V137, P856, DOI 10.1046/j.1365-2133.1997.19782088.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rosenfeld ME, 1998, SEMIN REPROD ENDOCR, V16, P249, DOI 10.1055/s-2007-1016285; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Smits P, 1999, GENE, V226, P253, DOI 10.1016/S0378-1119(98)00558-7; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson A, 1996, J BIOL CHEM, V271, P22976, DOI 10.1074/jbc.271.38.22976; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHAO Q, 1998, GENE DEV, V12, P3803	63	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3200	3212		10.1038/sj.onc.1203636	http://dx.doi.org/10.1038/sj.onc.1203636			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918575				2022-12-28	WOS:000088019200009
J	Tee, AR; Proud, CG				Tee, AR; Proud, CG			DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling	ONCOGENE			English	Article						DNA damage; apoptosis; mTOR; p70 S6 kinase; initiation factor; mRNA translation	DEPENDENT PROTEIN-KINASE; INITIATION-FACTOR 4G; P70 S6 KINASE; MESSENGER-RNA TRANSLATION; INDUCED APOPTOSIS; CELL-PROLIFERATION; SIGNALING PATHWAY; FACTOR 4E; FACTOR SUBUNIT; PHAS-I	Treatment of cells with DNA-damaging agents, such as etoposide, can cause growth arrest or apoptosis, Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E, These effects were not prevented by the general caspase inhibitor, Z-VAD.FMK, These findings indicate caspase-independent inhibition of signalling pathways that involve the mammalian target of rapamycin (mTOR), Similar effects were observed in response to two other DNA-damaging agents, cisplatin and mitomycin-C, These events preceded apoptosis, which was assessed by caspase-3 activity assays and FAGS analysis, This shows that inhibition of mTOR signalling is not a consequence of apoptosis, although it may play a role in the events that precede cell death. 4E-BP1 was cleaved during apoptosis yielding a fragment that retained the ability to bind eIF4E. Cleavage of 4E-BP1 was inhibited by treatment of the cells with Z-VAD.FMK, indicating it is caspase-dependent. Insulin elicited full activation of p70 S6 kinase and phosphorylation of 4E-PB1 in etoposide-treated cells prior to the onset of apoptosis, but not during cell death. This suggests that mTOR signalling becomes irreversibly inhibited only after entry into apoptosis.	Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Wellcome Trust Bldg Complex,Dow St, Dundee DD1 5EH, Scotland.			Proud, Christopher/0000-0003-0704-6442; Tee, Andrew/0000-0002-5577-4631				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, CANCER SURV, V27, P293; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Ishizuka T, 1997, BIOCHEM BIOPH RES CO, V230, P386, DOI 10.1006/bbrc.1996.5967; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meyuhas Oded, 1996, V30, P363; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Palom Y, 1998, ONCOL RES, V10, P509; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Proud CG, 1997, BIOCHEM J, V328, P329; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SHI YF, 1995, CANCER RES, V55, P1982; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; SULLIVAN D M, 1987, NCI (National Cancer Institute) Monographs, P73; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takizawa T, 1999, J BIOCHEM-TOKYO, V125, P391, DOI 10.1093/oxfordjournals.jbchem.a022299; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Tronov VA, 1999, BIOCHEMISTRY-MOSCOW+, V64, P345; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451	68	106	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3021	3031		10.1038/sj.onc.1203622	http://dx.doi.org/10.1038/sj.onc.1203622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871854				2022-12-28	WOS:000087581400009
J	Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P				Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P			Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis	ONCOGENE			English	Article						SERCA1; Hepatitis B Virus; calcium; apoptosis; cancer	NF-KAPPA-B; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; SARCOPLASMIC-RETICULUM; TRANSGENIC MICE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; DNA-BINDING; IN-VITRO	We have used the Hepatitis B Virus DIVA genome as a probe to identify genes clonally mutated in vivo, in human liver cancers. In a tumor, HBV-DNA mas found to be integrated into the gene encoding Sarco/Endoplasmic Reticulum Calcium ATPase (SERCA), which pumps calcium, an important intracellular messenger for cell viability and growth, from the cytosol to the endoplasmic reticulum. The HBV X gene promoter cis-activates chimeric HBV X/SERCA1 transcripts, with splicing of SERCA1 exon II, encoding C-terminally truncated SERCA1 proteins. Two chimeric HBV X/SERCA1 proteins accumulate in the tumor and form dimers. III vitro analyses have demonstrated that these proteins localize to the ER, determine its calcium depletion and induce cell death. We have also shown that these biological effects are related to expression of the SERCA, rather than of the viral moiety. This report involves for the first time the expression of mutated SERCA proteins in vivo in a tumor cell proliferation and in vitro in the control of cell viability.	Necker Inst, U370 INSERM, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Univ Paris Sud, U442 INSERM, F-91405 Orsay, France; CEA, URA CNRS 2096, F-91191 Gif Sur Yvette, France; Inst Pasteur, F-75015 Paris, France; Ctr Natl Genotypage, F-91057 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay	Paterlini-Brechot, P (corresponding author), Necker Inst, U370 INSERM, 156 Rue Vaugirard, F-75015 Paris, France.		CAPIOD, Thierry/K-4234-2017; Chami, Mounia/S-6471-2019; Beckmann, Jacques S/A-9772-2008; Devrim, Gozuacik/C-3330-2008	CAPIOD, Thierry/0000-0002-8448-7041; Chami, Mounia/0000-0003-1498-7187; Beckmann, Jacques S/0000-0002-9741-1900; Devrim, Gozuacik/0000-0001-7739-2346; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; Falson, Pierre/0000-0002-9760-4577				Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chung DC, 1998, CANCER RES, V58, P3706; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GRAEF E, 1994, ONCOGENE, V9, P81; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; HEILMANN C, 1985, J BIOL CHEM, V260, P788; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KEKULE AS, 1994, PRIMARY LIVER CANC E, V13; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOHN EC, 1995, CANCER RES, V55, P1856; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Koike K, 1998, HEPATITIS B VIRUS, P133; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN MH, 1989, BIOCHEM BIOPH RES CO, V164, P14, DOI 10.1016/0006-291X(89)91676-8; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PATERLINI P, 1994, PRIMARY LIVER CANC E, V12, P167; PATERLINI P, 1990, VIRAL HEPATITIS LIVE, P556; Peacocke M, 1999, NAT GENET, V21, P252, DOI 10.1038/6758; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pineau P, 1996, J VIROL, V70, P7280, DOI 10.1128/JVI.70.10.7280-7284.1996; PircDanoewinata H, 1996, WIEN KLIN WOCHENSCHR, V108, P752; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Raney AK, 1991, MOL BIOL HEPATITIS B, P1; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259	70	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2877	2886		10.1038/sj.onc.1203605	http://dx.doi.org/10.1038/sj.onc.1203605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871838				2022-12-28	WOS:000087544500001
J	Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW				Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW			Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR	ONCOGENE			English	Article						apoptosis; BCL-XL; PAX transcription factors; rhabdomyosarcoma	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; MUSCLE DEVELOPMENT; CELL-SURVIVAL; GENES; EXPRESSION; DIFFERENTIATION; DOMAIN; MYOD; DNA	The aberrant expression of the transcription factors PAN3 and PAX3/FKHR associated with rhabdomyosarcoma (RMS), solid tumors displaying muscle cell features, suggests that these proteins play an important role in the pathogenesis of RMS. We could previously demonstrate that one of the oncogenic functions of PAS3 and PAX3/FKHR in RMS is protection from apoptosis, BCL-XL is a prominent anti-apoptotic protein present in normal skeletal muscle and RMS cells. In the present study, we establish that BCL-XL is transcriptionally modulated bai PAX3 and PAX3/FMHR, since enhanced expression of both PAX proteins stimulates transcription of endogenous BCL-XL mRNA in a cell type specific manner. Further, we present evidence that both PAX3 and PAX3/FKHR can transcriptionally activate the Bcl-x gene promoter in cotransfection assays. Using electrophoretic mobility shift assays, an ATTA binding site for PAX3 and PAX3/FKHR could be localized in the upstream promoter region (position -42 to -39), Finally, ectopic overexpression of either PAY3, PAX3/FKHR or BCL-XL can rescue tumor cells from apoptosis induced by antisense treatment. These results suggest that at least part of the anti-apoptotic effect of PAX3 and PAX3/FKHR is mediated through direct transcriptional modulation of the prominent anti-apoptotic protein BCL-XL.	Univ Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biochem, Zurich, Switzerland; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Pennsylvania	Schafer, BW (corresponding author), Univ Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.		Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/A-1588-2008; Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/C-6734-2008	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Schafer, Beat/0000-0001-5988-2915				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2969; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Frascella E, 1998, CANCER GENET CYTOGEN, V102, P104, DOI 10.1016/S0165-4608(97)00352-X; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SCHAFER BW, 1998, GEN PHYSL BIOPHYS, V17, P1; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wang W, 1998, CANCER RES, V58, P4426; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	42	86	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2921	2929		10.1038/sj.onc.1203607	http://dx.doi.org/10.1038/sj.onc.1203607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871843				2022-12-28	WOS:000087544500006
J	Behrens, A; Jochum, W; Sibilia, M; Wagner, EF				Behrens, A; Jochum, W; Sibilia, M; Wagner, EF			Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation	ONCOGENE			English	Article						C-Jun N-terminal phosphorylation; tumorigenesis; Ras; Fos; Src	CELL-CYCLE PROGRESSION; NUCLEOTIDE EXCHANGE FACTOR; EMBRYONAL CARCINOMA-CELLS; TRANSGENIC MICE; HA-RAS; ACTIVATION DOMAIN; PROTEIN; MOUSE; AP-1; EXPRESSION	The nuclear phosphoprotein c-Jun is a major component of the AP-1 transcription factor, whose activity is augmented by many oncogenes, An important mechanism to stimulate AP-1 function is N-terminal phosphorylation of c-Jun at the serine residues 63 and 73 by the c-Jun N-terminal kinases (JNKs), Mice and cells harboring a mutant allele of c-jun, which has the JNK phosphoacceptor serines changed to alanines (junAA), were used to determine the function of c-Jun N-terminal phosphorylation (JNP) during oncogenic transformation in vitro and ill ripe. JunAA immortalized fibroblasts expressing v-ras and v-fos showed reduced tumorigenicity in nude mice, but the efficiency of v-src transformation was unaffected by the lack of JNP. To assess the significance of JNP in tumour development in vivo, two transgenic mouse tumour models were employed. Skin tumour development caused by constitutive activation of the ras pathway by KS-SOS-P expression and c-fos-induced osteosarcoma formation were impaired in mice lacking JNP. Inhibition of JNP may, therefore, be a novel therapeutic strategy to inhibit tumour growth in vivo.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Sibilia, Maria/0000-0001-6129-5613; Behrens, Axel/0000-0002-1557-1143; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTER CA, 1988, ONCOGENE, V2, P207; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REDMOND SMS, 1988, ONCOGENE, V2, P259; Rutberg SE, 1996, ONCOGENE, V13, P167; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SIBILIA M, 2000, UNPUB; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VOGT PK, 1992, CANCER, V69, P2610, DOI 10.1002/1097-0142(19920515)69:10<2610::AID-CNCR2820691035>3.0.CO;2-J; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WANG ZQ, 1995, CANCER RES, V55, P6244; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	40	167	173	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2657	2663		10.1038/sj.onc.1203603	http://dx.doi.org/10.1038/sj.onc.1203603			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851065				2022-12-28	WOS:000087193000001
J	Song, JI; Grandis, JR				Song, JI; Grandis, JR			STAT signaling in head and neck cancer	ONCOGENE			English	Article						TGF-alpha; EGFR; STAT proteins; squamous cell carcinoma; head and neck	EPIDERMAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMAS; FACTOR RECEPTOR GENE; BRONCHIAL EPITHELIAL-CELLS; GASTRIN-RELEASING PEPTIDE; EGF-RECEPTOR; TGF-ALPHA; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS	The upper aerodigestive tract is predisposed to the formation of multiple primary tumors due to field cancerization. TGF-alpha/EGFR autocrine signaling appears to play an important role in squamous cell carcinoma of the head and neck (SCCHN) and upregulation of TGF-alpha and EGFR is an early event in SCCHN carcinogenesis. STAT proteins, including Stat3, are activated by TGF-alpha and EGFR and strategies that downmodulate TGF-alpha or EGFR inhibit SCCHN cell proliferation and abrogate Stat3 activation. Targeting Stat3 leads to SCCHN growth inhibition, increases apoptosis and a downmodulation of Bcl-x(L) expression in head and neck tumors. These studies support the role of Stat3 as an oncogene, which is activated early in SCCHN carcinogenesis, and efforts to understand EGFR-mediated Stat3 signaling could facilitate novel strategies that will interfere with this growth promoting pathway.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.							*AM JOINT COMM CAN, 1983, MAN STAG CANC, P25; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bos M, 1997, CLIN CANCER RES, V3, P2099; BOYLE P, 1992, Current Opinion in Oncology, V4, P471; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Califano J, 1996, CANCER RES, V56, P2488; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CASTIGLIANO SG, 1968, J AM DENT ASSOC, V77, P580, DOI 10.14219/jada.archive.1968.0275; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DeGiovanni C, 1996, CANCER RES, V56, P3898; DEMICHELE MA, AM J RESP CELL MOL B, V11, P66; Dhooge IJ, 1998, LARYNGOSCOPE, V108, P250, DOI 10.1097/00005537-199802000-00017; DIMERY IW, 1993, JNCI-J NATL CANCER I, V85, P95, DOI 10.1093/jnci/85.2.95; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EISBRUCH A, 1987, CANCER RES, V47, P3603; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, CLIN CANCER RES, V4, P13; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; GRANDIS JR, 1999, IN PRESS P NATL ACAD; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; Hierholzer C, 1998, AM J PHYSIOL-LUNG C, V275, pL611, DOI 10.1152/ajplung.1998.275.3.L611; HONG WK, 1983, NEW ENGL J MED, V308, P75, DOI 10.1056/NEJM198301133080204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JAMES R, 1984, ANNU REV BIOCHEM, V53, P259; JOVANOVIC A, 1994, ORAL ONCOL, V30B, P225; KAWAMOTO T, 1991, JPN J CANCER RES, V82, P403, DOI 10.1111/j.1349-7006.1991.tb01863.x; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LARSON JT, 1990, OTOLARYNG HEAD NECK, V103, P14, DOI 10.1177/019459989010300103; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MASHBERG A, 1993, J NATL CANCER I, V85, P1525, DOI 10.1093/jnci/85.18.1525-a; MAXWELL SA, 1989, CANCER RES, V49, P1130; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Niu GL, 1999, CANCER RES, V59, P5059; *NY AM CAN SOC, 1990, CANC STAT; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PARTRIDGE M, 1989, BRIT J CANCER, V60, P542, DOI 10.1038/bjc.1989.310; ROBERTS AB, 1985, CANCER SURV, V4, P683; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sartor CI, 1997, CANCER RES, V57, P978; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; SIEGFRIED JM, 1993, ANAT RECORD, V236, P241, DOI 10.1002/ar.1092360129; Siegfried JM, 1997, AM J RESP CRIT CARE, V156, P358, DOI 10.1164/ajrccm.156.2.9608047; SLAUGHTER DP, 1946, SURGERY, V20, P133; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; *US DEP HLTH HUM S, 1991, CANC OR CAV PHAR STA; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEICHSELBAUM RR, 1989, HEAD NECK-J SCI SPEC, V11, P437, DOI 10.1002/hed.2880110510; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOSHIDA K, 1990, INT J CANCER, V45, P131, DOI 10.1002/ijc.2910450124; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	69	317	352	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2489	2495		10.1038/sj.onc.1203483	http://dx.doi.org/10.1038/sj.onc.1203483			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851047				2022-12-28	WOS:000087459400004
J	Gire, V; Marshall, C; Wynford-Thomas, D				Gire, V; Marshall, C; Wynford-Thomas, D			PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS	ONCOGENE			English	Article						RAS; intra-cellular signals; PI-3-kinase; MAP kinase; epithelial; thyroid	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; IN-VITRO; TRANSFORMATION; SUFFICIENT; PATHWAYS; GROWTH; DIFFERENTIATION; EXPRESSION	In contrast to its growth-inhibitory effect on primary mesenchymal cells, RAS oncogene activation induces a proliferative phenotype in normal human thyroid epithelial cells in vitro, consistent with its putative role in tumour initiation. Using this model, we previously showed that activation of the MAP kinase (MAPK) pathway is necessary, but not sufficient for the proliferative response to mutant (V12) H-RAS. Were we extend this work to show that another major RAS effector - phosphatidylinositol-3-kinase (PI-3-K) - while also insufficient alone, is able to synergize with MAPK activation to mimic the effect of mutant RAS, albeit at reduced efficiency. Furthermore we show that PI-3-K is an absolute requirement for the proliferative response to RAS in these cells, acting via suppression of RAS-induced apoptosis. These data extend our understanding of RAS signalling in a clinically-relevant cell context and point to the use of PI-3-K inhibitors as potential therapeutic agents for targetting human cancers induced by RAS mutation.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Ctr Cellular & Mol Biol, Canc Res Campaign, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; Treinies I, 1999, MOL CELL BIOL, V19, P321; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	40	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2269	2276		10.1038/sj.onc.1203544	http://dx.doi.org/10.1038/sj.onc.1203544			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822377				2022-12-28	WOS:000086974300001
J	Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L				Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L			Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6	ONCOGENE			English	Article						papillomavirus E6 protein; protein kinase A; Dlg; PDZ-domain; ubiquitin; cervical cancer	PROTEASOME-MEDIATED DEGRADATION; CALCIUM-INDUCED DIFFERENTIATION; LARGE TUMOR-SUPPRESSOR; CELL-CYCLE REGULATION; P70 S6 KINASE; IN-VIVO; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; HPV-18 E6; P53	The protein Kinase A (PKA) pathway was found to selectively regulate the function of oncogenic but not non-oncogenic E6 proteins, High risk E6 proteins are phosphorylated at their D1g/PDZ binding motif at the C-terminus by a PKA like activity. This PKA and PDZ binding module is found only for human PV, is strictly conserved in all the transforming HPVs and is absent in all the low risk HPV types. We present evidence of a conditional regulation of E6 induced degradation of Dig, HPV18E6 positive but not HPV negative keratinocytes exhibit increased Dig steady state levels under conditions of high PKA activity, with a concomitant increase in the presence of Dig at tight junctions, vitro binding experiments show that E6 phosphorylation by PKA reduces its binding to Dig and molecular modelling can explain this observation in a structural context, E6 dependent degradation of Dig in cells with high PKA levels is inhibited and this is dependent on phosphorylation of the PDZ binding site in E6, In contrast, the degradation of p53 induced by E6 is not affected by PKA, We propose a differential regulation of E6 for the ubiquitin mediated degradation of specific E6 target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8010 Graz, Austria	International Center for Genetic Engineering & Biotechnology (ICGEB); Austrian Academy of Sciences	Kuhne, C (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Amenitsch, Heinz/0000-0002-0788-1336				Balda MS, 1998, J CELL SCI, V111, P541; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; deVilliers EM, 1997, INT J CANCER, V73, P356, DOI 10.1002/(SICI)1097-0215(19971104)73:3<356::AID-IJC9>3.3.CO;2-S; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fernandez A, 1995, Prog Cell Cycle Res, V1, P241; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Maki CG, 1996, CANCER RES, V56, P2649; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIM D, 1994, ONCOGENE, V9, P1869; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	59	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5884	5891		10.1038/sj.onc.1203988	http://dx.doi.org/10.1038/sj.onc.1203988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127819				2022-12-28	WOS:000165563100007
J	Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R				Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R			Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins	ONCOGENE			English	Article						adenovirus E4-ORF1; MAGI-1; papillomavirus; E6; PDZ	LARGE TUMOR-SUPPRESSOR; READING FRAME-1 ENCODES; MOLECULAR CHARACTERIZATION; TIGHT JUNCTION; SEPTATE JUNCTIONS; GUANYLATE KINASE; MAMMARY-TUMORS; HUMAN HOMOLOG; CREF CELLS; TYPE-9	The oncoproteins of small DNA tumor viruses promote tumorigenesis by complexing with cellular factors intimately involved in the control of cell proliferation. The major oncogenic determinants for human adenovirus type 9 (Ad9) and high-risk human papillomaviruses (HPV) are the E4-ORF1 and E6 proteins, respectively. These seemingly unrelated viral oncoproteins are similar in that their transforming activities in cells depend, in part, on a carboxyl-terminal PDZ domain-binding motif which mediates interactions with the cellular PDZ-protein DLG. Here we demonstrated that both Ad9 E4-ORF1 and high-risk HPV E6 proteins also bind to the DLG-related PDZ-protein MAGI-1. These interactions resulted in MAGI-1 being aberrantly sequestered in the cytoplasm by the Ad9 E4-ORF1 protein or being targeted for degradation by high-risk HPV E6 proteins. Transformation-defective mutant viral proteins, however, were deficient for these activities. Our findings indicate that MAGI-1 is a member of a select group of cellular PDZ proteins targeted by both adenovirus E4-ORF1 and high-risk HPV E6 proteins and, in addition, suggest that the tumorigenic potentials of these viral oncoproteins depend, in part, on an ability to inhibit the function of MAGI-1 in cells.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Baylor College of Medicine; International Center for Genetic Engineering & Biotechnology (ICGEB)	Javier, R (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058541, R01CA58541, R01 CA058541-06] Funding Source: Medline; NIAID NIH HHS [T32 AI007471, T32AI07471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Harlow E, 1988, ANTIBODIES LABORATOR, P359; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Howley M. P., 1996, FIELDS VIROLOGY, P2045; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MCALLISTER RM, 1971, NATURE-NEW BIOL, V230, P279, DOI 10.1038/newbio230279a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; PRASAD R, 1993, CANCER RES, V53, P5624; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	37	234	247	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5270	5280		10.1038/sj.onc.1203906	http://dx.doi.org/10.1038/sj.onc.1203906			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077444	Green Accepted			2022-12-28	WOS:000165059700008
J	Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP				Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP			Novel p53 splice site mutations in three families with Li-Fraumeni syndrome	ONCOGENE			English	Article						p53; germline mutation; Li-Fraumeni syndrome; alternate splicing	CANCER-PRONE FAMILY; CELL-LINES; GENE; TP53; DATABASE; PATIENT; POLYMORPHISM; DEFICIENCY; PROTEIN; TUMORS	Germline mutations in the p53 tumor suppressor gene predispose to a variety of cancers in families with Li-Fraumeni syndrome. Most germline p53 mutations observed to date cause amino acid substitutions in the protein's central sequence-specific DNA binding domain. Outside this conserved core region, however, we found novel alterations in sequences that regulate precursor mRNA splicing in three Li-Fraumeni syndrome families. Two splice site mutations affected the consensus sequence at the splice donor sites of introns 1 and 9, and produced unstable variant transcripts in normal cells. A third mutation at the splice acceptor site of intron 9 generated splicing at a cryptic acceptor site in intron 9, These splice site alterations emphasize the need to examine both noncoding and untranslated regions of the p53 gene for germline mutations in Li-Fraumeni syndrome families.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Skin Dis Res Ctr, Boston, MA 02115 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, FP (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.							Antonarakis SE, 1998, HUM MUTAT, V11, P1; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIRCH JM, 1994, CANCER RES, V54, P1298; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Darling TN, 1998, J INVEST DERMATOL, V110, P165, DOI 10.1046/j.1523-1747.1998.00103.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FELIX CA, 1993, ONCOGENE, V8, P1203; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maquat LE, 1996, AM J HUM GENET, V59, P279; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Soria JM, 1996, THROMB HAEMOSTASIS, V75, P870; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976	33	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4230	4235		10.1038/sj.onc.1203758	http://dx.doi.org/10.1038/sj.onc.1203758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980596				2022-12-28	WOS:000089032900005
J	Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P				Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P			Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone	ONCOGENE			English	Article						gene array; cancer therapy; hsp90 chaperone; 17-allylamino-17-demethoxygeldanamycin	ROUS-SARCOMA VIRUS; RAT-KIDNEY CELLS; IN-VIVO; HEAT-SHOCK; GLUCOCORTICOID RECEPTOR; CDNA MICROARRAY; DT-DIAPHORASE; GELDANAMYCIN; KINASE; PROTEIN	A number of molecular therapeutic agents, derived from exploiting our knowledge of the oncogenic pathways that are frequently deregulated in cancer, are now entering clinical trials. One of these is the novel agent 17-allylamino-17-demethoxygeldanamycin that acts to inhibit the hsp90 molecular chaperone. Treatment of four human colon cancer cell lines with iso-effective concentrations of this agent resulted in depletion of c-raf-1 and akt and inhibition of signal transduction. We have used gene expression array analysis to identify genes responsive to treatment with this drug. The expression of hsp90 client protein genes was not affected, but hsc hsp70, hsp90 beta, keratin 8, keratin 18 and caveolin-1 were deregulated following treatment. These observations were consistent with inhibition of signal transduction and suggested a possible mechanism of resistance or recovery from 17-allylamino-17-demethoxygeldanamycin treatment. The results shed light on the molecular mode of action of the hsp90 inhibitors, and suggest possible molecular markers of drug action for use in hypothesis testing clinical trials.	Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK	Workman, P (corresponding author), Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, E Block,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Clarke, Paul/0000-0001-9342-1290; Banerji, Udai/0000-0003-1503-3123				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Brunton VG, 1998, CANCER CHEMOTH PHARM, V41, P417, DOI 10.1007/s002800050760; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chavany C, 1996, J BIOL CHEM, V271, P4974; DeRisi J, 1996, NAT GENET, V14, P457; Egorin MJ, 1998, CANCER RES, V58, P2385; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Khan J, 1998, CANCER RES, V58, P5009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Martin S, 1998, EUR PHYS J D, V4, P1, DOI 10.1007/s100530050178; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; MURAKAMI Y, 1991, BIOCHEM J, V301, P63; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sgroi DC, 1999, CANCER RES, V59, P5656; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Strawn L M, 1998, Expert Opin Investig Drugs, V7, P553, DOI 10.1517/13543784.7.4.553; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Vasilevskaya IA, 1999, CANCER RES, V59, P3935; Vlahos Chris J., 1995, Drugs of the Future, V20, P165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZOU J, 1996, CELL, V94, P471	51	168	176	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4125	4133		10.1038/sj.onc.1203753	http://dx.doi.org/10.1038/sj.onc.1203753			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962573				2022-12-28	WOS:000088955100006
J	Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G				Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G			Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues	ONCOGENE			English	Article						human telomerase reverse transcriptase; hepatocellular carcinoma; immunohistochemical detection	DISEASED PEDIATRIC LIVER; DNA POLYMERASE-ALPHA; MONOCLONAL-ANTIBODY; HEPATOCELLULAR-CARCINOMA; PROGENITOR CELLS; IMMUNOHISTOCHEMICAL DETECTION; PROLIFERATING HEPATOCYTES; DUCTULAR HEPATOCYTES; CATALYTIC COMPONENT; IMMORTAL CELLS	Although telomerase activity in hepatocellular carcinoma (HCC) increases in accordance with degree of histological undifferentiation, it is unknown whether the level of telomerase activity in HCC reflects of the degree of activity in individual cells or the frequency of telomerase-positive HCC cells. Non-cancerous liver tissues exhibit low but significant levels of telomerase activity, but the nature of telomerase-positive cells in these tissues is unclear, In this study, we performed immunohistochemical staining using specific antibody against telomerase reverse transcriptase (hTERT) protein in 15 HCC samples and 13 adjacent non-cancerous liver tissues, There were hTERT-positive hepatocytes, though very low frequency, in non-cancerous liver tissues. The frequencies in hTERT positive hepatocytes were very well correlated with clinicopathological parameters and telomerase activity levels: the average frequencies of chronic hepatitis was 0.2%, liver cirrhosis 0.2%, well-differentiated HCC 3.0%, moderately differentiated HCC 28%, and poorly differentiated HCC 95%, The intensity of staining varied among cells within a given specimen, and correlation with degree of histological undifferentiation was less obvious. Portions of migrating lymphocytes and biliary epithelial cells were also hTERT-positive. These findings indicate that the upregulation of telomerase activity with degree of undifferentiation of HCC is mainly due to the increase in frequency of hTERT positive HCC cells.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Minami Ku, Hiroshima 7348551, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2260027, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Nakayama, Jun-ichi/C-6003-2011; Ishikawa, Fuyuki/AAU-4056-2021	Nakayama, Jun-ichi/0000-0002-5597-8239; Ishikawa, Fuyuki/0000-0002-5580-2305				Baumann U, 1999, HEPATOLOGY, V30, P112, DOI 10.1002/hep.510300140; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crosby HA, 1998, AM J PATHOL, V152, P771; Crosby HA, 1998, HEPATOLOGY, V28, P980, DOI 10.1002/hep.510280412; Demetris AJ, 1996, AM J PATHOL, V149, P439; DEVOS R, 1992, AM J PATHOL, V140, P1441; DUNSFORD HA, 1985, AM J PATHOL, V118, P218; DUNSFORD HA, 1989, CANCER RES, V49, P4894; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; ELMORE LW, 1991, CANCER RES, V51, P5752; EVARTS RP, 1989, CANCER RES, V49, P1541; GOLDLUST A, 1995, EPILEPSY RES, V22, P1, DOI 10.1016/0920-1211(95)00028-9; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Haque S, 1996, LAB INVEST, V75, P699; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Novikoff PM, 1996, AM J PATHOL, V148, P1473; Ogami M, 1999, LAB INVEST, V79, P15; Ohyashiki K, 1997, CANCER RES, V57, P2100; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Roskams T, 1996, HISTOPATHOLOGY, V28, P291, DOI 10.1046/j.1365-2559.1996.d01-438.x; Ruck P, 1996, AM J PATHOL, V148, P321; SEKI S, 1990, HUM PATHOL, V21, P1020, DOI 10.1016/0046-8177(90)90251-Y; SEKI S, 1991, HEPATOLOGY, V14, P781, DOI 10.1002/hep.1840140507; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Takahashi S, 2000, EUR J CANCER, V36, P496, DOI 10.1016/S0959-8049(99)00284-1; Takaishi H, 2000, CANCER, V88, P312, DOI 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.3.CO;2-I; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 1998, JPN J CANCER RES, V89, P1099, DOI 10.1111/j.1349-7006.1998.tb00502.x; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	41	51	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3888	3893		10.1038/sj.onc.1203733	http://dx.doi.org/10.1038/sj.onc.1203733			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951582				2022-12-28	WOS:000088614300007
J	Gil, J; Esteban, M				Gil, J; Esteban, M			The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors	ONCOGENE			English	Article						PKR; apoptosis; FADD; caspases	TUMOR-SUPPRESSOR P53; EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; INFLUENZA-VIRUS INFECTION; NF-KAPPA-B; CELL-DEATH; DEPENDENT PATHWAY; ANTICANCER DRUGS; EXPRESSION; LIGAND; DOMAIN	The interferon-induced dsRNA-dependent protein kinase (PKR) induces apoptosis of mammalian cells. Apoptosis induction bq PKR involves phosphorylation of the translational factor eIF-2 alpha and activation of the transcriptional factor NF-kappa B, but caspase pathways activated by PKR are not known. Upregulation of Fas mRNA by PKR has been suggested to play a role in PKR-induced apoptosis. To learn how PKR induces apoptosis, we have analysed the role of molecules in death receptor pathways. We showed the involvement of the FADD-caspase 8 pathway on PKR-induced apoptosis based on four experimental findings: upregulation of caspase 8 activity during PKR-induced apoptosis, blocking of PKR-induced apoptosis by the use of a chemical inhibitor of caspase 8, and inhibition of PKR-induced apoptosis by expression of both a FADD dominant negative or a viral FLIP molecule. Significantly, despite the PKR-mediated upregulation of Fas mRSA expression, the Fas receptor-ligand pathway is not needed for PKR-induced apoptosis. Antibodies that inhibit TNF alpha-TNFR1 or Fas-FasL interactions were not able to block PKR-induced apoptosis. Taken together, our observations establish the involvement of caspase 8 in PKR-induced apoptosis and suggest that death receptors other than Fas or TNFR1 or, alternatively, a novel mechanism involving FADD independently of death receptors, are responsible for PKR-induced apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Gil, Jesus/C-7739-2012; Esteban, Mariano/ABG-5375-2020	Gil, Jesus/0000-0002-4303-6260; Esteban, Mariano/0000-0003-0846-2827				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Brun A, 1996, VIROLOGY, V225, P227, DOI 10.1006/viro.1996.0592; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P715; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez A, 1996, J MED VIROL, V50, P342, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;342::AID-JMV10&gt;3.0.CO;2-K; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suarez P, 1996, J VIROL, V70, P2876; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vazquez MI, 1998, J VIROL, V72, P10126; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WATANABE FR, 1992, NATURE, V356, P314; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	74	86	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3665	3674		10.1038/sj.onc.1203710	http://dx.doi.org/10.1038/sj.onc.1203710			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951573				2022-12-28	WOS:000088568300013
J	McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW				McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW			A different function for a critical tryptophan in c-Raf and Hck	ONCOGENE			English	Article						Raf; Ras; Src; kinase	PROTEIN-KINASE-C; SRC FAMILY; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; CELLS; C-RAF-1; PATHWAY; VIVO	The similarity of the catalytic domains of Raf and Src family members suggests that functions of homologous residues may be similar in both kinase families. A tryptophan residue, W260, in the WEI region of the Src family kinase Hck has an important role in regulating ATP binding. We tested the hypothesis that the tryptophan, W342, in the WEI region of c-Raf may have a similar role to the W260 of Hck. Mutation of W260 to A in Hck activates kinase activity, but me found that mutation of W342 to A in c-Raf inactivates the kinase activity. Mutating W342 to aspartate (D), lysine (K) or histidine (H) also inactivated c-Raf whether assayed as a purified immunoprecipitate or when recruited to the plasma membrane. A constitutively active c-Raf can be generated by mutating two regulatory tyrosines to aspartate. When placed into this active c-Raf mutant, mutation of W342 to D, K or H enabled phosphorylation and activation of the c-Raf substrate MEK at the plasma membrane but not in an immunoprecipitation assay. We conclude that (1) Tryptophan has a different role in the WEI regions of c-Raf and Hck, (2) W342 is not directly involved in MEK binding as both positive and negative residues at 342 are permissive for MEK activation at the membrane in a constitutively active c-Raf mutant, (3) Factors at the membrane are capable of potentiating activation of c-Raf containing mutated W342 in a hyperactivated c-Raf, but not in a wild type c-Raf and (4) There is a stringent structural requirement for W at residue 342 in c-Raf.	Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Howard Hughes Med Inst, Charlottesville, VA 22908 USA	University of Virginia; Howard Hughes Medical Institute; University of Virginia	McPherson, RA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Box 577, Charlottesville, VA 22908 USA.							Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dent P, 1997, CELL SIGNAL, V9, P539, DOI 10.1016/S0898-6568(97)00048-X; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Xia K, 1999, MOL CELL BIOL, V19, P4819; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	25	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3616	3622		10.1038/sj.onc.1203678	http://dx.doi.org/10.1038/sj.onc.1203678			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951567				2022-12-28	WOS:000088568300007
J	Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A				Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A			Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras	ONCOGENE			English	Article						myelodysplastic syndrome; Shc; PI3-K; MAPK; transformation	GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; MULTIPLE SIGNALING PATHWAYS; HEMATOPOIETIC-CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; MATRIX ADHESION; IGF-I; P53; DIFFERENTIATION	32D cells expressing,v-Ha-Ras fail to show a transformed phenotype. Since Ras requires an active IGF-1R for transformation of fibroblasts, we asked whether expression of IRS-1 or Shc (two of the major substrates of the IGF-1R) could co-operate with oncogenic Ras in transforming 32D cells. We find that IRS-1, but not Shc, in combination with v-Ha-Ras generates a fully transformed phenotype in 32D cells, 32D cells expressing both IRS-1 and v-Ha-Ras (32D/IRS1/Ras) survive and proliferate in the absence of IL-3, do not undergo granulocytic differentiation in the presence of G-CSF and form tumors in nu/nu and syngeneic mice, In contrast, 32D cells expressing singly IRS-1 or v-Ha-Ras exhibit only a block in differentiation capacity. Over-expression of Shc proteins, by itself, promotes differentiation of 32D cells. Concomitant expression of IRS-1 and v-Ha-Ras synergistically phosphorylates ERK-1 and ERK-2 whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells. Furthermore, transformed 32D/IRS1/Ras cells display high levels of PI3-K activation and undergo rapid apoptosis when exposed to PI3-K inhibitors. The data indicate that: (1) a fully transformed phenotype in 32D cells is generated when a block in differentiation (v-Ha-Ras) is coupled with another differentiation block (IRS-1); (2) PI3-K and MAPK activity are required for the survival of transformed cells; (3) the signals generated by IRS-1 and oncogenic Ras converge on ERK and PI3-K resulting in high levels of activation.	Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, I-00158 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Marchetti, Alessandra/AAD-5498-2019; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/ABH-6846-2020; Rizzo, Maria/HGD-6576-2022; Soddu, Silvia/K-2467-2018	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; MARCHETTI, ALESSANDRA/0000-0001-9706-848X	NCI NIH HHS [P01 CA 56309, CA 53424] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ASKEW DS, 1991, ONCOGENE, V6, P1915; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BOS JL, 1989, CANCER RES, V49, P4682; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; DEWS M, 2000, IN PRESS ENDOCRINOLO, V141; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; GREENBERGER JS, 1983, FED PROC, V42, P2762; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; KASTAN MB, 1991, CANCER RES, V51, P4279; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANFRANCONE L, 1995, ONCOGENE, V10, P907; MAVILIO F, 1989, ONCOGENE, V4, P301; METCALF D, 1985, BLOOD, V65, P357; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soon L, 1999, MOL CELL BIOL, V19, P3816; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1996, MOL CELL BIOL, V16, P2509	38	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3245	3255		10.1038/sj.onc.1203664	http://dx.doi.org/10.1038/sj.onc.1203664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918581				2022-12-28	WOS:000088019300003
J	Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ				Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ			Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4	ONCOGENE			English	Article						FGFR; transformation; Stats; signal transduction	FIBROBLAST-GROWTH-FACTOR; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; MYELOPROLIFERATIVE DISORDER FUSES; LIGAND-INDEPENDENT ACTIVATION; LETHAL SKELETAL DYSPLASIA; FACTOR RECEPTOR-3 GENE; THANATOPHORIC DYSPLASIA; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION	The fibroblast growth factor receptor (FC;FR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650 --> Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3, To compare the signaling activity of FGFR family members, this activating mutation aas generated in FGFR1, FGFR3, and FGFR I. We show that the kinase domains of FGFR1, FGFR3, and FGFR3 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-gamma, and MAPK was also stimulated by all three 'TDII-like' FGFR derivatives. Additionally, activation of Stat1 and Stat3 mas observed in cells expressing the activated FGFR deriVatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR3, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012581] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE12581] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hart KC, 1997, ONCOGENE, V14, P945, DOI 10.1038/sj.onc.1200908; HATTORI Y, 1992, CANCER RES, V52, P3367; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOUHARA H, 1995, ONCOGENE, V10, P2315; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lin HY, 1996, J NEUROSCI, V16, P4579; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STARK KL, 1991, DEVELOPMENT, V113, P641; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEBSTER MK, 1998, GENE THER MOL BIOL, V1, P365; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	78	207	214	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3309	3320		10.1038/sj.onc.1203650	http://dx.doi.org/10.1038/sj.onc.1203650			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918587				2022-12-28	WOS:000088019300009
J	Schroeder, JA; Troyer, KL; Lee, DC				Schroeder, JA; Troyer, KL; Lee, DC			Cooperative induction of mammary tumorigenesis by TGF alpha and Wnts	ONCOGENE			English	Article						TGF alpha; MMTV; Wnt; mammary tumorigenesis; transgenics	GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; TUMOR VIRUS; TRANSGENIC MICE; BETA-CATENIN; C-MYC; E-CADHERIN; EXPRESSION; GENE; TRANSFORMATION	We previously reported that multiparous WAP-TGF alpha transgenic mice develop mammary gland carcinomas with complete incidence, TGF alpha-induced tumors appear stochastically and with relatively long latency, indicating an additional requirement for other genetic alterations, To identify genes that cooperate with TGF alpha in mammary tumorigenesis, we used a retroviral insertion approach featuring a cloned and infectious hybrid MMTV (C3H/Mtv-1; (Shackleford and Varmus, 1988)), Tumor latency,vas decreased approximately 30% in MMTV-infected WAP-TGF alpha transgenic animals compared to noninfected transgenic controls, and >30% of the corresponding tumors displayed evidence of integrated C3H/Mtv-1 DNA, PCR-based analyses of DNAs from two virus-infected, transgenic tumors revealed integration of hybrid MMTV in 3' untranslated exons of the Wnt-1 or Wnt-3 oncogenes, Moreover, Northern blots confirmed dramatic induction of Wnt-1 or Wnt-3 transcripts in the respective turners, indicating that MMTV integration resulted in activated expression of these genes, Semi-quantitative RT-PCR analyses showed that overexpression of Wnt-1 or Wnt-3 was a common occurrence in MMTV-infected WAP-TGF alpha tumors, and some noninfected WAP-TGF alpha tumors also shelved evidence of elevated Wnt-3 transcripts, Collectively, these results reveal cooperative induction of mammary gland tumorigenesis by simultaneous deregulation of EGF-like (TGF alpha) and Wnt growth factors.	Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lee, DC (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.			schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA71341, CA61896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA071341, R01CA061896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; BRANDTCARLSON C, 1993, VIROLOGY, V193, P171, DOI 10.1006/viro.1993.1113; BUI TD, 1996, ONCOGENE, P1249; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHOOI KF, 1994, CANCER RES, V54, P6434; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; GOLOVKINA TV, 1994, J VIROL, V68, P5019, DOI 10.1128/JVI.68.8.5019-5026.1994; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; HUGUET EL, 1994, CANCER RES, V54, P2615; Ilyas M, 1997, J PATHOL, V182, P128; Julius MA, 1999, ONCOGENE, V18, P149, DOI 10.1038/sj.onc.1202268; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERSON DO, 1985, J VIROL, V54, P525, DOI 10.1128/JVI.54.2.525-531.1985; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shibata T, 1996, ONCOGENE, V13, P883; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wang YS, 1996, J BIOL CHEM, V271, P4468; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Xu L, 1996, VIROLOGY, V215, P113, DOI 10.1006/viro.1996.0014	34	26	29	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3193	3199		10.1038/sj.onc.1203652	http://dx.doi.org/10.1038/sj.onc.1203652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918574				2022-12-28	WOS:000088019200008
J	Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA				Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA			E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes	ONCOGENE			English	Article						keratinocyte; E2F-1; differentiation; carcinogenesis	HUMAN PAPILLOMAVIRUS TYPE-16; SKIN TUMOR-DEVELOPMENT; CARCINOMA CELL-LINE; S-PHASE ENTRY; WILD-TYPE P53; TRANSCRIPTION FACTOR; DNA-BINDING; EPITHELIAL-CELLS; IN-VIVO; TERMINAL DIFFERENTIATION	Squamous differentiation of keratinocytes is associated with decreases in E2F-1 mRNA expression and E2F activity, and these processes are disrupted in squamous cell carcinoma cell lines. We now show that E2F-1 mRNA expression is increased in primary squamous cell carcinomas of the skin relative to normal epidermis, To explore the relationship between E2F-1 and squamous differentiation further, we examined the effect of altering E2F activity in primary human keratinocytes induced to differentiate. Promoter activity for the proliferation-associated genes, cdc2 and keratin 14, are inhibited during squamous differentiation. This inhibition can be inhibited by overexpression of E2F-1 in keratinocytes, Overexpression of E2F-1 also suppressed the expression of differentiation markers (transglutaminase type 1 and keratin 10) in differentiated keratinocytes, Blocking E2F activity by transfecting proliferating keratinocytes with dominant negative E2F-1 constructs inhibited the expression of cdc2 and E2F-1, but did not induce differentiation. Furthermore, expression of the dominant negative construct in epithelial carcinoma cell lines and normal keratinocytes decreased expression from the cdc2 promoter. These data indicate that E2F-1 promotes keratinocyte proliferation-specific marker genes and suppresses squamous differentiation-specific marker genes. Moreover, these data indicate that targeted disruption of E2F-1 activity may have therapeutic potential for the treatment of squamous carcinomas.	Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia	University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia.		saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010; Dicker, Tony/F-6007-2010; Frazer, Ian/A-1137-2007	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529; Dicker, Tony/0000-0001-8539-2960; Frazer, Ian/0000-0002-8002-4680				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Arany I, 1997, IN VIVO, V11, P157; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BETZ NA, 1995, MOL CARCINOGEN, V12, P66, DOI 10.1002/mc.2940120203; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; Chiang SY, 1997, P NATL ACAD SCI USA, V94, P2811, DOI 10.1073/pnas.94.7.2811; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GILLES C, 1994, INT J CANCER, V58, P847, DOI 10.1002/ijc.2910580617; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HILDITCHMAGUIRE PA, 1998, THESIS U QUEENSLAND, P275; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JETTEN AM, 1989, CANCER RES, V49, P3990; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kikuchi Arata, 1992, Journal of Dermatological Science, V4, P83, DOI 10.1016/0923-1811(92)90063-H; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; MOORE GE, 1975, CANCER RES, V35, P2684; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEUMAN T, 1995, EXP CELL RES, V217, P363, DOI 10.1006/excr.1995.1098; PAGANO M, 1992, ONCOGENE, V7, P1681; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rook A, 1998, TXB DERMATOLOGY; Saunders N, 1999, CANCER RES, V59, P399; Saunders NA, 1998, CANCER RES, V58, P1646; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHARPE GR, 1994, ARCH DERMATOL RES, V286, P476, DOI 10.1007/BF00371575; Sladek TL, 1996, CELL PROLIFERAT, V29, P579, DOI 10.1111/j.1365-2184.1996.tb00973.x; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUDA K, 1994, NEUROREPORT, V5, P1749, DOI 10.1097/00001756-199409080-00015; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wang J, 1996, J CELL BIOCHEM, V62, P405; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welter JF, 1996, J BIOL CHEM, V271, P11034; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	84	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2887	2894		10.1038/sj.onc.1203610	http://dx.doi.org/10.1038/sj.onc.1203610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871839				2022-12-28	WOS:000087544500002
J	Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G				Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G			Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein Delta BRCA1(17aa)	ONCOGENE			English	Article						BRCA1; translational regulation	SPORADIC BREAST-CANCER; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; PROMOTER REGION; SPLICE VARIANTS; FAMILIAL BREAST; TUMOR-FORMATION	Expression of the breast and ovarian cancer gene BRCA1 is regulated at both the transcriptional and post-transcriptional levels. We found that the expression of the BRCA1 protein may also be regulated at the translational level. In addition to an AUG start codon at position 1, BRCA1 mRNA has a second in-frame AUG (+17) that acts as an alternative start codon to generate a novel BRCA1 protein that lacks the first 17 amino acids (Delta BRCA1(17aa)). We fused cDNAs encoding the second exon of BRCA1 of the wild-type BRCA1 gene (wt-BRCA1) and a mutated BRCA1 gene (mt-BRCA1), in which the first initiation site and its Kozak consensus sequence were abolished, with the nucleophosmin (NPM) reporter gene and used them for in vitro and in vivo translation assays, In both systems, the wt-BRCA1-NPM constructs produced two distinct proteins (18 and 16 kD) begun from the first and second AUGs, The mt-BRCA1-NPM constructs produced only the shorter 16-kD protein lacking the first 17 amino acids of the BRCA1 gene. Next, we analysed the N-terminal protein sequence of purified BRCA1 protein from normal thymocytes and found two different BRCA1 proteins, derived from translation of the first and second in-frame AUGs, Thus, BRCA1 protein expression can be regulated at the translation level in normal cells, Characterization of Delta BRCA1(17aa) may shed light on the function and regulation of BRCA1 in normal cells as well as the pathogenesis of breast and ovarian cancers.	NYU Med Ctr, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Inghirami, G (corresponding author), NYU Med Ctr, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		PROLLA, GABRIEL/T-3669-2018; Prolla, Gabriel/AAH-6332-2019; Rostagno, Agueda/A-5801-2008	CHIARLE, Roberto/0000-0003-1564-8531; Rostagno, Agueda/0000-0002-6817-2074	NATIONAL CANCER INSTITUTE [T32CA009454, R21CA066229] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA66229, CA-2T32CA09454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown MA, 1996, ONCOGENE, V12, P2507; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; COLIZAN JE, CURR PROTOCOLS PRO S; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Cui JQ, 1998, ONCOL REP, V5, P591; Dobrovic A, 1997, CANCER RES, V57, P3347; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; INGHIRAMI G, 1994, BLOOD, V83, P3581; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	53	20	21	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2767	2773		10.1038/sj.onc.1203599	http://dx.doi.org/10.1038/sj.onc.1203599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851077				2022-12-28	WOS:000087318500005
J	Fognani, C; Rondi, R; Romano, A; Blasi, F				Fognani, C; Rondi, R; Romano, A; Blasi, F			cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain	ONCOGENE			English	Article						MAP kinase; protein-protein interaction; Rel; NF-kappa B transcription factor; signal transduction; transcriptional regulation	NF-KAPPA-B; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-KINASE; V-REL; TRANSCRIPTIONAL ACTIVITY; P65 SUBUNIT; DNA-BINDING; IN-VIVO; ACTIVATION	The activity of transcription factors is often modulated by signal responsive protein kinases, Rel/NF-kappa B transcription factors are regulated by I kappa B inhibitors, the phospharylation of which causes ubiquitination and degradation, resulting in nuclear translocation of NF-kappa B and activation of target genes. Here we report pull-down and immunoprecipitation experiments showing that a mammalian 66 kDa protein kinase binds murine c-Rel, both in vitro and in vitro. This kinase appears to hare at least two binding sites on c-Rel, a proline-directed serine/ threonine substrate specificity similar to MAP kinases and to specifically phosphorylate the C-terminal domain of murine c-Rel at an ERI: consensus site.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, I-20132 Milan, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS European Institute of Oncology (IEO)	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, Via Olgettina 58, I-20132 Milan, Italy.			Blasi, Francesco/0000-0001-9406-1784				Abe MK, 1999, MOL CELL BIOL, V19, P1301; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	48	15	15	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2224	2232		10.1038/sj.onc.1203543	http://dx.doi.org/10.1038/sj.onc.1203543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822372				2022-12-28	WOS:000086974100007
J	Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC				Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC			Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis	ONCOGENE			English	Article						p53 RE; c-Ha-Ras; transactivation; Ras.GTP; p53-stability	PROTEIN-KINASE-C; CELL-CYCLE MACHINERY; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; BINDING-SITE; NEUROBLASTOMA-CELLS; PHORBOL ESTER; FIRST INTRON; T-ANTIGEN; IN-VITRO	p53 protein is a sequence-specific transcriptional activator which induces the expression of a number of cellular genes involved in different metabolic pathways, We report that the computer-selected sequence in human and mouse C-Ha-Ras gene confers to a reporter gene the ability to be directly transactivated by wild-type p53 either ovrespressed or activated in response to a cellular stress. By analysing human transformed cell lines, we showed, at both mRNA and protein level, that the endogenous C-Ha-Ras gene expression is positively regulated by wt p53 protein, The stimulation of c-Ha-Ras gene expression in Saos-2Ts cells by a temperature shift down to the permissive temperature for the p53-wt conformation is associated with a significant increase in the activated form of p21(e-11a-Ras) protein. Furthermore, in human transformed cell lines, the transient expression of a dominant interfering mutant of c-Ha-Ras greatly reduced the ability of p53 to induce apoptosis and inhibited the p53-dependent transactivation. This is due, at least in part, to a decrease in the protein (but not mRNA) level of the transiently expressed p53, indicating that inactivation of p21(e-11a-Ras) signalling pathways led to a specific degradation of p53 protein, We therefore suggest that, by inducing c-Ha-Ras, p53 activates a positive feedback loop that counteracts the negative feedback loop mediated by Mdm2.	CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France; Univ Dundee, Dept Biochem, CRC, Cell Transformat Res Grp, Dundee DD1 4HN, Scotland	CEA; University of Dundee	May, E (corresponding author), CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, BP6, F-92265 Fontenay Aux Roses, France.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANNON JV, 1990, EMBO J, V9, P1595; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAY E, 1989, ONCOGENE, V4, P1037; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; ROMANO JW, 1989, ONCOGENE, V4, P1483; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; YAMATO K, 1995, ONCOGENE, V11, P1; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YonishRouach E, 1995, ONCOGENE, V11, P2197; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZHANG W, 1995, INT J ONCOL, V7, P1021; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	56	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5831	5841		10.1038/sj.onc.1203960	http://dx.doi.org/10.1038/sj.onc.1203960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127813				2022-12-28	WOS:000165563100001
J	Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC				Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC			Tumor-associated Apc mutations in Mlh1(-/-) Apc(1638N) mice reveal a mutational signature of Mlh1 deficiency	ONCOGENE			English	Article						Mlh1; Apc; colorectal cancer; mouse models; mutation analysis	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; CARCINOMA CELL-LINES; FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; BETA-CATENIN; SUPPRESSOR PROTEIN; DNA MISMATCH; MOUSE MODEL; SACCHAROMYCES-CEREVISIAE	Apc(1638N) mice, which are heterozygous for a germline mutation in Ape, typically de, clop three to five spontaneous intestinal tumors per animal, in most cases this is associated,vith allelic loss of wildtype Ape. We have previously reported that the multiplicity of intestinal tumors is increased dramatically by crossing Apc(1638N) with an Mlh1-deficient mouse strain that represents an animal model of hereditary non-polyposis colorectal cancer (HNPCC). The increased tumor multiplicity in these mice was associated with somatic mutations in the Ape tumor suppressor gene, Here, we have examined the nature and distribution of 91 Ape mutations implicated in the de, development of intestinal tumors in Mlh1 (-/-) Apc(1638N) animals. Protein truncation mutations were detected in a majority of tumor samples, indicating that the prevailing mechanism of Ape mutation in tumors is altered from allelic loss to intragenic mutation as a result of Mlh1 deficiency, The observed mutations were a mixture of base substitutions (27%) and frameshifts (73%). Most frameshifts wire detected within dinucleotide repeats and there were prominent mutational hotspots within sequences of this sort at codons 927-929, 1209-1211 and 1461-1464, The observed Ape mutations caused protein truncation upstream of the third 20 amino acid beta -catenin binding domain and the first Axin-binding SAMP repeat, yielding Ape proteins that are predicted to be deficient in destabilizing beta -catenin, Our results reveal a characteristic mutational signature in APC that is attributable to Mlh1 deficiency. This demonstrates a direct effect of Mlh1 deficiency in the mutation of Apc in these tumors, and provides data that clarify the role of Mlh1 in mammalian DNA mismatch repair.	Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Brown, AMC (corresponding author), Rockefeller Univ, Strang Canc Res Lab, 1230 York Ave, New York, NY 10021 USA.		Kucherlapati, Raju/ABC-8807-2021		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065031] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA047207, R01CA067944, R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-65031, CA76329, CA67944, R01 CA047207] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEVY DB, 1994, CANCER RES, V54, P5953; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyaki M, 1999, CANCER RES, V59, P4506; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Saparbaev M, 1996, GENETICS, V142, P727; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH KJ, 1994, CANCER RES, V54, P3672; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umar A, 1998, GENETICS, V148, P1637; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N	60	39	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5755	5763		10.1038/sj.onc.1203962	http://dx.doi.org/10.1038/sj.onc.1203962			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126362				2022-12-28	WOS:000165477700007
J	Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB				Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB			MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells	ONCOGENE			English	Article						MMAC1/PTEN; bladder cancer; growth suppression; doxorubicin; chemosensitization	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; GERMLINE MUTATIONS; COWDEN-DISEASE; P53 GENE; GLIOBLASTOMA-MULTIFORME; MULTIDRUG-RESISTANCE; NATURAL-HISTORY; PTEN/MMAC1 GENE; PTEN	The development and progression of bladder cancer is associated with multiple alterations in the genome, including loss of chromosome 10. Recently, MMAC1/ PTEN, a phosphatidylinositol phosphatase, has been mapped to chromosome 10q23. We previously demonstrated that MMAC1/PTEN has tumor suppressive properties in glioblastoma and prostate cancer. To investigate the efficacy of gene therapy with MMAC1/ PTEN, we examined whether the exogenous introduction of MMAC1/PTEN via an adenoviral vector (Ad-MMAC) can inhibit tumor growth and reverse drug resistance to doxorubicin in human bladder cancer cells. Human bladder cancer cell lines UM-UC-3 and T24 were infected with Ad-MMAC to induce exogenous expression of MMAC1/PTEN. The cells were then analysed for cell growth and expression of phosphorylated protein kinase B (Akt/PKB) and MMAC1/PTEN. UM-UC-6dox, a doxorubicin resistant subline, was infected with Ad-MMAC to evaluate its role in reversing drug resistance to doxorubicin. We found that MMAC1/ PTEN suppressed tumor growth in UM-UC-3 and T24 cells with arrest in the G1 phase of the cell cycle. We also showed that gene therapy with MMAC1/PTEN abrogated phosphorylated Akt/PKB expression in UM-UC-3, T24 and UMUC-6dox cells, and restored doxorubicin sensitivity in UM-UC-6dox. These data demonstrate that MMAC1/PTEN can induce growth suppression and increase sensitivity to doxorubicin in bladder cancer cells and suggest that the MMAC1/ PTEN gene and its pathways can be therapeutic targets for bladder cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Grossman, HB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Davies, Michael/GWV-2527-2022		NATIONAL CANCER INSTITUTE [U01CA056973, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA56973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Cookson MS, 1997, J UROLOGY, V158, P62, DOI 10.1097/00005392-199707000-00017; Corral DA, 1997, WORLD J UROL, V15, P139, DOI 10.1007/BF02201986; Dahia PLM, 1997, CANCER RES, V57, P4710; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; FUJIWARA T, 1994, CANCER RES, V54, P2287; Guldberg P, 1997, CANCER RES, V57, P3660; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Herr HW, 1997, WORLD J UROL, V15, P84, DOI 10.1007/BF02201977; KANAMARU H, 1989, UROL RES, V17, P259; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; KIM WJ, 1995, JPN J CANCER RES, V86, P969, DOI 10.1111/j.1349-7006.1995.tb03009.x; Kozlowski J, 1999, J UROLOGY, V162, P1581, DOI 10.1016/S0022-5347(05)68170-0; KROFT SH, 1994, LAB INVEST, V71, P158; Levine RL, 1998, CANCER RES, V58, P3254; LI DM, 1997, CANCER RES, V57, P2130; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU J, 2000, IN PRESS MOL CARCINO; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Maxwell GL, 1998, CANCER RES, V58, P2500; NAITO S, 1995, JPN J CANCER RES, V86, P1112, DOI 10.1111/j.1349-7006.1995.tb03028.x; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Pu YS, 1996, J UROLOGY, V156, P271, DOI 10.1016/S0022-5347(01)66015-4; Rhei E, 1997, CANCER RES, V57, P3657; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sano T, 1999, CANCER RES, V59, P1820; SHINOHARA N, 1993, J UROLOGY, V150, P505, DOI 10.1016/S0022-5347(17)35536-2; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; TANAKA M, 1995, CANCER RES, V55, P3228; Tashiro H, 1997, CANCER RES, V57, P3935; Thakar M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P633; USANSKY JI, 1991, SELECT CANCER THER, V7, P139, DOI 10.1089/sct.1991.7.139; Wang SI, 1997, CANCER RES, V57, P4183; Warde P, 1997, WORLD J UROL, V15, P125, DOI 10.1007/BF02201984; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	46	97	107	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5406	5412		10.1038/sj.onc.1203918	http://dx.doi.org/10.1038/sj.onc.1203918			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103942				2022-12-28	WOS:000165302300012
J	Knapp, JI; Heppner, C; Hickman, AB; Burns, AL; Chandrasekharappa, SC; Collins, FS; Marx, SJ; Spiegel, AM; Agarwal, SK				Knapp, JI; Heppner, C; Hickman, AB; Burns, AL; Chandrasekharappa, SC; Collins, FS; Marx, SJ; Spiegel, AM; Agarwal, SK			Identification and characterization of JunD missense mutants that lack menin binding	ONCOGENE			English	Article						MEN1; menin; JunD; mutagenesis; two-hybrid; tumor suppressor	ENDOCRINE-NEOPLASIA TYPE-1; C-JUN; MUTATION ANALYSIS; ACTIVATED TRANSCRIPTION; GERMLINE MUTATIONS; AP-1 COMPLEX; CELL-GROWTH; GENE; PROTEIN; FOS	Menin, the product of the MEN1 tumor suppressor gene, binds to the AP1 transcription factor JunD and represses JunD transcriptional activity. The effects of human or mouse JunD missense mutations upon menin interaction were studied by random and alanine scanning mutagenesis of the menin binding region of JunD (amino acids 1-70). JunD mutant proteins were tested for menin binding in a reverse yeast two-hybrid assay, and for transcriptional regulation by menin in AP1-reporter assays. Random mutagenesis identified two different mutations that disrupted menin interaction at mouse JunD amino acid 42 (G42E and G42R). Mutation G42A generated by alanine scanning did not affect menin binding, likely reflecting the conserved nature of this amino acid substitution. Furthermore, by size exclusion chromatography menin co-migrated with wild type JunD but not with the JunD mutant tested (G42E). Alanine scanning mutagenesis of residues 30-55 revealed two different amino acids, P41 and P44, of mouse JunD that mere critical for interaction with menin. Mouse JunD missense mutants P41A, G42R, G42E and P44A failed to bind menin and also escaped menin's control over their transcriptional activity. At lower amounts of transfected menin, the transcriptional effect of menin on the mutants P41A, G42R and G42E was changed from repression to activation, similar to that with c-jun, In conclusion, a small N-terminal region of JunD mediates a key difference between JunD and c-jun, and a component of this difference is dependent on JunD binding to menin.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Agarwal, SK (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Room 9C-101,10 Ctr Dr,MSC 1802, Bethesda, MD 20892 USA.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043310, ZIEDK043006, Z01DK043006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000062] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bartsch D, 1998, EUR J ENDOCRINOL, V139, P416, DOI 10.1530/eje.0.1390416; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; BERGER I, 1991, ONCOGENE, V6, P561; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hai N, 1999, EUR J ENDOCRINOL, V141, P475, DOI 10.1530/eje.0.1410475; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Marx S, 1998, GENETIC BASIS HUMAN, P489; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; METIVIER C, 1993, ONCOGENE, V8, P2311; Mutch MG, 1999, HUM MUTAT, V13, P175, DOI 10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Poncin J, 1999, HUM MUTAT, V13, P54, DOI 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; Thepot D, 2000, DEVELOPMENT, V127, P143; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	36	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4706	4712		10.1038/sj.onc.1203832	http://dx.doi.org/10.1038/sj.onc.1203832			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032020				2022-12-28	WOS:000089528800004
J	Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM				Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM			Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells	ONCOGENE			English	Article						apoptosis; tumor; growth inhibition	FACTOR-I RECEPTOR; BREAST-CANCER; EXPRESSION; APOPTOSIS; DIFFERENTIATION; IDENTIFICATION; INHIBITION; INDUCTION; LINES; RISK	Insulin-like growth factor binding proteins (IGFBPs) are secreted into the extra-cellular matrix and inhibit cell growth through IGF-dependent and -independent mechanisms. In this study, we investigated the role of IGFBP-6, a relatively unexplored member of the IGFBP family, in the proliferation of non-small cell lung cancer (NSCLC) cells. Infection of NSCLC cell lints in vitro with an adenovirus expressing human IGFBP-6 under the control of a CMV promoter (Ad5CMV-BP6) reduced NSCLC cell number through activation of programmed cell death, as shown by cell staining with Hoechst 33342 or DIVA end-labeling with bromodeoxyuridine triphosphate, The growth regulatory effect of IGFBP-6 was investigated in vivo by intratumoral injection of Ad5CMV-BP6 in NSCLC xenografts established in nu/nu mice. A single injection of Ad5CMV-BP6 reduced the size of NSCLC xenografts by 45%. These findings indicate that IGFBP-6 is a potent inducer of programmed cell death in cancer cells and support investigations into IGFBP-6 as a potential target in cancer therapeutics.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 80,1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [R29CA067353, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R29 CA67353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Dunn SE, 1998, CANCER RES, V58, P3353; Fang BL, 1997, ANAL BIOCHEM, V254, P139, DOI 10.1006/abio.1997.2417; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grellier P, 1998, CANCER RES, V58, P1670; Gucev ZS, 1996, CANCER RES, V56, P1545; HAVEMANN K, 1990, J STEROID BIOCHEM, V37, P877, DOI 10.1016/0960-0760(90)90436-O; Hongo A, 1998, CANCER RES, V58, P2477; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; HWANG CC, 1995, CANCER LETT, V94, P157, DOI 10.1016/0304-3835(95)03845-N; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Lee CT, 1996, CANCER RES, V56, P3038; Liu YM, 1998, CANCER RES, V58, P570; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Scotlandi K, 1998, CANCER RES, V58, P4127; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VAVERDE AM, 1998, MOL ENDOCRINOL, V12, P688; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151	31	63	70	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4432	4436		10.1038/sj.onc.1203813	http://dx.doi.org/10.1038/sj.onc.1203813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980619				2022-12-28	WOS:000089271900014
J	Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P				Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P			Gene replacement with the human BRCA1 locus: tissue specific expression and rescue of embryonic lethality in mice	ONCOGENE			English	Article						transgenic; BRCA1; tumor suppressor; gene transfer	OVARIAN-CANCER; BRCA1-DEFICIENT MICE; BREAST CARCINOMAS; MEIOTIC CELLS; DNA-REPAIR; MUTATIONS; P53; REGION; SUSCEPTIBILITY; METHYLATION	We have generated transgenic mice that harbor a 140 kb genomic fragment of the human BRCA1 locus (TgN.BRCA1(GEN)). We find that the transgene directs appropriate expression of human BRCA1 transcripts in multiple mouse tissues, and that human BRCA1 protein is expressed and stabilized following exposure to DIVA damage, Such mice are completely normal, with no overt signs of BRCA1 toxicity commonly observed when BRCA1 is expressed from heterologous promoters. Most importantly, however, the transgene rescues the otherwise lethal phenotype associated with the targeted hypomorphic allele (Brca1(Delta exIISA)). Brca1(-/-); TgN.BRCA1(GEN) bigenic animals develop normally and can be maintained as a distinct line. These results show that a 140 kb fragment of chromosome 17 contains all elements necessary for the correct expression, localization, and function of the BRCA1 protein, Further, the model provides evidence that function and regulation of the human BRCA1 gene can be studied and manipulated in a genetically tractable mammalian system.	Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Guys Hosp, Div Med & Mol Genet, GKT, Sch Med, London SE1 9RT, England; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Melbourne; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Lane, TF (corresponding author), Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave,27-139 CHS, Los Angeles, CA 90095 USA.		Brown, Melissa A/F-1451-2010	Lane, Timothy F./0000-0002-0210-970X; Brown, Melissa/0000-0002-2830-9259	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; *BIC, 1999, BREAST CANC INF COR; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN JJ, 1999, CANCER RES, V59, P1752; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WILSON CA, 1997, ONCOGENE, V9, P1; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	35	20	21	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4085	4090		10.1038/sj.onc.1203760	http://dx.doi.org/10.1038/sj.onc.1203760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962568				2022-12-28	WOS:000088955100001
J	Epinat, JC; Dvorin, EL; Gilmore, TD				Epinat, JC; Dvorin, EL; Gilmore, TD			Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells	ONCOGENE			English	Article						v-Rel; retroviral oncogene; transcription factor; malignant transformation; NF-kappa B; envelope sequences	VIRUS STRAIN-T; ONCOGENE; DOMAIN; ACTIVATION; SEQUENCES	The retroviral oncoprotein v-Rel is a chimeric protein that has 11 helper virus-derived Envelope (Env) amino acids (aa) at its N terminus. Within these N-terminal Env aa of v-Rel there are three aa substitutions compared to the Rev-A helper virus Env, These aa substitutions have previously been shown to impart a number of unique properties onto v-Rel, including increased transforming and transactivating ability. In this study, we have analysed the sequence requirements for the Env aa to influence several properties of v-Rel, Phe residues at aa 3 and 9 are critical for an N-terminal transactivation function of v-Rel, and the analysis of several Env mutants demonstrates that transactivation ability parallels the transforming ability of v-Rel, Substitutions of conservative aa, such as leucine and tyrosine, for Phe 3 and 9 are tolerated for transactivation in chicken embryo fibroblasts and for transformation of chicken spleen cells. In contrast, the substitution of 10 Phe residues at the N terminus of v-Rel does not enable transactivation, indicating that a distinct structure surrounding Phe-3 and Phe-9 is essential for v-Rel function. We also show that the addition of the v-Rel Env aa to the N terminus of human c-Rel can enable it to activate transcription. Taken together, these results indicate that Phe residues at positions 3 and 9 have been selected for their ability to enhance the oncogenicity of v-Rel by increasing its ability to activate transcription.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.			Dvorin, Evan/0000-0001-5037-2783	NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT GV, 1990, ONCOGENE, V5, P625; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEWALRAMANI VN, 1992, J VIROL, V66, P3026, DOI 10.1128/JVI.66.5.3026-3031.1992; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SMARDOVA J, 1995, ONCOGENE, V10, P2017; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	16	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3131	3137		10.1038/sj.onc.1203651	http://dx.doi.org/10.1038/sj.onc.1203651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918567				2022-12-28	WOS:000088019200001
J	Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS				Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS			Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays	ONCOGENE			English	Article						oral cancel; tumor progression; oncogenes; tumor suppressor genes; biomarkers	APOPTOSIS; DISEASE; CANCER	Although risk factors for squamous cell carcinomas of the head and neck (HNSCC) are well recognized, very little is known about the molecular mechanisms responsible for this malignancy. Furthermore, the ability to investigate gene expression profiles at different stages of tumor progression is usually limited by the remarkable heterogeneity of these neoplastic lesions. Here, we show the successful use of laser capture microdissection (LCM) to procure specific cell populations. The 5000 cells from representative sets of HNSCC and their matching normal tissues are sufficient to extract RNA of high integrity for the synthesis of labeled amplified cDNA probes which can then be hybridized to these membranes arrayed with known human cancer-related cDNAs. Furthermore, when compared to normal tissues, we demonstrate a consistent decrease in expression of differentiation markers such as cytokeratins, and an increase in the expression of a number of signal transducing and cell cycle regulatory molecules, as well as growth and angiogenic factors and tissue degrading proteases. Unexpectedly, we also found that most HNSCC overexpress members of the wnt and notch growth and differentiation regulatory system, thus suggesting that the,wnt and notch pathways mag contribute in squamous cell carcinogenesis. This experimental approach may facilitate the identification candidate markers for the early detection of preneoplastic lesions, as well as novel targets for pharmacological intervention in this disease.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Wayne State Univ, Div Hematol Oncol, Detroit, MI USA; Prince Songkla Univ, Fac Dent, Dept Oral Biol & Occlus, Hat Yai, Thailand	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wayne State University; Prince of Songkla University	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BARTKOVA J, 1995, CANCER RES, V55, P949; Desai SB, 1999, J IMMUNOTHER, V22, P186, DOI 10.1097/00002371-199905000-00002; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Granville DJ, 1998, LAB INVEST, V78, P893; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peterson LA, 1998, CANCER RES, V58, P5326; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	15	239	272	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3220	3224		10.1038/sj.onc.1203703	http://dx.doi.org/10.1038/sj.onc.1203703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918578				2022-12-28	WOS:000088019200012
J	Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P				Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P			Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1	ONCOGENE			English	Article						proteasome; cDNA microarray; gene expression; ATF3; GADD153; MAD1	PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; UBIQUITIN/PROTEASOME PATHWAY; DNA MICROARRAY; CANCER-CELLS; PROTEIN; STRESS; APOPTOSIS; GROWTH; MYC	The ubiquitin/proteasome pathway has been implicated in a wide variety of cellular processes and the number of substrates degraded by the proteasome is impressive. Most prominently, the stability of a large number of transcription factors is regulated by ubiquitination. To elucidate pathways regulated by the proteasome, gene expression profiles were generated, comparing changes of mRNA expression of 7900 genes from the UniGene collection upon exposure of cells to the proteasome inhibitors Lactacystin, Lactacystin-beta-lactone or MG132 by means of microarray based cDNA hybridization, The three profiles were very similar, but differed significantly from a gene expression profile generated with the histone deacetylase inhibitor Trapoxin A, indicating that the observed alterations were indeed due to proteasome inhibition, Two of the most prominently induced genes encoded the growth arrest and DNA damage inducible protein Gadd153 and the activating transcription factor ATF3, both transcription factors of the CCAAT/enhancer binding protein (C/EBP) family. ii third gene encoded for the transcriptional repressor and c-Myc antagonist Mad1. Our results suggest that proteasome inhibition leads to upregulation of specific members of transcription factor families controlling cellular stress response and proliferation.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis	Furst, P (corresponding author), Novartis Pharma AG, Oncol Res, WKL-125-13-14, CH-4002 Basel, Switzerland.							Adams J, 1999, CANCER RES, V59, P2615; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAI JPF, 1995, J PHARM PHARMACOL, V47, P674, DOI 10.1111/j.2042-7158.1995.tb05858.x; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bush KT, 1997, J BIOL CHEM, V272, P9086; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen CH, 1996, ONCOGENE, V13, P1659; Drexler HCA, 1998, APOPTOSIS, V3, P1, DOI 10.1023/A:1009604900979; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Goodbourn S, 1997, BIOCHEM SOC T, V25, P498, DOI 10.1042/bst0250498; Han S, 1999, ONCOL REP, V6, P569; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; ICHIHARA A, 1995, MOL BIOL REP, V21, P49, DOI 10.1007/BF00990970; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Machiels BM, 1997, CYTOMETRY, V28, P243; MASUMOTO M, 1996, FEBS LETT, V395, P143; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; *PE APPL BIOS, US B ABI PRISM 7700, V2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang X, 1998, J IMMUNOL, V160, P788; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wolfe B, 1997, ISSUES SCI TECHNOL, V13, P17; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2913	2920		10.1038/sj.onc.1203606	http://dx.doi.org/10.1038/sj.onc.1203606			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871842				2022-12-28	WOS:000087544500005
J	Brandvold, KA; Neiman, P; Ruddell, A				Brandvold, KA; Neiman, P; Ruddell, A			Angiogenesis is an early event in the generation of myc-induced lymphomas	ONCOGENE			English	Article						angiogenesis; lymphoma; c-myc; v-myc oncogene; avian retrovirus	NON-HODGKINS-LYMPHOMAS; C-MYC; TUMOR ANGIOGENESIS; CELL; VIRUS; FABRICIUS; BURSA; GENE; IDENTIFICATION; TRANSFORMATION	Angiogenesis was identified as an early consequence of myc gene overexpression in two models of retroviral lymphomagenesis. Avian leukosis virus (ALV) induces bursal lymphoma in chickens after proviral c-myc gene integration, while the HB-1 retrovirus carries a v-myc oncogene and also induces metastatic lymphoma. Immunohistochemical studies of the effects of increased c-myc or v-myc overexpression revealed early angiogenesis within myc-transformed bursal follicles, which persisted in lymphomas and metastases. Abnormal vessel growth was consistently detected within 13 days after transplantation of a few myc-overexpressing progenitors into ablated bursal follicles, suggesting that these angiogenic changes may support the initial expansion of tumor precursors, as well as later stage lymphomagenesis, Conditioned media from myc-overexpressing B cell lines promoted proliferation of vascular endothelium in vitro, while media from B cells expressing low myc levels showed little effect. Moreover, ectopic myc overexpression in the low myc B cell lines increased production of the endothelial growth activity, indicating that myc induces secretion of angiogenic factors from B cells. These findings demonstrate that myc overexpression in lymphocytes generates an angiogenic phenotype in vitro as well as in vivo.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISTER K, 1983, J VIROL, V46, P337, DOI 10.1128/JVI.46.2.337-346.1983; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1989, VIROLOGY, V170, P433, DOI 10.1016/0042-6822(89)90434-0; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; Ribatti D, 1998, BRIT J CANCER, V77, P1900, DOI 10.1038/bjc.1998.316; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vacca A, 1998, INT J CLIN LAB RES, V28, P55, DOI 10.1007/s005990050018	26	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2780	2785		10.1038/sj.onc.1203589	http://dx.doi.org/10.1038/sj.onc.1203589			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851079				2022-12-28	WOS:000087318500007
J	Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A				Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A			Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage	ONCOGENE			English	Article						p53; KAI1; p53-transcriptional target; DNA damage	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; CELLULAR-RESPONSE; BINDING FUNCTION; CANCER; GROWTH; EXPRESSION; PROTEIN; IDENTIFICATION; PROGRESSION	The p53 tumor suppressor protein functions to monitor the integrity of the genome. If a damage is detected, p53 binds tightly to specific sequence elements in the DNA and induces the transactivation of genes involved in various growth regulatory processes such as cell cycle progression, DNA repair and apoptosis, A p53-binding site was recently identified in the promoter region of the metastatic suppressor KAI1 gene, suggesting that this gene was a direct transcriptional target of p53. To test the relevance of this hypothesis, we studied the endogenous KAI1 expression in a series of human cell lines with varying p53 status in response to genotoxic treatment as well as in different cellular models exhibiting an inducible p53 activity. Overall, our data indicate that KAI1 expression is not significantly modulated by p53. This observation provides a direct evidence that the presence of a p53-binding site in regulatory domains is not a sufficient criteria to define a p53-transcriptional target gene.	INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Puisieux, A (corresponding author), INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, 28 Rue Laennec, F-69008 Lyon, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; PUISIEUX, Alain/0000-0002-9938-3798				Adachi M, 1996, CANCER RES, V56, P1751; Bacus SS, 1996, ONCOGENE, V12, P2535; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Guillot C, 1996, CLIN CANCER RES, V2, P1439; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Guo XZ, 1996, CANCER RES, V56, P4876; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	22	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2461	2464		10.1038/sj.onc.1203580	http://dx.doi.org/10.1038/sj.onc.1203580			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828889				2022-12-28	WOS:000087018400012
J	Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B				Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B			Regulation of CDC25B phosphatases subcellular localization	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinases; CDC25B; localization; nuclear export sequence	NUCLEAR EXPORT; FISSION YEAST; TRANSCRIPTION FACTOR; MITOTIC INDUCER; PROTEIN-KINASE; CDK REGULATION; DNA-DAMAGE; MITOSIS; SIGNAL; TRIGGERS	The CDC25B dual specificity phosphatase is involved in the control of the G2/M transition of the cell cycle. Subcellular localization might represent an important aspect of the regulation of its activity, We have examined in transiently transfected asynchronous HeLa cells the localization of HA-tagged CDC25B proteins and found that they are nuclear or cytoplasmic suggesting the existence of an active shuttling. Accordingly, localization analysis of deletion and truncation proteins indicates that CDC25B contains a putative nuclear localization signal located between residues 335 and 353. We also demonstrated that a short 58 residues deletion of the amino-terminus end of CDC25B is sufficient to retain it to the nucleus, Mutational analysis indicates that a nuclear export sequence is located between residues 28 and 40. In addition, treatment of the cells with the exportin inhibitor, Leptomycin B, has the same effect, The mutation of Ser-323, a residue that is essential for the interaction with 14-3-3 proteins, also abolishes cytoplasmic staining. The subcellular localization of CDC25B is therefore dependent on the combined effects of a nuclear localization signal, a nuclear export signal and on the interaction with 14-3-3 proteins.	Univ Toulouse 3, LBCMCP, CNRS UMR5088, F-31062 Toulouse, France; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Tokyo	Ducommun, B (corresponding author), Univ Toulouse 3, LBCMCP, CNRS UMR5088, 118 Route Narbonne, F-31062 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; Forrest, Alistair/A-6597-2008; BALDIN, Véronique/Y-8397-2019; Gabrielli, Brian G/B-3655-2011	Forrest, Alistair/0000-0003-4543-1675; BALDIN, Véronique/0000-0001-8523-0494; Gabrielli, Brian G/0000-0003-3933-1651; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	31	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2179	2185		10.1038/sj.onc.1203545	http://dx.doi.org/10.1038/sj.onc.1203545			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822367				2022-12-28	WOS:000086974100002
J	Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T				Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T			Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src	ONCOGENE			English	Article						ADAM/MDC family; meltrin alpha/ADAM12; SH3 domain; Src family; Grb2/Ash; tyrosine phosphorylation	NECROSIS-FACTOR-ALPHA; ROUS-SARCOMA VIRUS; METALLOPROTEASE-DISINTEGRIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INTRACELLULAR MATURATION; HOMOLOGY-3 DOMAINS; CELL-ADHESION; MOUSE EMBRYO; PROTEIN	Meltrin alpha /ADAM12 is a member of the ADAM/MDC family proteins characterized by the presence of metalloprotease and disintegrin domains. This protein also contains a single transmembrane domain and a relatively long cytoplasmic domain containing several proline-rich sequences. These sequences are compatible with the consensus sequences for binding the Src homology 3 (SH3) domains. To determine whether the proline-rich sequences interact with SH3 domains in several proteins, binding of recombinant SH3 domains to the meltrin alpha cytoplasmic domain was analysed by pull-down assays. The SH3 domains of Src and Yes bound strongly, but that of Abl or phosphatidylinositol 3-kinase p85 subunit did not. Full-length Grb2/Ash bound strongly, whereas its N-terminal SH3 domain alone did less strongly. Src and Grb2 in bovine brain extracts also bound to meltrin alpha cytoplasmic domain on affinity resin, Furthermore, immunoprecipitation with alpha monoclonal antibody to meltrin alpha resulted in coprecipitation of Src and Grb2 with meltrin alpha in cell extracts, suggesting that Src and Grb2 are associated in vivo with meltrin alpha cytoplasmic domain. This notion was also supported by the findings that exogenously expressed meltrin cytoplasmic domain coexisted with Src and Grb2 on the membrane ruffles. The C-terminal Tyr901 of meltrin alpha was phosphorylated both initio and in cultured cells by v-Src. These results may imply that meltrin alpha cytoplasmic domain is involved in a signal transduction for some biological function through the interaction with SH3-containing proteins.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan	Chiba University; University of Tokyo	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022					ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTER N, 1997, CURRENT PROTOCOLS PR; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P321, DOI 10.1093/oxfordjournals.jbchem.a123899; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; Endo T, 1998, J CELL SCI, V111, P1081; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MIKI H, 1994, J BIOL CHEM, V269, P5489; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 1999, J CELL SCI, V112, P579; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	61	46	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5842	5850		10.1038/sj.onc.1203986	http://dx.doi.org/10.1038/sj.onc.1203986			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127814				2022-12-28	WOS:000165563100002
J	Foos, G; Hauser, CA				Foos, G; Hauser, CA			Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness	ONCOGENE			English	Article						prostate cancer; Ets2 overexpression; dominant negative Ets2; transformation	MEDIATED CELLULAR-TRANSFORMATION; COLON-CANCER CELLS; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; CARCINOMA CELLS; RAS; ACTIVATION; PROTEIN; LINES	The Ets family of transcription factors are important downstream targets in cellular transformation, as altering Ets activity has been found to reverse the transformed phenotype of Ras transformed mouse fibroblasts and of several human tumor cell lines. To determine whether Ets factors are important targets in the largely uncharacterized aberrant signaling in prostate cancer, we have altered Ets activity in the prostate tumor cell line PPC-1, by stable expression of either full-length Ets2, or a dominant inhibitor of Ets activity, the Ets2 DNA binding domain (Ets2DBD). Analysis of multiple independent clonal cell lines revealed that expression of either Ets2 or the Ets2DBD inhibited the anchorage-independent growth of PPC-1 cells up to 20-fold. In contrast to our previous findings with Ras-transformed NIH3T3 cells, PPC-1 cell lines expressing either Ets2 or the EtsDBD exhibited slower attached cell growth, increased Ets-dependent gene expression, and up to a 10-fold increase in apoptotic cell death. The p21(cip) gene was identified as a potential target of altered Ets signaling. Interestingly, the two distinct Ets2 constructs had strikingly different effects on in vitro invasiveness. Expression of the Ets2DBD almost completely blocked PPC-1 cell invasion through Matrigel, whereas overexpression of full-length Ets2 did not inhibit invasion. Overall, these results demonstrate that the balance of Ets factor activity can regulate multiple aspects of the transformed phenotype of PPC-1 prostate tumor cells, including anchorage-independent growth, survival, and invasiveness.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Hauser, CA (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA063130, R01CA074547] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130, CA74547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BORNER MM, 1995, CANCER RES, V55, P2122; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHEN TR, 1993, CYTOGENET CELL GENET, V62, P183, DOI 10.1159/000133468; Chen ZQ, 1997, CANCER RES, V57, P2013; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; HUNCHAREK M, 1995, CANCER EPIDEM BIOMAR, V4, P681; Konishi N, 1997, PROSTATE, V30, P53; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Rees S, 1996, BIOTECHNIQUES, V20, P102; Royai R, 1996, SEMIN ONCOL, V23, P35; Sapi E, 1998, CANCER RES, V58, P1027; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Shi XB, 1996, WORLD J UROL, V14, P318, DOI 10.1007/BF00184605; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Webber MM, 1997, PROSTATE, V30, P58; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673	47	32	33	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5507	5516		10.1038/sj.onc.1203946	http://dx.doi.org/10.1038/sj.onc.1203946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114728				2022-12-28	WOS:000165396100011
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			An alternatively spliced isoform of B-Myb is a transcriptional inhibitor	ONCOGENE			English	Article						B-myb; cyclin; transactivation; cycle	CELL-CYCLE REGULATION; C-MYB; V-MYB; A-MYB; MESSENGER-RNA; PROTEIN TRUNCATION; MIM-1 GENE; S-PHASE; ACTIVATION; EXPRESSION	B-Myb is a highly conserved member of the Myb transcription factor family. The primary transcript of the B-myb gene is spliced alternatively in two mRNAs which either contain or lack a sequence corresponding to the so-called exon 9A of c-myb, Recent studies showed that full-length B-Myb containing the exon 9A encoded amino acids is a cell cycle regulated transcription factor whose activity is stimulated by cyclin A/Cdk 2-dependent phosphorylation at the carboxyl-terminus of B-Myb. We have now investigated in more detail the transactivation potential of the shorter isoform of B-Myb lacking exon 9A, Here, we show that B-Myb lacking exon 9A has no transactivation activity even in the presence of cyclin A. This inactivity of the shorter isoform of B-Myb is not due an improper subcelluar localization, Our work suggests that B-Myb lacking exon 9A may act as an inhibitor for full-length B-Myb mediated transactivation, Furthermore, by analysing the transactivation potential of Gal4/B-Myb fusion proteins we have identified the amino-terminal part of the exon 9A as the principal transactivation domain of full-length B-Myb, The results presented here demonstrate that B-myb encodes both an activator and an inhibitor of transcription and, thus, reveal an additional level of regulation of B-Myb activity beside the known cyclin dependent mechanisms.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland	University of Munster; Novartis	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Ferrari, Stefano/I-7357-2016; Buchinger, Sebastian/M-3003-2013	Ferrari, Stefano/0000-0002-6607-215X; Buchinger, Sebastian/0000-0003-4859-8972				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU YL, 1991, ONCOGENE, V6, P1549; Kamano H, 1995, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; METTUS RV, 1994, ONCOGENE, V9, P3077; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Robinson C, 1996, ONCOGENE, V12, P1855; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	50	9	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5428	5434		10.1038/sj.onc.1203937	http://dx.doi.org/10.1038/sj.onc.1203937			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114719				2022-12-28	WOS:000165396100002
J	Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R				Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R			Induction of p21(WAF1/CIP1) and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling	ONCOGENE			English	Article						cell cycle control; Src oncoprotein; STAT3; cyclin D1; p21; WAF1/CIP1	DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH-FACTOR; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; V-SRC; CDK INHIBITORS; CELLULAR-TRANSFORMATION; POTENTIAL MEDIATOR	While the activated viral Src oncoprotein, v-Src, induces uncontrolled cell growth, the mechanisms underlying cell cycle deregulation by v-Src have not been fully defined. Previous studies demonstrated that v-Src induces constitutively active STAT3 signaling that is required for cell transformation and recent data have implicated STAT3 in the transcriptional control of critical cell cycle regulators. Here we show in mouse fibroblasts stably transformed by v-Src that mRNA and protein levels of p21 (WAF1/CIP1), cyclin D1, and cyclin E are elevated. Using reporter constructs in transient-transfection assays, the cyclin D1 and p21 promoters were both found to be transcriptionaly induced by v-Src in a STAT3-dependent manner. The kinase activities of cyclin D/CDK4, 6 and cyclin E/CDK2 complexes were only slightly elevated, consistent with the findings that coordinate increases in p21, cyclin D1 and cyclin E resulted in an increase in cyclin/CDK/p21 complexes. Similar results were obtained in NTH3T3 and BALB/c 3T3 cells stably transformed by v-Src, indicating that these regulatory events associated with STAT3 signaling represent common mechanisms independent of cell line or clonal variation. These findings suggest that STAT3 has an essential role in the regulation of critical cell cycle components in v-Src transformed mouse fibroblasts.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Besser D, 1999, MOL CELL BIOL, V19, P1401; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; Frank DA, 1999, MOL MED, V5, P432; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Geng Y, 1996, ONCOGENE, V12, P1173; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lonardo F, 1999, CANCER RES, V59, P2470; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	72	255	276	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5419	5427		10.1038/sj.onc.1203947	http://dx.doi.org/10.1038/sj.onc.1203947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114718				2022-12-28	WOS:000165396100001
J	Hirst, SK; Grandori, C				Hirst, SK; Grandori, C			Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts	ONCOGENE			English	Article						Myc-ER; Myc-S; WI38; human fibroblasts; cell-cycle; apoptosis; Myc target genes	C-MYC; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; TARGET GENES; CELL-GROWTH; IN-VIVO; MAX; APOPTOSIS; PROTEINS; TRANSFORMATION	We have explored the effects of the conditional MYC-estrogen receptor fusion protein, MYC-ERT(TM), in human mortal fibroblasts, WI38, on cell-cycle entry, apoptosis and gene expression, The results indicate that activation of MYC-ER(TM) in WI38 cells is sufficient to cause S phase entry of quiescent cells, which is preceded by phosphorylation of Rb and activation of the Cdk2-associated kinase, We also analysed the MYC protein variant, MYC-S, which lacks part of the transcriptional activation domain but includes the conserved MYC box II and 26 amino acids N-terminal to it, MYC-S was previously shown to promote proliferation and apoptosis of immortalized rodent cell lines, The results indicate that MYC-S has undetectable activity as an inducer of S phase or apoptosis of quiescent WI38 cells. However, Myc-S stimulates proliferation of WI38 cells in the presence of 10% fetal calf serum, Surprisingly, we found that MYC-S, previously considered solely a repressor of specific reporter genes, is instead a weak transactivator of endogenous target genes both in mortal and immortalized cells. In addition, MYC-S exhibit a weak repressor activity upon an endogenous target gene only in immortalized cells, MYC-S transcriptional properties suggest that MYC box II and the adjacent N-terminal amino acids, while not sufficient for full repression function, participate in transactivation of endogenous target genes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Grandori, C (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.				NCI NIH HHS [CA75125, CA20525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R29CA075125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Eilers M, 1999, MOL CELLS, V9, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1995, ONCOGENE, V11, P635; RABINOVITCH PS, 1994, METHOD CELL BIOL, V41, P263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5189	5197		10.1038/sj.onc.1203904	http://dx.doi.org/10.1038/sj.onc.1203904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064456				2022-12-28	WOS:000090124100008
J	Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B				Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B			The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades	ONCOGENE			English	Article						docking; phosphorylation; Ras; transcription; repression; export	ACTIVATED PROTEIN-KINASES; TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; C-JUN; TRANSDUCTION PATHWAY; SIGNALING SPECIFICITY; UV-LIGHT; HA-RAS; DOMAIN; JNK	The ternary complex factors (TCFs), Elk-1, Sap-1a and Net, are key integrators of the transcriptional response to different signalling pathways. Classically, three MAP kinase pathways, involving ERK, JNK, and p38, transduce various extracellular stimuli to the nucleus. Net is a repressor that is converted into an activator by Ras/ERK signalling. Net is also exported from the nucleus in response to stress stimuli transduced through the JNK pathway, leading to relief from repression. Here we show that ERK and p38 bind to the D box and that binding is required for phosphorylation of the adjacent C-terminally located C-domain, The D box as web as the phosphorylation sites in the C-domain (the DC element) are required for transcription activation by Pas. On the other hand, JNK binds to the J box in the middle of the protein, and binding is required for phosphorylation of the adjacent EXport motif. Both the binding and phosphorylation sites (the JEX element) are important for Net export. In conclusion, specific targeting of Net by MAP kinase pathways involves two different docking sites and phosphorylation of two different domains. These two elements, DC and JEX, mediate two distinct functional responses.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ducret C, 1999, MOL CELL BIOL, V19, P7076; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	46	49	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5063	5072		10.1038/sj.onc.1203892	http://dx.doi.org/10.1038/sj.onc.1203892			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042694				2022-12-28	WOS:000089930100003
J	Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V				Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V			Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation	ONCOGENE			English	Article						prolactin; prolactin receptor; breast cancer; antagonist; signaling; proliferation	GROWTH-HORMONE RECEPTOR; PROTEIN-KINASE-C; CARCINOMA CELLS; EXPRESSION; BINDING; GENE; INDUCTION; APOPTOSIS; FAMILY; STAT3	The involvement of human prolactin (hPRL) in breast cancer has been recently reconsidered based on its autocrine/paracrine proliferative effect described in human mammary tumor epithelial cells. Therefore, there is growing interest in the development of potent hPRL antagonists that may inhibit this effect. We previously designed hPRL analogs displaying antagonistic properties in a human transcriptional bioassay. We now report that the most potent of those analogs, G129R-hPRL, antagonizes all hPRL-induced effects analysed in various breast cancer cell lines, including cell proliferation. The analog per sc lacks intrinsic agonistic activity on PRL receptor-activated signaling cascades, cell proliferation and apoptosis, indicating that its mode of action only occurs through competitive inhibition of hPRL. We provide some molecular basis of this antagonistic effect by demonstrating that G129R-hPRL competitively inhibits hPRL-activation of the JAK-STAT and MAPK pathways, two signaling cascades involved in the mitogenic effect of hPRL in mammary epithelial cells. This competitive inhibition persists for at least 48 h, as evidenced by long term analysis of STAT5b activation or of progression through cell cycle. These results are the first demonstration at the molecular level that hPRL antagonists interfering with receptor dimerization disrupt signaling events in breast cancer cells, which prevents hPRL-induced cell proliferation.	Fac Med Necker Enfants Malad, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Goffin, V (corresponding author), Fac Med Necker Enfants Malad, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		Llovera, Marta/AAE-4230-2021; Llovera, Marta/B-5585-2009; GOFFIN, Vincent/G-3322-2013; Kelly, Paul/A-7951-2008	Llovera, Marta/0000-0001-8399-6867; GOFFIN, Vincent/0000-0002-8021-3086; JEAY, SEBASTIEN/0000-0001-7476-3340				BANERJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61, DOI 10.1016/0303-7207(92)90102-C; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GORDON KE, 2000, BREAST CANCER RES, V2, P1; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1999, J BIOL CHEM, V274, P26033, DOI 10.1074/jbc.274.37.26033; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Schaber JD, 1998, CANCER RES, V58, P1914; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; WATERS SB, 1989, MOL CELL ENDOCRINOL, V63, P159, DOI 10.1016/0303-7207(89)90092-0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	85	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4695	4705		10.1038/sj.onc.1203846	http://dx.doi.org/10.1038/sj.onc.1203846			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032019				2022-12-28	WOS:000089528800003
J	Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD				Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD			Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways	ONCOGENE			English	Article						Rit; Ras; signaling; transformation; lipid modification; farnesyltransferase	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; R-RAS; CELLULAR-TRANSFORMATION; FARNESYLTRANSFERASE INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; INDEPENDENT PATHWAYS; SIGNALING PATHWAYS; BIOLOGICAL ASSAYS	The biological functions of Rit (Ras-like protein in tissues) and Rin (Ras-like protein in neurons), members of a novel branch of Ras-related GTP-binding proteins that are similar to 50% identical to Ras, have not been characterized. Therefore, we assessed their activity in growth control, transformation and signaling. NM cells stably expressing a constitutively activated mutant of Rit [Rit(79L)] (analogous to the oncogenic mutant H-Ras(61L)) demonstrated strong growth transformation, proliferating rapidly in low serum and forming colonies in soft agar and tumors in nude mice. Although Rit(79L) alone did not promote morphologically transformed foci, it cooperated with both Raf and RhoA to form Rac/Rho-like foci, Rin [Rin(78L)] cooperated only with Raf, Rit(79L) but not Rin(78L) stimulated transcription from luciferase reporter constructs regulated by SRF, NF-kappa B, Elk-l and Jun. However, neither activated ERK, JNK or p38, or PI3-K/Akt kinases in immune complex kinase assays. Interestingly, although Rit lacks any known recognition signal for C-terminal lipidation, Rit-transformed cell growth and survival in low serum is dependent on a farnesylated protein, as treatment with farnesyltransferase inhibitors caused apoptosis, Rin cooperated with Raf in focus assays but did not otherwise function in these assays, perhaps due to a lack of appropriate effector pathways in NIH3T3 fibroblasts for this neural-specific Ras family member. In summary, although Rit shares most core effector domain residues with Ras, our results suggest that Rit uses novel effector pathways to regulate proliferation and transformation.	Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; Jefferson University	Cox, AD (corresponding author), Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.			Chan, Tung/0000-0001-6574-9555; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA67771, CA70692] Funding Source: Medline; NEI NIH HHS [EY11231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Du W, 1999, CANCER RES, V59, P4208; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIRODALISI JJ, 2000, IN PRESS METHODS ENZ, V332; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Osada M, 1999, MOL CELL BIOL, V19, P6333; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAEZ R, 1994, ONCOGENE, V9, P2977; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YEN A, 1994, EUR J CELL BIOL, V65, P103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	60	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4685	4694		10.1038/sj.onc.1203836	http://dx.doi.org/10.1038/sj.onc.1203836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032018				2022-12-28	WOS:000089528800002
J	Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L				Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L			Activation of the NF-kappa B pathway by Caspase 8 and its homologs	ONCOGENE			English	Article						NF-kappa B; caspase; FADD; death effector domain; MRIT; cFLIP	DOMAIN-CONTAINING PROTEIN; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; INDUCED APOPTOSIS; CD95 FAS/APO-1; KINASE-ALPHA; TNF; FADD; INTERACTS; INDUCTION	Caspase 8 is the most proximal caspase in the caspase cascade and has been known for its role in the mediation of cell death by various death receptors belonging to the TNFR family. We have discovered that Caspase 8 can activate the NF-kappa B pathway independent of its activity as a pro-apoptotic protease, This property is localized to its N-terminal prodomain, which contains two homologous death effector domains (DEDs). Caspase 10 and MRIT, two DEDs-containing homologs of Caspase 8, can similarly activate the NF-kappa B pathway. Dominantnegative mutants of the Caspase 8 prodomain can block NF-kappa B induced by Caspase 8, FADD and several death receptors belonging to the TNFR family. Caspase 8 can interact with multiple proteins known to be involved in the activation of the NF-kappa B pathway, including the serine-threonine kinases RIP, NIK, IKK1 and IKK2, Thus, DEDs-containing caspases and caspase homolog(s) may have functions beyond their known role in the mediation of cell death.	UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	188	200	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4451	4460		10.1038/sj.onc.1203812	http://dx.doi.org/10.1038/sj.onc.1203812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002417				2022-12-28	WOS:000089236800001
J	Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY				Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY			Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3 '-kinase/Akt signal transduction pathway	ONCOGENE			English	Article						angiopoietin-2; endothelial cells; apoptosis; PI 3 '-kinase; Akt	TIE2 RECEPTOR; ANGIOGENESIS; EXPRESSION; GROWTH; PHOSPHORYLATION; MECHANISMS; LIGANDS; CLONING; HYPOXIA; VEGF	The angiopoietin-Tie2 system in endothelial cells is an important regulator of vasculogenesis and vascular integrity, High levels of angiopoietin-2 (Ang2) mRNA are observed in vascular activation during tumorigenesis. Although Ang2 is known to be a naturally occurring antagonist of angiopoietin-1 (Ang1) in vivo, the exact function of Ang2 itself is not known. Here, we found that a high concentration of Ang2 (800 ng/ml) acts as an apoptosis survival factor for endothelial cells during serum deprivation apoptosis, The survival effect of high concentration Ang2 was blocked by pre-treatment with soluble Tie2 receptor and the PI 3'-kinase-specific inhibitors, wortmannin and LY294002. Accordingly, 800 ng/ml of Ang2 induced phosphorylation of Tie2, the p85 subunit of phosphatidylinositol 3'-kinase (PI 3'-kinase), and serine-threonine kinase Akt at Ser473 in the human umbilical vein endothelial cells; lower concentrations of Ang2 (50-400 ng/ml) did not produce notable effects. These findings indicate that at high concentrations, Ang2, like Ang1, can be an apoptosis survival factor for endothelial cells through the activation of the Tie2 receptor, PI 3'-kinase and Akt, and thus may be a positive regulator of tumor angiogenesis.	Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Cardiovasc Res Inst, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Dept Biomed Engn, Chonju 560180, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Koh, GY (corresponding author), Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20, Chonju 560180, South Korea.		Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011	Kim, Injune/0000-0001-9244-815X				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dunk C, 2000, AM J PATHOL, V156, P2185, DOI 10.1016/S0002-9440(10)65089-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	28	255	270	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4549	4552		10.1038/sj.onc.1203800	http://dx.doi.org/10.1038/sj.onc.1203800			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002428				2022-12-28	WOS:000089236800012
J	Shao, ZM; Nguyen, M; Barsky, SH				Shao, ZM; Nguyen, M; Barsky, SH			Human breast carcinoma desmoplasia is PDGF initiated	ONCOGENE			English	Article						PDGF; desmoplasia; breast carcinoma; paracrine growth factors; dominant-negative mutants; c-ras(H)	GROWTH-FACTOR-II; DOMINANT-NEGATIVE MUTANTS; MESSENGER-RNA EXPRESSION; MCF-7 CELLS; TUMOR-GROWTH; NUDE-MICE; IN-VIVO; CANCER; RECEPTOR; GENE	The desmoplastic response to human breast carcinoma is a host myofibroblast-mediated collagenous response exhibiting synergistic effects on tumor progression. Although many paracrine interactions between breast carcinoma cells and myofibroblasts have been characterized, the event(s) which initiate desmoplasia have remained undefined. Our studies utilized c-ras(H) transfected MCF-7 cells which overexpress ras p21 and which are weakly tumorigenic in ovariectomized nude mice. The xenografts are desmoplastic and comprised of 30% myofibroblasts and 60 mg/g of interstitial collagen. III sits hybridization studies of these xenografts reveal a stromal gene expression pattern (stromelysin-3, IGF-II and TIMP-1) identical to that observed in human tumor desmoplasia. 17-beta estradiol increases c-ras(H) MCF-7 growth but abolishes desmoplasia. c-ras(H) MCF-7 in vitro constitutively produce myofibroblast mitogenic activity which competes with PDGF in a receptor binding assay. This myofibroblast mitogenic activity is unaltered by 17-beta estradiol/tamoxifen pretreatment irt vitro. Transfection of c-ras(H) MCF-7,vith a PDGF-A dominant negative mutant, 1308, produced by site-directed mutagenesis (serine -->cystcine(129)) reduces both homo- and heterodimer secretion of PDGF by as much as 90% but does not interfere with the secretion of other growth factors. Clones with low PDGF, though tumorigenic, are nondesmoplastic. Our results suggest that breast carcinoma-secreted PDGF is the major initiator of tumor desmoplasia.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.				NCI NIH HHS [CA01351, CA40225, CA71195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R01CA040225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BARSKY SH, 1987, CANCER RES, V47, P1663; BARSKY SH, 1987, BIOCHEM BIOPH RES CO, V149, P1125, DOI 10.1016/0006-291X(87)90525-0; BARSKY SH, 1984, AM J PATHOL, V115, P329; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CULLEN KJ, 1991, CANCER RES, V51, P4978; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1981, J NATL CANCER I, V67, P335; DVORAK HF, 1981, SCIENCE, V212, P923, DOI 10.1126/science.7195067; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; LIEUBEAU B, 1994, CANCER RES, V54, P6526; MALIK R, 1991, CANCER RES, V51, P5626; MANNI A, 1994, CANCER RES, V54, P2934; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; MIURA M, 1994, CANCER RES, V54, P2472; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAUNDORF H, 1992, J CANCER RES CLIN, V119, P35, DOI 10.1007/BF01209485; NOGUCHI M, 1993, MOL CELL ENDOCRINOL, V92, P69, DOI 10.1016/0303-7207(93)90076-V; O'Connell JT, 1998, HUM PATHOL, V29, P1517, DOI 10.1016/S0046-8177(98)90024-7; OSBORNE CK, 1990, BREAST CANCER RES TR, V15, P3, DOI 10.1007/BF01811884; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PERES R, 1987, CANCER RES, V47, P3425; Povlsen C O, 1980, Antibiot Chemother (1971), V28, P15; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SINGER C, 1995, CANCER RES, V55, P2448; SOMMERS CL, 1990, CANCER RES, V50, P67; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tomlinson J, 1999, CLIN CANCER RES, V5, P3516; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	40	178	182	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4337	4345		10.1038/sj.onc.1203785	http://dx.doi.org/10.1038/sj.onc.1203785			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980609	Bronze			2022-12-28	WOS:000089271900004
J	Corvi, R; Berger, N; Balczon, R; Romeo, G				Corvi, R; Berger, N; Balczon, R; Romeo, G			RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma	ONCOGENE			English	Article						RET rearrangement; oncogene; PTC; interphase FISH; RET; PCM-1; fusion gene	TYROSINE KINASE; ONCOGENE REARRANGEMENTS; RET PROTOONCOGENE; AUTOANTIGEN; CENTROSOME; ACTIVATION; CHERNOBYL; DELETION; CHILDREN; CHROMOSOME-10	The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10:17 translocation. We previously developed a dual-color FISH test to detect these RET rearrangements in interphase nuclei of thyroid lesions. This approach allowed us to detect a novel translocation involving the RET region, which was not detectable by RT-PCR with specific primers for known rearrangements. A combination of RT-PCR and RACE analyses finally led to the identification of the fusion gene, which involves the 5' portion of PCM-I, a gene coding for a centrosomal protein with distinct cell cycle distribution, and the RET tyrosine kinase (TK) domain. FISH analysis confirmed the chromosomal localization of PCM-I on chromosome 8p21-22, a region commonly deleted in several tumors. Immunohistochemistry, using an antibody specific for the C-terminal portion of PCM-1 showed that the protein level is drastically decreased and its subcellular localization is altered in thyroid tumor tissue with respect to normal thyroid. However, heterozygosity is retained for seven microsatellite markers in the 8p21-22 region, suggesting that the nonrearranged PCM-1 allele is not lost and that the translocation is balanced.	Int Agcy Res Canc, F-69372 Lyon, France; Hop Antiquaille Lyon, Clin Endocrinol, F-69005 Lyon, France; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; University of South Alabama	Corvi, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Balczon R, 1999, CELL MOTIL CYTOSKEL, V42, P60, DOI 10.1002/(SICI)1097-0169(1999)42:1<60::AID-CM6>3.0.CO;2-7; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Bao LM, 1998, MOL BIOL REP, V25, P111, DOI 10.1023/A:1006814217037; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Chinen K, 1996, CYTOGENET CELL GENET, V75, P190, DOI 10.1159/000134480; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EMI M, 1992, CANCER RES, V52, P5368; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, CANCER RES, V58, P198; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; OHATA H, 1994, GENOMICS, V24, P404, DOI 10.1006/geno.1994.1640; PASINI B, 1995, ONCOGENE, V11, P1737; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Scarpato R, 1997, CYTOGENET CELL GENET, V79, P153, DOI 10.1159/000134708; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tallini G, 1998, CLIN CANCER RES, V4, P287; Tong Q, 1997, J BIOL CHEM, V272, P9043	33	66	84	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4236	4242		10.1038/sj.onc.1203772	http://dx.doi.org/10.1038/sj.onc.1203772			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980597				2022-12-28	WOS:000089032900006
J	Fitzgerald, K; Harrington, A; Leder, P				Fitzgerald, K; Harrington, A; Leder, P			Ras pathway signals are required for notch-mediated oncogenesis	ONCOGENE			English	Article						Notch; Ras; transformation; compound; inhibition	PROTEIN-KINASE-C; DEVELOPING DROSOPHILA EYE; BREAST-CANCER; NEOPLASTIC TRANSFORMATION; SELECTIVE INHIBITOR; IN-VIVO; EXPRESSION; MAMMARY; ELEGANS; TRANSDUCTION	The Notch genes of C, elegans, Drosophila melanogaster and vertebrates encode receptors responsible for cell fate decisions during development. These Notch receptors and their ligands, Delta and Jagged, have been implicated in several human diseases. Truncated, constitutively active mutant forms of the Notch receptor appear to be involved in human T-cell leukemia, mammary carcinomas in mice, and a tumorous germline phenotype in C, elegans. Since activated Notch induces solitary tumors in transgenic mice, it is highly likely that collaborating genetic events are required for tumor formation, We have assessed four signal transduction pathways to determine which might play additional roles in malignant transformation in concert with activated Notch4. Our results suggest that transformation by Notch does not, as might have been expected, depend on the Src-like kinases Lck and Fyn, nor upon signals from protein kinase A and C (PKA, PKC). Rather, transformation by Notch requires active signals from the Erk/MAP kinase and PI-3 kinase pathways downstream of Ras.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Davidson N E, 1996, Cancer Treat Res, V83, P91; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENNIPMAN A, 1989, CANCER RES, V49, P516; JACOBS C, 1983, CANCER RES, V43, P1696; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Levitan D, 1998, DEVELOPMENT, V125, P3101; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Miller DT, 1998, DEVELOPMENT, V125, P2327; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; NISHIZUKA Y, 1988, ACTA HAEMATOL JAPON, V51, P1321; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Price JV, 1997, GENETICS, V147, P1139; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tanyi J, 1999, Pathol Oncol Res, V5, P90, DOI 10.1053/paor.1999.0201; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WILKINSON HA, 1995, GENETICS, V141, P513	42	131	134	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4191	4198		10.1038/sj.onc.1203766	http://dx.doi.org/10.1038/sj.onc.1203766			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980592				2022-12-28	WOS:000089032900001
J	Lopez-Borges, S; Lazo, PA				Lopez-Borges, S; Lazo, PA			The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein	ONCOGENE			English	Article						VRK1; p53; mdm-2; kinase; autophosphorylation; nuclear localization signal	DAMAGE-INDUCED PHOSPHORYLATION; DROSOPHILA CLOCK GENE; DNA-DAMAGE; MULTISITE PHOSPHORYLATION; SUBSTRATE DETERMINANTS; DOUBLE-TIME; IN-VITRO; ENCODES; DOMAIN; ACTIVATION	The tumour suppressor p53 protein integrates multiple signals regulating cell cycle progression and apoptosis, This regulation is mediated by several kinases that phosphorylate specific residues in the different functional domains of the p53 molecule. The human VRK1 protein is a new kinase related to a poxvirus kinase, and more distantly to the casein kinase 1 family. We have characterized the biochemical properties of human VRK1 from HeLa cells. VRK1 has a strong autophosphorylating activity in st several Ser and Thr residues. VRK-1 phosphorylates acidic proteins, such as phosvitin and casein, and basic proteins such as histone 2b and myelin basic protein. Because some transcription factors are regulated by phosphorylation, we tested as substrates the N-transactivation domains of p53 and c-Jun fused to GST. Human c-Jun is not phosphorylated by VRK1. VRK1 phosphorylates murine p53 in threonine 18. This threonine is within the p53 hydrophobic loop (residues 13-23) required for the interaction of p53 with the cleft of its inhibitor mdm-2. The VRK1 C-terminus domain (residues 268-396) that contains a nuclear localization signal targets the protein to the nucleus, as determined by using fusion proteins with the green fluorescent protein. We conclude that VRK1 is an upstream regulator of p53 that belongs to a nerv signalling pathway.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Inst Salud Carlos III, CSIC, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel de Unamuno, Salamanca 37007, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025				BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAUD G, 1995, J VIROL, V69, P1819, DOI 10.1128/JVI.69.3.1819-1826.1995; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown JM, 1999, CANCER RES, V59, P1391; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Ferrer M, 1999, ONCOGENE, V18, P2253, DOI 10.1038/sj.onc.1202551; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN SQ, 1992, J VIROL, V66, P2717, DOI 10.1128/JVI.66.5.2717-2723.1992; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Prives C, 1999, J PATHOL, V187, P112; REMPEL RE, 1990, J VIROL, V64, P574, DOI 10.1128/JVI.64.2.574-583.1990; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRAKTMAN P, 1989, J BIOL CHEM, V264, P21458; TUAZON PT, 1991, ADV SEC MESS PHOSPHO, V23, P123; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657	61	109	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3656	3664		10.1038/sj.onc.1203709	http://dx.doi.org/10.1038/sj.onc.1203709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951572	Bronze			2022-12-28	WOS:000088568300012
J	Ahmad, M; Shi, YF				Ahmad, M; Shi, YF			TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention	ONCOGENE			English	Article						apoptosis; thyroid cancer; Fas; TNF-alpha; TRAIL	DEATH RECEPTORS; CYTOCHROME-C; LIGAND TRAIL; PROTEIN; EXPRESSION; MODULATION; INHIBITOR; CASPASES; MELANOMA; PATHWAY	To determine whether the apoptotic machinery of thyroid cancer cells is functional and could be activated for tumoricidal purposes, we examined the apoptosis induced by the cytokines TNF-alpha, Fas and TRAIL in thyroid cancer cell lines, NPA. and SW579. Interestingly, out of these cytokines, only TRAIL was able to trigger significant apoptosis, The tumoricidal effect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines, The anti-apoptotic proteins like FLAME-1, Bcl-2 and Bcl-xL are believed to be such CHX-sensitive inhibitors in various types of cancer cells. We, however provide the evidence using NPA and SW579 cell lines that these proteins were not affected by the CHX treatment in thyroid cancer cells. The apoptosis of thyroid cancer cells,vas mediated by the classical activation of caspases that in turn activated the DNA Fragmentation Factor (DFF-45). To elucidate the role of individual caspases in TRAIL-mediated apoptosis, the inhibitory effects of several general and specific tetrapeptide caspase inhibitors were studied. The inhibitors of caspase-1, -6, -8, and -9 as well as general upstream inhibitors of apoptosis could dramatically inhibit TRAIL-induced apoptosis in thyroid cancer cells. Caspase-2 and -3 inhibitors, on the other hand, had no significant effect. When the cells were treated with either agonistic Fas antibody (CH11) or TNF-alpha, no apoptotic changes mere observed, The apoptosis induced by agonistic Fas Ab could be seen only after a prolonged exposure (24 h) to CHX, whereas TNF-alpha had no effect even in the presence of CHX. The efficacy of TRAIL nas also tested on other types of thyroid cancer cells like ARO, FRO (anaplastic carcinoma) and TPC-1 (papillary carcinoma) and compared to that triggered by other death inducing cytokines Fast and TNF-alpha. Again TRAIL tvas more potent in triggering apoptosis than Fas and TNF-alpha. Since TRAIL is effective in selectively killing thyroid tumor cells without affecting normal thyrocytes and also does not cause organ toxicity and inflammation in vivo, its potential for the treatment of thyroid cancer seems very promising.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Ahmad, M (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, 226,MBC-03,POB 3354, Riyadh 11211, Saudi Arabia.		Shi, Yufei/ABG-5228-2020	Shi, Yufei/0000-0002-6999-0191				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Burow ME, 1998, CANCER RES, V58, P4940; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rudin CM, 1997, ANNU REV MED, V48, P267; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi Y, 1996, BRIT J CANCER, V74, P1336, DOI 10.1038/bjc.1996.546; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tung WS, 1996, MOL CARCINOGEN, V15, P5; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Zhang XD, 1999, CANCER RES, V59, P2747	31	46	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3363	3371		10.1038/sj.onc.1203679	http://dx.doi.org/10.1038/sj.onc.1203679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918593				2022-12-28	WOS:000088198100004
J	Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R				Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R			A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts	ONCOGENE			English	Article						c-myc; cell proliferation; cell cycle	CELL-CYCLE PROGRESSION; E CDK2 KINASE; ACTIVATES TRANSCRIPTION; RESPONSIVE GENES; IN-VIVO; S-PHASE; TRANSFORMATION; EXPRESSION; INHIBITION; PROTEINS	The c-myc gene is frequently over-expressed in human cancers and is involved in regulation of proliferation, differentiation and apoptosis, c-Myc is a transcription factor that acts primarily by regulating the expression of other genes. However, it has been very difficult to identify bona fide c-Myc target genes that explain its diverse biological activities. The recent generation of c-myc deficient Rat1A fibroblasts with a profound and stable growth defect provides a new system to search for genes that can substitute for c-myc in proliferation. In this study, we hale attempted to identify genes that rescue the slow growth phenotype of c-myc null cells through introduction of a series of potent cell cycle regulatory genes and several retroviral cDNA expression libraries. None of the candidate genes tested, including SV40 T-antigen and adenovirus E1A, caused reversal of the c-myc null growth defect. Furthermore, extensive screens with high-complexity retroviral cDNA libraries from three different tissue sources revealed that only c-myc and N-myc rescued the c-myc null slow-growth phenotype. Our data support the notion that there are no functional equivalents of the myc family of protooncogenes and also suggest that there are no c-Myc-activated gents that alone can substitute for c-Myc in control of cell proliferation.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423	NATIONAL CANCER INSTITUTE [R29CA076418] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	36	52	53	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3330	3334		10.1038/sj.onc.1203639	http://dx.doi.org/10.1038/sj.onc.1203639			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918589	Green Published			2022-12-28	WOS:000088019300011
J	Jove, R				Jove, R			Preface: STAT signaling	ONCOGENE			English	Editorial Material						signal transducer and activator of transcription; STAT			H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.								0	51	55	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2466	2467		10.1038/sj.onc.1203549	http://dx.doi.org/10.1038/sj.onc.1203549			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851044				2022-12-28	WOS:000087459400001
J	Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C				Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C			Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2	ONCOGENE			English	Article						apoptosis; cytochrome c; caspases; Bcl-2; ER stress; BFA	PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NF-KAPPA-B; BREFELDIN-A; FAMILY PROTEINS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; X-L; ACTIVATION; CERAMIDE	Apoptosis involves mitochondrial steps such as the release of the apoptogenic factor cytochrome c which are effectively blocked by Bcl-2, Although Bcl-2 may have a direct action on the mitochondrial membrane, it also resides and functions on the endoplasmic reticulum (ER), and there is increasing evidence for a role of the ER in apoptosis regulation as well. Here we uncover a hitherto unrecognized, apoptotic crosstalk between the ER and mitochondria that is controlled by Bcl-2, After triggering massive ER dilation due to an inhibition of secretion, the drug brefeldin A (BFA) induces the release of cytochrome c from mitochondria in a caspase-8- and Bid-independent manner. This is followed by caspase-3 activation and DNA/nuclear fragmentation. Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5), Similar findings were obtained with tunicamycin, an agent interfering with IV-linked glycosylations in the secretory system, Thus, apoptotic agents perturbing ER functions induce a novel crosstalk between the ER and mitochondria that can be interrupted by ER-based Bcl-2.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.		Egger, Charlotte/T-6517-2019	Egger, Charlotte/0000-0001-6501-5703				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chandra NC, 1998, J BIOL CHEM, V273, P19715, DOI 10.1074/jbc.273.31.19715; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	60	270	277	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2286	2295		10.1038/sj.onc.1203592	http://dx.doi.org/10.1038/sj.onc.1203592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822379				2022-12-28	WOS:000086974300003
J	Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M				Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M			Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release	ONCOGENE			English	Article						CD95; hyperthermia; cytochrome c; glioma; mitochondria	HUMAN-MALIGNANT GLIOMA; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CD95L-INDUCED APOPTOSIS; GENE-TRANSFER; FUNCTIONS DOWNSTREAM; CASPASE ACTIVATION; DEATH RECEPTORS; LETHAL WEAPON; MITOCHONDRIA	CD95L-induced apoptosis involves caspase activation and is facilitated when RNA and protein synthesis are inhibited. Here, we report that hyperthermia sensitizes malignant glioma cells to CD95L- and APO2L-induced apoptosis in the absence, but not in the presence, of inhibitors of RNA and protein synthesis. Hyperthermia does not alter CD95 expression at the cell surface and does not modulate the morphology of CD95-mediated cell death on electron microscopy, Bcl-2 gene transfer inhibits apoptosis and abrogates the sensitization mediated by hyperthermia, Hyperthermia does not overcome resistance to apoptosis conferred by the viral caspase inhibitor, crm-A, indicating the absolute requirement for the activation of crm-A-sensitive caspases, probably caspase 8, for apoptosis, CD95L-evoked DEVD-amc-cleaving caspase activity is enhanced by hyperthermia, suggesting that hyperthermia operates up-stream of caspase processing to promote apoptosis, There is no uniformly enhanced processing of three caspase 3 substrate, poly-ADP ribose polymerase (PARP), protein kinase C (PKC) delta and DNA fragmentation factor (DFF) 45, Yet, hyperthermia promotes CD95L-evoked DNA fragmentation, Interestingly, hyperthermia enhances the CD95L-evoked release of cytochrome c in the absence, but not in the presence, of CHX. In contrast, the reduction of the mitochondrial membrane potential is enhanced by hyperthermia both in the absence and presence of CHX, and enhanced cytochrome c release is not associated with significantly enhanced caspase 9 processing. The potentiation of cytochrome c release at hyperthermic conditions in the absence of CHX is abrogated by Bcl-2, Thus, either hyperthermia or inhibition of protein synthesis by CHX potentiate cytotoxic cytokine-induced apoptosis, These pathways show no synergy, but rather redundance, indicating that CHX may function to promote apoptosis in response to cytotoxic cytokines by inhibiting the synthesis of specific proteins whose synthesis, function or degradation is temperature-sensitive.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KLOSTERGAARD J, 1992, CANCER RES, V52, P5271; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; WATANABE N, 1988, CANCER RES, V48, P650; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yount GL, 1998, CANCER RES, V58, P3819	37	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2338	2345		10.1038/sj.onc.1203554	http://dx.doi.org/10.1038/sj.onc.1203554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822385				2022-12-28	WOS:000086974300009
J	Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM				Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM			Loss of p21(WAF1/CIP1) accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model	ONCOGENE			English	Article						p21(WAF1/CIP1); mammary tumor model; ras oncogene	CELL-CYCLE ARREST; NIH 3T3 CELLS; HA-RAS; SKIN CARCINOGENESIS; GROWTH ARREST; C-MYC; MALIGNANT CONVERSION; INDUCED APOPTOSIS; ACTIVATED RAS; G(1) ARREST	Upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and subsequent cell growth arrest or senescence is one mechanism by which normal cells are believed to respond to stress induced by the constitutively activated GTPase Ras. We hypothesize that in the absence of p21, the onset of Ras-dependent oncogenesis is accelerated. To test this hypothesis, we crossed MMTV/v-Ha-ras transgenic mice into a p21-deficient background. By 63 days of age, all 8 ras/p21(-/-) mice developed either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors. In contrast, by the same age, only one out of nine of the ras/p21(+/+) mice developed a tumor. Furthermore, by 94 days of age, half of the ras/p21(-/-) mice, but none of the ras/p21(+/+) mice, developed mammary tumors. p21-deficiency also accelerated the development of salivary (T-50 = 66 days for ras/21(-/-) vs T-50 = 136 days for ras/p21(+/+)) and Harderian (T-50 = 52 days for ras/p21(-/-) vs T-50>221 days for ras/p21(+/+)) tumors. Furthermore, two out of the eight ras/p21(-/-) mice had metastatic lesions, one in its lungs, the other in its abdomen. None of the nine ras/p21(+/+) mice had metastatic lesions. By 4 months of age, the mammary tumor multiplicity was 10-fold greater in ras/p21(-/-) (average 3.40 tumors/mouse) than in ras/p21(+/+) (average 0.33 tumor/mouse) mice. However, once the tumors appeared, their growth rate, apoptosis level, and mitotic index were not affected by the loss of p21, suggesting that loss of p21 is critical in early but not late events of Ras oncogenesis. Altogether, the results show that tumor onset in MMTV/v-Ha-ras mice is p21-dependent with loss of p21 associated with earlier tumor appearance and increased tumor multiplicity and aggressiveness.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Pathol & Lab Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia, Tampa, FL 33612 USA.				NCI NIH HHS [CA67771, CA72694, CA78038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072694, P01CA078038, U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Arber N, 1996, ONCOGENE, V12, P1903; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOS JL, 1989, CANCER RES, V49, P4682; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; CHOOI KF, 1994, CANCER RES, V54, P6434; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Davis R W, 1980, Methods Enzymol, V65, P404; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GAO X, 1995, ONCOGENE, V11, P1395; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HEATH LA, 1992, INT J CANCER, V51, P310, DOI 10.1002/ijc.2910510222; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; IWAMOTO T, 1990, ONCOGENE, V5, P535; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MILLER BE, 1988, CANCER RES, V48, P5747; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NAMBA H, 1995, CANCER RES, V55, P2075; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; Ritland SR, 1997, CANCER RES, V57, P3520; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SANDGREN EP, 1989, ONCOGENE, V4, P715; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAYLOR CR, 1994, HUM PATHOL, V25, P263, DOI 10.1016/0046-8177(94)90198-8; Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Weinberg WC, 1999, CANCER RES, V59, P2050; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1999, MOL CELL BIOL, V19, P4819; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908	75	83	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5338	5347		10.1038/sj.onc.1203956	http://dx.doi.org/10.1038/sj.onc.1203956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103935				2022-12-28	WOS:000165302300005
J	Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U				Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U			IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects	ONCOGENE			English	Article						casein kinase 1; mitotic checkpoint; chromosome segregation; centrosome amplification; micronucleation	CELL-CYCLE PROGRESSION; SPINDLE CHECKPOINT; MOLECULAR-CLONING; P53 PROTEIN; DNA-DAMAGE; I ISOFORM; PHOSPHORYLATION; EXPRESSION; MOUSE; FIBROBLASTS	The p53-targeted kinases casein kinase 1 delta (CK1 delta) and casein kinase 1 epsilon (CK1 epsilon) have been proposed to be involved in regulating DNA repair and chromosomal segregation. Recently, we showed that CK1 delta localizes to the spindle apparatus and the centrosomes in cells with mitotic failure caused by DNA-damage prior to mitotic entry. We provide here evidence that 3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261), a novel inhibitor of CK1 delta and CK1 epsilon, triggers the mitotic checkpoint control. At low micromolar concentrations IC261 inhibits cytokinesis causing a transient mitotic arrest. Cells containing active p53 arrest in the postmitotic G1 phase by blockage of entry into the S phase. Cells with non-functional p53 undergo postmitotic replication developing an 8N DNA content. The increase of DNA content is accompanied by a high amount of micronucleated and apoptotic cells. Immunfluorescence images show that at low concentrations IC261 leads to centrosome amplification causing multipolar mitosis. Our data are consistent with a role for CK1 delta and CK1 epsilon isoforms in regulating key aspects of cell division, possibly through the regulation of centrosome or spindle function during mitosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Heinrich Pette Institute; University of Hamburg; University of Dundee	Knippschild, U (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ENDOW SA, 1994, J CELL SCI, V107, P859; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FujikawaYamamoto K, 1997, CELL STRUCT FUNCT, V22, P399, DOI 10.1247/csf.22.399; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 1998, CANCER RES, V58, P396; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Longenecker KL, 1998, ACTA CRYSTALLOGR D, V54, P473, DOI 10.1107/S0907444997011724; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MILNE DM, 1992, ONCOGENE, V7, P1361; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mountain V, 2000, ANAT REC, V261, P14, DOI 10.1002/(SICI)1097-0185(20000215)261:1<14::AID-AR5>3.0.CO;2-E; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OTTO A, 1993, ONCOGENE, V8, P2591; Palazzo RE, 1999, J CELL SCI, V112, P1291; ROBERTS JR, 1990, CANCER RES, V50, P710; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sablina AA, 1998, J CELL SCI, V111, P977; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Santos JA, 1996, J CELL SCI, V109, P1847; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; SINGH TJ, 1983, ARCH BIOCHEM BIOPHYS, V220, P615, DOI 10.1016/0003-9861(83)90454-X; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; THOMAS NSB, 1991, ONCOGENE, V6, P317; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDRE DD, 1989, J CELL SCI, V94, P245; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yang PF, 2000, J BIOL CHEM, V275, P18905, DOI 10.1074/jbc.M002134200; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	66	103	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5303	5313		10.1038/sj.onc.1203939	http://dx.doi.org/10.1038/sj.onc.1203939			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103931				2022-12-28	WOS:000165302300001
J	Meplan, C; Richard, MJ; Hainaut, P				Meplan, C; Richard, MJ; Hainaut, P			Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells	ONCOGENE			English	Article						p53; zinc; chelator; metallothionein; metals	WILD-TYPE P53; DNA-BINDING ACTIVITY; IN-VITRO; NNN'N'-TETRAKIS-(2-PYRIDYLMETHYL)ETHYLENE DIAMINE; TRANSITION-METALS; KAPPA-B; METALLOTHIONEIN; CONFORMATION; ACTIVATION; EXPRESSION	The tumor suppressor p53 is a transcription factor which binds DNA through a structurally complex domain stabilized by a zinc atom. Zinc chelation disrupts the architecture of this domain, inducing the protein to adopt an immunological phenotype identical to that of many mutant forms of p53, In this report, we used Zn-65 to show that incorporation of zinc within the protein was required for folding in the 'wild-type' conformation capable of specific DNA-binding, Using a cellular assay, we show that addition of extracellular zinc at concentrations within the physiological range (5 muM) was required for renaturation and reactivation of wild-type p53, Among other divalent metals tested (Cd2+, Cu2+, Co2+, Fe2+ and Ni2+), only Co2+ at 125 muM had a similar effect. Recombinant metallothionein (MT), a metal chelator protein, was found to modulate p53 conformation in vitro. In cultured cells, overexpression of MT by transfection could modulate p53 transcriptional activity. Taken together, these results suggest that zinc binding plays a regulatory role in the control of p53 folding and DNA-binding activity.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; Ctr Hosp & Univ Albert Michalon, Biochim Lab C, F-38043 Grenoble 9, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biochem Res Ctr, Dundee DD1 9SY, Scotland.		Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Kaelin WG, 1998, SCIENCE, V281, P57, DOI 10.1126/science.281.5373.57; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KILLE P, 1991, FEBS LETT, V295, P171, DOI 10.1016/0014-5793(91)81411-Z; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Linke SP, 1997, CANCER RES, V57, P1171; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parat MO, 1999, BIOL TRACE ELEM RES, V70, P51, DOI 10.1007/BF02783849; Parat MO, 1998, BIOL TRACE ELEM RES, V65, P261, DOI 10.1007/BF02789101; PATTISON SE, 1986, FASEB J, V45, P2805; PATTISON SE, 1986, AM J PHYSIOL, V250, pE677, DOI 10.1152/ajpendo.1986.250.6.E677; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Roesijadi G, 1998, J BIOL CHEM, V273, P17425, DOI 10.1074/jbc.273.28.17425; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Schmidt C, 1999, ARCH BIOCHEM BIOPHYS, V364, P91, DOI 10.1006/abbi.1999.1107; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VALLEE BL, 1991, METHOD ENZYMOL, V205, P3; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WLOSTOWSKI T, 1993, BIOMETALS, V6, P71, DOI 10.1007/BF00140106; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zalewski P D, 1994, Chem Biol, V1, P153, DOI 10.1016/1074-5521(94)90005-1; Zalewski PD, 1996, REPROD FERT DEVELOP, V8, P1097, DOI 10.1071/RD9961097; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	63	195	199	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5227	5236		10.1038/sj.onc.1203907	http://dx.doi.org/10.1038/sj.onc.1203907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077439				2022-12-28	WOS:000165059700003
J	Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP				Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP			The anti-proliferative effects of 1 alpha,25(OH)(2)D-3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression	ONCOGENE			English	Article						BRCA1; 1 alpha,25(OH)(2)D-3; vitamin D-3 receptor; antisense; gene expression	VITAMIN-D-RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CLONAL PROLIFERATION; GROWTH-RETARDATION; POTENT INHIBITORS; ANDROGEN RECEPTOR; OVARIAN-CANCER; DIFFERENTIATION; LINES	The anti-proliferative action of the seco-steroid hormone 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3] extends to some, but not all breast and prostate cancer cell lines. By elucidating the molecular mechanisms mediating the sensitivity of these cells, we can identify critical target genes regulated directly or indirectly by 1 alpha,25(OH)(2)D-3 and pathways potentially disrupted during transformation. In this study, we demonstrated the induction of expression of BRCA1 mRNA and protein as well as transcriptional activation from the BRCA1-promoter by 1 alpha,25(OH)(2)D-3 in the sensitive breast cancer cell line MCF-7, This was not observed in the 1 alpha,25(OH)(2)D-3-resistant breast cancer cell Line MDA-MB-436. The induction of BRCA1 mRNA was blocked by cyclohexamide, This indicated that transcriptional activation was mediated indirectly by the vitamin D receptor (VDR). Inhibition of VDR protein levels by stable transformation of the anti-sense VDR in MCF-7 reduced the sensitivity of MCF-7 to 1 alpha,25(OH)(2)D-3 by 50-fold. In addition, the induction of BRCA1 protein and transcriptional activation of a BRCA1 promoter-luciferase reporter construct was abrogated in the stable transformant with the greatest reduction of VDR levels. Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 was strongly associated with an ability to modulate BRCA1 protein. Furthermore, the expression of the estrogen receptor in these cell lines strongly correlated with their sensitivity to 1 alpha,25(OH)(2)D-3 and their ability to modulate BRCA1 expression. Taken together, our data support a model whereby the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 are mediated, in part, by the induction of BRCA1 gene expression via transcriptional activation by factors induced by the VDR and that this pathway is disrupted during the development of prostate and breast cancers.	Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Birmingham; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Campbell, MJ (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England.		Campbell, Moray J/A-1311-2013; Campbell, Moray/ABF-1264-2021	Campbell, Moray/0000-0002-3355-0928				ARASON A, 1993, AM J HUM GENET, V52, P711; Asou H, 1998, BLOOD, V92, P2441, DOI 10.1182/blood.V92.7.2441.2441_2441_2449; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Campbell MJ, 1997, J CELL BIOCHEM, V66, P413, DOI 10.1002/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.3.CO;2-0; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CARRUBA G, 1994, CANCER RES, V54, P1190; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872; ELSTNER E, 1995, CANCER RES, V55, P2822; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fasco MJ, 1998, MOL CELL ENDOCRINOL, V138, P51, DOI 10.1016/S0303-7207(98)00048-3; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GAO X, 1995, CANCER RES, V55, P1002; Gennari L, 1998, J CLIN ENDOCR METAB, V83, P939, DOI 10.1210/jc.83.3.939; Gombart AF, 1997, LEUKEMIA, V11, P1673, DOI 10.1038/sj.leu.2400840; GUDAS JM, 1995, CANCER RES, V55, P4561; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; ISSACS WB, 1994, COLD SPRING HARB SYM, V59, P653; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Langston AA, 1996, AM J HUM GENET, V58, P881; Leygue E, 1999, CANCER RES, V59, P1175; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lundin AC, 1999, CANCER RES, V59, P2332; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Suarez F, 1998, J CLIN ENDOCR METAB, V83, P3563, DOI 10.1210/jcem.83.10.5199; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VILJOEN TC, 1995, PROSTATE, V27, P160, DOI 10.1002/pros.2990270307; Vladusic EA, 1998, CANCER RES, V58, P210; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83	48	89	90	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5091	5097		10.1038/sj.onc.1203888	http://dx.doi.org/10.1038/sj.onc.1203888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042697				2022-12-28	WOS:000089930100006
J	Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA				Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA			Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells	ONCOGENE			English	Article						p130; G0; growth arrest; pRb	LARGE-T-ANTIGEN; PHOSPHOAMINO ACID ANALYSIS; LAYER CELLULOSE PLATES; PRB-RELATED PROTEINS; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSOR; FUNCTIONAL INACTIVATION; TUMOR-SUPPRESSOR; FAMILY PROTEINS	The retinoblastoma family of proteins including pRB, p107 and p130 undergoes cell cycle dependent phosphorylation during the mid-G1 to S phase transition. This phosphorylation is dependent upon the activity of cyclin D/cdk4. In contrast to pRB and p107, p130 is phosphorylated during G0 and the early GT phase of the cell cycle, We observed that p130 is specifically phosphorylated on serine and threonine residues in T98G cells arrested in G0 by serum deprivation or density arrest. Identification of the phospho-serine and phosphothreonine residues revealed that most were clustered within a short co-linear region unique to p130, defined as the Loop, Deletion of the Loop region resulted in a change in the phosphorylation status of p130 under growth arrest conditions. Notably, deletion of the Loop did not affect the ability of p130 to bind to E2F-4 or SV40 Large T antigen, to induce growth arrest in Saos-2 cells, and to become hyperphosphorylated during the proliferative phase of the cell cycle. p130 undergoes specific G0 phosphorylation in a manner that distinguishes it from pRB and p107.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	DeCaprio, JA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Mayer 457,44 Binney St, Boston, MA 02115 USA.			Litovchick, Larisa/0000-0002-9540-597X	NATIONAL CANCER INSTITUTE [R01CA063113, T32CA009031, T32CA009361] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09031, R01-CA63113, 2T32CA09361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 1999, ELECTROPHORESIS, V20, P372, DOI 10.1002/(SICI)1522-2683(19990201)20:2<372::AID-ELPS372>3.0.CO;2-R; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HERZINGER T, 1995, ONCOGENE, V10, P2079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Moberg K, 1996, MOL CELL BIOL, V16, P1436; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starborg M, 1996, J CELL SCI, V109, P143; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLF DA, 1995, ONCOGENE, V10, P2067; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5116	5122		10.1038/sj.onc.1203893	http://dx.doi.org/10.1038/sj.onc.1203893			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042701				2022-12-28	WOS:000089930100010
J	Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT				Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT			SPI-1 transforming properties depend upon specifically activated forms of the EPOR	ONCOGENE			English	Article						friend erythroleukemia; SPI-1/PU.1; SFFV GP55; erythropoietin receptor; oncogene cooperation	ERYTHROID PROGENITOR CELLS; PU.1 TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; PRIMARY ERYTHROBLASTS; DIFFERENTIATION; PROLIFERATION; ERYTHROLEUKEMIA; PHOSPHORYLATION; EXPRESSION; KINASE	Friend erythroleukemia induced in mice by the spleen focus forming virus (SFFV) is a multi-step process, The pre-leukemic phase of the disease results from the abnormal activation of the Erythropoietin (Epo) receptor by the gp55 env gene product of SFFV, Later in disease progression, the emergence of leukemic clones is associated with recurrent genetic events, in particular the activation of the expression of SPI-1, an ETS family transcriptional regulator. We show here that the expression of either SPI-1 or GP55 with the mouse EPOR in arian primary erythroblasts only marginally affects their normal Epo-induced terminal differentiation. In contrast, the co-expression of GP55 and SPI-1 resulted in inhibition of Epo-induced differentiation of EPOR-expressing erythroblasts, promoting instead their proliferation. Co-expression of SPI-1 and GP55 also inhibited the apoptotic cell. death program normally induced in response to Epo withdrawal. This cooperation between SPI-1 and GP55 to induce primary erythroblast transformation suggests that progression of Friend erythroleukemia critically depends upon inter-dependent interactions between the molecular events specific of the early and late phase of the disease.	Ctr Univ Orsay, Inst Curie, CNRS, UMR146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ghysdael, J (corresponding author), Ctr Univ Orsay, Inst Curie, CNRS, UMR146, Bat 110, F-91405 Orsay, France.		GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016					Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; HANKINS WD, 1980, CELL, V22, P693; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Tamir A, 1999, MOL CELL BIOL, V19, P4452; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	23	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5106	5110		10.1038/sj.onc.1203886	http://dx.doi.org/10.1038/sj.onc.1203886			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042699				2022-12-28	WOS:000089930100008
J	Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS				Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS			Adhesion to fibronectin via beta 1 integrins regulates p27(kip1) levels and contributes to cell adhesion mediated drug resistance (CAM-DR)	ONCOGENE			English	Article						beta 1 integrins; drug resistance; p27(kip1); cell adhesion; myeloma; CAM-DR	DEPENDENT KINASE INHIBITOR; HEMATOPOIETIC PROGENITOR PROLIFERATION; BALB/C 3T3 CELLS; CYCLE PROGRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CONTACT INHIBITION; HL-60 CELLS; IN-VIVO; APOPTOSIS	The tumor cell environment may influence drug response through interactions with the extracellular matrix (ECM). We recently reported that adhesion of myeloma cells to fibronectin (FN), via beta 1 integrins is associated with a cell adhesion mediated drug resistance (CAM-DR), Activation of beta 1 integrins is known to influence both apoptosis and cell growth. We hypothesized that the FN mediated cytoprotection mag be in part due to perturbations in cell cycle progression. In this report we demonstrate that adhesion of myeloma cells to FN results in a G(1) arrest associated,vith increased p27(kip1) protein levels and inhibition of cyclin A and E associated kinase activity. Disruption of cells from FN adhesion resulted in a rapid recruitment of cells into S phase, a decrease in p27(kip1) levels, and reversion to a drug sensitive phenotype. Treatment of cells with p27(Kip1) antisense oligonucleotides did not affect FN adhesion; however, p27(Kip1) protein levels were reduced and cells became sensitive to cytotoxic drugs. These studies demonstrate that beta 1 mediated adhesion of myeloma cells to FN regulates p27(Kip1) levels and that p27(kip1) levels are causally related to CAM-DR. Disruption of beta 1 integrin mediated FN adhesion may represent a potential target for the potentiation of drug induced apoptosis.	Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Dalton, WS (corresponding author), Univ S Florida, Dept Oncol, Tampa, FL 33612 USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BOHNSACK JF, 1994, BLOOD, V83, P543; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hoyt DG, 1996, CANCER RES, V56, P4146; Hurley RW, 1997, EXP HEMATOL, V25, P321; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; JENSEN GS, 1993, AM J HEMATOL, V43, P29, DOI 10.1002/ajh.2830430108; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Katayose Y, 1997, CANCER RES, V57, P5441; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naumann U, 1999, BIOCHEM BIOPH RES CO, V261, P890, DOI 10.1006/bbrc.1999.1126; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pozzi M, 1998, J CELL BIOL, V142, P587; Ruan S, 1998, CANCER RES, V58, P1538; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SOLARY E, 1993, BLOOD, V81, P1359; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang MWJ, 1998, CELL GROWTH DIFFER, V9, P105; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	293	317	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4319	4327		10.1038/sj.onc.1203782	http://dx.doi.org/10.1038/sj.onc.1203782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980607				2022-12-28	WOS:000089271900002
J	Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH				Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH			Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4	ONCOGENE			English	Article						mutation; signal transduction; Smad; TGF-beta-transcription; tumor suppressor gene	GROWTH-FACTOR-BETA; COLON-CANCER CELLS; TGF-BETA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DPC4 SMAD4; PROTEINS; PROMOTER; RECEPTOR; GENE	Smads, the intracellular effecters of transforming growth factor-beta (TGF-beta) family members, are somatically mutated at high frequency in particular types of human cancers. Certain of these mutations affect the Smad amino-terminal domain, which, in the case of Smad3 and Smad4, binds DNA. We investigated the functional consequences of four missense mutations in the Smad4 amino-terminal domain found in human tumors. The mutant proteins were found to have impaired abilities to bind DNA although they were fully capable of forming complexes with Smad3, All four Smad4 mutants showed decreased protein stability compared to wild-type Smad3. Two of the Smad4 mutants (G65V and P130S) were translocated to the nucleus and were capable of transactivating a Smad-dependent promoter in a ligand-dependent manner. In contrast, the L43S and R100T mutants were not translocated efficiently to the nucleus and consequently resulted in severely defective transcriptional responses to TGF-beta. Moreover, we demonstrate here the critical importance of two basic residues in the beta-hairpin loop of Smad3 or Smad4 for DNA binding, consistent with predictions from the Smad3 crystal structure. In addition, our results reveal that in the TGF-beta-induced heteromeric signaling complex, loss of DNA binding of Smad4 can be compensated by Smad3, however, both Smad3 and Smad3 are needed for efficient DNA binding and signaling. In conclusion, mutations in the amino-terminal domain of Smad4, that are found in cancer, show loss of multiple functional properties which may contribute to tumorigenesis.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; Netherlands Cancer Institute	Heldin, CH (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Moustakas, Aristidis/0000-0001-9131-3827; Itoh, Susumu/0000-0002-7967-0730				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DECAESTECKER MP, 2000, IN PRESS J NATL CANC; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; LEDAI J, 1999, MOL CARCINOG, V26, P37; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; PARDALI K, 2000, IN PRESS J BIOL CHEM; Piek E, 1999, J CELL SCI, V112, P4557; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, V95, P3; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	55	79	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4396	4404		10.1038/sj.onc.1203798	http://dx.doi.org/10.1038/sj.onc.1203798			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980615				2022-12-28	WOS:000089271900010
J	Attwell, S; Roskelley, C; Dedhar, S				Attwell, S; Roskelley, C; Dedhar, S			The integrin-linked kinase (ILK) suppresses anoikis	ONCOGENE			English	Article						apoptosis; protein kinase B; fibronectin; caspases	DEPENDENT CELL-SURVIVAL; FOCAL ADHESION KINASE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; APOPTOSIS; DEATH; B/AKT; AKT; PATHWAYS; GROWTH	Disruption of integrin-extracellular matrix interactions in normal epithelial cells induces apoptosis, a process termed anoikis, Reduced sensitivity to anoikis appears to be an important hallmark of oncogenic transformation, particularly in the process of metastasis, Several pathways have been implicated in the suppression of anoikis, however, the events which take place proximal to the integrin receptors remain unclear. Integrin-linked kinase (ILK) is an integrin-interacting protein kinase which has been identified as a potential PDK-2, as it is capable of phosphorylating PKB/Akt on Ser-473, and stimulating its activity, Here, we show that ILK activity is stimulated upon adhesion of SCP2 mouse mammary epithelial cells to fibronectin, and inhibited in suspended cells. Overexpression of ILK in the anoikis-sensitive SCP2 cells results in a profound inhibition of anoikis, as determined by annexin V binding and activation of caspases 8 and 3, This effect is reversible by the transfection and expression of a dominant-negative, kinase deficient ILK (ILK KD), as well as by a dominant negative PKB/Akt (PKB AAA). On the other hand, transfection of a dominant negative form of FAK (FRNK) failed to reverse the suppression of anoikis by ILK, Furthermore, inhibition of ILK activity induced anoikis in tno anoikis-resistant human breast cancer cell lines. These findings suggest that ILK plays a major role in the suppression of anoikis.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6P 6P2, Canada; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	28	199	210	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3811	3815		10.1038/sj.onc.1203711	http://dx.doi.org/10.1038/sj.onc.1203711			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949937				2022-12-28	WOS:000088568400015
J	del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A				del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A			Involvement of p53 and interleukin 3 in the up-regulation of CD95 (APO-1/Fas) by X-ray irradiation	ONCOGENE			English	Article						apoptosis; CD95 (Fas/Apo-1); IL-3; p53; X-ray irradiation	DRUG-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; RECEPTOR/LIGAND SYSTEM; DEATH DOMAIN; DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; ANTICANCER DRUGS; PERIPHERAL-BLOOD	Interleukin 3-dependent hone marrow and Ba/F3 cells present constitutive Fas expression. A dose dependent increase in Fas surface expression was induced in these cells by X-ray irradiation. Using primary cell cultures and established cell lines derived from p53-null mice (p53(-/-)), we demonstrated that the increase in Fas expression upon X-ray irradiation is dependent on the presence of at least one wild-type p53 allele. Fas induction by X-ray irradiation was negatively modulated by IL-3; an earlier Fas induction was observed in the absence of IL-3 or at low IL-3 concentrations. However, IL-3 withdrawal in non-irradiated cells did not induce an increase in Fas expression. X-ray irradiation of Ba/F3 cells induced the expression of functional Fas receptors. Therefore, in IL-3-dependent cells, IL-3 regulates the rate of Fas expression, which is correlated with the degree of apoptosis observed in X-irradiated cells. Finally, we demonstrate that IL-3 controls the degree of Fas expression induced by irradiation through a p53-mediated pathway.	CSIC, Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Silva, A (corresponding author), CSIC, Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Gil-Lamaignere, Cristina/A-3866-2013					Akagi T, 1998, LEUKEMIA LYMPHOMA, V28, P483, DOI 10.3109/10428199809058355; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Booker JK, 1998, J IMMUNOL, V161, P4536; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; IWAI K, 1994, BLOOD, V84, P1201; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li T, 1996, CELL GROWTH DIFFER, V7, P107; MARVEL J, 1994, ONCOGENE, V9, P1117; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; MIYASHITA T, 1995, CELL, V80, P293; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MULLNER EW, 1997, IMMUNOLOGY METHODS M; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; SATA M, 1988, NAT MED, V4, P415; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAMURA T, 1995, ONCOGENE, V11, P1939; WARASUKAMA H, 1988, EUR J IMMUNOL, V18, P97; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	49	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3647	3655		10.1038/sj.onc.1203662	http://dx.doi.org/10.1038/sj.onc.1203662			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951571				2022-12-28	WOS:000088568300011
J	Klausen, P; Pedersen, L; Jurlander, J; Baumann, H				Klausen, P; Pedersen, L; Jurlander, J; Baumann, H			Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells	ONCOGENE			English	Article						HepG3 cells; IL-6 type cytokines; IL-10; p27kip1; growth arrest	CYTOKINE RECEPTOR SUPERFAMILY; HEPATIC CELLS; RESPONSE ELEMENTS; DEPENDENT PHOSPHORYLATION; HEMATOPOIETIN RECEPTORS; GROWTH-INHIBITION; MELANOMA-CELLS; P27(KIP1); EXPRESSION; CANCER	We analysed the regulation of G1-phase progression in relation to cytokine receptor signalling in HepG2 hepatoma cells, stably transduced with the IL-10 receptor after stimulation with Oncostatin M (OSM), IL-6. Leukaemia Inhibitory Factor (LIF) and IL-10. All cytokines induced STAT3 phosphorylation to approximately the same level, but only OSM, and to a lesser extent IL-6, induced STAT5 phosphorylation. The cytokines also stimulated phosphorylation of ERK in the order of decreasing effectiveness: OSM>IL-6>LIF>IL-10. The same order of activity of the cytokines was observed on inhibition of DNA synthesis and accumulation of cells in the G1-phase of the cell cycle. These processes were accompanied by a decrease in cyclin A expression and CDK2 activity, and enhanced accumulation of p27kip1. The level of p27kip1 mRNA expression was unaffected by the cytokines, and maintenance of the elevated level of p27kip1 occurred independently of de novo protein synthesis. Furthermore, inhibition of proteasomal activity increased the level of p27kip1 in the unstimulated cells to the same level as in OSM-treated cells. Inhibition of MEK activation completely abrogated OSM and IL-6 induced p27kip1 accumulation, while expression of dominant negative STAT5 decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation.	Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, DK-2100 Copenhagen, Denmark; Roswell Pk Canc Inst, Dept Mol & Cell Biol, Buffalo, NY 14263 USA	Rigshospitalet; University of Copenhagen; Roswell Park Cancer Institute	Klausen, P (corresponding author), Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.			Klausen, Pia/0000-0001-9386-9167	NCI NIH HHS [CA 26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TAKIZAWA H, 1993, CANCER RES, V53, P4175; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wiznerowicz M, 1998, ADV EXP MED BIOL, V451, P441	33	55	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3675	3683		10.1038/sj.onc.1203707	http://dx.doi.org/10.1038/sj.onc.1203707			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951574				2022-12-28	WOS:000088568300014
J	Gandarillas, A; Davies, D; Blanchard, JM				Gandarillas, A; Davies, D; Blanchard, JM			Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication	ONCOGENE			English	Article						epidermis; mitosis; cell size; flow cytometry; cell fate; endoreduplication	EPIDERMAL STEM-CELLS; TERMINAL DIFFERENTIATION; PATTERN-FORMATION; DNA-REPLICATION; TARGET GENES; IN-VITRO; EXPRESSION; APOPTOSIS; PROLIFERATION; INDUCTION	The relationship between cell cycle and differentiation in human keratinocytes is poorly understood, It is believed that keratinocytes suppress DNA replication and cell cycle arrest in G0 before they initiate terminal differentiation, However, a temporal separation between both events has not been established. Moreover, c-Myc promotes keratinocyte differentiation without causing cell cycle arrest. To address these paradoxes we have analysed cell cycle control during normal and c-Myc-promoted differentiation. Continuous activation of c-Myc or initiation of terminal differentiation results in a block of G2/M, cellular growth, endoreplication and polyploidy. Keratinocytes abandon G1, continue replicating DNA as they differentiate terminally and become polyploid. In fact, simply blocking mitosis with nocodazole resulted in increased cell size, terminal differentiation and endoreplication. This indicates that terminal differentiation associates with defective cell cycle progression and provides a novel insight into c-Myc biology.	CNRS, Inst Genet Mol, F-34293 Montpellier 5, France; Imperial Canc Res Fund, FACS Lab, London WC2A 3PX, England	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Cancer Research UK	Gandarillas, A (corresponding author), CNRS, Inst Genet Mol, F-34293 Montpellier 5, France.			Davies, Derek/0000-0002-6977-4181				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; BenBassat H, 1997, CANCER RES, V57, P3741; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS E, 1993, J CELL SCI, P197; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Grafi G, 1998, EXP CELL RES, V244, P372, DOI 10.1006/excr.1998.4213; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; Harvat BL, 1998, J CELL SCI, V111, P1185; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hawkins NC, 1996, DEVELOPMENT, V122, P281; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOFFMAN R, 1989, BLOOD, V74, P1196; Hudson DL, 1996, INT J CANCER, V66, P457, DOI 10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V; Hulskamp M, 1999, INT REV CYTOL, V186, P147; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; JACKSTON LA, 1999, CELL, V98, P779; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; KIRK D, 1980, CELL BIOL INT REP, V4, P83, DOI 10.1016/0309-1651(80)90013-2; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; MEYEROWITZ EM, 1994, CURR OPIN GENET DEV, V4, P602, DOI 10.1016/0959-437X(94)90079-I; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; NAKATANI S, 1992, ARCH DERMATOL RES, V284, P349, DOI 10.1007/BF00372038; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; ORMEROD EM, 1990, FLOW CYTOMETRY PRACT, P69; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENNEYS NS, 1970, ARCH DERMATOL, V101, P323, DOI 10.1001/archderm.101.3.323; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINKUS H, 1966, ARCH DERMATOL, V94, P351, DOI 10.1001/archderm.94.3.351; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; REISS M, 1987, CANCER RES, V47, P6705; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Solari F, 1996, J CELL SCI, V109, P1203; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1991, J CELL SCI, V99, P397; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185	66	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3278	3289		10.1038/sj.onc.1203630	http://dx.doi.org/10.1038/sj.onc.1203630			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918584				2022-12-28	WOS:000088019300006
J	Smithgall, TE; Briggs, SD; Schreiner, S; Lerner, EC; Cheng, HY; Wilson, MB				Smithgall, TE; Briggs, SD; Schreiner, S; Lerner, EC; Cheng, HY; Wilson, MB			Control of myeloid differentiation and survival by Stats	ONCOGENE			English	Article						stat; cytokine; differentiation; survival; tyrosine kinase	ERYTHROLEUKEMIA CELL-LINE; PROTEIN-TYROSINE PHOSPHATASES; STIMULATING FACTOR-RECEPTOR; BCL-X-L; ERYTHROPOIETIN RECEPTOR; ERYTHROID-DIFFERENTIATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; LEUKEMIA-CELLS; GROWTH ARREST	Hematopoiesis involves a complex array of growth factors that regulate the survival and proliferation of immature progenitors, influence differentiation commitment, and modulate end-stage cell functions. This minireview is focused on the role of Stat activation in the development of myeloid cells in response to hematopoietic cytokines, Much of the evidence implicating Stats in these cellular processes comes from studies of mutant cytokine receptors selectively uncoupled from Stat activation, dominant-inhibitory Stat mutants, and mice with targeted disruptions of Stat genes. Together these approaches provide strong evidence that Stat activation, particularly of Stat3 and Stat5, plays an important role in myeloid differentiation and survival.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.			Briggs, Scott D/0000-0003-2852-3594				Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Lacombe C, 1998, HAEMATOLOGICA, V83, P724; Link DC, 1999, BLOOD, V94, p471A; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA O, 1994, BLOOD, V84, P1501; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; SENSIS Y, 1999, MOL CELL BIOL, V19, P7436; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU G, 1989, J BIOL CHEM, V264, P10276	61	110	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2612	2618		10.1038/sj.onc.1203477	http://dx.doi.org/10.1038/sj.onc.1203477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851060				2022-12-28	WOS:000087459400017
J	O'Connor, DJ; Lu, X				O'Connor, DJ; Lu, X			Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb	ONCOGENE			English	Article						E2F1; p53; transcription; DNA damage; hypoxia; stress response	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; DNA-DAMAGE; CELL-CYCLE; P53-INDEPENDENT APOPTOSIS; DEREGULATED EXPRESSION; PROTEIN; FAMILY; DEGRADATION; LEADS	One of the common features of cellular response to stress is cell cycle arrest or apoptosis, E2F is one of the key factors which controls cell cycle progression. Overexpression of E2F-1 can also induce apoptosis, In order to understand the role of E2F-1 in cellular response to stress, we studied the E2F-1 response in various cell lines to different types of stress signals including UV irradiation, cisplatin, etoposide and hypoxia, We showed here that the expression level of E2F-1 can be up regulated by the treatment of DNA damage agents as well as hypoxia, The kinetics of E2F-1 increase was dependent on the types of inducer and was similar to that of p53, However, stress signals can induce E2F-1 expression independently of p53 and Rb, Furthermore, the induced E2F-1 was transcriptionally inactive, All these results suggested that E2F-1 may play a very important role in cellular response to stress and this novel role of E2F-1 is independent of its transactivation function.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152				Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; Blattner C, 1999, MOL CELL BIOL, V19, P3704; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang YY, 1997, CANCER RES, V57, P3640; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	35	65	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2369	2376		10.1038/sj.onc.1203540	http://dx.doi.org/10.1038/sj.onc.1203540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828878				2022-12-28	WOS:000087018400001
J	Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A				Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A			Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; 1p36; tumor suppressor gene	MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENES; CHROMOSOME 1P36.3; ALLELIC LOSS; N-MYC; DNA; APOPTOSIS; PROTEIN; CANCER; UBIQUITINATION	Loss of heterozygosity of the distal region of chromosome Ip where tumor suppressor gene(s) might harbor is frequently observed in many human cancers including neuroblastoma (NBL) with MYCN amplification and poor prognosis. We have identified for the first time a homozygously deleted region at the marker D1S244 within the smallest region of overlap at 1p36.2-p36.3 in two NBL cell lines, NB-1 and NB-C201 (MASS-NB-SCH1), although our genotyping has suggested the possibility that both lines are derived from the same origin. The 800-kb PAC contig covering the entire region of homozygous deletion was made and partially sequenced (about 60%). The estimated length of the deleted region was 500 kb. We have, thus far, identified sis genes within the region which include three known genes (DFF45, PGD, and CORT) as well as three other genes which have been reported during processing our present project for the last 31/2 years (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14). They include the genes related to apoptosis, glucose metabolism, ubiquitin-proteasome pathway, a neuronal microtubule-associated motor molecule and biogenesis of peroxisome. At least three genes (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14) were differentially expressed at high levels in favorable and at low levels in unfavorable subsets of primary neuroblastoma. Since the Ip distal region is reported to be imprinted, those differentially expressed genes could be the new members of the candidate NBL suppressor, although RT-PCR-SSCP analysis has demonstrated infrequent mutation of the genes so far identified. Full-sequencing and gene prediction for the region of homozygous deletion would elucidate more detailed structure of this region and might lead to discovery of additional candidate genes.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 3620806, Japan; RIKEN, Gen Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Natl Canc Ctr, Res Inst, Canc Gen Div, Chuoh Ku, Tokyo 1040045, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi 9808575, Japan; RIKEN Gene Bank, Tsukuba, Ibaraki 3050074, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Helix Res Inst Inc, Biol Technol Lab, Chiba 2920812, Japan; Hisamitsu Pharmaceut Co Inc, Tsukuba Res Labs, Cent Res Ctr, New Technol Dev Dept, Tsukuba, Ibaraki 3050856, Japan	Chiba Cancer Center; RIKEN; University of Tokyo; National Cancer Center - Japan; Tohoku University; RIKEN; Tokyo Medical & Dental University (TMDU); Eisai Co Ltd; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.		Horii, Akira/AAW-2839-2021; Hattori, Masahira/C-6958-2016; Hattori, Masahira/AAD-3785-2019	Horii, Akira/0000-0002-3967-3291; Hattori, Masahira/0000-0001-9467-0344; 				AMLER LC, 1995, ONCOGENE, V10, P1095; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Carling T, 1999, INT J CANCER, V83, P80, DOI 10.1002/(SICI)1097-0215(19990924)83:1<80::AID-IJC15>3.0.CO;2-E; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN FS, 1995, MICROW OPT TECHN LET, V10, P297, DOI 10.1002/mop.4650100512; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENOMOTO H, 1994, ONCOGENE, V9, P2785; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; He LS, 1998, CANCER RES, V58, P4238; Hiraiwa H, 1997, CANCER, V79, P2036, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2036::AID-CNCR27>3.3.CO;2-M; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTINSSON T, 1995, CANCER RES, V55, P5681; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; Nagai M, 2000, INT J ONCOL, V16, P907; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Sunahara M, 1998, INT J ONCOL, V13, P319; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Takemura R, 1996, J NEUROSCI, V16, P31; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Tsui SKW, 1996, BIOCHEM GENET, V34, P367, DOI 10.1007/BF00554412; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Will GK, 1999, MOL CELL BIOL, V19, P2265; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10	43	71	77	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4302	4307		10.1038/sj.onc.1203786	http://dx.doi.org/10.1038/sj.onc.1203786			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980605				2022-12-28	WOS:000089032900014
J	Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M				Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M			Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas	ONCOGENE			English	Article						TGF-beta(1); Smad4; Ras; Erk; urokinase; carcinoma	GROWTH-FACTOR-BETA; PROTEIN-KINASE KINASE; CELL-CYCLE ARREST; TGF-BETA; EPITHELIAL-CELLS; UROKINASE EXPRESSION; P21(WAF1) EXPRESSION; COLORECTAL CANCERS; INVASIVE PHENOTYPE; SIGNALING PATHWAY	Smad4 functions as a transcription factor in TGF-beta signalling. We have investigated the role of Smad4 in the TGF-beta(1) cell responses of transformed PDV keratinocytes, which contain a Ras oncogene, and of non-tumorigenic MCA3D keratinocytes, by transfecting both cell lines with a dominant-negative Smad4 construct. Smad4 mediates TGF-beta(1)-induced up-regulation of p21(Cip1) and growth arrest in MCA3D cells, However, in PDV keratinocytes, Smad4 is only partially involved in TGF-beta(1)-induced growth inhibition, and does not mediate enhancement of p21(Cip1) levels by the growth factor. TGF-beta(1) activates Ras/Erk signalling activity in both cell lines, PD098059, a specific inhibitor of MEK, disminishes TGF-beta(1)-induced p21(Cip1) levels in PDV but not in MCA3D cells, suggesting an involvement of Erk in upregulation of p21(Cip1) by TGF-beta(1) in PDV cells, PDV dominant-negative Smad4 cell transfectants, but not MCA3D transfectants, showed constitutive hyperactivation of the Ras/Erk signalling pathway, increased secretion of urokinase, higher motility properties, and a change to a fibroblastoid cell morphology associated in vivo with the transition from a well differentiated to a poorly differentiated tumour phenotype. infection of MCA3D control and dominant negative Smad4 cell transfectants with retroviruses carrying a Ras oncogene led to enhanced p21(Cip1) and urokinase secreted levels, independently of TGF-beta(1) stimulation, that were reduced by PD098059, These results suggest that Smad4 acts inhibiting Ras-dependent Erk signalling activity in Ras-transformed keratinocytes. Loss of Smad4 function in these cells results in hyperactivation of Erk signalling and progression to undifferentiated carcinomas.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; UAM, Fac Med, Dept Anat Patol, Hosp Princesa, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.		Quintanilla, Miguel/K-9293-2017	Quintanilla, Miguel/0000-0002-2124-7657				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1990, GASTROENTEROLOGY, V99, P416, DOI 10.1016/0016-5085(90)91024-Z; BURNS PA, 1991, ONCOGENE, V6, P2363; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Farina AR, 1998, INT J CANCER, V75, P721; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; Grau AM, 1997, CANCER RES, V57, P3929; HADDOW S, 1991, ONCOGENE, V6, P1465; Hahn SA, 1998, DIGESTION, V59, P493, DOI 10.1159/000007526; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunt KK, 1998, CANCER RES, V58, P5656; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Min HY, 1996, CANCER RES, V56, P2428; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rozenblum E, 1997, CANCER RES, V57, P1731; Santibanez JF, 1999, J CELL BIOCHEM, V74, P61, DOI 10.1002/(SICI)1097-4644(19990701)74:1<61::AID-JCB7>3.3.CO;2-2; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Simon C, 1996, CANCER RES, V56, P5369; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	53	63	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4134	4145		10.1038/sj.onc.1203764	http://dx.doi.org/10.1038/sj.onc.1203764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962574	Green Submitted			2022-12-28	WOS:000088955100007
J	Hakak, Y; Hsu, YS; Martin, GS				Hakak, Y; Hsu, YS; Martin, GS			Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt	ONCOGENE			English	Article						shp-2; src; akt; cbl; transformation; apoptosis	TYROSINE-PHOSPHATASE SHP-2; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOTYROSINE PHOSPHATASE; TRANSFORMED FIBROBLASTS; PROTOONCOGENE PRODUCT; FOCAL ADHESION; P85 SUBUNIT; RAS; 3-KINASE; CELL	The protein-tyrosine phosphatase Shp-2 is a positive modulator of the Ras/mitogen-activated protein kinase pathway and a putative substrate of the transforming non-receptor tyrosine kinase v-Src, To characterize the role of Shp-2 in cellular transformation and signaling by v-Src, we expressed v-Src in normal and Shp-2-deficient mouse embryo fibroblasts. Expression of Shp-2 was found to be necessary for morphological transformation by v-Src: Shp-2+/+ cells became rounded or spindly upon v-Src expression, whereas Shp-2-deficient cells remained relatively hat, v-Src-induced reorganization of the actin cytoskeleton and the formation of podosomes were compromised in Shp-2-deficient cells. Shp-2 deficiency also reduced v-Src-induced activation of the anti-apoptotic protein kinase Akt. The reduced activation of Akt in Shp-2-deficient cells correlated with a reduction in the association of the p85 regulatory subunit of PI3-kinase with the adapter protein Chl. Activation of PI3-kinase by v-Src may be mediated by the association of the adapter protein Cbl with the p85 subunit, Since activation of Akt is dependent on PI3-kinase, this suggests that the effect of Shp-2 on Akt activation may be mediated, at least in part, by its effects on the interaction between Pw-kinase and Chi, The defect in activation of the Akt survival pathway also correlated with enhanced sensitivity of Shp-2-deficient cells to an apoptosis-inducing agent. These results implicate Shp-2 in v-Src-induced cytoskeletal reorganization and activation of the Akt cell survival pathway.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Martin, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, 401 Barker Hall 3204, Berkeley, CA 94720 USA.				NCI NIH HHS [CA17542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017542, R37CA017542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fincham VJ, 1999, J CELL SCI, V112, P947; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Oh ES, 1999, MOL CELL BIOL, V19, P3205; PENG ZY, 1995, ONCOGENE, V11, P1955; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3164	3171		10.1038/sj.onc.1203655	http://dx.doi.org/10.1038/sj.onc.1203655			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918571				2022-12-28	WOS:000088019200005
J	Langlais, P; Dong, LQ; Hu, DR; Liu, F				Langlais, P; Dong, LQ; Hu, DR; Liu, F			Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family	ONCOGENE			English	Article						Grb10; Src; IR; SH2	ADAPTER PROTEIN GRB10; RECEPTOR-BINDING-PROTEIN; FACTOR-I RECEPTORS; INSULIN-RECEPTOR; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAIN; SHC PROTEINS; V-SRC; GROWTH	Treatment of cells with insulin and protein tyrosine phosphatase inhibitors such as vanadate and pervanadate resulted in the tyrosine phosphorylation of Grb10, a Src homology 2 (SH2) and pleckstrin homology domain-containing adaptor protein,which binds to a number of receptor tyrosine kinases including the insulin receptor (IR), Although Grb10 binds directly to the kinase domain of the IR, our data show that Grb10 is not a direct substrate for the IR tyrosine kinase. Consistent with this finding, Grb10 tyrosine phosphorylation in cells was inhibited by herbimycin A, a relatively specific inhibitor for members of the Src tyrosine kinase family, and by the expression of dominant negative Src or Fyn. In addition, Grb10 tyrosine phosphorylation was stimulated by expression of constitutively active Src or Fyn in cells and by incubation with purified Src or Fyn in vitro. The insulin stimulated or Src/Fyn-mediated tyrosine phosphorylation iir vivo was significantly reduced when Grb10 tyrosine 67 was changed to glycine. This mutant form of Grb10 bound with higher affinity to the IR in cells than that of the wild-type protein, suggesting that tyrosine phosphorylation of Grb10 may normally negatively regulate its binding to the IR, Our data show that Grb10 is a new substrate for members of the Src tyrosine kinase family and that the tyrosine phosphorylation of the protein may play a potential role in cell signaling processes mediated by these kinases.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DELALUNA S, 1988, GENE, V62, P121; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Wang J, 1999, MOL CELL BIOL, V19, P6217; WENG Z, 1994, MOL CELL BIOL, V14, P509; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHANG B, 1991, J BIOL CHEM, V266, P990	45	34	34	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2895	2903		10.1038/sj.onc.1203616	http://dx.doi.org/10.1038/sj.onc.1203616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871840				2022-12-28	WOS:000087544500003
J	Mazumder, S; Gong, B; Almasan, A				Mazumder, S; Gong, B; Almasan, A			Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells	ONCOGENE			English	Article						Cyclin E; cyclin dependent kinase 2; apoptosis; ionizing radiation; caspase-3	S-PHASE ENTRY; THYMOCYTE APOPTOSIS; CDK INHIBITORS; ACTIVATION; KINASE; TRANSITION; CANCER; DEATH; P53; FIBROBLASTS	Cyclin E is essential for progression through the G1 phase of the cell cycle and initiation of DNA replication by interacting with, and activating its catalytic partner, the cyclin-dependent kinase 2 (Cdk2), We found a substantial increase in cyclin E mRNA, accompanied by increased production of cyclin E protein and cyclin E/ Cdk2 kinase activity in multiple myeloma and lymphoma cells following irradiation. Cyclin E expression increased early in a time and dose-dependent manner, with a threefold induction reached 8h following gamma-irradiation, Run-on analyses indicated a predominantly transcriptional regulation of cyclin E, Stable overexpression of cyclin E, but not cyclin D1, sensitized IM-9 cells to gamma-irradiation-induced apoptosis; in contrast, a dominant-negative Cdk2, prevented apoptosis. Irradiation of cyclin E overexpressing cells led to an enhanced caspase activation and exposure of the phosphatidylserine on the plasma membrane, two key markers of apoptosis, events which were completely abolished in cells expressing a dominant-negative Cdk2, This study identifies cyclin E as a target for activation by ionizing radiation and which plays a functional role in apoptosis of hematopoietic cells. Oncogene (2000) 19, 2828-2835.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Almasan, A (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40, Cleveland, OH 44195 USA.		Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82858, CA81504, R01 CA082858, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong BD, 1999, CELL GROWTH DIFFER, V10, P491; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lawrence TS, 1996, CANCER RES, V56, P3203; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Martin JMC, 1999, CANCER RES, V59, P1134; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MAZARS GR, 1992, ONCOGENE, V7, P1015; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sauter ER, 1999, CANCER RES, V59, P4876; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	38	54	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2828	2835		10.1038/sj.onc.1203623	http://dx.doi.org/10.1038/sj.onc.1203623			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851086	Green Accepted			2022-12-28	WOS:000087403600004
J	Reddy, EP; Korapati, A; Chaturvedi, P; Rane, S				Reddy, EP; Korapati, A; Chaturvedi, P; Rane, S			IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled	ONCOGENE			English	Review						IL-3/GM-CSF/IL-5; JAKs; STATs; Src kinases; signal transduction	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; PROGENITOR-CELL LINE; DNA-BINDING ACTIVITY; INTERLEUKIN-5 TRANSDUCE SIGNALS; HEMATOPOIETIC GROWTH-FACTORS; MEMBRANE-PROXIMAL DOMAIN; MURINE LEUKEMIA-VIRUS	Hematopoiesis is the cumulative result of intricately regulated signal transduction cascades that are mediated by cytokines and their cognate receptors, Proper culmination of these diverse signaling pathways forms the basis for an orderly generation of different cell types and aberrations in these pathways is an underlying cause for diseases such as cancer. Over the past several years, downstream events initiated upon cytokine/growth factor stimulation have been a major focus of biomedical research. As a result, several hey concepts have emerged allowing a better understanding of the complex signaling processes, A group of novel transcription factors, termed signal transducers and activators of transcription (STATs) appear to orchestrate the downstream events propagated by cytokine/growth factor interactions with their cognate receptors, Until recently, the JAK proteins were considered to be the tyrosine kinases, which dictated the levels of phosphorylation and activation of STAT proteins, forming the basis of the JAK-STAT model. However, over the past few years, increasing evidence has accumulated which indicates that at least some of the STAT protein activation may be mediated by members of the Src gene family following cytokine/growth factor stimulation. Studies have demonstrated that the Src-family of tyrosine kinases can phosphorylate and activate certain STAT proteins, in lieu of JAK kinases, In such a scenario, JAK kinases may be more crucial to phosphorylation of the cytokine/growth factor receptors and in the process create docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src-kinases and other signaling intermediates, Tyrosine phosphorylation and activation of STAT proteins can be achieved either by JAKs or Src-kinases depending on the nature of STAT that is being activated. This forms the basis for the JAK-Src-STAT model proposed in this review, The concerted action of JAK kinases, members of the Src-kinase family and STAT proteins, leads to cell proliferation and cell survival, the end-point of the cytokine/growth factor stimulus.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Claret, Francois X/R-2104-2016; Reddy, E. Premkumar/F-6233-2011	Claret, Francois X/0000-0003-4629-6495; 	NCI NIH HHS [CA98239] Funding Source: Medline; NIEHS NIH HHS [ES09225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BARRY SC, 1994, J BIOL CHEM, V269, P8488; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; delPeso L, 1997, SCIENCE, V278, P687; Doyle SE, 1998, BLOOD, V92, P867; Durstin M, 1996, J IMMUNOL, V157, P534; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Frank DA, 1996, LEUKEMIA, V10, P1724; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1992, J BIOL CHEM, V267, P15842; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1983, J IMMUNOL, V131, P282; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; KING FJ, 1990, ONCOGENE, V5, P337; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KRUGER A, 1991, ONCOGENE, V6, P245; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu JJ, 1998, J BIOMED SCI, V5, P446, DOI 10.1007/BF02255934; Liu L, 1997, J BIOL CHEM, V272, P10998; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Nicola NA, 1996, BLOOD, V87, P2665, DOI 10.1182/blood.V87.7.2665.bloodjournal8772665; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKUDA K, 1992, BLOOD, V79, P2880; Orban PC, 1999, BLOOD, V94, P1614, DOI 10.1182/blood.V94.5.1614.417k22_1614_1622; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RAINES MA, 1992, BLOOD, V79, P3350; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; ROVERA G, 1987, ONCOGENE, V1, P29; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1996, ONCOGENE, V12, P839; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHEN Y, 1992, CYTOGENET CELL GENET, V61, P175, DOI 10.1159/000133401; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stomski FC, 1999, BLOOD, V94, P1933; TAKAKI S, 1994, INT ARCH ALLERGY IMM, V104, P36, DOI 10.1159/000236746; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VALTIERI M, 1987, J IMMUNOL, V138, P3829; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; ZON LI, 1995, BLOOD, V86, P2876	172	180	188	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2532	2547		10.1038/sj.onc.1203594	http://dx.doi.org/10.1038/sj.onc.1203594			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851052				2022-12-28	WOS:000087459400009
J	Kao, SY; Lemoine, FJ; Marriott, SJ				Kao, SY; Lemoine, FJ; Marriott, SJ			HTLV-1 Tax protein sensitizes cells to apoptotic cell death induced by DNA damaging agents	ONCOGENE			English	Article						HTLV-1; Tax; apoptosis; nucleotide excision repair; DNA damage	VIRUS TYPE-I; NF-KAPPA-B; TRANSFORMS RAT FIBROBLASTS; LEUKEMIA-VIRUS; INDUCTION; GENE; ACTIVATION; EXPRESSION; TRANSACTIVATOR; INTEGRATION	Transient HTLV-1 Tax expression suppresses cellular nucleotide excision repair, and this effect correlates with Tax transactivation of the proliferating cell nuclear antigen promoter. The inability to repair DNA damage typically induces apoptotic cell death, Therefore, we in investigated the effect of Tax-mediated suppression of DIVA repair on apoptosis in stable Tax-expressing cells. Constitutive Tax expression reduced cellular nucleotide excision repair activity compared with parental and control cells. Tax-expressing cells were also more sensitive to apoptosis induced by DNA damaging agents than control cells. Even though Tax-expressing cells displayed reduced DNA repair, they showed increased DNA replication following UV damage. These results suggest that Tax suppresses the cell's ability to repair DNA damage and stimulates DIVA replication even in the presence of damage. The inability to repair DNA damage is likely to stimulate apoptotic cell death in the majority of Tax-expressing cells while the ability to promote DNA replication may also allow the survival of a small population of cells. We propose that together these effects contribute to the monoclonal nature and low efficiency of HTLV-1 transformation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER; NCI NIH HHS [CA09197, CA-77371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJITA M, 1995, ONCOGENE, V11, P15; GESSAIN A, 1985, LANCET, V2, P407; Hall AP, 1998, J PATHOL, V186, P209; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KELLAND LR, 1993, CRIT REV ONCOL HEMAT, V15, P191, DOI 10.1016/1040-8428(93)90042-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitajima I, 1996, J BONE MINER RES, V11, P200; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; Los M, 1998, J IMMUNOL, V161, P3050; Lydy SL, 1998, VIROLOGY, V250, P60, DOI 10.1006/viro.1998.9378; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; POIESZ BJ, 1980, J VIROL, V64, P5682; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SANDBERG AA, 1991, CHROMOSOMES HUMAN CA; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2240	2248		10.1038/sj.onc.1203559	http://dx.doi.org/10.1038/sj.onc.1203559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822374				2022-12-28	WOS:000086974100009
